<SEC-DOCUMENT>0000950170-24-054448.txt : 20240507
<SEC-HEADER>0000950170-24-054448.hdr.sgml : 20240507
<ACCEPTANCE-DATETIME>20240507160143
ACCESSION NUMBER:		0000950170-24-054448
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		61
CONFORMED PERIOD OF REPORT:	20240331
FILED AS OF DATE:		20240507
DATE AS OF CHANGE:		20240507

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Neumora Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001885522
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				844367680
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41802
		FILM NUMBER:		24921653

	BUSINESS ADDRESS:	
		STREET 1:		490 ARSENAL WAY, SUITE 200
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		(857) 760-0900

	MAIL ADDRESS:	
		STREET 1:		490 ARSENAL WAY, SUITE 200
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RBNC Therapeutics, Inc.
		DATE OF NAME CHANGE:	20210929
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>nmra-20240331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-05-07T10:26:51.3196+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nmra="http://www.neumoratx.com/20240331" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:srt="http://fasb.org/srt/2023" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-Q</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_a577262a-b2bf-4067-85e6-ae1d80ff9768" name="dei:EntityCentralIndexKey" contextRef="C_387b8b88-6529-413e-9474-299a471851cb">0001885522</ix:nonNumeric><ix:nonNumeric id="F_9b206e6e-5fee-403a-bef2-f31e29027818" name="dei:DocumentFiscalPeriodFocus" contextRef="C_387b8b88-6529-413e-9474-299a471851cb">Q1</ix:nonNumeric><ix:nonNumeric id="F_52b4600f-6913-4e25-9c5f-375cfb09464b" name="dei:CurrentFiscalYearEndDate" contextRef="C_387b8b88-6529-413e-9474-299a471851cb">--12-31</ix:nonNumeric><ix:nonNumeric id="F_8e72c77a-0627-4e13-9d7e-12c8667c6873" name="dei:AmendmentFlag" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonFraction id="F_e748573f-5fcd-435c-b320-b9707be7bc34" name="us-gaap:CommitmentsAndContingencies" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" unitRef="U_USD" xsi:nil="true"/><ix:nonFraction id="F_92a64cbe-414d-4323-a4eb-a1db34c1b207" name="us-gaap:CommitmentsAndContingencies" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" unitRef="U_USD" xsi:nil="true"/><ix:nonFraction id="F_fc1674b5-31ae-4580-a05a-09485f8e145a" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_2dbd3db6-c2fd-461e-bc93-e4f0d0af4663" unitRef="U_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">0.1274</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="nmra-20240331.xsd"/></ix:references><ix:resources><xbrli:context id="C_33ed239b-f1e7-4dbe-9413-6d412b79e979"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:MarketAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eae3f164-5e78-4151-9e37-d2d160340f1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_59764801-e98b-441b-813d-c795a4f77342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_65092f10-0d2e-4c03-9fd8-87313bbab41c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_60ca0d63-6992-4ed9-96cd-ba37575ee0f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8cc2fb07-49d2-42cc-96c7-07529ebadb72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5832b785-c82b-4724-84f7-7e1c54e65756"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_af1ae46a-387b-4cc6-b7c4-deac557cbf45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nmra:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenIncLicensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0fd1591b-b097-48b9-96e0-c77fef141b7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d4ca77dd-2b7a-4c72-9d67-3f3c267a7400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nmra:LiquidityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_908e2fe1-8e96-4b2a-b94e-f5e7dea5b0a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2a684aa7-255a-43da-9bf9-acf6d3b4352e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nmra:EmployeeStockOptionAndAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_07471f87-b4eb-4e19-b637-f10364df9c08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d4c8d898-2127-41b5-99f4-5fed585e8a39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a0e6e5ef-74d3-4484-9f60-7605a23196e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:AlairionIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AlairionMergerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:AchievementOfSpecifiedCommercializationEventsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51f3d1d1-4794-40b6-9e06-602baca00e1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_03e46424-d2af-4dcd-b68b-3725a6f17401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_997939ff-f371-43ae-8539-1f8d55163ef5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eeb0b484-a788-4f77-8681-695af51358cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7427bdec-5be3-45d2-91f7-391af97bab20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:AlairionIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AlairionMergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43bd04fb-3740-4cf7-b83c-a9a404955351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a935b0c-89b2-44d4-8a74-37a27e755eae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nmra:PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_395f7b48-e0c5-40be-babe-b38226abdb22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:MarketAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e555a578-5b2d-4468-956c-3321ccffb3aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nmra:AdditionalSharesOfCapitalStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_20c204e8-32e7-4a99-afcf-776f05f42ab0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_27e98a1d-ba3b-4cf3-99f9-3fdadc737b90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:SyllableLifeSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:SyllableMergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_34c9a333-0792-46d3-8d3d-3200c56c14bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nmra:EarlyExercisedStockOptionsSubjectToFutureVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_15533d05-1a02-4a98-bae1-62dca64d295c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nmra:PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d2f7696-8e65-434a-b57a-0fff8a7da606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a41d013c-1391-41b3-90a7-49ba49d11331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_934561fc-3ca0-4e9c-afc9-cab561a511ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_55f7cf54-c65c-4834-922b-fada916481b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d5479116-b1c4-4d64-a307-24d1e08db08f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:MarketAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_739e5e64-0cd3-46ad-bc1c-ca25045bf637"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7a80754f-9ec5-4887-bba9-4311a2728d25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:MarketAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cc78fb10-fe96-458e-9b51-d23d300acb4b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmra:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_26c72768-5590-4025-8159-fc37393751a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:TwoThousandAndFifteenTsriLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_93cb25ef-3bf9-4722-9f0f-76e81b2a808d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_785b6f2c-3814-4a67-a525-c56234244751"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_70e6e56b-1627-4b50-b58c-c7079cb8e79e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d5bbb135-9ec5-40dc-99e5-5f2b31f645d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6715b955-aac8-4773-8111-47fd843a4a8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9e7d5678-cc71-4b15-86ec-dc798d97ec7a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:DevelopmentAndRegulatoryApprovalMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:NavacaprantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d7ebe7a9-9b3e-43ca-b7d5-0155ac61a792"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_387b8b88-6529-413e-9474-299a471851cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5eeee25b-8ab1-4a9f-98dc-9fd6387ddc80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:VanderbiltLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e9c77ce3-3b44-4cf6-b432-fc188546ac82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:SyllableLifeSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:SyllableMergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7642d8ba-9722-4366-8e63-768f192c1673"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4fa032ad-c930-4482-a337-4a8a1b1ede42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6fcb7871-8d09-408d-8dc0-0412fca292a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:VanderbiltLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:AchievementOfSpecifiedDevelopmentEventsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5ae90723-14e8-439e-81a2-861cd015a4de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a1a5b45-cd15-4c5f-8018-f47ae86a02cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e5c437fa-ca9f-4a34-a6dd-cd8d4e53f5bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a69bb320-f60a-431d-9ea6-2f940a271bbb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a19bca81-450f-43b2-9071-1243ab1b452a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e356d7aa-aadb-4a43-9704-349d4130949f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cf493e6f-190e-4be5-9281-315bbffa2f51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:MarketAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a190bc1-8994-483b-9102-8e2f78b28bc1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0311f6e7-f6e3-443f-9af6-6ed78e813333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:VanderbiltLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7fa44ea-606a-4dcc-824f-a24a6ed67327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nmra:PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1c718a38-50b6-430d-81b1-4a6d12e7d922"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b7c53efd-2f73-4e8f-aeaf-4c1bb51e739b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3492c0b5-ea1d-4cce-912d-8ddfd975d853"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:VanderbiltSponsoredResearchAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1f06d786-a166-4605-9c3f-8826e794ff47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d76dcd2b-4bbc-41b1-8598-911a369433df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:AwardsWithPerformanceConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_776fbd65-9035-41d6-b661-57b9c9289144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_05417fea-1510-4361-a4a9-baae7ef69f42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nmra:RestrictedCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:AwardsWithPerformanceConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_da6c85e3-9c01-4bd3-ae51-498329b996bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">nmra:PerformanceConditionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa35f881-a2e4-44a8-bf69-7086dc821033"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2113c554-0c81-4a7b-979d-5577fd8f2940"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cb7d09d2-6022-4de5-837f-3706586031b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:TwoThousandAndFifteenTsriLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-11-01</xbrli:startDate><xbrli:endDate>2015-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e06ff9ea-6ac1-463f-a171-26aa417330c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_22d38837-90bd-43aa-9c93-8f13f37f99e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_555b90da-9109-4cae-936b-dac6310ce148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_02b50e0e-46e6-4a57-acee-f328831ee84b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d06cc3be-3868-4b27-8b88-efa3b16b4417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_57949529-090f-4b07-8503-88af5ca1f576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_33dd1233-920e-4439-a019-1de4439f0bdd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6e7d7080-8e14-4f39-8b8c-749fc8d79976"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:VanderbiltSponsoredResearchAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_24425110-363c-4304-86c3-338011263481"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenResearchAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d2b19e7-2597-4087-9ada-8de5a4121c58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_251ee5d8-0c7f-4f9d-a0ce-8c700c53c157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_77c53b90-3f1c-4948-9874-3efee2daaf4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d8423cb-a654-4705-bc38-351fdb1ead9c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b7650c04-d7d2-470d-8cdd-f4a7c34c3ee7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7192706f-bc17-41ba-8cf3-0a9e6b1ad84d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d17d3110-5d3b-4f67-a03a-3459f5097a7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_58d3b1a6-51e2-4cfa-8ee9-64532995d7ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3e1fdf9f-0c41-49d6-bdc7-817ef4cf3889"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nmra:PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e8193643-0d56-40a9-b0e8-aa7a9093b9b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1c88b9f4-137c-4a7d-a570-37859d14341b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6605667a-124d-429a-9742-9590d104c8b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a2bb8dd3-a77e-4977-bb71-27730b31dc5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_77008896-6cba-4a73-a7b9-c5a0409529ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c0384758-481a-481e-9efc-b953da92377b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1bb45cba-2398-4df6-8cdb-80b9b69e2e24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_38d1ee4e-868f-457c-9d3a-08007be1e356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenIncLicensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d082d3da-55b1-47ee-a8c5-4a74e9aacbc1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d05c50a8-ba36-4fd1-84d9-0b85ac41d16f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:VanderbiltLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:AchievementOfSpecifiedCommercializationEventsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2dbd3db6-c2fd-461e-bc93-e4f0d0af4663"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2b466a11-59bd-42da-b1ba-1391e584e43b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_187481d3-58da-4836-be9f-97cca6f7c199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_62937b0d-82a4-455d-b20c-613131a128e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fddb666c-28f9-47a3-90ab-b07ceb2c7598"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4252d2b2-e04b-48d1-85b6-0e7e74735ae9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenResearchAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_525f8d27-e52b-4d90-aae6-72f3a411fae6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e25bb6fd-163c-4c2e-a895-464771d27c28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_18f69ced-ee72-4bc6-9740-8d6abfc2c287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1b53b7d9-62ee-44e4-a34f-0d741a2336fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6d6c1116-4ad2-4a9c-88a8-b3a45ef44006"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:ParkinsonsResearchVenturesFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_77cfdb28-9e47-4558-b8db-21bed2f9143f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f302022e-1a9e-474c-a0c7-dc6743de3517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f813a615-5ec3-4225-add3-4edef1f0b0da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:NavacaprantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_310a84d7-31f9-4782-844c-698837e7d4e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b9e1e62e-8665-4095-88dc-e415a74bf039"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornCarveoutPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d605d37-23c6-4f30-8d3a-a3a25b1de12d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_00a508a8-d895-4261-b068-9f4d68a32812"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1eca2e79-7a8a-4acf-aa36-a5b1bfaffd3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:MarketAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_29326ae4-2f07-4dd9-ac50-8fbdc7b576a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2a31bc5a-9b88-4b0c-a97e-5b7a3ab157b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_08d37b25-304c-48fb-acac-c44b7eb4f93d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c76761b1-4f4c-4b1c-9b56-2a77a0b656cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b8b16692-cbc0-4367-b249-644373e8d0f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_014dbf4d-9c71-491e-bae9-913a30763050"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_909c052f-7ffa-437f-92ce-194f4b68b6f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:MarketAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba9c409c-cf95-4c6b-a1de-281f2042bc5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_31d52667-94b6-48d2-b574-45d574a0f09b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c27ac2f8-7a27-4804-87d3-3bbc8e87144e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7a1aaed2-b5ef-4825-a2cb-ef3ae69d40ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:MarketAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_638d684a-75f7-48d0-a1b0-227583ccf014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:VanderbiltIprDAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_77d7002e-e37b-46f4-8b74-d60274250475"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b006d350-7cd4-4054-a767-ad0723607854"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:CommercialMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenIncLicensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:AmgenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nmra:CaseTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ce5b0975-4f9d-4afa-a419-e3ce04cc3ecb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nmra:EmployeeStockOptionAndAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0caaf123-e9b7-419b-a654-8ce6c344421a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5ea749b2-350e-4a76-be5d-6ec287b9f397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f4c941c3-9b74-4cf3-bf81-e52a1de6cb41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7da00584-584d-4a38-a226-8df0e7c5789c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_44ecaf5c-05ec-4fc1-a4b3-34fd3c08ceb5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a613c3d9-8372-4ff1-9b67-609500a6441a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a5ae6113-d278-4442-b891-5cdcd2698c04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornCarveoutPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_376fc925-1109-451f-b742-d347b9400872"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmra:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b52dabe9-8de8-4682-9783-5765240d1d61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:BlackthornTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fa50bcc6-f909-4f28-9b54-3cce67927d90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_118d5793-6b58-4c11-bd9e-24a1b0197692"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0a096f27-ed84-4bfd-9a47-aba4b2779d76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_829340ea-2a8e-4dd9-8fc4-4651e162611a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-19</xbrli:startDate><xbrli:endDate>2023-09-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_adde3b8d-d812-4a53-b229-03202c183eb7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ee2b185-99f7-4bd5-9ca0-f9d76e4edb87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aff62d54-a840-4155-a58f-4ca78842f976"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nmra:RestrictedCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:AwardsWithPerformanceConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6a59c933-f461-45be-9258-2eeefba9dd39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a162142f-a9f4-4c93-8b5d-13311233637b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:AwardsWithPerformanceConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f506a8da-d1e3-4763-89af-d777851aeab1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:MarketAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a88c6ce-e846-4492-ae0b-e6b735a43fb1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:VanderbiltLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:VanderbiltIprDAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eccfdb09-aec6-4147-bb3a-627442594df7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_04b84919-0f66-4a40-b2c6-b4440e68e095"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c7dcb4ff-f9ea-4129-bb6e-4ce2d5a96a56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:DevelopmentAndRegulatoryApprovalMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:Nmra511Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10a4bee1-f023-4318-b204-afcaf55d14c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:TwoThousandAndFifteenTsriLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_241e97c5-2790-4988-bdd5-728453731091"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">nmra:ServiceConditionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a90b5a54-f1c7-43a2-a245-7aab2d94f07b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_efc6daa1-495e-4af5-8a13-fe64bc5588ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c07a2ba4-b437-458f-928b-576f968fde0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nmra:EarlyExercisedStockOptionsSubjectToFutureVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0f5b5752-1f37-4791-b9a2-a1fd4665f647"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3929f877-fd38-4a94-9e5b-54676a4e9e57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9622b93d-0fee-4c35-979b-ac055cc9685e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_39142c7c-f586-4ac5-b162-38a428111720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2ea68049-f744-4490-8038-a161b824989a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:BlackthornTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1ad31ded-f058-420f-adc9-5e78ca23eebb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_79158f11-43a3-45ef-a4fa-baf694b1a1dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c04ac888-4277-45d9-a4b1-48542ea0cbd2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:Nmra511Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b39dc12-964c-4b06-983f-1dd2a2960d34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e4e3a7e0-9ae1-4a99-a9a2-37ef23ba354a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_99673cd6-c93c-488e-a35a-1c624f6dcd54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a1bec7e-9028-4893-9a01-f2631f4b8268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenIncLicensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:AmgenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nmra:CaseOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8eca9c19-7868-4c41-b853-b66e96530c89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmra:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5e8a8262-f68c-4d54-b803-90f9002df20b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_43d25bda-98a9-43db-9b57-e1c5583f0e82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:BlackthornTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bcf2dda4-ea5e-486c-b486-680ccab2876c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a8941767-b9c2-4978-8d8c-996384d2b743"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:MarketAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_63ea549e-a21c-49a4-aa4c-6bb788b17014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61a3990c-bdca-4b24-aaa5-3144c2b02eed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenResearchAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5e016890-9da0-47f3-9793-42aec2feff28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e81dd9f-5d49-4381-8c61-747848c7d435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_636c0850-3f38-4c68-923e-8a9192036aec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a2a11bd1-3578-49a9-bc75-aaa978ce9086"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f5ac940-84de-48e5-ae64-41ee00fc2d79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_222a51e8-068b-4c5a-9701-3a50110c9a80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_98e4cbee-233e-4294-91dc-1bfd8e5796c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenResearchAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_727eaf32-52e9-4c5c-a6c1-0994953c8d5b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:SyllableLifeSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:SyllableMergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b09e08a3-63fc-490c-a2b1-f49e28aca678"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:ParkinsonsResearchVenturesFundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_29e92089-1d1d-45de-90cf-b5665e9d2c96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenResearchAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2491722f-cf98-415e-ae66-46193d72f8d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:AwardsWithPerformanceConditionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3c8b66e7-6cb2-408d-90ae-bc995d83fe8b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenResearchAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8afd36af-329a-4960-a319-26b63e51bf46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nmra:RestrictedCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:AwardsWithPerformanceConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_52904f82-0764-43ac-8bcb-0b6094dd317b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornCarveoutPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba5b5e93-9d73-4a23-8fdd-272f7a933478"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c40c0b1-14e6-4ada-8bd6-1d23c649c6ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d7f8b41-ab55-4cad-89a8-122b00ff6bb3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba11dd75-605e-4c4e-9798-9cc2968450e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:BlackthornTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d5c12c1d-523a-4e2f-a7e6-1b8c3d85f7ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:AlairionIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AlairionMergerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:AchievementOfSpecifiedDevelopmentEventsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_28cf5026-31c2-4237-a961-7cf7d3167b00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nmra:AdvisorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_14e89b9f-b5c9-4179-91f4-e162088b136c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:NavacaprantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c407007a-f71b-4362-a5e7-9ede4f3ae224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3700265e-5b94-44f5-97b6-9328d7c4e21d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_37094d88-e7f6-4b83-a8b8-9f256b675b10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61fc95eb-f3e2-41fe-a985-6942d28b52ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec34d5ee-6cf7-4a70-a875-58e1015081f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8cd94762-0e2e-45f6-a01e-01085a86a854"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4fd44d42-dc78-4882-9e7d-7c2d3d98f539"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:VanderbiltLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_42afd269-c212-4524-8ff6-bdd4937462c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmra:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c58e805b-70de-4471-9304-e335b5edcd5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_96f5c202-287c-4650-8120-d3a9b7c6fa82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenIncLicensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ba84d33-97e9-4add-951a-69e5ffd8a70a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_345bf6ed-eb39-4b95-8e9c-d73a88a49e29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e34b0512-dfda-4a27-98ed-cf663dd4f181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_70fddc6b-c6f5-476e-99bd-8e5dcdebf0ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dff92dc7-7e5a-4082-a3f9-80aea9d28b77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0cee2f31-d69c-4bb4-80be-9b786c85fd34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_673045b2-3dfa-4a5c-a957-7ad525519202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b533a66d-d823-48df-b3a5-6934efcf05e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:SharesReservedForFutureIssuanceUnderThePlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df6fdf4a-265c-48a0-90df-8045faa562ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmra:TwoThousandTwentyThreeEmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Agreements"><xbrli:measure>nmra:Agreements</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Milestones"><xbrli:measure>nmra:Milestones</xbrli:measure></xbrli:unit><xbrli:unit id="U_GBP"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:unit id="U_Program"><xbrli:measure>nmra:Program</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div class="section-group" style="margin:auto;padding-left:0.5in;width:7.5in;padding-right:0.5in;"><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">                                                                                                                                                                                                                                                                                                                                                                    03ROC</span></p><p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, DC 20549</span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:5pt;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3eefbb28-901a-44fb-b701-7a854f905d32" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">10-Q</span></ix:nonNumeric></span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:5pt;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Mark One)</span></p>
   <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:4%;"/>
     <td style="width:96%;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_bf4f729b-7d77-4b32-b0cd-804f495f5907" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
     <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the quarterly period ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d1fbf388-1980-4a58-9e1a-d9d297edc3c6" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_786df56e-e542-46e5-a387-ccbea61e60ed" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2024</span></ix:nonNumeric></span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">OR</span></p>
   <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:4%;"/>
     <td style="width:96%;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_b551a316-b249-43db-a4f4-c5eacd142c1a" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the transition period from ___________ to ___________</span></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commission File Number: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1c2bdf6c-bc2c-495e-a292-06f89e511ecb" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">001-41802</span></ix:nonNumeric></span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:5pt;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:22pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3cd738a9-e020-4ca1-9543-4d060f60d37e" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:22pt;font-family:Times New Roman;min-width:fit-content;">NEUMORA THERAPEUTICS, INC.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:22pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Exact Name of Registrant as Specified in its Charter)</span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;"/>
     <td style="width:50%;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_ca83d9df-9c74-46fd-a6c2-d2e4d21fcc0d" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
     <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_5861bc5f-75a3-4799-832c-28f21b3fd980" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">84-4367680</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">incorporation or organization)</span></p></td>
     <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(I.R.S. Employer<br/>Identification No.)</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_850f1ba9-6f21-465e-9d94-65a2bfaf0227" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">490 Arsenal Way</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_9bb10ea6-62a7-4661-97f9-2b990c0a6b4c" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 200</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_3ea995d3-d278-4c84-9040-7f6fed20ceef" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Watertown</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_252e805b-3e0d-4ea7-9be9-4fa083c85bd7" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
     <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_215dc85d-7342-4a46-9292-ce9b02d067a8" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">02472</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
     <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e785e839-4387-4f3e-bfe2-23bbc26c86c8" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">857</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e46f6646-0b49-47fc-80fe-246714679865" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">760-0900</span></ix:nonNumeric></span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:38%;"/>
     <td style="width:1%;"/>
     <td style="width:15%;"/>
     <td style="width:1%;"/>
     <td style="width:45%;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Symbol(s)</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_93a62a5d-719a-4e2e-893b-b31866998c59" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, par value $0.0001 per share</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"> </span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_0e1a1669-bacf-4f77-b874-a26d48abc58d" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">NMRA</span></ix:nonNumeric></span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_40d1009d-8de9-48d5-a07e-06a088e0dd21" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_83ae9c88-2392-4b9f-8eda-d648eca44dc2" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746; </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">   No  </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2bfe97e8-3bd3-4765-ab27-2ecb6b9dcc2d" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746; </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">   No  </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:18.9%;"/>
     <td style="width:1%;"/>
     <td style="width:55.84%;"/>
     <td style="width:1.06%;"/>
     <td style="width:20.1%;"/>
     <td style="width:1%;"/>
     <td style="width:2.1%;"/>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Large accelerated filer</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated filer</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_a1cba030-d9c5-454c-8200-a914993ecc53" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Smaller reporting company</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_b65aebd5-7d7e-4f5f-a408-74f36de49352" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging growth company</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_45e97e21-84e6-4f96-bb1e-b05f5c3de2cb" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_8ddcc7d2-d05d-4bad-a6e3-acba3d5d9f8e" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes  &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">   No  </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c5c69b49-9934-422f-83de-1b5baec20883" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.     Yes  </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744; </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">   No  &#9746;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">As of May 1, 2024, the registrant had </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d72e85ca-95f4-4327-9553-250b7ba061fd" contextRef="C_efc6daa1-495e-4af5-8a13-fe64bc5588ff" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">159,523,997</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, $0.0001 par value per share, outstanding.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Special Note Regarding Forward-Looking Statements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Quarterly Report on Form 10-Q contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;positioned,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding the potential market size and size of the potential patient populations for our product candidates and any future product candidates, if approved for commercial use; </span></div></div><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our clinical and regulatory development plans including any anticipated program milestones related thereto; </span></div></div><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; </span></div></div><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations with regard to the results of our clinical studies, preclinical studies and research and development programs, including the timing and availability of data from such studies; </span></div></div><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our estimates of the number of patients that we will enroll in our clinical trials and the timing of their enrollment; </span></div></div><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing of commencement of future preclinical studies and clinical trials and research and development programs; </span></div></div><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to acquire, discover, develop and advance product candidates into, and successfully complete, clinical trials; </span></div></div><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to reduce the time or increase the likelihood of success of our research and development relative to the traditional drug discovery paradigm using our precision neuroscience approach; </span></div></div><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to improve, and the rate of improvement in, our precision neuroscience approach, or to realize benefits from such improvements; </span></div></div><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations related to our precision neuroscience approach, including but not limited to whether it will have the same impact as data-driven precision medicine has had on the oncology field; </span></div></div><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to achieve our mission to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases; </span></div></div><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to scale our company; </span></div></div><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing of milestone payments; </span></div></div><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our intentions and our ability to establish collaborations and/or partnerships, and whether such collaborations and/or partnerships are successful; </span></div></div><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing or likelihood of regulatory filings and approvals for our product candidates; </span></div></div><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our commercialization, marketing and manufacturing, including any capabilities and expectations related thereto; </span></div></div><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to keep pace with new technological developments; </span></div></div><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">impact from future regulatory, judicial, and legislative changes or developments in the United States and foreign countries;</span></div></div><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our intentions with respect to the commercialization of our product candidates, if approved; </span></div></div><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the pricing and reimbursement of our product candidates, if approved; </span></div></div><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the implementation of our business model and strategic plans for our business and product candidates, including additional indications for which we may pursue; </span></div></div><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to maintain our technical operations infrastructure to avoid errors, delays, or cybersecurity breaches; </span></div></div><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">i</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to effectively manage our growth, including our ability to retain and recruit personnel, and maintain our culture; </span></div></div><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates, including the projected terms of patent protection; </span></div></div><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">estimates of our expenses, future revenue, capital requirements, our needs for additional financing and our ability to obtain additional capital; </span></div></div><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the period over which we estimate our existing cash, cash equivalents, and marketable securities will be sufficient to fund our future operating expenses and capital expenditure requirements; </span></div></div><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the performance of our third-party suppliers and manufacturers; </span></div></div><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding the time during which we will be an emerging growth company under the JOBS Act; </span></div></div><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact to our business from general political conditions, including but not limited to, disruptions in U.S. government operations and funding, geopolitical conflicts such as the war between Russia and Ukraine, the war between Israel and Hamas, and any sanctions or other repercussions that may result therefrom;</span></div></div><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact to our business from general economic conditions, including but not limited to, rising inflation, recession risk, low consumer confidence and increasing interest rates; </span></div></div><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developments and projections relating to our competitors and our industry, including competing products; and </span></div></div><div style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">other risks and uncertainties, including those listed under the caption &#8220;Risk Factors&#8221; in this Quarterly Report on Form 10-Q. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These forward-looking statements are based on management&#8217;s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and management&#8217;s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be inaccurate. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section titled &#8220;Risk Factors&#8221; and elsewhere in this Quarterly Report on Form 10-Q. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements contained herein for any reason after the date of this report to conform these statements to new information, actual results or changes in our expectations, except as required by applicable law.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Investors and others should note that we may announce material business and financial information to our investors using our investor relations website, Securities and Exchange Commission filings, webcasts, press releases and conference calls. We use these mediums, including our website, to communicate with the public about our company, our business and other issues. It is possible that the information that we make available may be deemed to be material information. We, therefore, encourage investors and others interested in our company to review the information that we make available on our website.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ii</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="toc_page"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table o</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">f Contents</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:10.526%;"/>
     <td style="width:83.874%;"/>
     <td style="width:5.6%;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="text-indent:6.85pt;vertical-align:middle;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART I.</span></p></td>
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_i"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">FINANCIAL INFORMATION</span></a></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1.</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Financial Statements (Unaudited)</span></a></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Condensed Consolidated Balance Sheets</span></a></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_operations_and_com_loss"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</span></a></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_statements_of_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Condensed Consolidated Statements of Cash Flows</span></a></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#organization_and_liquidity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span></a></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 2.</span></p></td>
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_managements_discussion"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 3.</span></p></td>
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_and_qualitative"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 4.</span></p></td>
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_and_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Controls and Procedures</span></a></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Part II.</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">OTHER INFORMATION</span></a></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1.</span></p></td>
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Legal Proceedings</span></a></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1A.</span></p></td>
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Risk Factors</span></a></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 2.</span></p></td>
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#unregistered_sales_of_equity_securities"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 3.</span></p></td>
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#defaults_upon_senior_securities"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Defaults Upon Senior Securities</span></a></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 4.</span></p></td>
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 5.</span></p></td>
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Other Information</span></a></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 6.</span></p></td>
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibits</span></a></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Signatures</span></a></p></td>
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">86</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">iii</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Part I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Financial Information</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Item 1. Financial Statements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Condensed Cons</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">olidated Balance Sheets</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">in thousands)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:67.393%;"/>
     <td style="width:1.6%;"/>
     <td style="width:1%;"/>
     <td style="width:12.703000000000001%;"/>
     <td style="width:1%;"/>
     <td style="width:1.6%;"/>
     <td style="width:1%;"/>
     <td style="width:12.703000000000001%;"/>
     <td style="width:1%;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31,<br/>2024</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(unaudited)</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6eb7ae7f-57e5-4406-94d8-eaa0f2feb892" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">182,927</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_282e5490-9a55-4c9b-92d6-09d55a88a8d1" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">374,038</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term marketable securities</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0bf749a1-f5cc-4d4c-97f4-35016a84b0e9" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">239,788</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_877037ce-959e-4158-b48f-835306c4e7b5" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,944</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e46e67d0-6462-4385-9ab3-95465a06cf54" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,070</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d646503-c382-4716-92a1-3a0f7f9924bd" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,297</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c3321b6-3f83-40df-bb11-a71840aad07a" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">442,785</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61cbb0ed-0096-4219-89b5-cd3e6588e1e0" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">478,279</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term marketable securities</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_276c4705-982a-4a6d-98bc-fa95e369a228" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">302</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44659730-d2f0-44c2-afc0-47dfbda795a8" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,845</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a14f5738-e2d3-42e5-a6b3-c57cc104fbb9" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,635</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96a6f166-acba-44f5-b266-e0f7fe10fac9" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,790</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e80a13f3-f3c3-4cbe-80c7-9170e4a2352e" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,276</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f00fca87-98ab-434a-a2ef-97cb413f79d8" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,068</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22cfa908-8a7f-4d8c-aadc-faa300ba3f57" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,213</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_afe8866e-552d-44fb-b3d0-e8dc46992124" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,213</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2716c90-4e52-4300-9815-cc1cfc76fa2f" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">450,211</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_528fb34b-9d06-4ed5-bdd8-3b99e30f61aa" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">496,195</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities and Stockholders&#8217; Equity</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_359468e8-7400-40e5-8da4-432d0880b3c1" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,492</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9efbb4c5-f034-41a2-b13a-bc9b726b7f97" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">337</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued liabilities</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5db67e3-37b3-4f62-874a-e1d6b63d256a" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,493</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13e3b0d9-7149-44b3-8cca-8b8dc8644424" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,257</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Early exercise liability, current portion</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03de554c-0702-43c6-a6a7-a21e0f030d4b" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="nmra:EarlyExerciseLiabilityCurrentPortion" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a8308a6-b4a0-4ccd-9a73-cdfb84183ecf" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="nmra:EarlyExerciseLiabilityCurrentPortion" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">139</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities, current portion</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4a9cdad-94d2-4dc8-a803-76af21d49a24" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,491</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57613688-c6ec-40c9-982d-fe95bf8e19bf" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,378</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54160886-b6e6-41ff-81e9-a14cc90a68dd" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,609</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60257557-8c8c-49de-894e-7cf3f458eecf" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,111</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities, net of current portion</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51d5ff34-66bf-487a-bd2e-fe5397fba999" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">938</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4326f655-c3de-4ac6-8560-e757401ec2c8" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,853</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Early exercise liability, net of current portion</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c17d0dfa-5df0-4fd1-9e45-a4c2332f82d7" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="nmra:EarlyExerciseLiabilityNetOfCurrentPortion" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">122</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_730bf2b2-53a2-4786-b670-c75fc06f9ef6" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="nmra:EarlyExerciseLiabilityNetOfCurrentPortion" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">155</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d58fe715-0b77-4039-a68e-d57e2cdb8762" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,669</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c07f7c63-cd45-4f07-b4e4-761b4efcfdbb" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,119</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_e748573f-5fcd-435c-b320-b9707be7bc34;"><span style="-sec-ix-hidden:F_92a64cbe-414d-4323-a4eb-a1db34c1b207;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies (Note 7)</span></span></span></span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders&#8217; equity:</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4c21445-3d35-4f81-91e7-9bb991ea66fd" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f93cfa06-6771-4a83-aa77-dca106de1dbf" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9fa3acde-6409-4570-8eb2-89899ae68e15" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,181,829</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9fc40c2f-fd4a-44c5-bd10-d83c1815d708" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,172,570</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_215ff3fb-b917-4870-a7c0-3101572e0d33" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">148</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9078dfb7-5d4e-4d1b-bfbe-ed7498159ff7" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">76</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_201afc90-08f5-44ba-998e-5dc4166492e1" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">757,155</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7fbb144-66c7-4bf6-8fe2-0f6ddffc5cc2" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">703,434</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33613ee1-1611-4ce5-af21-1d3c5a66660b" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">424,542</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1fb24385-865d-421c-b5a0-1e744952e079" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">469,076</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e768d83-0037-42dc-8975-574a228e47c2" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">450,211</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df9e4bd8-4c64-4460-a230-ac59fac6427f" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">496,195</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_operations_and_com_loss"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Condensed Consolidated Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> of Operations and Comprehensive Loss</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:Times New Roman;min-width:fit-content;">unaudited</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">in thousands, except per share amounts)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:66.993%;"/>
     <td style="width:1.62%;"/>
     <td style="width:1%;"/>
     <td style="width:12.883000000000001%;"/>
     <td style="width:1%;"/>
     <td style="width:1.62%;"/>
     <td style="width:1%;"/>
     <td style="width:12.883000000000001%;"/>
     <td style="width:1%;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5718e36-781a-4c8c-9e8f-3d677f1e1455" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,757</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9723076b-5253-4507-95e0-90f60a5b3d48" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,485</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff833b62-3660-4e57-bb0d-d052081c8f1f" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,317</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0677a5d-9ca3-43f7-b120-65e8cfcca351" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,683</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_635635d8-f506-4562-9297-786610464cff" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,074</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd5f7517-1d99-4d05-b199-ab07ba709fe4" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,168</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3498ecd-376f-473b-9803-c08c47418809" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">60,074</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22e4e1ff-e2dd-449b-8efd-ed4e935d56e1" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39,168</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense):</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed982cd7-665d-4e5b-b329-c7b7c8f718b5" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:InterestIncomeExpenseNonoperatingNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,365</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_59d74893-e134-4eb0-b5be-83871da88e1b" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:InterestIncomeExpenseNonoperatingNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,569</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other expense, net</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3fe22fa1-f093-434c-905b-145a085db7e6" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebbee606-8898-445c-beb5-99d1613e1840" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">26</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other income</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4273e62-14e9-41a9-8434-e04d54b7b7e9" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,353</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28adbd2d-6cb4-4363-8e22-817338fe1be6" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,543</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a69bd2fb-c9b3-4dfa-a5e8-dabfad7843cc" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">53,721</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69ebf725-b96d-47a4-aff4-29a9bc58bb78" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">35,625</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive income (loss):</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain (loss) on marketable securities</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52c4e30e-e719-494d-bd99-596db94a87fa" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">72</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_386eca35-bc91-4e43-830f-0a9d08bfae8f" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">476</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive loss</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b136ccfe-a002-414d-9a6d-25c247b15bf0" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">53,793</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_206efc8e-4ee0-4542-839c-30feb1641e68" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">35,149</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6c94882-f514-4b10-9dfc-5ce9ac5ce6c7" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_bf12d685-4e92-4ed2-bbeb-3eeae03b61bd" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.34</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a529aad-e4b1-40c0-b687-0ea8cc2e1d8d" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_18d0d3fc-df7a-42ff-b21a-a7970aa5dc98" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.22</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares outstanding, basic and diluted</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f93f05d8-28ca-4e79-becd-e730ec077440" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_932e4831-62db-4176-8877-385265d66bbb" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">157,943</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e79b083f-2ed6-4b5e-8349-35699c2f54ab" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a7b5705b-2388-4c04-9332-086cb089198b" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,277</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these condensed consolidated financial statements</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
   <hr style="page-break-after:always;"/></div>
  <div class="section-group" style="margin:auto;padding-left:0.5in;width:10in;padding-right:0.5in;"><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Condensed Consolidated Statements of Convertib</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">le Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(unaudited, in thousands)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.403%;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:26.625%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:5.121%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:5.601%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:5.121%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:4.721%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:6.801%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:7.982%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:7.001%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:6.021%;"/>
     <td style="width:1%;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Convertible<br/>Preferred Stock</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional<br/>Paid-In</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Other<br/>Comprehensive</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>Stockholders&#8217;</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Capital</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Loss</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deficit</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Equity</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27b8bc53-c94b-464d-8c20-1d6a4d8c12c9" contextRef="C_a2a11bd1-3578-49a9-bc75-aaa978ce9086" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">158,832</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a3db9dd-f427-449c-9a0e-a82da5212643" contextRef="C_a2a11bd1-3578-49a9-bc75-aaa978ce9086" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48ba287d-5fce-44ea-829d-e11a9ee217d8" contextRef="C_77008896-6cba-4a73-a7b9-c5a0409529ff" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,172,570</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_699a198a-5ad7-4cb9-9e72-aff688214893" contextRef="C_3700265e-5b94-44f5-97b6-9328d7c4e21d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">76</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_068d363b-374a-4e3b-bd4b-1201aff7781b" contextRef="C_62937b0d-82a4-455d-b20c-613131a128e9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">703,434</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60351eec-4e89-463b-993f-ca251be2e5a6" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">469,076</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock upon exercise of stock options</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a726b40f-fe6e-4da2-b86d-34c60a7b162a" contextRef="C_a2bb8dd3-a77e-4977-bb71-27730b31dc5a" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">525</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69178926-c7a3-4000-91dc-7539a347f2b6" contextRef="C_65092f10-0d2e-4c03-9fd8-87313bbab41c" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,845</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5d2d50a-137a-4e8f-bae2-2556bab89763" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,845</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vesting of restricted common stock</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b43afab2-d8c7-40a5-98c5-191a46df79ea" contextRef="C_65092f10-0d2e-4c03-9fd8-87313bbab41c" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2411488a-fd0c-46f4-80f0-fcfe622a1e26" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized loss on marketable debt securities</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96f6a3b8-78dc-4d3f-aea2-186ecda84ede" contextRef="C_222a51e8-068b-4c5a-9701-3a50110c9a80" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">72</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85b29862-eed8-462b-8a05-270896003c8b" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">72</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b400f4f-c095-488b-a41b-b6a7dc11a38c" contextRef="C_65092f10-0d2e-4c03-9fd8-87313bbab41c" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,373</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40a543e7-2c0a-48ec-b87c-5e3eac8c5c56" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,373</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88f8f1e3-3115-46fa-be03-4823656ed71a" contextRef="C_58d3b1a6-51e2-4cfa-8ee9-64532995d7ed" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">53,721</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28bd515f-5c14-4cbf-8930-7e9779fcdeda" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">53,721</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of March 31, 2024</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a4320b0-d31a-40ab-8383-ea2c0f16fe0a" contextRef="C_04b84919-0f66-4a40-b2c6-b4440e68e095" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">159,357</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7694db4-95d7-4309-b64d-1b6d8ac549ad" contextRef="C_04b84919-0f66-4a40-b2c6-b4440e68e095" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8d1ca73-7fe1-4cbc-9037-182cff13e068" contextRef="C_673045b2-3dfa-4a5c-a957-7ad525519202" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,181,829</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_774e97d7-8ecd-43ba-acf0-ff3167eb7832" contextRef="C_310a84d7-31f9-4782-844c-698837e7d4e0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">148</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea536fe0-2ec3-4448-81cd-caab7878f97b" contextRef="C_5e016890-9da0-47f3-9793-42aec2feff28" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">757,155</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5e7382e-a825-42ba-8001-4f03b02b9313" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">424,542</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.403%;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:26.625%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:5.121%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:5.601%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:5.121%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:4.721%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:6.801%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:7.982%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:7.001%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:1%;"/>
     <td style="width:6.021%;"/>
     <td style="width:1%;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Convertible<br/>Preferred Stock</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional<br/>Paid-In</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Other<br/>Comprehensive</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>Stockholders&#8217; <br/>Equity</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Capital</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Loss</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deficit</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Deficit)</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5204de70-fa80-4846-9f78-d26089ca0bf8" contextRef="C_636c0850-3f38-4c68-923e-8a9192036aec" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,417</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c5e7698-80b6-407f-b3b7-a1bb20812dad" contextRef="C_636c0850-3f38-4c68-923e-8a9192036aec" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">843,687</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6b81fb8-d4b3-41cb-b31c-c52760eac7a6" contextRef="C_eeb0b484-a788-4f77-8681-695af51358cb" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,612</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34cfc5b8-783d-4e64-9309-afc96aea4107" contextRef="C_eeb0b484-a788-4f77-8681-695af51358cb" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca014da9-08ac-4398-b8c9-0200582664c5" contextRef="C_44ecaf5c-05ec-4fc1-a4b3-34fd3c08ceb5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,430</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8a3e825-6f23-4518-b494-b64449c00735" contextRef="C_37094d88-e7f6-4b83-a8b8-9f256b675b10" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">774</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40d5954e-e40e-4a20-8e8c-2fd042def043" contextRef="C_3a1a5b45-cd15-4c5f-8018-f47ae86a02cb" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">467,509</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4262880a-e6ec-4482-827f-0367acf667bc" contextRef="C_d4c8d898-2127-41b5-99f4-5fed585e8a39" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">446,850</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock upon exercise of stock options</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22ca5209-05b6-444d-bc45-20ea9efa9494" contextRef="C_70fddc6b-c6f5-476e-99bd-8e5dcdebf0ae" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">219</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_452c6966-f064-4fda-b1c0-450d454a488a" contextRef="C_e356d7aa-aadb-4a43-9704-349d4130949f" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">602</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1103069-3f09-438f-b854-817166b5c053" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">602</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repurchase of unvested early exercised stock options</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2bc2b15-e512-4b0e-b852-5bfd46d06326" contextRef="C_70fddc6b-c6f5-476e-99bd-8e5dcdebf0ae" name="nmra:RepurchaseOfUnvestedEarlyExercisedStockOptions" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">123</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vesting of restricted common stock</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3007542e-51f5-42a3-b5c7-818920e7407c" contextRef="C_e356d7aa-aadb-4a43-9704-349d4130949f" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,282</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a159514-9997-4c2c-8fbc-1b5262ce36ae" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,282</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain on marketable debt securities</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23ad09ba-3818-4e41-a660-1dc96a160111" contextRef="C_99673cd6-c93c-488e-a35a-1c624f6dcd54" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">476</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df8c8cb7-3f86-4dcd-91c8-fae87dd53494" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">476</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_322db808-9e7a-463f-b1aa-b3038faad6c7" contextRef="C_e356d7aa-aadb-4a43-9704-349d4130949f" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,195</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f30831fd-0cf6-49a2-8976-b396fe8fa2ce" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,195</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69834a17-b928-43de-a527-6b86f2f19fdb" contextRef="C_70e6e56b-1627-4b50-b58c-c7079cb8e79e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">35,625</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30662a22-28bf-4992-93d6-c4a15ba32e66" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">35,625</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of March 31, 2023</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1defb9b4-6a5f-434e-8dc8-6dfd2c49ca7d" contextRef="C_60ca0d63-6992-4ed9-96cd-ba37575ee0f4" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,417</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3379ebb4-5b0c-42ac-b13b-40992e491f88" contextRef="C_60ca0d63-6992-4ed9-96cd-ba37575ee0f4" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">843,687</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63606504-4f75-4235-ad0f-7acaefc42f92" contextRef="C_8d2f7696-8e65-434a-b57a-0fff8a7da606" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,708</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39fd5025-b4de-401f-9947-2751957368e5" contextRef="C_8d2f7696-8e65-434a-b57a-0fff8a7da606" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39ca3604-d455-4377-b9b9-271c28a78eee" contextRef="C_a41d013c-1391-41b3-90a7-49ba49d11331" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,509</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be7c52ff-c774-4465-8e48-9b3907bae0ad" contextRef="C_997939ff-f371-43ae-8539-1f8d55163ef5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">298</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3598823-e74b-4a8c-948b-96a382ffd438" contextRef="C_118d5793-6b58-4c11-bd9e-24a1b0197692" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">503,134</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b83aab39-8629-44b2-9862-1d9d6fef003a" contextRef="C_908e2fe1-8e96-4b2a-b94e-f5e7dea5b0a3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">477,920</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.403%;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.403%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
   <hr style="page-break-after:always;"/></div>
  <div class="section-group" style="margin:auto;padding-left:0.5in;width:7.5in;padding-right:0.5in;"><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_statements_of_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Condensed Consolidate</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">d Statements of Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(unaudited, in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:66.993%;"/>
     <td style="width:1.58%;"/>
     <td style="width:1%;"/>
     <td style="width:12.923%;"/>
     <td style="width:1%;"/>
     <td style="width:1.58%;"/>
     <td style="width:1%;"/>
     <td style="width:12.923%;"/>
     <td style="width:1%;"/>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Operating activities:</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b8d8157-6b17-4ef8-885b-bd1cb8461a5b" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">53,721</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d78900e-827c-47d3-9ce5-48bdc53191d6" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">35,625</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8536f477-7369-4d14-940e-3fa561c35898" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,373</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ecd94f6-42c6-4ca3-900e-714eae4691b1" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,195</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-cash operating lease expense</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0753ed0-8af9-4734-ae1b-b6bfb4dd92ea" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="nmra:NoncashOperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">791</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d1d9be9-6880-4bc6-80b6-7ab8a0963847" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="nmra:NoncashOperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">799</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9dc34b5a-2b45-4780-98c5-9c28f614f7ec" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">158</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1fff50e-40ca-4d20-9e4b-f99e38231c69" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">158</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net accretion of investments in marketable securities</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f2b6eb4-009a-4e35-be44-ce7ca051c8eb" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:InvestmentIncomeAmortizationOfDiscount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,147</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_468f6e5d-c0a1-49c0-bb1c-572a7d0a166a" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:InvestmentIncomeAmortizationOfDiscount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">892</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other noncash expenses</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4a0e7e3-9d9d-4f7e-aed9-b4c81c3241de" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56005fe1-a850-44f2-b3e3-d4f9fa6a090c" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,351</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ce7d7bc-a881-465e-b3cd-68413e4e12d6" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,858</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4f6f22f-ced8-4329-8653-39158cff2fc5" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,155</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5999b2b5-e8b0-488f-a97a-e34ee2b87a28" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,012</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued liabilities</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45409f82-bc36-461f-8100-4e556a1b4a21" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,113</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40f4d58f-246f-4e89-8214-bb3b55935de6" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">736</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ca3fcd8-a6de-4ff3-8ee6-11999838f0bd" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">802</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5ed4e2f-771b-48c9-9e52-3b4ab7b70ac0" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">801</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed4b1ed6-aa3e-4bf7-99da-fc3b9ead0951" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">42,955</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ca73c43-e6dd-4748-bd06-6e14836cc526" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">33,041</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Investing activities:</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of marketable securities</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab641b2a-a779-477a-b6ac-5414a978adb2" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185,804</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22df7074-ce37-44e3-9648-8ac80c4b19e1" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,483</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from sales and maturities of marketable securities</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_646fd5af-7404-4661-a56c-fdaaf342a5f5" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,578</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62bfe705-3b47-4a4b-bb03-8f22d404fff0" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,336</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of property and equipment</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c25c101-3a5a-4ddd-842a-7907fea3b464" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for acquisition of assets</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_485a51d1-cd9a-4d60-830e-1b82f54a2eab" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">775</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash (used in) provided by investing activities</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_556cf880-71e9-408f-af3e-cee394adf0ed" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">150,001</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0d657aa-d519-4a7b-a4bf-5b962d933ec1" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,817</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financing activities:</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from exercise of stock options</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c5b9193-94da-4287-a318-279de8858497" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,845</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28c857e5-dce6-496c-b798-048121124d45" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">602</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repurchase of unvested early exercised shares</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4f97ea5-791d-40ab-a8dd-f06be0d88367" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="nmra:RepurchaseOfUnvestedEarlyExercisedShares" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">491</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payments for deferred offering costs</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b46de920-9cc2-4067-871b-c809ae0ae5cc" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75dad495-10b2-4d9c-9f05-d30f037ecac9" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,845</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2001704f-e2ef-4d53-8541-ac64cfaed6ac" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">101</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net change in cash and cash equivalents and restricted cash</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae5bd915-4c0c-43eb-9608-61dd4f91d2a0" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">191,111</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_72379e6d-0966-47eb-b384-13a9f13181bd" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">30,123</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents and restricted cash at beginning of year</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1c48687-4127-4862-a133-2bc7327f6e0d" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">375,251</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e12f8d4-c2ce-4626-9caf-7e5bffb49d27" contextRef="C_d4c8d898-2127-41b5-99f4-5fed585e8a39" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">242,206</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents and restricted cash at end of year</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf0346e2-0ad3-4d92-a48d-af35fad43454" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">184,140</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d028eea1-6cc6-4a80-b60c-2f48feb31301" contextRef="C_908e2fe1-8e96-4b2a-b94e-f5e7dea5b0a3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">212,083</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Components of cash and restricted cash:</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_250f4f09-73a9-41c1-944c-93585a42a686" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">182,927</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_321fdae6-25ec-44de-8ff4-e0575f5a865f" contextRef="C_908e2fe1-8e96-4b2a-b94e-f5e7dea5b0a3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">210,870</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66bcafa4-ead2-415c-943e-1a3dbd63559d" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,213</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e484e1ce-9c17-4c57-bec6-f933b6856972" contextRef="C_908e2fe1-8e96-4b2a-b94e-f5e7dea5b0a3" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,213</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash and cash equivalents and restricted cash</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0c579ee-73e8-4241-a0f5-038b83abe583" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:RestrictedCashAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">184,140</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84cd1e55-c16d-46cc-9f1e-2e5394d14d86" contextRef="C_908e2fe1-8e96-4b2a-b94e-f5e7dea5b0a3" name="us-gaap:RestrictedCashAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">212,083</ix:nonFraction></span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4033c9c8-70eb-479e-a153-7983ee423960" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="organization_and_liquidity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.	</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Organization and Liquidity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Description of Business</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Neumora Therapeutics, Inc. (the Company), was originally incorporated in the State of Delaware in November 2019, and is headquartered in Watertown, Massachusetts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. The Company&#8217;s therapeutic pipeline currently consists of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24f09f01-5e4e-48fe-82d3-62aad67495e9" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="nmra:NumberOfClinicalAndPreclinicalNeurosciencePrograms" unitRef="U_Program" decimals="INF" format="ixt-sec:numwordsen">seven</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, the Company has devoted a significant portion of its financial resources and efforts to building its organization, acquiring technologies and companies, executing clinical and preclinical studies, conducting research and development, identifying and developing potential product candidates, building its precision neuroscience tools, organizing and staffing the Company, business planning, establishing, maintaining and protecting its intellectual property portfolio, raising capital and providing general and administrative support for these operations. The Company has not generated revenue from the sale of products.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s most advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of major depressive disorder (MDD) and other neuropsychiatric diseases. In 2023, the Company initiated a Phase 3 program called the KOASTAL program evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company anticipates releasing topline results from the KOASTAL-1 study in the fourth quarter of 2024 and topline results from the KOASTAL-2 and KOASTAL-3 studies in the first half of 2025. We also expect to initiate a Phase 2 study for navacaprant in bipolar depression in the second quarter of 2024 and anticipate releasing results from that study in 2025.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reverse Stock Split</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 8, 2023, the Company&#8217;s board of directors approved an amended and restated certificate of incorporation to effect a reverse split of shares of the Company&#8217;s common stock and convertible preferred stock on a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_94197fa7-7c97-46ab-9f96-0203fbe500ca" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_fc1674b5-31ae-4580-a05a-09485f8e145a;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7.8463</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-for-1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> basis (the &#8220;Reverse Stock Split&#8221;). The par value and authorized shares of the common stock and convertible preferred stock were not adjusted as a result of the Reverse Stock Split. All share data and per share data amounts for all periods presented in the condensed consolidated financial statements and notes thereto have been retrospectively adjusted to reflect the effect of the Reverse Stock Split.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Initial Public Offering</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 19, 2023, the Company completed its initial public offering (IPO), pursuant to which it issued and sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8bcb8e0e-50ec-48ef-832f-5f1a8209bb18" contextRef="C_829340ea-2a8e-4dd9-8fc4-4651e162611a" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">14,710,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock at a price to the public of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_520f903e-8d20-4931-8069-16935da129bb" contextRef="C_77d7002e-e37b-46f4-8b74-d60274250475" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">17.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, resulting in net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b81032f-4b3e-479c-bd90-75f2844f8044" contextRef="C_829340ea-2a8e-4dd9-8fc4-4651e162611a" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">226.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, after deducting underwriting discounts and commissions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65063df7-2c2e-40c9-bf7d-a0c0d7d795d9" contextRef="C_829340ea-2a8e-4dd9-8fc4-4651e162611a" name="nmra:UnderwritingDiscountsAndCommissions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and other offering expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25dfbf81-cecc-4b3d-98d4-ce121a3b9776" contextRef="C_829340ea-2a8e-4dd9-8fc4-4651e162611a" name="nmra:OfferingExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Upon the closing of the IPO, the Company&#8217;s outstanding convertible preferred stock automatically converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2848b012-9a46-4f14-98bb-41f2bba7db9d" contextRef="C_77d7002e-e37b-46f4-8b74-d60274250475" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">104,417,415</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock (see Note 9).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the completion of its IPO, on September 19, 2023, the Company&#8217;s certificate of incorporation was amended and restated to authorize </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4bcfa4d2-ebd5-408f-8d99-827afc081d23" contextRef="C_77d7002e-e37b-46f4-8b74-d60274250475" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">700,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87fb104e-679e-4c67-834b-414e31ab5f19" contextRef="C_77d7002e-e37b-46f4-8b74-d60274250475" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1524b4bb-bc5e-48cd-8ffc-32042ae15bd7" contextRef="C_77d7002e-e37b-46f4-8b74-d60274250475" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">50,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of preferred stock, par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a14428c3-fbfe-410a-b15d-ec9101dc7e22" contextRef="C_77d7002e-e37b-46f4-8b74-d60274250475" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has incurred net losses and negative cash flows from operations since inception and as of March 31, 2024, had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2fefc21-bea7-4829-8ecb-d04895d9fc8e" contextRef="C_d4ca77dd-2b7a-4c72-9d67-3f3c267a7400" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">757.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. As of March 31, 2024, the Company had cash, cash equivalents and marketable securities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24e1e012-2170-4a25-ab77-eda8f495f4c6" contextRef="C_d4ca77dd-2b7a-4c72-9d67-3f3c267a7400" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">423.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which are available to fund future operations. The Company believes that its existing cash, cash equivalents and marketable securities as of March 31, 2024 will be sufficient to support operations for at least the next 12 months from the date these condensed consolidated financial statements are issued.</span></p><ix:exclude><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
      <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company expects to incur additional losses in the future as it continues its research and development efforts, advances its product candidates through preclinical and clinical development, enhances its precision</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">neuroscience approach and programs, expands its product pipeline, seeks regulatory approval, prepares for commercialization, as well as hires additional personnel, protects its intellectual property and grows its business. The Company will need to raise additional capital to support its continuing operations and pursue its long-term business plan, including to complete the development and commercialization of its product candidates, if approved. Such activities are subject to significant risks and uncertainties, including clinical failure which can impact the Company&#8217;s ability to secure additional funding. The Company expects to finance its cash needs through a combination of public or private equity offerings or debt financings or other capital sources, which may include strategic collaborations or other arrangements with third parties, or other sources of financing. However, there is no guarantee that any of these financing or opportunities will be executed or realized on favorable terms, if at all, and some could be dilutive to existing stockholders.</span></p></ix:nonNumeric></div><div style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_09d151a9-5506-483a-85ce-843e7ab043f4" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.	Summary of Significant Accounting Policies and Basis of Presentation</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_26967402-1873-42ae-86cf-ed4d89647c9f" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis of Presentation and Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting. The condensed consolidated financial statements include all accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_54ebbfef-98bb-4f93-8d77-79361f7fd5b0" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="nmra:UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unaudited Interim Condensed Consolidated Financial Statements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The condensed consolidated balance sheet as of March 31, 2024, condensed consolidated statements of operations and comprehensive loss, statement of stockholders&#8217; equity (deficit), and the condensed consolidated statements of cash flows</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the three months ended March 31, 2024 and 2023, and related notes to condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for the fair statement of the Company&#8217;s consolidated financial position, results of operations and cash flows for the periods presented. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2023 included herein was derived from the audited consolidated financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements as of and for the year ended December 31, 2023 included in the Company&#8217;s Annual Form 10-K.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_62247006-92af-4a5f-a2b6-a8b034f2baee" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. These estimates form the basis for judgments the Company makes about the carrying values of assets and liabilities that are not readily apparent from other sources. The Company bases its estimates and judgments on historical experience and on various other assumptions that the Company believes are reasonable under the circumstances. These estimates are based on management&#8217;s knowledge about current events and expectations about actions the Company may undertake in the future. These judgments, estimates and assumptions are used for, but not limited to, accrued research and development expenses, accounting for acquisitions of assets, fair value of certain assets and liabilities, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the fair value of the Company&#8217;s convertible preferred stock, the fair value of the Company&#8217;s common stock,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock-based compensation, the measurement of right-of-use assets and lease liabilities and related incremental borrowing rate, and uncertain tax positions and the valuation allowance for net deferred tax assets. Actual results may differ from the Company&#8217;s estimates.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d40c0aa8-9c99-4c50-b8f2-409c15d78327" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="nmra:RisksAndUncertaintiesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks and Uncertainties</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to certain risks and uncertainties, including, but not limited to, changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: successfully develop, manufacture, and market any approved products; obtain regulatory approval from the U.S. Food and Drug Administration or foreign regulatory agencies prior to commercial sales; new technological innovations; dependence on key personnel, protection of intellectual property; compliance with governmental regulations; uncertainty of market acceptance of any approved products; product liability; and the need to obtain additional financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
      <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b2927095-d22b-4958-b4eb-1ea5673a41e2" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Marketable Securities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company invests its excess cash in marketable debt securities with high credit ratings including but not limited to money market funds, securities issued by the U.S. government and its agencies, commercial paper, certificates of deposit, and corporate debt securities that are accounted for as available-for-sale and carried at fair value. Marketable securities are classified as short-term or long-term based on the maturity date and their availability to meet current operating requirements. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income in the condensed consolidated statements of operations and comprehensive loss. Realized gains and losses on marketable securities, if any, are included in other income (expense), net. The cost of securities sold is determined based on the trade date using the specific identification method.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company periodically assesses its available-for-sale debt securities for impairment. For debt securities in an unrealized loss position, this assessment first considers the Company&#8217;s intent to sell, or whether it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of these criteria are met, the debt security&#8217;s amortized cost basis is written down to fair value within other income (expense), net. For debt securities in an unrealized loss position that do not meet the aforementioned criteria, the Company assesses whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and any adverse conditions specifically related to the security is considered, among other factors. If this assessment indicates that a credit loss may exist, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses will be recorded in other income (expense), net, limited by the amount that the fair value is less than the amortized cost basis. Any additional impairment not recorded through an allowance for credit losses is recognized in other comprehensive income (loss). Changes in the allowance for credit losses are recorded as provision for (or reversal of) credit loss expense. Losses are charged against the allowance when management believes the un-collectability of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met. These changes are recorded in other income (expense), net.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_37bfea6e-e431-4637-a16c-462722440f96" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The Company measures fair value by maximizing the use of observable inputs, where available, and minimizing the use of unobservable inputs when measuring fair value. Financial assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized in the fair value hierarchy based upon the lowest level of input that is significant to the fair value as follows:</span></p><p style="margin-left:36pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></p><p style="margin-left:36pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2&#8212;Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></p><p style="margin-left:36pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value of the instrument.</span></p></ix:nonNumeric></div><div style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_18da1644-1bb9-4ad4-8afc-d529e64dfab2" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and Development Expenses and Related Prepaid Assets and Accrued Liabilities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development expenses primarily consist of internal research and development expense, including personnel-related expenses (such as salaries, benefits and noncash stock-based compensation) and other expenses, including laboratory supplies and other non-capital equipment utilized for in-house research, research and consulting expenses, software development costs, license fees and allocated expenses, including facilities costs and depreciation and amortization; external research and development expenses incurred under arrangements with vendors conducting research and development services on its behalf, such as contract research organizations (CROs), preclinical testing organizations and contract manufacturing organizations (CMOs). Costs to develop the Company&#8217;s platform information technologies are recorded as research and development expense unless the criteria to be capitalized as internal-use software costs is met. Payments made prior to the receipt of goods or services to be used in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
        <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">research and development are capitalized, evaluated for current or long-term classification, and included in prepaid expenses and other current assets or other assets in the condensed consolidated balance sheets based on when the goods are received or the services are expected to be received or consumed, and recognized in research and development expenses when they are realized.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is required to estimate expenses resulting from its obligations under contracts with vendors, service providers and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in cash flows that do not match the periods over which materials or services are provided. The Company estimates and records accrued expenses for the related research and development activities based on the level of services performed but not yet invoiced pursuant to agreements established with its service providers, according to the progress of preclinical studies, clinical trials or related activities, and discussions with applicable personnel and service providers as to the progress or state of consummation of goods and services.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the course of a clinical trial, the rate of expense recognition is adjusted if actual results differ from the Company&#8217;s estimates. The Company estimates accrued expenses as of each balance sheet date in its condensed consolidated financial statements based on the facts and circumstances known at that time. The clinical trial accrual is dependent in part upon the timely and accurate reporting of CROs, CMOs and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its estimate may vary from the actual results. To date, the Company has not experienced material differences between its accrued expenses and actual expenses.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_30b33607-7187-4d3f-8f7c-9cdc7260f148" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss includes net loss and certain changes in stockholders&#8217; equity (deficit) that are excluded from net loss, such as unrealized losses on the Company&#8217;s available-for-sale marketable securities.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9f7a4454-b60d-4999-b5e8-99f85781e62f" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="nmra:EmergingGrowthCompanyStatusPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging Growth Company Status</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_141c308f-03bc-40fa-9d35-d47e00dca518" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent Accounting Pronouncements Not Yet Adopted</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(ASU 2023-09), which requires issuers to make additional discloses on an annual basis related to specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis, disclose additional information about income taxes paid as well as other disaggregated disclosures. ASU 2023-09 will be effective for the Company as of January 1, 2025 for annual periods. The Company is evaluating the impact of this ASU on its condensed consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (ASU 2023-07), which requires issuers to make additional disclosures with respect to segment expenses, including required disclosure on an annual and interim basis for significant segment expenses and other segment items. ASU 2023-07 also permits the disclosure of more than one measure of a segment&#8217;s profit or loss. ASU 2023-07 will be effective for the Company as of January 1, 2024 for annual periods and as of January 1, 2025 for interim periods. The Company is evaluating the impact of this ASU on its condensed consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_67aad6d9-c710-4860-9093-b8abafb426b9" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" escape="true"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.	Cash Equivalents and Marketable Securities</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a3da43b8-a942-4174-8b3c-2c570b2e3270" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables summarize the amortized cost and fair value of the Company&#8217;s cash equivalents and marketable securities by major investment category for the periods indicated:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.38%;"/>
         <td style="width:1.22%;"/>
         <td style="width:1%;"/>
         <td style="width:9.184000000000001%;"/>
         <td style="width:1%;"/>
         <td style="width:1.22%;"/>
         <td style="width:1%;"/>
         <td style="width:9.184000000000001%;"/>
         <td style="width:1%;"/>
         <td style="width:1.22%;"/>
         <td style="width:1%;"/>
         <td style="width:9.184000000000001%;"/>
         <td style="width:1%;"/>
         <td style="width:1.22%;"/>
         <td style="width:1%;"/>
         <td style="width:9.184000000000001%;"/>
         <td style="width:1%;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gain</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Loss</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78d3fa5f-248e-4b2b-8afe-3637a31fba85" contextRef="C_1c718a38-50b6-430d-81b1-4a6d12e7d922" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,817</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3a4d071-d1c6-4a01-9745-9f6179002774" contextRef="C_c58e805b-70de-4471-9304-e335b5edcd5f" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a77a754-d1b6-41a3-8e93-33077c784a5f" contextRef="C_c58e805b-70de-4471-9304-e335b5edcd5f" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ae9deea-2d2c-44f0-8ce3-668dfa150054" contextRef="C_1c718a38-50b6-430d-81b1-4a6d12e7d922" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,817</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6b199f0-9479-4ef3-bd42-eb7318f43206" contextRef="C_59764801-e98b-441b-813d-c795a4f77342" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,817</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a617533b-7ab0-4f96-8c63-59ed72f8ad2b" contextRef="C_b7650c04-d7d2-470d-8cdd-f4a7c34c3ee7" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a23cedf-04bf-4811-9852-9ecca9f1c3d5" contextRef="C_b7650c04-d7d2-470d-8cdd-f4a7c34c3ee7" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_614d7a5d-729e-48f4-9739-51c4b20fd903" contextRef="C_59764801-e98b-441b-813d-c795a4f77342" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,817</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_749ab38d-7f82-4bb1-a43f-665d75d13d11" contextRef="C_9622b93d-0fee-4c35-979b-ac055cc9685e" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,612</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55824032-4593-4f7a-b929-7de2ebc8ae31" contextRef="C_f302022e-1a9e-474c-a0c7-dc6743de3517" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d60e3630-9ce7-40b5-8a6d-b3ff632ebd14" contextRef="C_f302022e-1a9e-474c-a0c7-dc6743de3517" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16fc30a1-c252-4ea0-888a-7c960daec083" contextRef="C_9622b93d-0fee-4c35-979b-ac055cc9685e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,577</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificates of deposit</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23b3cdb9-634d-4ca2-8960-fd697a4438c5" contextRef="C_6605667a-124d-429a-9742-9590d104c8b0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,669</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0779944b-474c-438d-ab5b-f89f60655c92" contextRef="C_3d8423cb-a654-4705-bc38-351fdb1ead9c" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64ccafdf-922c-4449-83ff-2537a833e735" contextRef="C_3d8423cb-a654-4705-bc38-351fdb1ead9c" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_936866e0-9ae5-4d2d-b221-2e64e1479240" contextRef="C_8d605d37-23c6-4f30-8d3a-a3a25b1de12d" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,671</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency debt securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbb6b17b-d7ea-4b55-8f74-c45325d0713a" contextRef="C_c27ac2f8-7a27-4804-87d3-3bbc8e87144e" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">122,660</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc34eecf-2cd6-4a74-80c5-b473eb29577c" contextRef="C_6715b955-aac8-4773-8111-47fd843a4a8d" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03160122-cb85-46d0-bc6c-78b66d1709bb" contextRef="C_6715b955-aac8-4773-8111-47fd843a4a8d" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2267f6cf-fd8e-414e-84d0-f4c55dcf1962" contextRef="C_3c40c0b1-14e6-4ada-8bd6-1d23c649c6ce" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">122,552</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e974460a-65de-4bb9-84f0-2515adc1771f" contextRef="C_934561fc-3ca0-4e9c-afc9-cab561a511ca" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,297</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43fa5ce7-6ffd-4024-a583-c3ab67104162" contextRef="C_adde3b8d-d812-4a53-b229-03202c183eb7" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0168580-24f1-4825-8ad6-a9e6d8c67a3f" contextRef="C_adde3b8d-d812-4a53-b229-03202c183eb7" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6111472d-ba13-45a4-b298-f36a4589851e" contextRef="C_934561fc-3ca0-4e9c-afc9-cab561a511ca" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,290</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total marketable securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24cfe10d-77f4-4bdb-9e30-390005bc30a1" contextRef="C_c407007a-f71b-4362-a5e7-9ede4f3ae224" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">240,238</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d4a5531-a0fc-4a09-9e8e-5d4328505c17" contextRef="C_3d2b19e7-2597-4087-9ada-8de5a4121c58" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e4bb367-289c-40d7-aa57-b0df883de556" contextRef="C_3d2b19e7-2597-4087-9ada-8de5a4121c58" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">157</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b69614b-50a9-4f5e-91fb-9c6f2907536b" contextRef="C_c407007a-f71b-4362-a5e7-9ede4f3ae224" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">240,090</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents and marketable securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4eb21b69-e87b-425d-b912-4f3ef99cc3a8" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">383,055</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7d4290c-3cb5-4da4-a577-77899ca23427" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_579d45c5-ec46-4758-8fd9-9456ddcc14ad" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">157</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_519508d5-8025-4a69-93cd-3c8f72563bfb" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">382,907</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.38%;"/>
         <td style="width:1.22%;"/>
         <td style="width:1%;"/>
         <td style="width:9.184000000000001%;"/>
         <td style="width:1%;"/>
         <td style="width:1.22%;"/>
         <td style="width:1%;"/>
         <td style="width:9.184000000000001%;"/>
         <td style="width:1%;"/>
         <td style="width:1.22%;"/>
         <td style="width:1%;"/>
         <td style="width:9.184000000000001%;"/>
         <td style="width:1%;"/>
         <td style="width:1.22%;"/>
         <td style="width:1%;"/>
         <td style="width:9.184000000000001%;"/>
         <td style="width:1%;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gain</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Loss</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3877e6c3-6ac3-4b33-a587-95738d4ae2ba" contextRef="C_9a190bc1-8994-483b-9102-8e2f78b28bc1" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">306,801</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3957ff51-89c4-4e67-bf05-be86938e6125" contextRef="C_8cc2fb07-49d2-42cc-96c7-07529ebadb72" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2839391b-dd99-4dbc-b78c-080f64eb45eb" contextRef="C_8cc2fb07-49d2-42cc-96c7-07529ebadb72" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f51b53fc-c80b-46ef-b0cf-510df8646f42" contextRef="C_9a190bc1-8994-483b-9102-8e2f78b28bc1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">306,801</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb1f34d0-e942-4bde-92da-76bf6f7041e5" contextRef="C_7f5ac940-84de-48e5-ae64-41ee00fc2d79" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,455</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_957973fc-7734-4a05-ae06-5def7069023d" contextRef="C_77cfdb28-9e47-4558-b8db-21bed2f9143f" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a129ef68-d6f8-4176-916d-5af73710b83f" contextRef="C_77cfdb28-9e47-4558-b8db-21bed2f9143f" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_940f539e-339f-4866-9f84-e680222732d0" contextRef="C_7f5ac940-84de-48e5-ae64-41ee00fc2d79" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,461</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency debt securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b41110eb-d372-4752-97bf-9f18d90f0023" contextRef="C_31d52667-94b6-48d2-b574-45d574a0f09b" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,998</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d56f8446-afb2-42cb-b133-b6eef653fc4b" contextRef="C_d06cc3be-3868-4b27-8b88-efa3b16b4417" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7fcbb90-c6a3-453e-8a2c-898fdc3c0e1e" contextRef="C_d06cc3be-3868-4b27-8b88-efa3b16b4417" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41dce103-af42-4946-8f3a-84f32d89d364" contextRef="C_31d52667-94b6-48d2-b574-45d574a0f09b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,992</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1572640d-c406-4b6f-97f6-0f61b9a1ceb5" contextRef="C_555b90da-9109-4cae-936b-dac6310ce148" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">362,254</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e0bde1d-c4da-486b-ae34-03e93f775b7f" contextRef="C_d17d3110-5d3b-4f67-a03a-3459f5097a7e" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54500337-e522-4d21-aef0-fd0351e66628" contextRef="C_d17d3110-5d3b-4f67-a03a-3459f5097a7e" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a108abe-49a0-4d8e-8d8b-2f0dfc0d1d96" contextRef="C_555b90da-9109-4cae-936b-dac6310ce148" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">362,254</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6fac3f3-b962-4a1d-9d2e-e36aefe58601" contextRef="C_8cd94762-0e2e-45f6-a01e-01085a86a854" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,534</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_599f7adf-f1be-4ca3-8680-376035dd3e3f" contextRef="C_0caaf123-e9b7-419b-a654-8ce6c344421a" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bee8de1c-ce3a-4d43-ac92-f1e11746f3b5" contextRef="C_0caaf123-e9b7-419b-a654-8ce6c344421a" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4eeb2ea-641c-436f-8e1d-11ce79848276" contextRef="C_8cd94762-0e2e-45f6-a01e-01085a86a854" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,547</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency debt securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9d24d97-cd6b-4a15-b966-b5b7ee20a594" contextRef="C_55f7cf54-c65c-4834-922b-fada916481b2" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,515</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6c040f4-aecb-438b-becb-d977dcffb8c4" contextRef="C_fddb666c-28f9-47a3-90ab-b07ceb2c7598" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_978cedc5-a76e-488c-aad3-82ad648eec38" contextRef="C_fddb666c-28f9-47a3-90ab-b07ceb2c7598" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5758799-ea11-441d-aadf-5713918ffb01" contextRef="C_55f7cf54-c65c-4834-922b-fada916481b2" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,424</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17fceeeb-f345-481d-984e-f9f39bb344f2" contextRef="C_ba5b5e93-9d73-4a23-8fdd-272f7a933478" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,816</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_acc2f2a4-f585-4056-841c-b7487c90a498" contextRef="C_29326ae4-2f07-4dd9-ac50-8fbdc7b576a5" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_845e92a9-f467-4778-9b71-2a7152538391" contextRef="C_29326ae4-2f07-4dd9-ac50-8fbdc7b576a5" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0572eccc-a19e-4b52-8d08-325cb4bd5272" contextRef="C_ba5b5e93-9d73-4a23-8fdd-272f7a933478" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,818</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total marketable securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e824736e-0681-44f5-aa6b-ece99acd0afc" contextRef="C_e5c437fa-ca9f-4a34-a6dd-cd8d4e53f5bd" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,865</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80db1c40-80d6-4a30-8429-bc3cb7123984" contextRef="C_251ee5d8-0c7f-4f9d-a0ce-8c700c53c157" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc2ec614-6ac9-4714-bf8d-25fffdf95505" contextRef="C_251ee5d8-0c7f-4f9d-a0ce-8c700c53c157" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3850837a-afc4-4825-b895-2add85055e7e" contextRef="C_e5c437fa-ca9f-4a34-a6dd-cd8d4e53f5bd" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,789</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents and marketable securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98f92f57-5d9a-44ea-be63-5c5131e5b81e" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">452,119</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf762d0e-3db1-48c8-b472-50724c7f61e5" contextRef="C_3929f877-fd38-4a94-9e5b-54676a4e9e57" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f720018c-bf4b-4b1c-a884-a4bc5124a56d" contextRef="C_3929f877-fd38-4a94-9e5b-54676a4e9e57" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4c70aaa-bc60-4f6f-8726-3619297cd8e6" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">452,043</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_437c2099-824a-4b8b-928c-9f9abb10ef75" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s marketable securities by contractual maturity were (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:76.28%;"/>
         <td style="width:2%;"/>
         <td style="width:1%;"/>
         <td style="width:19.72%;"/>
         <td style="width:1%;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Within one year</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c68e5f9-2e37-425b-9abf-4dcd968b5b71" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">239,788</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">After one year through two years</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_adcd52cb-fe42-4ea6-ae21-45c03ec434f8" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="nmra:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">302</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total marketable securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5aa9c6c6-e114-49b9-8721-9c5de78b5316" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="nmra:EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">240,090</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, the Company has not realized any material gains or losses on its marketable securities, including any impairment charges on its securities related to expected credit losses. As of March 31, 2024, the aggregate difference between the amortized cost and fair value of each security in an unrealized loss position was de minimis. Since any provision for expected credit losses for a security held is limited to the amount the fair value is less than its amortized cost, no allowance for expected credit loss was deemed necessary at March 31, 2024 (see Note 4).</span></p></ix:nonNumeric></div><div style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ab5a781c-1033-4858-ab93-802cd3c40d6c" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" escape="true"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4.	Fair Value Measurements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The carrying amounts of the Company&#8217;s financial instruments, including prepaid expenses and other current assets, accounts payable, accrued liabilities and the current portion of operating lease liabilities approximate fair value due to the short-term nature of those instruments.</span></p><ix:exclude><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
      <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d298a54d-315f-48de-903d-80f2bda8d1ba" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables summarize the Company&#8217;s assets and liabilities measured at fair value on a recurring basis by level within the valuation hierarchy:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.38%;"/>
         <td style="width:1.22%;"/>
         <td style="width:1%;"/>
         <td style="width:9.184000000000001%;"/>
         <td style="width:1%;"/>
         <td style="width:1.22%;"/>
         <td style="width:1%;"/>
         <td style="width:9.184000000000001%;"/>
         <td style="width:1%;"/>
         <td style="width:1.22%;"/>
         <td style="width:1%;"/>
         <td style="width:9.184000000000001%;"/>
         <td style="width:1%;"/>
         <td style="width:1.22%;"/>
         <td style="width:1%;"/>
         <td style="width:9.184000000000001%;"/>
         <td style="width:1%;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad122b7b-374c-4778-a23e-cca858586d4c" contextRef="C_e34b0512-dfda-4a27-98ed-cf663dd4f181" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,817</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a556276e-932b-4905-8a49-65c41463a8d2" contextRef="C_20c204e8-32e7-4a99-afcf-776f05f42ab0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4815f321-bcd6-4910-8c59-cfbbb73d1e21" contextRef="C_aa35f881-a2e4-44a8-bf69-7086dc821033" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e370c6c0-41cd-4566-afe4-6b0826538ec9" contextRef="C_e25bb6fd-163c-4c2e-a895-464771d27c28" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,817</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_faff5f3e-c59a-463c-b4e3-9c3fff28b477" contextRef="C_525f8d27-e52b-4d90-aae6-72f3a411fae6" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c86ec78-ba7a-43b7-a14f-56d1f09f067b" contextRef="C_33dd1233-920e-4439-a019-1de4439f0bdd" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,577</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_430896fb-b3d6-40f7-a7f2-ea5e4417ef80" contextRef="C_0cee2f31-d69c-4bb4-80be-9b786c85fd34" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3c41ff7-3086-432b-b402-6b91686940c4" contextRef="C_5ae90723-14e8-439e-81a2-861cd015a4de" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,577</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificates of deposit</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee797dd1-1ae7-4a4d-bad9-456805e710c2" contextRef="C_a613c3d9-8372-4ff1-9b67-609500a6441a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd03764b-9187-4af8-9c90-ffe1c6f6c61e" contextRef="C_7ee2b185-99f7-4bd5-9ca0-f9d76e4edb87" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,671</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a66b7b2b-9b05-49df-9d1f-791595d6b93a" contextRef="C_0cee2f31-d69c-4bb4-80be-9b786c85fd34" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_edc65077-5aea-4207-b683-87137bcfb1b6" contextRef="C_43bd04fb-3740-4cf7-b83c-a9a404955351" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,671</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency debt securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_faa42cfe-cfa9-498e-b195-52a214c9d899" contextRef="C_22d38837-90bd-43aa-9c93-8f13f37f99e1" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">115,062</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c34d7c3f-e3bf-4343-a813-bed92c2a8784" contextRef="C_2a31bc5a-9b88-4b0c-a97e-5b7a3ab157b0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,490</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55c2f5ad-39cb-4e8c-a3ee-eca7aa5362cc" contextRef="C_2113c554-0c81-4a7b-979d-5577fd8f2940" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7ec89af-390b-4eae-80df-3a3aabab5238" contextRef="C_e8193643-0d56-40a9-b0e8-aa7a9093b9b1" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">122,552</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9eb4fdf0-7b88-4f44-8126-d30596e18200" contextRef="C_63ea549e-a21c-49a4-aa4c-6bb788b17014" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2b724e5-65b2-4c9d-8fe2-5388ed40681a" contextRef="C_dff92dc7-7e5a-4082-a3f9-80aea9d28b77" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,290</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e58e139-7b9b-469e-a18d-28d63d352628" contextRef="C_1b53b7d9-62ee-44e4-a34f-0d741a2336fd" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d0a1c70-8e8a-4282-bf59-48967ad8f7c7" contextRef="C_d5bbb135-9ec5-40dc-99e5-5f2b31f645d2" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,290</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at fair value</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef47d2e7-3f28-4477-b449-bd2695250319" contextRef="C_51f3d1d1-4794-40b6-9e06-602baca00e1a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">257,879</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd8579ca-3582-4fe6-a84f-b903ccd9cbd9" contextRef="C_77c53b90-3f1c-4948-9874-3efee2daaf4c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125,028</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_540c1f51-6f50-41cd-9418-6fb5b1d7b5c8" contextRef="C_bcf2dda4-ea5e-486c-b486-680ccab2876c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90a2623a-8d05-4967-b7c8-b3b130890eee" contextRef="C_5ea749b2-350e-4a76-be5d-6ec287b9f397" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">382,907</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.38%;"/>
         <td style="width:1.22%;"/>
         <td style="width:1%;"/>
         <td style="width:9.184000000000001%;"/>
         <td style="width:1%;"/>
         <td style="width:1.22%;"/>
         <td style="width:1%;"/>
         <td style="width:9.184000000000001%;"/>
         <td style="width:1%;"/>
         <td style="width:1.22%;"/>
         <td style="width:1%;"/>
         <td style="width:9.184000000000001%;"/>
         <td style="width:1%;"/>
         <td style="width:1.22%;"/>
         <td style="width:1%;"/>
         <td style="width:9.184000000000001%;"/>
         <td style="width:1%;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9f00b14-200f-407c-89df-15a4265a2a34" contextRef="C_739e5e64-0cd3-46ad-bc1c-ca25045bf637" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">306,801</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f41ee61e-1724-4b87-a1a1-bef2d8b88f6e" contextRef="C_7192706f-bc17-41ba-8cf3-0a9e6b1ad84d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bbbb6aa3-f3a0-4c2c-aa52-db71381e0c3a" contextRef="C_a19bca81-450f-43b2-9071-1243ab1b452a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74cb1bfd-9285-411e-8858-cbe36fc3deee" contextRef="C_07471f87-b4eb-4e19-b637-f10364df9c08" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">306,801</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85e1b017-25a1-4415-a416-16c6b082f432" contextRef="C_9b39dc12-964c-4b06-983f-1dd2a2960d34" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a1a9fc5-e2ed-4127-8ad2-cb8531c09d1e" contextRef="C_39142c7c-f586-4ac5-b162-38a428111720" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90,008</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09e304dc-6fc3-4d84-90ae-3585462e03dc" contextRef="C_1f06d786-a166-4605-9c3f-8826e794ff47" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0b3a536-1148-4a7c-8897-048c14b4e91d" contextRef="C_a90b5a54-f1c7-43a2-a245-7aab2d94f07b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90,008</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency debt securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3a6aeb3-cca2-4e05-9164-3746f0cbf4a8" contextRef="C_18f69ced-ee72-4bc6-9740-8d6abfc2c287" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,473</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64e1eabf-5206-483b-9db0-57ce1dd6ed0b" contextRef="C_5e8a8262-f68c-4d54-b803-90f9002df20b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,943</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3099e979-bb4e-4ca8-b3bc-0ccde3e619cd" contextRef="C_02b50e0e-46e6-4a57-acee-f328831ee84b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3beaa0a-ddba-4e03-8f36-7a75011ea284" contextRef="C_79158f11-43a3-45ef-a4fa-baf694b1a1dd" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,416</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b710e4f-7669-49b2-92c1-480006a7a7c4" contextRef="C_a69bb320-f60a-431d-9ea6-2f940a271bbb" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6392449-069e-4eff-bac9-f2222840d55a" contextRef="C_61fc95eb-f3e2-41fe-a985-6942d28b52ef" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,818</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b33a4b0-341c-4a61-8314-b4e8dcf87235" contextRef="C_08d37b25-304c-48fb-acac-c44b7eb4f93d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6cc365d-97a3-478b-a1e0-0b21f23c21ec" contextRef="C_c0384758-481a-481e-9efc-b953da92377b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,818</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at fair value</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_088155c3-08bf-4895-816d-264930bec9e5" contextRef="C_03e46424-d2af-4dcd-b68b-3725a6f17401" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">326,274</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73a9181a-3854-4d71-965c-51c735e969d0" contextRef="C_d7ebe7a9-9b3e-43ca-b7d5-0155ac61a792" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125,769</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9604817-f66f-427c-9e33-fb71abd7dadc" contextRef="C_eccfdb09-aec6-4147-bb3a-627442594df7" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_582bb91f-e507-4c12-aaa4-0517f8d28d61" contextRef="C_0fd1591b-b097-48b9-96e0-c77fef141b7f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">452,043</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds are highly liquid and actively traded marketable securities that generally transact at a stable $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4b1dc26-1e45-4004-8aa1-c2b67e43a447" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:NetAssetValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> net asset value representing its estimated fair value. The Company estimates the fair value of its commercial paper, certificates of deposit, U.S. government and agency debt securities, and corporate debt securities by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data, and other observable inputs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9d55c613-7b54-42bb-a37a-6def7091311b" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" escape="true"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5.	Balance Sheet Components</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_24c4e62d-80c5-4550-bcb6-cc96473d5afc" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid Expenses and Other Current Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:60.692%;"/>
         <td style="width:1.2%;"/>
         <td style="width:1%;"/>
         <td style="width:15.603%;"/>
         <td style="width:1%;"/>
         <td style="width:1.7%;"/>
         <td style="width:1%;"/>
         <td style="width:16.802999999999997%;"/>
         <td style="width:1%;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31,</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid research and development costs ($</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0da3cd0d-f91e-420b-9600-c31dbb454977" contextRef="C_7da00584-584d-4a38-a226-8df0e7c5789c" name="nmra:PrepaidResearchAndDevelopmentCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;million and $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d95b9b56-7066-41a4-8c90-b3ba542c7a09" contextRef="C_b7c53efd-2f73-4e8f-aeaf-4c1bb51e739b" name="nmra:PrepaidResearchAndDevelopmentCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><br/>&#160;&#160;&#160;&#160;million from related party in 2024 and 2023, respectively)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe62a08d-2cb2-49d7-b6fe-06d54ac4bf27" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="nmra:PrepaidResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,603</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53bce9b3-2e8a-45e4-a23f-70a88d165e3c" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="nmra:PrepaidResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,085</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid other</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_abb50c77-9e73-43af-9585-55af4d8b004a" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:OtherPrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,561</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7ff0bed-c6ad-4365-b32c-d55265241f2f" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:OtherPrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,273</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other receivables</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2d6acc2-30c0-4e40-bbdc-9a55f9559828" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:OtherReceivablesNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">906</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ab02bfc-32c5-4fbf-ba79-f81473b18757" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:OtherReceivablesNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">939</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4aad6850-9d44-4d92-8be2-24ff710eec50" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,070</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67dbae1a-3971-44eb-a827-3c848e8821f6" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,297</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
        <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8972c27c-5d66-44fa-ad0a-4513f9014bbb" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued Liabilities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued liabilities consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:63.473%;"/>
         <td style="width:1.86%;"/>
         <td style="width:1%;"/>
         <td style="width:13.943%;"/>
         <td style="width:1%;"/>
         <td style="width:1.7%;"/>
         <td style="width:1%;"/>
         <td style="width:15.023%;"/>
         <td style="width:1%;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31,</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Compensation and benefits</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dfe9241c-04ef-419f-ae7c-9f14751cea48" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,660</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebbdc20c-b9c5-4b6c-bb83-05941acd0c36" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,011</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued research and development services ($</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f20196c-56a6-40ab-9fdb-487fc02976f2" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="nmra:AccruedResearchAndDevelopmentServicesDueToRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;million and $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24545204-e59c-4996-a6bf-870575f062c7" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="nmra:AccruedResearchAndDevelopmentServicesDueToRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;<br/>&#160;&#160;&#160;&#160;&#160;million due to related party in 2024 and 2023, respectively)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3780bce-476b-4093-92f8-2e3d59a0d5ba" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="nmra:AccruedResearchAndDevelopmentServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,442</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_493b20ce-a0df-479b-a792-9744b6c06f9c" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="nmra:AccruedResearchAndDevelopmentServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,004</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional services</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e53c8f7-3e41-4109-bc3d-44f3c102098a" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">926</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea5ae909-f3b5-419f-b1fb-50231a24ae4f" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">787</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued clinical trial and preclinical costs</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d4a5e92-6b5b-4999-abc6-59b145b0ef0a" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="nmra:AccruedClinicalTrialAndPreclinicalCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,923</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e6552ec-f90b-4a57-acf1-0b1486db2616" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="nmra:AccruedClinicalTrialAndPreclinicalCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,705</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96f9b162-5511-484c-9912-56e790cf5575" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">542</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1eb44274-759f-4d7b-bd19-18b810e83a39" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">750</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued liabilities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2f0d2ab-b193-43ee-b8c7-b94bcd0fd3ab" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,493</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d74997d-26ad-40ce-92af-799053dfc355" contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,257</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f8f7658b-5477-49db-bb4a-cd3e79ad295d" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:BusinessCombinationDisclosureTextBlock" escape="true"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6.	Acquisitions of Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BlackThorn Therapeutics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2020, the Company entered into an agreement and plan of merger (BlackThorn Merger Agreement) to acquire all of the equity interests of BlackThorn Therapeutics, Inc. (BlackThorn), which became effective in September 2020. The Company acquired BlackThorn for its in-process research and development programs, including an antagonist of the kappa opioid veceptor (navacaprant (NMRA-140)) for the treatment of major depressive disorders and an antagonist of the vasopressin 1a veceptor (NMRA-511) for the treatment of agitation in Alzheimer's disease. The Company also gained access to a cloud-based computational psychiatry and data platform that was being developed to support drug target identification, patient stratification and objective clinical trial endpoints. Both navacaprant and NMRA-511 were exclusively licensed to BlackThorn by The Scripps Research Institute (TSRI). The acquisition was accounted for as an acquisition of assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The BlackThorn Merger Agreement requires the Company to pay the former stockholders of BlackThorn contingent consideration (i) with respect to navacaprant, in the form of development and regulatory approval milestones of up to an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29491aa1-9fa0-416f-9e8b-7b15ae77b63e" contextRef="C_9e7d5678-cc71-4b15-86ec-dc798d97ec7a" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">365.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which includes a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9e10a45f-02f1-4a33-88b7-f54426cb0661" contextRef="C_f813a615-5ec3-4225-add3-4edef1f0b0da" name="nmra:MilestonePaymentDueDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">milestone payment that became due in October 2023 upon dosing the first patient in the Phase 3 clinical trial for navacaprant,</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and sales-based milestones of up to an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9350c617-c7d6-40b3-a82b-ad8b76820581" contextRef="C_14e89b9f-b5c9-4179-91f4-e162088b136c" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">450.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and (ii) with respect to NMRA-511, in the form of development and regulatory approval milestones of up to an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7949898a-e7c3-4d84-a109-e9f2c1a6ccbc" contextRef="C_c7dcb4ff-f9ea-4129-bb6e-4ce2d5a96a56" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and sales-based milestones of up to an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c98c338-56bb-497d-90db-a11a48069579" contextRef="C_c04ac888-4277-45d9-a4b1-48542ea0cbd2" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (BlackThorn Milestones). At the Company&#8217;s sole discretion, the BlackThorn Milestone payments may be settled in cash or shares of the Company, or a combination of both, subject to the provisions of the BlackThorn Merger Agreement, other than one development milestone in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42a585a4-0f8d-4fb2-b818-457f05891775" contextRef="C_f4c941c3-9b74-4cf3-bf81-e52a1de6cb41" name="nmra:ContingentConsiderationMilestonePaymentSettledInCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which must be settled in cash. None of the BlackThorn Milestones were subject to liability classification and/or derivative accounting and any such contingent consideration will be recognized when the contingency is resolved, and the consideration becomes payable. The Company settled the Phase 3 navacaprant dosing milestone in December 2023 by issuing </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58e4835c-72b6-4e14-aee6-740900412661" contextRef="C_43d25bda-98a9-43db-9b57-e1c5583f0e82" name="nmra:SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,072,445</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock based on the volume weighted average price per share prior to the date the milestone was met and paying cash of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5da03ea-067f-4d36-a954-557d0e0cd635" contextRef="C_2ea68049-f744-4490-8038-a161b824989a" name="us-gaap:PaymentsToAcquireBusinessesGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to the former stockholders of BlackThorn and participants in the carveout plan (discussed </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">below). As a result, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e355293-e563-4ffd-96b5-1fd221149ffd" contextRef="C_ba11dd75-605e-4c4e-9798-9cc2968450e3" name="nmra:AcquiredInProcessResearchAndDevelopedExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">60.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in acquired in-process research and developed expenses in the fourth quarter of 2023 related to the BlackThorn Milestones. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_588a6283-da7b-48bf-8dc6-5444505365d4" contextRef="C_ec34d5ee-6cf7-4a70-a875-58e1015081f3" name="nmra:NumberOfMilestoneAchieved" unitRef="U_Milestones" decimals="INF" format="ixt:fixed-zero">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ne of the other Blackthorn Milestones have been achieved and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c0510b3-5b49-46c0-b49d-78cdeed9066e" contextRef="C_b52dabe9-8de8-4682-9783-5765240d1d61" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> such amounts were deemed due or payable as of March 31, 2024.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">BlackThorn Carveout Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The BlackThorn Merger Agreement required that the Company establish a carveout plan (the BlackThorn Carveout Plan), pursuant to which each BlackThorn stock option holder as of immediately prior to the closing date was allocated a certain number of units (the BlackThorn Carveout Units) based on the number of shares underlying the outstanding options held by each participant at that time. Each BlackThorn Carveout Unit represents a right to receive a portion of the BlackThorn Milestone payment (the BlackThorn Carveout Payments) upon the later of (i) the achievement of a BlackThorn Milestone and (ii) the vesting of the BlackThorn Carveout Unit.</span></p><ix:exclude><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
      <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The BlackThorn Carveout Units vest based on time-based schedules that mirror the vesting schedules for the original option awards held by each participant. As of the closing date in September 2020, a portion of the BlackThorn Carveout Units corresponding to the pre-acquisition service periods were fully vested (Vested Carveout Units). The remainder of the BlackThorn Carveout Units vest subject to the continued service of the participants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Vested Carveout Units represent contingent consideration for the acquisition as they are attributable to pre-acquisition services rendered by the participants and continuing service is not required for the participants to receive future payments upon a BlackThorn Milestone being achieved. The Company recognizes the contingent consideration obligation for the Vested Carveout Units when the contingency is resolved, and the consideration becomes payable. The BlackThorn Carveout Units that were unvested as of the closing date are dependent on the continued service of participants and were deemed to be a compensation arrangement. The Company recognizes compensation starting from the time payment becomes probable over each participant&#8217;s service period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company settled the Phase 3 navacaprant dosing milestone in December 2023. The Company recognized contingent consideration related to Vested Carveout Units, which was included in acquired in-process research and developed expenses in the fourth quarter of 2023 related to the BlackThorn Milestones as described above. In addition, the Company recognized and paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7252b5c9-5342-499d-b6cd-5282124c4470" contextRef="C_b9e1e62e-8665-4095-88dc-e415a74bf039" name="us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in compensation related to the BlackThorn Carveout Units that were a compensatory arrangement in 2023. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_690a9b1a-d9dc-4082-b6f6-0a47d5291855" contextRef="C_52904f82-0764-43ac-8bcb-0b6094dd317b" name="nmra:NumberOfMilestoneAchieved" unitRef="U_Milestones" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ne of the other BlackThorn Milestones had been achieved and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_236fe411-4e05-4702-9fb9-c3a85941fb3a" contextRef="C_a5ae6113-d278-4442-b891-5cdcd2698c04" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> such amounts were deemed due or payable as of March 31, 2024.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Syllable Life Sciences, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2020, the</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company entered into an agreement and plan of merger (Syllable Merger Agreement) to acquire all of the outstanding equity of Syllable Life Sciences, Inc. (Syllable). The Company acquired Syllable to gain access the rights granted to Syllable under an exclusive license agreement (as amended, the Harvard License Agreement) with President and Fellows of Harvard College (Harvard) and an associated behavior analysis machine learning and computer vision software tool which Syllable was developing to identify and quantify behavior as an indicator of neurological conditions. The transaction was accounted for as an acquisition of assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The former stockholders of Syllable are entitled to contingent consideration in the form of development milestones of up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81cc288a-b972-45c5-8ff2-67b221c039d0" contextRef="C_e9c77ce3-3b44-4cf6-b432-fc188546ac82" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (Syllable Milestones). At the Company&#8217;s sole discretion, the Syllable Milestone payments may be settled, in cash or shares equity of the Company, or a combination of both, subject to the provisions of the Syllable Merger Agreement and were not subject to liability classification and/or derivative accounting. Any such contingent consideration will be recognized when the contingency is resolved, and the consideration becomes payable. As of March 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11638da2-34a6-4b10-8917-ac47201d6bf1" contextRef="C_727eaf32-52e9-4c5c-a6c1-0994953c8d5b" name="nmra:NumberOfMilestoneAchieved" unitRef="U_Milestones" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ne of the Syllable Milestones had been achieved and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80104984-94f7-4657-a742-4599295ac2cf" contextRef="C_27e98a1d-ba3b-4cf3-99f9-3fdadc737b90" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> such amounts were deemed due or payable.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Alairion, Inc.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2020, the Company entered into an agreement and plan of merger (Alairion Merger Agreement) to acquire all of the outstanding equity of Alairion, Inc. (Alairion). The acquisition of Alairion allowed the Company to expand its program pipeline by gaining rights to two preclinical stage research and development programs focused on the treatment of sleep disorders, an H1 receptor antagonist program (the H1 Program) and a GABA receptor positive allosteric modulator program (the GABA Program). The acquisition also provided the Company with access to a license for software that records sleep and related drug discovery and optimization technology platform. The transaction was accounted for as an acquisition of assets.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The holders of Alairion common stock outstanding as of immediately prior to the closing date received non-transferable rights to future milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d38274a-b806-4423-beab-90c3b68ce3bf" contextRef="C_d5c12c1d-523a-4e2f-a7e6-1b8c3d85f7ed" name="nmra:ContingentConsiderationMilestonePayment" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">33.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon the achievement of specified development events and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_486cf307-9a74-4f74-b682-26403fa32a93" contextRef="C_a0e6e5ef-74d3-4484-9f60-7605a23196e7" name="nmra:ContingentConsiderationMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">135.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon the achievement of specified commercialization events related to the H1 Program and the GABA Program (the Alairion Milestones).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Alairion Milestone payments may be settled, at the Company&#8217;s sole discretion, in cash or shares of the Company, or a combination of both, subject to the provisions of the Alairion Merger Agreement. None of the Alairion Milestones were subject to liability classification and/or derivative accounting and any such contingent consideration will be recognized when the contingency is resolved, and the consideration becomes payable. As of March 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46bc85ab-1a70-47be-9474-a62896d8d7eb" contextRef="C_7427bdec-5be3-45d2-91f7-391af97bab20" name="nmra:NumberOfMilestoneAchieved" unitRef="U_Milestones" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ne of the Alairion Milestones have been recognized. In March 2022, the Company paused the active program acquired from Alairion while it assesses pre-IND feedback received from the FDA and continues to consider alternative options for that program.</span></p><ix:exclude><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
      <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amgen Inc. Licenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2021, the Company entered into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed67d1f8-09be-4bb3-b4c9-4b8420f0bd9c" contextRef="C_57949529-090f-4b07-8503-88af5ca1f576" name="nmra:NumberOfLicenseAgreements" unitRef="U_Agreements" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> license agreements with Amgen Inc. (Amgen) pursuant to which it obtained exclusive, worldwide licenses to develop, manufacture, use, commercialize and distribute products containing compounds that are directed to, in one case, CK1&#948;, and in the other case, glucocerebrosidase (GCase), both for the treatment of neurodegenerative diseases (the Amgen License Agreements) and related know-how and clinical material (collectively, the Amgen IPR&amp;D Assets). The Company accounted for these transactions as acquisitions of assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Concurrently, the Company also executed a research collaboration agreement as well as a stock purchase agreement with Amgen. Both agreements were deemed to be separate transactions and not accounted for as part of the acquisition of assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total upfront consideration transferred to Amgen of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_812d903f-c40b-4439-85b2-129c550bae8e" contextRef="C_af1ae46a-387b-4cc6-b7c4-deac557cbf45" name="nmra:UpfrontConsiderationTransferredShares" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares of the Company's Series A-2 convertible preferred stock, with an acquisition date fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e14f2fdc-512e-452a-9944-7a9f4d3fa979" contextRef="C_af1ae46a-387b-4cc6-b7c4-deac557cbf45" name="nmra:AcquisitionDateFairValueOfSharesTransferred" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">157.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was allocated to the Amgen IPR&amp;D Assets and expensed in 2021.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under these </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79b53ca4-de41-4323-91eb-0137f76c28f0" contextRef="C_57949529-090f-4b07-8503-88af5ca1f576" name="nmra:NumberOfLicenseAgreements" unitRef="U_Agreements" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> license agreements, Amgen is eligible to receive contingent consideration up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9f50c3b-6c8b-4811-addf-f434c2358a9e" contextRef="C_9a1bec7e-9028-4893-9a01-f2631f4b8268" name="us-gaap:PaymentsToAcquireBusinessesGross" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">360.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in commercial milestone payments per product payable in cash with a compound directed to CK1&#948; and up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_838f0539-fb8a-4ae1-87e2-c227bf6ac5f7" contextRef="C_b006d350-7cd4-4054-a767-ad0723607854" name="us-gaap:PaymentsToAcquireBusinessesGross" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">360.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in commercial milestone payments per product payable in cash with a compound directed to GCase, in each case, upon the achievement of certain sales thresholds and single digit royalties on potential future net sales, related to CK1&#948; or GCase (the Amgen Milestones). Such contingent consideration was not subject to liability classification and/or derivative accounting and will be recognized when the contingency is resolved, and the consideration becomes payable. As of March 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96b1c9ed-c746-4a1e-a445-3807e93880b3" contextRef="C_38d1ee4e-868f-457c-9d3a-08007be1e356" name="nmra:NumberOfMilestoneAchieved" unitRef="U_Milestones" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ne of the Amgen Milestones had been achieved and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff0a49a9-4979-4526-8b50-ceaef819171e" contextRef="C_96f5c202-287c-4650-8120-d3a9b7c6fa82" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> such amounts were deemed due or payable.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, until a specified period of time following the achievement of the first successful Phase 2 clinical trial for any licensed product, if the Company chooses to sell, transfer, sublicense or divest rights to a licensed product in certain major markets, Amgen has a period of time to enter into an agreement with the Company for such rights. The Company determined that these rights of first negotiation were not freestanding instruments from the Amgen License Agreements and did not meet the definition of a derivative.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Vanderbilt License</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2022, the Company and Vanderbilt University (Vanderbilt) entered into a license agreement (Vanderbilt License Agreement). Pursuant to the Vanderbilt License Agreement, as amended, the Company obtained an exclusive, worldwide royalty-bearing, sublicensable (subject to certain restrictions) license under certain patent rights and a non-exclusive, worldwide, royalty-bearing, sublicensable (subject to certain restrictions) license under certain know-how covering small molecule positive allosteric modulators (PAMs) predominantly of the muscarinic acetylcholine receptor subtype 4 (M4) to develop, manufacture, and commercialize products, processes and services covered by such patent rights or that incorporate or use such know-how, for any and uses (the Vanderbilt IPR&amp;D Assets). Concurrently, the Company also executed a sponsored research agreement (see Note 8) with Vanderbilt. The sponsored research agreement was deemed to be a separate transaction and not accounted for as part of the acquisition of assets. The acquisition of Vanderbilt IPR&amp;D Assets became effective in February 2022.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The licensed patent rights are subject to Vanderbilt&#8217;s right to use the patent rights for research, internal non-commercial use, and educational purposes. The Company intends to develop the PAMs for the treatment of schizophrenia and other neuropsychiatric disorders. The Company has agreed to use commercially reasonable efforts to develop and commercialize licensed products, and to achieve certain development milestones.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company paid Vanderbilt a non-refundable, non-creditable upfront cash payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef484f24-4b6a-4221-9f97-eddcb2857ea6" contextRef="C_4a88c6ce-e846-4492-ae0b-e6b735a43fb1" name="nmra:UpfrontCashPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the Vanderbilt IPR&amp;D Assets, which was immediately recognized as acquired in-process research and development expense in the condensed consolidated statement of operations and comprehensive loss as it was determined to have no alternative future use as of the acquisition date. Under the Vanderbilt License Agreement, Vanderbilt is eligible to receive contingent consideration payable in cash up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a1abb5b-bf17-4826-9835-9461c627ffc4" contextRef="C_6fcb7871-8d09-408d-8dc0-0412fca292a2" name="us-gaap:PaymentsToAcquireBusinessesGross" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">42.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon the achievement of specified development milestones and up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e761cc8-067d-4f5b-b713-8d0bd01f2f7a" contextRef="C_d05c50a8-ba36-4fd1-84d9-0b85ac41d16f" name="us-gaap:PaymentsToAcquireBusinessesGross" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">380.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon the achievement of commercial milestone events as well as tiered royalties at mid-single digit percentages on potential future net sales, subject to specified reductions for the lack of patent coverage, generic entry and payment obligations for third-party licenses (the Vanderbilt Milestones). In addition, the Company is obligated to pay Vanderbilt low-double-digit percentage of sublicense income it receives for sublicenses entered into before the achievement of a specified event. Such contingent consideration was not subject to liability classification and/or derivative accounting and will be recognized when the contingency is resolved, and the consideration becomes payable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> In October 2023, a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29ef8772-6fc1-4121-99cc-8df4904eeadd" contextRef="C_5eeee25b-8ab1-4a9f-98dc-9fd6387ddc80" name="nmra:ContingentConsiderationMilestonePaymentSettledInCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million Vanderbilt Milestone was achieved and settled in cash in November 2023 and was recognized in acquired in-process research and developed expenses in the fourth quarter of 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8d30bda-f092-4ab1-b83a-dd0fdc317601" contextRef="C_4fd44d42-dc78-4882-9e7d-7c2d3d98f539" name="nmra:NumberOfMilestoneAchieved" unitRef="U_Milestones" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ne of the other Vanderbilt Milestones had been achieved and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f9b1916-b614-4e3e-a95e-d22aa338e39c" contextRef="C_638d684a-75f7-48d0-a1b0-227583ccf014" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> such amounts were deemed due or payable as of March 31, 2024.</span></p><ix:exclude><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
      <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the Company also had an exclusive option, exercisable for a specified period of time, to negotiate an exclusive license to certain patent rights conceived or developed by Vanderbilt in the course of carrying out the sponsored research pursuant to a sponsored research agreement the between the Company and Vanderbilt, which was entered into at the same time as the Vanderbilt License Agreement. The Company determined that the right to negotiate was not a freestanding instrument from the Vanderbilt License Agreement and did not meet the definition of a derivativ</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e. The Company exercised the above disclosed exclusive option and the parties executed an agreement in December 2023 pursuant to which the Company licensed certain patent rights in return for a payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26235c2f-f0a6-434b-888e-cf9feb915f29" contextRef="C_0311f6e7-f6e3-443f-9af6-6ed78e813333" name="nmra:AcquiredInProcessResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million that was recognized in acquired in-process research and developed expenses in the fourth quarter of 2023.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f3ef9db2-7d45-4ff4-b425-606eb8ea1bd4" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7.	Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indemnification</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors&#8217; and officers&#8217; insurance.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other Commitments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has various manufacturing, clinical, research and other contracts with vendors in the conduct of the normal course of its business. Such contracts are generally terminable with advanced written notice and payment for any products or services received by the Company through the effective time of termination and any non-cancelable and non-refundable obligations incurred by the vendor at the effective time of the termination. In the case of terminating a clinical trial agreement at a particular site, the Company would also be obligated to provide continued support for appropriate medical procedures at that site until completion or termination.</span></p></ix:nonNumeric></div><div style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e4f718a8-f5f0-4fee-9989-8e127c7a965f" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8.	Strategic License and Research and Collaboration Agreements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2015 TSRI License Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the acquisition of BlackThorn (see Note 6), the Company gained certain exclusive rights to intellectual property related to Kappa Opioid Receptor and V1aR Receptor Antagonist programs as well as an oxytocin receptors positive allosteric modulator program (collectively, the TSRI Programs) under a license agreement between BlackThorn and TSRI originally entered into in November 2015 (as amended, the 2015 TSRI License Agreement). The technology licensed under the 2015 TSRI License Agreement is used in the Company&#8217;s navacaprant and NMRA-511 research and development programs.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:18pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the 2015 TSRI License Agreement, the Company is obligated, among other things, to pay TSRI (i) a nominal annual license fee due and payable on the first day of each calendar year and after the fourth anniversary creditable against any royalties due for such calendar year, (ii) development and regulatory milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71f606f3-cbd7-495f-907b-18512106e4d6" contextRef="C_cb7d09d2-6022-4de5-837f-3706586031b6" name="nmra:DevelopmentAndRegulatoryMilestonePayments" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in aggregate for the first product from each TSRI Program, which are contingent upon achieving specific development and regulatory milestone events, (iii) commercial milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b661d9b-912f-41a5-8e5f-ce7aade77de0" contextRef="C_cb7d09d2-6022-4de5-837f-3706586031b6" name="nmra:CommercialMilestonePayments" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in aggregate for each occurrence, which are contingent upon achieving specified commercialization milestone events, (iv) tiered low-single digit royalties on future net sales of each royalty-bearing product and (v) a percentage ranging from the mid-single digits to sub teen double digits of any sublicensing revenues the Company receives. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2023, the Phase 3 navacaprant dosing milestone was met and the Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f896790d-5c5d-4f8a-8620-4d63c8d8773f" contextRef="C_26c72768-5590-4025-8159-fc37393751a8" name="nmra:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to TSRI, which was recognized in acquired in-process research and developed expenses in the fourth quarter of 2023. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23c48ac5-5d19-4cde-897c-b231930c9f9b" contextRef="C_10a4bee1-f023-4318-b204-afcaf55d14c2" name="nmra:MilestonesAchieved" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ne of the other milestones have</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> been achieved and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2536f419-37b8-4732-947f-60bae20e71e9" contextRef="C_10a4bee1-f023-4318-b204-afcaf55d14c2" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> royalties were due under the 2015 TSRI License Agreement as of March 31, 2024.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Collaboration Agreement with Amgen</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2021, and concurrently with the Amgen License Agreements (see Note 6), the Company entered into a research collaboration agreement with Amgen (Amgen Collaboration Agreement) to collectively discover drug targets, biomarkers, and other insights associated with central nervous system (CNS) diseases utilizing Amgen&#8217;s deCODE genetics and human data research capabilities. The Company received exclusive rights under intellectual property generated in the collaboration to exploit therapeutic compounds and diagnostics for use with therapeutics in the CNS field and Amgen received exclusive rights to exploit therapeutic</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
      <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compounds and diagnostics for use with therapeutics outside of the CNS field. The agreement is governed by the Joint Research Committee (JRC), which is made up of equal representatives from each of the Company and Amgen to manage the progress and direction of research and development activities. All decisions made by the JRC shall be by consensus with each party having one vote, and if the JRC cannot reach a consensus, the dispute shall be referred to each company&#8217;s executive officers. If the executive officers fail to reach a consensus, the Company will have final decision-making authority provided that the matter does not relate to the approval of, or any material change to, a project, decisions to acquire rights from a third party, decisions or activities that are in conflict with Amgen&#8217;s database usage or data access rights, or the approval of external costs and expenses relating to certain new data generation activities or certain new dataset acquisitions, as such matters require mutual agreement.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In return for Amgen performing research and development activities under the agreement, the Company is committed to making non-refundable, non-creditable quarterly payments over the first two years totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1fd2bfea-b11e-4969-b990-ab9f43763cec" contextRef="C_61a3990c-bdca-4b24-aaa5-3144c2b02eed" name="nmra:ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and for the third year $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2da8675-8b60-40c7-a2a4-b1367b6eca8c" contextRef="C_98e4cbee-233e-4294-91dc-1bfd8e5796c3" name="nmra:ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">12.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Additionally, the Company will reimburse Amgen for certain direct, out-of-pocket external costs and expenses that are incurred in the performance of the activities under the Amgen Collaboration Agreement.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_29e1841b-f9f6-46aa-aec9-f2b2a90cdc94" contextRef="C_61a3990c-bdca-4b24-aaa5-3144c2b02eed" name="nmra:CollaborationAgreementTerminationDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term of the agreement is up to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e938ee1b-7ca2-4123-82a5-b64f8b44cb31" contextRef="C_3c8b66e7-6cb2-408d-90ae-bc995d83fe8b" name="nmra:CollaborationAgreementTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, although it will terminate after three years if the Company and Amgen do not mutually agree upon a compensation structure for years four and five. If the parties do not reach an agreement at least 30 days prior to the end of year three, the Amgen Collaboration Agreement will automatically terminate upon its third anniversary. Further, either party can terminate the Amgen Collaboration Agreement upon material uncured breach or bankruptcy by the other party, in which case all amounts that have become due through the date of termination are non-refundable.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:18pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amgen also has an exclusive option to negotiate, and the right of first negotiation, to obtain exclusive, worldwide licenses to research, develop, commercialize, and otherwise exploit up to two therapeutic compounds or any pharmaceutical product containing such therapeutic compound arising from the collaboration. That right exists with respect to each compound for a certain period of time following positive Phase 2 results for that compound. The Company determined that these rights were not freestanding instruments from the Amgen Collaboration Agreement and did not meet the definition of a derivative. Upon execution of the Amgen Collaboration Agreement in September 2021, the Company was obligated to start paying Amgen non-refundable quarterly payments. As of March 31, 2024 and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> December 31, 2023, the related prepaid research and development costs included in the condensed consolidated balance sheets were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a65c07e3-8f18-4834-8199-266f14ff3600" contextRef="C_24425110-363c-4304-86c3-338011263481" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14e43f4b-f737-4979-a9e5-a80427d1ea05" contextRef="C_4252d2b2-e04b-48d1-85b6-0e7e74735ae9" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, within prepaid expenses and other current assets. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_627494d7-59bc-4dfe-bb14-095311ed979a" contextRef="C_61a3990c-bdca-4b24-aaa5-3144c2b02eed" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> research and development expense was incurred during the three months ended March 31, 2024. The Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_943956c3-152f-4a26-808f-cdf2330323b2" contextRef="C_29e92089-1d1d-45de-90cf-b5665e9d2c96" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of related research and development expenses during the three months ended March 31, 2023.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sponsored Research Agreement with Vanderbilt</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2022, concurrently with the Vanderbilt License Agreement (see Note 6), the Company entered into a sponsored research agreement with Vanderbilt (Vanderbilt Research Agreement), pursuant to which Vanderbilt agreed to provide the Company research services to develop a M4 PAM back-up program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In return for Vanderbilt performing research and development activities under the agreement, the Company agreed to make quarterly payments for research up to a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9022a59-d11d-4134-af18-edd5382cc134" contextRef="C_6e7d7080-8e14-4f39-8b8c-749fc8d79976" name="nmra:ResearchAndCollaborationAgreementQuarterlyPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million on an annual basis. The term of the agreement ended in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_700e3994-1bc6-45d8-8c4b-fa7d6d5124a4" contextRef="C_3492c0b5-ea1d-4cce-912d-8ddfd975d853" name="nmra:ResearchAgreementExpiryDate" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In addition, the Company also had an exclusive option to negotiate an exclusive license to certain patent rights conceived or developed by Vanderbilt in the course of carrying out the sponsored research (see Note 6).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
      <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Parkinson's Research Ventures Funding Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2024, the Company entered into a research funding agreement with Parkinson's Research Ventures Limited (PRV), pursuant to which PRV agreed to provide the Company funding up to a total of &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae6fc0d2-0688-49e5-b8fe-ff8b94c76a31" contextRef="C_6d6c1116-4ad2-4a9c-88a8-b3a45ef44006" name="nmra:FundsProvidedForPreClinicalResearchAndDevelopmentActivities" unitRef="U_GBP" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in two tranches to carry out preclinical research and development activities related to the Company&#8217;s NLPR3 program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The first tranche of &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7076630-9f5e-4fe7-896c-a5b004457915" contextRef="C_b09e08a3-63fc-490c-a2b1-f49e28aca678" name="nmra:FundsReceivedUponExecutionOfAgreement" unitRef="U_GBP" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was due upon execution of the agreement and was received in March 2024, for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aed71e16-2308-469e-8422-1eef13d0b362" contextRef="C_b09e08a3-63fc-490c-a2b1-f49e28aca678" name="nmra:PaymentsForExecutionOfAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company is eligible to receive the second tranche of &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb9970c3-cf34-4fd2-919c-cca43747ae0c" contextRef="C_b09e08a3-63fc-490c-a2b1-f49e28aca678" name="nmra:FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone" unitRef="U_GBP" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon the completion of certain development milestones. The Company concluded the funding arrangement was an obligation to perform services and the funding received is recognized as a contra-R&amp;D expense as project costs are incurred. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a49d7932-f948-450c-be4a-77b4f12a5cb3" contextRef="C_b09e08a3-63fc-490c-a2b1-f49e28aca678" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> costs were incurred during the three months ended March 31, 2024. Upon achievement of certain development, regulatory or commercial trigger events, the Company agreed to pay PRV in aggregate an amount equal to no more than four times the funding provided by PRV i.e., a maximum repayment amount of up to &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40a0bf84-2f95-4699-9b58-c51a3d4de179" contextRef="C_b09e08a3-63fc-490c-a2b1-f49e28aca678" name="nmra:MaximumRepaymentAmountAgreedToPay" unitRef="U_GBP" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The trigger event payments meet the derivative scope exception under Accounting Standards Codification (ASC) 815 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivatives and Hedging,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and therefore do not need to be bifurcated and separately accounted for.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_1ef1cebf-c3ff-4d3b-914e-fb4e42cf5750" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9.	Stockholders&#8217; Equity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preferred Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subsequent to the IPO, the Company's board of directors has the authority to issue up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f999c82-dee1-4094-a946-4bbb466b9bc5" contextRef="C_eae3f164-5e78-4151-9e37-d2d160340f1e" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">50,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of preferred stock in one or more series with rights, preferences and privileges to be determined. There are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ae0491d-8700-42be-a7d3-f3df5eb70f77" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_31f95567-da32-482e-833c-f5099be9d810" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of preferred stock issued and outstanding as of March 31, 2024.</span></p><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stock outstanding in the condensed consolidated balance sheet and condensed consolidated statement of stockholders&#8217; equity as of March 31, 2024 includes </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd456ed3-96e9-488a-97ee-6bd52f10b13c" contextRef="C_241e97c5-2790-4988-bdd5-728453731091" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">447,931</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of restricted stock that vest based on service conditions and are subject to the Company&#8217;s right of repurchase upon termination of services and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fa15bb1-9118-43f0-92b9-156910fc2b05" contextRef="C_da6c85e3-9c01-4bd3-ae51-498329b996bc" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">637,240</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of restricted stock that vest based on performance conditions (see Note 10). </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b8b3ed85-1705-44c1-b1ea-7054558f6944" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="nmra:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" escape="true" continuedAt="F_b8b3ed85-1705-44c1-b1ea-7054558f6944_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stock reserved for future issuance consisted of the following:</span></ix:nonNumeric></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_b8b3ed85-1705-44c1-b1ea-7054558f6944_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:78.02%;"/>
         <td style="width:1.7%;"/>
         <td style="width:1%;"/>
         <td style="width:18.28%;"/>
         <td style="width:1%;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares reserved for options and restricted stock units issued under the plans</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df725ebb-1115-4200-a625-af79fcda532f" contextRef="C_c76761b1-4f4c-4b1c-9b56-2a77a0b656cd" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,084</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares reserved for future issuance under the plans</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9cb1b06-bf25-4b3f-93cf-e07d79910d8d" contextRef="C_b533a66d-d823-48df-b3a5-6934efcf05e7" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,965</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8cef0eee-d84d-4e67-8d7d-cbcba7af9674" contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,049</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:continuation></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the Company may be required to issue additional shares of its capital stock if certain milestone conditions are met pursuant to the contingent consideration associated with the Company&#8217;s acquisitions of assets (see Note 6). In December 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1626199-2cb9-4d2a-ace4-24179016a17b" contextRef="C_7642d8ba-9722-4366-8e63-768f192c1673" name="nmra:SharesIssuedUponAchievementOfMilestone" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,072,445</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock were issued related to BlackThorn Merger Agreement upon achievement of the Phase 3 navacaprant dosing milestone that was met in October 2023. As of March 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_136f755b-00df-4787-be64-aad7f7724854" contextRef="C_e555a578-5b2d-4468-956c-3321ccffb3aa" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares have been reserved for potential future issuances as no other BlackThorn Milestones have been achieved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_378ba44f-0ca4-48a1-91cf-b0bfa66a237b" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10.	Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 Equity Incentive Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2023, the Company adopted the 2023 Equity Incentive Plan (the 2023 Plan) that became effective in connection with the Company&#8217;s IPO. The 2023 Plan provides for the grant of stock options, restricted stock awards, restricted stock unit awards, and other stock-based awards to employees, directors, and non-employee service providers of the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Awards granted under the 2023 Plan expire no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a8412ec6-6747-4cad-a51a-e65a2edf80e5" contextRef="C_376fc925-1109-451f-b742-d347b9400872" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of grant. The price of stock options shall not be less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_195b1328-6384-486e-a709-5618f8a5d8e2" contextRef="C_42afd269-c212-4524-8ff6-bdd4937462c1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the estimated fair value on the date of grant and typically vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3bf6dbef-69d8-43c1-ba82-5d872c03d7f5" contextRef="C_376fc925-1109-451f-b742-d347b9400872" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period although may be granted with different vesting terms. The 2023 Plan initially reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_091522ba-fb96-43b5-8a16-dc1b5108849c" contextRef="C_cc78fb10-fe96-458e-9b51-d23d300acb4b" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,373,061</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock for the issuance of future awards and provides for an automatic annual increase in the number of shares of common stock reserved for future issuance under the 2023 Plan.</span></p><ix:exclude><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
      <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 Employee Share Purchase Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2023, the Company adopted the 2023 Employee Share Purchase Plan (the 2023 ESPP) that became effective in connection with the Company&#8217;s IPO. The 2023 ESPP initially reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed5fc810-10e0-4afd-bb0a-8808e1ddc9f8" contextRef="C_df6fdf4a-265c-48a0-90df-8045faa562ed" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,526,984</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock for the issuance of future awards and provides for an automatic annual increase in the number of shares of common stock reserved for future issuance under the 2023 ESPP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2020 Equity Incentive Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2020, the Company adopted the 2020 Equity Incentive Plan (the 2020 Plan) that provides for the grant of stock options, restricted stock awards, restricted stock unit awards, and other stock-based awards to employees, directors, and non-employee service providers of the Company. The 2020 Plan was suspended in connection with the Company&#8217;s IPO and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d48870cd-cd9e-4a94-a4bd-9f3653d6ab7c" contextRef="C_8eca9c19-7868-4c41-b853-b66e96530c89" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> further grants will be made under the 2020 Plan. The 2020 Plan continues to govern the terms and conditions of outstanding awards granted under the 2020 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2015 Equity Incentive Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon the closing of the BlackThorn acquisition in September 2020, the Company assumed BlackThorn&#8217;s 2015 Equity Incentive Plan (the 2015 Plan, and collectively with the 2020 Plan and 2023 Plan, the Plans), pursuant to which outstanding stock options previously granted under the 2015 Plan converted into stock options to purchase common stock of the Company, which remain subject to the terms and conditions of the 2015 Plan. The 2015 Plan was suspended in connection with the closing of the acquisition of BlackThorn in September 2020.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_be3f0803-d18f-4544-8296-1deaebe168e0" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock Option Activity</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:41.692%;"/>
         <td style="width:1%;"/>
         <td style="width:1%;"/>
         <td style="width:13.877%;"/>
         <td style="width:1%;"/>
         <td style="width:1.42%;"/>
         <td style="width:1%;"/>
         <td style="width:10.058%;"/>
         <td style="width:1%;"/>
         <td style="width:1%;"/>
         <td style="width:1%;"/>
         <td style="width:11.418%;"/>
         <td style="width:1%;"/>
         <td style="width:1.42%;"/>
         <td style="width:1%;"/>
         <td style="width:10.118%;"/>
         <td style="width:1%;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding<br/>Stock Options</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price Per<br/>Share</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (years)</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic <br/>Value</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands, except per share amounts and years)</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66d52b8b-3f04-487a-b658-f0f7fc5678e2" contextRef="C_2b466a11-59bd-42da-b1ba-1391e584e43b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,783</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd523eb7-f300-44cd-812e-9b1fe65e9f6e" contextRef="C_2b466a11-59bd-42da-b1ba-1391e584e43b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.39</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_074145c5-e271-4c61-b3f9-037a53d9b580" contextRef="C_1ad31ded-f058-420f-adc9-5e78ca23eebb" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.7</span></ix:nonNumeric></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_973fc961-ea91-4525-b721-309688fed3bf" contextRef="C_2b466a11-59bd-42da-b1ba-1391e584e43b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">146,966</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_646feb95-8bc0-499a-8a44-8a2c441319cc" contextRef="C_9e81dd9f-5d49-4381-8c61-747848c7d435" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,841</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa6e17b6-50d9-4557-9e35-1b5432f12f49" contextRef="C_9e81dd9f-5d49-4381-8c61-747848c7d435" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">17.43</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7450e597-fb8c-43a6-844f-d1703bd38d11" contextRef="C_9e81dd9f-5d49-4381-8c61-747848c7d435" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">525</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_333219f4-7a13-45b0-ae93-935271e55e10" contextRef="C_9e81dd9f-5d49-4381-8c61-747848c7d435" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.51</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Canceled and forfeited</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d439e03f-158d-4b0a-baa8-b2656850c8df" contextRef="C_9e81dd9f-5d49-4381-8c61-747848c7d435" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">884</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b84f3685-b05d-4c46-8d9d-c2452cedf2cb" contextRef="C_9e81dd9f-5d49-4381-8c61-747848c7d435" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.93</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expired</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a64515a7-84ba-4323-b8a0-8b14915379f5" contextRef="C_9e81dd9f-5d49-4381-8c61-747848c7d435" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">85</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d568806-f559-4e69-a8b9-0bb7c51c2633" contextRef="C_9e81dd9f-5d49-4381-8c61-747848c7d435" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.37</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of March 31, 2024</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62fdda0e-946b-4529-8f37-05cec5063b73" contextRef="C_1c88b9f4-137c-4a7d-a570-37859d14341b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,130</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2cbd004-e011-4c1b-bf2f-e0146547cb90" contextRef="C_1c88b9f4-137c-4a7d-a570-37859d14341b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.60</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_7b79cc8b-f06c-4088-8bc9-e00a1224110b" contextRef="C_9e81dd9f-5d49-4381-8c61-747848c7d435" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.8</span></ix:nonNumeric></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ff4f571-b70a-4377-9a38-2c0b4b83cc3d" contextRef="C_1c88b9f4-137c-4a7d-a570-37859d14341b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90,736</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested as of March 31, 2024</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b009c4ac-c39e-4932-a032-7d7509b89501" contextRef="C_1c88b9f4-137c-4a7d-a570-37859d14341b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,667</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a65e5d8-00fa-4f14-9aac-0522b20c5fb5" contextRef="C_1c88b9f4-137c-4a7d-a570-37859d14341b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.43</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_5cf3f81e-4d69-4385-8e28-3af06510a230" contextRef="C_9e81dd9f-5d49-4381-8c61-747848c7d435" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.6</span></ix:nonNumeric></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ca9d750-a2b1-476e-bb70-24518555e156" contextRef="C_1c88b9f4-137c-4a7d-a570-37859d14341b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,256</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable as of March 31, 2024</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2da9ba4-28c0-469a-8b6b-c7293d25ba39" contextRef="C_1c88b9f4-137c-4a7d-a570-37859d14341b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,659</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dad4992d-e152-45c5-b1d0-0f9e1de8c5e3" contextRef="C_1c88b9f4-137c-4a7d-a570-37859d14341b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.44</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_25ceaf91-1b38-4a20-a46a-fa85069e2727" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.6</span></ix:nonNumeric></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e9a481e-5d07-493f-b2f6-2c25524a38a6" contextRef="C_1c88b9f4-137c-4a7d-a570-37859d14341b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,145</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The stock option activity table above excludes options granted to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8703996a-45c4-4bce-b345-247c2680464f" contextRef="C_d082d3da-55b1-47ee-a8c5-4a74e9aacbc1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">446,068</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock that were originally granted with market conditions to one of the Company&#8217;s executives.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted Stock Activity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s Plans allow for the grant of restricted common stock and restricted stock units to certain employees, executives, non-employee scientific advisors, and third-party service providers. The restrictions lapse over time primarily according to service-based vesting conditions of each award. In the event of a voluntary or involuntary termination of the holder&#8217;s continuous provision of services to the Company, any unvested portion of the restricted stock award is automatically forfeited.</span></p><ix:exclude><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
      <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ea720ed3-72f2-4aa3-a277-cee873c48072" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company&#8217;s restricted stock activity:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:45.46%;"/>
         <td style="width:1.06%;"/>
         <td style="width:1%;"/>
         <td style="width:9.74%;"/>
         <td style="width:1%;"/>
         <td style="width:1.28%;"/>
         <td style="width:1%;"/>
         <td style="width:11.64%;"/>
         <td style="width:1%;"/>
         <td style="width:1%;"/>
         <td style="width:1%;"/>
         <td style="width:9.86%;"/>
         <td style="width:1%;"/>
         <td style="width:1.16%;"/>
         <td style="width:1%;"/>
         <td style="width:10.8%;"/>
         <td style="width:1%;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares of<br/>Restricted<br/>Common<br/>Stock</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value<br/>Per Share</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares of<br/>Restricted<br/>Stock<br/>Units</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average Grant<br/>Date Fair<br/>Value Per<br/>Share</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands, except per share amounts)</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding and unvested as of December 31, 2023</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab42e0ba-246c-40c2-8046-bfc1b5a9e188" contextRef="C_345bf6ed-eb39-4b95-8e9c-d73a88a49e29" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">840</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18726885-3971-4f51-ac45-1a1995a45a1e" contextRef="C_345bf6ed-eb39-4b95-8e9c-d73a88a49e29" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.11</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55f35dd9-fa13-4daa-b3ec-8e44223b0a8e" contextRef="C_0a096f27-ed84-4bfd-9a47-aba4b2779d76" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">353</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4391cf48-d8d7-4f04-a699-8a2e3624d91b" contextRef="C_0a096f27-ed84-4bfd-9a47-aba4b2779d76" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">17.00</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b54049d5-1b6f-4683-8835-204f3bae8c72" contextRef="C_b8b16692-cbc0-4367-b249-644373e8d0f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4120c0cf-753b-4b2c-ae1c-845b97b8af74" contextRef="C_b8b16692-cbc0-4367-b249-644373e8d0f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af909d70-029c-4406-ade5-7db7953f7063" contextRef="C_4fa032ad-c930-4482-a337-4a8a1b1ede42" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,165</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e328ac90-d91c-4053-bd1a-e9298e4d3c52" contextRef="C_4fa032ad-c930-4482-a337-4a8a1b1ede42" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.07</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43a98596-f210-4896-9b44-9ddc34ba63ff" contextRef="C_b8b16692-cbc0-4367-b249-644373e8d0f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">190</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7bfc494-5bf5-4733-a5c2-83a18ec2ae0d" contextRef="C_b8b16692-cbc0-4367-b249-644373e8d0f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.26</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ffd3f149-4bd9-47bf-a662-8d2a3229df99" contextRef="C_4fa032ad-c930-4482-a337-4a8a1b1ede42" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76add3bc-9de7-448c-9578-0a4e31322617" contextRef="C_4fa032ad-c930-4482-a337-4a8a1b1ede42" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited and canceled</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52b19b59-f3b3-4162-a66e-64db0a1503be" contextRef="C_b8b16692-cbc0-4367-b249-644373e8d0f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03bc0b60-2974-4873-b093-2dbf4dd604c0" contextRef="C_b8b16692-cbc0-4367-b249-644373e8d0f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_091e1838-f174-4021-a739-fc26282319a9" contextRef="C_4fa032ad-c930-4482-a337-4a8a1b1ede42" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ec30fa8-8c7b-444c-b595-5d9ca72c6371" contextRef="C_4fa032ad-c930-4482-a337-4a8a1b1ede42" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.07</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding and unvested as of March 31, 2024</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a4fe474-2677-4d9e-b874-2e8851d163cb" contextRef="C_e06ff9ea-6ac1-463f-a171-26aa417330c4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">650</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d46e8cb1-7156-441b-ab0c-6dd62981c7cd" contextRef="C_e06ff9ea-6ac1-463f-a171-26aa417330c4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.81</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ed2a24c-8915-41da-9cc5-615f17430902" contextRef="C_e4e3a7e0-9ae1-4a99-a9a2-37ef23ba354a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,508</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b319a3fa-c1c5-4d8c-a7ed-dc9ed3d91f64" contextRef="C_e4e3a7e0-9ae1-4a99-a9a2-37ef23ba354a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">17.83</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The restricted stock activity table above excludes </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22f3f9b5-c5c8-4f37-9e5a-fa0890d281e4" contextRef="C_28cf5026-31c2-4237-a961-7cf7d3167b00" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">254,896</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of restricted common stock issued to certain of the Company&#8217;s scientific advisors which vest based on the achievement of certain performance conditions to be separately defined and approved by the Company&#8217;s board of directors. As the performance conditions had not been determined as of March 31, 2024, the criteria for establishing a grant date, and accordingly a measurement date, were not met as of that date.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Award with Market and Performance Conditions</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2021, the Company granted stock options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25451282-cd44-46c1-a167-2024b58b2e3f" contextRef="C_909c052f-7ffa-437f-92ce-194f4b68b6f0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">446,068</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock to one of its executive officers with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1a245fc-13d7-4d38-8032-12abfce7b30d" contextRef="C_395f7b48-e0c5-40be-babe-b38226abdb22" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">2.52</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share that contained both market and service conditions (the Market Award). Subject to the holder&#8217;s continued service, the Market Award provided for vesting in four equal tranches once the Company&#8217;s stock price exceeded certain thresholds. The original grant-date fair value of the Market Award of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ba44f46-7ca4-452d-9ae0-ab067d0f2a4c" contextRef="C_d5479116-b1c4-4d64-a307-24d1e08db08f" name="nmra:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was determined using a Monte Carlo simulation model using an expected volatility of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64ff4917-7d4f-4f85-8a26-82eb780dada6" contextRef="C_d5479116-b1c4-4d64-a307-24d1e08db08f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and risk-free rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0997d74c-aead-425f-91d3-b29bf0de4499" contextRef="C_d5479116-b1c4-4d64-a307-24d1e08db08f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2022, the Company amended the terms of the Market Award such that the award would vest in three modified tranches. One tranche of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0206696-7614-4ede-acb3-75d413952300" contextRef="C_33ed239b-f1e7-4dbe-9413-6d412b79e979" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">223,034</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock options was based on a performance condition and two tranches of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e183219a-42f3-405e-84c7-547651a659b9" contextRef="C_1eca2e79-7a8a-4acf-aa36-a5b1bfaffd3a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_884ea0df-61a5-4f34-ad23-72cb3318e252" contextRef="C_f506a8da-d1e3-4763-89af-d777851aeab1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">111,517</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock options each were based on revised Company stock price thresholds and/or vesting schedules, subject to the holder&#8217;s continued service. The modification resulting in a performance-based tranche was determined to be a probable-to-improbable modification and the modification resulting in two revised market-based tranches were determined to be probable-to-probable modifications. The modification resulted in $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54e955cd-f02f-4785-bbb2-277105e25e09" contextRef="C_7a1aaed2-b5ef-4825-a2cb-ef3ae69d40ab" name="nmra:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in total incremental expense.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2023, the Company amended the terms such that vesting schedule for the two tranches of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6ceffca-6368-4b46-981f-825a0e64c889" contextRef="C_cf493e6f-190e-4be5-9281-315bbffa2f51" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_90d0f39a-ea10-4ea3-aed5-d720a8b4be68" contextRef="C_7a80754f-9ec5-4887-bba9-4311a2728d25" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">111,517</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock options each that were based on the Company stock price thresholds would instead vest monthly over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f71d0437-8a7a-417c-894b-cb3e24506585" contextRef="C_a8941767-b9c2-4978-8d8c-996384d2b743" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, subject to the holder&#8217;s continued service. The modification of the two market-based tranches were deemed to be probable-to-probable modifications. The modification resulted in $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0a9fe4a-a8ec-4d89-b9e3-cabde7897202" contextRef="C_a8941767-b9c2-4978-8d8c-996384d2b743" name="nmra:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in total incremental expense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The unrecognized original grant-date fair value, together with incremental expense, is recognized as compensation for each tranche over the requisite service period. For the three months ended March 31, 2024 stock-based compensation related to the tranches was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31d822dd-051d-47ce-82f8-4062008d593f" contextRef="C_93cb25ef-3bf9-4722-9f0f-76e81b2a808d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-2" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, including expense related to the performance-based tranche for which the condition was met upon completion o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">f the Company's IPO. For the three months ended March 31, 2023, stock-based compensation related to the market-based tranches was not material and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_59a38d55-646a-4c7c-a736-1c9a89efe5a3" contextRef="C_5ba84d33-97e9-4add-951a-69e5ffd8a70a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> expense was recognized for the performance-based tranche as the performance condition was not probable of being met.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Awards with Performance Conditions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2020, the Company approved grants of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d894baa-5c2e-45fb-a2e4-6af86b7fbf4e" contextRef="C_2491722f-cf98-415e-ae66-46193d72f8d6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">700,965</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock options and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_427e6e06-31a2-4769-a71a-fa4e423fb832" contextRef="C_05417fea-1510-4361-a4a9-baae7ef69f42" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">892,136</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of restricted common stock to certain of the Company&#8217;s scientific advisors, which vest based on the achievement of performance conditions to be determined and continued service to the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, the Company&#8217;s board of directors established performance conditions for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1db665eb-3653-48a4-b544-ec0c91f5085d" contextRef="C_a162142f-a9f4-4c93-8b5d-13311233637b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">401,462</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock options, such that the criteria for establishing a grant date, and accordingly a measurement date, were met for these performance stock options and the remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb726891-1ecc-4674-a11e-1e503ae4ede6" contextRef="C_d76dcd2b-4bbc-41b1-8598-911a369433df" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">299,503</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock options with performance conditions to be established were cancelled in July 2023 because certain of the Company&#8217;s scientific advisors were terminated. Further, as of March 31, 2024, the performance conditions for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eccac582-ab7e-4831-ace5-852ba00546b3" contextRef="C_aff62d54-a840-4155-a58f-4ca78842f976" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">382,344</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
      <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restricted </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">common stock were established,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9094eaf3-a162-4e2e-9ec3-4fbda6efc7aa" contextRef="C_8afd36af-329a-4960-a319-26b63e51bf46" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">254,896</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of restricted common stock with performance conditions to be established were cancelled in July 2023 because the consulting agreements with certain of the Company&#8217;s scientific advisors were terminated, and the performance conditions for the remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_105102b5-4030-4101-803a-510ae9d398e8" contextRef="C_aff62d54-a840-4155-a58f-4ca78842f976" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">254,896</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of restricted common stock have yet to be established.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-Based Compensation</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_67f7b646-5a36-4525-9f1a-323a0c7b4c3f" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes total stock-based compensation included in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.734%;"/>
         <td style="width:1.64%;"/>
         <td style="width:1%;"/>
         <td style="width:12.082%;"/>
         <td style="width:1%;"/>
         <td style="width:1.5%;"/>
         <td style="width:1%;"/>
         <td style="width:13.043000000000001%;"/>
         <td style="width:1%;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6cd9b3e0-0ace-4a87-9bdd-c310af6457b0" contextRef="C_9d7f8b41-ab55-4cad-89a8-122b00ff6bb3" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,812</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8e8e148-a2f8-4831-aebe-24832dccaa3e" contextRef="C_ba9c409c-cf95-4c6b-a1de-281f2042bc5f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,403</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2b029ca-c24a-4805-9985-b5ec47c48de9" contextRef="C_1bb45cba-2398-4df6-8cdb-80b9b69e2e24" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,561</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f8d2934-a390-4414-81f9-e97fa82595f1" contextRef="C_fa50bcc6-f909-4f28-9b54-3cce67927d90" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">792</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3458ae92-ff34-4cb8-bf87-8e3fd1294f67" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,373</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8331aa64-be29-4977-9e2c-1779fdc5287c" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,195</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, there was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4eb076ac-a23d-48d3-aa8f-ec615d4f448e" contextRef="C_5832b785-c82b-4724-84f7-7e1c54e65756" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">89.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21c4a091-93d9-43c8-8efb-05acbf49d9be" contextRef="C_e06ff9ea-6ac1-463f-a171-26aa417330c4" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">28.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of unrecognized stock-based compensation related to stock options and restricted stock outstanding, respectively, including stock options and restricted common stock for which achievement of milestones was not probable, which were expected to be recognized over a weighted-average remaining service period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bb7b135c-5de2-446c-953d-8c2d94fbf788" contextRef="C_785b6f2c-3814-4a67-a525-c56234244751" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.6</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years and</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_de0d6d3d-1432-4de3-be91-f850de448125" contextRef="C_b8b16692-cbc0-4367-b249-644373e8d0f7" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.4</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years, respectively.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_294c7710-f690-4151-a188-b4cdcb4e5f96" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11.	Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_295cf180-346f-4992-982f-a7a350dc5e76" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the computation of basic and diluted net loss per share:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:58.352%;"/>
         <td style="width:1.94%;"/>
         <td style="width:1%;"/>
         <td style="width:16.323%;"/>
         <td style="width:1%;"/>
         <td style="width:1.94%;"/>
         <td style="width:1%;"/>
         <td style="width:17.442999999999998%;"/>
         <td style="width:1%;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands, except per share amounts)</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Numerator:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d47d0c4-98c3-46a9-aada-ef709464e1af" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">53,721</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de3d8d88-0ea2-4929-b640-ba70b527c6f7" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">35,625</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Denominator:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2b2bedb-6ebe-4837-8e28-dcb5b8874ccd" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a1d90e25-a335-4440-b60b-e1747c62a555" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">157,943</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_463fabb4-6240-4268-bc3c-899c2448f76f" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_50fe71e6-97fd-4fd0-a757-98edb8493b5d" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,277</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f7d3c49-9c24-4174-9e60-7f43c66c0ea6" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_66e6e894-267f-4a58-aa1f-0d009233fc3b" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.34</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34c0feb9-75cb-45ee-a776-b1098c1c6e39" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_50fb3df0-b2f9-472d-9050-263523ed0e83" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.22</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f130a879-c953-499f-af37-404aba724fc9" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following outstanding potentially dilutive common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;"/>
         <td style="width:1.16%;"/>
         <td style="width:1%;"/>
         <td style="width:13.357%;"/>
         <td style="width:1%;"/>
         <td style="width:1.16%;"/>
         <td style="width:1%;"/>
         <td style="width:13.357%;"/>
         <td style="width:1%;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31,</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible preferred stock</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb552cd7-3c0e-4f2a-a1a3-b16387e6acd3" contextRef="C_014dbf4d-9c71-491e-bae9-913a30763050" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f46f02bb-bea9-45f3-a8f7-ca7a0735e323" contextRef="C_0f5b5752-1f37-4791-b9a2-a1fd4665f647" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,417</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock options and restricted stock units</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89add92d-94c7-47ff-a81b-9103d52d9dd0" contextRef="C_2a684aa7-255a-43da-9bf9-acf6d3b4352e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,084</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36174d1d-aa36-44d3-a883-423e1ec4b37d" contextRef="C_ce5b0975-4f9d-4afa-a419-e3ce04cc3ecb" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,777</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Performance stock options (with performance conditions to be established)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7bf6b1ac-da1c-4ab7-9101-d2f2e656f5d7" contextRef="C_15533d05-1a02-4a98-bae1-62dca64d295c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5582ac9b-f1d5-47c6-b7ac-a97356f6011c" contextRef="C_4a935b0c-89b2-44d4-8a74-37a27e755eae" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">300</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Early exercised stock options subject to future vesting</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2263d476-ff07-48b6-ab9f-97f8f39c322e" contextRef="C_34c9a333-0792-46d3-8d3d-3200c56c14bf" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">55</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eba61142-3ee3-4256-8856-b2854ab44446" contextRef="C_c07a2ba4-b437-458f-928b-576f968fde0c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">116</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted stock awards</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5f86da8-2220-40f8-873e-b9ec655e0276" contextRef="C_776fbd65-9035-41d6-b661-57b9c9289144" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">650</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0cb0e78-158f-4bff-a80c-dc86eef925a4" contextRef="C_187481d3-58da-4836-be9f-97cca6f7c199" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,314</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Performance restricted stock (with performance conditions to be established)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d1408a2-0f17-484b-a169-9eefe9695f0c" contextRef="C_a7fa44ea-606a-4dcc-824f-a24a6ed67327" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">255</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a7ec12c9-ac56-41b9-bc34-105ca47bbb83" contextRef="C_3e1fdf9f-0c41-49d6-bdc7-817ef4cf3889" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">510</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0aa36bd-c593-45b2-8dc9-aad3a6b0f86a" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,044</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c9ea7df-3f4f-4884-9980-c387417dc004" contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">117,434</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
        <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_82546d90-daf7-4b49-9645-c610dabbbcda" contextRef="C_387b8b88-6529-413e-9474-299a471851cb" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12.	Related Party Transactions</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024 and December 31, 2023, the Company was obligated to pay Amgen $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2368e10-9279-4437-afa9-ef5c2973faf2" contextRef="C_24425110-363c-4304-86c3-338011263481" name="nmra:RelatedPartyTransactionObligationWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4a42939-036c-4a2b-9ea5-aea8849c5d63" contextRef="C_4252d2b2-e04b-48d1-85b6-0e7e74735ae9" name="nmra:RelatedPartyTransactionObligationWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, under the Amgen Collaboration Agreement, which was recorded within current liabilities on the condensed consolidated balance sheets. As of March 31, 2024 and December 31, 2023, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7f38d90-433e-41cd-9e43-2ad2520dd0e5" contextRef="C_24425110-363c-4304-86c3-338011263481" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5470acc7-b99b-4722-8d81-380cb9b4aa68" contextRef="C_4252d2b2-e04b-48d1-85b6-0e7e74735ae9" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, related to amounts prepayable to Amgen were recorded as prepaid expenses and other current assets on the condensed consolidated balance sheets. During the three months ended March 31, 2024 and 2023, the Company recorded </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c10d6da-9d42-42ab-9c48-97cf9eb7cd27" contextRef="C_61a3990c-bdca-4b24-aaa5-3144c2b02eed" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">nil</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4eed374d-701a-42e3-89e9-59c3a86948e8" contextRef="C_29e92089-1d1d-45de-90cf-b5665e9d2c96" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, of research and development expenses with Amgen.</span></p></ix:nonNumeric></div><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_7_managements_discussion"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Management&#8217;s Dis</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cussion and Analysis of Financial Condition and Results of Operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q, as well as our audited consolidated financial statements and notes thereto and the related Management's Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC) on March 7, 2024. This discussion and analysis contains forward-looking statements based upon current beliefs, plans, and expectations related to future events and our future performance that involves risks, uncertainties, and assumptions, such as statements regarding our intentions, plans, objectives, and expectations for our business. Our actual results and the timing of selected events could differ materially from those discussed in the forward-looking statements as a result of several factors including those set forth in the section titled &#8220;Risk Factors.&#8221; See also the section titled &#8220;Special Note Regarding Forward-Looking Statements&#8221;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. We have rapidly scaled our therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Our most advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of major depressive disorder (MDD) and other neurophyschiatric disorders, which we believe has the potential to provide significant advantages relative to the standard of care, if approved. In 2023, we initiated our pivotal Phase 3 KOASTAL program that is evaluating navacaprant monotherapy in patients with moderate to severe MDD. The KOASTAL program includes three replicate Phase 3 studies, KOASTAL-1, KOASTAL-2 and KOASTAL-3 as well as an</span><span style="color:#184051;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">open-label extension study, KOASTAL-LT, which is designed to evaluate the long-term safety of navacaprant. All of the KOASTAL program studies were initiated in 2023. We anticipate releasing topline results from the KOASTAL-1 study in the fourth quarter of 2024 and topline results from the KOASTAL-2 and KOASTAL-3 studies in the first half of 2025. We also expect to initiate a Phase 2 study for navacaprant in bipolar depression in the second quarter of 2024 and anticipate releasing results from that study in 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As shown in the table below, our current pipeline includes seven programs, three of which are in clinical development and four of which are in preclinical development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img235846496_0.jpg" alt="img235846496_0.jpg" style="width:644px;height:439px;"/>&#160;</p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We were incorporated in November 2019 and commenced operations thereafter. To date, we have focused primarily on building our organization, acquiring technologies and companies, developing our precision neuroscience approach, identifying and developing potential product candidates, executing clinical and preclinical studies, organizing and staffing our company, business planning, establishing our intellectual property portfolio, raising capital and providing general and administrative support for these operations. We do not have any products approved for sale, we have not generated any revenue from the sale of products, and we do not expect to generate revenue from the sale of our product candidates until we complete clinical development, submit regulatory filings, and receive approvals from the applicable regulatory bodies for such product candidates, if ever.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2023, we completed our initial public offering (IPO) pursuant to which we issued and sold an aggregate of 14,710,000 shares of our common stock at a price to the public of $17.00 per share. We received aggregate net proceeds of $226.5 million after deducting underwriting discounts and commissions of $17.5 million and other offering expenses of $6.0 million. As of March 31, 2024, we had $423.0 million in cash, cash equivalents and marketable securities. Based upon our current operating plan, we believe that our existing cash, cash equivalents and marketable securities, will enable us to fund our operating expenses and capital expenditure requirements through at least the next 12 months following the issuance of the condensed consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since our inception, we have incurred significant net losses, which are primarily attributable to acquired intangible in-process research and development intangible asset (IPR&amp;D) costs pursuant to our acquisitions, which occurred in 2020 and were accounted for as an acquisition of assets. We expect to continue to incur significant losses for the foreseeable future as we continue to advance the development of our product candidates and approach, and incur additional costs associated with being a public company. Our net losses were $53.7 million and $35.6 million for the three months ended March 31, 2024 and 2023, respectively. As of March 31, 2024, we had an accumulated deficit of $757.2 million. Our primary use of our capital resources is to fund our operating expenses, which consist primarily of expenditures related to identifying, acquiring, developing, and in-licensing our precision neuroscience approach and product candidates, and conducting preclinical studies and clinical trials, and to a lesser extent, general and administrative expenditures. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our net losses may fluctuate significantly from period to period, depending on the timing of our clinical trials and our expenditures on research and development activities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will need substantial additional funding to support our continuing operations and pursue our long-term business plan, including to complete the development and commercialization of our product candidates, if approved. Until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our operations through public or private equity offerings or debt financings or other capital sources, which may include strategic collaborations or other arrangements with third parties, or other sources of financing. We may not be able to raise additional capital on terms acceptable to us or at all. If we are unable to raise additional capital on acceptable terms when needed, our business, results of operations, and financial condition would be adversely affected. The amount and timing of </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our future funding requirements will depend on many factors including the successful advancement of our precision neuroscience approach, programs, and product candidates. Our ability to raise additional funds may also be adversely impacted by potential worsening global economic conditions and disruptions to, and volatility in, the credit and financial markets in the United States and worldwide.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acquisitions of Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have completed various acquisitions. For details regarding our acquisitions, see Note 6 &#8211; Acquisitions of Assets to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Strategic License and Research and Collaboration Agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have assumed license arrangements with certain third parties as a result of our acquisitions and have entered into several additional agreements with various parties. For details regarding these agreements, see Note 8 </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8211;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Strategic License and Research and Collaboration Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to our condensed consolidated financial statements included elsewhere in this Quarterly Report </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">on Form 10-Q</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contingent Consideration</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">BlackThorn Contingent Consideration</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the terms of the BlackThorn Merger Agreement, we are required to pay the former stockholders of BlackThorn contingent consideration (i) with respect to navacaprant, in the form of development and regulatory approval milestones of up to an aggregate amount of $365.0 million, which includes a milestone payment that became due and was paid in the fourth quarter of 2024 upon dosing the first patient in the Phase 3 clinical trial for navacaprant, and sales-based milestones of up to an aggregate amount of $450.0 million and (ii) with respect to NMRA-511, in the form of development and regulatory approval milestones of up to an aggregate amount of $100.0 million, and sales-based milestones of up to an aggregate amount of $100.0 million (BlackThorn Milestones). At the Company&#8217;s sole discretion, the BlackThorn Milestone payments may be settled in cash or shares of the Company, or a combination of both, subject to the provisions of the BlackThorn Merger Agreement, other than one development milestone in the amount of $10.0 million, which</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">must be settled in cash. In December 2023, we issued 6,072,445 shares of common stock based on the volume weighted average price per share prior to the date the milestone was met and paid $2.3 million in cash in satisfaction of the Phase 3 navacaprant milestone to the former stockholders of BlackThorn and participants in the carveout plan. As of March 31, 2024,</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">none of the other BlackThorn Milestones have been achieved and no such related amounts were deemed due or payable.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Vanderbilt Contingent Consideration</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the terms of the Vanderbilt License Agreement, we are required to pay Vanderbilt contingent consideration payable in cash up to an aggregate of $42.4 million upon the achievement of specified development milestones and up to an aggregate of $380.0 million upon the achievement of commercial milestone events as well as tiered royalties at mid-single digit percentages on potential future net sales. We achieved a $2.0 million development milestone in October 2023, which was paid in cash in November 2023. As of March 31, 2024, none of the other Vanderbilt milestones have been achieved and no such related amounts were deemed due or payable.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Components of Operating Results</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses consist of external and internal expenses, and primarily relate to our discovery efforts and development of our precision neuroscience approach, programs, and product candidates. We account for acquired in-process research and development (IPR&amp;D) expenses from our strategic acquisitions, which account for a significant portion of our operating expenses, separately from research and development expenses.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">External research and development expenses include, among others, amounts incurred with contract research organizations (CROs), contract manufacturing organizations (CMOs), preclinical testing organizations and other vendors that conduct research and development activities on our behalf. Internal research and development expenses include, among others, personnel-related costs, including salaries, benefits and stock-based compensation for employees engaged in research and development functions, laboratory supplies and other non-capital equipment utilized for in-house research, software development costs and allocated expenses including facilities costs and depreciation and amortization.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because we are working on multiple research and development programs at any one time, we track our external expenses by the stage of program, clinical or preclinical. However, our internal expenses, including unallocated costs, employees and infrastructure are not directly tied to any one program and are deployed across multiple programs. As such, we do not track internal expenses on a specific program basis.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expense research and development costs as incurred. Amounts recorded for external goods or services incurred for research and development activities that have not yet been invoiced are included in accrued liabilities in our condensed consolidated balance sheets and often represent estimates. We estimate accrued expenses and the related research and development expense based on the level of services performed but not yet invoiced pursuant to agreements established with our service providers, according to the progress of preclinical studies, clinical trials or related activities, and discussions with applicable personnel and service providers as to the progress or state of consummation of goods and service. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our condensed consolidated financial statements as prepaid expenses or other current assets or accrued liabilities. Nonrefundable advance payments that we make for goods or services to be received in the future for use in research and development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect our research and development expenses to increase substantially for the foreseeable future as we incur costs to further develop our precision neuroscience approach and advance our programs and product candidates through clinical development and pursue regulatory approval of our product candidates. The process of conducting the necessary clinical and preclinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain. As a result of the uncertainties discussed below, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our research and development expenses may vary significantly based on factors such as:</span></p><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">per patient trial costs;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of trials required for approval;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of sites included in the trials;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the countries in which the trials are conducted;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the length of time required to enroll eligible patients;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of patients that participate in the trials;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the drop-out or discontinuation rates of patients;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential additional safety monitoring requested by regulatory agencies;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the duration of patient participation in the trials and follow-up;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost and timing of manufacturing our product candidates;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the phase of development of our product candidates;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the efficacy and safety profile of our product candidates;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number and scope of preclinical and IND-enabling studies;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effectiveness of our precision neuroscience approach at identifying target patient populations and utilizing the approach to enrich our patient population in our clinical trials;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">employee-related costs for personnel engaged in the design, development, testing and enhancement of our precision neuroscience related technology;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which we establish additional collaboration or license agreements;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether we choose to partner any of our product candidates and the terms of such partnership; and</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of general economic conditions, such as rising inflation and increasing interest rates.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A change in the outcome of any of these variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. We may never succeed in obtaining regulatory approval for any of our product candidates. We may obtain unexpected results from our preclinical studies and future clinical trials.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acquired In-Process Research and Development</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Acquired in-process research and development expenses consist of existing research and development projects at the time of the acquisition. Projects that qualify as IPR&amp;D assets represent those that have not yet reached technological feasibility and have no alternative future use. Our acquisitions of assets have all included IPR&amp;D assets that had not yet reached technological feasibility and had no alternative future use, which resulted in a write-off of these IPR&amp;D assets to acquired in-process research and development expenses in our condensed consolidated statement of operations and comprehensive loss.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses include, among others, personnel-related costs, including salaries, benefits, and stock-based compensation for our employees in executive, finance, and other administrative functions, legal fees, professional fees incurred for accounting, audit, and tax services, recruiting costs, and other allocated expenses, including facilities costs and depreciation and amortization not included in research and development expenses. Legal fees are included within general and administrative expenses and are related to corporate and intellectual property related matters.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect our general and administrative expenses to increase substantially in the foreseeable future as we continue to support our research and development activities, grow our business and, if any of our product candidates receive marketing approval, commence commercialization activities. We will also continue to incur additional expenses associated with operating as a public company, including increased expenses related to audit, legal, regulatory, and tax-related services associated with maintaining compliance with the rules and regulations of the SEC and standards applicable to public companies, additional insurance expenses, investor relations activities and other administrative and professional services.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income (Expense)</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Income</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest income consists of interest earned on our cash equivalents and marketable securities.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results of Operations</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">For the Three Months Ended March </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">31, 2024 and 2023</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our result of operations for the periods presented:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:57.972%;"/>
     <td style="width:1.4%;"/>
     <td style="width:1%;"/>
     <td style="width:10.062000000000001%;"/>
     <td style="width:1%;"/>
     <td style="width:1.4%;"/>
     <td style="width:1%;"/>
     <td style="width:10.882%;"/>
     <td style="width:1%;"/>
     <td style="width:1.4%;"/>
     <td style="width:1%;"/>
     <td style="width:10.882%;"/>
     <td style="width:1%;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,757</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,485</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,272</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,317</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,683</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,634</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60,074</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,168</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,906</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(60,074</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(39,168</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(20,906</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense):</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,365</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,569</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,796</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense), net</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(12</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(26</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other income (expense)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,353</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,543</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,810</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(53,721</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(35,625</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(18,096</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our research and development expenses by program for the periods presented:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:57.171%;"/>
     <td style="width:1.38%;"/>
     <td style="width:1%;"/>
     <td style="width:9.902000000000001%;"/>
     <td style="width:1%;"/>
     <td style="width:1.38%;"/>
     <td style="width:1.38%;"/>
     <td style="width:1%;"/>
     <td style="width:10.702%;"/>
     <td style="width:1%;"/>
     <td style="width:1.38%;"/>
     <td style="width:1%;"/>
     <td style="width:10.702%;"/>
     <td style="width:1%;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="7" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="7" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Direct external program expenses:</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Navacaprant (NMRA-140) program</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,319</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,494</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,825</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">NMRA-511 program</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,887</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,734</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">153</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">NMRA-266 program</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,589</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,068</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">521</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preclinical programs</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,344</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,410</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(66</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Internal and unallocated expenses:</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Personnel-related costs</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,875</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,300</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,575</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other costs</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,743</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,479</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(8,736</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total research and development expenses</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,757</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,485</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,272</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses increased by $16.3 million, or 55%, to $45.8 million for the three months ended March 31, 2024, from $29.5 million for the three months ended March 31, 2023 as we ramped up our clinical and preclinical programs and related activities. Direct external program expenses increased by $22.4 million, of which $21.8 million was related to the Phase 3 clinical trials for navacaprant and $0.5 million was attributable to the Phase 1 clinical trial for NMRA-266. Internal and unallocated expenses decreased by $6.2 million, which were primarily due to a decrease in contracted research and consulting activities of $8.7 million, attributable to decreased activities under our research and collaboration agreements with Amgen and with other vendors, which was</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">partially offset by an increase in personnel related costs of $2.6 million as we increased our headcount, including $1.4 million related to stock-based compensation.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses increased by $4.6 million, or 48%, to $14.3 million for the three months ended March 31, 2024 from $9.7 million for the three months ended March 31, 2023 as we continued to expand our administrative functions to support our business. The increase was primarily attributable to $4.8 million of higher personnel-related costs as we increased our headcount, including $3.8 million related to stock-based compensation, and a $0.4 million increase in insurance costs, which were partially offset by a decrease in professional services of $0.5 million.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Income</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest income increased by $2.8 million to $6.4 million for the three months ended March 31, 2024 from $3.6 million for the three months ended March 31, 2023, which was attributable to interest earned on our higher balances in cash equivalents and marketable securities.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sources of Liquidity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, we had $423.0 million of cash, cash equivalents and marketable securities. Prior to our IPO we primarily funded our operations with the net proceeds from the sale and issuance of our convertible preferred stock and convertible promissory notes and raised gross cash proceeds of over $600 million including from the sale of convertible preferred stock, borrowings pursuant to convertible promissory notes and cash acquired in our acquisitions of assets. On September 19, 2023, we completed our IPO pursuant to which we issued and sold an aggregate of 14,710,000 shares of common stock at a price to the public of $17.00 per share. We received aggregate net proceeds of $226.5 million after deducting underwriting discounts and commissions of $17.5 million and other offering expenses of $6.0 million.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since our inception, we have not generated any revenue from the sale of products and we have incurred significant net losses and negative cash flows from operations. Our primary use of our capital resources is to fund our operating expenses, which consist primarily of expenditures related to identifying, acquiring, developing, and in-licensing our precision neuroscience approach, programs, and product candidates, and conducting preclinical studies and clinical trials, and to a lesser extent, general and administrative expenditures. We have not yet commercialized any products and we do not expect to generate revenue from sales of any product candidates for a number of years, if ever. As of March 31, 2024, we had an accumulated deficit of $757.2 million.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Future Funding Requirements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect our expenses and operating losses will increase substantially over the foreseeable future as we continue our research and development efforts, advance our product candidates through clinical and preclinical development, enhance our precision neuroscience approach and programs, expand our product pipeline, seek regulatory approval, prepare for commercialization, as well as hire additional personnel and protect our intellectual property, Furthermore, as a result of the completion of our IPO on September 19, 2023, we have incurred and will continue to incur additional costs associated with being a public company. We also expect to increase the size of our administrative function to support the growth of our business. Our net losses may fluctuate significantly from period to period, depending on the factors described below. We are subject to the risks typically related to the development of new products, and we may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect our business. The expected increase in expenses will be driven in large part by our ongoing activities, and our future capital requirements will depend on many factors, including:</span></p><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope, timing, progress, costs and results of discovery, preclinical development and clinical trials for our current or future product candidates;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of clinical trials required for regulatory approval of our current or future product candidates;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs, timing and outcome of regulatory review of any of our current or future product candidates;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs associated with acquiring or licensing additional product candidates, technologies or assets, including the timing and amount of any milestones, royalties or other payments due in connection with our acquisitions and licenses;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of manufacturing clinical and commercial supplies of our current or future product candidates;</span></div></div><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effectiveness of our precision neuroscience approach at identifying target patient populations and utilizing our approach to enrich our patient population in our clinical trials;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to maintain existing, and establish new, strategic collaborations or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to access additional multimodal patient datasets;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expenses to attract, hire and retain skilled personnel;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of operating as a public company;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate reimbursement from third-party and government payers;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effect of macroeconomic trends including inflation and rising interest rates;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">addressing any potential supply chain interruptions or delays, including those related to geopolitical issues;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effect of competing technological and market developments; and</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which we acquire or invest in business, products and technologies.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based upon our current operating plan, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements through at least the next 12 months following the issuance of the condensed consolidated financial statements. However, we anticipate that we will need to raise additional financing in the future to fund our operations, including the commercialization of any approved product candidates. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. We may also raise additional financing on an opportunistic basis in the future. We expect to continue to expend significant resources for the foreseeable future.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To complete the development and commercialization of our product candidates, if approved, we will require substantial additional funding. Until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our operations through public or private equity offerings or debt financings or other capital sources, which may include strategic collaborations or other arrangements with third parties, or other sources of financing.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our cash flows for the periods presented:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:67.634%;"/>
     <td style="width:1.64%;"/>
     <td style="width:1%;"/>
     <td style="width:12.062000000000001%;"/>
     <td style="width:1%;"/>
     <td style="width:1.64%;"/>
     <td style="width:1%;"/>
     <td style="width:13.023%;"/>
     <td style="width:1%;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash (used in) provided by:</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating activities</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(42,955</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(33,041</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Investing activities</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(150,001</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,817</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financing activities</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,845</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net change in cash and cash equivalents and<br/>&#160;&#160;&#160;restricted cash</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(191,111</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(30,123</span></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Activities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in operating activities for the three months </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ended March 31</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, 2024 was $43.0 million, which consisted of a net loss of $53.7 million, which was partially offset by a change in our net operating assets and liabilities of $3.6 million and $7.2 million in</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">noncash charges. The change in our net operating assets and liabilities primarily resulted from a decrease of $7.4 million in prepaid expenses and other current assets related to our clinical programs and an increase of $1.2 million in accounts payable primarily due to the timing of our accounts payable, partially offset by a decrease in accrued liabilities related to our clinical programs and a decrease in operating lease liabilities of $0.8 million. The noncash charges primarily consisted of $7.4 million of stock-based compensation, $0.8 million of noncash operating lease expense and $0.2 million of depreciation and amortization, partially offset by $1.1 million of net accretion of discounts on marketable securities.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in operating activities for the three months ended March 31, 2023 was $33.0 million, which consisted of a net loss of $35.6 million, partially offset by $2.3 million in noncash charges and a $0.3 million change in our net operating assets and liabilities. The noncash charges primarily consisted of $2.2 million of stock-based compensation, $0.8 million of noncash operating lease expense and $0.2 million of depreciation and amortization, partially offset by $0.9 million of net accretion of discounts on marketable securities. The change in our net operating assets and liabilities primarily resulted from a decrease of $7.9 million in prepaid expenses and other current assets and other assets primarily related to our collaboration with Amgen, partially offset by a decrease of $6.7 million in accounts payable and accrued liabilities due to the timing of our accounts payable and a decrease of $0.8 million in operating lease liabilities.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investing Activities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in investing activities for the three months </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ended March 31, 2024 </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">was $150.0 million, which primarily consisted of $185.8 million in purchases of marketable securities, partially offset by $36.6 million in proceeds from sales and maturities of marketable securities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by investing activities for the three months ended March 31, 2023 was $2.8 million, which consisted of $44.3 million in proceeds </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">from sales and maturities </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of marketable securities, partially offset by purchases of marketable securities of $41.5 million.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financing Activities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by financing activities for the three months </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ended March 31, 2024 </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">was $1.8 million, which consisted of proceeds from the exercise of stock options.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by financing activities for the three months ended March 31, 2023 was $0.1 million, which consisted of $0.6 million from the exercise of stock options, partially offset by $0.5 million in repurchases of unvested early exercised shares</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Contractual Obligations and Other Commitments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, our contractual obligations and commitments relate primarily to our operating lease for</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our office and laboratory facilities located in Massachusetts with a noncancelable lease term expiring in June 2025. Additionally, as of March 31, 2024, we have amounts due to Amgen pursuant to our September 2021 research and collaboration arrangement within the next year totaling $6.3 million. See Note 8 &#8211; Strategic License and Research and Collaboration Agreements</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to our condensed consolidated financial statements for further information.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have entered into a number of acquisitions of assets that are summarized in Note 6 &#8211; Acquisitions of Assets to our condensed consolidated financial statements. As part of these acquisitions of assets, we are obligated to pay cash and/or stock for future contingent payments that are dependent upon future events, and in some cases, vesting by the recipient of the contingent payment, such as our achievement of certain development, regulatory, and commercial milestones. We have also assumed license arrangements with various third parties, primarily as a result of our acquisitions, and have entered into additional agreements that are summarized in Note 8 &#8211;Strategic License and Research and Collaboration Agreements</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to our condensed consolidated financial statements. In accordance with these agreements, we are obligated to pay, among other items, future contingent payments that are uncertain and dependent upon future events such as our achievement of certain development, regulatory, and commercial milestones royalties, and sublicensing revenue in the future, as applicable. For example, in October 2023, in connection with our acquisition of BlackThorn, a milestone became due upon dosing the first patient in the Phase 3 clinical trial for navacaprant, which was settled in stock and cash in December 2023. In October 2023, in connection with our Vanderbilt License Agreement, a development milestone of $2.0 million became due, which was paid in cash in November 2023.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Accounting Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management&#8217;s discussion and analysis of the financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with the U.S. generally accepted accounting principles, or GAAP. The preparation of our condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosures. Our estimates are based on historical experience and on various other factors that are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have been no material changes to our critical accounting estimates from those described under in "Management's Discussion and Analysis of Financial Condition and Results of Operations </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8211; Critical Accounting Estimates" included in our 2023 Annual Report on Form 10-K filed with the SEC on March 7, 2024.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Note 2 to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for more information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">JOBS Act Accounting Smaller Reporting Company Elections</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until those standards apply to private companies.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our consolidated financial statements and our interim condensed consolidated financial statements may or may not be comparable to companies that comply with new or revised accounting pronouncements as of public companies&#8217; effective dates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also a &#8220;smaller reporting company,&#8221; as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have elected to take advantage of certain of the scaled disclosures available to smaller reporting companies, and will be able to take advantage of these scaled disclosures for so long as the market value of our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and the market value of our voting and non-voting common stock held by non- affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_7a_quantitative_and_qualitative"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Quantitative and Qualitativ</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e Disclosures About Market Risk.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a smaller reporting company, as defined by Rule 12b-2 under the Securities and Exchange Act of 1934, as amended (the Exchange Act) and in Item 10(f)(1) of Regulation S-K, and are not required to provide the information under this item.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_9a_controls_and_procedures"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 4. Cont</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">rols and Procedures.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, management, with the participation and supervision of our Chief Executive Officer and our Chief Financial Officer, have evaluated our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of March 31, 2024, our disclosure controls and procedures were effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the three months ended March 31, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART II&#8212;OTHER INFORMATION</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1. Leg</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">al Proceedings.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are not currently a party to any material legal proceedings. From time to time, we may, however, in the ordinary course of business become involved in legal proceedings. Regardless of outcome, litigation could have a material adverse effect on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors, and there can be no assurances that favorable outcomes will be obtained.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 1A. Ris</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">k Factors.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RISK FACTORS</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investing in shares of our common stock involves a high degree of risk. You should carefully consider the following risks and uncertainties, together with all of the other information contained in this Quarterly Report on Form 10-Q, including our unaudited condensed consolidated financial statements and related notes and the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before making an investment decision. The risks described below are not the only ones facing us. Many of the following risks and uncertainties are, and will be, exacerbated by any worsening of the global business and economic environment. The occurrence of any of the following risks, or of additional risks and uncertainties not presently known to us or that we currently believe to be immaterial, could materially and adversely affect our business, financial condition, reputation, or results of operations. In such case, the trading price of shares of our common stock could decline, and you may lose all or part of your investment.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Summary Risk Factors</span></p><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical-stage biopharmaceutical company and have incurred significant losses since our inception, and we expect to incur losses for the foreseeable future. We have no products approved for commercial sale and may never achieve or maintain profitability.</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our substantial contingent consideration and related obligations from our acquisitions of assets and license and collaboration agreements may result in dilution to our stockholders, may be a drain on our cash resources, or may cause us to incur debt obligations to satisfy the payment obligations.</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our limited operating history may make it difficult to evaluate our prospects and likelihood of success.</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will require additional funding in order to finance operations. If we are unable to raise capital when needed, or on acceptable terms, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to successfully identify, develop and commercialize any product candidates, or experience significant delays in doing so, our business, financial condition and results of operations will be materially adversely affected.</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We were founded with a mission to redefine neuroscience drug development, a field that has seen very limited success. The ability to successfully develop drugs in this field is extremely difficult and is subject to a number of unique challenges.</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have invested and expect to continue to invest in acquiring product candidates, technologies and assets, as well as research and development efforts that further enhance our product pipeline. Such investments may affect our operating results, and, if the return on these investments is lower or develops more slowly than we expect, our revenue and operating results may suffer.</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have experienced rapid growth since our inception in November 2019, and expect to continue to grow in the future. If we fail to effectively manage our growth, we may not be able to execute on our business objectives.</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We operate in highly competitive and rapidly changing industries, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.	 	</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical and preclinical drug development is a lengthy and expensive process, with an uncertain outcome. Our clinical and preclinical programs have experienced delays and may experience additional delays or may never advance, which would adversely affect our ability to obtain regulatory approvals or commercialize our product candidates on a timely basis or at all, which could have an adverse effect on our business.</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The development and commercialization of drug products is subject to extensive regulation, and the regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates on a timely basis or at all, our business will be substantially harmed.</span></div></div><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We depend on intellectual property licensed from third parties and we are currently party to in-license agreements under which we acquired rights to use, develop, manufacture and/or commercialize certain of our proprietary technologies and product candidates. If we breach our obligations under these agreements or if any of these agreements is terminated, or otherwise experience disruptions to our business relationships with our licensors, we may be required to pay damages, lose our rights to such intellectual property and technology, or both, which would harm our business.</span></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Limited Operating History, Financial Condition and Need for Additional Capital</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are a clinical&#8209;stage biopharmaceutical company and have incurred significant losses since our inception, and we expect to incur losses for the foreseeable future. We have no products approved for commercial sale and may never achieve or maintain profitability.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical&#8209;stage biopharmaceutical company with a limited operating history. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We have incurred significant losses since our inception in November 2019, have no products approved for commercial sale, have not generated any revenue from product sales, have financed our operations principally through proceeds from sales of common stock, convertible preferred stock and convertible promissory notes and expect to incur significant losses for the foreseeable future. We expect that it will be several years before we have a commercialized product and generate revenue from product sales. Our net loss was $53.7 million and $35.6 million for the three months ended March 31, 2024 and 2023, respectively. As of March 31, 2024, we had an accumulated deficit of $757.2 million. Our losses have resulted principally from acquired in-process research and development from our acquisitions of assets, expenses incurred in the research and development of our product candidates, as well as from costs associated with our preclinical studies and clinical trials and management and administrative costs and other expenses that we have incurred while building our business infrastructure.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect our expenses and operating losses will continue to increase substantially for the foreseeable future as we expand our research and development efforts, advance our clinical candidates to potentially registrational trials, identify and acquire product candidates, complete preclinical studies and initiate additional clinical trials, seek regulatory approval and commercialization of our product candidates and operate as a public company. We anticipate that our expenses will continue to increase substantially as we:</span></p><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continue clinical and preclinical development of our current and future product candidates and initiate additional preclinical studies and clinical trials;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seek regulatory approval of our current and future product candidates;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acquire additional product candidates, technologies, multimodal patient datasets and other assets for our business;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expand our operational, financial and management systems and increase personnel, including personnel to support our clinical and preclinical development, manufacturing and commercialization efforts;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continue to develop, perfect, maintain and defend our intellectual property portfolio; and</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">incur additional legal, accounting or other expenses in operating our business, including the additional costs associated with operating as a public company.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have devoted a significant portion of our financial resources and efforts to building our organization, acquiring technologies and companies, executing clinical and preclinical studies, conducting research and development, identifying and developing potential product candidates, building our precision neuroscience approach, organizing and staffing our company, business planning, establishing, maintaining and protecting our intellectual property portfolio, raising capital and providing general and administrative support for these operations. We have not completed development and commercialization of any of our product candidates with most still being in relatively early development.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To become and remain profitable, we must succeed in identifying, developing, conducting successful clinical trials, obtaining regulatory approval for, and eventually commercializing, products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our product candidates, continuing to discover and develop additional product candidates, obtaining regulatory and marketing approval for any product candidates that successfully complete clinical trials, accessing manufacturing capacity, establishing marketing capabilities, commercializing and ultimately selling any products. We may never succeed in any or all of these activities and, even if we do, we may never generate revenue that is sufficient to achieve profitability. Even if we do achieve profitability, we may not be able to sustain profitability or meet outside expectations for our profitability. If we are unable to achieve or sustain profitability or to meet outside expectations for our profitability, the price of our common stock could be materially adversely affected.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the numerous risks and uncertainties associated with biopharmaceutical and biotechnology products and drug development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by the U.S. Food and Drug Administration (FDA) or comparable foreign regulatory authorities to perform studies in addition to those we currently anticipate, or if there are any delays in commencing or completing our clinical trials or the development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of any of our product candidates, our expenses could increase and commercial revenue could be further delayed and become more uncertain, which will have a material adverse impact on our business.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our substantial contingent consideration and related obligations from our acquisitions of assets and license and collaboration agreements may result in dilution to our stockholders, may be a drain on our cash resources, or may cause us to incur debt obligations to satisfy the payment obligations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with our acquisitions of assets in late 2020, we entered into arrangements whereby the former stockholders of those companies are entitled to substantial contingent consideration payments upon the occurrence of certain events. For example, in connection with our acquisition of BlackThorn Therapeutics, Inc. (BlackThorn), a privately held company, the former BlackThorn stockholders are entitled to contingent consideration (i) with respect to navacaprant (NMRA&#8209;140), in the form of development and regulatory approval milestones of up to an aggregate amount of $365.0 million, which includes a milestone payment that became due in October 2023 upon dosing the first patient in the Phase 3 clinical trial for navacaprant, which was primarily settled by issuing unregistered shares of our common stock in December 2023, and sales&#8209;based milestones of up to an aggregate amount of $450.0 million and (ii) with respect to NMRA&#8209;511, in the form of development and regulatory approval milestones of up to an aggregate amount of $100.0 million and sales&#8209;based milestones of up to an aggregate amount of $100.0 million (BlackThorn Milestone Payments). With the exception of one development milestone in the amount of $10.0 million that is required to be settled in cash, the remaining BlackThorn Milestone Payments may be settled in cash or shares of our equity, or a combination of both, at our sole discretion. In connection with the BlackThorn acquisition, we also became obligated under its license agreement with TSRI for, among other obligations, development and regulatory milestone payments of up to $1.5 million in aggregate for the first product from each of the TSRI programs and commercial milestone payments of up to $3.5 million in aggregate for each occurrence.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of our September 2021 license agreements with Amgen, we are obligated to pay Amgen up to an aggregate of $720.0 million in commercial milestone payments upon the achievement of certain sales thresholds and single digit royalties on potential annual worldwide net sales related to the CK1&#948; or GCase programs. In addition, under the collaboration agreement with Amgen, we committed to making quarterly payments to Amgen for their collaboration activities over three years totaling $62.5 million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of our license agreement, as amended, with Vanderbilt University (Vanderbilt), we are obligated to pay Vanderbilt up to an aggregate of $422.4 million in development and commercial milestone payments upon the achievement of certain development milestones, which includes a milestone payment of $2.0 million that became due in October 2023, and sales thresholds, and mid&#8209;single digit royalties on potential future net sales.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to satisfy our obligations to make these payments, if and when they are triggered, we may need to issue equity or convertible debt securities that may cause dilution to our stockholders, or we may use our existing cash or incur debt obligations to satisfy the payment obligations in cash, which may adversely affect our financial position. In addition, these obligations may impede our ability to raise money in future public offerings of debt or equity securities or to obtain a third&#8209;party line of credit.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See the sections titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Acquisitions of Assets&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Strategic License and Research and Collaboration Agreements&#8221; in this Quarterly Report on Form 10-Q for additional information regarding these agreements.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our limited operating history may make it difficult to evaluate our prospects and likelihood of success.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical&#8209;stage biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects. Since our inception in November 2019, we have devoted substantially all of our resources and efforts to building our organization, acquiring technologies and companies, executing preclinical studies and clinical trials, conducting research and development, identifying and developing potential product candidates, building our precision neuroscience tools, organizing and staffing our company, business planning, establishing, maintaining and protecting our intellectual property portfolio, raising capital and providing general and administrative support for these operations. All of our product candidates are in either clinical development or in preclinical stages of development, and we have not yet demonstrated our ability to successfully complete any late&#8209;stage or registrational/pivotal clinical trials, obtain regulatory approvals, manufacture a commercial scale product or arrange for a third party to do so on our behalf or conduct sales and marketing activities necessary for successful product commercialization. Additionally, we expect our financial condition and operating results to continue to fluctuate significantly from period to period due to a variety of factors, many of which are beyond our control. Consequently, any predictions you may make about our future success or viability may not be as accurate as they could be if we had a longer operating history.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and risks frequently experienced by clinical&#8209;stage biotechnology and biopharmaceutical companies in rapidly evolving fields. We also may need to transition from a company with a research focus to a company capable of supporting commercial activities. If we do not adequately address these risks and difficulties or successfully make such a transition, it could have a material adverse effect on our business.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will require additional funding in order to finance operations. If we are unable to raise capital when needed, or on acceptable terms, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Developing biopharmaceutical products, including conducting preclinical studies and clinical trials, is a very time&#8209;consuming, expensive and uncertain process that takes years to complete. We expect our expenses to continue to increase in connection with our ongoing activities, particularly as we conduct clinical trials of, and seek regulatory and marketing approval for, our product candidates. Even if one or more of our product candidates is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. To date, we have funded our operations principally through private financings. We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the clinical and preclinical development of our product candidates, continue to develop and deploy our precision neuroscience approach, commence additional preclinical studies and clinical trials, and continue to identify and develop additional product candidates either through internal development or through acquisitions or in&#8209;licensing product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, if we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Accordingly, we will need to obtain substantial additional funding in order to support our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future regulatory approval or commercialization efforts.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to continue to expend significant resources for the foreseeable future. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management from our day&#8209;to&#8209;day activities, which may adversely affect our ability to develop our product candidates. Our future capital requirements will depend on many factors, including but not limited to:</span></p><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope, timing, progress, costs and results of discovery, preclinical development and clinical trials for our current or future product candidates;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of clinical trials required for regulatory approval of our current or future product candidates;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs, timing and outcome of regulatory review of any of our current or future product candidates;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs associated with acquiring or licensing additional product candidates, technologies or assets, including the timing and amount of any milestones, royalties or other payments due in connection with our acquisitions and licenses;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of manufacturing clinical and commercial supplies of our current or future product candidates;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property&#8209;related claims, including any claims by third parties that we are infringing upon their intellectual property rights;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effectiveness of our precision neuroscience approach at identifying target patient populations and utilizing our approach to enrich our patient population in our clinical trials;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to maintain existing, and establish new, strategic collaborations or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to access additional multimodal patient datasets;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expenses to attract, hire and retain skilled personnel;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of operating as a public company;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate reimbursement from third&#8209;party and government payers;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effect of macroeconomic trends including inflation and rising interest rates;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">addressing any potential supply chain interruptions or delays;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effect of competing technological and market developments; and</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which we acquire or invest in business, products and technologies.</span></div></div><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to raise additional funds will depend on financial, economic, political and market conditions and other factors, over which we may have no or limited control. Additional funds may not be available when we need them, on terms that are acceptable to us, or at all. If we fail to obtain necessary capital when needed on acceptable terms, or at all, it could force us to delay, limit, reduce or terminate our product development programs, future commercialization efforts or other operations. Because of the numerous risks and uncertainties associated with research, product development and commercialization of product candidates, we are unable to predict the timing or amount of our working capital requirements or when or if we will be able to achieve or maintain profitability.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, we will need to continue to rely on additional financing to achieve our business objectives and adequate additional financing may not be available to us on acceptable terms, or at all.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations with our existing cash, cash equivalents and marketable securities, the net proceeds from our initial public offering, any future equity or debt financings and upfront and milestone and royalties payments, if any, received under any future licenses or collaborations. If we raise additional capital through the sale of equity or convertible debt securities, or issue any equity or convertible debt securities in connection with a collaboration agreement or other contractual arrangement, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of our common stock. In addition, the possibility of such issuance may cause the market price of our common stock to decline. For example, in December 2023, we settled a Phase 3 navacaprant milestone owed to Blackthorn stockholders by primarily issuing shares of our common stock. Debt financing, if available, may result in increased fixed payment obligations and involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends or acquiring, selling or licensing intellectual property rights or assets, which could adversely impact our ability to conduct our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our intellectual property, technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. We could also be required to seek funds through arrangements with collaborators or others at an earlier stage than otherwise would be desirable. Any of these occurrences may have a material adverse effect on our business, operating results and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain the majority of our cash and cash equivalents in accounts with major U.S. and multi&#8209;national financial institutions, and our deposits at certain of these institutions exceed insured limits. Market conditions and changes in financial regulations and policies can impact the viability of these institutions. In the event of failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely affect our business and financial position. In addition, changes in regulations governing financial institutions are beyond our control and difficult to predict; consequently, the impact of such changes on our business and results of operations is difficult to predict and may have an adverse effect on us.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Business</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to successfully identify, develop and commercialize any product candidates, or experience significant delays in doing so, our business, financial condition and results of operations will be materially adversely affected.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to generate revenue from sales of any of our approved product candidates, which we do not expect will occur for at least the next several years, depends heavily on the successful identification, development, regulatory approval and eventual commercialization of any product candidates, which may never occur. We have never generated revenue from sales of any products, and we may never be able to develop, obtain regulatory approval for, or commercialize, a marketable product. All of our product candidates will require significant clinical development, regulatory approval, establishment of sufficient manufacturing supply, including commercial manufacturing supply, and may require us to build a commercial organization and make substantial investment and significant marketing efforts before we generate any revenue from product sales. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The successful development of our product candidates will depend on several factors, including, but not limited to, the following:</span></p><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successful and timely completion of preclinical studies and clinical trials for which the FDA, or any comparable foreign regulatory authority, agree with the design, endpoints, or implementation;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">receiving regulatory approvals, allowances or authorizations for conducting future clinical trials;</span></div></div><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">initiation and successful patient enrollment in, and completion of, clinical trials on a timely basis;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to demonstrate to the satisfaction of the FDA or any comparable foreign regulatory authority that the applicable product candidate is safe and effective as for its intended uses;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to demonstrate to the satisfaction of the FDA or any comparable foreign regulatory authority that the applicable product candidate&#8217;s risk&#8209;benefit ratio for its proposed indication is acceptable;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">timely receipt of marketing approvals for our product candidates from applicable regulatory authorities;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">addressing any potential supply chain interruptions or delays;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent of any required post&#8209;marketing approval commitments to applicable regulatory authorities; and</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishing, scaling up and scaling out, either alone or with third&#8209;party manufacturers, manufacturing capabilities of clinical supply for our clinical trials and commercial manufacturing, if any of our product candidates are approved.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully develop and commercialize our product candidates, which would materially adversely affect our business, financial condition, and results of operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, clinical or regulatory setbacks to other companies developing similar products or within adjacent fields may impact the clinical development of and regulatory pathway for our current or future product candidates, or may negatively impact the perceptions of value or risk of our technologies.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We were founded with a mission to redefine neuroscience drug development, a field that has seen very limited success. The ability to successfully develop drugs in this field is extremely difficult and is subject to a number of unique challenges.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Drug development in the field of brain diseases, and neuropsychiatric disorders and neurodegenerative diseases in particular, has seen very limited success historically. We estimate over $110 billion have been spent on neuroscience research and development since 2019 in the United States alone, representing approximately 33% of all disease&#8209;specific spending. However, only approximately 12% of all new therapies approved during this time period have been for the treatment of brain diseases. From 2011 to 2020, clinical development success rates for new drug candidates that employed patient selection biomarkers were approximately 16% compared to approximately 8% for patients without patient selection biomarkers according to the BIO; however, clinical success depends on a number of factors and employing a patient selection biomarker approach does not guarantee that our product candidates will be approved and commercialized. Developing a product candidate for treatment of these brain diseases is extremely difficult and subjects us to a number of unique challenges, including obtaining regulatory approval from the FDA and other regulatory authorities who have only a limited set of precedents to rely on.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We intend to work closely with the FDA and comparable foreign regulatory authorities to perform the requisite scientific analyses and evaluation in an effort to obtain regulatory approval for our product candidates; however, the process of developing our product candidates may be more complex and time&#8209;consuming relative to other more well&#8209;known approaches to drug development. We cannot be certain that our approach will lead to the development of product candidates that effectively and safely address the underlying brain diseases.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, given the history of clinical failures in this field, future clinical or regulatory failures by us or others may have result in further negative perception of the likelihood of success in this field, which may significantly and adversely affect the market price of our common stock.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have invested and expect to continue to invest in acquiring product candidates, technologies and assets, as well as research and development efforts that further enhance our product pipeline. Such investments may affect our operating results, and, if the return on these investments is lower or develops more slowly than we expect, our revenue and operating results may suffer.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have invested and expect to continue to invest in acquiring potential product candidates to enhance our product pipeline, technologies and assets. These activities and investments involve significant time, risks, and uncertainties, including the risk that the associated expenses may affect our operating results, that such investments may not generate products that can be successfully developed or technologies that can be effectively used by us, and cause significant drains on capital resources and commit us to substantial financial obligations. While we believe that we must continue to invest a significant amount of time and resources in the development of our product pipeline, if we do not achieve the benefits anticipated from these investments, or if the achievement of these benefits is delayed, our business, operating results and prospects may be materially adversely affected.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have experienced rapid growth since our inception in November 2019, and expect to continue to grow in the future. If we fail to effectively manage our growth, we may not be able to execute on our business objectives.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2023, we had 108 full&#8209;time employees and, as of March 31, 2024, we had grown to 120 full&#8209;time employees. We expect continued growth in the number of our employees and the scope of our operations, particularly as we continue our current and future clinical trials and preclinical studies, initiate and conduct investigational new drug application (IND)&#8209;enabling studies and build out our clinical operations, regulatory, quality and manufacturing infrastructure. In addition to headcount growth, we have made a number of acquisitions of assets, and entered into a significant strategic collaboration with Amgen and in&#8209;licensed programs from Amgen and Vanderbilt. These activities have added significant complexity to our organization, including a number of clinical and preclinical programs that we are now developing. These programs require significant infrastructure and headcount to effectively prosecute.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To manage our anticipated future growth, we will continue to implement and improve our managerial, operational, and financial systems, expand our facilities, and continue to recruit and train additional qualified personnel. Due to the complexity in managing a company that has scaled very quickly and anticipates continued growth, we may not be able to scale our headcount and operations effectively to manage the expansion of our product pipeline or recruit and train the necessary additional personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, future growth imposes significant added responsibilities on members of management, including: identifying, recruiting, integrating, maintaining, and motivating additional employees; managing our internal development efforts effectively, including the clinical and FDA review process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and improving and scaling our operational, financial and management controls, reporting systems and procedures.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently rely on certain independent organizations, advisors, and consultants to provide certain services, including strategic, financial, business development, and research and development services, as well as certain aspects of regulatory approval and manufacturing. There can be no assurance that the services of independent organizations, advisors, and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants or contract manufacturing organizations is compromised for any reason, our clinical trials may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on reasonable terms, or at all.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to develop product candidates, leverage our precision neuroscience approach and our future growth depends on attracting, hiring and retaining our key personnel and recruiting additional qualified personnel.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends upon the continued contributions of our key management and scientific personnel, many of whom have been instrumental for us and have substantial experience with developing therapies, identifying potential product candidates and building the technologies related to the clinical development of our product candidates. Given the specialized nature of brain diseases and our approach, there is an inherent scarcity of experienced personnel in these fields. As we continue developing our product candidates in our pipeline, we will require personnel with medical, scientific, or technical qualifications specific to each program. The loss of key personnel, in particular our neuroscientists, would delay our research and development activities. Despite our efforts to retain valuable employees, members of our team may terminate their employment with us on short notice. The competition for qualified personnel in the biotechnology and biopharmaceutical industries is intense, and our future success depends upon our ability to attract, retain, and motivate highly skilled scientific, technical and managerial employees. We face competition for personnel from other companies, universities, public and private research institutions, and other organizations. If our recruitment and retention efforts are unsuccessful in the future, it may be difficult for us to implement our business strategy, which would have a material adverse effect on our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, our clinical operations and research and development programs depend on our ability to attract and retain highly skilled scientists, data scientists, and engineers, particularly in Massachusetts and California.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is powerful competition for skilled personnel in these geographical markets, and we have from time to time experienced, and we expect to continue to experience, difficulty in hiring and retaining employees with appropriate qualifications on acceptable terms, or at all. Many of the companies with which we compete for experienced personnel have greater resources than we do, and any of our employees may terminate their employment with us at any time. If we hire employees from competitors or other companies, their former employers may attempt to assert that these employees or we have breached legal obligations, resulting in a diversion of our time and resources and, potentially, damages. In addition, job candidates and existing employees often consider the value of the stock awards they receive in connection with their employment. If the perceived benefits of our stock awards decline, it may harm our ability to recruit and retain highly skilled employees. If we fail to attract new personnel or fail to retain and motivate our current personnel, our business and future growth prospects would be harmed.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not realize the benefits of assets that we have acquired, or will acquire in the future, or other strategic transactions that we have or will consummate.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our approach represents an aggregation of innovation and assets from multiple companies and academic institutions, including BlackThorn, Syllable and Alairion as well as Amgen, TSRI and Vanderbilt. Further, a key component of our strategy is to acquire and in&#8209;license assets and technologies to support the growth of our product pipeline and to enhance our Precision Toolbox. As such, we actively evaluate various strategic transactions on an ongoing basis. We may acquire other assets, businesses, products or technologies, as well as pursue joint ventures or investments in complementary businesses. The success of our strategic transactions and any future strategic transactions depends on the risks and uncertainties involved including:</span></p><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unanticipated liabilities related to acquired companies or joint ventures;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulties integrating acquired personnel, technologies, and operations into our existing business;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">retention of key employees;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">diversion of management time and focus from operating our business to the management of acquisition and integration efforts, strategic alliances or joint ventures challenges;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increases in our expenses and reductions in our cash available for operations and other uses;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disruption in our relationships with collaborators or suppliers; and</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">possible write&#8209;offs or impairment charges relating to acquired businesses or joint ventures.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of these risks or uncertainties occur, we may not realize the anticipated benefit of any acquisition or strategic transaction. For example, less than one year following the acquisition of Propellex, we terminated and are no longer developing the program we acquired from Propellex. We have ceased the development of our NMRA&#8209;094 product candidate for the treatment of obstructive sleep apnea (OSA) that we acquired from Alairion based on pre-IND feedback we received from the FDA. Additionally, foreign acquisitions and joint ventures are subject to additional risks, including those related to integration of operations across different cultures and languages, currency risks, potentially adverse tax consequences of overseas operations and the particular economic, political and regulatory risks associated with specific countries.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses, impairments or write&#8209;offs of goodwill or impairments and write&#8209;offs of in&#8209;process research and development assets, any of which could harm our financial condition.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have relied on, and in the future will continue to rely on, third&#8209;party datasets and databases to build and enhance our precision neuroscience approach. If we are not able to access additional data sets or develop enhancements to our precision neuroscience approach, our ability to execute on our strategy may be limited.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to execute on our drug development strategy depends in part on our ability to enhance and improve our precision neuroscience approach. As part of this approach, we interrogate public, partnered and proprietary datasets across neuropsychiatric and neurodegenerative diseases, currently encompassing genetic, imaging, electroencephalogram (EEG), digital and clinical data. We rely on these datasets and data analytics for identifying or validating some of our biomarker&#8209;target relationships. The success of our precision neuroscience approach and any enhancement to our approach depends on several factors, including access to and generation of additional multimodal patient datasets, whether public, partnered or proprietary, development of more advanced proprietary machine learning capabilities and increased computational storage and processing capacity. If we are unable to access additional datasets or they are not available on acceptable terms, or if we are otherwise unsuccessful in enhancing our approach, we may be limited in our precision neuroscience capabilities and not be able to fully utilize a precision neuroscience drug development strategy.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, access to public data sets may be limited by governmental or other restrictions, including restrictions on commercial application by government or government sponsored organizations or privacy related restrictions. See the risk factor &#8220;We face potential liability related to the privacy of health information we utilize in the development of product candidates, as well as information we obtain from clinical trials sponsored by us from research institutions and directly from individuals&#8221; for additional information on privacy related considerations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We operate in highly competitive and rapidly changing industries, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The biotechnology and biopharmaceutical industries are highly competitive and subject to significant and rapid technological change. Our success is highly dependent on our ability to discover, develop and obtain marketing approval for new and innovative products on a cost&#8209;effective basis and to market them successfully. In doing so, we face and will continue to face intense competition from a variety of businesses, including large biopharmaceutical and biotechnology companies, academic institutions, government agencies and other public and private research organizations. These organizations may have significantly greater resources than we do and conduct similar research, seek patent protection and establish collaborative arrangements for research, development, manufacturing, and marketing of products that compete with our product candidates. Mergers and acquisitions in the biotechnology and biopharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With the proliferation of new drugs and therapies for our target indications, we expect to face increasingly intense competition as new technologies become available. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. The highly competitive nature of and rapid technological changes in the biotechnology and biopharmaceutical industries could render our product candidates or our technology obsolete, less competitive or uneconomical. Our competitors may, among other things:</span></p><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">have significantly greater financial, manufacturing, marketing, drug development, technical, and human resources than we do;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">develop and commercialize products that are safer, more effective, less expensive, more convenient or easier to administer, or have fewer or less severe side effects;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain quicker regulatory approval;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish superior proprietary positions covering our products and technologies;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">implement more effective approaches to sales and marketing; or</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">form more advantageous strategic alliances.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should any of these factors occur, our business, financial condition and results of operations could be materially adversely affected.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, any collaborators may decide to market and sell products that compete with the product candidates that we have agreed to license to them, and any competition by our collaborators could also have a material adverse effect on our future business, financial condition, and results of operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in developing or acquiring technologies complementary to, or necessary for, our programs.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because we have limited financial and managerial resources, we focus on research programs, therapeutic platforms, and product candidates that we identify for specific indications. Additionally, we have contractual commitments under the agreements for various product candidate assets that we acquired from third parties, as well as our license and collaboration agreements, to use commercially reasonable efforts to develop certain programs and, thus, do not have unilateral discretion to vary from such agreed to efforts. In addition, we have contractual commitments to conduct certain development plans, and thus may not have discretion to modify such development plans, including clinical trial designs, without agreement from our collaboration partner. As a result, we may forego or delay pursuit of opportunities with other therapeutic platforms or product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs, therapeutic platforms, and product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing, or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely upon third&#8209;party providers of cloud&#8209;based infrastructure to host our platforms. Any disruption in the operations of these third&#8209;party providers, limitations on capacity, or interference with our use could adversely affect our business, financial condition, and results of operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We outsource substantially all of the technological infrastructure relating to our hosted platform to third&#8209;party hosting services, such as Amazon Web Services. We have no control over any of these third parties, and while we attempt to reduce risk by minimizing reliance on any single third party or its operations, we cannot guarantee that such third&#8209;party providers will not experience system interruptions, outages or delays, or deterioration in their performance. We need to be able to access our computational platform at any time, without interruption or degradation of performance. Our hosted platform depends on protecting the virtual cloud infrastructure hosted by third&#8209;party hosting services by maintaining its configuration, architecture, features, and interconnection specifications, as well as protecting the information stored in these virtual data centers, which is transmitted by third&#8209;party Internet service providers. We have experienced and expect that in the future we may again experience interruptions, delays and outages in service and availability from time to time due to a variety of factors, including infrastructure changes, human or software errors, website hosting disruptions and capacity constraints. Any limitation on the capacity of our third&#8209;party hosting services could adversely affect our business, financial condition, and results of operations. In addition, any incident affecting our third&#8209;party hosting services&#8217; infrastructure that may be caused by cyber&#8209;attacks, natural disasters, fire, flood, severe storm, earthquake, power loss, telecommunications failures, terrorist or other attacks, and other disruptive events beyond our control could negatively affect our cloud&#8209;based solutions. A prolonged service disruption affecting our cloud&#8209;based solutions could damage our reputation or otherwise harm our business. We may also incur significant costs for using alternative equipment or taking other actions in preparation for, or in reaction to, events that damage the third&#8209;party hosting services we use.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event that our service agreements with our third&#8209;party hosting services are terminated, or there is a lapse of service, elimination of services or features that we utilize, interruption of internet service provider connectivity, or damage to such facilities, we could experience interruptions in access to our platform as well as significant delays and additional expense in arranging or creating new facilities and services and/or re&#8209;architecting our hosted software solutions for deployment on a different cloud infrastructure service provider, which could adversely affect our business, financial condition, and results of operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our security measures are breached or unauthorized access to our other data is otherwise obtained, our data may be perceived as not being secure and we may incur significant liabilities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use a set of proprietary tools to generate, analyze, and derive novel insights from our data. As a result, unauthorized access to or security breaches of our data, as a result of third&#8209;party action, employee or contractor error, malfeasance, or otherwise could require notification to individuals, governmental authorities, supervisory bodies, the media and other parties pursuant to privacy and security laws and result in the loss or corruption of, or other damage to information, claims and litigation, indemnity obligations, damage to our reputation, and other liability. Our collaborators and other third parties we work with may also suffer similar security breaches of data that we rely on. Because the techniques used to obtain unauthorized access or sabotage systems change frequently and generally are not identified until they are launched against a target, we and those we collaborate with may be unable to anticipate these techniques or implement adequate preventative measures. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. In addition, if our employees or contractors fail to adhere to practices we have established to maintain a firewall between our internal drug discovery team and our teams that work with external individuals, including our collaborators, or if the technical solutions we have adopted to maintain the firewall malfunction, our collaborators may lose confidence in our ability to maintain the confidentiality of their intellectual property, we may have trouble attracting new collaborators, we may be subject to breach of contract claims by our collaborators, and we may suffer reputational and other harm as a result. Federal, state and foreign laws and regulations may also expose us to enforcement actions and investigations by regulatory authorities, and potentially result in regulatory penalties, fines and significant legal liability, if our information technology security efforts fail. Any or all of these issues could result in reputational damage or subject us to third&#8209;party lawsuits or other action or liability, which could adversely affect our operating results and the further development and commercialization of our products. Our insurance may not be adequate to cover losses associated with such events, and in any case, such insurance may not cover all of the types of costs, expenses, and losses we could incur to respond to and remediate a security breach.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our precision neuroscience tools utilize third&#8209;party open source software, and any failure to comply with the terms of one or more of these open source software licenses could adversely affect our business, subject us to litigation, or create potential liability.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our precision neuroscience tools include software licensed by third parties under any one or more open source licenses, and we expect to continue to incorporate open source software in our precision neuroscience tools in the future. While we have a process in place for monitoring the use of open source software by our employees, we cannot ensure we are aware of every instance of such use or have validated the quality or source of such software, or that we are in compliance with the terms of the applicable open source licenses or our current policies and procedures. There have been claims against companies that use open source software in their products and services asserting that the use of such open source software infringes the claimants&#8217; intellectual property rights. As a result, we could be subject to suits by third parties claiming that what we believe to be licensed open source software infringes such third parties&#8217; intellectual property rights. Additionally, if an author or other third party that distributes such open source software were to allege that we had not complied with the conditions of one or more of these licenses, we could be required to incur significant legal expenses defending against such allegations and could be subject to significant damages and required to comply with onerous conditions or restrictions on these solutions, which could disrupt the distribution and sale of these solutions. Litigation could be costly for us to defend, have a negative effect on our business, financial condition, and results of operations, or require us to devote additional research and development resources to change our precision neuroscience tools. Furthermore, these third&#8209;party open source providers could experience service outages, data loss, privacy breaches, cyber&#8209;attacks, and other events relating to the applications and services they provide that could diminish the utility of these services and which could harm our business as a result.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of open source software may entail greater risks than use of third&#8209;party commercial software, as open source licensors generally do not provide warranties or other contractual protections regarding infringement claims or the quality of the code, including with respect to security vulnerabilities where open source software may be more susceptible. In addition, certain open source licenses require that source code for software programs that interact with such open source software be made available to the public at no cost and that any modifications or derivative works to such open source software continue to be licensed under the same terms as the open source software license. The terms of various open source licenses to which we are subject have not been interpreted by courts in the relevant jurisdictions, and there is a risk that such licenses could be construed in a manner that imposes unanticipated conditions or restrictions on our ability to market or provide our software and data. By the terms of certain open source licenses, we could be required to release the source code of our proprietary software, and to make our proprietary software available under open source licenses, if we combine our proprietary software with open source software in a certain manner. In the event that portions of our proprietary software are determined to be subject to an open source license, we could be required to publicly release the affected portions of our source code, re&#8209;engineer all or a portion of our precision neuroscience tools, or otherwise be limited in the licensing of our precision neuroscience tools, each of which could reduce or eliminate the value of our precision neuroscience tools. Disclosing our proprietary source code could allow our competitors to create similar products with lower development effort and time and ultimately could result in a loss of sales. Furthermore, any such re&#8209;engineering or other remedial efforts could require significant additional research and development resources, and we may not be able to successfully complete any such re&#8209;engineering or other remedial efforts. Any of these events could create liability for us and damage our reputation, which could have a material adverse effect on our revenue, business, results of operations, and financial condition and the market price of our shares.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to the Development and Clinical Testing of Our Product Candidates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical and preclinical drug development is a lengthy and expensive process, with an uncertain outcome. Our clinical and preclinical programs have experienced delays and may experience additional delays or may never advance, which would adversely affect our ability to obtain regulatory approvals or commercialize our product candidates on a timely basis or at all, which could have an adverse effect on our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to obtain FDA approval to market our product candidates, we must demonstrate the safety and efficacy of our product candidates in humans to the satisfaction of the FDA. To meet these requirements, we will have to conduct adequate and well&#8209;controlled clinical trials. Clinical testing is expensive, time&#8209;consuming and subject to uncertainty. Conducting preclinical testing and clinical trials represents a lengthy, time&#8209;consuming and expensive process. The length of time may vary substantially according to the type, complexity and novelty of the program, and often can be several years or more per program. Delays associated with programs for which we are directly conducting preclinical studies may cause us to incur additional operating expenses. The commencement and rate of completion of preclinical studies and clinical trials for a product candidate may be delayed by many factors, including, but not limited to:</span></p><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inability to generate sufficient preclinical or other </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">data to support the initiation of clinical studies;</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">timely completion of preclinical laboratory tests, animal studies and formulation studies in accordance with FDA&#8217;s Good Laboratory Practice (GLP) requirements and other applicable regulations;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approval by an independent Institutional Review Board (IRB) or ethics committee at each clinical site before each trial may be initiated;</span></div></div><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in reaching a consensus with regulatory agencies on study design and obtaining regulatory authorization to commence clinical trials; delays in reaching agreement on acceptable terms with prospective contract research organizations (CROs), and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in identifying, recruiting and training suitable clinical investigators;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in recruiting suitable patients to participate in our clinical trials;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of our product candidates for use in clinical trials or the inability to do any of the foregoing;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">insufficient or inadequate supply or quality of product candidates or other materials necessary for use in clinical trials, or delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for clinical trials;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">imposition of a temporary or permanent clinical hold by regulatory authorities;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developments on trials conducted by competitors for related technology that raises FDA or foreign regulatory authority concerns about risk to patients of the technology broadly, or if the FDA or a foreign regulatory authority finds that the investigational protocol or plan is clearly deficient to meet its stated objectives;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in recruiting, screening and enrolling patients and delays caused by patients withdrawing from clinical trials or failing to return for post&#8209;treatment follow&#8209;up;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulty collaborating with patient groups and investigators;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure by our CROs, other third parties or us to adhere to clinical trial protocols; failure to perform in accordance with the FDA&#8217;s or any other regulatory authority&#8217;s good clinical practice (GCP) requirements, or applicable regulatory guidelines in other countries;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits, or occurrence of adverse events in trial of the same class of agents conducted by other companies;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes to the clinical trial protocols;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical sites deviating from trial protocol or dropping out of a trial;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the standard of care on which a clinical development plan was based, which may require new or additional trials;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">selection of clinical endpoints that require prolonged periods of observation or analyses of resulting data;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of clinical trials of our product candidates being greater than we anticipate;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical trials of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon development of such product candidates;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">transfer of manufacturing processes to larger&#8209;scale facilities operated by a contract manufacturing organization (CMO) and delays or failure by our CMOs or us to make any necessary changes to such manufacturing process; and</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">third parties being unwilling or unable to satisfy their contractual obligations to us.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials must be conducted in accordance with the FDA and other applicable regulatory authorities&#8217; legal requirements, regulations or guidelines, and are subject to oversight by these governmental agencies and ethics committees or IRBs at the medical institutions where the clinical trials are conducted. We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA or comparable foreign regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. For example, nonclinical safety pharmacology studies of NMRA&#8209;511 indicate that the dose limiting toxicities were CNS observations including tremor and convulsions, which led to a partial clinical hold on our IND that was removed when we amended the protocol to include tremors as a stopping criterion. Further, in April 2024, our Phase 1 trial of NMRA-266 was placed on clinical hold by the FDA after data from nonclinical studies showed convulsions in rabbits. We are working with the FDA to evaluate the potential to resolve the clinical hold. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">42</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, conducting clinical trials in foreign countries, as we may do for our product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Delays in the completion of any preclinical studies or clinical trials of our product candidates will increase our costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate product revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Any delays to our preclinical studies or clinical trials that occur as a result could shorten any period during which we may have the exclusive right to commercialize our product candidates and our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies with respect to clinical trials may change and additional government regulations may be enacted. For instance, the regulatory landscape related to clinical trials in the EU recently evolved. The EU Clinical Trials Regulation (CTR) which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. While the Clinical Trials Directive required a separate clinical trial application (CTA), to be submitted in each member state in which the clinical trial takes place, to both the competent national health authority and an independent ethics committee, the CTR introduces a centralized process and only requires the submission of a single application for multi-center trials. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. Clinical trials for which an application was submitted (i) prior to January 31, 2022 under the Clinical Trials Directive, or (ii) between January 31, 2022 and January 31, 2023 and for which the sponsor has opted for the application of the EU Clinical Trials Directive remain governed by said Directive until January 31, 2025. After this date, all clinical trials (including those which are ongoing) will become subject to the provisions of the CTR. Compliance with the CTR requirements by us and our third-party service providers, such as Contract research organizations (CRO), may impact our developments plans.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It is currently unclear to what extent the UK will seek to align its regulations with the EU. The UK regulatory framework in relation to clinical trials is derived from existing EU legislation (as implemented into UK law, through secondary legislation).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 17, 2022, the UK Medicines and Healthcare products Regulatory Agency (MHRA), launched an eight-week consultation on reframing the UK legislation for clinical trials. The UK Government published its response to the consultation on March 21, 2023 confirming that it would bring forward changes to the legislation. These resulting legislative amendments will determine how closely the UK regulations are aligned with the CTR. A decision by the UK not to closely align its regulations with the new approach adopted in the EU may have an effect on the cost of conducting clinical trials in the UK as opposed to other countries.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Results of preclinical studies or clinical trials of any product candidates may not be predictive of the results of future preclinical studies or clinical trials.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To obtain the requisite regulatory approvals to market and sell any of our product candidates, we or any collaborator for such product candidate must demonstrate through extensive preclinical studies and clinical trials that the product candidate is safe and effective in humans. Before an IND can be submitted to the FDA and become effective, which is a prerequisite for conducting clinical trials on human subjects in the United States, a product candidate must successfully progress through extensive preclinical studies, which include preclinical laboratory testing, animal studies, and formulation studies, certain of which must be conducted in accordance with GLP. We cannot be certain of the timely completion or outcome of any preclinical studies. We also cannot predict if the FDA or comparable regulatory authorities will allow our proposed clinical programs to proceed or if the outcome of our preclinical studies will ultimately support further development of our programs. Additionally, we cannot be sure that we will be able to submit INDs or similar applications with respect to our product candidates on the timelines we expect, if at all, and we cannot be sure that submission of IND or similar applications will result in the FDA or other regulatory authorities allowing clinical trials to begin.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, success in preclinical studies or early clinical trials does not ensure that later preclinical studies or clinical trials will be successful. A number of companies in the biotechnology and biopharmaceutical industries have suffered significant setbacks in clinical trials, even after positive results in earlier preclinical studies. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including previously unreported adverse events. The design of a clinical trial can determine whether its results will support approval of a product, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. In addition, clinical and preclinical data are often susceptible to varying interpretations and analyses. Notwithstanding any potential promising results in earlier studies, we cannot be certain that we will not face similar setbacks. In addition, the results of our preclinical animal studies, including our non&#8209;human primate studies, may not be predictive of the results of outcomes in subsequent clinical trials on human subjects. Product candidates in clinical trials may fail to show the desired pharmacological properties or safety and efficacy traits despite having progressed through preclinical studies.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail to receive positive results in preclinical studies or clinical trials of any product candidate, the development timeline and regulatory approval and commercialization prospects for that product candidate, and, correspondingly, our business and financial prospects, would be negatively impacted.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our product candidates may have serious adverse, undesirable, or unacceptable side effects or other properties that may delay or prevent marketing approval. If such side effects are identified following approval, if any, the commercial profile of any approved label may be limited, or we may be subject to other significant negative consequences following marketing approval, if any.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects that may be caused by our product candidates could cause us or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign authorities. The drug&#8209;related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, if our product candidates are associated with undesirable side effects in clinical trials or have characteristics that are unexpected, we may elect to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk&#8209;benefit perspective, which may limit the commercial expectations for the product candidate if approved. We may also be required to modify our study plans based on findings in our ongoing preclinical studies or clinical trials. For example, in a rat study, at its highest dose (100 mg/kg/day) navacaprant was observed to have skin&#8209;related phototoxicity of erythema, edema and flaking additionally ocular phototoxicity (corneal edema). While no phototoxicity has been observed in our Phase 1 clinical trials, we monitored visual acuity and corneal integrity in our Phase 2 clinical trial to confirm there was no phototoxicity in humans. Though we did not observe any phototoxicity effects in our Phase 2 clinical trial, if phototoxicity is experienced in our later&#8209;stage clinical trials, the labeling implications of such safety warnings may limit any future product sales, if navacaprant is approved.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the product candidate. It is possible that as we test our product candidates in larger, longer and more extensive clinical trials, including with different dosing regimens, or as the use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, may be reported by subjects. If such side effects become known later in development or upon approval, if any, such findings may harm our business, financial condition and prospects significantly.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event that any of our product candidates receives marketing approval and we or others later identify undesirable or unacceptable side effects caused by such products, a number of potentially significant negative consequences could result, including:</span></p><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may withdraw or limit approvals of such products and require us to take our approved product off the market;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies, or issue other communications containing warnings or other safety information about the product;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may require a medication guide outlining the risks of such side effects for distribution to patients, or that we implement a risk evaluation and mitigation strategy (REMS), plan to ensure that the benefits of the product outweigh its risks;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to change the dose or the way the product is administered, conduct additional clinical trials, or change the labeling of the product;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be subject to limitations on how we may promote or manufacture the product;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sales of the product may decrease significantly;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be subject to litigation or product liability claims; and</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our reputation may suffer.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of these events could prevent us or our potential future partners from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of any products.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interim, topline, or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available or as we make changes to our manufacturing processes and are subject to audit and verification procedures that could result in material changes in the final data.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may publicly disclose preliminary or topline data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then&#8209;available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the topline or preliminary data we previously published. As a result, topline and preliminary data should be viewed with caution until the final data are available.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our vaccine candidates may be harmed, which could harm our business, prospects, financial condition or results of operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will depend on enrollment and retention of patients in our clinical trials for our product candidates. If we experience delays or difficulties enrolling or retaining patients in our clinical trials, our research and development efforts and business, financial condition and results of operations could be materially adversely affected.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Successful and timely completion of clinical trials will require that we enroll and retain a sufficient number of patient candidates. Any clinical trials we conduct may be subject to delays for a variety of reasons, including as a result of patient enrollment taking longer than anticipated, patient withdrawal or adverse events. These types of developments could cause us to delay the trial or halt further development.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our clinical trials will compete with other clinical trials that are in the same therapeutic areas as our product candidates, and this competition reduces the number and types of patients available to us, as some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because the number of qualified clinical investigators and clinical trial sites is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. The eligibility criteria of our clinical studies, and in particular, any eligibility criteria we may establish using our precision neuroscience approach, may limit the pool of available study participants as we will require that patients have specific characteristics that we can measure or to assure their disease is either severe enough or not too advanced to include them in a study.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patient enrollment depends on many factors, including:</span></p><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the size and nature of the patient population;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the severity of the disease under investigation;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">eligibility criteria for the trial;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the proximity of patients to clinical sites;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the design of the clinical protocol;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to obtain and maintain patient consents;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the risk that patients enrolled in clinical trials will drop out of the trials before the administration of our product candidates or trial completion;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of competing clinical trials;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of new drugs approved for the indication the clinical trial is investigating; and</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available therapies.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These factors may make it difficult for us to enroll enough patients to complete our clinical trials in a timely and cost&#8209;effective manner. Delays in the completion of any clinical trial of our product candidates will increase our costs, slow down our product candidate development and approval process, and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, some of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The estimates of market opportunity and forecasts of market growth included in our public disclosures may prove to be smaller than we believe, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We intend to initially focus our product candidate development on treatments for various neuropsychiatric disorders and neurodegenerative diseases. Our projections of addressable patient populations within any particular disease state that may benefit from treatment with our product candidates are based on our estimates. Market opportunity estimates and growth forecasts included in our public disclosures are subject to significant uncertainty and are based on assumptions and estimates. These estimates, which have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, and market research, may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. Additionally, the potentially addressable patient population for our product candidates may not ultimately be amenable to treatment with our product candidates. Our market opportunity may also be limited by future competitor treatments that enter the market. If any of our estimates prove to be inaccurate, the market opportunity for any product candidate that we or our strategic partners develop could be significantly diminished and have an adverse material impact on our business.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if approved, our products may not gain market acceptance, in which case we may not be able to generate product revenues, which will materially adversely affect our business, financial condition, and results of operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if the FDA or any comparable foreign regulatory authority approves the marketing of any product candidates that we develop, physicians, healthcare providers, patients, or the medical community may not accept or use them. Additionally, the product candidates that we are developing are based on our proprietary approach, which are new technologies. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenues or any profits from operations. The degree of market acceptance of any of our product candidates will depend on a variety of factors, including:</span></p><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing of market introduction of the product candidate as well as competitive products;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the clinical indications for which a product candidate is approved;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the terms of any approvals and the countries in which approvals are obtained;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number and clinical profile of competing products;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential and perceived advantages of our product candidates over alternative treatments;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to provide acceptable evidence of safety and efficacy;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the prevalence and severity of any side effects;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of an approved product candidate for use as a combination therapy;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">relative convenience and ease of administration;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cost&#8209;effectiveness;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patient diagnostics and screening infrastructure in each market;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effectiveness of sales and marketing efforts;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approval of other new therapies for the same indications;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">marketing and distribution support;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adverse publicity about our product candidates;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">availability of coverage, adequate reimbursement and sufficient payment from health maintenance organizations and other insurers, both public and private, for our product candidates, or the procedures utilizing our product candidates, if approved;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the willingness of patients to pay out&#8209;of&#8209;pocket in the absence of coverage by third&#8209;party payors and government authorities; and</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">other potential advantages over alternative treatment methods.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our product candidates fail to gain market acceptance, this will have a material adverse impact on our ability to generate revenues to provide a satisfactory, or any, return on our investments. Even if some products achieve market acceptance, the market may prove not to be large enough to allow us to generate significant revenues.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">47</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We currently have no marketing, sales, or distribution infrastructure and we intend to either establish a sales and marketing infrastructure or outsource this function to a third party. Either of these commercialization strategies carries substantial risks to us.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Given our stage of development, we currently have no marketing, sale, and distribution capabilities. If any of our product candidates complete clinical development and are approved, we intend to either establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize our product candidates in a legally compliant manner, or to outsource this function to a third party. There are risks involved if we decide to establish our own sales and marketing capabilities or enter into arrangements with third parties to perform these services. To the extent that we enter into collaboration agreements with respect to marketing, sales or distribution, our product revenue may be lower than if we directly marketed or sold any approved products. Such collaborative arrangements with partners may place the commercialization of our products outside of our control and would make us subject to a number of risks including that we may not be able to control the amount or timing of resources that our collaborative partner devotes to our products or that our collaborator&#8217;s willingness or ability to complete its obligations, and our obligations under our arrangements may be adversely affected by business combinations or significant changes in our collaborator&#8217;s business strategy.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to enter into these arrangements on acceptable terms or at all, we may not be able to successfully commercialize any approved products. If we are not successful in commercializing any approved products, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses, which would have a material adverse effect on our business, financial condition, and results of operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may become exposed to costly and damaging liability claims, either when testing our product candidates in the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing, and use of biopharmaceutical products. While we currently have no products that have been approved for commercial sale, the future use of product candidates by us in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients that use the product, healthcare providers, pharmaceutical companies, or others selling such products. Any claims against us, regardless of their merit, could be difficult and costly to defend and could materially adversely affect the market for our product candidates or any prospects for commercialization of our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although the clinical trial process is designed to identify and assess potential side effects, it is always possible that a drug, even after regulatory approval, may exhibit unforeseen side effects. If any of our product candidates were to cause adverse side effects during clinical trials or after approval of the product candidate, we may be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even successful defense against product liability claims would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: decreased demand for our product candidates; injury to our reputation; withdrawal of clinical trial participants; initiation of investigations by regulators; costs to defend the related litigation; a diversion of management&#8217;s time and our resources; substantial monetary awards to trial participants or patients; product recalls, withdrawals or labeling, marketing or promotional restrictions; loss of revenue; exhaustion of any available insurance and our capital resources; the inability to commercialize any product candidate; and a decline in our share price.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we maintain adequate product liability insurance for our product candidates, it is possible that our liabilities could exceed our insurance coverage. We intend to expand our insurance coverage to include the sale of commercial products if we obtain marketing approval for any of our product candidates. However, we may be unable to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims, and our business operations could be impaired.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Regulatory Environment</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The development and commercialization of drug products is subject to extensive regulation, and the regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time&#8209;consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates on a timely basis if at all, our business will be substantially harmed.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The clinical development, manufacturing, labeling, packaging, storage, recordkeeping, advertising, promotion, export, import, marketing, distribution, adverse event reporting, including the submission of safety and other post&#8209;marketing information and reports, and other possible activities relating to our product candidates are subject to extensive regulation. In the United States, obtaining marketing approval for a new drug requires the submission of a New Drug Application (NDA) to the FDA, and we are not permitted to market any product candidate in the United States until we obtain approval from the FDA of the NDA for that product candidate. An NDA must be supported by extensive clinical and preclinical data, as well as extensive information regarding pharmacology, chemistry, manufacturing, and controls. Outside the United States, many comparable foreign regulatory authorities employ similar approval processes.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not previously submitted an NDA to the FDA or similar marketing application to comparable foreign authorities, for any product candidate, and we cannot be certain that any of our product candidates will receive regulatory approval. Obtaining approval of an NDA can be a lengthy, expensive, and uncertain process, and as a company we have no experience with the preparation of an NDA submission or any other marketing application. In addition, the FDA has the authority to require a REMS as part of an NDA or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe&#8209;use criteria and requiring treated patients to enroll in a registry.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates could fail to receive regulatory approval for many reasons, including the following:</span></p><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere, or regulatory authorities may not accept a submission due to, among other reasons, the content or formatting of the submission;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may fail to approve our manufacturing processes or facilities or those of third&#8209;party manufacturers with which we contract for clinical and commercial supplies; and</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations, and prospects. The FDA and comparable foreign regulatory authorities have substantial discretion in the approval process, and determining when or whether regulatory approval will be obtained for any of our product candidates. For example, regulatory authorities in various jurisdictions have in the past had, and may in the future have, differing requirements for, interpretations of and opinions on our clinical and preclinical data. As a result, we may be required to conduct additional preclinical studies, alter our proposed clinical trial designs, or conduct additional clinical trials to satisfy the regulatory authorities in each of the jurisdictions in which we hope to conduct clinical trials and develop and market our products, if approved. Further, even if we believe the data collected from clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA or any comparable foreign regulatory authority.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">49</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post&#8209;marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, FDA and foreign regulatory authorities may change their approval policies and new regulations may be enacted. For instance, the EU pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe initiative, launched by the European Commission in November 2020. The European Commission&#8217;s proposal for revision of several legislative instruments related to medicinal products (potentially reducing the duration of regulatory data protection, revising the eligibility for expedited pathways, etc.) was published on April 26, 2023. The proposed revisions remain to be agreed and adopted by the European Parliament and European Council and the proposals may therefore be substantially revised before adoption, which is not anticipated before early 2026. The revisions may, however, have a significant impact on the pharmaceutical industry and our business in the long term.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if our product candidates obtain regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the FDA or a comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, testing, safety, efficacy, labeling, packaging, distribution, import, export, adverse event reporting, storage, advertising, promotion, and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post&#8209;marketing information and reports, registration, as well as continued compliance with current good manufacturing practices (cGMPs) and similar foreign requirements, and GCPs for any clinical trials that we conduct post&#8209;approval, all of which may result in significant expense and limit our ability to commercialize such products. In addition, any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post&#8209;marketing testing, including Phase 4 clinical trials, and additional surveillance to monitor the safety and efficacy of the product candidate.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP and similar foreign regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any approved marketing application. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, quality control, and distribution.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:</span></p><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issue warning letters or untitled letters;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issue, or require us to issue, safety&#8209;related communications, such as safety alerts, field alerts, &#8220;Dear Doctor&#8221; letters to healthcare professionals, or import alerts;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">impose civil or criminal penalties;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspend, limit, or withdraw regulatory approval;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspend any of our preclinical studies and clinical trials;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refuse to approve pending applications or supplements to approved applications;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">impose restrictions on our operations, including closing our and our contract manufacturers&#8217; facilities; or</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seize or detain products, refuse to permit the import or export of products, or require us to conduct a product recall.</span></div></div><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate adverse publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products, if approved. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, the policies of the FDA and of comparable foreign regulatory authorities may change and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off&#8209;label uses. If we are found or alleged to have improperly promoted off&#8209;label uses, we may become subject to significant liability.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about drug products. These regulations include standards and restrictions for direct&#8209;to&#8209;consumer advertising, industry&#8209;sponsored scientific and educational activities, promotional activities involving the internet and off&#8209;label promotion. For example, any regulatory approval that the FDA grants is limited to those indications and patient populations for which a drug is deemed to be safe and effective by the FDA.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While physicians in the United States may choose, and are generally permitted, to prescribe products in their independent medical judgment for uses that are not described in the product&#8217;s labeling and for uses that differ from those tested in clinical trials and approved by the regulatory authorities, our ability to promote any of our products candidates, if approved, will be narrowly limited to those indications and populations that are specifically approved by the FDA or such other regulatory agencies, and if we are found to have promoted such off&#8209;label uses, we may become subject to significant liability. For example, the federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off&#8209;label promotion. The government has also required companies to enter into consent decrees or imposed permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain, or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved, or commercialized in a timely manner or at all, which could negatively impact our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs or modifications to approved drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. In addition, during the COVID&#8209;19 pandemic, the FDA postponed most inspections of domestic and foreign manufacturing facilities at various points. Even though the FDA has resumed standard inspection operations of domestic facilities where feasible, and any resurgence of COVID&#8209;19 or emergence of new variants may lead to inspectional or administrative delays. If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti&#8209;corruption laws, and anti&#8209;money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended (FCPA), the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti&#8209;bribery and anti&#8209;money laundering laws in the countries in which we conduct activities. Anti&#8209;corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties to sell our products outside the United</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">51</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government&#8209;affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain laws and regulations require us to test our product candidates on animals before initiating clinical trials involving humans. Animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities may be interrupted, delayed, or become more expensive.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business operations and current and future relationships with healthcare professionals, principal investigators, consultants, vendors, customers, and third&#8209;party payors in the United States and elsewhere are subject to applicable anti&#8209;kickback, fraud and abuse, false claims, physician payment transparency, and other healthcare laws and regulations, which could expose us to substantial penalties, contractual damages, reputation harm, administrative burdens, and diminished profits.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Healthcare providers, healthcare facilities and institutions and third&#8209;party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, healthcare facilities and institutions, principal investigators, consultants, customers, and third&#8209;party payors may expose us to broadly applicable fraud and abuse and other healthcare laws, including, without limitation, the federal Anti&#8209;Kickback Statute and the federal False Claims Act, that may constrain the business or financial arrangements and relationships through which we research, sell, market, and distribute any product candidates for which we obtain marketing approval. In addition, we may be subject to physician payment transparency laws and regulation by the federal government and by the states and foreign jurisdictions in which we conduct our business. The applicable federal, state, and foreign healthcare laws that affect our ability to operate include, but are not limited to, the following:</span></p><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Anti&#8209;Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving, or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under any U.S. federal healthcare program, such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the U.S. federal civil and criminal false claims laws, including the civil False Claims Act, which prohibit, among other things, including through civil whistleblower or qui tam actions, individuals or entities from knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using, or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease, or conceal an obligation to pay money to the U.S. federal government. Pharmaceutical manufacturers can cause false claims to be presented to the U.S. federal government by, among other things, engaging in impermissible marketing practices, such as the off&#8209;label promotion of a product for an indication for which it has not received FDA approval. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti&#8209;Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items, or services. Similar to the federal Anti&#8209;Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate it in order to have committed a violation;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the U.S. Physician Payments Sunshine Act and its implementing regulations, which requires, among other things, certain manufacturers of drugs and devices that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare and Medicaid Services, or CMS, information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by such physicians and their immediate family members;</span></div></div><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">52</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">analogous U.S. state laws and regulations, including: state anti&#8209;kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements, and claims involving healthcare items or services reimbursed by any third&#8209;party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws requiring the registration of pharmaceutical sales representatives; and</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">similar healthcare laws and regulations in foreign jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is not always possible to identify and deter employee misconduct or business noncompliance, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. We have entered into consulting and scientific advisory board arrangements with physicians and other healthcare providers, including some who could influence the use of our product candidates, if approved. Compensation under some of these arrangements includes the provision of stock or stock options in addition to cash consideration. Because of the complex and far&#8209;reaching nature of these laws, it is possible that governmental authorities could conclude that our payments to physicians may not be fair market value for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">bona fide </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">services or that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal, and administrative penalties, damages, fines, exclusion from government&#8209;funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of noncompliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time&#8209;consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our employees, independent contractors, principal investigators, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to the risk of employee fraud or other misconduct. We cannot ensure that our compliance controls, policies, and procedures will in every instance protect us from acts committed by our employees, agents, contractors, or collaborators that would violate the laws or regulations of the jurisdictions in which we operate, including, without limitation, employment, foreign corrupt practices, trade restrictions and sanctions, environmental, competition, and patient privacy and other privacy laws and regulations. Misconduct by employees could include failures to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards we may establish, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately, or disclose unauthorized activities to us. In particular, sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self&#8209;dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, labeling, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">53</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material and adverse effect on our business, financial condition, results of operations and prospects, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, individual imprisonment, disgorgement of profits, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting or oversight obligations if we become subject to a corporate integrity agreement or other agreement to resolve allegations of noncompliance with the law, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and pursue our strategy.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Current and future legislation may increase the difficulty and cost for us and any future collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the ACA), was enacted, which substantially changed the way healthcare is financed by both governmental and private payors. Among the provisions of the ACA of importance to the biopharmaceutical and biotechnology industries are the following:</span></p><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacturers and importers of certain branded prescription drugs are required to pay an annual, nondeductible fee according to their market share of all such sales;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% of the average manufacturer price for most branded drugs, and to 13.0% for generic drug;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs, including our product candidates, that are inhaled, infused, instilled, implanted, or injected;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">extension of manufacturers&#8217; Medicaid rebate liability to covered outpatient drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expansion of the entities eligible for discounts under the 340B drug pricing program;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a new Patient&#8209;Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishment of a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Thus, the ACA remains in effect in its current form. Prior to the Supreme Court&#8217;s decision, President Biden issued an Executive Order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The Executive Order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the IRA) into law, which, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. It is unclear how other healthcare reform measures of the Biden administration or other efforts, if any, to challenge, repeal or replace the ACA, will impact our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminated the statutory Medicaid drug rebate cap, beginning January 1, 2024. The rebate was previously capped at 100% of a drug&#8217;s average manufacturer price. Further, in August 2011, the Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers. These reductions went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect until 2032, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, unless additional action is taken by Congress.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, heightened governmental scrutiny is likely to continue over the manner in which manufacturers set prices for their marketed products, which already has resulted in several Congressional inquiries, proposed and enacted legislation and executive orders issued by the President designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. Most recently, the IRA marks the most significant action by Congress with respect to the biopharmaceutical industry since adoption of the ACA in 2010. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023), and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties. The IRA permits the Secretary of the Department of Health and Human Services (HHS) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. For that and other reasons, it is currently unclear how the IRA will be effectuated, and while the impact of the IRA on the biopharmaceutical industry cannot yet be fully determined, it is likely to be significant.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, individual states in the United States have passed legislation and implemented regulations designed to control biopharmaceutical product pricing and costs. Similar developments have occurred outside of the United States, including in the European Union where healthcare budgetary constraints have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. To obtain reimbursement or pricing approval in some European Union member states, we may be required to conduct studies that compare the cost&#8209;effectiveness of our product candidates to other therapies that are considered the local standard of care.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot predict the likelihood, nature, or extent of government regulation that may arise from the IRA or future legislation or administrative action in the United States or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we are able to commercialize any product candidate, coverage and adequate reimbursement may not be available or such product candidate may become subject to unfavorable pricing regulations or third&#8209;party coverage and reimbursement policies, which would harm our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The regulations that govern regulatory approvals, pricing, and reimbursement for drug products vary widely from country to country. Some countries require approval of the sale price of a drug product before it can be marketed. In many countries, the pricing review period begins after marketing approval is granted. In some foreign markets, prescription drug product pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain regulatory approval.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to commercialize any products successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from third&#8209;party payors, such as government authorities, private health insurers, and other organizations. Even if we succeed in bringing one or more products to the market, these products may not be considered cost&#8209;effective, and the amount reimbursed for any products may be insufficient to allow us to sell our products on a competitive basis. Because our programs are in the relatively early stages of development, we are unable at this time to determine their cost effectiveness or the likely level or method of coverage and reimbursement. Increasingly, the third&#8209;party payors who reimburse patients or healthcare providers are requiring that drug companies provide them with predetermined discounts from list prices, and are seeking to reduce the prices charged or the amounts reimbursed for drug products. If the price we are able to charge for any products we develop, or the coverage and reimbursement provided for such products, is inadequate in light of our development and other costs, our return on investment could be affected adversely.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There may be significant delays in obtaining reimbursement for newly&#8209;approved drug products, and coverage may be more limited than the purposes for which the drug product is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drugs product will be reimbursed in all cases or at a rate that covers our costs, including research, development, manufacture, sale, and distribution.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">55</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interim reimbursement levels for new drug products, if applicable, may also be insufficient to cover our costs and may not be made permanent. Reimbursement rates may be based on payments allowed for lower cost drug products that are already reimbursed, may be incorporated into existing payments for other services and may reflect budgetary constraints or imperfections in Medicare data. Net prices for drug products may be reduced by mandatory discounts or rebates required by third&#8209;party payors and by any future relaxation of laws that presently restrict imports of drug products from countries where they may be sold at lower prices than in the United States. Obtaining coverage and adequate reimbursement for our product candidates may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. Third&#8209;party payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often a time&#8209;consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Decisions regarding the extent of coverage and amount of reimbursement to be provided for any product candidates that we develop will be made on a payor&#8209;by&#8209;payor basis. One payor&#8217;s determination to provide coverage for a drug does not assure that other payors will also provide coverage and adequate reimbursement for the drug. Additionally, a third&#8209;party payor&#8217;s decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal, and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. The continuing efforts of the government, insurance companies, managed care organizations, and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</span></p><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the demand for our product candidates, if we obtain regulatory approval;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to set a price that we believe is fair for our products;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain coverage and reimbursement approval for a product;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to generate revenue and achieve or maintain profitability;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the level of taxes that we are required to pay; and</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of capital.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our inability to promptly obtain coverage and adequate reimbursement from both third&#8209;party payors for the product candidates that we may develop and for which we obtain regulatory approval could have a material and adverse effect on our business, financial condition, results of operations, and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face potential liability related to the privacy of health information we utilize in the development of product candidates, as well as information we obtain from clinical trials sponsored by us from research institutions and directly from individuals.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The global data protection landscape is rapidly evolving and we and our partners and vendors are, or may become, subject to various federal, state, and foreign data protection laws and regulations (i.e., laws and regulations that address personal information, data privacy and security). Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. If we fail to comply with these laws and regulations, we may be subject to litigation, regulatory investigations, enforcement notices, enforcement actions, fines, and criminal or civil penalties, as well as adverse publicity and a potential loss of business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations that govern the collection, use, disclosure, and protection of health&#8209;related and other personal information could apply to our operations or the operations of our partners. For example, most healthcare providers, including research institutions from which we obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009. HIPAA imposes obligations on &#8220;covered entities,&#8221; including certain healthcare providers, health plans and healthcare clearinghouses, as well as their respective &#8220;business associates&#8221; that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information. We could potentially face substantial criminal or civil penalties if we violate HIPAA. For example, we could be subject to significant penalties if we knowingly receive individually identifiable health information from a HIPAA&#8209;covered</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">56</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information, or otherwise violate applicable HIPAA requirements related to the protection of such information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, the Federal Trade Commission (FTC) also has authority to initiate enforcement actions against entities that mislead customers about HIPAA compliance, make deceptive statements about privacy and data sharing in privacy policies, fail to limit third-party use of personal health information, fail to implement policies to protect personal health information or engage in other unfair practices that harm customers or that may violate Section 5 of the FTC Act. Even when HIPAA does not apply, according to the Federal Trade Commission (FTC) violating consumers&#8217; privacy rights or failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute a violation of the FTC Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Additionally, federal and state consumer protection laws are increasingly being applied by FTC and states&#8217; attorneys general to regulate the collection, use, storage, and disclosure of personal or personally identifiable information, through websites or otherwise, and to regulate the presentation of website content.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For our clinical trials, we may maintain sensitive personal information, including health information, that we receive throughout the clinical trial process, in the course of our research collaborations, and directly from individuals (or their healthcare providers) who enroll in our patient assistance programs. As such, we may be subject to state laws and regulations governing the privacy and security of personal information or requiring notification of affected individuals and state regulators in the event of a breach of personal information. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. For example, the California Consumer Privacy Act, as amended by the California Privacy Rights Act (collectively, the CCPA) requires covered businesses that process the personal information of California residents to, among other things: (i) provide certain disclosures to California residents regarding the business&#8217;s collection, use, and disclosure of their personal information; (ii) receive and respond to requests from California residents to access, delete, and correct their personal information, or to opt out of certain  disclosures of their personal information; and (iii) enter into specific contractual provisions with service providers that process California resident personal information on the business&#8217;s behalf. Although there are limited exemptions for health&#8209;related information, including clinical trial data, the CCPA may increase our compliance costs and potential liability. Similar laws have been passed in other states, and are continuing to be proposed at the state and federal level, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Complying with U.S. federal and state data privacy and security laws, regulations, amendments to or re&#8209;interpretations of existing data privacy and security laws and regulations and contractual or other obligations relating to privacy, data protection, data transfers, data localization or information security may require us to make changes to our processes, incur substantial operational costs, modify our data practices and policies and restrict our business operations. Any actual or perceived failure by us to comply with these laws, regulations or other obligations may lead to significant fines, penalties, regulatory investigations, lawsuits, significant costs for remediation, damage to our reputation or other liabilities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also or may become subject to rapidly evolving data protection laws, rules and regulations in foreign jurisdictions. Any clinical trial programs and research collaborations that we engage in outside the United States may implicate international data protection laws, including, in the European Economic Area (EEA), the General Data Protection Regulation (GDPR), which became effective in 2018. The GDPR imposes stringent operational requirements for processors and controllers of the personal data of individuals within the EEA. Among other things, the GDPR requires detailed notices for clinical trial subjects and investigators, as well as requirements regarding the security of personal data and notification of data processing obligations or security incidents to appropriate data protection authorities or data subjects. If our privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices, and/or enforcement actions requiring us to change the way we use personal data and/or fines. In addition to statutory enforcement, a personal data breach can lead to adverse publicity and a potential loss of business. Further, from January 1, 2021, companies have had to comply with both the GDPR and the United Kingdom GDPR (UK GDPR), which, together with the amended UK Data Protection Act 2018, imposes separate but similar obligations to those under the GDPR. The UK GDPR mirrors the fines under the GDPR, imposing fines up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of global turnover.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">57</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EEA and the United States remains uncertain. Case law from the Court of Justice of the European Union (CJEU) states that reliance on the standard contractual clauses &#8209; a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism &#8209; alone may not necessarily be sufficient in all circumstances and that transfers must be assessed on a case&#8209;by&#8209;case basis. On July 10, 2023, the European Commission adopted its Adequacy Decision in relation to the new EU-US Data Privacy Framework (DPF) rendering the DPF effective as an EU GDPR transfer mechanism to U.S. entities self&#8209;certified under the DPF. On October 12, 2023, the UK Extension to the DPF also came into effect (as approved by the UK Government), as data transfer mechanism to U.S. entities self-certified under the DPF. As the regulatory guidance and enforcement landscape in relation to data transfers continue to develop, we could suffer additional costs, complaints, and/or regulatory investigations or fines, and/ or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results. These laws and regulations may apply, not only to us, but also to vendors that store or otherwise process data on our behalf, such as information technology vendors. If such a vendor misuses data we have provided to it, or fails to safeguard such data, we may be subject to litigation, regulatory investigations, enforcement notices, and/or enforcement actions, as well as adverse publicity and a potential loss of business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are likely to be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws. Claims that we have violated individuals&#8217; privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time&#8209;consuming to defend, and could result in adverse publicity that could harm our business. Moreover, even if we take all necessary action to comply with regulatory requirements, we could be subject to a hack or data breach, which could subject us to fines and penalties, as well as reputational damage.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, we use artificial intelligence (AI), machine learning, and automated decision-making technologies (collectively, AI Technologies) throughout our business. The regulatory framework for AI Technologies is rapidly evolving as many federal, state and foreign government bodies and agencies have introduced or are currently considering additional laws and regulations. Additionally, existing laws and regulations may be interpreted in ways that would affect the operation of our AI Technologies. As a result, implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or market perception of their requirements may have on our business and may not always be able to anticipate how to respond to these laws or regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Already, certain existing legal regimes (e.g., relating to data privacy) regulate certain aspects of AI Technologies, and new laws regulating AI Technologies are expected to enter into force in the United States and the EU in 2024. In the United States, the Biden administration issued a broad Executive Order on the Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence (2023 AI Order), that sets out principles intended to guide AI design and deployment for the public and private sector and signals the increase in governmental involvement and regulation over AI Technologies. The 2023 AI Order established certain new requirements for the training, testing and cybersecurity of sophisticated AI models and large scale compute centers used to train AI models. The 2023 AI Order also instructed several other federal agencies to promulgate additional regulations within specific timeframes from the date of the 2023 AI Order regarding the use and development of AI Technologies. Agencies such as the Department of Commerce and the Federal Trade Commission have issued proposed rules governing the use and development of AI Technologies. Legislation related to AI Technologies has also been introduced at the federal level and is advancing at the state level. For example, the California Privacy Protection Agency is currently in the process of finalizing regulations under the CCPA regarding the use of automated decision-making. Such additional regulations may impact our ability to develop, use and commercialize AI Technologies in the future.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In Europe, on March 13, 2024, the European Parliament passed the EU Artificial Intelligence Act (EU AI Act) which establishes a comprehensive, risk-based governance framework for artificial intelligence in the EU market. The EU AI Act will enter into force twenty days after its publication in the Official Journal of the EU and will be fully effective two years later. The EU AI Act will apply to companies that develop, use and/or provide AI in the EU and includes requirements around transparency, conformity assessments and monitoring, risk assessments, human oversight, security, accuracy, general purpose AI and foundation models, and proposes fines for breach of up to 7% of worldwide annual turnover. In addition, on September 28, 2022, the European Commission proposed two Directives seeking to establish a harmonized civil liability regime for AI in the EU in order to facilitate civil claims in respect of harm caused by AI and to include AI-enabled products within the scope of the EU&#8217;s existing strict product liability regime. Once fully applicable, the EU AI Act and the Liability Directives will have a material impact on the way AI is regulated in the EU. Recent case law from the CJEU has taken an expansive view of the scope of the GDPR&#8217;s requirements around automated decision making and introduced uncertainty in the interpretation of these rules. The EU AI Act, and developing interpretation and application of the GDPR in respect of automated decision making, together with developing guidance and/or decisions in this area, may affect our use of AI Technologies and our ability to provide, improve or commercialize our business, require additional compliance measures and changes to our operations and processes, result in increased compliance costs and potential increases in civil claims against us, and could adversely affect our business, operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">58</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It is possible that further new laws and regulations will be adopted in the United States and in other non-U.S. jurisdictions, or that existing laws and regulations, including competition and antitrust laws, may be interpreted in ways that would limit our ability to use AI Technologies for our business, or require us to change the way we use AI Technologies in a manner that negatively affects the performance of our business and the way in which we use AI Technologies. We may need to expend resources to adjust our operations in certain jurisdictions if the laws, regulations, or decisions are not consistent across jurisdictions. Further, the cost to comply with such laws, regulations, or decisions and/or guidance interpreting existing laws, could be significant and would increase our operating expenses (such as by imposing additional reporting obligations regarding our use of AI Technologies). Such an increase in operating expenses, as well as any actual or perceived failure to comply with such laws and regulations, could adversely affect our business, financial condition and results of operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Dependence on Third Parties</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We contract with third parties for the manufacture of our product candidates. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or drugs or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not currently have the infrastructure or internal capability to manufacture supplies of our product candidates for use in development and commercialization. We rely, and expect to continue to rely, on third&#8209;party manufacturers for the production of our product candidates for preclinical studies and clinical trials under the guidance of members of our organization. We do not have long&#8209;term supply agreements. Furthermore, while the raw materials for our product candidates are sourced from multiple suppliers, in some cases, the drug product is sourced from a single&#8209;source supplier. If we were to experience an unexpected loss of supply of any of our product candidates or any of our future product candidates for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to continue to rely on third&#8209;party manufacturers for the commercial supply of any of our product candidates for which we obtain marketing approval. We may be unable to maintain or establish required agreements with third&#8209;party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third&#8209;party manufacturers, reliance on third&#8209;party manufacturers entails additional risks, including:</span></p><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the failure of the third party to manufacture our product candidates according to our schedule, or at all, including if our third&#8209;party contractors give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the reduction or termination of production or deliveries by suppliers, or the raising of prices or renegotiation of terms;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the termination or nonrenewal of arrangements or agreements by our third&#8209;party contractors at a time that is costly or inconvenient for us;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the breach by the third&#8209;party contractors of our agreements with them;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the failure of third&#8209;party contractors to comply with applicable regulatory requirements;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the failure of the third party to manufacture our product candidates according to our specifications;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or study drug or placebo not being properly identified;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the misappropriation of our proprietary information, including our trade secrets and know&#8209;how.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have complete control over all aspects of the manufacturing process of, and are dependent on, our contract manufacturing partners for compliance with cGMP or similar foreign regulations for manufacturing both active drug substances and finished drug products. Third&#8209;party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or a comparable foreign regulatory authority, they will not be able to secure and/or maintain marketing approval for their manufacturing facilities. In addition, we do not have control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain marketing approval for or market our product candidates, if approved. Our failure, or the failure of our third&#8209;party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">59</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or drugs and harm our business and results of operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current and anticipated future dependence upon others for the manufacture of our product candidates or drugs may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2024, there was congressional activity, including the introduction of the BIOSECURE Act (H.R. 7085) in the House of Representatives and a substantially similar Senate bill (S.3558).  If these bills become law, or similar laws are passed, they would have the potential to severely restrict the ability of U.S. biopharmaceutical companies like us to purchase products or services from, or otherwise collaborate with, certain Chinese biotechnology companies &#8220;of concern&#8221; without losing the ability to contract with, or otherwise receive funding from, the U.S. government. It is possible some of our contractual counterparties could be impacted by the legislation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Supply sources could be interrupted from time to time and, if interrupted, there is no guarantee that supplies could be resumed within a reasonable time frame and at an acceptable cost or at all.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on our manufacturers to purchase from third&#8209;party suppliers the materials necessary to produce our product candidates for our preclinical studies and intend to continue to rely on these third parties for any clinical trials that we undertake. There are a limited number of suppliers for raw materials that we use to manufacture our drugs and there may be a need to assess alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our product candidates for our preclinical studies, clinical trials, and if approved, ultimately for commercial sale. We do not have any control over the process or timing of the acquisition of these raw materials by our manufacturers. Moreover, we currently do not have any agreements for the commercial production of these raw materials. We cannot be sure that these suppliers will remain in business, or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these materials for our intended purpose. In addition, the lead time needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event a new supplier must be used. The time and effort to qualify a new supplier could result in additional costs, diversion of resources, or reduced manufacturing yields, any of which would negatively impact our operating results. Although we generally do not begin a clinical trial unless we believe we have a sufficient supply of a product candidate to complete the clinical trial, any significant delay in the supply of a product candidate, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a third&#8209;party manufacturer could considerably delay completion of our clinical trials, product testing, and potential regulatory approval of our product candidates. If our manufacturers or we are unable to purchase these raw materials after regulatory approval has been obtained for our product candidates, the commercial launch of our product candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements, or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not currently have the ability to independently conduct any clinical trials. We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators and third&#8209;party CROs, to conduct our preclinical studies and clinical trials and to monitor and manage data for our clinical and preclinical programs. We rely on these parties for execution of our preclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third&#8209;party contractors and CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our products candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators, and trial sites. If we or any of our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations (or similar regulatory requirements outside of the United States). Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, these investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, that they devote to our product candidates and clinical trials. If independent investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of any product candidates that we develop. In addition, the use of third&#8209;party service providers may require us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors, or if we are liquidated. Further, some of these agreements may also be terminated by such third parties on short notice, or under certain circumstances, including our insolvency.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is a limited number of third&#8209;party service providers that specialize or have the expertise required to achieve our business objectives. Many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. If any of our relationships with these third&#8209;party laboratories, CROs or clinical investigators terminate, we may not be able to enter into arrangements with alternative laboratories, CROs, or investigators or to do so in a timely manner or on commercially reasonable terms. If laboratories, CROs, or clinical investigators do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our preclinical or clinical protocols, regulatory requirements or for other reasons, our preclinical or clinical trials may be extended, delayed, or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenues could be delayed. Switching or adding additional laboratories or CROs (or investigators) involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new laboratory or CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Additionally, CROs may lack the capacity to absorb higher workloads or take on additional capacity to support our needs. Though we carefully manage our relationships with our contracted laboratories and CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition, and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not realize the benefits of any collaborative or licensing arrangement, and if we fail to enter into new strategic relationships our business, financial condition, commercialization prospects, and results of operations may be materially adversely affected.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. Therefore, for some of our product candidates, we may in the future decide to enter into collaborations with pharmaceutical or biopharmaceutical companies for the development and potential commercialization of those product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face significant competition in seeking appropriate collaborators. Collaborations are complex and time&#8209;consuming to negotiate and document. We may also be restricted under existing and future collaboration agreements from entering into agreements on certain terms with other potential collaborators. We may not be able to negotiate collaborations on acceptable terms, or at all. If our strategic collaborations do not result in the successful development and commercialization of product candidates, or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. Moreover, our estimates of the potential revenue we are eligible to receive under any strategic collaborations we may enter into may include potential payments related to therapeutic programs for which our collaborators may discontinue development in the future. If that were to occur, we may have to curtail the development of a particular product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of our sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we will not be able to bring our product candidates to market and generate product revenue.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In instances where we have or do enter into collaborations, we could be subject to the following risks, each of which may materially harm our business, commercialization prospects, and financial condition:</span></p><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not be able to control the amount and timing of resources that is required of us to complete our development obligations or that the collaboration partner devotes to the product development or marketing programs;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the collaboration partner may experience financial difficulties;</span></div></div><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">61</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to relinquish important rights such as marketing, distribution, and intellectual property rights;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a collaborator could move forward with a competing product developed either independently or in collaboration with third parties, including our competitors;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we and our collaboration partner may disagree regarding the development plan for research and development projects or product candidates on which we are collaborating (for example, we may disagree with a collaboration partner regarding target indications or inclusion or exclusion criteria for a clinical trial); or</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">business combinations or significant changes in a collaborator&#8217;s business strategy may adversely affect our willingness to complete our obligations under any arrangement.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we license products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. We cannot be certain that, following a strategic transaction or license, we will achieve the results, revenue, or specific net income that justifies such transaction.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Intellectual Property</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We depend on intellectual property licensed or acquired from third parties and we are currently party to in&#8209;license agreements under which we acquired rights to use, develop, manufacture and/or commercialize certain of our proprietary technologies and product candidates. If we breach our obligations under these agreements or if any of these agreements is terminated, or otherwise experience disruptions to our business relationships with our licensors, we may be required to pay damages, lose our rights to such intellectual property and technology, or both, which would harm our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are dependent on patents, know&#8209;how, and proprietary technology, both our own and licensed from others. We are a party to intellectual property license agreements and in the future, we may enter into additional license agreements. For example, with respect to developing our product candidates, we have licensed or acquired, as the case may be, certain intellectual property from Amgen, Blackthorn, TSRI and Vanderbilt. These license and acquisition agreements impose, and we expect that future license and acquisition agreements will impose, various diligence, milestone payment, royalty and other obligations on us. If we fail to comply with our obligations under these agreements, we may be required to pay damages and the licensor may have the right to terminate the license. Any termination of these licenses could result in the loss of significant rights and could harm our ability to develop, manufacture and/or commercialize our product candidates. See the section titled &#8220;Business&#8212;Intellectual Property&#8212;In&#8209;Licensing and Collaboration Agreements&#8221; in the Annual Report on Form 10-K filed on March 7, 2024 for additional information regarding these key agreements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the agreements under which we license or acquire intellectual property or technology to or from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed or acquired prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. Our business also would suffer if any current or future licensors fail to abide by the terms of the license, if the licensors fail to enforce licensed patents against infringing third parties, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to successfully obtain rights to required third&#8209;party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant research programs or product candidates and our business, financial condition, results of operations and prospects could suffer.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">62</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues and is complicated by the rapid pace of scientific discovery in our industry.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disputes may also arise between us and our current and future licensors regarding intellectual property subject to a license or collaboration agreement, including those relating to:</span></p><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope of rights granted under the license or collaboration agreement and other interpretation&#8209;related issues;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the license agreement;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our right to sublicense patent and other rights to third parties under collaborative development relationships;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether we are complying with our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the priority of invention of patented technology;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">rights upon termination of the license agreements;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope and duration of exclusivity obligations of each party to the license agreements;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the amount and timing of payments owed under license agreements; and</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the allocation of ownership of inventions and know&#8209;how resulting from the joint creation or use of intellectual property by our licensors or collaborators and by us and our partners.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The resolution of any contractual interpretation dispute that may arise, if unfavorable to us, could have a material adverse effect on our business, financial condition, results of operations and prospects. Such resolution could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, increase what we believe to be our financial or other obligations under the relevant agreement or decrease the third party&#8217;s financial or other obligations under the relevant agreement. Furthermore, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. We are generally also subject to all of the same risks with respect to protection of intellectual property that we license as we are for intellectual property that we own, which are described below. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize our products could suffer.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We depend, in part, on our licensors to file, prosecute, maintain, defend, and enforce certain patents and patent applications that are material to our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain patents and patent applications relating to our product candidates are owned or controlled by certain of our licensors. In some circumstances, we may not have the right to control the preparation, filing, prosecution, maintenance, and defense of patent applications or patents covering technology that we license from third parties. In such circumstances, our licensors generally have rights to file, prosecute, maintain, and defend the licensed patents in their name, generally with our right to comment on such filing, prosecution, maintenance, and defense, with some obligation for the licensor to consider or incorporate our comments. We generally have the first right to enforce our exclusively licensed patent rights against third parties, although our ability to settle such claims often requires the consent of the licensor. If our licensors or any future licensees having rights to file, prosecute, maintain, and defend our patent rights fail to conduct these activities for patents or patent applications covering any of our product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using, or selling competing products. We cannot be certain that such activities by our licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. Pursuant to the terms of the license agreements with some of our licensors, the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents and, even in the circumstances where we have the right to pursue such enforcement or defense, we cannot ensure the cooperation of our licensors. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate our business. In addition, even when we have the right to control patent prosecution of licensed patents and patent applications, enforcement of licensed patents, or defense of claims asserting the invalidity of those patents, we may still be adversely affected or prejudiced by actions or inactions of our licensors and their counsel that took place prior to or after our assuming control. This could cause us to lose rights in any applicable intellectual property that we in&#8209;license, and as a result our ability to develop and commercialize product candidates may be adversely affected and we may be unable to prevent competitors from making, using and selling competing products.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">63</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Given the breadth of the application of our precision neuroscience approach, in order to increase our ability to exploit our technologies, we may enter into collaborations and/or strategic partnerships in the future, and we may not realize the anticipated benefits of such collaborations or partnerships. We may not be able to do so or to realize the potential benefits of such transactions, which may cause us to alter or delay our development and commercialization plans.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development collaborations and strategic partnerships are prevalent in the biopharmaceutical industry. The breadth of the application of our precision neuroscience approach is an attractive technology for potential collaborations and/or strategic partnerships. These transactions are subject to numerous risks, which may include the following:</span></p><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators have significant discretion in determining the efforts and resources that they will apply to a collaboration, and may not commit sufficient efforts and resources, or may misapply those efforts and resources;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not pursue development and commercialization of collaboration product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results or changes in their strategic focus;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may delay, provide insufficient resources to, or modify or stop clinical trials for collaboration product candidates;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators could develop or acquire products outside of the collaboration that compete directly or indirectly with our products or product candidates;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disputes may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of our product candidates, or that result in costly litigation or arbitration that diverts management attention and resources;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborations may be terminated and, if terminated, may result in a need for additional capital and personnel to pursue further development or commercialization of the applicable product candidates; and</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may own or co&#8209;own intellectual property covering our products that results from our collaborating with them, and in such cases, we may not have the exclusive right to commercialize such intellectual property.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The development and potential commercialization of our product candidates will require substantial additional capital to fund expenses. We may form or seek further strategic alliances, create joint ventures or collaborations, or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop, including in territories outside the United States or for certain indications. These transactions can entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management&#8217;s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write&#8209;downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business. As a result, if we enter into acquisition or in&#8209;license agreements or strategic partnerships, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction or such other benefits that led us to enter into the arrangement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time&#8209;consuming and complex. We may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy. If and when we collaborate with a third party for development and commercialization of a product candidate, we can expect to relinquish some or all of the control over the future success of that product candidate to the third party. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of our technologies, product candidates and market opportunities. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. We may also be restricted under any license agreements from entering into agreements on certain terms or at all with potential collaborators.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of these risks, we may not be able to realize the benefit of our existing collaboration or any future collaborations or licensing agreements we may enter into. In addition, there have been a significant number of recent business combinations among large</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">64</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pharmaceutical companies that have resulted in a reduced number of potential future collaborators and changes to the strategies of the combined company. As a result, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product candidate, reduce or delay one or more of our other development programs, delay the potential commercialization or reduce the scope of any planned sales or marketing activities for such product candidate, or increase our expenditures and undertake development, manufacturing or commercialization activities at our own expense. If we elect to increase our expenditures to fund development, manufacturing or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates may also require specific components to work effectively and efficiently, and rights to those components may be held by others. We may be unable to in&#8209;license any compositions, methods of use, processes or other third&#8209;party intellectual property rights from third parties that we identify. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, which would harm our business. In that event, we may be required to expend significant time and resources to develop or license replacement technology. Even if we are able to obtain a license, it may be non&#8209;exclusive, thereby giving our competitors access to the same technologies licensed to us. Any delays in entering into new collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies, which could harm our business prospects, financial condition and results of operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, some of our owned and in&#8209;licensed patents or patent applications or future patents are or may be co&#8209;owned with third parties. If we are unable to obtain an exclusive license to any such third&#8209;party co&#8209;owners&#8217; interest in such patents or patent applications, such co&#8209;owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co&#8209;owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Furthermore, our owned and in&#8209;licensed patents may be subject to a reservation of rights by one or more third parties. Any of the foregoing could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be successful in obtaining or maintaining necessary rights for our product pipeline which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We own or license from third parties certain intellectual property rights necessary to develop our product candidates. The growth of our business will likely depend in part on our ability to acquire or in&#8209;license additional proprietary rights, including to expand our product pipeline. In that event, we may be required to expend considerable time and resources to develop or license replacement technology. For example, our programs may involve additional technologies or product candidates that may require the use of additional proprietary rights held by third parties. Furthermore, other pharmaceutical companies and academic institutions may also have filed or are planning to file patent applications potentially relevant to our business. Our product candidates may also require specific formulations or other technology to work effectively and efficiently. These formulations or technology may be covered by intellectual property rights held by others. From time to time, in order to avoid infringing these third&#8209;party rights, we may be required to license technology from additional third parties to further develop or commercialize our product candidates. We may be unable to acquire or in&#8209;license any relevant third&#8209;party intellectual property rights, including any such intellectual property rights required to manufacture, use or sell our product candidates, that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, and as a result we may be unable to develop or commercialize the affected product candidates, which would harm our business. We may need to cease use of the compositions or methods covered by such third&#8209;party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license under such intellectual property rights, any such license may be non&#8209;exclusive, which may allow our competitors&#8217; access to the same technologies licensed to us.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program. If we are unable to successfully obtain rights to required third&#8209;party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business and financial condition could suffer.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">65</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The licensing and acquisition of third&#8209;party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third&#8209;party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be dependent on intellectual property licensed or sublicensed to us from, or for which development was funded or otherwise assisted by, the U.S. government and/or government agencies, such as the National Institutes of Health, for development of our technology and product candidates. Failure to meet our own obligations to our licensors or upstream licensors, including such government agencies, may result in the loss of our rights to such intellectual property, which could harm our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The U.S. government and/or government agencies have provided, and in the future may provide, funding, facilities, personnel or other assistance in connection with the development of the intellectual property rights owned by or licensed to us. The U.S. government and/or government agencies may have retained rights in such intellectual property, including the right to grant or require us to grant mandatory licenses or sublicenses to such intellectual property to third parties under certain specified circumstances, including if it is necessary to meet health and safety needs that we are not reasonably satisfying or if it is necessary to meet requirements for public use specified by federal regulations, or to manufacture products in the United States. Any exercise of such rights, including with respect to any such required sublicense of these licenses, could result in the loss of significant rights and could harm our ability to commercialize licensed products. For example, the research resulting in certain of our in&#8209;licensed patent rights and technology was funded in part by the U.S. government. As a result, the government may have certain rights, or march&#8209;in rights, to such patent rights and technology. These rights may permit the government to disclose our confidential information to third parties and to exercise march&#8209;in rights to use or allow third parties to use our licensed technology.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to obtain and maintain sufficient intellectual property protection for our product candidates and approach, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected. We cannot ensure that patent rights relating to inventions described and claimed in our pending patent applications will issue or that patents based on our patent applications will not be challenged and rendered invalid and/or unenforceable.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We or our licensors have filed, and we anticipate that in the future we will file additional patent applications both in the United States and in other countries, as appropriate. However, we cannot predict:</span></p><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if and when any patents will issue;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the degree and range of protection any issued patents will afford us against competitors, including whether third parties will find ways to invalidate or otherwise circumvent our patents;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether others will apply for or obtain patents claiming aspects similar to those covered by our patents and patent applications;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether we will need to initiate litigation or administrative proceedings to defend our patent rights, which may be costly whether we win or lose; or</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether the patent applications that we own or in&#8209;license will result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our product candidates and approach. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel discoveries and technologies that are important to our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obtaining and enforcing patents is expensive and time&#8209;consuming, and we may not be able to file and prosecute all necessary or desirable patent applications or maintain and/or enforce patents that may issue based on our patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development results before it is too late to obtain patent protection. Although we enter into non&#8209;disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach these agreements and disclose such results before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to enforce patent rights also depends on our ability to detect infringement. It may be difficult to detect infringers who do not advertise the components or methods that are used in connection with their products and services. Such proceedings could also provoke</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">66</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">third parties to assert claims against us, including that some or all of the claims in one or more of our patents are invalid or otherwise unenforceable. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s or potential competitor&#8217;s product or service. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded if we were to prevail may not be commercially meaningful. If we initiate lawsuits to protect or enforce our patents, or litigate against third&#8209;party claims, such proceedings would be expensive and would divert the attention of our management and technical personnel.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Composition of matter patents for biopharmaceutical products often provide a strong form of intellectual property protection for those types of products, as such patents provide protection without regard to any method of use. We cannot be certain, however, that the claims in our pending patent applications covering the composition of matter of our product candidates will be considered patentable by the United States Patent and Trademark Office (USPTO), or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid and enforceable by courts in the United States or foreign countries. Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#8220;off&#8209;label&#8221; for those uses that are covered by our method of use patents. Although off&#8209;label prescriptions may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement can be difficult to prevent or prosecute.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The strength of patents in the biotechnology, biopharmaceutical and data science fields can be uncertain, and evaluating the scope of such patents involves complex legal, factual and scientific analyses and has in recent years been the subject of much litigation, resulting in court decisions, including Supreme Court decisions, which have increased uncertainties as to the ability to enforce patent rights in the future. The patent applications that we own or in&#8209;license may fail to result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the validity, enforceability, or scope thereof, which may result in such patents being narrowed, invalidated, or held unenforceable. In the event of litigation or administrative proceedings, we cannot be certain that the claims in any of our issued patents will be considered valid by courts in the United States or foreign countries. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing their products to avoid being covered by our claims. If the breadth or strength of protection provided by the patent applications we hold with respect to our product candidates is threatened, this could dissuade companies from collaborating with us to develop, and could threaten our ability to commercialize, our product candidates. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States, or vice versa. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not identify relevant third&#8209;party patents or may incorrectly interpret the relevance, scope or expiration of a third&#8209;party patent, which might adversely affect our ability to develop and market our products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third&#8209;party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that our products are not covered by a third&#8209;party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">One aspect of the determination of patentability of our inventions depends on the scope and content of the &#8220;prior art,&#8221; information that was or is deemed available to a person of skill in the relevant art prior to the priority date of the claimed invention. There may be prior art of which we are not aware that may affect the patentability of our patent claims or, if issued, affect the validity or enforceability of a patent claim. Further, we may not be aware of all third&#8209;party intellectual property rights potentially relating to our product candidates or their intended uses, and as a result the impact of such third&#8209;party intellectual property rights upon the patentability of our own patents and patent applications, as well as the impact of such third&#8209;party intellectual property upon our freedom to operate, is highly uncertain. Because patent applications in the United States and most other countries are confidential for typically a period of 18 months after filing, or may not be published at all, we cannot be certain that we were the first to file any patent application related to our product candidates. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Furthermore, for U.S. applications in which all claims are entitled to a priority date before March 16, 2013, an interference proceeding can be provoked by a third party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. For U.S. applications containing a claim not entitled to priority before March 16, 2013, there is a greater level of uncertainty in the patent law in view of the passage of the America Invents Act, which brought into effect significant changes to the U.S. patent laws, including new procedures for challenging pending patent applications and issued patents.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our patents or pending patent applications may be challenged in the courts or patent offices in the United States and abroad. For example, we may be subject to a third&#8209;party pre&#8209;issuance submission of prior art to the USPTO or become involved in post&#8209;grant review procedures, oppositions, derivations, reexaminations, or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">review proceedings, in the United States or elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated, or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Any failure to obtain or maintain patent protection with respect to our product candidates could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></p><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may be able to make product candidates that are similar to ours but that are not covered by the claims of the patents that we own or have exclusively licensed;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it is possible that our pending patent applications will not lead to issued patents;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issued patents that we own or have exclusively licensed may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we cannot predict the scope of protection of any patent issuing based on our patent applications, including whether the patent applications that we own or in&#8209;license will result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the claims of any patent issuing based on our patent applications may not provide protection against competitors or any competitive advantages, or may be challenged by third parties;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if enforced, a court may not hold that our patents are valid, enforceable and infringed;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which will be costly whether we win or lose;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may choose not to file a patent in order to maintain certain trade secrets or know&#8209;how, and a third party may subsequently file a patent covering such intellectual property;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may fail to adequately protect and police our trademarks and trade secrets; and</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the patents of others may have an adverse effect on our business, including if others obtain patents claiming subject matter similar to or improving that covered by our patents and patent applications.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should any of these events occur, they could significantly harm our business, results of operations and prospects.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">68</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information. If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know&#8209;how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce, and any other elements of our product candidates, technology and product discovery and development processes that involve proprietary know&#8209;how, information, or technology that is not covered by patents. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share our facilities or third&#8209;party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Because we expect to rely on third parties in the development and manufacture of our product candidates, we must, at times, share trade secrets with them. Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Trade secrets and confidential information, however, may be difficult to protect. We seek to protect our trade secrets, know&#8209;how and confidential information, including our proprietary processes, in part, by entering into confidentiality agreements with our employees, consultants, outside scientific advisors, contractors, and collaborators. We require our employees to enter into written employment agreements containing provisions of confidentiality and obligations to assign to us any inventions generated in the course of their employment. With our consultants, contractors, and outside scientific collaborators, these agreements typically include invention assignment obligations. We cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, outside scientific advisors, contractors, and collaborators might intentionally or inadvertently disclose our trade secret information to competitors. In addition, competitors may otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time&#8209;consuming, and the outcome is unpredictable. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, or misappropriation of our intellectual property by third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results, and financial condition.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Third&#8209;party claims of intellectual property infringement against us or our collaborators may prevent or delay our product discovery and development efforts.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and biopharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">review, post&#8209;grant review and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. Furthermore, patent reform and changes to patent laws add uncertainty to the possibility of challenge to our patents in the future. We cannot assure you that our product candidates and other proprietary technologies we may develop will not infringe existing or future patents owned by third parties. Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and time consuming and, even if resolved in our favor, is likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the fields in which we are developing our product candidates. We cannot provide any assurances that third&#8209;party patents do not exist which might be enforced against our current product candidates or future products, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties. As the biotechnology and biopharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. Third parties may assert that we infringe their patents or other intellectual property, or that we are otherwise employing their proprietary technology without authorization, and may sue us. There may be third&#8209;party patents of which we are currently unaware with claims to compositions, formulations, methods of manufacture, or methods of use or treatment that cover our product candidates. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our product candidates and other proprietary technologies we may develop, could be found to be infringed by our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">69</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product candidate. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, third parties, our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may obtain patents in the future that may prevent, limit or otherwise interfere with our ability to make, use and sell our product candidates, and may claim that use of our technologies or the manufacture, use, or sale of our product candidates infringes upon these patents. If any such third&#8209;party patents were held by a court of competent jurisdiction to cover our technologies or product candidates, or if we are found to otherwise infringe a third party&#8217;s intellectual property rights, the holders of any such patents may be able to block, including by court order, our ability to develop, manufacture or commercialize the applicable product candidate unless we obtain a license under the applicable patents or other intellectual property, or until such patents expire or are finally determined to be held invalid or unenforceable. Such a license may not be available on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non&#8209;exclusive, thereby giving our competitors access to the same technologies licensed to us. If we are unable to obtain a necessary license to a third&#8209;party patent on commercially reasonable terms, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The biopharmaceutical and biotechnology industries have produced a considerable number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we were sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity may be difficult. For example, in the United States, proving invalidity in court requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents, and there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on our business and operations. In addition, we may not have sufficient resources to bring these actions to a successful conclusion.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third parties asserting their patent or other intellectual property rights against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates or force us to cease some of our business operations. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business, cause development delays, and may impact our reputation. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties, or redesign our infringing products, which may be impossible on a cost&#8209;effective basis or require substantial time and monetary expenditure. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patents are of national or regional effect, and filing, prosecuting, maintaining and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can have a different scope and strength than do those in the United States. In addition, the laws of some foreign countries, particularly certain developing countries, do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement rights are not as strong as those in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or adequate to prevent them from competing.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property, particularly those relating to biopharmaceutical products, which could make it difficult in those jurisdictions for us to stop the infringement or misappropriation of our patents or other intellectual property rights, or the marketing of competing products in violation of our proprietary rights. Proceedings to enforce our patent and other intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business. Furthermore, such proceedings could put our patents at risk of being invalidated, held unenforceable, or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims of infringement or misappropriation against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Similarly, if our trade secrets are disclosed in a foreign jurisdiction, competitors worldwide could have access to our proprietary information and we may be without satisfactory recourse. Such disclosure could have a material adverse effect on our business. Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. In addition, certain developing countries, including China and India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we and our licensors may have limited</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">70</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">remedies if patents are infringed or if we or our licensors are compelled to grant a license to a third party, which could materially diminish the value of those patents. In addition, many countries limit the enforceability of patents against government agencies or government contractors. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, geo&#8209;political actions in the United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of our patent applications or those of any current or future licensors and the maintenance, enforcement or defense of our issued patents or those of any current or future licensors. For example, the United States and foreign government actions related to Russia&#8217;s conflict in Ukraine, the ongoing conflict between Israel and Hamas, and other matters may limit or prevent filing, prosecution, and maintenance of patent applications in Russia, Israel and other countries. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications, resulting in partial or complete loss of patent rights in Russia, Israel and other countries. If such an event were to occur, it could have a material adverse effect on our business. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit inventions owned by patentees from the United States without consent or compensation. Consequently, we would not be able to prevent third parties from practicing our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Finally, Europe&#8217;s planned Unified Patent Court or the UPC may, in particular, present uncertainties for our ability to protect and enforce our patent rights against competitors in Europe. In 2012, the European Patent Package, or the EU Patent Package, regulations were passed with the goal of providing a single pan&#8209;European Unitary Patent system and a new European Unified Patent Court for litigation involving European patents.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Unitary Patent system and UPC successfully launched on June 1, 2023. Under the UPC, all European patents, including those issued prior to ratification of the European Patent Package, now by default automatically fall under the jurisdiction of the UPC. The UPC provides our competitors with a new forum to centrally revoke our European patents, and allows for the possibility of a competitor to obtain pan&#8209;European injunctions. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize our technology and product candidates and, resultantly, on our business, financial condition, prospects and results of operations. It will be several years before we will understand the scope of patent rights that will be recognized and the strength of patent remedies that will be provided by the UPC. Under the current EU Patent Package, we have the right to opt our patents out of the UPC over the first seven years of the court&#8217;s existence, but doing so may preclude us from realizing the benefits of the new unified court. Moreover, if we do not meet all of the formalities and requirements for opt-out under the UPC, our future European patents could remain under the jurisdiction of the UPC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our issued patents, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk&#8209;adjusted cost of bringing and enforcing such a claim or action, which typically last for years before they are concluded, may be too high or not in the best interest of our company or our stockholders, or it may be otherwise impractical or undesirable to enforce our intellectual property against some third parties. Our competitors or other third parties may be able to sustain the costs of complex patent litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. In such cases, we may decide that the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings and that the more prudent course of action is to simply monitor the situation or initiate or seek some other non&#8209;litigious action or solution. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials, continue our internal research programs, in&#8209;license needed technology or other product candidates, or enter into development partnerships that would help us bring our product candidates to market.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">71</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents or other intellectual property or the intellectual property of our licensors, which could be expensive, time&#8209;consuming, and unsuccessful.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competitors may infringe our patents or other intellectual property or the intellectual property of our licensors. To cease such infringement or unauthorized use, we may be required to file patent infringement claims, which can be expensive and time&#8209;consuming and divert the time and attention of our management and scientific personnel. Our pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. In addition, in an infringement proceeding or a declaratory judgment action, a court may decide that one or more of our patents is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceeding could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interference or derivation proceedings provoked by third parties or brought by the USPTO may be necessary to determine the priority of inventions with respect to, or the correct inventorship of, our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially\ reasonable terms. Litigation, interference, derivation or other proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or before the USPTO or comparable foreign authority.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim we infringe their patents or that the patent covering our product candidate is invalid or unenforceable, or both. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent, including lack of novelty, obviousness, non&#8209;enablement or insufficient written description or that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re&#8209;examination, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">review, post&#8209;grant review, and equivalent proceedings in foreign jurisdictions, such as opposition or derivation proceedings. Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover and protect our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention, or decide that the other party&#8217;s use of our patented technology falls under the safe harbor to patent infringement under 35 U.S.C. &#167; 271I(1). With respect to the validity of our patents, for example, we cannot be certain that there is no invalidating prior art of which we, our patent counsel, and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates and such an outcome may limit our ability to assert our patents against those parties or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Such a loss of patent protection could have a material adverse impact on our business. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">72</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity, and is therefore costly, time&#8209;consuming, and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs, and may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our owned and licensed patents. Recent patent reform legislation in the United States and other countries, including the Leahy&#8209;Smith America Invents Act, or the Leahy&#8209;Smith Act, signed into law on September 16, 2011, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy&#8209;Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost&#8209;effective avenues for competitors to challenge the validity of patents. These include allowing third&#8209;party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post&#8209;grant proceedings, including post&#8209;grant review, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">review, and derivation proceedings. After March 2013, under the Leahy&#8209;Smith Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013, but before we file an application covering the same invention, could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (1) file any patent application related to our product candidates and other proprietary technologies we may develop or (2) invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing the claimed invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. However, the Leahy&#8209;Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents once obtained. Depending on decisions by Congress, the federal courts, the USPTO and the relevant law&#8209;making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in a series of cases, the U.S. Supreme Court held that certain claims do not present patentable subject matter (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Mayo Collaborative Services v. Prometheus Laboratories, Inc. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(2012); </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Assoc. for Molecular Pathology v. Myriad Genetics, Inc. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(2013); </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Alice Corp. v. CLS Bank International </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(2014)). Although we do not believe that any of the patents owned or licensed by us will be found invalid based on these decisions, we cannot predict how future decisions by Congress, the federal courts or the USPTO may impact the value of our patents.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non&#8209;compliance with these requirements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. Although an inadvertent lapse on us or our patent maintenance vendors, can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non&#8209;payment of fees, and failure to properly legalize and submit formal documents. In any such event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The lives of our patents may not be sufficient to effectively protect our products and business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patents have a limited lifespan. In the United States, if all maintenance fees are paid timely, the natural expiration of a patent is generally 20 years after its first effective filing date. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such product candidates are commercialized. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic medications. The launch of a generic version of one of our products in particular would be likely to result in an</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">73</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">immediate and substantial reduction in the demand for that product, which could have a material adverse effect on our business, financial condition, results of operations and prospects. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to ours. In addition, although upon issuance in the United States a patent&#8217;s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. A patent term extension based on regulatory delay may be available in the United States. However, only a single patent can be extended for each marketing approval, and any patent can be extended only once, for a single product. Moreover, the scope of protection during the period of the patent term extension does not extend to the full scope of the claim, but instead only to the scope of the product as approved. Laws governing analogous patent term extensions in foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple patents from a single patent family. Additionally, we may not receive an extension if we fail to exercise due diligence during the testing phase or regulatory review process, apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration and may take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to launch their product earlier than might otherwise be the case, and our revenue could be reduced, possibly materially. If we do not have sufficient patent life to protect our products, our business and results of operations will be adversely affected.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be subject to claims that former employees, collaborators, or other third parties have an interest in our patents or other intellectual property as an inventor or co&#8209;inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding co&#8209;ownership of potential joint inventions. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We or our licensors may have relied on third&#8209;party consultants or collaborators or on funds from third parties, such as the U.S. government, such that we or our licensors are not the sole and exclusive owners of the patents we in&#8209;licensed. If other third parties have ownership rights or other rights to our patents, including in&#8209;licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self&#8209;executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current or future trademarks or trade names may be challenged, infringed, circumvented or declared generic or descriptive, or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in other foreign jurisdictions. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">74</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, any name we have proposed to use with our product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA (or an equivalent administrative body in a foreign jurisdiction) objects to any of our proposed proprietary product names, it may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. If we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Ownership of Our Common Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our stock price may be volatile or may decline regardless of our operating performance, resulting in substantial losses for investors.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The market price of our common stock may be highly volatile and may fluctuate substantially as a result of a variety of factors, some of which are related in complex ways. The market price of our common stock may fluctuate significantly in response to numerous factors, many of which are beyond our control, including the factors listed below and other factors described in this &#8220;Risk Factors&#8221; section of this Quarterly Report on Form 10-Q:</span></p><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the commencement, enrollment, or results of current and future preclinical studies and clinical trials we may conduct, or changes in the development status of our product candidates;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adverse results or delays in clinical trials;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unanticipated serious safety concerns related to the use of our product candidates;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including, without limitation, the issuance by the FDA of a &#8220;refusal to file&#8221; letter or a request for additional information;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in laws or regulations, including, but not limited to, preclinical study or clinical trial requirements for approvals;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">negative clinical outcomes or other adverse events related to product candidates being developed by others in the CNS field;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">publication of research reports about us or our industry, or CNS programs in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any adverse changes to our relationship with manufacturers or suppliers;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacturing, supply or distribution shortages;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our failure to commercialize our product candidates;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">general political conditions, including but not limited to, disruptions in U.S. government operations and funding, geopolitical conflicts such as the war between Russia and the Ukraine, the war between Israel and Hamas, and any sanctions or other repercussions that may result therefrom;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">general economic conditions, including but not limited to, rising inflation, recession risk, low consumer confidence and increasing interest rates;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">additions or departures of key scientific or management personnel;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">variations in our results of operations;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our cash position;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></div></div><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">75</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcements made by us or our competitors of new product and service offerings, acquisitions, strategic relationships, joint ventures, or capital commitments;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our inability to establish collaborations, if needed;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to effectively manage our growth;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the market valuations of similar companies;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">press reports, whether or not true, about our business;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sales or perceived potential sales of our common stock by us or our stockholders in the future;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">overall fluctuations in the equity markets;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ineffectiveness of our internal controls;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes or developments in the global regulatory environment;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">litigation involving us, our industry or both, or investigations by regulators into our operations or those of our competitors;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">impact from the COVID&#8209;19 pandemic, or any future pandemic, on us or third parties with which we engage; and</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">other events or factors, many of which are beyond our control.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the stock market in general and biotechnology and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating, which may limit or prevent investors from selling their shares at or above the price paid for the shares and may otherwise negatively affect the liquidity of our common stock.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect our operating results to be subject to quarterly fluctuations, which will make it difficult for us to predict our future results. Our net loss and other operating results will be affected by numerous factors, including:</span></p><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">timing and variations in the level of expense related to the current or future development of our programs, including but not limited to, the timing of the milestone payments;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to enroll patients in clinical trials and timing and status of enrollment for our clinical trials;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">results of clinical trials, or the addition or termination of clinical trials or funding support by us or potential future partners;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the need to conduct unanticipated clinical trials or trials that are larger or more complex than anticipated;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">competition from products that compete with our product candidates, and changes in the competitive landscape of our industry, including consolidation among our competitors or partners;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any delays in regulatory review or approval of our product candidates;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">stock&#8209;based compensation estimates;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in general political conditions, including but not limited to, disruptions in U.S. government operations and funding, geopolitical conflicts such as the war between Russia and the Ukraine, the war between Israel and Hamas, and any sanctions or other repercussions that may result therefrom;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in general economic conditions, including but not limited to, rising inflation, recession risk, low consumer confidence and increasing interest rates;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our execution of any collaboration, licensing or similar arrangements, and the timing of payments we may make or receive under potential future arrangements or the termination or modification of any such potential future arrangements;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any intellectual property infringement, misappropriation or violation lawsuit or opposition, interference or cancellation proceeding in which we may become involved;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">additions and departures of key personnel;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin&#8209;offs, joint ventures, strategic investments or changes in business strategy;</span></div></div><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">76</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if any product candidate we may develop receive regulatory approval, the timing and terms of such approval and market acceptance and demand for such product candidates;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing and cost to establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval and intend to commercialize on our own or jointly with current or future collaborators;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved, and existing and potential future products that compete with any of our product candidates;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to commercialize our product candidates, if approved, inside and outside of the United States, either independently or working with third parties;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to establish and maintain collaborations, licensing or other arrangements;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to adequately support future growth;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential unforeseen business disruptions that increase our costs or expenses;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory developments affecting current or future product candidates or those of our competitors; and</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">impact from the COVID&#8209;19 pandemic, or any future pandemic, on us or third parties with which we engage.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates owned approximately 48% of our outstanding voting stock. Therefore, these stockholders will have the ability to influence us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. In addition, certain of our principal stockholders, including Amgen, ARCH Venture Partners and Mubadala Capital, have designated certain of our directors for election to the Board. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market could cause our common stock price to fall.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our existing stockholders sell, or indicate an intention to sell, or if the market perceives that such existing stockholders might sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline. As of March 31, 2024, we had outstanding a total of 159,357,595 shares of common stock and approximately 48% of such shares were beneficially owned by our directors, officers, and holders of 5% or more of our common stock. In addition, shares of common stock that are either subject to outstanding options or reserved for future issuance under our employee benefit plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and Rule 144 and Rule 701 under the Securities Act of 1933, as amended (Securities Act). If these additional shares of common stock are sold, or there is a perception that they will be sold, in the public market, the trading price of our common stock could decline. Further, certain holders of shares of our common stock are entitled to rights with respect to the registration of their shares under the Securities Act. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, in the future, we may issue additional shares of common stock, or other equity or debt securities convertible into common stock, in connection with a financing, acquisition, employee arrangement, or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and could cause the price of our common stock to decline.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We do not currently intend to pay dividends on our common stock and, consequently, our stockholders&#8217; ability to achieve a return on their investment will depend on appreciation of the value of our common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings to support operations and to finance the growth and development of our business. We do not intend to declare or pay any cash dividends on our capital stock in the foreseeable future. As a result, any investment return on our common stock will depend upon increases in the value for our common stock, which is not certain.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">77</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Provisions in our amended and restated certificate of incorporation and our amended and restated bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could depress the market price of our common stock by acting to discourage, delay, or prevent a change in control of our company or changes in our management that the stockholders of our company may deem advantageous. These provisions, among other things:</span></p><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish a staggered board of directors divided into three classes serving staggered three&#8209;year terms, such that not all members of the board of directors will be elected at one time;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">authorize our board of directors to issue new series of preferred stock without stockholder approval and create, subject to applicable law, a series of preferred stock with preferential rights to dividends or our assets upon liquidation, or with superior voting rights to our existing common stock;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">eliminate the ability of our stockholders to call special meetings of stockholders;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">eliminate the ability of our stockholders to fill vacancies on our board of directors;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish advance notice requirements for nominations for election to our Board or for proposing matters that can be acted upon by stockholders at our annual stockholder meetings;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">permit our board of directors to establish the number of directors;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provide that our board of directors is expressly authorized to make, alter or repeal our amended and restated bylaws;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provide that stockholders can remove directors only for cause and only upon the approval of not less than 66&#8209;2/3% of all outstanding shares of our voting stock;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require the approval of not less than 66&#8209;2/3% of all outstanding shares of our voting stock to amend our amended and restated bylaws and specific provisions of our certificate of incorporation; and</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the jurisdictions in which certain stockholder litigation may be brought.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a Delaware corporation, we are subject to the anti&#8209;takeover provisions of Section 203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in a business combination specified in the statute with an interested stockholder (as defined in the statute) for a period of three years after the date of the transaction in which the person first becomes an interested stockholder, unless the business combination is approved in advance by a majority of the independent directors or by the holders of at least two&#8209;thirds of the outstanding disinterested shares. The application of Section 203 of the Delaware General Corporation Law could also have the effect of delaying or preventing a change of control of our company.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our amended and restated certificate of incorporation provides an exclusive forum in the Court of Chancery of the State of Delaware for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the sole and exclusive forum, to the fullest extent permitted by law, for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a breach of a fiduciary duty owed by any director, officer or other employee to us or our stockholders, (3) any action asserting a claim against us or any director, officer, or other employee arising pursuant to the Delaware General Corporation Law, (4) any action to interpret, apply, enforce, or determine the validity of our second amended and restated certificate of incorporation or amended and restated bylaws or (5) any other action asserting a claim that is governed by the internal affairs doctrine, is the Court of Chancery of the State of Delaware (or another state court or the federal court located within the State of Delaware if the Court of Chancery does not have or declines to accept jurisdiction), in all cases subject to the court&#8217;s having jurisdiction over indispensable parties named as defendants. In addition, our amended and restated certificate of incorporation provides that the federal district courts of the United States are the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act but that the forum selection provision does apply to claims brought to enforce a duty or liability created by the Exchange Act.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law for the specified types of actions and proceedings, the provisions may result in increased costs to stockholders to bring a claim for any such dispute and may have the effect of discouraging lawsuits against us or our directors and officers. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, financial condition, and operating results. For example, under the Securities Act, federal courts have concurrent jurisdiction over all suits brought to enforce any duty or liability created by the Securities Act, and investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Any person or entity purchasing or otherwise acquiring any interest in our shares of capital stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">78</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">will be deemed to have notice of and consented to this exclusive forum provision, but will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to use our net operating loss carryforwards and other tax attributes may be limited.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the Code), if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three&#8209;year period, the corporation&#8217;s ability to use its pre&#8209;change net operating loss carryforwards (NOLs) and other pre&#8209;change tax attributes (such as research and development tax credits) to offset its post&#8209;change income or taxes may be limited. We may have experienced ownership changes in the past and may experience additional ownership changes in the future as a result of subsequent shifts in our stock ownership (some of which are outside our control). As a result, our ability to use our pre&#8209;change NOLs and tax credits to offset future taxable income, if any, could be subject to limitations. Similar provisions of state tax law may also apply. As a result, even if we attain profitability, we may be unable to use a material portion of our NOLs and tax credits.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General Risk Factors</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If securities or industry analysts either do not publish research about us or publish inaccurate or unfavorable research about us, our business or our market, or if they change their recommendations regarding our common stock adversely, the trading price or trading volume of our common stock could decline.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading market for our common stock is influenced in part by the research and reports that securities or industry analysts may publish about us, our business, our market, or our competitors. If one or more of these analysts initiate research with an unfavorable rating or downgrade our common stock, provide a more favorable recommendation about our competitors or publish inaccurate or unfavorable research about our business, our common stock price would likely decline. If any analyst covering us were to cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause the trading price or trading volume of our common stock to decline.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As widely reported, global credit and financial markets have experienced extreme volatility and disruptions over the past several months, including concerns about declines in consumer confidence, declines in economic growth, increases in the rate of inflation, increases in borrowing rates and changes in liquidity and credit availability, and uncertainty about economic stability, including most recently in connection with actions undertaken by the U.S. Federal Reserve Board to address inflation, the failure of banks, the military conflict in Ukraine, the war between Israel and Hamas and supply chain disruptions. There can be no assurance that future deterioration in global credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive, if at all possible. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">An active trading market for our common stock may not develop or be sustained.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to our initial public offering in September 2023, there was no public market for shares of our common stock. Our common stock is currently listed on the Nasdaq Global Select Market under the symbol &#8220;NMRA&#8221;. The price for our common stock may vary and an active or liquid market in our common stock may not be sustained. The lack of an active market may impair the value of your shares, your ability to sell your shares at the time you wish to sell them and the prices that you may obtain for your shares. An inactive market may also impair our ability to raise capital by selling our common stock and our ability to acquire other companies, products or technologies by using our common stock as consideration.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The continuing impact of &#8220;Brexit&#8221; may have a negative effect on our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following a national referendum and subsequent legislation, the United Kingdom formally withdrew from the European Union, commonly referred to as &#8220;Brexit,&#8221; and ratified a trade and cooperation agreement governing its future relationship with the European Union. Among other things, the agreement, which became effective in 2021, addresses trade, economic arrangements, law enforcement, judicial cooperation and governance. While the agreement provides a framework for cooperation between the UK and the EU including for example the mutual recognition of Good Manufacturing Practice (GMP) inspections of manufacturing facilities for medicinal products, it does not contain wholesale mutual recognition of pharmaceutical regulations and product standards. There may therefore be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">79</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">divergent local requirements in the UK compared to the EU in the future, which may increase the costs of conducting clinical and development activities in the UK.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot yet predict the full implications of Brexit, including whether it will increase our operational costs or otherwise have a negative effect on our business, financial condition or results of operations, which could reduce the price of our common stock.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are an emerging growth company and a smaller reporting company, and any decision on our part to comply only with certain reduced reporting and disclosure requirements applicable to emerging growth companies and smaller reporting companies could make our common stock less attractive to investors.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act and a &#8220;smaller reporting company,&#8221; as defined in the Exchange Act. For as long as we continue to be an emerging growth company, we may choose to take advantage of exemptions from various reporting requirements applicable to other public companies but not to emerging growth companies, including:</span></p><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">not being required to have our independent registered public accounting firm audit our internal control over financial reporting under Section 404 of the Sarbanes&#8209;Oxley Act;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reduced disclosure obligations regarding executive compensation in our periodic reports and annual report on Form 10&#8209;K; and</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">exemptions from the requirements of holding non&#8209;binding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We could be an emerging growth company for up to five years following the completion of our initial public offering. Our status as an emerging growth company will end as soon as any of the following takes place:</span></p><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the last day of the fiscal year in which we have more than $1.235 billion in annual revenue;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the date we qualify as a &#8220;large accelerated filer,&#8221; with at least $700.0 million of equity securities held by non&#8209;affiliates;</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the date on which we have issued, in any three&#8209;year period, more than $1.0 billion in non&#8209;convertible debt securities; or</span></div></div><div style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the last day of the fiscal year ending after the fifth anniversary of the completion of our initial public offering.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to use this extended transition period for any new or revised accounting standards during the period in which we remain an emerging growth company; however, we may adopt certain new or revised accounting standards early. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even after we no longer qualify as an emerging growth company, we may continue to qualify as a smaller reporting company, which would allow us to rely on certain reduced disclosure requirements, such as an exemption from providing selected financial data and executive compensation information. We are also exempt from the requirement to obtain an external audit on the effectiveness of internal control over financial reporting provided in Section 404(b) of the Sarbanes-Oxley Act. These exemptions and reduced disclosures due to our status as a smaller reporting company mean that our auditors do not review our internal controls over financial reporting and may make it harder for investors to analyze our results of operations and financial prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot predict if investors will find our common stock less attractive if we choose to rely on any of the exemptions afforded to emerging growth companies and smaller reporting companies. If some investors find our common stock less attractive because we rely on any of these exemptions, there may be a less active trading market for our common stock and the market price of our common stock may be more volatile.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The requirements of being a public company may strain our resources, result in more litigation, and divert management&#8217;s attention.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to the reporting requirements of the Exchange Act, the Sarbanes&#8209;Oxley Act, the Dodd&#8209;Frank Wall Street Reform and Consumer Protection Act, or the Dodd&#8209;Frank Act, the listing requirements of Nasdaq, and other applicable securities rules and regulations. Complying with these rules and regulations has increased and will increase our legal and financial compliance costs, make some activities more difficult, time consuming or costly and increase demand on our systems and resources. The Exchange Act requires, among other things, that we file annual, quarterly, and current reports with respect to our business and operating results. The Sarbanes&#8209;Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We are required to disclose changes made in our internal control and procedures on a quarterly basis. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, management&#8217;s attention may be diverted from other business concerns, which could adversely affect our business and operating results. We may also need to hire additional employees or engage outside consultants to comply with these requirements, which will increase our costs and expenses.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">80</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, changing laws, regulations, and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs, and making some activities more time consuming. These laws, regulations, and standards are subject to varying interpretations, in many cases due to their lack of specificity and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations, and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from revenue&#8209;generating activities to compliance activities. If our efforts to comply with new laws, regulations, and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business may be adversely affected.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These new rules and regulations may make it more expensive for us to obtain director and officer liability insurance and, in the future, we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on our audit committee and compensation committee, and qualified executive officers.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">By disclosing information in filings required by us as a public company, our business and financial condition will continue to become more visible, which we believe may result in threatened or actual litigation, including by competitors and other third parties. If those claims are successful, our business could be seriously harmed. Even if the claims do not result in litigation or are resolved in our favor, the time and resources needed to resolve them could divert our management&#8217;s resources and seriously harm our business.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or manmade disasters or business interruptions, for which we are predominantly self&#8209;insured. We rely on third&#8209;party manufacturers to produce our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers were affected by a man&#8209;made or natural disaster or other business interruption. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to maintain proper and effective internal controls over financial reporting our ability to produce accurate and timely financial statements could be impaired.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 404 of the Sarbanes&#8209;Oxley Act, our management is required to report upon the effectiveness of our internal control over financial reporting when we lose our status as an &#8220;emerging growth company&#8221; and become an &#8220;accelerated filer&#8221; or a &#8220;large accelerated filer.&#8221; At that point, we will be required to have an independent registered public accounting firm attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex, judgmental and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we will need to implement additional financial and management controls, reporting systems and procedures and hire additional accounting and finance staff.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations, or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if we and/or our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our consolidated financial statements, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">81</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to the periodic reporting requirements of the Exchange Act. We must design our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well&#8209;conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision&#8209;making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make a required related party transaction disclosure. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our estimates or judgments relating to our critical accounting policies prove to be incorrect or financial reporting standards or interpretations change, our results of operations could be adversely affected.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with generally accepted accounting principles in the United States (U.S. GAAP), requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances, as provided in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Critical Accounting Policies and Estimates.&#8221; The results of these estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Significant assumptions and estimates used in preparing our consolidated financial statements include but are not limited to stock&#8209;based compensation and evaluation of acquisitions of assets and other similar transactions as well as clinical trial accruals. Our results of operations may be adversely affected if our assumptions change or if actual circumstances differ from those in our assumptions, which could cause our results of operations to fall below the expectations of securities analysts and investors, resulting in a decline in the trading price of our common stock.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we regularly monitor our compliance with applicable financial reporting standards and review new pronouncements and drafts thereof that are relevant to us. As a result of new standards, changes to existing standards and changes in their interpretation, we might be required to change our accounting policies, alter our operational policies, and implement new or enhance existing systems so that they reflect new or amended financial reporting standards, or we may be required to restate our audited consolidated financial statements, unaudited condensed consolidated financial statements and related notes. Such changes to existing standards or changes in their interpretation may also have an adverse effect on our reputation, business, financial position, and profit.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our information technology systems, or those used by our third&#8209;party research institution collaborators, CROs, CDMOs, or other contractors or consultants, may fail or suffer cyberattacks or security breaches.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are increasingly dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course of business, we collect, store and transmit confidential information (including but not limited to intellectual property, proprietary business information, clinical trial data, and personal information of our employees and contractors). It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We also have outsourced elements of our operations to third parties, and as a result we manage a number of third&#8209;party contractors who have access to our confidential information.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Despite the implementation of security measures, our information technology systems and those of our future CROs and CDMOs, and other contractors and consultants are vulnerable to attack, damage, or interruption from hacking, cyberattacks, &#8220;phishing&#8221; attacks and other social engineering schemes, computer viruses and malware (e.g., ransomware), malicious code, denial or degradation of service attacks, sophisticated nation&#8209;state and nation&#8209;state supported actors, unauthorized access or use by persons within our organization, natural disasters, terrorism, war and telecommunication and electrical failures, employee theft or misuse, human error, and fraud. Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. As a result of the continued hybrid working environment, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We and certain of our service providers are from time to time subject to cyberattacks and security incidents, including social engineering and phishing attacks. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. Although to our knowledge we have not experienced any such material system failure, accident, or security breach to date, if such an event were to occur and negatively affect, our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">82</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and significantly increase our costs to recover or reproduce the data. Further, we cannot assure that our data protection efforts and our investment in information technology will prevent significant breakdowns, data leakages, breaches in our systems or other cyber incidents that could have a material adverse effect upon our reputation, business, operations or financial condition.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Likewise, we rely on our third&#8209;party research institution collaborators for research and development of our product candidates and other third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their information technology systems could also have a material adverse effect on our business. To the extent that any disruption or security incident were to result in an actual or perceived loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information or patient information, we could incur liability and the further development and commercialization of our product candidates could be delayed. Furthermore, significant disruptions of our internal information technology systems or security breaches could result in the loss, misappropriation, and/or unauthorized access, use, or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information, and personal information), which could result in financial, legal, business, and reputational harm to us. For example, any such event that leads to unauthorized access, use, or disclosure of personal information, including personal information regarding our clinical trial subjects or employees, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business. Further, our insurance coverage may not be sufficient to cover the financial, legal, business or reputational losses that may result from an interruption or breach of our systems.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have and will enter into collaboration, license, contract research and/or manufacturing relationships with organizations that operate in certain countries that are at heightened risk of theft of technology, data and intellectual property through direct intrusion by private parties or foreign actors, including those affiliated with or controlled by state actors. Accordingly, our efforts to protect and enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license, and we may be at heightened risk of losing our proprietary intellectual property rights around the world, including outside of such countries, to the extent such theft or intrusion destroy the proprietary nature of our intellectual property.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or biopharmaceutical companies. Although we try to ensure that individuals working for or collaborating with us do not use the proprietary information or know&#8209;how of others in their work for us, we may be subject to claims that we or our employees, consultants, or independent contractors have inadvertently or otherwise used or disclosed confidential information proprietary to these third parties or our employees&#8217; former employers, or that we caused an employee to breach the terms of his or her non&#8209;competition or non&#8209;solicitation agreement. We may be subject to claims that patents and applications we have filed to protect inventions of our employees, consultants, advisors or other third parties, even those related to one or more of our product candidates, are rightfully owned by their former or concurrent employer. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to our product candidates, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation or the threat thereof may adversely affect our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results of operations and financial condition. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We could be subject to securities class action litigation.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results, or financial condition. Additionally, the dramatic increase in the cost of directors&#8217; and officers&#8217; liability insurance may cause us to opt for lower overall policy limits or to forgo insurance that we may otherwise rely on to cover significant defense costs, settlements, and damages awarded to plaintiff.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">83</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="unregistered_sales_of_equity_securities"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></p><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent Sales of Unregistered Securities.</span></div></div><p style="margin-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(b)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Proceeds.</span></div></div><p style="margin-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 19, 2023, our registration statement on Form S-1 (File No. 333- 274229) relating to our IPO of common stock became effective. The IPO closed on September 19, 2023 at which time we issued 14,710,000 shares of common stock at a public offering price of $17.00 per share. We received net proceeds from the IPO of approximately $226.6 million, after deducting the underwriting discounts and commissions of $17.5 million and expenses of $6.0 million. None of the expenses associated with the IPO were paid to directors, officers, persons owning 10% or more of any class of equity securities, or to our affiliates. J.P. Morgan Securities LLC, BofA Securities, Inc., Stifel, Nicolaus &amp; Company, Incorporated, Guggenheim Securities, LLC, RBC Capital Markets, LLC and William Blair &amp; Company, L.L.C. acted as joint book-running managers for the offering.</span></p><p style="margin-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There has been no material change in the planned use of proceeds from the IPO from that described in the Annual Form 10-K filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act on March 7, 2024.</span></p><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(c)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issuer Purchases of Equity Securities.</span></div></div><p style="margin-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="defaults_upon_senior_securities"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Defaults Upon Senior Securities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tem 4. Mine Safety Disclosures.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_9b_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 5. Other I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nformation.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">84</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 6. E</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">xhibits.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:8%;"/>
     <td style="width:1.3%;"/>
     <td style="width:60%;"/>
     <td style="width:1%;"/>
     <td style="width:6.4%;"/>
     <td style="width:8.22%;"/>
     <td style="width:6.86%;"/>
     <td style="width:1%;"/>
     <td style="width:7.22%;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Incorporated by Reference</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filed</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Form</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Herewith</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1885522/000119312523237644/d541406dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Certificate of Incorporation, as amended, currently in effect.</span></a></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
     <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9/19/2023</span></p></td>
     <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1885522/000119312523237644/d541406dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Bylaws, as amended, currently in effect.</span></a></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
     <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9/19/2023</span></p></td>
     <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reference is made to Exhibits </span><a href="https://www.sec.gov/Archives/edgar/data/1885522/000119312523237644/d541406dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">3.1</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;through </span><a href="https://www.sec.gov/Archives/edgar/data/1885522/000119312523237644/d541406dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">3.2</span></a></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1885522/000119312523231902/d241143dex42.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Common Stock Certificate.</span></a></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1/A</span></p></td>
     <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9/11/2023</span></p></td>
     <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1#</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="nmra-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Non-Employee Director Compensation Program.</span></a></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2#</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="nmra-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">RBNC Therapeutics, Inc. Milestone Carveout Plan</span></a></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.1</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="nmra-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.2</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="nmra-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.1+</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="nmra-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.2+</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="nmra-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.INS</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.SCH</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
    </tr>
   </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:86.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"># Indicates management contract or compensatory plan.</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">+ This certification accompanies the Quarterly Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed "filed" by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">85</span></p></div>
   <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIG</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NATURES</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.22%;"/>
     <td style="width:4%;"/>
     <td style="width:7%;"/>
     <td style="width:43.78%;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Neumora Therapeutics, Inc.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: May 7, 2024</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Henry O. Gosebruch</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Henry O. Gosebruch</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: May 7, 2024</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Joshua Pinto, Ph.D.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Joshua Pinto, Ph.D</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">86</span></p></div>
   <hr style="page-break-after:always;"/></div>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>nmra-ex10_1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html>
 <head>
  <title>EX-10.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div class="section-group" style="margin:auto;padding-left:0.5in;width:7.5in;padding-right:0.5in;"><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0125in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">NEUMORA THERAPEUTICS, INC.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.013194444444444444in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM</font></p><p style="margin-left:0.05pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0125in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(as amended through March 13, 2024)</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Neumora Therapeutics, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) Non-Employee Director Compensation Program, as amended herein (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Program</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), has been adopted under the Company&#x2019;s 2023 Incentive Award Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and shall be effective as of March 13, 2024 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). Capitalized terms not otherwise defined herein shall have the meaning ascribed in the Plan.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Compensation</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effective as of the Effective Date, annual retainers will be paid in the following amounts to Non- Employee Directors:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:82%;"></td>
     <td style="width:18%;"></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
     <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;text-indent:5.05pt;border-left:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="margin-left:5.05pt;text-indent:0;font-size:12pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-Employee Director:</font></p></td>
     <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:12pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;margin-right:0.07013888888888889in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$45,000</font></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
     <td style="border-right:0.5pt solid #000000;text-indent:5.05pt;border-left:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="margin-left:5.05pt;text-indent:0;font-size:12pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lead Independent Director:</font></p></td>
     <td style="border-right:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:12pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;margin-right:0.07013888888888889in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$25,000</font></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
     <td style="border-right:0.5pt solid #000000;text-indent:5.05pt;border-left:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="margin-left:5.05pt;text-indent:0;font-size:12pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Audit Committee Chair:</font></p></td>
     <td style="border-right:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:12pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;margin-right:0.07013888888888889in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$20,000</font></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
     <td style="border-right:0.5pt solid #000000;text-indent:5.05pt;border-left:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="margin-left:5.05pt;text-indent:0;font-size:12pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Compensation Committee Chair:</font></p></td>
     <td style="border-right:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:12pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;margin-right:0.07013888888888889in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$15,000</font></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
     <td style="border-right:0.5pt solid #000000;text-indent:5.05pt;border-left:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="margin-left:5.05pt;text-indent:0;font-size:12pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nominating and Corporate Governance Committee Chair:</font></p></td>
     <td style="border-right:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:12pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;margin-right:0.07013888888888889in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$10,000</font></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
     <td style="border-right:0.5pt solid #000000;text-indent:5.05pt;border-left:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="margin-left:5.05pt;text-indent:0;font-size:12pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Audit Committee Member (non-Chair):</font></p></td>
     <td style="border-right:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:12pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;margin-right:0.07013888888888889in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$10,000</font></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
     <td style="border-right:0.5pt solid #000000;text-indent:5.05pt;border-left:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="margin-left:5.05pt;text-indent:0;font-size:12pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Compensation Committee Member (non-Chair):</font></p></td>
     <td style="border-right:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:12pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;margin-right:0.07013888888888889in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$7,500</font></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
     <td style="border-right:0.5pt solid #000000;text-indent:5.05pt;border-left:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="margin-left:5.05pt;text-indent:0;font-size:12pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nominating and Corporate Governance Committee Member (non-Chair):</font></p></td>
     <td style="border-right:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:12pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;margin-right:0.07013888888888889in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$5,000</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">All annual retainers are additive and will be paid in cash quarterly in arrears promptly following the end of the applicable calendar quarter, but in no event more than 30 days after the end of such quarter. In the event a Non-Employee Director does not serve as a Non-Employee Director, or in the applicable positions described above, for an entire calendar quarter, the retainer paid to such Non-Employee Director shall be prorated for the portion of such calendar quarter actually served as a Non-Employee Director, or in such position, as applicable.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Election to Receive Restricted Stock Units In Lieu of Annual Retainer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:38.542%;"></td>
     <td style="width:61.458%;"></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
     <td style="text-indent:2.5pt;vertical-align:top;"><p style="margin-left:2.5pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General:</font></p></td>
     <td style="vertical-align:top;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Each Non-Employee Director may elect to convert all or a portion of his or her annual retainer into a number of Restricted Stock Units (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Retainer RSUs</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201d;) granted under the Plan or any other applicable Company equity incentive plan then- maintained by the Company covering a number of shares of Common Stock calculated by dividing (i) the amount of the annual retainer that would have otherwise been paid to such Non-Employee Director on the applicable grant date by (ii) the per share Fair Market Value as of the date of grant (such election, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Retainer RSU Election</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201d;).</font></p><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Each award of Retainer RSUs will be granted on the fifth day of the month immediately following the end of the quarter for which the corresponding portion of the annual retainer was earned, except that if such fifth day of the month is not a trading day, the applicable award of Retainer RSUs will be granted on the next trading day following such date. Each award of Retainer RSUs will be fully vested on the date of grant.</font></p></td>
    </tr>
   </table><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
   <hr style="page-break-after:always;"><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:38.542%;"></td>
     <td style="width:61.458%;"></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="text-indent:2.5pt;vertical-align:top;"><p style="margin-left:2.5pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:top;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Election Method:</font></p></td>
     <td style="vertical-align:top;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Each Retainer RSU Election must be submitted to Company in the form and manner specified by the Board of Directors of the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201d;) or Compensation Committee of the Board (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Compensation Committee</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201d;). An individual who fails to make a timely Retainer RSU Election shall not receive Retainer RSUs and instead shall receive the applicable annual retainer in cash. Retainer RSU Elections must comply with the following timing requirements:</font></p><div style="margin-left:0.11944444444444446in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.610444378956782%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Initial Election</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Each individual who first becomes a Non-Employee Director may make a Retainer RSU Election with respect to annual retainer payments scheduled to be paid in the same calendar year as such individual first becomes a Non-Employee Director (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Initial Election</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The Initial Election must be submitted to the Company on or prior to the date that the individual first becomes a Non-Employee Director (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Initial Election Deadline</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and the Initial Election shall become final and irrevocable as of the Initial Election Deadline.</font></div></div><div style="margin-left:0.11944444444444446in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.610444378956782%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Annual Election</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. No later than December 31 of each calendar year, or such earlier deadline as may be established by the Board or the Compensation Committee, in its discretion (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Annual Election Deadline</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), each individual who is a Non-Employee Director as of immediately prior to the Annual Election Deadline may make a Retainer RSU Election with respect to the annual retainer relating to services to be performed in the following calendar year (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Annual Election</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The Annual Election must be submitted to the Company on or prior to the applicable Annual Election Deadline and shall become effective and irrevocable as of the Annual Election Deadline.</font></div></div><div style="margin-left:0.11944444444444446in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.610444378956782%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Deferral of Settlement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Board, the Compensation Committee or their respective authorized designee may, in its discretion, provide an individual who is a Non-Employee Director with the opportunity to defer the delivery of the shares underlying Retainer RSUs that would otherwise be delivered to the individual hereunder. Any such deferral election shall be subject to such rules, conditions and procedures as shall be determined by the Board or the Compensation Committee, in its sole discretion, which rules, conditions and procedures shall at all times comply with the requirements of Section 409A of the Code, unless otherwise specifically determined by the Board or the Compensation Committee. If an individual elects to defer the delivery of the shares underlying Retainer RSUs in accordance herewith, settlement of the deferred Retainer RSUs shall be made in accordance with the terms of the Retainer RSU Election.</font></div></div></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:top;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
   <hr style="page-break-after:always;"><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:38.542%;"></td>
     <td style="width:61.458%;"></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Equity Compensation</font></p></td>
     <td style="vertical-align:top;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:top;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Initial Equity Grant:</font></p></td>
     <td style="vertical-align:top;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Each Non-Employee Director who is initially elected or appointed to serve on the Board on or after the Effective Date shall be granted Awards under the Plan or any other applicable Company equity incentive plan then-maintained by the Company having an aggregate grant date fair value (disregarding forfeitures) equal to $725,000 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Initial Grant</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201d;). The Initial Grant shall be composed of an Option and Award of Restricted Stock Units (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">RSUs</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201d;) as follows: (i) 50% of the Initial Grant shall be an Option (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Initial Option</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201d;) to purchase that number of shares of Common Stock calculated by dividing (x) $362,500 by (y) the per share grant date fair value of the Option, rounded down; and (ii) 50% of the Initial Grant shall be an Award of that number of RSUs (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Initial RSUs</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201d;) calculated by dividing (x) $362,500 by (y) Fair Market Value as of the date of grant, rounded down. The grant date fair value of the Initial Option shall be calculated based on Fair Market Value as of the date of grant and using assumptions published in the Company&#x2019;s most recent periodic report with such information as of the date of grant.</font></p><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Initial Grant will be automatically granted on the date on which such Non-Employee Director commences service on the Board, and will (i) for the Initial Option, vest as to 1/36</font><font style="color:#000000;top:-5.628pt;white-space:pre-wrap;font-size:8.040000000000001pt;position:relative;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;of the shares subject thereto on each monthly anniversary of the applicable date of grant and (ii) for the Initial RSUs, one-third shall vest each year on the anniversary of the applicable date of grant in equal annual amounts; in each case such that the shares subject to the Initial Grant are fully vested on the third anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Board through each such vesting date.</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:top;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Annual Stock Option Grant:</font></p></td>
     <td style="vertical-align:top;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Each Non-Employee Director who (i) has been serving on the Board for at least four months as of each meeting of the Company&#x2019;s stockholders on or after the Effective Date(each, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Annual Meeting</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201d;) and (ii) will continue to serve as a Non- Employee Director immediately following such meeting, shall be granted Awards under the Plan or any other applicable Company equity incentive plan then-maintained by the Company having an aggregate grant date fair value (disregarding forfeitures) equal to $400,000 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Annual Grant</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201d;). The Annual Grant shall be composed of a mix of an Option and Award of RSUs as follows: (i) 50% of the Annual Grant shall be an Option (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Annual Option</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201d;) to purchase that number of shares of Common Stock calculated by dividing (x) $200,000 by (y) the per share grant date fair value of the Option, rounded down; and (ii) 50% of the Initial Grant shall be an Award of that number of RSUs (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Annual RSUs</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201d;) calculated by dividing (x) $200,000 by (y) Fair Market Value as of the date of grant, rounded down. The grant date fair value of the Annual Option shall be calculated based on Fair Market Value as of the date of grant and using assumptions published in the Company&#x2019;s most recent periodic report with such information as of the date of grant.</font></p></td>
    </tr>
   </table><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
   <hr style="page-break-after:always;"><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:38.542%;"></td>
     <td style="width:61.458%;"></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:top;text-align:right;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Annual Grant will be automatically granted on the date of the applicable Annual Meeting, and will vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Non-Employee Director continuing in service on the Board through such vesting date.</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The per share exercise price of each Option granted to a Non-Employee Director shall equal the Fair Market Value of a share of Common Stock on the date the Option is granted.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The term of each Option granted to a Non-Employee Director shall be ten years from the date the Option is granted, subject to earlier termination in connection with cessation of Board service.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Members of the Board who are employees of the Company or any parent or subsidiary of the Company who subsequently terminate their employment with the Company and any parent or subsidiary of the Company and remain on the Board will not receive an Initial Grant, but to the extent that they are otherwise eligible, will be eligible to receive, after termination from employment with the Company and any parent or subsidiary of the Company, Annual Grants as described above.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Change in Control</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Upon a Change in Control of the Company, all outstanding equity awards granted under the Plan and any other equity incentive plan maintained by the Company that are held by a Non-Employee Director shall become fully vested and/or exercisable, irrespective of any other provisions of the Non-Employee Director&#x2019;s Award Agreement.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reimbursements</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company shall reimburse each Non-Employee Director for all reasonable, documented, out- of-pocket travel and other business expenses incurred by such Non-Employee Director in the performance of his or her duties to the Company in accordance with the Company&#x2019;s applicable expense reimbursement policies and procedures as in effect from time to time.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Miscellaneous</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The other provisions of the Plan shall apply to the Awards granted automatically pursuant to this Program, except to the extent such other provisions are inconsistent with this Program. All applicable terms of the Plan apply to this Program as if fully set forth herein, and all grants of Awards hereby are subject in all respects to the terms of the Plan. The grant of any Awards under this Program shall be made solely by and subject to the terms set forth in a written agreement in a form previously approved by the Board for use under the Plan and duly executed by an executive officer of the Company.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">* * * * *</font></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
   <hr style="page-break-after:always;"></div>
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>nmra-ex10_2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html>
 <head>
  <title>EX-10.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div class="section-group" style="margin:auto;padding-left:1in;width:6.5in;padding-right:1in;"><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.2</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">RBNC THerapeutics, Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">MILESTONE CARVEOUT Plan</font></p><div style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.769%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Purpose</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  RBNC Therapeutics, Inc.,  a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), entered into that certain Agreement and Plan of Merger dated as of June 1, 2020 with BlackThorn Therapeutics, Inc. (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">BlackThorn</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and Fortis Advisors LLC (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Stockholders&#x2019; Representative</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;, such agreement the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Merger Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; and such transaction thereunder the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Merger</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The purpose of this RBNC Therapeutics, Inc. Milestone Carveout Plan, as may be amended from time to time (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), is to reinforce and encourage the continued attention and dedication of key employees and consultants of the Company who provided services to BlackThorn prior to the Merger by providing such employees and consultants an opportunity to receive a portion of the Milestone Payments (as defined below). </font></div></div><div style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.769%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Definitions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The following terms as used herein shall have the meanings set forth in this Section 2.</font></div></div><div style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.538%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Administrator</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Board of Directors of the Company.  The Administrator may delegate any or all of its duties under the Plan to one or more members of the Administrator who are not Participants in the Plan or, solely with respect to ministerial duties, to one or more officers of the Company and such member(s) or officer(s) shall have all of the authority of the Administrator with respect to such delegated duties.  </font></div></div><div style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.538%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Carveout Plan Milestone Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; with respect to any Milestone Payment shall be equal to the product obtained by multiplying (a) such Milestone Payment (before reduction attributable to the Plan) by (b) the quotient (expressed as a percentage) obtained by dividing (i) the number of Units outstanding as of such Milestone Trigger Event (whether vested or unvested) by (ii) the number of Fully-Diluted Common Shares.</font></div></div><div style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.538%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Closing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall have the meaning ascribed to such term in the Merger Agreement.  </font></div></div><div style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.538%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean the Internal Revenue Code of 1986, as amended.</font></div></div><div style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.538%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Fully-Diluted Common Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall have the meaning ascribed to such term in the Merger Agreement.  </font></div></div><div style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.538%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Milestone Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall have the meaning ascribed to such term in the Merger Agreement.  </font></div></div><div style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.538%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Milestone Trigger Event</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall have the meaning ascribed to such term in the Merger Agreement.  </font></div></div><div style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.538%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Participants</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean those individuals set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereto, as may be amended by the Stockholders&#x2019; Representative prior to Closing.</font></div></div><div style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.538%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.9</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Per Unit Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean, upon a Milestone Trigger Event, the payment per Unit equal to the Carveout Plan Milestone Payment for such Milestone Trigger Event </font></div></div><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
   <hr style="page-break-after:always;"><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">divided by the aggregate number of Units outstanding as of the date of the applicable Milestone Trigger Event.</font></div></div><div style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.538%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.10</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Time-Vesting Schedule</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the vesting schedule applicable to a Participant&#x2019;s Units set forth on Exhibit A.</font></div></div><div style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.538%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.11</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Unit</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean a unit that, upon vesting, represents the right to receive a portion of the Carveout Plan Milestone Payment in connection with each Milestone Trigger Event.</font></div></div><div style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.538%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.12</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Vesting Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; with respect to a Unit in connection with a Carveout Plan Milestone Payment shall mean the later of (i) the achievement of the Milestone Trigger Event applicable to such Carveout Plan Milestone Payment and (ii) the vesting of the applicable Unit pursuant to the Time-Vesting Schedule. </font></div></div><div style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.769%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Administration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div><div style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.538%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Administrator</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Plan shall be administered by the Administrator. </font></div></div><div style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.538%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Authority of the Administrator</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Subject to the provisions of the Plan, the Administrator shall have full authority and discretion to take any actions it deems necessary or advisable for the administration of the Plan.  The Administrator has authority to prescribe, amend and rescind rules and regulations relating to the Plan and to make all other determinations necessary or advisable for Plan administration, in each case, consistent with the terms of the Plan.  All decisions, interpretations and other actions of the Administrator shall be final, conclusive and binding on all parties who have an interest in the Plan.  In so administering the Plan, the Administrator shall consider in good faith the recommendations of the Stockholders&#x2019; Representative.  Subject to the prior consent of the Stockholders&#x2019; Representative, the Administrator may amend the Plan in its discretion, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> that, after the Closing, it may not increase the number of Units under the Plan, reduce any Participant&#x2019;s Units or otherwise materially and adversely affect any Participant without also obtaining such Participant&#x2019;s consent. In addition, (i) the vesting of any Participant&#x2019;s Units may not be accelerated without the prior consent of the Stockholders&#x2019; Representative and (ii) any payment, either in stock or cash, made by the Company with respect to any Unit shall be authorized by the Stockholders&#x2019; Representative prior to such payment being made.</font></div></div><div style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.538%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Administrator Liability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  No member of the Administrator will be liable for any action or determination made by the Administrator with respect to the Plan or any payment made under the Plan.  No member of the Administrator shall be personally liable for any action, determination or interpretation made in good faith with respect to this Plan or any amounts paid hereunder. </font></div></div><div style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.769%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Allocation of Units.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  The allocation of the Units to be awarded to Participants hereunder shall be as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Stockholders&#x2019; Representative may amend </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> prior to the Closing to remove a Participant and to add new Participant(s), or increase existing, Units.  The Administrator shall notify each Participant of his or her Unit allocation as soon as administratively practicable after the Effective Date (as defined in Section 17 below).  Any Units which are forfeited by a Participant pursuant to Section 5 shall be reallocated to the Company Stockholders (as defined in the Merger Agreement) in accordance with his, her or its Indemnity </font></div></div><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">||</font></p></div>
   <hr style="page-break-after:always;"><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pro Rata Share (as defined in the Merger Agreement) and paid as soon as practicable following such forfeiture (but no less frequently than quarterly).</font></div></div><div style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.769%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Vesting</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Forfeiture</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Each Unit shall vest in respect of a Milestone Trigger Event on the Vesting Date(s) applicable to such  Milestone Trigger Event.  If a Participant&#x2019;s employment or other service relationship with the Company or its affiliates (including, without limitation, BlackThorn) terminates, such Participant shall forfeit any Units that have not satisfied the Time-Vesting Schedule as of such termination date and the right to receive any payment with respect to such forfeited Units. The Administrator shall provide quarterly updates to the Stockholders&#x2019; Representative with respect to the forfeiture of any Units.  For the avoidance of doubt, if a Participant&#x2019;s employment or other service relationship with the Company or its affiliates terminates following satisfaction of the Time-Vesting Schedule in respect of any Units but prior to the achievement of a Milestone Trigger Event, then such Units shall remain outstanding and shall be eligible to vest upon achievement of such Milestone Trigger Event.</font></div></div><div style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.769%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Payment in respect of Units</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Upon the occurrence of a Milestone Trigger Event, each Participant shall be entitled to receive a payment equal to the product of the number of vested Units held by such Participant times the Per Unit Payment with respect to such Milestone Trigger Event.  Thereafter, on each Vesting Date, such Participant shall be entitled to receive a payment equal to the product of the number of Units vesting on such Vesting Date times the Per Unit Payment in respect of such Milestone Trigger Event.  Each Participant who becomes entitled to payment hereunder shall be paid such payment as soon as practicable following the applicable Vesting Date, but no later than March 15 of the year following the year in which the applicable Vesting Date occurs. </font></div></div><div style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.769%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Form of Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Payment hereunder shall be made at the same time and in the same form of consideration as is received by Milestone Payment Recipients (as defined in the Merger Agreement); provided that (i) any payment in the form of shares shall comply with applicable securities laws (and, if the Company reasonably determines that such issuance cannot be made in compliance with applicable securities laws, such Participant shall be paid in cash), (ii) the Administrator, in consultation with the Stockholders&#x2019; Representative, may determine to pay a portion of such payment in cash or publicly-traded securities sufficient for the Participant to satisfy any applicable taxes, and (iii) in no event will such payment be made later than March 15 of the year following the year in which the right to payment accrued.  The value of any such payment shall be determined at the time of and using the same methodology as determining the amount of the payment of the Milestone Payment to the Milestone Payment Recipients.</font></div></div><div style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.769%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Assumption of Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company, whether pursuant to the Merger or otherwise, to expressly assume and agree to perform the obligations under this Plan in the same manner and to the same extent the Company would be required to perform if no such succession had taken place.</font></div></div><div style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.769%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Withholding Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  All amounts payable hereunder shall be subject to applicable state, federal and local income, employment and excise tax withholding. </font></div></div><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">||</font></p></div>
   <hr style="page-break-after:always;"><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><div style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.769%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Assignment or Transfer of Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company may assign this Plan and its rights and obligations hereunder in whole, but not in part, only to any corporation or other entity with or into which the Company may hereafter merge or consolidate or to which the Company may transfer all or substantially all of its assets if, in any such case, said corporation or other entity shall by operation of law or expressly in writing assume all obligations of the Company hereunder as fully as if it had been originally made a party hereto; the Company may not otherwise assign this Plan or any of its rights and obligations hereunder.  Subject to the foregoing, the terms and provisions of this Plan shall be binding upon any successor to the Company, and such successor shall accordingly be liable for the payment of all benefits which become due and payable under the Plan with respect to the Participants.  No Participant&#x2019;s rights hereunder shall be anticipated, assigned, attached, garnished, optioned, transferred or made subject to any creditor&#x2019;s process, whether voluntarily, involuntarily or by operation of law, except as approved by the Administrator.  </font></div></div><div style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.769%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Employment Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  No provision of the Plan shall be construed to give any person any right to become, to be treated as, or to remain an employee or other service provider of the Company or any of its affiliates.  The Company or its affiliate, as applicable, reserves the right to terminate any Participant&#x2019;s employment or other service at any time and for any reason or for no reason, with or without cause and with or without advance notice.</font></div></div><div style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.769%;text-indent:0;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Equity Interest</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Neither the Plan nor any allocation of Units hereunder creates or conveys any equity or ownership interest in the Company nor any rights commonly associated with such interests, including, without limitation, the right to vote on any matters put before the stockholders of the Company.  </font></div></div><div style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.769%;text-indent:0;display:inline-flex;justify-content:flex-start;">13.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Payments Not Deemed to be Salary; No ERISA Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  No payment payable under the Plan shall be deemed salary or other compensation to any Participant for purposes of computing benefits to which a Participant may be entitled under any vacation, disability, profit sharing, pension plan or other arrangement of the Company or any of its subsidiaries for the benefit of employees or independent contractors except as may otherwise be specifically provided for by such plan or other arrangement.  This Plan is intended to constitute an &#x201c;unfunded&#x201d; plan for incentive compensation, and is not intended to constitute a plan subject to the provisions of the Employee Retirement Income Security Act of 1974, as amended (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ERISA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Nothing contained in the Plan and no action taken pursuant to the provisions of the Plan shall create or be considered to create a trust or fund, or any obligation to fund or otherwise secure the payment of any amounts due under the Plan, or any kind or fiduciary relationship between the Company and any Participant or any of its other employees or a security interest of any kind in any property of the Company in favor of any Participant or any other person.</font></div></div><div style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.769%;text-indent:0;display:inline-flex;justify-content:flex-start;">14.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Further Limitations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The approval of this Plan by the Company&#x2019;s Board of Directors and the stockholders shall not be construed as creating any limitations on the power of the Company&#x2019;s Board of Directors to adopt such other incentive arrangements as it may deem desirable, including without limitation, the granting of cash incentives, stock options and restricted stock under existing or other plans or other arrangements.  </font></div></div><div style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.769%;text-indent:0;display:inline-flex;justify-content:flex-start;">15.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Parachute Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Notwithstanding anything herein to the contrary, if any payment or benefit a Participant would receive from the Company pursuant to this Plan or otherwise (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) would (a) constitute a &#x201c;parachute payment&#x201d; within the meaning of </font></div></div><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">||</font></p></div>
   <hr style="page-break-after:always;"><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 280G of the Code, and (b) but for this Section 15, be subject to the excise tax imposed by Section 4999 of the Code (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Excise Tax</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), then such Payment shall be equal to the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax.  If a reduction in the Payment is to be made, (x) the Payment will be paid only to the extent permitted under the immediately preceding sentence, and the Participant will have no rights to any additional payments and/or benefits constituting the Payment, and (y) reduction in payments and/or benefits will occur in the following order: (1) reduction of cash payments; (2) cancellation of accelerated vesting of equity awards other than stock options; (3) cancellation of accelerated vesting of stock options; and (4) reduction of other benefits payable to the Participant.  In the event that acceleration of vesting of equity award compensation is to be reduced, such acceleration of vesting will be cancelled in the reverse order of the date of grant of the Participant&#x2019;s equity awards.  In no event will the Company or any stockholder be liable to any Participant for any amounts not paid as a result of the operation of this Section 15.  The accounting firm engaged by the Company for general tax purposes as of the day prior to the Closing will perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the acquiring company or otherwise refuses to make such calculations, the Company will appoint a nationally recognized tax firm to make the determinations required hereunder.  The Company will bear all expenses with respect to the determinations by such firm required to be made hereunder.  The accounting firm engaged to make the determinations hereunder will provide its calculations, together with detailed supporting documentation, to the Company and the Participants within fifteen (15) days before the Closing (if requested at that time by the Company or the Participant) or such other reasonable time as requested by the Company or a Participant.  If the accounting firm determines that no Excise Tax is payable with respect to a Payment, it will furnish the Company with documentation reasonably acceptable to the Company that no Excise Tax will be imposed with respect to such Payment.  Any good faith determinations of the accounting firm made hereunder will be final, binding and conclusive upon the Company and the Participants.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div><div style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.769%;text-indent:0;display:inline-flex;justify-content:flex-start;">16.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  For the avoidance of doubt, it is intended that the benefits payable under this Plan satisfy, to the greatest extent possible, the exemption from the application of Section 409A of the Code provided under Treasury Regulation Section 1.409A-1(b)(4).  Notwithstanding the foregoing, the Company does not guarantee any particular tax effect for income provided to the Participants pursuant to this Plan.  Except for the responsibility of the Company or its successor to withhold applicable income and employment taxes from compensation paid or provided to a Participant, neither the Company nor any successor shall be liable for the payment of any applicable taxes, penalties, interest, costs, fees, including attorneys&#x2019; fees, or other liability incurred by a Participant in connection with compensation paid or provided to the Participant pursuant to this Plan.  </font></div></div><div style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.769%;text-indent:0;display:inline-flex;justify-content:flex-start;">17.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Duration and Amendments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div><div style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.538%;text-indent:0;display:inline-flex;justify-content:flex-start;">17.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Term of the Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Plan shall be effective as of the date it is approved by the Company&#x2019;s Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and shall terminate upon the payment of all amounts payable hereunder.  </font></div></div><div style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.538%;text-indent:0;display:inline-flex;justify-content:flex-start;">17.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Right to Amend the Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Except as provided herein, the Plan may be amended at any time or from time to time by the Administrator.  </font></div></div><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">||</font></p></div>
   <hr style="page-break-after:always;"><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><div style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.769%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Execution</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  To record the adoption of the Plan, the Company has caused its authorized officer to execute the same.</font></div></div><div style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.769%;text-indent:0;display:inline-flex;justify-content:flex-start;">19.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Choice of Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  All questions concerning the construction, validation and interpretation of the Plan will be governed by the law of the State of California without regard to its conflict of laws provision.</font></div></div><div style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.769%;text-indent:0;display:inline-flex;justify-content:flex-start;">20.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Funding</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  No provision of the Plan shall require the Company, for purpose of satisfying any obligations under the Plan, to purchase assets or place any assets in a trust or other entity to which contributions are made or otherwise to segregate any assets, nor shall the Company maintain separate bank accounts, books, records or other evidence of the existence of a segregated or separately maintained or administered fund for such purposes.  Participants shall have no rights under the Plan other than as unsecured general creditors of the Company or its successor.</font></div></div><div style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.769%;text-indent:0;display:inline-flex;justify-content:flex-start;">21.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Dispute Resolution</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ny controversy, claim or dispute arising out of or relating to this Plan (other than any controversy, claim or dispute arising out of the interpretation and construction of this Plan, which shall be in the sole authority and discretion of the Administrator as contemplated by Section 3) shall be settled by arbitration administered by the American Arbitration Association in accordance with the Employment Arbitration Rules, a copy of which can be found at </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">https://www.adr.org/sites/default/files/EmploymentRules_Web_2.pdf</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> as of the Effective Date.  The arbitration proceedings shall be conducted before one neutral arbitrator unless one party requests a panel of three neutral arbitrators.  If one party makes a request for a panel of three neutral arbitrators, the arbitration proceedings shall be conducted before three neutral arbitrators, and the party or parties requesting a panel of three neutral arbitrators must bear any additional costs of the arbitration incurred because of the two additional arbitrators.  The place of the arbitration shall be San Francisco County, California.  The arbitrators will have no authority to award punitive damages but will have the authority to make awards incorporating relief of an equitable nature.  The arbitrator(s) shall apply the laws of the State of California except where such law is contrary to the provisions of this Section 21.  </font></div></div><div style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.769%;text-indent:0;display:inline-flex;justify-content:flex-start;">22.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Third Party Beneficiaries</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Stockholder Representative is hereby named and recognized as an intended third party beneficiary to the Plan and may enforce the provisions hereof.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">||</font></p></div>
   <hr style="page-break-after:always;"><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT A</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Participants, Allocation of Units and Vesting Schedule</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">||</font></p></div>
   <hr style="page-break-after:always;"></div>
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>nmra-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div class="section-group" style="margin:auto;padding-left:0.5in;width:7.5in;padding-right:0.5in;"><div style="min-height:0.5in;"></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Henry O. Gosebruch, certify that:</font></p><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Quarterly Report on Form 10-Q of Neumora Therapeutics, Inc;</font></div></div><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">[Omitted];</font></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.2%;"></td>
     <td style="width:5.06%;"></td>
     <td style="width:3.06%;"></td>
     <td style="width:46.68%;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: May 7, 2024</font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Henry O. Gosebruch</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Henry O. Gosebruch</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Executive Officer</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
   <hr style="page-break-after:always;"></div>
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>nmra-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div class="section-group" style="margin:auto;padding-left:0.5in;width:7.5in;padding-right:0.5in;"><div style="min-height:0.5in;"></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Joshua Pinto, certify that:</font></p><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Quarterly Report on Form 10-Q of Neumora Therapeutics, Inc;</font></div></div><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">[Omitted];</font></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.2%;"></td>
     <td style="width:5.06%;"></td>
     <td style="width:3.06%;"></td>
     <td style="width:46.68%;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: May 7, 2024</font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Joshua Pinto, Ph.D.</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Joshua Pinto, Ph.D.</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Financial Officer</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
   <hr style="page-break-after:always;"></div>
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>nmra-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div class="section-group" style="margin:auto;padding-left:0.5in;width:7.5in;padding-right:0.5in;"><div style="min-height:0.5in;"></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.1</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Quarterly Report of Neumora Therapeutics, Inc. (the &#x201c;Company&#x201d;) on Form 10-Q for the period ending March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p><div style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.2%;"></td>
     <td style="width:5.06%;"></td>
     <td style="width:3.06%;"></td>
     <td style="width:46.68%;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: May 7, 2024</font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Henry O. Gosebruch</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Henry O. Gosebruch</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Executive Officer</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
   <hr style="page-break-after:always;"></div>
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>nmra-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div class="section-group" style="margin:auto;padding-left:0.5in;width:7.5in;padding-right:0.5in;"><div style="min-height:0.5in;"></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.2</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Quarterly Report of Neumora Therapeutics, Inc. (the &#x201c;Company&#x201d;) on Form 10-Q for the period ending March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p><div style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.2%;"></td>
     <td style="width:5.06%;"></td>
     <td style="width:3.06%;"></td>
     <td style="width:46.68%;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: May 7, 2024</font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Joshua Pinto, Ph.D.</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Joshua Pinto, Ph.D</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Financial Officer</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
   <hr style="page-break-after:always;"></div>
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img235846496_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img235846496_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" Q&$?D# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "F2?='UI],D^Z/K0!8C_ -6OTIU-C_U:_2G4AA1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!7D_X^%_"K]4)/^/A?
MPJ_0P"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 55L_^/M_H?YU:JK9_\?;_ $/\Z.@&C1114@%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 4;3_D)/]6K5K*M/^0D_P!6
MK5IRW!!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\4B+;ZG"NZ6 'AESC>OMR ?0GZ5$J;CJ7"K&3L=E1114&H45FZ_JJ:'X?O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/4***Y/XEWES8?#[5+FSN)K>X3RMLL+E&7,J X(Y'!(J$KNQJW97.LHKY/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "F2?='UI],D^Z/K0!8C_U:_2G4V/\ U:_2
MG4AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!7D_X^%_"K]4)/\ CX7\*OT, HHHI %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %5;/\ X^W^A_G5JJMG_P ?;_0_SHZ
M:-%%%2 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBBBN<[ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M** "BBB@ HHHH **** "JMG_ ,?;_0_SJU56S_X^W^A_G1T T:***D HHHH
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** /C:OHGX-_\B!'_P!?,O\
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M%/\ R4K2/^VW_HEZZ5_#..7\7YGTO1117,=AX;\=/^0[I7_7LW_H5<U\*?\
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MQ7L?P*_Y ^K_ /7PG_H)HGI =)WJ7/6:***YCL"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@"EK'_ "!+_P#Z]I/_ $$UXQ\%_P#6:U](/_9Z]GUC
M_D"7_P#U[2?^@FO&/@O_ *S6OI!_[/6L/A9C/XXGK%%%%!H%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,D^Z/K3Z9)]T
M?6@"Q'_JU^E.IL?^K7Z4ZD,**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** *\G_ !\+^%7ZH2?\?"_A5^A@%%%%( HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JK9_\ 'V_T
M/\ZM55L_^/M_H?YT= -&BBBI **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH HVG_(2?ZM6K65:?\A)_JU:M.6X(****D84444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %>3?'7_D#Z1_U\/\ ^@BO6:\\^+'AG6/$VFZ=#I%I]I>&9FD'F(F
M1@?>(JX.TD9U4W!V/"O#_P#R,FE_]?<7_H8KZXKYUT?X8>,;76["XFT?;%%<
MQN[?:83A0P)/#U]%555IVL1032=PHHHK(W"O-/CA_P B59_]A%/_ $7)7I=<
M-\5/#^J>)/#%M9Z3:_:+A+U963S%3"A'!.6('5A50^)$5%>+L?.MI_Q^0?\
M71?YU]AU\VV_PL\:)<Q.VC857!)^U0],_P"_7TE6E5IVL94(M7NBMJ%A;:II
MUQ87<8DM[B,QR+Z@C]#[U\M>+/#=SX5\0W&F7&2@.^"0_P#+2(D[6_3!]P:^
MKJX[XC>#1XMT BV1?[3M<R6S<#?QS&2>@/\ ,#MFIISY675I\RNMSQSX9^+C
MX7\1K'<2!=.O<13[C@(<_*_X9.?8GVKZ4KYH_P"%4^-?^@+_ .34/_Q=>V^
M5\0V_AY+'Q'9&"XM<1Q2F9)/-3MG:QY'3GV]ZJJD]411<E[K1P_QE\'RS2)X
MEL(&?:@2]"#H!]V0]SQP?0 >]>/V5[<Z=>PWEG,\-Q"VZ.1#@J:^P6574JP!
M4C!!'!%>2>*O@O'=W,EWX=N([<N2S6D^0@/^P0.!UX.?J!T(5%:S%5I._-$L
M^'?C5I=S!'#KL$MI<@ //$F^)CZX'S#Z8/UK5U'XP^$[.#?:W%Q?2$'$<,#)
M@]LEPO'TS7C5]\/?%M@S++H5W)CO OG _P#?&:K0^"O%$[;4\/ZD#_MVSH/S
M(%5R0W)]K46EB?QEXSO_ !CJ8GN (K6+(M[=3D(#W/JQXR:F\!>$;CQ7X@BB
M,3_V? P>ZE'15_NY]3C&/J>U='H'P7UN]G#ZU)'I]N#\R*ZR2,/;:2H_$_A7
MM>B:)8>'M*BT[3H1%!'^+.W=F/<G_/%$IJ*M$(4I2?-(OHB1QK'&JJB@!548
M  [ 5Q_Q*\)MXJ\,D6T>[4+1O-M\8RW]Y,GU'ZJ*[*BL$[.YU-)JS/CB2-X9
M'CD1DD0E65A@J1U!'K7KWA'XS?9K6*R\1Q2R^6NU;R/YF8#/WQW/09'X^M=?
MXR^&&E^*IGOH938ZDP&947<DF/[R\9/;(/YUY'J?PL\6Z;(0-.%W&!GS+5PX
M/X'#?I6_-&:U.3EG3=T>P/\ %KP8L!D&J.[8SY:VTN[Z<KC]:X;Q7\9YKVWE
MLO#]JUO%(I5KJX ,F#UVJ,@?4D]>@-<!_P (=XFW[/\ A'M5SG'_ !YR8_/&
M*U]-^%OB[467_B6?98R<&2ZD5 ON5^]W["A0@M1NI4EHD<;7T9\'HI(_ $)=
M&4//(R[AC<,]1ZC@UG>&?@UI>FLEQK4W]HSC!\D#;"#SU[MVZXZ=*],1$CC6
M.-55% "JHP !V J:DTU9%T:3B[L\H^.O_('TC_KX?_T$5Y!X?_Y&32_^ON+_
M -#%>Z_%CPSK'B;3=.ATBT^TO#,S2#S$3 (P/O$5YQH_PP\8VNMV%Q-H^V**
MYC=V^TPG"A@2>'JH22B14C)SND?154=8TFTUS2;G3+Y"]M<)M< X(YR"/<$
MCZ5>HKG.L^2?$.A7?AO7+G2[P#S86X9>CJ>0P]B/\*Z_X3^+O[ U_P#LVZD
MT^_(4EC@1R_PM]#T/U![5Z;\3?!#>*](2XL(P=5M/]4,A?-0D90DX^HS[^M>
M1?\ "J?&O_0%_P#)J'_XNNE24HZG&X2A.\4?1>K:C%I&D7FHSX\NVA:4@G&<
M#.,^IZ?C7R7J-]-J>I75_<',US*TKGW8Y/\ .O:M<L?'FM_#JUT6;2'_ +1\
MT)=2_:XOWL2C*DG?U)QGGJI/>N C^$_C-I45]("*2 6-S"=H]>'J:=H[LJMS
M2:LCLOAK\.-&U?PJNIZ[I[3RW,K&',SIB,<#A2.I#=>V*['_ (53X*_Z O\
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MR6^E6<$J[9(X$1AG."% -6JP9TK8****!A1110 4444 %%%% !1110 4444
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MSINHPZO:?9GFF5HQYB/D 8/W2:UJ23CHSGHQDIZH]#HHHKG.P**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** *6L?\ ($O_ /KVD_\ 037C'P7_ -9K
M7T@_]GKV?6/^0)?_ /7M)_Z":\8^"_\ K-:^D'_L]:P^%F,_CB>L4444&@44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4R
M3[H^M/IDGW1]: +$?^K7Z4ZFQ_ZM?I3J0PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH KR?\ 'POX5?JA)_Q\+^%7Z& 4
M444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"JMG_P ?;_0_SJU56S_X^W^A_G1T T:***D HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@"C:?\A)_JU:M95I_R$G^K5JTY;@@H
MHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!2UC_D"
M7_\ U[2?^@FO&/@O_K-:^D'_ +/7L^L?\@2__P"O:3_T$UXQ\%_]9K7T@_\
M9ZUA\+,9_'$]8HHHH- HHHH **Y:7XC>%(97BDU7#HQ5A]GEX(_X#3?^%E>$
M?^@M_P"2TO\ \33LR>>/<ZNBN4_X65X1_P"@M_Y+2_\ Q-7+/QMX:OI%C@UB
MVWMPHD)CR?3Y@*+,.>/<WZ*16#*&4@@C(([TM(H**** "BBB@ HHHH ****
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MQU%,&TMS6HJEI>JV6M6"WNGS>=;N2%?8RY(.#P0#5VD 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)/NCZT^F2?='
MUH L1_ZM?I3J;'_JU^E.I#"BBB@ HJCJVL6&A6)O=2G\BW#!2^QFY/3A036!
M_P +-\'_ /07_P#):;_XBBS8G)+=G6T5R7_"S?!__07_ /):;_XBE7XE^$'8
M*-8&3ZV\H'ZK3Y7V%SQ[G645FZ;K^D:QD:?J-M<,.J)(-P_#K6E2*3OL%%4=
M6UBPT*Q-[J4_D6X8*7V,W)Z<*":KZ)XFT?Q'Y_\ 9-Y]H\C;YG[ITV[LX^\!
MGH:+"NKV-:BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%8E_XOT+3-632KN_$=ZY4"(1.W+=,D @9]S183:6YMT444#"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@"O)_Q\+^%7ZH2?\?"_A5^A@%%%%( HHK$UOQ;H
M?AR>*'5;[[/)*N]!Y3OD9Q_"IHM<3:6YMT5R'_"T/!W_ $&/_):;_P"(H_X6
MAX._Z#'_ )+3?_$4^5]A<\>YU]%<I#\2O"$S;4UF,'_;AD0?JHKHK'4;+4X!
M/8W<%S$?XX9 P_2DTT-23V99HHK$UOQ;H?AR>*'5;[[/)*N]!Y3OD9Q_"IHM
M<&TMS;HJGI>J6>M:=%J&GS>=:RYV2;2N<$J>" >H-7*!A1110 4444 %%%%
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MLJT_Y"3_ %:M6G+<$%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH ****
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ML/6B*N[#G+E5STNPU?3-5\S^SM1M+SR\;_L\ZR;,YQG:3C.#^54_^$N\,_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@"EK'_($O\ _KVD_P#037C'P7_UFM?2#_V>O9]8_P"0)?\
M_7M)_P"@FO&/@O\ ZS6OI!_[/6L/A9C/XXGK%%%%!H%%%% 'S#<P_:-?F@W;
M?,NF3.,XRV*](_X4M_U'_P#R3_\ LZ\\_P"9I_[??_9Z^F:UDVMCEI0C*]SR
MG_A2W_4?_P#)/_[.L;7/A3JNEV<EW:7,=_'&"S(B%9,>H7G/'O\ G7M]%3SL
MU=&!X3\/O&5SHNJPZ?=3/)IMPPCV,<B)B0 P]O4>]>[5\T^*;:&S\5ZK;VX
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M.D^%W_(BVO\ UUD_]"-=E7&_"[_D1;7_ *ZR?^A&NRHEN5#X4%%%%24%%%%
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M **** *-I_R$G^K5JUE6G_(2?ZM6K3EN""BBBI&%%%% !1110 4444 %%%%
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M1P!D],5:^-VH_9_"MG8JP#75R"1GDH@)/'U*UR'PO\ +XC_XFNK!VTN"0B*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[/7L^L?\@2__ .O:3_T$UXQ\%_\ 6:U](/\ V>M8?"S&?QQ/6****#0****
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M_P"V7_HU*XWX,_\ ']JW_7*/^;4U\+)E_%1V7Q*_Y)_J?_;+_P!&I7$?!O\
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M9&6%0HE0<MD>H&2#U.,<\8R/A'=:A;W5WIT]O<+9RIYT;-&VQ7& <'H,@_\
MCHKUBBES:6*]FN;F1Y;\4K'7M7O;:WL=-NI["W3>6B3=ND/7@<G Q^9K8\#>
M!+'2](AN]2LDFU*9=[B= WD@]% /0XZ]\YKL[R]MM/M7N;R>."!!EGD; %<)
MJ'Q>T6WD*6=K=7>"?GP(U/TSS^8%--M60FHQES29V\FEZ?+%Y4EC;/'C&QH5
M(Q],5X?\1_#5KX=UV(V*[+6ZC,BQYSL8'# >W0_B:W;OXRWC9%EI$$7'!FE+
M_C@!:XSQ)X@UCQ'+!=ZHH6,!A $BV(!P2%/4]NI-5%-,SJSA):'M7P^O9+_P
M/ILDK[I$5HB>>BL5'_CH%<A\:?\ F!_]M_\ VG72?"[_ )$6U_ZZR?\ H1KF
M_C3_ ,P/_MO_ .TZE?$7+^$=)\+O^1%M?^NLG_H1KLJXWX7?\B+:_P#763_T
M(UV5*6YI#X4%%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSQCUSQZ1/HVEW-L;>;3K22$]8VA4C\L5Y+9?&">QL+>SBT6'RX(EB3]^>B@
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M0WI?_7LW_H573^(RK? ;_P +==T?3_!B07NJV-M-Y\A\N:X1&P<<X)S7:?\
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MNRP4@,O/J,_I7TSIMT;W2[2[.,SPI(=HP/F4'C\Z^6M?U'5-5UB6]U@,+R4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*PSD%_D!&.^6K!^&'B'Q+XEL[J^UCR#9*1'!((MCR./O$8.,#Z=3[&J7QNU
MV_A2TLE(!NKH%AGJJ@G^96D[N:3&N6--N)A? K3@UWJ^IL.4C2W0^NXEF_\
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MZ(L+./3].M;*+_5V\*1+QV4 #^56***R-PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ^9_&COKWQ2OH!DM+>K:*$Y^[B/CWX_.OI9$2.-8XU544 *JC  '8"OFSQ
MU:W'AGXG75VJ$$W2W\!)(#[FWY'_  +</PKW3P[XVT+Q+!&UE?1+<, 6M96"
MRJ?3!Z_49%;5%HK'/2:4I)[G0UB^+]4&B^$=4O\ >R-%;L(V0X(=OE7G_>(J
M_?ZG8Z7 9[^\AMHPI;,KA<@=<>OX5X1\3_B#%XF>/2M*9_[-@?>\I&//<< @
M==HYZ]<].!40BY,TJ344)\%]-^U^-7O#C;96[N,CG<WR#]"U?0=<)\*?#,GA
M[PKYUU#Y=[?L)I ?O*F/D4_@2<=MQ%=M<7,%G;O<74\<$$8R\DKA54>I)X%%
M1WD*E'EAJ2TUW2.-I)&544$LS'  '<FJ5CKFDZI*T6GZI97<BKN9+>X20@>I
M )XJW/"EQ;R0R?<D4HWT(Q4&M^QD6'C#P_JFJ?V;8:I!<W6&(2++ @=3N Q^
MM;=?+?A[5;KP)XU2>Y@+/:2-#<18P64\-C/YCZ#M7T;I'BC1-=A633M2MYB0
M"8]X#KGH"IY%:3AR[&5.IS;[CM;\-Z/XCM_)U6PBN, A'(PZ9_NL.17@7Q!\
M!2>"[R&XM9WFTZ<XBD<CS$<#.UL8^H(_I7T5>7]GI\7FWMW!;1_WYI @_,FO
M"?BOXXL/$DMKINE-YUK:N9'N,$!W(P N>< 9Y[YXZ9+I.5_(FNHVN]ST_P"&
MGB&;Q'X,M[BZ<R75N[6TSG.6*X()SU)4KD^N:Z^N(^%&C3:/X%M_/4I)>2-=
M%3U 8 +_ ..J#^-=/?:[I&F3K!J&JV-I*R[Q'<7"1L5R1G!(XR#^51)>\[&D
M'[JN:%%1P7$-U D]O-'-#(-R21L&5AZ@C@BI*DL*J:I>KINDWM\V-MM \QSG
M&%4GM]*MUQ7Q6U'^S_A]? ,%>Y9+=<GKDY('K\H:FE=V%)V39XS\/-!A\5^-
M8[?48VGM@DD]RNXJ6&,#D8(^9EKVG_A5/@K_ * O_DU-_P#%UQ/P*TW,^KZH
MP&%5+=#CU.YN?P6O:*TJ2?-9&-&"Y;M'(1?"[P9$^]=$0G_;GE8?D6Q70Z;H
MNF:/&4TW3[:T4]?)B"D_4CK5ZBLVV]S912V05\Z^- ?$_P 7Y;"$$JUS%9C/
M&, *Q/MG<<^E?0\LJ00O+(P6-%+,Q[ <DU\^?#&)]<^*/]H2CS"GGWDFX#JV
M1DY_VG!^M:4]+LRK:VB?0D<<<,211(J1HH5448"@= !V%>?_ !GNFM_ ?E*V
M!<7<<3#^\ &?'YJ#^%>A5PWQ;TQ]1\ W+QC<UI*ESCV&5/Y!B?PJ(?$BZGP.
MQY!X7^&VL^+-);4;"YL(X1*8ML\CAL@ ]E(QSZUM?\*/\3?\_P!I/_?V3_XW
M6C\&_%]CIL5UH6HW*6_FR^=;22L A8@!ER>AX&/7GOU]BO=4L-.M#=7MY!!!
MM+;Y' !&,\>OX5K.<D[&,*<)1N>&?\*/\3?\_P!I/_?V3_XW7HGPU\%:CX-M
MM134)[65KET*?9V9@ H/7*CUKB_$_P 8-2FUU;;POM^RH?+5FAWM<L>,@'D#
MT'4]_0>PZ0=1.D6IU80C4#&#.(1A0WH.3TZ=:F;E;4JG&'-[O0X3XUV0N/!<
M-R -]M=HV<?PL&4C\ROY58^#5W]H\ I%DG[-<R1<]LX?_P!GK8^(UFM]\/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH1-GL3\O]:^C:\+^(_AB?1-?DU2UC9;&ZD\Q73_EE*>2N>W.2/K@=*[3PO\
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M:@;@#VR2H^A-<S\%_P#D,ZG_ ->Z_P#H5;?QDTN>ZT>PU&)6=+21UD"C.U7
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M#R1%+FW8AD;[LT9]#Z$=^Q]Q4PUBXE5/=FI/8^A?^$2\-_\ 0O:3_P" 4?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% &1XITZ\U?PQJ&G6$L45S<Q&)6E)"@'ALD
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M4&M+<Z=]BBGD81H[[Q&P9<8V8SAO6N^\8Z5?ZYX5OM+TV6&*YN55 \S$*%W
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <[XN\&Z;XPL%@O08Y
MXSF&YC WIZCW!]*\=U+X,>)K21OL9M;Z,#*E)/+8^Q#8 /XU]"45<9N.QG.E
M&6K/FZV^$?C&>94DT^*W4D R2W,9 ]_E)/Z5Z/X/^$5CH5S'J&K3K?WD;!HX
MU7$49'?GECWYQCT[UZ513=23%&C&+N%<SX]T'4?$WA:72M-DMXY)I4+M.[*N
MQ3N_A!R<A>*Z:BH3L[FC5U8\_P#AKX"O?!KZC-J,UI--<A%C-NS':HR3DD#J
M2.W:O0***&VW=BC%15D<1XU^&NF^+I#>I*UGJ> //4;ED Z!ESZ<9&#]<8KR
MV_\ @YXKM9'%M%;7J _*T4X4D?1\8_SUKZ)HJHU)(F5*,M3YM@^$GC*:0*^F
MQP#^])<QD?\ CK$UW_A+X-VVEW45]KMQ'>SQMN6VC'[G/8L2,M], ?6O4Z*;
MJ28HT8K4*\B\;?##Q#XH\57>J076FQ02!%B22:3<%50.<(1R<GCUKUVBIC)Q
M=T7*"DK,K:=9IIVF6EE&04MX4A4@8X4 =/PJS114E!7$?$GPEJWC#3K&RTV>
MUB2*5I9?M$C*"<87 53GJWI^M=O133L[BDE)69RGP^\*3>$?#AL;IH'NI)FE
MD> DJ<X Y(!Z =JZNBBAN[N"22L@HHHI#,[7[2ZU#P_J%E9-$MS<6[Q1M*2%
M!88R< ^OI7%_#7X?7_@^\O[K4I[662>-(XOL[LP R2V=RC_9QCWKT6BFI-*Q
M+BF[A371)(VCD561@0RL,@@]B*=12*/$_%?P8N_MTEUX;DB>VD);[)*^UH_9
M6/!'7K@CCKUKFK;X1^,9YE233XK=20#)+<QD#W^4D_I7TC16BJR1BZ$&[GG_
M (%^&%IX6F&H7TJ7FI8PC!?DA_W<]3CN:] HHJ&VW=FL8J*LBMJ-HNH:9=V3
M@%;B%XB#TPRD?UKQ33O@AK(U&V.HWNG&R$BF<0RR%RF>0N4')''6O=**<9N.
MQ,H1EN-CCCAB2*)%2-%"JBC 4#H .PIU%%26>3?$#X47.L:I-K&A/%YTYW3V
MLC;=S?WD/3GJ0<=SGG%<3;?"'QA/<^5)8P6R?\]9;E"O_CI)_2OH^BM%5DE8
MRE1BW<\I7X+VEOX5O+:.>.YUN=5"7,V4CB(8$A0 3R!C)R3[9-;GPU\&ZIX.
MMM1@U&>TE6X='C^SNS8(!!SN4>WK7=45+FVK,I4XIW1YC\1?A[KOC'7H+NRN
M;"*UAMQ$JSRN&+;B2<!"!U Z]J]#TJQ&F:/96"G(M;>.$'UVJ!_2K=%)R;5A
MJ*3;,GQ'X=L/%&C2Z;J"$QL=R.OWHW&<,/<9/YD5X=JGP;\465RRV*6^H0_P
M/'*L;$9[JY&#WX)'O7T/151FX[$SIQGN?/6E_!GQ/>2#[:+;3X^YDE$C?@$R
M#^8KVGPMX5T[PEI0LK!"6;YIIW'SRMZGV]!V_,G<HHE-RW"%.,=CF_'>AZEX
MD\+3:5ID\$,L[IYC3L54H#DC(4GJ!6?\./!ESX-TJ[AOIH);JYF#$P$E0@&
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MX(0JW[[7I'7T2U"G]7->LT57/(CV4.QSWAOP7HOA96:PMRUPPPUQ,0TA'IG
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M,IS<79(^IO[?T;_H+V'_ ($I_C1_;^C?]!>P_P# E/\ &OEG^RA_SV_\=_\
MKT?V4/\ GM_X[_\ 7J_JY'M9=CZF_M_1O^@O8?\ @2G^-']OZ-_T%[#_ ,"4
M_P :^6?[*'_/;_QW_P"O1_90_P">W_CO_P!>CZN'M9=CZF_M_1O^@O8?^!*?
MXT?V_HW_ $%[#_P)3_&OEG^RA_SV_P#'?_KT?V4/^>W_ ([_ /7H^KA[678^
MIO[?T;_H+V'_ ($I_C1_;^C?]!>P_P# E/\ &OEG^RA_SV_\=_\ KT?V4/\
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M[_\ 7H^KA[678^IO[?T;_H+V'_@2G^-']OZ-_P!!>P_\"4_QKY9_LH?\]O\
MQW_Z]']E#_GM_P"._P#UZ/JX>UEV/J;^W]&_Z"]A_P"!*?XT?V_HW_07L/\
MP)3_ !KY9_LH?\]O_'?_ *]']E#_ )[?^.__ %Z/JX>UEV/J;^W]&_Z"]A_X
M$I_C1_;^C?\ 07L/_ E/\:^6?[*'_/;_ ,=_^O1_90_Y[?\ CO\ ]>CZN'M9
M=CZF_M_1O^@O8?\ @2G^-']OZ-_T%[#_ ,"4_P :^6?[*'_/;_QW_P"O1_90
M_P">W_CO_P!>CZN'M9=CZF_M_1O^@O8?^!*?XT?V_HW_ $%[#_P)3_&OEG^R
MA_SV_P#'?_KT?V4/^>W_ ([_ /7H^KA[678^IO[?T;_H+V'_ ($I_C1_;^C?
M]!>P_P# E/\ &OEG^RA_SV_\=_\ KT?V4/\ GM_X[_\ 7H^KA[678^IO[?T;
M_H+V'_@2G^-']OZ-_P!!>P_\"4_QKY9_LH?\]O\ QW_Z]']E#_GM_P"._P#U
MZ/JX>UEV/J;^W]&_Z"]A_P"!*?XT?V_HW_07L/\ P)3_ !KY9_LH?\]O_'?_
M *]']E#_ )[?^.__ %Z/JX>UEV/J;^W]&_Z"]A_X$I_C1_;^C?\ 07L/_ E/
M\:^6?[*'_/;_ ,=_^O1_90_Y[?\ CO\ ]>CZN'M9=CZF_M_1O^@O8?\ @2G^
M-']OZ-_T%[#_ ,"4_P :^6?[*'_/;_QW_P"O1_90_P">W_CO_P!>CZN'M9=C
MZF_M_1O^@O8?^!*?XT?V_HW_ $%[#_P)3_&OEG^RA_SV_P#'?_KT?V4/^>W_
M ([_ /7H^KA[678^IO[?T;_H+V'_ ($I_C1_;^C?]!>P_P# E/\ &OEG^RA_
MSV_\=_\ KT?V4/\ GM_X[_\ 7H^KA[678^IO[?T;_H+V'_@2G^-']OZ-_P!!
M>P_\"4_QKY9_LH?\]O\ QW_Z]']E#_GM_P"._P#UZ/JX>UEV/J;^W]&_Z"]A
M_P"!*?XT?V_HW_07L/\ P)3_ !KY9_LH?\]O_'?_ *]']E#_ )[?^.__ %Z/
MJX>UEV/J;^W]&_Z"]A_X$I_C1_;^C?\ 07L/_ E/\:^6?[*'_/;_ ,=_^O1_
M90_Y[?\ CO\ ]>CZN'M9=CZF_M_1O^@O8?\ @2G^-']OZ-_T%[#_ ,"4_P :
M^6?[*'_/;_QW_P"O1_90_P">W_CO_P!>CZN'M9=CZF_M_1O^@O8?^!*?XT?V
M_HW_ $%[#_P)3_&OEG^RA_SV_P#'?_KT?V4/^>W_ ([_ /7H^KA[678^IO[?
MT;_H+V'_ ($I_C1_;^C?]!>P_P# E/\ &OEG^RA_SV_\=_\ KT?V4/\ GM_X
M[_\ 7H^KA[678^IO[?T;_H+V'_@2G^-']OZ-_P!!>P_\"4_QKY9_LH?\]O\
MQW_Z]']E#_GM_P"._P#UZ/JX>UEV/J;^W]&_Z"]A_P"!*?XT?V_HW_07L/\
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M[_\ 7H^KA[678^IO[?T;_H+V'_@2G^-']OZ-_P!!>P_\"4_QKY9_LH?\]O\
MQW_Z]']E#_GM_P"._P#UZ/JX>UEV/J;^W]&_Z"]A_P"!*?XT?V_HW_07L/\
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M[_\ 7H^KA[678^IO[?T;_H+V'_@2G^-']OZ-_P!!>P_\"4_QKY9_LH?\]O\
MQW_Z]']E#_GM_P"._P#UZ/JX>UEV/J;^W]&_Z"]A_P"!*?XT?V_HW_07L/\
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M[_\ 7H^KA[678^IO[?T;_H+V'_@2G^-']OZ-_P!!>P_\"4_QKY9_LH?\]O\
MQW_Z]']E#_GM_P"._P#UZ/JX>UEV/J;^W]&_Z"]A_P"!*?XT?V_HW_07L/\
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M[_\ 7H^KA[678^IO[?T;_H+V'_@2G^-']OZ-_P!!>P_\"4_QKY9_LH?\]O\
MQW_Z]']E#_GM_P"._P#UZ/JX>UEV/J;^W]&_Z"]A_P"!*?XT?V_HW_07L/\
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M N<;^F:X/^RA_P ]O_'?_KT?V5_TV_\ '?\ Z]5&BTK$N<G).VQ]&?VWI/\
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M ,=_^O1[%A[278^C/[;TG_H*67_@0G^-']MZ3_T%++_P(3_&OG/^RA_SV_\
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M*67_ ($)_C1_;>D_]!2R_P# A/\ &OG/^RA_SV_\=_\ KT?V4/\ GM_X[_\
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M_04LO_ A/\:/[;TG_H*67_@0G^-?.?\ 90_Y[?\ CO\ ]>C^RA_SV_\ '?\
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ML/:2['T9_;>D_P#04LO_  (3_&C^V])_Z"EE_P"!"?XU\Y_V4/\ GM_X[_\
M7H_LH?\ /;_QW_Z]'L6'M)=CZ,_MO2?^@I9?^!"?XT?VWI/_ $%++_P(3_&O
MG/\ LH?\]O\ QW_Z]']E#_GM_P"._P#UZ/8L/:2['T9_;>D_]!2R_P# A/\
M&C^V])_Z"EE_X$)_C7SG_90_Y[?^._\ UZ/[*'_/;_QW_P"O1[%A[278^C/[
M;TG_ *"EE_X$)_C1_;>D_P#04LO_  (3_&OG/^RA_P ]O_'?_KT?V4/^>W_C
MO_UZ/8L/:2['T9_;>D_]!2R_\"$_QH_MO2?^@I9?^!"?XU\Y_P!E#_GM_P".
M_P#UZ/[*'_/;_P =_P#KT>Q8>TEV/HS^V])_Z"EE_P"!"?XT?VWI/_04LO\
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MYI'_ $%;'_P(3_&OFS^RA_SV_P#'?_KT?V4/^>W_ ([_ /7H]BP]K+L?2?\
M;FD?]!6Q_P# A/\ &C^W-(_Z"MC_ .!"?XU\V?V4/^>W_CO_ ->C^RA_SV_\
M=_\ KT>Q8>UEV/I/^W-(_P"@K8_^!"?XT?VYI'_05L?_  (3_&OFS^RA_P ]
MO_'?_KT?V4/^>W_CO_UZ/8L/:R['TG_;FD?]!6Q_\"$_QH_MS2/^@K8_^!"?
MXU\V?V4/^>W_ ([_ /7H_LH?\]O_ !W_ .O1[%A[678^D_[<TC_H*V/_ ($)
M_C1_;FD?]!6Q_P# A/\ &OFS^RA_SV_\=_\ KT?V4/\ GM_X[_\ 7H]BP]K+
ML?2?]N:1_P!!6Q_\"$_QH_MS2/\ H*V/_@0G^-?-G]E#_GM_X[_]>C^RA_SV
M_P#'?_KT>Q8>UEV/I/\ MS2/^@K8_P#@0G^-']N:1_T%;'_P(3_&OFS^RA_S
MV_\ '?\ Z]']E#_GM_X[_P#7H]BP]K+L?2?]N:1_T%;'_P "$_QH_MS2/^@K
M8_\ @0G^-?-G]E#_ )[?^.__ %Z/[*'_ #V_\=_^O1[%A[678^D_[<TC_H*V
M/_@0G^-']N:1_P!!6Q_\"$_QKYL_LH?\]O\ QW_Z]']E#_GM_P"._P#UZ/8L
M/:R['TG_ &YI'_05L?\ P(3_ !H_MS2/^@K8_P#@0G^-?-G]E#_GM_X[_P#7
MH_LH?\]O_'?_ *]'L6'M9=CZ3_MS2/\ H*V/_@0G^-']N:1_T%;'_P "$_QK
MYL_LH?\ /;_QW_Z]']E#_GM_X[_]>CV+#VLNQ])_VYI'_05L?_ A/\:/[<TC
M_H*V/_@0G^-?-G]E#_GM_P"._P#UZ/[*'_/;_P =_P#KT>Q8>UEV/I/^W-(_
MZ"MC_P"!"?XT?VYI'_05L?\ P(3_ !KYL_LH?\]O_'?_ *]']E#_ )[?^.__
M %Z/8L/:R['TG_;FD?\ 05L?_ A/\:/[<TC_ *"MC_X$)_C7S9_90_Y[?^._
M_7H_LH?\]O\ QW_Z]'L6'M9=CZ3_ +<TC_H*V/\ X$)_C1_;FD?]!6Q_\"$_
MQKYL_LH?\]O_ !W_ .O1_90_Y[?^._\ UZ/8L/:R['TG_;FD?]!6Q_\  A/\
M:/[<TC_H*V/_ ($)_C7S9_90_P">W_CO_P!>C^RA_P ]O_'?_KT>Q8>UEV/H
MR36]),ZD:I98X_Y>$_QJ[_;NC_\ 05L?_ A/\:^9QI2XYE.?]VD_LH?\]O\
MQW_Z]'L6'M)=CZ9_MW1_^@K8_P#@0G^-']NZ/_T%;'_P(3_&OF;^RA_SV_\
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M=_\ KT>P8>UEV/IG^W='_P"@K8_^!"?XT?V[H_\ T%;'_P "$_QKYF_LH?\
M/;_QW_Z]']E#_GM_X[_]>CV##VLNQ],_V[H__05L?_ A/\:/[=T?_H*V/_@0
MG^-?,W]E#_GM_P"._P#UZ/[*'_/;_P =_P#KT>P8>UEV/IG^W='_ .@K8_\
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M'_Z"MC_X$)_C1_;NC_\ 05L?_ A/\:^9O[*'_/;_ ,=_^O1_90_Y[?\ CO\
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M_05L?_ A/\:^9O[*'_/;_P =_P#KT?V4/^>W_CO_ ->CV##VLNQ],_V[H_\
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M\:^9O[*'_/;_ ,=_^O1_90_Y[?\ CO\ ]>CV##VLNQ],_P!NZ/\ ]!6Q_P#
MA/\ &C^W='_Z"MC_ .!"?XU\S?V4/^>W_CO_ ->C^RA_SV_\=_\ KT>P8>UE
MV/IG^W='_P"@K8_^!"?XT?V[H_\ T%;'_P "$_QKYF_LH?\ /;_QW_Z]']E#
M_GM_X[_]>CV##VLNQ],_V[H__05L?_ A/\:/[=T?_H*V/_@0G^-?,W]E#_GM
M_P"._P#UZ/[*'_/;_P =_P#KT>P8>UEV/IG^W='_ .@K8_\ @0G^-']NZ/\
M]!6Q_P# A/\ &OF;^RA_SV_\=_\ KT?V4/\ GM_X[_\ 7H]@P]K+L?3/]NZ/
M_P!!6Q_\"$_QJM::YI(NF)U2R P>3<)Z_6OF_P#LH?\ /;_QW_Z]*=*7'$IS
M_NT>Q8>TEV/I_P#M_1O^@M8?^!*?XT?V_HW_ $%K#_P)3_&OE_\ LH?\]O\
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ML/:R['U!_;^C?]!:P_\  E/\:/[?T;_H+6'_ ($I_C7R_P#V4/\ GM_X[_\
M7H_LH?\ /;_QW_Z]'U=A[678^H/[?T;_ *"UA_X$I_C1_;^C?]!:P_\  E/\
M:^7_ .RA_P ]O_'?_KT?V4/^>W_CO_UZ/J[#VLNQ]0?V_HW_ $%K#_P)3_&C
M^W]&_P"@M8?^!*?XU\O_ -E#_GM_X[_]>C^RA_SV_P#'?_KT?5V'M9=CZ@_M
M_1O^@M8?^!*?XT?V_HW_ $%K#_P)3_&OE_\ LH?\]O\ QW_Z]']E#_GM_P".
M_P#UZ/J[#VLNQ]0?V_HW_06L/_ E/\:/[?T;_H+6'_@2G^-?+_\ 90_Y[?\
MCO\ ]>C^RA_SV_\ '?\ Z]'U=A[678^H/[?T;_H+6'_@2G^-']OZ-_T%K#_P
M)3_&OE_^RA_SV_\ '?\ Z]']E#_GM_X[_P#7H^KL/:R['U!_;^C?]!:P_P#
ME/\ &C^W]&_Z"UA_X$I_C7R__90_Y[?^._\ UZ/[*'_/;_QW_P"O1]78>UEV
M/J#^W]&_Z"UA_P"!*?XT?V_HW_06L/\ P)3_ !KY?_LH?\]O_'?_ *]']E#_
M )[?^.__ %Z/J[#VLNQ]0?V_HW_06L/_  )3_&C^W]&_Z"UA_P"!*?XU\O\
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M8?\ @2G^-?+_ /90_P">W_CO_P!>C^RA_P ]O_'?_KT?5V'M9=CZ@_M_1O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIUMXFO;72H%AM('\I0&9LLO#$EB3][/MP*AT#0+WQ%J:65DG/620_=C7U/\
MGFKYE:XK:V,NBO<]&^&>@Z;$C74)O[@#YGF/RYQ@X0<8^N?K6Z/"_A\+M_L/
M3L?]>J9_E6+Q$>A?LV?-]%>\:M\./#VIHQBMOL4Q'$EN< ?\!Z?H*\?\1^'+
MWPSJ9M+L!E8;HIE^[(OJ/0^H[?D:N%6,]B7%HJZ)_P A[3O^OJ+_ -"%?3%?
M,^B?\A[3O^OJ+_T(5],5CB=T73/%_B[_ ,C7:_\ 7BG_ *')7 U[/XL\%7/B
MGQC!*9/(L(K-%DFQDL=[G:H]<'KVR*WK#P-X;TZ/:FE03'NUPOFD_P#?60/P
MJHUHQBD)P;9\]45]#7_@CPWJ$)CDTFVB[AK=/*8'_@./R/%>0^,O!TWA6[C*
MRM/93D^5*5P5/]UNV<?GZ"KA6C)V)<&CEZ[[PY\2_P#A'] MM+_LC[1Y&[]Y
M]IV;MS%NFT^N.M<#7KO@KP5X>U?PC8WU]I_FW,OF;W\Z1<XD8#@,!T IU7%1
M]X(WOH<[XG^(_P#PD>ARZ;_97V?S&5O,^T;\8.>FT?SKA*]9\=>#= T;PK/>
MV%AY-PCH%?SI&P"P!X+$5Y-12<7'W0E>^H45V_@OX?R>(X?M]]*]OI^2$\O&
M^4C(.">  >^#TQ[UZA:>"?#5E&4BT>V<$Y)F7S3GZMG\NE*=:,78:@V?/%%?
M2)\+Z PP=#TW\+5!_2L'6OAIH6I0'[)#_9]S_#)#DK]"I.,?3!J5B(]1^S9X
M95W1K>*[US3[>==T4MS'&ZY(RI8 C(]J-6TF[T34YK"]0)-$><'(8=B#W!KU
M7P%X1T.\\-:9J]Q8[[X.TGF^:X^99&"G ;'&!VK2<U&-R8QN['?V]M!:0)!;
M0QPQ(,*D:A0/P%>.?%W_ )&NU_Z\4_\ 0Y*]HK%U?PGHFO7:76I67GS(@C5O
M-=<*"3C"D#J37'3FHRNS62NK'SG176?$/1M/T+Q%'::;;^1 ULLA7>S?,689
MRQ)["NQ\%>"O#VK^$;&^OM/\VYE\S>_G2+G$C <!@.@%=CJI14C)1;=CR*BO
M7O$OPWT^5M/MM#M!:RRS'SIC([A(PI))!)[X_$BNHT[P3X>TVS2W&EVUP5'S
M2W,2R.Q]22/Y5#KQM<?(SYYHKW/5_"'@^&^LGN]/CB-U,+=$CD:-"Q!(X4CT
MQ^(]JM?\*X\)_P#0*_\ )B7_ .*H^L1[![-G@5%=+XZT*'P_XGEM;6,1VLD:
MRPIN+84C!R3S]X-7-5JG=71+5@HKM_AQX6L_$-]>2ZE 9K2WC"A=S+EV/'((
M/ !_,5Z')\//"$,3R2:6%1%+,3<2\ =?XJSE6C%V8U!M7/!:*ENGADO)GMXO
M*@:1C''DG8N>!DYZ"HJU)"M7PS_R->C_ /7]!_Z&*RJU?#/_ "->C_\ 7]!_
MZ&*4MF-;GTC7%^+O'_\ PBNK16/]F?:O,@$V_P _9C+,,8VG^[^M=I7B_P 7
M?^1KM?\ KQ3_ -#DKBI14I69M)V6AK+\9%+#=H1"YY(N\D#_ +XKI/#OQ#TC
MQ!>"S"RVERWW$FQASZ CO['%>#U+;//'=PO;;_M"NIBV#+;L\8]\UT2H0:T,
MU-GU#7B_Q4T*/3M;AU&WCV17P8R #CS1U/X@@_7)KV<$E02,''(]*\[^+X']
MA:><#(N2,_\  37/1=IHTFM#QZBNJ^'^CV&N>)3::C!YT'D.^S>R\@C!RI![
MUZG_ ,*X\)_] K_R8E_^*KJG5C!V9DHMG@5%>N^"/AW:QV46I:W )IY0'CMY
M!\L:D?Q ]3ST/3ZUUMWX-\.7L#12:/9H"/O0Q"-A^*X-3*O%.PU!M'SK15K4
MXK6#5+N&R=I+6.5DB=F#%E!P#D #GK75^$/A[=>(8UO;R1K73S]T@?O)?]T'
M@#W/Y&M7)15V2DV['%45]"6/@7PU81A4TJ&8YR6N!YA/_?7'Y5;?PKX?D&&T
M33Q_NVR+_(5A]8CV+]FSYPHKV'7_ (4V%Q"9=$D:UG4<0R.7C;\3D@^^2/:O
M);RSN=/O);2[A:&XB;:Z-U!_SWK:%2,]B7%H@HHKKO!O@:X\3L;J:0V^G(VU
MI!]]SCHH_+)/ZTY245=B2N<C17T/8^"O#EA"L::3;2X&-]Q&)6/U+9INH^!_
M#FI6[1/I=O 3TDMD$3*<8R,<'Z'(]JQ^L1[%^S9\]45ZCI?PVBL_%\EIJ4#7
MNE/;N\$NYD^8,ORMM(PP!/L>OJ!UG_"N/"?_ $"O_)B7_P"*INO%"4&>!445
MZSX%\&Z!K/A6"]O[#SKAW<,_G2+D!B!P& K2<U!79*5SR:BO7O%7PZTTVMC#
MH5CY%U/=K&\IDD<+'L<DG)/' _EWKI-)\"^']+LU@.G6]W)CYYKF(2,Q]><X
M'L*S=>-KE<C/GVBO7OB)X7\/6'A^74H;1+2[5E2(0$(LA)Z%>G W'@ \=<5Y
M]X6\+7GBG4&M[=A%#$ 9IV&0@/3CN3@X'M5QJ)QYA.+3L85%>^Z9\//#>F(N
M;$7<H!!DNCOSDY^[]W\A6H/#&@ 8_L/3?_ 1/\*S>(CT17LV?-U%?06H> O#
M6H0LC:9% Q&!);_NV7W&./S!KR#Q=X1NO"M\J._G6DV3#.!C..JD=B/U_,"X
M58S=B7%HYRBBO??^%<>$_P#H%?\ DQ+_ /%4YU%#<(Q;/ J*]5U3X8QWGBF.
M+3HOL.DI"C32%V<LQ+9"[B<G 'L/T/8:=X'\.:;;K$FEV\Y'62Y02LQQC)SP
M/H,#VJ'7BD-09\]45]#WW@GPY?P-$^DVT.1]^WC$;#Z%:\NU#X:ZK!XECTVS
M!FM9AO2Z9<*B9YW^X]NO'K@.-:,@<&CB:*]XT7X=:!I4">?:K?7.W#RW W*3
MWPG0?J?>M2X\(>';J(QR:+8A3QF.$1G\UP:EXB-Q^S9\YT5WOCKP"N@PG4]-
M9FL-P62)N6ASP#GN">/8D=:X*MHR4E=$-6"BNX\%> )/$4:ZA?2-!IP;"A1\
MTV#@X/89XS_^NO3[3P3X:LD"QZ/;/@=9E\PG_OK-9SK1B[%*#9\\45](-X7\
M/L,'0]._"U0?TK!UGX9:%J,3FSC-A<$Y#Q$E?H5)QCZ8J5B(]1^S9X;15W5M
M)N]$U.:PO4"31'G!R&'8@]P:I5NG<S"BBBF 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3X0?\@&__P"OK_V45ROQ5MHX/&7F(N&N+9)'.<Y()7/MPH_*NJ^$'_(!O_\
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M>O"?AY&LOCO3%<9 :1OQ$;$?J*]_K3$/5(FFM+G'>./&Z^&(XK6UC2:_F4L
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#VCX1?\BI=?]?S_P#H$==]7 _"+_D5+K_K^?\ ] CKOJ\^K\;-X[!1
M116904444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% '+?$?_D0M3_[9?^C4KP*O??B/_P B%J?_ &R_]&I7@5=F'^$QJ;A1
M11700%=Q\*?^1Q/_ %ZO_-:X>NX^%/\ R.)_Z]7_ )K6=3X&5'<]NKYK\0_\
MC+JO_7Y-_P"AFOI2OFOQ#_R,NJ_]?DW_ *&:PPV[+J&_\/?%/]@:R+:YD L+
MLA9"S8$;=G]/8^WTKW6OEFO<OAQXF_MO1/L=R^;VR 1B229$_A;Z]C],]Z=>
M'VD$)=#L8XDA39&H5<EL#U)R?U-<#\7O^1:L_P#K\'_H#5Z#7GWQ>_Y%JS_Z
M_!_Z U8TOC14MCB/AI,D/CBT5^/,21%/OM)_I7O%?,6G7LFFZE;7L/\ K+>5
M9%YQG!SBOI2POH-2T^"]MFW0SH'0GK@^OO6F(CJF33>ECS7Q)\2-<T7Q%>Z=
M':6)C@DPADC<L5(!!.''8UE?\+=U_P#Y\]-_[]2?_%UV'CGP&?$DJW]C*D5^
MBA&63A)%'3D="*X:R^%WB.XN_+N8H;2$-@S/*K9'<@*23]#C\*J'LG'43YKE
MG_A;NO\ _/GIO_?J3_XNL_6_B)JVOZ3-IMW;6*0RE26B1PPPP(QEB.WI7MMG
MIUM9:=;V,<8:&"-8T#C/ %>7_%>]TQ'MM+M;:V%VC^=/)&@#(".%) [YSC/8
M>U$)0E*RB.2:6YR_@+_D>-+_ .NA_P#037T'7S;X;OETWQ+IMX[!8XKA"['L
MN<-^A-?253B%[R"GL>#?$J)H_'5\Q(Q(L3#'IY:C^E<E7LWC_P "W?B"\BU+
M370W"H(I(I&P& )((/KST_R>7T7X5:Q=W"G52EC;AOF =7D8>V"0,^I/'H:U
MA4BH*[)<7<](\#6XMO!6E1@8S#YG_?1+?UK/^)W_ "(]U_UTC_\ 0A76PPQV
M\$<$**D4:A$11@*H& !7)?$[_D1[K_KI'_Z$*YHN]1/S-'\)X37TCX9_Y%31
M_P#KQ@_] %?-U?2/AG_D5-'_ .O&#_T 5OB=D13W.0^+Y/\ PC]BO8W6?_'&
MKQVO8?B__P @&P_Z^O\ V4UX]5T/@%/<V?"5U]C\7:5-V^THA]@QVD_D:^C:
M^6:^BO"6OQ^(M @O 1YZ@1W"?W9 .?P/4>QK/$1V95-]#RSXJ6+6WC W&PA+
MJ%'W8."0-I'UPH_,5Q%?0_BOPK:^*=-$$K>5<1$M!.%R4/<'U!]/I7E,GPP\
M3I<^4MK!(G_/59UV_K@_I5TJL>6S9,HNYD^$+5KWQAI,*@G%RDAP.RG<?T!K
MZ+KCO!'@=/#"R75U*D]_*NTE1\L2^BD\G/<\=N/7I-6U2VT72Y]0NVVQ0KD@
M=6/91[D\5A5GSRT+BK+4\=^*MPL_C+RP<F"V2-N>AR6_]F%=5\(/^0#?_P#7
MU_[**\IU349M6U2YOY_]9/(7(';T'X#BO5OA!_R ;_\ Z^O_ &45M47+2L3%
MWD=SJMH;_1[ZS'6XMY(ASC[RD?UKYF961BK JP."",$&OJ6O,?&'PSGOM2EU
M'16B'GMNDMG.T!N[*??KCUS]*RH34;IE3C?8\GKZ!^']L]IX'TQ)  S(TG'H
MSEA^A%>?Z!\+-4N;Q7UH+:6JGYD617=^G VD@ ^N<^U>Q111P0I#"BQQ1J%1
M%& H'  'I55ZB:LA0BUJSC_BC<+!X*EC8D&>>.->.ISN_DIKQ*WM+F[8K;6\
MLS#J(T+$?E7H7Q9UQ;F_MM'@?*VV99L8(WD<#Z@9_P"^JV/A/KD=QI4NBR/B
M>V8R1 ]XV/./HQ.?]X54&X4[V$_>E8Y;3/%?C+PY:!KBUNIK%"!_IL#[5!X
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZI=>0)EC$?[MFSC=G[H/J*X.BM)14E9DIV=SWJ3XC>%&B<#5>2I _P!'E_\
MB:\%HHJ84U#8<I-G5>$/&]WX7E,+H;BPD.6A+8*'NR^_MWKU?3O'WAK48MRZ
ME';M@%DN?W9&>V3P?P)KY^HI3HQD[@IM'TB?$^@ 9_MS3?\ P+3_ !K&U7XD
M>'=-C/E7)O9L9$=N,C\6Z5X/14+#QZLKVC-CQ)XDO?$VIF[NSMC7(A@4_+$O
MH/4^I[_D!CT45NDDK(S"BBBF 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 >T?"+_ )%2Z_Z_G_\ 0(Z[ZN!^
M$7_(J77_ %_/_P"@1UWU>?5^-F\=@HHHK,H**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+OP7IOSIYB(8RH8$C:Q S^ !KP"BLZE/G5BHRL?4,]S!:QM)<3QQ(HRS2.%
M'KDUYCX\^(5M<64ND:+(LRR@I<7 'RA>A5<]<^O3'3.<CRRBLX4%%W>HW-L*
M***Z" HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "OIZSNHKRTAFCE2021AP48$'(]J^8:*RJ4^>VI49
M6/IR]U*QTZ%Y;V[A@1!DF1P*\<\?^-T\0LNGZ?G^SXG#F0@@RMCK@] ,]#7#
M45,**B[CE-L****W("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **7!(R <4E !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 444N"!D@XH 2BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#VCX1?\ (J77_7\__H$=
M=]7 _"/CPI=9_P"?Y_\ T".N^KSZOQLWCL%%%%9E!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM?I3J0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH KR?\?"_A5^J$G_'POX5?H8!1112 **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *JV?_'V_T/\ .K55;/\ X^W^A_G1
MT T:***D HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@"C:?\A)_JU:M95I_R$G^K5JTY;@@HHHJ1A1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!2UC_D"7__ %[2?^@FO&/@O_K-:^D'_L]>
MSZQ_R!+_ /Z]I/\ T$UXQ\%_]9K7T@_]GK6'PLQG\<3UBBBB@T"H;J?[-;O+
MMW;<<9QWQ4U5-3_Y!TOX?S%14;4&UV,ZTG&G*2W294_MO_IW_P#'_P#ZU']M
M_P#3O_X__P#6K(HKROK5;O\ D?/_ -H8C^;\%_D:_P#;?_3O_P"/_P#UJ/[;
M_P"G?_Q__P"M6111]:K=_P @_M#$?S?@O\C7_MO_ *=__'__ *U']M_]._\
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M -M_].__ (__ /6H_MO_ *=__'__ *U9%%'UJMW_ "#^T,1_-^"_R-?^V_\
MIW_\?_\ K4?VW_T[_P#C_P#]:LBBCZU6[_D']H8C^;\%_D:_]M_]._\ X_\
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MM5N_Y!_:&(_F_!?Y&O\ VW_T[_\ C_\ ]:C^V_\ IW_\?_\ K5D44?6JW?\
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M?_Q__P"M6111]:K=_P @_M#$?S?@O\C7_MO_ *=__'__ *U']M_]._\ X_\
M_6K(HH^M5N_Y!_:&(_F_!?Y&O_;?_3O_ ./_ /UJ/[;_ .G?_P ?_P#K5D44
M?6JW?\@_M#$?S?@O\C7_ +;_ .G?_P ?_P#K4?VW_P!._P#X_P#_ %JR**/K
M5;O^0?VAB/YOP7^1K_VW_P!._P#X_P#_ %J/[;_Z=_\ Q_\ ^M6111]:K=_R
M#^T,1_-^"_R-?^V_^G?_ ,?_ /K4?VW_ -.__C__ -:LBBCZU6[_ )!_:&(_
MF_!?Y&O_ &W_ -.__C__ -:C^V_^G?\ \?\ _K5D44?6JW?\@_M#$?S?@O\
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M_P#'_P#ZU9%%'UJMW_(/[0Q'\WX+_(U_[;_Z=_\ Q_\ ^M1_;?\ T[_^/_\
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M1/\ ZU']O_\ 3M_Y$_\ K5BT4?6JO?\ (/[0Q/\ -^"_R-K^W_\ IV_\B?\
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MB_\ UJYZBE]9J]P_M#$_S?@O\CH?^$H_Z<__ "+_ /6H_P"$H_Z<_P#R+_\
M6KGJ*/K-7N']H8G^;\%_D=#_ ,)1_P!.?_D7_P"M1_PE'_3G_P"1?_K5SU%'
MUFKW#^T,3_-^"_R.A_X2C_IS_P#(O_UJ/^$H_P"G/_R+_P#6KGJ*/K-7N']H
M8G^;\%_D=#_PE'_3G_Y%_P#K4?\ "4?].?\ Y%_^M7/44?6:O</[0Q/\WX+_
M ".A_P"$H_Z<_P#R+_\ 6H_X2C_IS_\ (O\ ]:N>HH^LU>X?VAB?YOP7^1T/
M_"4?].?_ )%_^M1_PE'_ $Y_^1?_ *U<]11]9J]P_M#$_P WX+_(Z'_A*/\
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M+B:.),XW2,%&?J:S8O%/AZ9]D6O:7(Q_A2\C)_G185T:U%%% PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH I
M:Q_R!+__ *]I/_037C'P7_UFM?2#_P!GKV?6/^0)?_\ 7M)_Z":\8^"_^LUK
MZ0?^SUK#X68S^.)ZQ1110:!534_^0=+^'\Q5NJFI_P#(.E_#^8K.M_#EZ,QQ
M'\&?H_R.=HHHKPSY0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH HVG_(2?ZM6K65:?\ (2?ZM6K3EN""BBBI&%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 51UG_D!:A_U[2?\ H)J]5'6?^0%J'_7M)_Z"
M:$)['R)73^/-,_LWQ&I52([JT@N4]]R -_X\&KF*]6^+FF?\27PSJJA.;5;9
MS_%]T,OX??\ \FNMNS1P15XL]*^'6JG5_ >ESNY>6./R)">N4.WGZ@ _C7A?
MQ+U+^T_'^J.%"K!)]F49S]P;3^H)KLO@_P"(XM+\/^(HIU)2S3[</FP&&W##
MV/RK]<^U>9Z-8R:[XCLK)B6>\N51V_WF^8_EDU$8VDV:SES0BC2\7Z:VDMHE
MLP()TJ&4Y7'+EV(_ DC\*]!^ W_,P?\ ;M_[5K%^.'_(ZV?_ &#D_P#1DE;7
MP&_YF#_MV_\ :M$G>G<(*U6QU_Q+\92>$M"C%GQJ%XQ2!B 1&!C<^""#C(&/
M>O ;+3];\6:JZ6L5QJ%Z_P [L6R>3U9B< 9/4FOI[6- T35P)M7L+6X$*$"2
M91\B]3SV%<5#XK^''@F>[&E%?M$KA9DLT>3.,]&8[<#GH:B$K+1:EU(7E>3T
M/)-4\ >*=&M)+J^TB5((UW/(CI(%'J=I.*M> O&.H>&M>M(Q<N=.FE6.X@8Y
M0*3@L!V(SGCK77^)?C1%J.FW>GZ;I#".YC>)I;IQG:P(/R+WY]:\BK57DO>1
MA+EB[P9]DU\>7?\ Q^3_ /71OYU]AU\>7?\ Q^3_ /71OYUG1ZFV(Z'U%X$_
MY$31/^O1/Y5RWQ/^(<OAL+I&DLHU*5-TLI&?(0],=BQ_3'N*ZGP)_P B)HG_
M %Z)_*OFGQ!J;ZQXAU#49#DW$[N/9<\#\!@4H1O)W'4FXP5A;2PUGQ1J;BVB
MN]1O7^:1R2[8Z99CT[#)-6M:\&>(O#T(GU32YH(>,R@K(@R<#+*2!^->]_#'
M0H=&\$6,BQH+B]C%S-(!RV[E1GV4C]?6NKN[6"^M);6ZB66"9"DD;#A@>HJG
M5L[$QH7C=O4\(^'OQ/NM(NX]-URYDN--D(5)I&W-;GH.3R4]1V[>A]]KY(\0
M:;_8WB'4=-#%EMKAXU8C&5!X/Y8KZ-^'&I2:KX!TJ>:0R2I&878CGY&*CZ\
M<TJL5\2*H3?PL^:]5_Y#%]_U\2?^A&K_ (@\37WB VD<\A%K9PI!;P@_*H50
M"?J<9)_#H*H:K_R&+[_KXD_]"->\_"#P[;:?X3BU5X$-[>LS^:PRRQ@E54>@
MX)]\_3&DI**N80BY.R.&^"FE/=^+9]1RPBL8#G!/+/\ * ?; 8_@*]^JO!8V
MMK///;V\44MP0TS(@4R$=VQU/O5BN><N9W.RG#D5@KQOX\_\R_\ ]O/_ +2K
MV2O&_CS_ ,R__P!O/_M*G3^)$UO@9S'P=_Y*!!_U[R_RKZ+KYT^#O_)0(/\
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M&2J=6;\%!/X5].ZWJ]CX0\,RWLB!;>TB"10@\L>B(/T^@Y[5Y;\#]"\R\O\
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M=W%G7T445B=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!2UC_ ) E_P#]>TG_ *":\8^"_P#K-:^D'_L]>SZQ_P @
M2_\ ^O:3_P!!->,?!?\ UFM?2#_V>M8?"S&?QQ/6****#0*J:G_R#I?P_F*M
MU4U/_D'2_A_,5G6_AR]&8XC^#/T?Y'.T445X9\H%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444  .#D5T>C:P9-MM<M\W1'/?V-<Y0"0<@X-:4ZC
MINZ-\/7G0GS1/0J*Q]$U0W4?D3']ZHX/]X5L5ZL)J<>9'T]&K&K!3B%%%%6:
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 4;3_D)/\ 5JU:RK3_ )"3_5JU:<MP04445(PHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM31+XVMX(V/[N7@^Q[&NG#U>25GLSOP&)]E4Y7LSKJ***],^C"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH HVG_ "$G^K5JUE6G_(2?ZM6K3EN""BBBI&%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4R:&.X@D@E7='(I1AG&01@T^B@#C?\ A5/@K_H"_P#D
MU-_\7781HL4:QH,*H"@>@%.HIMM[B44MD<E=?#+P?>7<UU/HX:::1I)&%Q*H
M+$Y)P&P.3T%;^D:-I^@Z<FGZ9;+;VJ$D(&+<DY))))/XFKU%#;>X**6J1@Z[
MX,\/^);J.YU>P^TS1IY:-YTB87).,*P[DU+H/A31/#'VC^Q[+[-]HV^;^]=]
MVW./O$X^\>GK6S11=VL'*KWL07ME;:C9RV=Y D]O*NUXY!D,*X*Y^"_A6>Y\
MV-M0MD_YY13@K_X\I/ZUZ)10I-;"<5+='/>'/!.@^%@6TVS N&&UKB4[Y"/3
M)Z#V&,X%4[KX9>#[R[FNI]'#332-)(PN)5!8G). V!R>@KK:*.9[W#EC:UC/
MA33/#NCB%9([6QLXA_K)"1&G;)8DX^M?)4[B6XDD7.&8L,^YKK?B=-<W?CS4
M[B6WFBB600Q%U."$4+D''<@G\:S_  OX.U7Q3J,<%K;NMON'G7+*0D:GOGN<
M=!71!<JNSEJ2<WRI;'T;X-A\CP3H<?S _8820W4$H"?U-;3*KJ58 J1@@C@B
MHK2VCL[."UBSY<,:QKGK@# _E4U<[W.M*RL<3J_PI\*:M,TWV26SE8DLUI)L
M!)_V2"H_ "J-I\%_"MM,'E;4+I?^><TX _\ '%4_K7HE%/GEW)]G'L5K#3[/
M2[-+2PMHK:W3[L<2A0/?Z^]6:**DLY"7X7>#9YGFDT?<[L68_:9ADGD_QUTN
MG:=:Z3I\-A91>5;0+MC3<6VCZDDU:HIMM[B44MD%%%%(85C:]X4T3Q/]G_MB
MR^T_9]WE?O73;NQG[I&?NCKZ5LT4)V$TGHSC?^%4^"O^@+_Y-3?_ !='_"J?
M!7_0%_\ )J;_ .+KLJ*KFEW%R1['.6'@+PKIDB26NB6HD0AE:0&0J1T(+$\U
MT=%%)MO<:26P5'/;PW4#P7$,<T,@VO'(H96'H0>"*DHI#. U#X.>%+Z8R1)>
M663DK;3#;^3AL?A3],^$'A33IQ+)#<WI7HMU+E<YZX4*#^.17>457/+N1[..
M]AL<<<,211(J1HH5448"@= !V%<#\9/^1 D_Z^8OZUZ!7#_%BPO-1\$/;V-I
M/=3&XC/EP1EVP,Y.!S1#XD%3X6>)_#[_ )'_ $7_ *^5_K7N6O\ PP\,^(+H
MW4MO+:7#<O):.$W_ %!!7/OC->0^!_#.OVGC?2+BYT/4H88[@%Y)+2154>I)
M&!7TA6E25GH948IQ::.)T7X4^%]%N4N1;S7DR'*-=N'"GUV@ ?F*[:BBLFV]
MS=12V,G7?#.C^)H88=7M/M*0L6C'F.F">#]TBJ6C^!/#6@:@M_IFF^1<JI4/
MY\C<'KPS$5T=%%WL'*KWL%%%%(9SGB'P+X?\3NTNH6(^TD ?:86*2<>I'!XX
MY!KFE^"7AA90YN=49<YV&9,?3A,_K7I%%4I274APB]6C(T+PQHWAJW:'2;&.
MWW???EG?ZL>3].@K7HHJ;W*22V,[6-!TOQ!:BVU6RBNH@25#Y!4GC((Y'X&N
M)G^"?A>64ND^IPJ?X(YD('_?2$_K7H]%-2:V$X1>Z.%TSX1^$]-N$F:VGO&3
MD"ZDW+GCDJ  >G0@CGI7<(B1QK'&JJB@!548  [ 4ZBAMO<:BEL(RJZE6 *D
M8((X(KBM7^%/A35IFF^R2V<K$EFM)-@)/^R05'X 5VU%";6P.*>YYO#\$_"\
M<FY[C4Y1_=>9 /T0&NST/PWI'ARU^SZ591VZG[SCEW_WF/)K5HIN3>XE"*V0
M5R$OPN\&SS/-)H^YW8LQ^TS#)/)_CKKZ*2;6PW%/<JZ=IUKI.GPV%E%Y5M N
MV--Q;:/J235JBBD,PM=\&^'_ !+<Q7&KZ<MQ-$FQ7\QT.W.<?*1D9)Z^II^A
M>$M"\,M,VD6"VS3 "1M[.2!T&6)('TK:HIW=K"Y5>]@HHHI#.<\0^!?#_B=V
MEU"Q'VD@#[3"Q23CU(X/''(-<TOP2\,+*'-SJC+G.PS)CZ<)G]:](HJE*2ZD
M.$7JT9&A>&-&\-6[0Z38QV^[[[\L[_5CR?IT%:]%%3>Y226P4444#"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *6L
M?\@2_P#^O:3_ -!->,?!?_6:U](/_9Z]GUC_ ) E_P#]>TG_ *":\8^"_P#K
M-:^D'_L]:P^%F,_CB>L4444&@54U/_D'2_A_,5;JIJ?_ "#I?P_F*SK?PY>C
M,<1_!GZ/\CG:***\,^4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ H!P<CK110!VNE7?VNQ1R?G'#5=KF/#ESLNG@)XD&1]173UZU"?/
M!,^HP=;VM%-[[!1116QU!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!1M/^0D_P!6K5K*M/\ D)/]6K5IRW!!
M1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"EK'_(
M$O\ _KVD_P#037C'P7_UFM?2#_V>O9]8_P"0)?\ _7M)_P"@FO&/@O\ ZS6O
MI!_[/6L/A9C/XXGK%%%%!H%5-3_Y!TOX?S%6ZJ:G_P @Z7\/YBLZW\.7HS'$
M?P9^C_(YVBBBO#/E HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** )[.;[/>12_P!U@37=@Y&1TKSVNYL)/.T^!^Y09KNP<MXGLY3/
MXH?,LT445W'LA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!1M/^0D_P!6K5K*M/\ D)/]6K5IRW!!1114C"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHVWSVF\K=[JNTY'UQ5<DMK$NI!*]SU:BL3PKXGM?%NBC4K2&>%-YC9)EP0P
MS@C@CGK6W4M6*3NKH****!A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!2UC_ ) E
M_P#]>TG_ *":\8^"_P#K-:^D'_L]>SZQ_P @2_\ ^O:3_P!!->,?!?\ UFM?
M2#_V>M8?"S&?QQ/6****#0*J:G_R#I?P_F*MU4U/_D'2_A_,5G6_AR]&8XC^
M#/T?Y'.T445X9\H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5U^@ONTF,?W2P_7/\ 6N0KJ_#ASIC#TE(_05U81_O#T<L=J_R-
M>BBBO2/H0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH HVG_(2?ZM6K65:?\A)_JU:M.6X(****D84444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M** "BBB@ HHHH **** "BBB@ HHHH **** *6L?\@2__ .O:3_T$UXQ\%_\
M6:U](/\ V>O9]8_Y E__ ->TG_H)KQCX+_ZS6OI!_P"SUK#X68S^.)ZQ1110
M:!534_\ D'2_A_,5;JIJ?_(.E_#^8K.M_#EZ,QQ'\&?H_P CG:***\,^4"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *ZOPX,:8
MQ]92?T%<I77Z"FW28S_>+']<?TKJPB_>'HY8KU_D:=%%%>D?0A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!1
MM/\ D)/]6K5K*M/^0D_U:M6G+<$%%%%2,**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&69"LM](USAAR%( 7\"%#?\  J\6^(/_ "/^M?\ 7RW]*^HU544*H 4#  '
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KN;"/R=/@3N$&
M:XVSA^T7D47]Y@#7=@8&!TKNP<=Y'LY3#64_D%%%%=Q[(4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4;3_D)
M/]6K5K*M/^0D_P!6K5IRW!!1114C"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@"EK'_($O_\ KVD_]!->,?!?_6:U](/_ &>O9]8_Y E_
M_P!>TG_H)KQCX+_ZS6OI!_[/6L/A9C/XXGK%%%%!H%5-3_Y!TOX?S%6ZJ:G_
M ,@Z7\/YBLZW\.7HS'$?P9^C_(YVBBBO#/E HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5J:)8FZNQ
M(P_=QG)]SZ5G11//*L<8RS' %=M86:V5HD*\D#YCZFNG#TN>5WLCOP&&]K4Y
MGLBS1117IGT84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %.CC>5PD:EF/0"KM
MCI%Q>G('EQ]W8?RKI[+3;>Q7]VN7[N>IKHI8>4]7HCNPV!J5M7HBCI6B+;$3
M7(#2]0O9:VJ**]&$(P5HGOT:,*,>6""BBBK-0HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"C:?
M\A)_JU:M95I_R$G^K5JTY;@@HHHJ1A1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO^1UU[_L(W'_ *,:OI/P7.]SX)T663&XV<0.!Z*!_2OFSQ=_R.NO?]A&X_\
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M!X5<R^#]$D;&6L(&./>-:\R^//\ S+__ &\_^TJSIMJ5C:JDX<S/+_#6B_\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4M8_Y
ME_\ ]>TG_H)KQCX+_P"LUKZ0?^SU[/K'_($O_P#KVD_]!->,?!?_ %FM?2#_
M -GK6'PLQG\<3UBBBB@T"JFI_P#(.E_#^8JW4-U!]IMWBW;=V.<9[YJ*B;@T
MNQG6BY4Y16[3.8HK7_L3_IX_\<_^O1_8G_3Q_P".?_7KROJM;M^1\_\ V?B/
MY?Q7^9D45K_V)_T\?^.?_7H_L3_IX_\ '/\ Z]'U6MV_(/[/Q'\OXK_,R**U
M_P"Q/^GC_P <_P#KT?V)_P!/'_CG_P!>CZK6[?D']GXC^7\5_F9%%:_]B?\
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M]B?]/'_CG_UZ/[$_Z>/_ !S_ .O1]5K=OR#^S\1_+^*_S,BBM?\ L3_IX_\
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M *]']B?]/'_CG_UZ/JM;M^0?V?B/Y?Q7^9D45K_V)_T\?^.?_7H_L3_IX_\
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M ,<_^O36T7:,_:/_ !S_ .O1]5K=OR%_9^(_E_%?YF516RN@[E!^T]?^F?\
M]>E_L#_IY_\ (?\ ]>CZK5[?D/\ L_$_R_BO\S%HK:_L#_IY_P#(?_UZ/[ _
MZ>?_ "'_ /7H^JU>WY!_9^)_E_%?YF+16U_8'_3S_P"0_P#Z]']@?]//_D/_
M .O1]5J]OR#^S\3_ "_BO\S%HK:_L#_IY_\ (?\ ]>C^P/\ IY_\A_\ UZ/J
MM7M^0?V?B?Y?Q7^9BT5M?V!_T\_^0_\ Z]']@?\ 3S_Y#_\ KT?5:O;\@_L_
M$_R_BO\ ,Q:*VO[ _P"GG_R'_P#7H_L#_IY_\A__ %Z/JM7M^0?V?B?Y?Q7^
M9BT5M?V!_P!//_D/_P"O1_8'_3S_ .0__KT?5:O;\@_L_$_R_BO\S%HK:_L#
M_IY_\A__ %Z/[ _Z>?\ R'_]>CZK5[?D']GXG^7\5_F8M%;7]@?]//\ Y#_^
MO1_8'_3S_P"0_P#Z]'U6KV_(/[/Q/\OXK_,Q:*VO[ _Z>?\ R'_]>C^P/^GG
M_P A_P#UZ/JM7M^0?V?B?Y?Q7^9BT5M?V!_T\_\ D/\ ^O1_8'_3S_Y#_P#K
MT?5:O;\@_L_$_P OXK_,Q:*VO[ _Z>?_ "'_ /7H_L#_ *>?_(?_ ->CZK5[
M?D']GXG^7\5_F8M%;7]@?]//_D/_ .O1_8'_ $\_^0__ *]'U6KV_(/[/Q/\
MOXK_ #,6BMK^P/\ IY_\A_\ UZ/[ _Z>?_(?_P!>CZK5[?D']GXG^7\5_F8M
M%;7]@?\ 3S_Y#_\ KT?V!_T\_P#D/_Z]'U6KV_(/[/Q/\OXK_,Q:*VO[ _Z>
M?_(?_P!>C^P/^GG_ ,A__7H^JU>WY!_9^)_E_%?YF+16U_8'_3S_ .0__KT?
MV!_T\_\ D/\ ^O1]5J]OR#^S\3_+^*_S,6BMK^P/^GG_ ,A__7H_L#_IY_\
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MB?Y?Q7^9BT5M?V!_T\_^0_\ Z]']@?\ 3S_Y#_\ KT?5:O;\@_L_$_R_BO\
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M_P (W_T]_P#D/_Z]'U:KV_(/[/Q/\OXK_,P:*WO^$;_Z>_\ R'_]>C_A&_\
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MPC?_ $]_^0__ *]'_"-_]/?_ )#_ /KT?5JO;\@_L_$_R_BO\S!HK>_X1O\
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M?Y?Q7^9SU%=#_P (O_T^?^0O_KT?\(O_ -/G_D+_ .O1]6J]@_L_$_R_BO\
M,YZBNA_X1?\ Z?/_ "%_]>C_ (1?_I\_\A?_ %Z/JU7L']GXG^7\5_F<]170
M_P#"+_\ 3Y_Y"_\ KT?\(O\ ]/G_ )"_^O1]6J]@_L_$_P OXK_,YZBNA_X1
M?_I\_P#(7_UZ/^$7_P"GS_R%_P#7H^K5>P?V?B?Y?Q7^9SU%=#_PB_\ T^?^
M0O\ Z]'_  B__3Y_Y"_^O1]6J]@_L_$_R_BO\SGJ*Z'_ (1?_I\_\A?_ %Z/
M^$7_ .GS_P A?_7H^K5>P?V?B?Y?Q7^9SU%=#_PB_P#T^?\ D+_Z]'_"+_\
M3Y_Y"_\ KT?5JO8/[/Q/\OXK_,YZBNC'AA/XKIC]$Q_6I4\-6J_>EE;\A36%
MJ=BEEV(?3\3EZ>D4DC81&8^@&:["/1;"+!$ 8C^\2:N)%'$,1HJCV&*TC@Y?
M:9O#*IOXY6.5MM NY\&0")?]KK^5;=GHEK:X9E\V3U?H/PK2HKIAAX0/0HX&
MC2UM=^8 8&!1116YV!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4;3_ )"3_5JU
M:RK3_D)/]6K5IRW!!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFN])TBTTJRE:)[_?YSKP?+7 VY]RW;L,=Z\7T#1+OQ%K=MI5D%\^=B SG"J
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M/QPODF\36%FIR;>UW-[%F/'Y*#^-8NB?%;Q)H6E1Z=$UK<0Q($B-S&6:-1T
M(89Q[YZ"N1U#4+K5=0GOKZ8S7,[;Y)" ,GZ#@?A1"FXN["I54HV1V?P@L#>_
M$"WEP"MI#).0?IL'ZN*^C:\V^#_A671=#DU6\C*76H!2BGJL(Y7\\Y_*O2:S
MJ.\C:C&T3S+XXNH\'V,9/S-?JP'L(Y,_S%>4?#Z'S_'VBIG&+E7_ .^<M_2N
M_P#CM>_-HMBO82S/Q_NA>?\ OJL'X+Z:UWXU:\*9CL[=VW>C-\H_0M^5:1TI
MF,]:MCZ#HHHKG.L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *6L?\@2_
M_P"O:3_T$UXQ\%_]9K7T@_\ 9Z]GUC_D"7__ %[2?^@FO&/@O_K-:^D'_L]:
MP^%F,_CB>L4444&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4R3[H^M/IDGW1]: +$?^K7Z4ZFQ_ZM?I3J0PHHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH KR?\?"_
MA5^J$G_'POX5?H8!1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *JV?_'V_P!#_.K55;/_ (^W^A_G1T T:***D HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"C:?\A)_JU:
MM95I_P A)_JU:M.6X(****D84444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG^5>PT4U.2ZDNG!N[1SWA_P3H7AJRDMK&TRTR%)IY3NDD4]03V'L,#VKE?\
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M8@ XVJ..!6XRJZE6 *D8((X(I:*3=RDDE9'GVO\ P@\/ZQ<27-JTVG3N2S"
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M1[K3+IY$@N4V.T1 8#VR"/TJ_12<F]6-125D>:?\*/\ #/\ S_:M_P!_8_\
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M*9YGM1YGM0 ^BF>9[4>9[4 /HIGF>U'F>U #Z*9YGM1YGM0 ^BF>9[4>9[4
M/HIGF>U'F>U #Z*9YGM1YGM0 ^BF>9[4>9[4 /HIGF>U'F>U #Z*9YGM1YGM
M0 ^BF>9[4>9[4 /HIGF>U'F>U #Z9)]T?6CS/:FL^X=* +4?^K7Z4ZJZS[5
MV]/>E^T#^[^M389/14'V@?W?UH^T#^[^M%@N3T5!]H']W]:/M _N_K18+D]%
M0?:!_=_6C[0/[OZT6"Y/14'V@?W?UH^T#^[^M%@N3T5!]H']W]:/M _N_K18
M+D]%0?:!_=_6C[0/[OZT6"Y/14'V@?W?UH^T#^[^M%@N3T5!]H']W]:/M _N
M_K18+D]%0?:!_=_6C[0/[OZT6"Y/14'V@?W?UH^T#^[^M%@N3T5!]H']W]:/
MM _N_K18+D]%0?:!_=_6C[0/[OZT6"Y/14'V@?W?UH^T#^[^M%@N3T5!]H']
MW]:/M _N_K18+D]%0?:!_=_6C[0/[OZT6"Y/14'V@?W?UH^T#^[^M%@N3T5!
M]H']W]:/M _N_K18+D]%0?:!_=_6C[0/[OZT6"Y/14'V@?W?UH^T#^[^M%@N
M3T5!]H']W]:/M _N_K18+D]%0?:!_=_6C[0/[OZT6"Y/14'V@?W?UH^T#^[^
MM%@N3T5!]H']W]:/M _N_K18+D]%0?:!_=_6C[0/[OZT6"Y/14'V@?W?UH^T
M#^[^M%@N3T5!]H']W]:/M _N_K18+D]%0?:!_=_6C[0/[OZT6"Y/14'V@?W?
MUH^T#^[^M%@N3T5!]H']W]:/M _N_K18+D]%0?:!_=_6C[0/[OZT6"Y/14'V
M@?W?UH^T#^[^M%@N3T5!]H']W]:/M _N_K18+D]%0?:!_=_6C[0/[OZT6"Y/
M14'V@?W?UH^T#^[^M%@N))_Q\+^%7ZS6DW2!L=*L?;1_<_6AH1:HJK]M']S]
M:/MH_N?K2LQW+5%5?MH_N?K1]M']S]:+,+EJBJOVT?W/UH^VC^Y^M%F%RU15
M7[:/[GZT?;1_<_6BS"Y:HJK]M']S]:/MH_N?K19A<M455^VC^Y^M'VT?W/UH
MLPN6J*J_;1_<_6C[:/[GZT687+5%5?MH_N?K1]M']S]:+,+EJBJOVT?W/UH^
MVC^Y^M%F%RU157[:/[GZT?;1_<_6BS"Y:HJK]M']S]:/MH_N?K19A<M455^V
MC^Y^M'VT?W/UHLPN6J*J_;1_<_6C[:/[GZT687+5%5?MH_N?K1]M']S]:+,+
MEJBJOVT?W/UH^VC^Y^M%F%RU157[:/[GZT?;1_<_6BS"Y:HJK]M']S]:/MH_
MN?K19A<M455^VC^Y^M'VT?W/UHLPN6J*J_;1_<_6C[:/[GZT687+5%5?MH_N
M?K1]M']S]:+,+EJBJOVT?W/UH^VC^Y^M%F%RU157[:/[GZT?;1_<_6BS"Y:H
MJK]M']S]:/MH_N?K19A<M455^VC^Y^M'VT?W/UHLPN6J*J_;1_<_6C[:/[GZ
MT687+5%5?MH_N?K1]M']S]:+,+EJBJOVT?W/UH^VC^Y^M%F%RU157[:/[GZT
M?;1_<_6BS"Y:HJK]M']S]:/MH_N?K19A<M455^VC^Y^M'VT?W/UHLPN6J*J_
M;1_<_6C[:/[GZT687+5%5?MH_N?K1]M']S]:+,+EJBJOVT?W/UH^VC^Y^M%F
M%RU157[:/[GZT?;1_<_6BS"Y:JK9_P#'V_T/\Z/MH_N?K44,_E3&3;G.>,T[
M:"-:BJ7]HC_GF?SH_M$?\\S^=3RL9=HJE_:(_P">9_.C^T1_SS/YT<K NT52
M_M$?\\S^=']HC_GF?SHY6!=HJE_:(_YYG\Z/[1'_ #S/YT<K NT52_M$?\\S
M^=']HC_GF?SHY6!=HJE_:(_YYG\Z/[1'_/,_G1RL"[15+^T1_P \S^=']HC_
M )YG\Z.5@7:*I?VB/^>9_.C^T1_SS/YT<K NT52_M$?\\S^=']HC_GF?SHY6
M!=HJE_:(_P">9_.C^T1_SS/YT<K NT52_M$?\\S^=']HC_GF?SHY6!=HJE_:
M(_YYG\Z/[1'_ #S/YT<K NT52_M$?\\S^=']HC_GF?SHY6!=HJE_:(_YYG\Z
M/[1'_/,_G1RL"[15+^T1_P \S^=']HC_ )YG\Z.5@7:*I?VB/^>9_.C^T1_S
MS/YT<K NT52_M$?\\S^=']HC_GF?SHY6!=HJE_:(_P">9_.C^T1_SS/YT<K
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M;!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M9VMZ#IOB*Q%EJMN9[8.)-@E=,L,XR5()Z]*T:* :N8>A>$-!\,RS2Z1IZV\D
MRA7?S'<D#L"Q.!].O'H*W***&[[B22V"BBB@84444 %%%% !1110 4QHHV.6
MC4GU(I]% #/)B_YY)_WR*/)B_P">2?\ ?(I]% #/)B_YY)_WR*/)B_YY)_WR
M*?10 SR8O^>2?]\BCR8O^>2?]\BGT4 ,\F+_ )Y)_P!\BCR8O^>2?]\BGT4
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M ,\F+_GDG_?(H\F+_GDG_?(I]% #/)B_YY)_WR*/)B_YY)_WR*?10 SR8O\
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M^>2?]\BCR8O^>2?]\BGT4 ,\F+_GDG_?(H\F+_GDG_?(I]% #/)B_P">2?\
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M_,/_ 'V*/MEK_P _,/\ WV*.>/</:0[HEV+_ '1^5&Q?[H_*HOMEK_S\P_\
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MEV+_ '1^5&Q?[H_*HOMEK_S\P_\ ?8H^V6O_ #\P_P#?8HYX]P]I#NB78O\
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MV6O_ #\P_P#?8HYX]P]I#NB78O\ ='Y4;%_NC\JB^V6O_/S#_P!]BC[9:_\
M/S#_ -]BCGCW#VD.Z)=B_P!T?E1L7^Z/RJ+[9:_\_,/_ 'V*/MEK_P _,/\
MWV*.>/</:0[HEV+_ '1^5&Q?[H_*HOMEK_S\P_\ ?8H^V6O_ #\P_P#?8HYX
M]P]I#NB78O\ ='Y4;%_NC\JB^V6O_/S#_P!]BC[9:_\ /S#_ -]BCGCW#VD.
MZ)=B_P!T?E1L7^Z/RJ+[9:_\_,/_ 'V*/MEK_P _,/\ WV*.>/</:0[HEV+_
M '1^5&Q?[H_*HA=VQZ7$1_X&*>LL;?=D0_1J.9/J-3B]F.V+_='Y4;%_NC\J
M6BJ*$V+_ '1^5&Q?[H_*EHH 38O]T?E1L7^Z/RI:* *\@ G4 #'%7?+3^XOY
M52D_X^%_"K]# ;Y:?W%_*CRT_N+^5.HI -\M/[B_E1Y:?W%_*G44 -\M/[B_
ME1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44 -\M/[B_
ME1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44 -\M/[B_
ME1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44 -\M/[B_
ME1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44 -\M/[B_
ME1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44 -\M/[B_
ME1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44 -\M/[B_
ME1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44 -\M/[B_
ME1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44 -\M/[B_
ME1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44 -\M/[B_
ME1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44 -\M/[B_
ME1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44 -\M/[B_E5:T56NF!4$8/!'O5NJM
MG_Q]O]#_ #I] +WE1_\ /-/^^11Y4?\ SS3_ +Y%/HJ &>5'_P \T_[Y%'E1
M_P#/-/\ OD4^B@!GE1_\\T_[Y%'E1_\ /-/^^13Z* &>5'_SS3_OD4>5'_SS
M3_OD4^B@!GE1_P#/-/\ OD4>5'_SS3_OD4^B@!GE1_\ /-/^^11Y4?\ SS3_
M +Y%/HH 9Y4?_/-/^^11Y4?_ #S3_OD4^B@!GE1_\\T_[Y%'E1_\\T_[Y%/H
MH 9Y4?\ SS3_ +Y%'E1_\\T_[Y%/HH 9Y4?_ #S3_OD4>5'_ ,\T_P"^13Z*
M &>5'_SS3_OD4>5'_P \T_[Y%/HH 9Y4?_/-/^^11Y4?_/-/^^13Z* &>5'_
M ,\T_P"^11Y4?_/-/^^13Z* &>5'_P \T_[Y%'E1_P#/-/\ OD4^B@!GE1_\
M\T_[Y%'E1_\ /-/^^13Z* &>5'_SS3_OD4>5'_SS3_OD4^B@!GE1_P#/-/\
MOD4>5'_SS3_OD4^B@!GE1_\ /-/^^11Y4?\ SS3_ +Y%/HH 9Y4?_/-/^^11
MY4?_ #S3_OD4^B@!GE1_\\T_[Y%'E1_\\T_[Y%/HH 9Y4?\ SS3_ +Y%'E1_
M\\T_[Y%/HH 9Y4?_ #S3_OD4>5'_ ,\T_P"^13Z* &>5'_SS3_OD4>5'_P \
MT_[Y%/HH 9Y4?_/-/^^11Y4?_/-/^^13Z* &>5'_ ,\T_P"^11Y4?_/-/^^1
M3Z* &>5'_P \T_[Y%'E1_P#/-/\ OD4^B@!GE1_\\T_[Y%'E1_\ /-/^^13Z
M* &>5'_SS3_OD4>5'_SS3_OD4^B@!GE1_P#/-/\ OD4>5'_SS3_OD4^B@!GE
M1_\ /-/^^11Y4?\ SS3_ +Y%/HH 9Y4?_/-/^^11Y4?_ #S3_OD4^B@!GE1_
M\\T_[Y%'E1_\\T_[Y%/HH 9Y4?\ SS3_ +Y%'E1_\\T_[Y%/HH 9Y4?_ #S3
M_OD4>5'_ ,\T_P"^13Z* *-F -18 <#=6K65:?\ (2?ZM6K3EN""BBBI&%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 4M8_Y E__ ->TG_H)KQCX
M+_ZS6OI!_P"SU[/K'_($O_\ KVD_]!->,?!?_6:U](/_ &>M8?"S&?QQ/6**
M**#0*J:G_P @Z7\/YBK=5-3_ .0=+^'\Q6=;^'+T9CB/X,_1_D<[1117AGR@
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 2)<31_<E<?1JM1:
MM=Q=7#CT851HJXU)1V9K"M4A\,FC=@UV-N)HRI]5Y%:4-S#<#,4BM]#7(4JN
MR,&5BI'<&NF&,FOBU.ZEF=6.D]3LZ*P+76I8\+.-Z_WAUK:@N(KA \3AA_*N
MVG6A4V/6H8JE6^%Z]ADG_'POX5?JA)_Q\+^%7ZV9TA1112 **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *JV?_ !]O]#_.K55;
M/_C[?Z'^='0#1HHHJ0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** *-I_R$G^K5JUE6G_(2?ZM6K3EN""BBBI&%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!2,RHI9B H&22> *6L/QEJ7]D^#=6O00'2V94).,,WRK^I%"5Q-V5SP#1O\
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M5D4>FY<'_P!!K>^+6HBP^'UX@.'NY([=3]3N/_CJM6'\#+9D\/:G=%<++=!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** *6L?\ ($O_ /KVD_\ 037C'P7_ -9K7T@_]GKV?6/^0)?_ /7M
M)_Z":\8^"_\ K-:^D'_L]:P^%F,_CB>L4444&@54U/\ Y!TOX?S%6ZJ:G_R#
MI?P_F*SK?PY>C,<1_!GZ/\CG:***\,^4"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "I(9I('#Q.5;VJ.BFFUJAIM.Z-ZUU%+J
M1 _RR<?0UNUP@.#D5T&E:OYFVWN6^;HKGO[&O0H8KF]V9[>#S#F?)5W[FW11
M17:>L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %5;/_C[?Z'^=6JJV?\ Q]O]#_.CH!HT445(!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% %&T_Y"3_ %:M6LJT_P"0D_U:M6G+
M<$%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O-_C5J)M?!D5FI.;RY56&>JJ"W\PM>D5X7\<M0
M$VOZ;IX)/V:W:0\="[8Z_1!5TU>1G5=H,T_@KX9M);*;Q#<P*]RLQAMF;G8
M!E@/7G&?8U[#7+?#G3QIO@#2(\',L/VALG.?,.[^1%=32F[R'3C:*/G'XD>&
MI?"'BY;W3R\5K<O]IMG3(,3@Y*@^QY'H"*]Q\'^)(?%?ARWU*/:LI_=W$:YQ
M'* -P^G((]B*A\<>&8_%7ABYL=J_:D'FVKGC;(.@SZ'[I^N>U>,?##Q.WA7Q
M4^GWY\JTO'$$X? \J0$A6)/0 D@_7/:M/CCYHR_AS\F?15?,6X^"OB>7N5<Q
MV-_N;:,,T1.<@9[H<]>]?3M>5?%GP'/JP'B#2HC)=11[;J%>LB#HRCN0.H[C
M&.G,TVD[,JM%M770]3CDCFB26)U>-U#*ZG(8'H0>XIU?.7@_XH:KX4A&GW$(
MOK!#A8I&*O%[*W/'L0?;%=Y_PO+0OLV[^S-2\_'W,)MS_O;L_I0Z<D.-:+6I
MZ@S*BEF("@9))X KYK^(WB?_ (2[Q6%L09+2V_T>V" DRG/+ =>3@#V J?Q3
M\3=<\6I_9UM#]CM)B$-O Q=Y23T+8!.<XP ,UVOPQ^&L^E7$>NZY%Y=THS;6
MK8)CR/OMZ-Z#MWYZ5%<FK,Y2]J^6.QWG@[0%\,^%K+3#CSD3=.0<@R-RV/;/
M ]@*\0^,%_\ ;/B!/$#D6D$< /'IO/ZN:^C*^8[5O^$I^*L<@.Z*[U3S/^V8
M?/8?W12I[ML=;2*BCZ,T+3QI.@:?IX!'V:W2,Y.>0H!Y^M:%%%9'0M#Y_P#B
MGX;;PMXG@UK2V-O#=N9$\H[?)F7!./3/WOS]*];\"^*%\5^&(+YL"ZC_ '5R
MH[2 <GV!X/XX[4WX@: ?$?@V^LXHA)=1@3VX[[UYP/<C<O\ P*O(O@[XA_LK
MQ4VFS2!;;45V8/:5>4/XY8?B/2MOBAYHY_@J>3/H2BBBL3H*FJ:E;:/I=UJ-
MV^VWMHS(YXR0.PSW/0#N2*^:K>RUGXE>,;EX0@N;@M*[2,WEPH!P"<$@=%''
M<5V_QJ\4[YX?#5LYVQ[9KO!ZL>40_0?-^(]*ZSX4>%?[ \,+>W"%;[40)7!'
M*)_ OY')^N.U;1]R-^ISR_>3Y>B//O\ A1_B;_G^TG_O[)_\;H_X4?XF_P"?
M[2?^_LG_ ,;KWZBI]K(KV$#Y<TFWG\+?$>QMKIHS+9ZA''*R'*D;@"1G'8GK
MBOJ.OF_XM6@LOB'=R1DKYZ1S#GH=H!Q^*U]#65['=:5;WY=!%+ LQ?/R@%<Y
MSZ4ZFJ3%1T<HGS]\2)7UWXIRV,19]KPV<8R>IQD#/3YF;^=?0]O!%:VT5O"@
M2*) B*.R@8 _*OG7P,I\1_%J&]F)(:YEO&(..1N9?PW;>/2OHZBII9!1UO(S
M]>U#^R?#^HZAN -M;22KDCE@I('/J<"O$/@KIYO/&<]])N(M+9F#9_C8A1GU
MX+UW_P 8]2^Q>!)+8,H>]G2+!/.T'>2/^^0#]:SO@?IOV?PU?:@<;KJX"  <
M[4''ZLW^31'2#82]ZHEV-_XIZ@-/^'NHX.'N-D">^YAG_P =#5S'P+T\QZ3J
MNHLO^NF2%2?1!DX_[['Y>U'QUN'71M(MA]R2X>0\]U7 _P#0C67\._B3HOA_
MP]:Z+=VE]]I\YOWD**R-N;@]01Z8P>G7L&D_9Z"<E[77H>@_$;Q%/X9\'W%W
M:OLNY76"%_[K-DD_4 &O'/!/P[O?&ZSZC<7WV>T68J\K#S))7ZM@9]QR>Y[\
MUZO\6-&N-8\#S?9E#O9RK=%><E55@V/?#$_A7EWP^^)7_"(6LFG7EFUQ8R2^
M:&B($D9. >#PPP!QD?6B%^3W=Q5+>T7-L>@6WP3\-0@&>YU&=N^954?D%S^M
M<+\4-!\/>%A8Z9I%MB[DS-/(\I=PH&%&">,DL>W0?AT^K?'.R6W(T?2KB2<C
MAKPJBJ?7"DEOID?6O)_$,NLW>I#4-<6875[&)U:5=I:,DJI [+\IQ["J@I7O
M(FHX6M%'T'\+=/.G_#W30WWYPT[8.1\S$C_QW;7CL;K!\:V>4[%&NMDMQC,Q
MQ_.OH/05C3P[IB1 "-;2(*!TQL&*\4^+WA.ZT[7Y/$-K&S6-V5,CK_RQEQCG
MT!P"#ZDCTJ8.\GYEU(V@FNA[W5+5]4M]%TBZU*Z.(;:,R-[^@'N3@?C7BVB_
M&W4[&QCM]2TV/4'C&T3"8Q,PXQNX8$]>>/\ ' \3^+/$?C>PFNKB-8=*LF4M
M'%\L8=B%&23\S<].PR<=:2I.^HW7C;3<O_#%)=?^*1U*=0[KY][+P,;FR,X_
MWG'2NT^.;,/#.FKD[3>9(SQG8W^)K+^!.GY?6-28'@1P(>W=F_DE=Y\1/#DG
MB;P?<V=LNZ[B87%NI.-SKGCZE2P'N13D[3%"+=)^9E_!TQGX?P!""PN)0_L<
M_P"&*[ZOFOP/X]O? ]S<6D]JT]E(Y,MNQV/'(."1GH> "#Z#I7?:A\<])2V;
M^S=*O9;@C@7.R-0?7Y2Q/TXI3A+FT'3JQ4;,N?&?7H[#PJFDHX^TZA(,J.HC
M4AB?S"CWY]#4'P/TUK?PW?Z@Z;3=W 53_>5!_BS5YE86&O\ Q,\5N[R&25R#
M-.P_=V\?8 =AZ#O^9KZ/TO3K70=$M["$K';6D07<QQP!RQ^O)-$O=CRBA><^
M?H>!_$B5]=^*<MC$6?:\-G&,GJ<9 ST^9F_G7T/;P16MM%;PH$BB0(BCLH&
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% %+6/\ D"7_ /U[2?\ H)KQCX+_ .LUKZ0?^SU[/K'_ "!+_P#Z]I/_
M $$UXQ\%_P#6:U](/_9ZUA\+,9_'$]8HHHH- JIJ?_(.E_#^8JW534_^0=+^
M'\Q6=;^'+T9CB/X,_1_D<[1117AGR@4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% '1:/JGF@6TY_>#[C>OM6S7"J
MS(P920P.0176Z9?"]M\G'FKPX_K7I86OS>Y+<][+\7SKV4]^A=HHHKL/4"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *JV?_'V_T/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.@1KB9I"HV]!DG%>G4I*SL.,N97"BBBD4%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %+6/\ D"7_ /U[2?\
MH)KQCX+_ .LUKZ0?^SU[/K'_ "!+_P#Z]I/_ $$UXQ\%_P#6:U](/_9ZUA\+
M,9_'$]8HHHH- JIJ?_(.E_#^8JW534_^0=+^'\Q6=;^'+T9CB/X,_1_D<[11
M17AGR@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !5FPNS9W2RC[O1AZBJU%5%N+NBH2<)*4=T=TC*Z!U.589!I:
MR-!N_-MV@8_-'T_W:UZ]FG-3BI(^KH555IJ:ZA1115FH4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %5;/_C[?Z'^=6JJV?\ Q]O]#_.CH!HT
M445(!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M%&T_Y"3_ %:M6LJT_P"0D_U:M6G+<$%%%%2,**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ!\K$ X)!Y]*;X2\/6OACP[;:=:OYF!OEES_ *QR!EA[>GL!61\5O^2:ZO\
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MQVC\%VC\*52"2NBJ51R?+(3Q+\3M%\+:P^F7UK?R3JBN6@C0K@].K@_I2?\
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M1@O4@#/%?+W@CQ1-X4\26]X)'%F[!+N,='C/4X[D9R/<>YKZ8UG_ ) 6H?\
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M*!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% %K3KC[-?129^7.&^AKL:X2NPTV<W&GQ.3EL8/U'%=^#GO$]
MG*JOQ4WZENBBBN\]D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "JMG_Q]O\ 0_SJU56S_P"/M_H?YT= -&BBBI **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH HVG_(2?ZM6K65:?\ (2?ZM6K3
MEN""BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"O>+^5=E\"O^0/J_\ U\)_Z":)?PPC_&/6:***YSK"N-^*W_)-=7_[8_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KH?#LNZ":+^ZP/Y__JKGJU_#[[;UT_O)_*M\-*U5'9@)
M\N(CYG24445ZY],%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!56S_P"/M_H?YU:JK9_\?;_0_P Z.@&C1114@%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 4;3_D)/]6K5K*M/^0D_U:M6G+<$
M%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JGJR/)HU]'&K,[6
M\@55&225/ %7** /D_\ X1'Q-_T+NK?^ 4G_ ,31_P (CXF_Z%W5O_ *3_XF
MOK"BMO;/L<_U==SY0'@_Q,S #P[JV3QS9R#^E:>F?#3Q9J=PL0TF6V7.&ENO
MW:K[\\G\ :^G**/;,%AX]SF/ _@VV\&Z.ULD@FNYR'N9]N-Q'0#_ &1DX^I/
M>HOB79W-_P##[5+:SMYKBX?RML4*%V;$J$X Y/ )KK**RYG>YMRKEY4?,OA;
MPMXAM_%VBSSZ#JD44=_ [R/9R*JJ)%)))'  KZ!\7?\ (E:]_P!@ZX_]%M6S
M6-XN_P"1*U[_ +!UQ_Z+:J<^9HB-/DBSY/KM=?\ "'B;P'J$L]G+>"TYV7UF
MS)E?1MO*GU!X]S7%5]DUM4GRV.>E34[GR-#;:OX@O_W45YJ%W*W+8:1F/4Y/
MZY->\?#3X?-X4AEU#4MC:I.NS:IR($ST![D\9/L .^?0:*RE4;5C>%%1=WJ,
MFACN()()D#Q2*4=3T8$8(KP/QE\)=3TJZDNM"A>^T]B2L*9::+OC'\0]",GU
M'<^_T5,9..Q<X*:U/DF+4]<T59+.*^U&P5OOP)*\0/U7(J]H?@WQ#XGNA]DL
M9BCO\]U."L:GN2QZGV&3[5]445I[7LC)8?NSG/!OA"S\'Z/]DMV,MQ+AKB<\
M>8WL.P'85E?%BPO-1\$/;V-I/=3&XC/EP1EVP,Y.!S7<45FI.]S9Q7+RGS?X
M'\,Z_:>-](N+G0]2AACN 7DDM)%51ZDD8%>[>*_#T7BCP[=:5*_EF0!HY,9V
M.#D''^>#6U13E-MW)A344T?)FM^&M7\.W<EOJ5E+%M.!+M)C<9ZJW0BKNG6W
MBWQ5&FFVLFIWUMD$1O,YA7'<[CM&*^IJ*OVOD9_5U?<^:_$WPTUO0;JU@M;2
M[U,20!Y9;6W9T5]S J, GH%ZXSFO3?@\FI6/AZ[TS4].O;1XK@RQ&XMVC#(P
M' ) R003^(KT>BI=1M69<:2C*Z/!?BMX?UK4?'$UQ8Z1?W4!@C D@MG=20.1
MD#%=9\&-*U'2]*U1-0L+JT9YT*+<0M&6&WJ,@9KTZBDYWCR@J24N8****@U"
MN3^)=G<W_P /M4MK.WFN+A_*VQ0H79L2H3@#D\ FNLHIIV=Q-75CY/\ ^$1\
M3?\ 0NZM_P" 4G_Q-'_"(^)O^A=U;_P"D_\ B:^L**U]L^QA]77<^5K;P+XJ
MNFVQ^']04_\ 36 QC\VQ7H_@WX-R6]Q!J'B.1"48.ME$=PS_ +;=.#V&1QUK
MV*BI=5LJ-"*=PKF_&WA&W\8:&;-W$5S&=]O,02$;W'<$<?KVKI**A.VJ-6DU
M9GREK/A37_#5TPOK"XB\LY6XC!:,XZ$../?U'?%5I+W7->,-I)<ZCJ.P@10M
M(\V">/E7GGZ5];45K[;R,/J_9GC?PU^&%S;7L6N:_"T+P,'M;1OO;AR'?TQV
M'7(YZ<^K:S_R M0_Z]I/_035ZJ.L_P#("U#_ *]I/_036;DY.[-8P48V1\B5
MV>J^#?$OA+R=5TY[HVLL0=+RS9E9 P!(?;RO7&>A_2N,KZ[T;_D!:?\ ]>T?
M_H(K>I+EL<M*"G<^4U35O$%]P+S4;M\#)W2N?QY->W_#'X=2>'2=8U95_M*1
M-L4(.?(4]<G^\>GL/KQZ7164JC:LC>%%1=WJ<G\2[.YO_A]JEM9V\UQ</Y6V
M*%"[-B5"< <G@$UXCX6\+>(;?Q=HL\^@ZI%%'?P.\CV<BJJB12221P *^FJ*
M49\JL.=)2E<****@U/ O''PIU'3;Z6]T&U>[T^1BPMX06D@]L=6'7!&?>N$@
MU36=(22VM[^_LE?[\4<SQANO4 C/>OKBBM55=K,PE03=T['R[X=\":_XGO$$
M-G-#;,V9+N="J*.Y!/WC[#].M?1_A_0K/PWHEOI=B#Y4(.6;[SL3DL?<G_#M
M6G14SFY%TZ:@>6_$KX:3:]=-K6C"/[9Y>)[8\><1T8'^]CCGK@?CXY)!KOAF
M[.]+_3)\XW#?$3CG@\9]:^M:*<:C2LR9T5)W6A\DRW&N>(9D$LVHZG*#M0.S
MS'Z#KZ_K7JWPU^&-W8W\.NZ]'Y,D6'MK0D%@V.&?TQV'7/7&,'V"BG*JVK((
MT4G=NYD^)?#]KXGT&XTN[^591E) N3&XZ,/\\@D=Z^=/$7P_\0^')I//L9+B
MU7D75NA>/&< G'W?H:^H:*F,W$J=)3/DO_A(O$'D_8_[9U/RON^3]JDV_3;F
MM/PW\/\ 7_$ETJ0V4MM;!@)+FX0HBCOC/WC[#]*^H:*OVO9&:H=V9N@:):^'
M=$MM+LP?)@7&YL9<GDL?<FO%_BMX?UK4?'$UQ8Z1?W4!@C D@MG=20.1D#%>
M]45G&33N:S@I*QYC\&-*U'2]*U1-0L+JT9YT*+<0M&6&WJ,@9KN?$7A^R\3Z
M--IE^K>4_P RNIPT;#HP]Q6K10Y7=QQBE'E/F/Q'\./$7AV=]UF]Y:CE;FU0
MNN/]H=5/UX]S6(VLZW-;#3GU+4)+<#;]F,[E0/3;G'K7UO16BJ]T8O#KHSYN
M\)_##6_$-S')=V\NGZ=PSS3*59U]$4\DGU/'UZ'Z&TS3;72--M]/LHO+MH$V
M(N<X'U[GO5NBHE-R-(4U#8\1^,6A:OJ?BZTGT_2KZ[B6P1#);V[R*&\R0XR
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M534_^0=+^'\Q6=;^'+T9CB/X,_1_D<[1117AGR@4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5HZ(V-4C'
MJ&'Z5G5?T;_D+0_\"_\ 036E+^)'U-\-_&AZK\SK****]H^K"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ JK9_\ 'V_T/\ZM55L_^/M_H?YT
M= -&BBBI **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH HVG_(2?ZM6K65:?\A)_JU:M.6X(****D84444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 52U>P_M71;_3O-\K[7;R0>
M9MW;-RE<XR,XSTJ[10!XW_PH;_J9?_)'_P"V5[)1152DY;DQA&.P4445)044
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %07MO]KL;BVW;/.B:/=C.,C&<5/10!XW_ ,*&_P"IE_\ )'_[97KM
ME;_9+&WMMV_R8ECW8QG QG%3T53DY;D1A&.P4445)84444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!2UC_D"7_\
MU[2?^@FO&/@O_K-:^D'_ +/7L^L?\@2__P"O:3_T$UXQ\%_]9K7T@_\ 9ZUA
M\+,9_'$]8HHHH- JIJ?_ "#I?P_F*MU4U/\ Y!TOX?S%9UOX<O1F.(_@S]'^
M1SM%%%>&?*!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !6EH:YU-3_ '5)_2LVMGP['FYFD_NJ!^?_ .JM
MJ"O41TX./-7BO,Z*BBBO8/J0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *JV?_'V_P!#_.K55;/_ (^W^A_G1T T:***D HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"C:?\A)_JU:M95I_P A
M)_JU:M.6X(****D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M1O\ 6M*TN1(]0U.RM'<95;B=8RP]0"1FJG_"7>&?^ABTG_P-C_\ BJXKXB_#
MW7?&&O07=E=6$=K#;B)4G=U;=DDGA2.X_*N/_P"%'^)O^?[2?^_LG_QNM%&-
MM68RG-/1'LO_  EWAG_H8M)_\#8__BJ/^$N\,_\ 0Q:3_P"!L?\ \57BMS\&
M-?L[66YN=3T:*")2[R//( H'4D^77%Z3H=[KNLIIFF(+B9V(#KD(%'5R2,A?
MJ/PSQ5*G%]275FM&CZUCDCFB26)U>-U#*ZG(8'H0>XKG]9\=>&_#]^;'5-2$
M%R%#E/)D? /3E5(K>MX$M;:*WCSLB0(N3S@# KYB\;3R:Y\0M9>'#-Y[QKT
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH I:Q_P @2_\ ^O:3_P!!->,?!?\ UFM?2#_V>O9]8_Y E_\
M]>TG_H)KQCX+_P"LUKZ0?^SUK#X68S^.)ZQ1110:!534_P#D'2_A_,5;JIJ?
M_(.E_#^8K.M_#EZ,QQ'\&?H_R.=HHHKPSY0**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z7P_%LLGD(^^
MW'T'^37-@$D #)/2NSLX!;6D40_A7GZUUX.-Y\W8]/*Z?-5<^Q/1117IGOA1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 55L_^/M_H?YU:JK9
M_P#'V_T/\Z.@&C1114@%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 4;3_D)/\ 5JU:RK3_ )"3_5JU:<MP04445(PHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6:O4JY?X=6']G?#_ $>+&#)!YY/'/F$O_)A745E-WDS>FK12"BBBI+"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** *6L?\ ($O_ /KVD_\ 037C'P7_ -9K7T@_]GKV
M?6/^0)?_ /7M)_Z":\8^"_\ K-:^D'_L]:P^%F,_CB>L4444&@54U/\ Y!TO
MX?S%6ZJ:G_R#I?P_F*SK?PY>C,<1_!GZ/\CG:***\,^4"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH HVG_(2?ZM6K65:?\A)_JU:M.6X(****D84444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,8^;:-QQ]<UK+2"1A#6JV>(:^JZ-\=4D+A8SJ-O,S'C"OM+=/JU>C?%?Q/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "M'2+'[7=;W'[J/D^Y["J=O
M]S.L48^9C^5=A:VR6ENL2#@=3ZFNK#4>>5WLCT,!A?:SYI?"B:BBBO4/H@HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JMG_P ?;_0_
MSJU56S_X^W^A_G1T T:***D HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@"C:?\A)_JU:M95I_R$G^K5JTY;@@HHHJ1A1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX:;IZ6,/.#*WWF_I5ZBBO5C%15D?24Z<:<5&.R"BBBJ+"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *JV?_ !]O]#_.K55;/_C[?Z'^
M='0#1HHHJ0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** *-I_R$G^K5JUE6G_(2?ZM6K3EN""BBBI&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% %+6/^0)?_P#7M)_Z":\8^"_^LUKZ0?\
ML]>SZQ_R!+__ *]I/_037C'P7_UFM?2#_P!GK6'PLQG\<3UBBBB@T"JFI_\
M(.E_#^8JW534_P#D'2_A_,5G6_AR]&8XC^#/T?Y'.T445X9\H%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 445:M]/N;D_)&0O]YN!5
M1BY.R1<(2F[15RK5VSTV:[(.-D?]XC^5:MKHT,)#2GS''KTK2  &!TKMI8-[
MS/5P^6-^]6^XHQ6L5JZ)&/3)/4UJU0D_X^%_"K]=]DDDCV(Q45RQ5D%%%%!0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 55L_
M^/M_H?YU:JK9_P#'V_T/\Z.@&C1114@%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 4;3_D)/\ 5JU:RK3_ )"3_5JU:<MP0444
M5(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY?\ O@T?9;C_ )]Y?^^#73T4?48]P_LJ'\S.8^RW'_/O+_WP:/LMQ_S[R_\
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MY?\ O@T?9;C_ )]Y?^^#73T4?48]P_LJ'\S.8^RW'_/O+_WP:/LMQ_S[R_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH HVG_ "$G^K5J
MUE6G_(2?ZM6K3EN""BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% %+6/^0)?_ /7M)_Z":\8^"_\ K-:^D'_L]>SZQ_R!+_\ Z]I/
M_037C'P7_P!9K7T@_P#9ZUA\+,9_'$]8HHHH- HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDGW1]:?3)/NCZT 6(_P#5
MK]*=38_]6OTIU(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 5Y/^/A?PJ_5"3_CX7\*OT, HHHI %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %5;/_C[?Z'^=6JJV?_'V
M_P!#_.CH!HT445(!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% %&T_Y"3_5JU:RK3_D)/\ 5JU:<MP04445(PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BHYW9(79!E@
M.!BL_P"W7?\ SR'_ 'R::5PN:E%9?VZ[_P">0_[Y-'VZ[_YY#_ODT^5BN:E%
M9?VZ[_YY#_ODT?;KO_GD/^^31RL+FI167]NN_P#GD/\ ODT?;KO_ )Y#_ODT
M<K"YJ45E_;KO_GD/^^31]NN_^>0_[Y-'*PN:E%9?VZ[_ .>0_P"^31]NN_\
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M<K"YJ45E_;KO_GD/^^31]NN_^>0_[Y-'*PN:E%9?VZ[_ .>0_P"^31]NN_\
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M<K"YJ45E_;KO_GD/^^31]NN_^>0_[Y-'*PN:E%9?VZ[_ .>0_P"^31]NN_\
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M<K"YJ45E_;KO_GD/^^31]NN_^>0_[Y-'*PN:E%9?VZ[_ .>0_P"^31]NN_\
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M<K"YJ45E_;KO_GD/^^31]NN_^>0_[Y-'*PN:E%9?VZ[_ .>0_P"^31]NN_\
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M<K"YJ45E_;KO_GD/^^31]NN_^>0_[Y-'*PN:E%9?VZ[_ .>0_P"^31]NN_\
MGD/^^31RL+FI167]NN_^>0_[Y-'VZ[_YY#_ODT<K"YJ45E_;KO\ YY#_ +Y-
M'VZ[_P">0_[Y-'*PN:E%9?VZ[_YY#_ODT?;KO_GD/^^31RL+FI167]NN_P#G
MD/\ ODT?;KO_ )Y#_ODT<K"YJ45E_;KO_GD/^^31]NN_^>0_[Y-'*PN:E%9?
MVZ[_ .>0_P"^31]NN_\ GD/^^31RL+FI167]NN_^>0_[Y-'VZ[_YY#_ODT<K
M"YJ45E_;KO\ YY#_ +Y-'VZ[_P">0_[Y-'*PN:E%9?VZ[_YY#_ODT?;KO_GD
M/^^31RL+FI167]NN_P#GD/\ ODT?;KO_ )Y#_ODT<K"YJ45E_;KO_GD/^^31
M]NN_^>0_[Y-'*PN:E%9?VZ[_ .>0_P"^31]NN_\ GD/^^31RL+FI167]NN_^
M>0_[Y-'VZ[_YY#_ODT<K"YJ45E_;KO\ YY#_ +Y-'VZ[_P">0_[Y-'*PN3ZQ
M_P @2_\ ^O:3_P!!->,?!?\ UFM?2#_V>O6KJYGGM)H94"Q21LKG:1@$8/-<
MGX3\/Z+H#79T>[:X,VSS=TRR;<9Q]T<=35QT31G)7DF=514>]O2C>WI3+)**
MCWMZ4;V]* )**CWMZ4;V]* )**CWMZ4;V]* )**CWMZ4;V]* )**CWMZ4;V]
M* )**CWMZ4;V]* )**CWMZ4;V]* )**CWMZ4;V]* )**CWMZ4;V]* )**CWM
MZ4;V]* )**CWMZ4;V]* )**CWMZ4;V]* )**CWMZ4;V]* )**CWMZ4;V]* )
M**CWMZ4;V]* )**CWMZ4;V]* )**CWMZ4;V]* )**CWMZ4;V]* )**CWMZ4;
MV]* )**CWMZ4;V]* )**CWMZ4;V]* )**CWMZ4;V]* )**CWMZ4;V]* )**C
MWMZ4;V]* )**CWMZ4;V]* )**CWMZ4;V]* )**CWMZ4;V]* )**CWMZ4;V]*
M )**CWMZ4;V]* )**CWMZ4;V]* )**CWMZ4;V]* )**CWMZ4;V]* )**CWMZ
M4;V]* )**CWMZ4;V]* )**CWMZ4;V]* )**CWMZ4;V]* )**CWMZ4;V]* )*
M*CWMZ4;V]* )**CWMZ4;V]* )**CWMZ4;V]* )**CWMZ4;V]* )**CWMZ4;V
M]* )**CWMZ4;V]* )**CWMZ4;V]* )**CWMZ4;V]* )*9)]T?6DWMZ4C,2.:
M +4?^K7Z4ZJRRN%  X^E+YTG]T?E4V"Y8HJOYTG]T?E1YTG]T?E18=RQ15?S
MI/[H_*CSI/[H_*BP7+%%5_.D_NC\J/.D_NC\J+!<L457\Z3^Z/RH\Z3^Z/RH
ML%RQ15?SI/[H_*CSI/[H_*BP7+%%5_.D_NC\J/.D_NC\J+!<L457\Z3^Z/RH
M\Z3^Z/RHL%RQ15?SI/[H_*CSI/[H_*BP7+%%5_.D_NC\J/.D_NC\J+!<L457
M\Z3^Z/RH\Z3^Z/RHL%RQ15?SI/[H_*CSI/[H_*BP7+%%5_.D_NC\J/.D_NC\
MJ+!<L457\Z3^Z/RH\Z3^Z/RHL%RQ15?SI/[H_*CSI/[H_*BP7+%%5_.D_NC\
MJ/.D_NC\J+!<L457\Z3^Z/RH\Z3^Z/RHL%RQ15?SI/[H_*CSI/[H_*BP7+%%
M5_.D_NC\J/.D_NC\J+!<L457\Z3^Z/RH\Z3^Z/RHL%RQ15?SI/[H_*CSI/[H
M_*BP7+%%5_.D_NC\J/.D_NC\J+!<L457\Z3^Z/RH\Z3^Z/RHL%RQ15?SI/[H
M_*CSI/[H_*BP7+%%5_.D_NC\J/.D_NC\J+!<L457\Z3^Z/RH\Z3^Z/RHL%RQ
M15?SI/[H_*CSI/[H_*BP7+%%5_.D_NC\J/.D_NC\J+!<L457\Z3^Z/RH\Z3^
MZ/RHL%RQ15?SI/[H_*CSI/[H_*BP7+%%5_.D_NC\J/.D_NC\J+!<L457\Z3^
MZ/RH\Z3^Z/RHL%RQ15?SI/[H_*CSI/[H_*BP7+%%5_.D_NC\J/.D_NC\J+!<
ML457\Z3^Z/RH\Z3^Z/RHL%PD_P"/A?PJ_6:SL7#$<U-]HF_N#\C3:$7**I_:
M)O[@_(T?:)O[@_(TK#N7**I_:)O[@_(T?:)O[@_(T6"Y<HJG]HF_N#\C1]HF
M_N#\C18+ERBJ?VB;^X/R-'VB;^X/R-%@N7**I_:)O[@_(T?:)O[@_(T6"Y<H
MJG]HF_N#\C1]HF_N#\C18+ERBJ?VB;^X/R-'VB;^X/R-%@N7**I_:)O[@_(T
M?:)O[@_(T6"Y<HJG]HF_N#\C1]HF_N#\C18+ERBJ?VB;^X/R-'VB;^X/R-%@
MN7**I_:)O[@_(T?:)O[@_(T6"Y<HJG]HF_N#\C1]HF_N#\C18+ERBJ?VB;^X
M/R-'VB;^X/R-%@N7**I_:)O[@_(T?:)O[@_(T6"Y<HJG]HF_N#\C1]HF_N#\
MC18+ERBJ?VB;^X/R-'VB;^X/R-%@N7**I_:)O[@_(T?:)O[@_(T6"Y<HJG]H
MF_N#\C1]HF_N#\C18+ERBJ?VB;^X/R-'VB;^X/R-%@N7**I_:)O[@_(T?:)O
M[@_(T6"Y<HJG]HF_N#\C1]HF_N#\C18+ERBJ?VB;^X/R-'VB;^X/R-%@N7**
MI_:)O[@_(T?:)O[@_(T6"Y<HJG]HF_N#\C1]HF_N#\C18+ERBJ?VB;^X/R-'
MVB;^X/R-%@N7**I_:)O[@_(T?:)O[@_(T6"Y<HJG]HF_N#\C1]HF_N#\C18+
MERBJ?VB;^X/R-'VB;^X/R-%@N7**I_:)O[@_(T?:)O[@_(T6"Y<HJG]HF_N#
M\C1]HF_N#\C18+ERBJ?VB;^X/R-'VB;^X/R-%@N7**I_:)O[@_(T?:)O[@_(
MT6"Y<HJG]HF_N#\C1]HF_N#\C18+ERBJ?VB;^X/R-'VB;^X/R-%@N7*JV?\
MQ]O]#_.F_:)O[@_(U'%*\<I9!ECVQ181KT5G_:[G_GF/^^31]KN?^>8_[Y-3
MRL=S0HK/^UW/_/,?]\FC[7<_\\Q_WR:.5A<T**S_ +7<_P#/,?\ ?)H^UW/_
M #S'_?)HY6%S0HK/^UW/_/,?]\FC[7<_\\Q_WR:.5A<T**S_ +7<_P#/,?\
M?)H^UW/_ #S'_?)HY6%S0HK/^UW/_/,?]\FC[7<_\\Q_WR:.5A<T**S_ +7<
M_P#/,?\ ?)H^UW/_ #S'_?)HY6%S0HK/^UW/_/,?]\FC[7<_\\Q_WR:.5A<T
M**S_ +7<_P#/,?\ ?)H^UW/_ #S'_?)HY6%S0HK/^UW/_/,?]\FC[7<_\\Q_
MWR:.5A<T**S_ +7<_P#/,?\ ?)H^UW/_ #S'_?)HY6%S0HK/^UW/_/,?]\FC
M[7<_\\Q_WR:.5A<T**S_ +7<_P#/,?\ ?)H^UW/_ #S'_?)HY6%S0HK/^UW/
M_/,?]\FC[7<_\\Q_WR:.5A<T**S_ +7<_P#/,?\ ?)H^UW/_ #S'_?)HY6%S
M0HK/^UW/_/,?]\FC[7<_\\Q_WR:.5A<T**S_ +7<_P#/,?\ ?)H^UW/_ #S'
M_?)HY6%S0HK/^UW/_/,?]\FC[7<_\\Q_WR:.5A<T**S_ +7<_P#/,?\ ?)H^
MUW/_ #S'_?)HY6%S0HK/^UW/_/,?]\FC[7<_\\Q_WR:.5A<T**S_ +7<_P#/
M,?\ ?)H^UW/_ #S'_?)HY6%S0HK/^UW/_/,?]\FC[7<_\\Q_WR:.5A<T**S_
M +7<_P#/,?\ ?)H^UW/_ #S'_?)HY6%S0HK/^UW/_/,?]\FC[7<_\\Q_WR:.
M5A<T**S_ +7<_P#/,?\ ?)H^UW/_ #S'_?)HY6%S0HK/^UW/_/,?]\FC[7<_
M\\Q_WR:.5A<T**S_ +7<_P#/,?\ ?)H^UW/_ #S'_?)HY6%S0HK/^UW/_/,?
M]\FC[7<_\\Q_WR:.5A<T**S_ +7<_P#/,?\ ?)H^UW/_ #S'_?)HY6%S0HK/
M^UW/_/,?]\FC[7<_\\Q_WR:.5A<T**S_ +7<_P#/,?\ ?)H^UW/_ #S'_?)H
MY6%S0HK/^UW/_/,?]\FC[7<_\\Q_WR:.5A<T**S_ +7<_P#/,?\ ?)H^UW/_
M #S'_?)HY6%S0HK/^UW/_/,?]\FC[7<_\\Q_WR:.5A<=:?\ (2?ZM6K618L6
MOLD<G.:UZ);@@HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!2UC_ ) E_P#]>TG_ *":\8^"_P#K-:^D'_L]>SZQ_P @2_\ ^O:3
M_P!!->,?!?\ UFM?2#_V>M8?"S&?QQ/6****#0**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *9)]T?6GTR3[H^M %B/_5K
M]*=38_\ 5K]*=2&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% %>3_ (^%_"K]4)/^/A?PJ_0P"BBBD 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 55L_\ C[?Z'^=6JJV?
M_'V_T/\ .CH!HT445(!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% %&T_Y"3_5JU:RK3_D)/]6K5IRW!!1114C"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@"EK'_($O_P#KVD_]!->,?!?_
M %FM?2#_ -GKV?6/^0)?_P#7M)_Z":\8^"_^LUKZ0?\ L]:P^%F,_CB>L444
M4&@445'/,MO"TK@E5QG'7K0VDKL4I**;>Q)16=_;-O\ W)?R'^-']LV_]R7\
MA_C6/UBE_,<_URA_,C1HK._MFW_N2_D/\:/[9M_[DOY#_&CZQ2_F#ZY0_F1H
MT5G?VS;_ -R7\A_C1_;-O_<E_(?XT?6*7\P?7*'\R-&BL[^V;?\ N2_D/\:/
M[9M_[DOY#_&CZQ2_F#ZY0_F1HT5G?VS;_P!R7\A_C1_;-O\ W)?R'^-'UBE_
M,'URA_,C1HK._MFW_N2_D/\ &C^V;?\ N2_D/\:/K%+^8/KE#^9&C16=_;-O
M_<E_(?XT?VS;_P!R7\A_C1]8I?S!]<H?S(T:*SO[9M_[DOY#_&C^V;?^Y+^0
M_P :/K%+^8/KE#^9&C16=_;-O_<E_(?XT?VS;_W)?R'^-'UBE_,'URA_,C1H
MK._MFW_N2_D/\:/[9M_[DOY#_&CZQ2_F#ZY0_F1HT5G?VS;_ -R7\A_C1_;-
MO_<E_(?XT?6*7\P?7*'\R-&BL[^V;?\ N2_D/\:/[9M_[DOY#_&CZQ2_F#ZY
M0_F1HT5G?VS;_P!R7\A_C1_;-O\ W)?R'^-'UBE_,'URA_,C1HK._MFW_N2_
MD/\ &C^V;?\ N2_D/\:/K%+^8/KE#^9&C16=_;-O_<E_(?XT?VS;_P!R7\A_
MC1]8I?S!]<H?S(T:*SO[9M_[DOY#_&C^V;?^Y+^0_P :/K%+^8/KE#^9&C16
M=_;-O_<E_(?XT?VS;_W)?R'^-'UBE_,'URA_,C1HK._MFW_N2_D/\:/[9M_[
MDOY#_&CZQ2_F#ZY0_F1HT5G?VS;_ -R7\A_C1_;-O_<E_(?XT?6*7\P?7*'\
MR-&BL[^V;?\ N2_D/\:/[9M_[DOY#_&CZQ2_F#ZY0_F1HT5G?VS;_P!R7\A_
MC1_;-O\ W)?R'^-'UBE_,'URA_,C1HK._MFW_N2_D/\ &C^V;?\ N2_D/\:/
MK%+^8/KE#^9&C16=_;-O_<E_(?XT?VS;_P!R7\A_C1]8I?S!]<H?S(T:*SO[
M9M_[DOY#_&C^V;?^Y+^0_P :/K%+^8/KE#^9&C16=_;-O_<E_(?XT?VS;_W)
M?R'^-'UBE_,'URA_,C1HK._MFW_N2_D/\:/[9M_[DOY#_&CZQ2_F#ZY0_F1H
MT5G?VS;_ -R7\A_C1_;-O_<E_(?XT?6*7\P?7*'\R-&BL[^V;?\ N2_D/\:/
M[9M_[DOY#_&CZQ2_F#ZY0_F1HT5G?VS;_P!R7\A_C1_;-O\ W)?R'^-'UBE_
M,'URA_,C1HK._MFW_N2_D/\ &C^V;?\ N2_D/\:/K%+^8/KE#^9&C16=_;-O
M_<E_(?XT?VS;_P!R7\A_C1]8I?S!]<H?S(T:*SO[9M_[DOY#_&C^V;?^Y+^0
M_P :/K%+^8/KE#^9&C16=_;-O_<E_(?XT?VS;_W)?R'^-'UBE_,'URA_,C1H
MK._MFW_N2_D/\:/[9M_[DOY#_&CZQ2_F#ZY0_F1HT5G?VS;_ -R7\A_C1_;-
MO_<E_(?XT?6*7\P?7*'\R-&BL[^V;?\ N2_D/\:/[9M_[DOY#_&CZQ2_F#ZY
M0_F1HT5G?VS;_P!R7\A_C1_;-O\ W)?R'^-'UBE_,'URA_,C1HK._MFW_N2_
MD/\ &C^V;?\ N2_D/\:/K%+^8/KE#^9&C16=_;-O_<E_(?XT?VS;_P!R7\A_
MC1]8I?S!]<H?S(T:*SO[9M_[DOY#_&C^V;?^Y+^0_P :/K%+^8/KE#^9&C16
M=_;-O_<E_(?XT?VS;_W)?R'^-'UBE_,'URA_,C1HK._MFW_N2_D/\:/[9M_[
MDOY#_&CZQ2_F#ZY0_F1HT5G?VS;_ -R7\A_C1_;-O_<E_(?XT?6*7\P?7*'\
MR-&BL[^V;?\ N2_D/\:/[9M_[DOY#_&CZQ2_F#ZY0_F1HTR3[H^M4?[9M_[D
MOY#_ !IK:Q;L.$E_(?XT?6*7\P?7*'\R-B/_ %:_2G5E)KELJ %)N/8?XT[^
MW;7_ )YS?D/\:7UBEW']<H?S(TZ*S/[=M?\ GG-^0_QH_MVU_P"><WY#_&CV
M]/N'URA_,C3HK,_MVU_YYS?D/\:/[=M?^><WY#_&CV]/N'URA_,C3HK,_MVU
M_P"><WY#_&C^W;7_ )YS?D/\:/;T^X?7*'\R-.BLS^W;7_GG-^0_QH_MVU_Y
MYS?D/\:/;T^X?7*'\R-.BLS^W;7_ )YS?D/\:/[=M?\ GG-^0_QH]O3[A]<H
M?S(TZ*S/[=M?^><WY#_&C^W;7_GG-^0_QH]O3[A]<H?S(TZ*S/[=M?\ GG-^
M0_QH_MVU_P"><WY#_&CV]/N'URA_,C3HK,_MVU_YYS?D/\:/[=M?^><WY#_&
MCV]/N'URA_,C3HK,_MVU_P"><WY#_&C^W;7_ )YS?D/\:/;T^X?7*'\R-.BL
MS^W;7_GG-^0_QH_MVU_N3?D/\:/;T^X?7*'\R-.BLX:U:'J7'U6IDU.S?I.H
M_P![BFJU-[-%1Q-&6TE]Y;HIB2QR?<=6^AI]:)W-DT]4%%%%,84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!7D_P"/A?PJ_5"3_CX7
M\*OT, HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %5;/_ (^W^A_G5JJMG_Q]O]#_ #HZ :-%%%2 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!1M/^0D_U:M6LJT_Y"3_5
MJU:<MP04445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR#
MXQ^+[_3KZQT?2[Z:U=4^T3R6\I1SG(525Y X)QWR/05ZY--';P23S.$BC4N[
M'HH R37R=XDUB37_ !'?ZFY8B>9FC#'.U,_*OX# K6E&[N85Y6C9%RQ\;^)+
M._M[EM<U*98I%<Q2W;LK@'.""2"#7U!8WD&HV$%[;.'@GC62-AW!&17RAK.B
M7FA7-O!>H%:>VCN8R.ZNN?T.5/N#7MGP8U\ZCX9ETJ5LRZ<^$R>3&Y)'Y'</
MIBJJQ5KHBA)J7*STNBBBL#J"BN&\5?%+1/#-T]DJO?WJ'#Q0D!8SZ,W8^PS7
M.V/QVLI;@+?Z'/;PGJ\,XE(_ JO\ZI0DU>Q#J03LV>MT5QNJ_$[P]I>DV.IA
MKB\MKPLJ&U52490"0P9A@_,.*E\*?$/2?&%_-9Z?;WL4D,7FL;A$4$9 XPQY
MYHY7:X^>-[7,KXQ:C?:9X1M)]/O;BTE:_1#);RM&Q7RY#C((XR!^5>>_#3Q'
MKE_\0=+MKS6=1N+=_-W1373NK8B<C()P>0#7KWCC6=#T/18;G7]-_M"T:X6-
M(O(27#E6(;#D#H&&>O-<UX4\8^!]5\2VEEH_AO['?R;_ "I_L,$>S",3\RL2
M,@$<>M7%^[L937OK4]'N)XK6VEN)Y%CAB0O([' 50,DGVQ7DGBKXTQ1;[7PU
M )7Y!O)U.T=1E%[]B"?R-=!\1_'&F:'97V@7,%V]W?:=)Y3QHI0;PZ#)+ ]1
MS@'BOG6G3@GJQ5JK6D3[)HKAO#_Q4T/Q)KEOI-G:ZBEQ<;MK31H%&U2QR0Y/
M13VKKM2U.RTBQDO=0N4M[:/[TCG@>GU/M6336C-E)-71;HKRG4/CGID,KII^
MDW-TJG"O+((@WOT8X^OZ55A^/$+-^_\ #TB+ZI=AC^J"J]G+L3[6'<]@HKG_
M  QXST7Q; S:;<-YR#,EM*-LB#.,D=".G()'-0^+O'&F>#/L?]HP7<OVO?L^
MSHK8V[<YW,/[PJ>5WL5S*U^ARGBKXRZ?IV^VT")+^Y!P9Y,B%>G3'+]QQCZF
MN_\ #UY-J'AG2KVY8-/<6<,LC 8RS("3@>YKY(KW?PC\5-#^Q:#H'V74?M?E
MV]EO\M-F_"IG._.,^V<=JUG3LM#"G5O+WF2?&?5=1TO2M+?3[^ZM&>=P[6\S
M1EAMZ'!&:Y/X4^(-:U'QQ#;WVKW]U 8)"8Y[EW4D#@X)Q7IWCO7?#VA6=I)X
MATK^T(I9&6)?L\<NQ@.3AR,?A6+X.\7>"]8\0)::)X>^PWIC9A-]BABPH'(W
M*Q-)/W-BI+]Y>YZ-117/>)O&VA^%(Q_:-R3.PREM"N^1NG;H.O<BLTK[&S:6
MK.AHKQ^;X\0JW[CP](Z^KW84_HAK;T3XR>']3G6"]CFTUVZ/+AH\^FX=/J1B
MJ=.78A58/J>BT4BLKJ&4@J1D$'@BLCQ-XDL_"ND'4[Z.>2$.L>V!06R>G4@?
MK4)7+;LKLV**XCP]\4]"\2:Q'IEI;7\4LBLP>=$5 %4DY(<]AZ5F^(/C-HVE
M7CVNG6SZFR$AI8Y D6?]EL'=]<8]":KDE>UB?:1M>YZ317E.F?'+3;FY$>I:
M5-91G_EK'+YP'U&T'\LUZC;7,%Y:Q7-M*DL$JATD0Y# ]"#0XM;CC.,MB6BB
MBI*.3^)=Y<V'P^U2YL[B:WN$\K;+"Y1ES*@.".1P2*\1\+>*?$-QXNT6"?7M
M4EBDOX$>-[R1E93(H(()Y!%?0/BO4-,TKPU=WNL6?VRPCV>;!Y2R;\NH'RL0
M#@D'GTK@-(\=?#V[UJPMK+PKY-W-<1QPR_V?;KL<L K9#9&#@Y'-:P?N[&%1
M7DM;'K%%%>:?\+P\,_\ /CJW_?J/_P".5FHM[&LI*.YZ717(>)_B-HGAB*)9
MF>XNY4#K:PD%E! (W\_+P:XU/CQ$9<2>'G6/^\MV"?RV#^=-0D]D)U(IV;/8
M:*QO#GBC2O%5@UWI<Y<(VV2-QM>,]MP]^QZ?E6S4M6*33U04444#"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH I:Q_R
M!+__ *]I/_037C'P7_UFM?2#_P!GKV?6/^0)?_\ 7M)_Z":\8^"_^LUKZ0?^
MSUK#X68S^.)ZQ1110:!534_^0=+^'\Q5NJFI_P#(.E_#^8K.M_#EZ,QQ'\&?
MH_R.=HHHKPSY0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** *\G_'POX5?JA)_Q\+^%7Z& 4444@"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JMG_Q]O\
M0_SJU56S_P"/M_H?YT= -&BBBI **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH HVG_(2?ZM6K65:?\ (2?ZM6K3EN""BBBI&%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWOOL_P!D_P!U]N[?^&<?A7C5?6'A'_D2M!_[!UO_ .BUJJLFEH10BI/4\_\
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MR/3:?:NE^,G_ "($G_7S%_6O&? 4SP>/=$=,9-TB<^C<']":]F^,G_(@2?\
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M .0=+^'\Q5NJFI_\@Z7\/YBLZW\.7HS'$?P9^C_(YVBBBO#/E HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JK9_\?;_
M $/\ZM55L_\ C[?Z'^='0#1HHHJ0"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** *-I_R$G^K5JUE6G_ "$G^K5JTY;@@HHHJ1A1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5S/CCQ=_PAFBPZC]A^V>9<+!Y?F^7C*LV<[3_=Z>]=-7FGQP
M_P"1*L_^PBG_ *+DJHJ[LR*C:BVC'3X\J74/X<(7/)%[D@?3RZ]<L[NWO[.&
M\M95EMYD$D;KT92,@U\>U[+\&/%Q._PS>2Y/,MD6)SZLGZ%A_P "]JUJ4TE=
M&-*JV[2/9*Y/QWXV_P"$*L[2X_L_[9]HD9-OG>7MP,Y^Z<UUE>3?'7_D#Z1_
MU\/_ .@BLH).5F;5&U%M$_A_XQ_V[K]EI?\ 8/D?:I1'YOVS=M]\;!G\Z]2K
MY;^'W_(_Z+_U\K_6OJ2JJ12>A%&3DM3R?5_C5_96M7^G?\(_YOV2XD@\S[9M
MW[6*YQY9QG'2J?\ POG_ *EK_P GO_M=>9^+O^1UU[_L(W'_ *,:L:M53C;8
MP=:=]SZYT+54US0K'5$C\H74*R>7NW;"1R,]\'(K0KS?X*ZF+OP=+8DG?97#
M  G/RO\ ,/ISNKTBN>2L['7!\T4S@?&_Q.B\':O%IR::+Z1H1*Y%SY>S)( (
MVGGC/XBN9_X7S_U+7_D]_P#:Z\_^(&I_VMXZU:Y#(R+,84*="J?(#GOG&?QK
MFJZ(TXVU.65:7,[,^G? GC;_ (36SN[C^S_L?V>14V^=YF[(SG[HQ6SXBU?^
MP/#][JOD>?\ 9H]_E;]N[G&,X./RKSGX%?\ ('U?_KX3_P!!-=E\1/\ DG^M
M?]>_]16,DE.QT1DW3N<%_P +Y_ZEK_R>_P#M='_"^?\ J6O_ ">_^UUXU7?Z
M3\(=?UG2;74K>\TQ8;F,2(LDL@8 ^N$(S^-;.$%N<T:E26QTW_"^?^I:_P#)
M[_[75JV^.U@SJ+K1+F)>-QBF60CUP"%S7-_\*/\ $W_/]I/_ ']D_P#C=<QX
MG\"Z[X35)-1@1K9VVK<0-N0MZ'H1^(&?P-)1IO8ISJK5GT5X;\6Z/XJM6FTN
MYWLG^LA<;9(_3(_#J.*VZ^2- UR\\.ZS;ZG9.5DB8%ES@2+GE&]C7UA97<6H
M6%M>P$F&XB66,GKM8 C]#6<X<IM2J<ZUW)Z**S=?U5-#\/W^IOC%M"SJ&Z,V
M/E'XG _&LS5NQP?B;XQ0:!X@NM*@T@W@MF"--]I\O+8Y &P]#Q^%+X7^+\7B
M+Q%:Z3+HYL_M)*K-]J\S# $@$;!UQC\:\(NKF6\NYKJ=R\TTC22,>I8G)/YF
MBWN)K2ZBN;>1HYH7$D;KU5@<@C\:Z?91L<7MY7/L2BL[0=7AU[0;+5+<@I<Q
M!\#^%NC+^!!'X5HUS':G<**** "BBB@#G?%GC/3?!UO;3:C%<RBX9E06ZJQX
M&3G<PXYKEO\ A>'AG_GQU;_OU'_\<KEOCG>B7Q!IEB&)\BV,A&> 7;'Y_(/T
MKS>PTC4]5\S^SM.N[SR\;_L\#2;,YQG:#C.#^5;QIQ<;LY9U9*5D>X_\+P\,
M_P#/CJW_ 'ZC_P#CE26_QJ\.7-S% EEJH:5P@)BCQDG'_/2O%O\ A$?$W_0N
MZM_X!2?_ !-6M,\)^(X]5LW?P_JJJLZ$L;.0 #<.>E/V<!>UJ'U-115+5-7T
M[1;0W6I7D-K"/XI&QGV ZD^PKG.LFO+NWL+.:\NI5BMX4,DCMT50,DUY$?CR
M-QV^&R1V)OL?^TZYKQ_\2[CQ4K:=8H]MI(8$AOOSXP1N] #R!]">V//ZWA25
MO>.6I6=_=/K_ $V\_M#2[2]\OR_M$*2[,YV[E!QGOUJU69X;_P"17TC_ *\H
M?_0!6G6+.E;!7*>.?'-MX*LK:1K<7=S<2;4M_-V':!RV<'@' _'V-,\7_$+2
M/"EO(AE6ZU'HEI$P)!QP7/\ "/U]J^>?$7B&_P#$^L2ZEJ$@:5OE1%^[&@Z*
MH]!D_F3WJX4[ZO8RJU5%66Y[9X1^+'_"5>(X-)_L7[+YJNWF_:M^-JD]-@]/
M6O2*^;OA'_R46Q_ZYR_^BVKZ1HJ12=D.C)RC=A11169J%%%% !1110 4444
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M+6WN]12<AA, _E ?=PIZ9Y.?;VKH?BMJ=AIG@.[L&>)+B[VQP0+@$_.&8X]
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MOQ8L+S4?!#V]C:3W4QN(SY<$9=L#.3@<U$?B-9?PSQCX;?\ )0]&_P"NK?\
MH#5]/U\Z?#_PUKUEX[TFXNM$U*"!)27EEM755&T]21@5]%U57<B@K1"BBBLC
M<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "K-E>/9S!@<H?O+ZU6HJ
MHR<7=%0G*$E*.Z.QBD6:-9$.589%/KGM(OO)E\ES^[<\>QKH:]>C552-SZ?"
MXA5Z?-UZA1116QTA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5Y/^/A?PJ_5"3_
M (^%_"K]# ****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !56S_ ./M_H?YU:JK9_\ 'V_T/\Z.@&C1114@%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4;3_ )"3_5JU:RK3
M_D)/]6K5IRW!!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/BS5+2'=Y4%P\2;CDX4X&?RK6^&6F?VGX_TQ2,I;N;EO;8,C_P >VU0\<?\
M(]:Y_P!?LO\ Z$:VO[UC"WNW/4?@5_R!]7_Z^$_]!-=E\1/^2?ZU_P!>_P#4
M5QOP*_Y ^K_]?"?^@FNR^(G_ "3_ %K_ *]_ZBN>7QG5#^$?+M?5'@3_ )$3
M1/\ KT3^5?*]=58?$CQ9IEA!8V>K>7;0($C3[/$=JCH,E<FMJD7):'/2FH.[
M/I^N,^*US;V_P[U))W4&8QQQ*?XGW@X'OA2?P->,O\4_&DB%6UI@#_=MXE/Y
MA:P-6U_5==E235+^:Z9!A?,;A?H.@K.-)IW9K.NFFDC.KZM\&Q2P>"M$CFSY
M@LHL@YR/E&!SZ#BO!/ G@2^\4ZI;S36TB:0C[IIVRH< \HI[D]..G-?2RJJ*
M%4 *!@ #@"BK);!AXM78M>2_&_7C!IUCH4,N&N6\^=03G8O"@^Q;)^J5ZU7R
MMXVUT>)/%U_J29\EG"0@_P!Q1M'YXS^-32C>5RZ\K1MW$\%Z#_PDGBVPTUCB
M%GWS'_IFHW,/Q Q]2*@\5:*_A[Q-?Z:R,J12MY1(/S1DY4\^V*]1^!VAM'#J
M&NRKCS,6L)]0"&?]=OY&HOCCH+;K#7H8\KC[+.P[=60_^A#/T]JUY_?L8>S_
M '?,6?@?KS36-]H,I&;<_:(/7:QPP^@.#_P(^U>N5\I>#M=_X1SQ78:FQ;R8
MY-LP7O&PPW'?@YQZ@5]6*RNH92"I&00>"*RJQL[F]"5XV["T445F;!1110!\
MT?%.^-]\0]2P24@V0KD=-JC/_CQ:NO\ A)J^B^&_#6I:AJNH6]JUQ<A%5V^=
MU10<A1R1ESTS7EFM7O\ :6NZA?;BXN+B24,>X9B14=CIM_J<ACL+*YNY!R5@
MB:0C\ *ZW&\;' IM3YD?2MG\2?"%_.(8-;A#D@#S8WB'YNH%=0CI)&LD;*R,
M 593D$'N#7Q_=V-W83&&\M9[:4?P31E#^1KM/AYX_NO#.IPV=[<.^C3-MD1_
MF\G/\:^@'<#MGC.*RE2TNC:-?6TCZ.KY>^(L\TWCW5Q+*[A)RJ!F)VC X'H*
M^H:YVW\#Z##KMUK3V8N+ZXD,A>?YPA_V1T'UZ^]1"2B[FE6#FK(\)LOA[J3>
M$[[Q%J :UM88/,@C8?/,3C!QV7GKU/ZUQU?47Q$_Y)_K7_7O_45\NUO3DY*[
M.:K!0:2/K;PW_P BOI'_ %Y0_P#H K.\?S2P> ]9DAD>.06YPR,01R!U%:/A
MO_D5](_Z\H?_ $ 5+K&E6^MZ1<Z;=-(L%PNQS&0&QG/!(/I7/U.RUXV/D^PT
M^]UB_2TL;>2YNI2=J(,D]R?_ *];GC#P=-X/_LZ"ZG66[N8FEE$?W$YP #U/
MN?\ )^CM$\.:1X=MO(TNQBMP1AG R[_[S'DUY#\=/^0[I7_7LW_H5;1J<TK(
MYI4N6%WN8'PC_P"2BV/_ %SE_P#1;5](U\W?"/\ Y*+8_P#7.7_T6U?2-15^
M(TP_PA11161N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP_F*MU4U/_D'2_A_,5G6_AR]&8XC^#/T?Y'.T445X9\H%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444  .#D=:Z?3+O[5:C<?G3AJYBKFF7/V:\4D_(_RM71AZG)/R9VX&O[*JK[
M/<ZBBBBO7/I0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *\G_'POX5?JA)_Q\+^
M%7Z& 4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "JMG_Q]O\ 0_SJU56S_P"/M_H?YT= -&BBBI **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH HVG_(2?ZM6K65:?\ (2?Z
MM6K3EN""BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-'<01SQ-NCD4.IQC((R*?2&%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4
MM8_Y E__ ->TG_H)KQCX+_ZS6OI!_P"SU[/K'_($O_\ KVD_]!->,?!?_6:U
M](/_ &>M8?"S&?QQ/6****#0*J:G_P @Z7\/YBK=5-3_ .0=+^'\Q6=;^'+T
M9CB/X,_1_D<[1117AGR@4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 =783_:+..3OC!^H
MJS6+H,O$L)/HP_K_ $K:KV:$^>FF?582K[2C&3"BBBMCH"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@"O)_Q\+^%7ZH2?\?"_A5^A@%%%%( HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ JK9_\?;_0_P ZM55L_P#C[?Z'
M^='0#1HHHJ0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** *-I_R$G^K5JUE6G_(2?ZM6K3EN""BBBI&%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC_\ B:U+>V@L[=+>U@C@@C&$CB0*JCT ' HG4NK(*='EE=DM%%%9&YYK\9]
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "OGCXPZ\NK>+Q90N6@TZ/R2,G'F$Y<_^@C_ (#7NVO:M'H6
M@WVJ2X*VT+.%/\3?PK^)P/QKY.FEN-2U"2:0F6YN92S'NSL<_J36U):W.?$2
MTY2%':-U=&*LIR&!P0?6OJ[PEK@\1^%[#5/E\R:/$H'9P<-^H->"_$;P<GA*
M^TY8>8;FT7<<D@S( LA'L>&^K'IQ75_ _7@EQ?:#,YQ(/M$ [9'#C\MI_ U5
M1<T;HBDW"?*SVFN-^*W_ "375_\ MC_Z.2NRKC?BM_R375_^V/\ Z.2L8_$C
MIG\+/ ?"/_(ZZ#_V$;?_ -&+7UA7R?X1_P"1UT'_ +"-O_Z,6O?/BAKVI>'?
M"B7NE7/V>X-TD9?8K_*0Q(PP(["M:JNTC"B^6+;.THKYH_X6MXU_Z#7_ )*P
M_P#Q%'_"UO&O_0:_\E8?_B*GV,BOK$3Z7HKYH_X6MXU_Z#7_ )*P_P#Q%?1N
MF327&E6<\K;I)($=CC&25!-3*#CN7"HI['R!7UAX1_Y$K0?^P=;_ /HM:^3Z
M]#U#XJZE'X?TS1]$S9I;6<,,MP<&1V5%!V_W1D$>I]JVJ1<K)'-2FH7;/H:B
MOE2'QMXI@G\Y/$&I%NN'N6=?^^22/TKV3X:?$6;Q3)+I>JK&NHQIYD<J#:)E
M& >.S#.>.H[#%92IM*YO"M&3L>CT4R::.W@DGF<)%&I=V/10!DFO!_%WQ?U/
M4+J6VT!S9V*MA9PO[V7&.>?NCCIUP>?2IC%RV+G-06I[W17RDOC/Q.DHD'B'
M5-P.<&Z<C\B<5Z'X(^+]U]LBT_Q-)&\#_*EZ%VLA[;\<$=L@#'?/46Z31$:\
M6[,]JKQ?XD^!/$NO^,);_3--\^V:&-0_GQKR!SPS U[17B_Q)\=^)= \82V&
MF:EY%LL,;!/(C;DCGEE)I4[WT'6Y>7WCI?A/X9UCPSINHPZO:?9GFF5HQYB/
MD 8/W2:]#KSSX3^)M8\3:;J,VKW?VEX9E6,^6B8!&3]T"LSXK^,=>\-:KI\&
MD7_V:.6!G<>2CY.['\2FAQ<I6",HQA?H>K45X/I7QBU6S\/WAU"47^J22;;;
M=&B+$NWEFV@9Y(P._/(KC[SQWXJOIS-)KU^A))VP3-$H_!<"FJ3)=>*/JBBO
M _!GQ:U/3[^*T\07)N].<[6GD7,D/^UD#+#U!R?3T,'BOXMZSJMY)%HTSZ?8
M*<(4QYL@]2W;Z#\S2]E*]A^WC:Y]!T5\L6/CWQ5I]P)HM>OI&'\-Q*9E/_ 7
MR*]\\ ^,E\9:&UQ)&D-[ VRXC3.T$]&&>QYXR<8-*5-QU'"JINQU=%5-3U*U
MTC3;C4+V7R[:!-[MC.!].Y[5X#XE^+6O:O<NNFS-IMF&^18O]8PYY9O7!Z#C
M^=*,'+8J=10W/HFBOE.#QKXHMY1(GB#4RP[27+N/R8D5ZK\/OBM)J][%I&OF
M)+J4A+>Y1=HE;IM8= Q/0C /3 [U*DTKD1K1D['J]%%?..H?%'QE!J5U#'K&
MU$F=5'V:$X ) _@J8P<MBYU%#<^CJ*^?/%?Q5U?48;:QTN\EM8XX4%Q<1'9)
M-+M&X@C[JYSC&,_D!J?"3Q#XFU7Q.UG<:I<W5A'"TLXN3YA]%PS<@Y([\@'C
MTITVE=D*M%RLC<^-&DZEJMIHZZ=I]W>&-Y2XMX6DVY"XSM!Q7(?!J&6/Q_+&
M\;J\=I*'5E(*D,H.1VYXKU?QSXWMO!NGJSP237=PK?9EV'9N&/O-Z<]!S7%?
M!70+P3W_ (DNU=4N$,,)8?ZW+!G;Z94#/U]*I/W-2917M58]@HKAOB)\0$\'
MVT=K:(DVJW"[XU<?+&F<;F]>00!['TY\2O?'WBN_DWRZ]>IR3B"0Q ?]\8J8
MTW+4N=:,78^IJ*^5[3QWXKLI \6OW[$'.)IC*/R?(KV7X<_$@>*BVFZDL<.J
M1J64IPLZCJ0">&'<?B.^"5-I7"%:,G8]#HHHK,U"OD_Q=_R.NO?]A&X_]&-7
MUA7R?XN_Y'77O^PC<?\ HQJVH[LY\1LBSHW@3Q)X@T\7VEZ;]HMBQ0/Y\:<C
MKPS U9N?AIXQM$#2:',P/_/*1)#^2L:]>^#?_(@1_P#7S+_2O0*)56G84:$7
M%,^/HY+S2[Y9(VFM;N!\@C*.C#]0:^AOAIXZ/BS37M;YO^)K:KF5@ !,I/#@
M#H>@(^GK@<_\;/#MLVF6_B"&-4NDE$$Y QYB$':3ZD$8^A]A7G'P\U1])\=Z
M5,KA4EF%O)N. 5?Y>?H2#]0*IVG&Y$;TYV/IC4X9+C2KR")=TDD#HHSC)*D"
MOG+_ (53XU_Z O\ Y-0__%U]&ZG-);Z5>3Q-MDC@=U.,X(4D5\Y?\+6\:_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"]I#[-1C'9@5/Y5TU<C:/
MY=Y"WHX_G775Z6"?N-'O95*]-Q[,****[3U HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M KR?\?"_A5^J$G_'POX5?H8!1112 **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *JV?_'V_P!#_.K55;/_ (^W^A_G1T T:***
MD HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"C:
M?\A)_JU:M95I_P A)_JU:M.6X(****D84444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=&!&0:Y#XK?\DUU?_MC_ .CDK/\ @]K_ /:WA#[!*1Y^FOY77DQG)0^W=?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% #D.V13Z$&NRKC%&Y@/4XKLZ]# _:/:RG:?R_4****[SV
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH KR?\?"_A5^J$G_ !\+^%7Z& 4444@"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JMG_ ,?;
M_0_SJU56S_X^W^A_G1T T:***D HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@"C:?\ (2?ZM6K65:?\A)_JU:M.6X(****D8444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%,E5WA=8Y#&[*0K@ [3ZX- #Z*\1\"_$+Q)?>.;72M:U,2V\
MK21,AMXU^<*<<JH/48_&O;JJ47%V9$)J:N@HHJO?7D&G6$][<N$@@C:21CV
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MT?9E*^;LV;LL3TR<=?6LY<EO=-X.I?WCY,KZP\(_\B5H/_8.M_\ T6M>:?\
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MNQG&1C.*F;3E=%TXM0LSX]KZ[T;_ ) 6G_\ 7M'_ .@BO*?^%#?]3+_Y(_\
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MQ,T>(?#R(_J]V6'Y!!_.I/\ A0W_ %,O_DC_ /;*5/@,H8;_ !&2O<"RP?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!);KON8E]7 _6NPKE]+3?J,0[ D_D*ZBO2P
M2]UL]W*HVIREYA1117:>J%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>3_CX7\*OU0D_
MX^%_"K]# ****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !56S_X^W^A_G5JJMG_ ,?;_0_SHZ :-%%%2 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!1M/^0D_P!6K5K*M/\
MD)/]6K5IRW!!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** -?0HLS22G^$;1^-;M4M*@\BQ7(PS_,:NU[&'ART
MTCZC!4_9T(I^H4445N=04444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5Y/^/A?PJ_5"3_C
MX7\*OT, HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %5;/_C[?Z'^=6JJV?\ Q]O]#_.CH!HT445(!1110 4444 %%%%
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M3:"S#/\ P)?RJ7XZW^S2=)TX'F6=YR..-B[1_P"AG_(KI?A1IO\ 9WP_LF8
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MKK*P4=(ML^<UMW\;?$&2*.XV#4;URLI3.U"20=N1T4=,UZ#_ ,*&_P"IE_\
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MD5[545?B-:-N0Y'XGF-?AQK!D&5V1@?7S%Q^N*XSX$Z?B#6-29#\S1P(W..
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ J>SMS<W*1CH3D_2H*Z#1K7RH3.P^9^GTK:A3]I-(Z<
M)0]M54>G4TP,  =J6BBO8/J0HHHI@%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>3_CX
M7\*OU0D_X^%_"K]# ****0!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !56S_X^W^A_G5JJMG_ ,?;_0_SHZ :-%%%2 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!1M/^0D_P!6
MK5K*M/\ D)/]6K5IRW!!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH I:Q9G4=$O[$#)N;:
M2'&<9W*1U_&ODF&.XFD6RB5B\LBJ(^F7Y _'D_G7V'15PGRF52ESVU,#P;X<
MC\+>&+735P9@/,N' 'SR-]X^^. /8"M^BBI;OJ:)65D%%%%(9\^?&6]>^\=I
M91DN;:WCB"*,G<V6_,AE_2O=M'L5TS1+&P5=HM[=(L?10*NT53E=)$1A:3?<
M*^<OB'X:O_"?BZ74[/STM+B8W%O<H?\ 5N3DKD="">,]L=>:^C:9+%'/&T<L
M:R1MPRN,@_A1"7*PJ0YU8^?8?C1XJBM/)==/FDQCSW@(?IUPK!<_A56^T7QA
MXNTJ\\3ZU+(+6UA+QF<;-P Z1H, #ID\9]S7OD'AS0[6Y%S;Z+IT,ZG(ECM4
M5@?7(&:TZOVB6R,_9-_$SQ?X#S(MQKL)^^ZP./H"X/\ Z$*Z7XS:C]D\"FU'
M6]N$B(QV7Y_YJ/SKT.BI<KRYBU"T.6YY-\"]/,>DZKJ++_KIDA4GT09./^^Q
M^7M7K-%%3)W=RH1Y58*\@^.&@^9;6&OQGYHC]EF'^R<LI_ [A_P(5Z_13C+E
M=PG'F5CS'X+:_P#;O#D^CRM^]T]\IDCF-R3^C;OS%>G444I.[N$5RJQ4U34[
M71]+N-1O7V6]NA=R!D_0>YZ5\XZ19WOQ(^(3/<\?:9#/<D<B.)<#'Y;4!]Q7
MTS151ERDSASM7V&0PQV\$<$*!(HU"(HZ* , 4^BBH-!DL23PO%(H:-U*LI[@
M\$5\V_#F8Z/\3;&&;(_>R6KCH<E64=_[V*^E:*N,K)HSG#F:?8\S^-NH"W\)
M6MD"V^ZN@>#QM0$G/XE:M?!K3C9^!OM+Q[6O+EY0Q R5&$'X94]?4^M>A44N
M;W>4?)[_ #!7SG\0))/$OQ5DL(3(W[Z*RC&1QT!QV W%C7T911"7*[A.'.K#
M(88[>".")=L<:A%&<X &!7S?\48;RS^(]_<RJZ&0QRP28P&4(H!'K@C'U%?2
M=5KS3K+48Q'?6=O=1CD+/$K@?@13A+E=Q5(<ZL>=?#;XAZUXMUB73[^UM!%#
M;&5IX4922"H&>2,G)/;]*P?C+X1NO[07Q):122P2($NMO/E%1A6_W2.,]B/>
MO8+'2=-TL,-/T^TM WWOL\*QY^N *N4<]I70O9MQY9,^<M(^+OBC2;)+4M:W
MJ(H5&NXV9E ]U89_'-6;:'QO\5KA%N)FCTQ'R9"GEVZ'V ^^W7U(SU ->WMX
M9T!YA,VAZ:TH.0YM(RP/7.<5J*JHH50 H&  . *IU%T1*I2VD]#YS^$;"#XC
M6T4G#M%,@&>X4G^AKZ(N;>&\M9K6XC$D$R-'(AZ,I&"/R-2UQGQ%\7:AX.T^
MQO;*U@GCEG,4OG!N/E) !!&#P?7I4M\\M"HQ5..IX]XI\"ZYX,U<W%B+J6T5
MM]O>VX(9/9BOW6'KW_2BW\7^/O$B#3+2_OKG?D;;>)5;WRZ@$#GN<5ZSX4^*
M6B:[8YU*ZM=+O58@PS2X4KV(9@!^&>WO6EJOQ%\*Z3;-*^L6URP7*Q6CB9F]
MAM. ?J16G,]FM3/DCNI61\]>)O#T_AS5H]-N91->F%9)PG(5VR=H/?C;SZD]
MN3]/:#I_]D^'].T_: ;:VCB; '+!0">/4Y-?/OAVWN_B#\2UN[J,,CSBYN1D
ME5C4C"Y], **^DJ55[(=!+5H\M^+'@.ZUTQ:WI,1EO(8_+G@4?-(@/#+ZL,G
M/J,8Z<^>:#\2O$WA:U_L]&BGAB^5(;V-F,7L,$$#VSBOI6J%[H>D:C)OOM+L
M;I^NZ>W1STQW'I4QGI9HJ5)M\T78^<]9\8>*O'4BV#;Y8V;<+.SB(4G/4@9)
M[=2<5ZI\-/AT/#<:ZOJBYU61,)'GBW4]1[L>Y[=![][9:;8:='Y=C96UJ@S\
ML$2H.>O %6J)5+JR'&E9\TG=GF?QMU 6_A*UL@6WW5T#P>-J DY_$K5KX-:<
M;/P-]I>/:UY<O*&(&2HP@_#*GKZGUKT*BIYO=Y2N3W^8*^<_B!))XE^*LEA"
M9&_?1648R..@..P&XL:^C**(2Y7<)PYU8B1(;.T5 5C@A0 ;FX50.Y/H!7SM
MX#W>(_BS!?39^>XEO'Y&0<,P_P#'MM?1U%$963"<.9KR(+VTBU"PN;*<$PW$
M312 ==K @_H:^9]6T+Q%\/-?6X1I86B<FWO8E^20?CQWP5/ZU]/TUT22-HY%
M5D8$,K#((/8BG"?**I3YSY^B^-?BF.V$30Z;*X!'FO"VX^_# ?I63;VOBKXG
M:ZLDIDN-I"/.4VPVZY]L#WQU/O7T$?"OAUI/,.@:67Z[C9QY_/%:D44<$:QQ
M1K'&O"J@P!^%5[1+9$>RD_B92L--31] ATZP!Q;0>7$3U) ZG/J>:^7](UC4
M_"'B,7L<2K?V[.CQ7*$\G(8,.#^H-?6%4+[0](U.027^E6-W(. T]NDA'XD5
M,)VO<JI3YK6>Q@?#OQ1J'BW0)=1U""VA99S"H@# -@ YP2<?>QU[5UU0VUI;
M64(AM;>*"('(2) JY^@J:I>KT-(II:A1112&%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 445+!;RW,FR)23W]!32;=D.,7)V0R.-Y7"(I9CT K
MI=.L%LXLM@RMU/I[4MCI\=FF?O2'JU7*]/#X?D]Z6Y[^"P/LO?G\7Y!11176
M>D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 5Y/^/A?PJ_5"3_ (^%_"K]
M# ****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !56S_ ./M_H?YU:JK9_\ 'V_T/\Z.@&C1114@%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 4;3_ )"3_5JU:RK3_D)/]6K5
MIRW!!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"JFI_P#(.E_#^8JW534_^0=+^'\Q6=;^'+T9CB/X,_1_D<[1117AGR@4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !113E1G
M;"*6/H!FF.UQM%:-OHUQ+@R8C7WZUKVVFV]L 0NY_P"\U=%/#3GOHCMHX"M4
MU:LO,R+/2);C#R_NX_U-;T%O%;1[(E"C]34M%>A2H1I[;GMX?"4Z"]W?N%%%
M%;'2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>3_CX7\*OU0D_X
M^%_"K]# ****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !56S_X^W^A_G5JJMG_Q]O\ 0_SHZ :-%%%2 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!1M/^0D_U:M6LJT_Y"3_
M %:M6G+<$%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]^+\S_A1_8UQ_?B_,_X5N44?4Z0?V;0\_O,/^QKC^_%^9_PH_L:X_OQ?F?\
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M7\*OT, HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %5;/_C[?Z'^=6JJV?_'V_P!#_.CH!HT445(!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% %&T_Y"3_5JU:RK3_D)/\
M5JU:<MP04445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BHYPYA<1_?QQ6?Y>H^K?]]"FE<#4HK+\O4?5O\ OH4>
M7J/JW_?0I\OF*YJ45E^7J/JW_?0H\O4?5O\ OH4<OF%S4HK+\O4?5O\ OH4>
M7J/JW_?0HY?,+FI167Y>H^K?]]"CR]1]6_[Z%'+YA<U**R_+U'U;_OH4>7J/
MJW_?0HY?,+FI167Y>H^K?]]"CR]1]6_[Z%'+YA<U**R_+U'U;_OH4>7J/JW_
M 'T*.7S"YJ45E^7J/JW_ 'T*/+U'U;_OH4<OF%S4HK+\O4?5O^^A1Y>H^K?]
M]"CE\PN:E%9?EZCZM_WT*/+U'U;_ +Z%'+YA<U**R_+U'U;_ +Z%'EZCZM_W
MT*.7S"YJ45E^7J/JW_?0H\O4?5O^^A1R^87-2BLOR]1]6_[Z%'EZCZM_WT*.
M7S"YJ45E^7J/JW_?0H\O4?5O^^A1R^87-2BLOR]1]6_[Z%'EZCZM_P!]"CE\
MPN:E%9?EZCZM_P!]"CR]1]6_[Z%'+YA<U**R_+U'U;_OH4>7J/JW_?0HY?,+
MFI167Y>H^K?]]"CR]1]6_P"^A1R^87-2BLOR]1]6_P"^A1Y>H^K?]]"CE\PN
M:E%9?EZCZM_WT*/+U'U;_OH4<OF%S4HK+\O4?5O^^A1Y>H^K?]]"CE\PN:E%
M9?EZCZM_WT*/+U'U;_OH4<OF%S4HK+\O4?5O^^A1Y>H^K?\ ?0HY?,+FI167
MY>H^K?\ ?0H\O4?5O^^A1R^87-2BLOR]1]6_[Z%'EZCZM_WT*.7S"YJ45E^7
MJ/JW_?0H\O4?5O\ OH4<OF%S4HK+\O4?5O\ OH4>7J/JW_?0HY?,+FI167Y>
MH^K?]]"CR]1]6_[Z%'+YA<U**R_+U'U;_OH4>7J/JW_?0HY?,+FI167Y>H^K
M?]]"CR]1]6_[Z%'+YA<U**R_+U'U;_OH4>7J/JW_ 'T*.7S"YJ45E^7J/JW_
M 'T*/+U'U;_OH4<OF%S4HK+\O4?5O^^A1Y>H^K?]]"CE\PN:E%9?EZCZM_WT
M*/+U'U;_ +Z%'+YA<U**R_+U'U;_ +Z%'EZCZM_WT*.7S"YJ45E^7J/JW_?0
MH\O4?5O^^A1R^87-2BLOR]1]6_[Z%'EZCZM_WT*.7S"YJ45E^7J/JW_?0H\O
M4?5O^^A1R^87-2BLOR]1]6_[Z%'EZCZM_P!]"CE\PN:E%9?EZCZM_P!]"CR]
M1]6_[Z%'+YA<U**R_+U'U;_OH4>7J/JW_?0HY?,+FI167Y>H^K?]]"CR]1]6
M_P"^A1R^87-2BLOR]1]6_P"^A1Y>H^K?]]"CE\PN:E%9?EZCZM_WT*/+U'U;
M_OH4<OF%S4HK+\O4?5O^^A1Y>H^K?]]"CE\PN:E%9?EZCZM_WT*/+U'U;_OH
M4<OF%S4HK+\O4?5O^^A1Y>H^K?\ ?0HY?,+FI167Y>H^K?\ ?0H\O4?5O^^A
M1R^87-2BLOR]1]6_[Z%'EZCZM_WT*.7S"YJ45E^7J/JW_?0H\O4?5O\ OH4<
MOF%S4HK+\O4?5O\ OH4>7J/JW_?0HY?,+FI167Y>H^K?]]"CR]1]6_[Z%'+Y
MA<U**R_+U'U;_OH4>7J/JW_?0HY?,+FI167Y>H^K?]]"CR]1]6_[Z%'+YA<U
M**R_+U'U;_OH4>7J/JW_ 'T*.7S"YJ45E^7J/JW_ 'T*/+U'U;_OH4<OF%S4
MHK+\O4?5O^^A1Y>H^K?]]"CE\PN:E%9?EZCZM_WT*/+U'U;_ +Z%'+YA<U**
MR_+U'U;_ +Z%'EZCZM_WT*.7S"YJ45E^7J/JW_?0H\O4?5O^^A1R^87-2BLO
MR]1]6_[Z%'EZCZM_WT*.7S"YJ45E^7J/JW_?0H\O4?5O^^A1R^87-2BLOR]1
M]6_[Z%'EZCZM_P!]"CE\PN:E%9?EZCZM_P!]"CR]1]6_[Z%'+YA<U**R_+U'
MU;_OH4>7J/JW_?0HY?,+FI167Y>H^K?]]"CR]1]6_P"^A1R^87-2BLOR]1]6
M_P"^A1Y>H^K?]]"CE\PN:E%9?EZCZM_WT*/+U'U;_OH4<OF%S4HK+\O4?5O^
M^A1Y>H^K?]]"CE\PN:E%9?EZCZM_WT*/+U'U;_OH4<OF%S4HK+\O4?5O^^A1
MY>H^K?\ ?0HY?,+FI167Y>H^K?\ ?0H\O4?5O^^A1R^87-2BLOR]1]6_[Z%'
MEZCZM_WT*.7S"YJ45E^7J/JW_?0H\O4?5O\ OH4<OF%S4HK+\O4?5O\ OH4>
M7J/JW_?0HY?,+FI167Y>H^K?]]"CR]1]6_[Z%'+YA<U**R_+U'U;_OH4>7J/
MJW_?0HY?,+FI167Y>H^K?]]"CR]1]6_[Z%'+YA<U**R_+U'U;_OH4>7J/JW_
M 'T*.7S"YJ45E^7J/JW_ 'T*/+U'U;_OH4<OF%S4HK+\O4?5O^^A1Y>H^K?]
M]"CE\PN:E%9?EZCZM_WT*/+U'U;_ +Z%'+YA<U**R_+U'U;_ +Z%'EZCZM_W
MT*.7S"YJ45E^7J/JW_?0H\O4?5O^^A1R^87-2BLOR]1]6_[Z%'EZCZM_WT*.
M7S"YJ45E^7J/JW_?0H\O4?5O^^A1R^87-2BLOR]1]6_[Z%'EZCZM_P!]"CE\
MPN:E%9?EZCZM_P!]"CR]1]6_[Z%'+YA<U**R_+U'U;_OH4>7J/JW_?0HY?,+
MFI167Y>H^K?]]"CR]1]6_P"^A1R^87-2BLOR]1]6_P"^A1Y>H^K?]]"CE\PN
M:E%9?EZCZM_WT*/+U'U;_OH4<OF%S4HK+\O4?5O^^A1Y>H^K?]]"CE\PN:E%
M9?EZCZM_WT*/+U'U;_OH4<OF%S4HK+\O4?5O^^A1Y>H^K?\ ?0HY?,+FI167
MY>H^K?\ ?0H\O4?5O^^A1R^87-2BLOR]1]6_[Z%'EZCZM_WT*.7S"YJ45E^7
MJ/JW_?0H\O4?5O\ OH4<OF%S4HK+\O4?5O\ OH4>7J/JW_?0HY?,+FI167Y>
MH^K?]]"CR]1]6_[Z%'+YA<U**R_+U'U;_OH4>7J/JW_?0HY?,+FI167Y>H^K
M?]]"CR]1]6_[Z%'+YA<U**R_+U'U;_OH4>7J/JW_ 'T*.7S"YJ45E^7J/JW_
M 'T*/+U'U;_OH4<OF%S4HK+\O4?5O^^A1Y>H^K?]]"CE\PN:E%9?EZCZM_WT
M*/+U'U;_ +Z%'+YA<U**R_+U'U;_ +Z%'EZCZM_WT*.7S"YJ45E^7J/JW_?0
MH\O4?5O^^A1R^87-2BLOR]1]6_[Z%'EZCZM_WT*.7S"Y/K'_ "!+_P#Z]I/_
M $$UXQ\%_P#6:U](/_9Z];NDNUM)FN2?($;&3)!&W'/Z5R7A.Y\,7+7?_",K
M$"NSS_+B9/7;G<!G^*KCHF9R5Y)G545'A_\ )HP_^33+)**CP_\ DT8?_)H
MDHJ/#_Y-&'_R: )**CP_^31A_P#)H DHJ/#_ .31A_\ )H DHJ/#_P"31A_\
MF@"2BH\/_DT8?_)H DHJ/#_Y-&'_ ,F@"2BH\/\ Y-&'_P F@"2BH\/_ )-&
M'_R: )**CP_^31A_\F@"2BH\/_DT8?\ R: )**CP_P#DT8?_ ": )**CP_\
MDT8?_)H DHJ/#_Y-&'_R: )**CP_^31A_P#)H DHJ/#_ .31A_\ )H DHJ/#
M_P"31A_\F@"2BH\/_DT8?_)H DHJ/#_Y-&'_ ,F@"2BH\/\ Y-&'_P F@"2B
MH\/_ )-&'_R: )**CP_^31A_\F@"2BH\/_DT8?\ R: )**CP_P#DT8?_ ":
M)**CP_\ DT8?_)H DHJ/#_Y-&'_R: )**CP_^31A_P#)H DHJ/#_ .31A_\
M)H DHJ/#_P"31A_\F@"2BH\/_DT8?_)H DHJ/#_Y-&'_ ,F@"2BH\/\ Y-&'
M_P F@"2BH\/_ )-&'_R: )**CP_^31A_\F@"2BH\/_DT8?\ R: )**CP_P#D
MT8?_ ": )**CP_\ DT8?_)H DHJ/#_Y-&'_R: )**CP_^31A_P#)H DHJ/#_
M .31A_\ )H DHJ/#_P"31A_\F@"2BH\/_DT8?_)H DHJ/#_Y-&'_ ,F@"2BH
M\/\ Y-&'_P F@"2BH\/_ )-&'_R: )*9)]T?6DP_^32,&QS0!:C_ -6OTIU5
ME$VT;<X[<TNV?W_.IL!8HJOMG]_SHVS^_P"=%AW+%%5]L_O^=&V?W_.BP7+%
M%5]L_O\ G1MG]_SHL%RQ15?;/[_G1MG]_P Z+!<L457VS^_YT;9_?\Z+!<L4
M57VS^_YT;9_?\Z+!<L457VS^_P"=&V?W_.BP7+%%5]L_O^=&V?W_ #HL%RQ1
M5?;/[_G1MG]_SHL%RQ15?;/[_G1MG]_SHL%RQ15?;/[_ )T;9_?\Z+!<L457
MVS^_YT;9_?\ .BP7+%%5]L_O^=&V?W_.BP7+%%5]L_O^=&V?W_.BP7+%%5]L
M_O\ G1MG]_SHL%RQ15?;/[_G1MG]_P Z+!<L457VS^_YT;9_?\Z+!<L457VS
M^_YT;9_?\Z+!<L457VS^_P"=&V?W_.BP7+%%5]L_O^=&V?W_ #HL%RQ15?;/
M[_G1MG]_SHL%RQ15?;/[_G1MG]_SHL%RQ15?;/[_ )T;9_?\Z+!<L457VS^_
MYT;9_?\ .BP7+%%5]L_O^=&V?W_.BP7+%%5]L_O^=&V?W_.BP7+%%5]L_O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!2UC_ ) E_P#]>TG_ *":
M\8^"_P#K-:^D'_L]>SZQ_P @2_\ ^O:3_P!!->,?!?\ UFM?2#_V>M8?"S&?
MQQ/6****#0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *9)]T?6GTR3[H^M %B/_5K]*=38_\ 5K]*=2&%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>3_ (^%_"K]
M4)/^/A?PJ_0P"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 55L_\ C[?Z'^=6JJV?_'V_T/\ .CH!HT445(!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_@!_:W]S\?\ @'6T5R5%'U_^[^/_   _M;^Y^/\ P#K:*Y*BCZ__ '?Q_P"
M']K?W/Q_X!UM%<E11]?_ +OX_P# #^UO[GX_\ ZVBN2HH^O_ -W\?^ ']K?W
M/Q_X!UM%<E11]?\ [OX_\ /[6_N?C_P#K:*Y*BCZ_P#W?Q_X ?VM_<_'_@'6
MT5R5%'U_^[^/_ #^UO[GX_\  .MHKDJ*/K_]W\?^ ']K?W/Q_P" =;17)44?
M7_[OX_\  #^UO[GX_P# .MHKDJ*/K_\ =_'_ ( ?VM_<_'_@'6T5R5%'U_\
MN_C_ , /[6_N?C_P#K:*Y*BCZ_\ W?Q_X ?VM_<_'_@'6T5R5%'U_P#N_C_P
M _M;^Y^/_ .MHKDJ*/K_ /=_'_@!_:W]S\?^ =;17)44?7_[OX_\ /[6_N?C
M_P  ZVBN2HH^O_W?Q_X ?VM_<_'_ (!UM%<E11]?_N_C_P  /[6_N?C_ , Z
MVBN2HH^O_P!W\?\ @!_:W]S\?^ =;17)44?7_P"[^/\ P _M;^Y^/_ .MHKD
MJ*/K_P#=_'_@!_:W]S\?^ =;17)44?7_ .[^/_ #^UO[GX_\ ZVBN2HH^O\
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MN_B']K_W/Q_X!VE%<711]>_N_B']K_W/Q_X!VE%<711]>_N_B']K_P!S\?\
M@':45Q=%'U[^[^(?VO\ W/Q_X!VE%<711]>_N_B']K_W/Q_X!VE%<711]>_N
M_B']K_W/Q_X!VE%<711]>_N_B']K_P!S\?\ @':45Q=%'U[^[^(?VO\ W/Q_
MX!VE%<6"1T.*>)I5Z2./HQI_7E_*-9LNL/Q_X!V-%<JFHW:=)V/UYJS%K=PG
M^L57'TQ6D<93>YM#-*+W31T-%9D.MV\G$@:,^_(K025)5RCAA[&MX5(3^%G;
M3KTZGP.X^BBBM#4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH KR?\ 'POX5?JA)_Q\+^%7Z& 4444@"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "JMG_P ?;_0_SJU56S_X^W^A_G1T
M T:***D HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@"C:?\A)_JU:M95I_R$G^K5JTY;@@HHHJ1A1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!2UC_D"7_\ U[2?^@FO&/@O_K-:^D'_ +/7
ML^L?\@2__P"O:3_T$UXQ\%_]9K7T@_\ 9ZUA\+,9_'$]8HHHH-#.UG_CS3_K
MH/Y&L.MS6?\ CS3_ *Z#^1K#KR<9_%/GLR_COT04445RGGA1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %/CEDB;=&[*?8TR
MBFG;8:;3NC8M=<886X3(_OK_ (5LQ2QS1AXV#*>XKCJE@N);:3?$Y4_H:ZZ6
M+E'26J/2P^93AI4U7XG7T50L=3CN@%?"2^G8_2K]>A"<9J\3VZ=6%2/-!W04
M4459H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>3_CX7\*OU0D_
MX^%_"K]# ****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !56S_X^W^A_G5JJMG_ ,?;_0_SHZ :-%%%2 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!1M/^0D_P!6K5K*M/\
MD)/]6K5IRW!!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MILD?]V-70_F6/\JY#PEX.U+QA?O;V6V.*)=TMQ(#L3T''4GL/K72>+?A)?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+JQN8;FW?[LD3AE/XBOFGQ)\._$'A>T-Y>PQ2V@.&GMW+*G( SD C)(QQ3/
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MTA\W?)]HB;&8V4<*Q/4BM%&+C=O4RE.:G9+0]QHHHK,U"BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 H)5@0
M<$=#73:;>B[@PQ_>+PP_K7,5/:7+6MPL@Z#@CU%;T*OLY>1UX/$NA4N]GN=;
M134=9(U=3D,,BG5ZY].G?5!1113 **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O
M)_Q\+^%7ZH2?\?"_A5^A@%%%%( HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ JK9_\?;_0_P ZM55L_P#C[?Z'^='0#1HHHJ0"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *-I_R
M$G^K5JUE6G_(2?ZM6K3EN""BBBI&%%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "L?Q7:3W_A'5[6U#-/+9RK&J
M=6.TX7\>GXUL44(35U8^.(W,4J2+C*D,,^U?1V@?%;PUK$$2W5XNGW9'SQW/
MRJ#[/]W'U(KFO'OPEFO[^75?#@3S)F+S6CL%!8\ED)XY/8X^O8>1:CHNIZ1(
MT>HV%S:E6V9EC*@GV/0_A72^6HCD7/29]6WUO:ZYHUW9B6.6"YA:)F4[@-PQ
MG@^^>M>4_P#"AO\ J9?_ "1_^V5Y+8:G?Z7-YVGWMQ:R'JT$A0GZXZUZ;X.^
M,-]#>QVGB619[1\+]J5 KQ'U8 88>O&>_-3R2C\+*]I";]Y'L^FVC6&EVEF\
MOG-!"D1DVXWE5 SC)QG'J:Y[QQXXL_!VG9.V;49E/V>VSU_VF]%'Z]!W(ZI6
M5U#*05(R"#P17RYX_P!8;6_&VIW6[=$DI@BQTV)\HQ]<$_C44X\SU-:L^2.A
M)JGQ&\5ZK<M*^L7%LI^[%:,8549S@;>3]22?>H+3QYXKLG#1:_?,0<_OI3*/
MR?->N?"7PCI]IX:M];GMXYK^[)D5Y$R85#$*%ST/&<CU]JW_ !WX*M_%VBR1
MQ1V\>IH0UO<R C!R,AB!D@C([]CVJ^>*=K&2IS<>:YF?#SXCKXMWV%]"EOJ<
M2;OD/R3+W*@\@CN.?7V%WXK?\DUU?_MC_P"CDKDO#/P@U;1-=LM4;6[>.2VE
M#XBB9MP[KR1P1P?J:ZWXK?\ )-=7_P"V/_HY*A\O.N4T3E[-\Q\\:#>Q:;XB
MTR_G#&&VNXII-HR=JN"<>^!75>)/BKXAUNY?[%<R:9:9.R*W?#XX^\XP2?IC
MK7&V%H^H:C:V4>=]Q*D2X&3EB ./QKZLT'P[IGAS3HK33[6*/8H#RA1OD/<L
M>I)K6<DM6C"E&4DTG9'SEIOQ"\5:7<++'K5U. <F.ZD,RM[?-G],5[]X(\6P
M^,- 6^$8BN8V\JXB!R%?&<COM(.1^(YQ7C?Q@T.ST?Q;%)8P"&.\@$KHHPN_
M<02/3. <>OUK?^!$SBYUN#^ I"_T(+C^M3-)QYD73<HSY6=A\5/$&J>&_#%M
M>:3=?9[A[U8F?RU?*E')&&!'517#_#_X@>*-<\<:=IVHZGYUI-YN^/[/$N<1
MLPY50>H%=-\</^1*L_\ L(I_Z+DKS/X4_P#)2M(_[;?^B7HBER-CG)JHE<]0
M^+/BC6?#-MI3Z/>?9FG>02'RD?< %Q]X''4UY?\ \+6\:_\ 0:_\E8?_ (BO
MHN_TG3=55%U'3[2\$>2@N(5DVYZXW XK+O?#OA'3K*:\O-#T:&WA0O)(UE'A
M0/\ @-1&44K-%SA)NZ=CPC_A:WC7_H-?^2L/_P 15G3_ (H^,I]2M89-8W(\
MR*P^S0C() /\%8'BS6;/6]=EN-.TZUL+%/D@B@A6/*@G#,%_B/Z=.U=[\)?
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MB<4XWL*E)J?+>Y[%1116!U!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %+
M6/\ D"7_ /U[2?\ H)KQCX+_ .LUKZ0?^SU[/K'_ "!+_P#Z]I/_ $$UXQ\%
M_P#6:U](/_9ZUA\+,9_'$]8HHHH-#.UG_CS3_KH/Y&L.MS6?^/-/^N@_D:PZ
M\G&?Q3Y[,OX[]$%%%%<IYX4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!N:'=;D:W8\KROTK8KD
M;68V]S'*#T//TKK00P!'(->IA*G-#E?0^ARVMSTN1[H6BBBNL]$**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@"O)_P ?"_A5^J$G_'POX5?H8!1112 **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *JV?_ !]O]#_.
MK55;/_C[?Z'^='0#1HHHJ0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** *-I_R$G^K5JUE6G_(2?ZM6K3EN""BBBI&%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUM$D4$2A$C08"@= !7'Q_%'P-#$D46KJD:*%5%M)@% Z #9P*?\ \+6\%?\
M0:_\E9O_ (BLY<TGL:PY(+1F[XFA-QX4UB!?O26,Z#ZE"*^2Z^QE:.>$,,/'
M(N>1P01Z5\EZ_I,NA:_?:7,&#6TS("W5EZJWXJ0?QJZ+W1&(6S/8/@UX7L!H
M;:]<6Z2WDLS)"S@$1HI'*CLVX'GV'OGNO$_A73?$^DW%K=6\7GLA\JXV_/&^
M."#U[#([BO/?@]XQT^'2F\/7TZ6]PDK/;M(0JR*V/ER?XLYX[@\=*]%\2^*-
M,\+:9)=W\Z!PI,4 8;Y3V"CZ]^@J)\W.:4^7D/E$@JQ5@01P0>U?47P\U"34
M_ .CW,I)?R3$2>IV,4S_ ..U\NN[.[.QRS')/O7U)X TZ32O FD6DN _D>8P
M'8N2^/K\U:5MC'#_ !,^7KB$V]S+ WWHW*'Z@XKU7X,>%[#4I+[6+^W2X-NZ
MQ0)( 5#$$LQ'<X(Q^/MCD/B-H[Z+XZU*)D*Q7$AN8CC *N<\>P.Y?^ UU'P>
M\7V.BW%WI&I3);QW;K)#,_"AP,$,>V1C'T/J*J;;A=$4TE4LSV?5M$TW7;*2
MUU&TBGC==N64;E]P>H(SU%?*>L:>VDZU?:<S;C:W#P[L8W;6(S^.,U]6:KK>
MFZ+IS7^H7<4-N%W!BPR_&<*/XC["OE77-1&KZ_J&I!"BW5Q),JGJH9B0/P%1
M1N:XBVG<][^#FH27W@-(I"3]DN9(%)],!Q_Z'C\*[^N"^#^G26'@**63 -Y.
M]P!W X09_P"^,_B*[VLI_$S:G\*"BBBI+"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L/Q7XGM_"6C#4K
MJVGGC,JQ;80,@G/)R1QQ^9%;E8GB[0_^$C\*ZAI8"^;+'F$L< 2#E>>W('X4
MU:^HI7MH<=H?QCLM:\0V6E_V5);I=2>4)GG!VD@XXQSEL#KW_"O2GC25"DB*
MZGJK#(-?'\D=SIUZT<BRV]U!)@@Y5XW!_,$&O7M!^.*I;)%KVG2/*HP;BTQ\
M_N4) !^AQ[#I6LZ?\ISTZW29W&M_#?PQK<4N_3H[6=^?/M0(V#8/.!P>N>1S
M7S9J5B^F:K>6$A#26L[PL1W*L0?Y5Z[K?QQA:TEBT/39UF=<)/=%1Y9]=@SG
M\_\ "O'0)KR[  :6>9\ #JS$_P!2:NFI+<BLX-^Z?2OPQOY-0^'NEO*27B5H
M,^R,57_QT"OG+6%*:W?HPPRW,@(]]QKZ@\'Z*_A[PEINERD&6&+,F.0'8EF
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M $%*X;XX?\CK9_\ 8.3_ -&25W/P5_Y$63_K]D_]!2N&^.'_ ".MG_V#D_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *Z?2IO.L$R>4^4US%;.@R_/-%Z@,/\ /Y5TX25JENYW
MY=4Y:Z7<VZ***]8^C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH KR?\?"_A5^J$
MG_'POX5?H8!1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *JV?_'V_T/\ .K55;/\ X^W^A_G1T T:***D HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"C:?\A)_JU:M95I_
MR$G^K5JTY;@@HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZQ110Y.6XHP4=CAO'7PZ_P"$UOK2Y_M7[']GB,>W[/YF[)SG.X8I_@3X>_\
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M+Q"5YLC!W<KSTZ<#GCFG^"OAK/X-UE[Z/7!<Q2Q&.6 VFS<.H.=YQ@CT]:]
MHI<\K6*]G&][!1114EA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %+6/\
MD"7_ /U[2?\ H)KQCX+_ .LUKZ0?^SU[/K'_ "!+_P#Z]I/_ $$UXQ\%_P#6
M:U](/_9ZUA\+,9_'$]8HHHH-#.UG_CS3_KH/Y&L.MS6?^/-/^N@_D:PZ\G&?
MQ3Y[,OX[]$%%%%<IYX4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5?T9]FHJ/[RD?U_I5"K.GG
M&H0'_:Q6E)VFGYFV'ERU8OS1U=%%%>V?6!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 5Y/^/A?PJ_5"3_CX7\*OT, HHHI %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %5;/_C[?Z'^=6JJV?_'V_P!#_.CH!HT4
M45(!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %
M&T_Y"3_5JU:RK3_D)/\ 5JU:<MP04445(PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ JO>V%GJ-O]GOK2"ZA)!\N>,.N1T.#Q5BB@#*M_
M#.@6EPEQ;:'IL,T9RDD=I&K*?4$#(K5HHH!*P4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% %+6/^0)?_ /7M)_Z":\8^"_\ K-:^D'_L
M]>SZQ_R!+_\ Z]I/_037C'P7_P!9K7T@_P#9ZUA\+,9_'$]8HHHH-#.UG_CS
M3_KH/Y&L.MS6?^/-/^N@_D:PZ\G&?Q3Y[,OX[]$%%%%<IYX4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5/99^W6^/^>B_SJ"K.GC.H0#_ &LU</B1I25ZD?5'5T445[A]<%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!7D_X^%_"K]4)/^/A?PJ_0P"BBBD 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+%I[%FCFCP)K>3&^,^O'4'L?Y'BJVK_#KPMJ]F\!TBVM7(^2:TC$3(><'Y<
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4M8_Y E_\
M]>TG_H)KQCX+_P"LUKZ0?^SU[/K'_($O_P#KVD_]!->,?!?_ %FM?2#_ -GK
M6'PLQG\<3UBBBB@T,[6?^/-/^N@_D:PZW-9_X\T_ZZ#^1K#KR<9_%/GLR_CO
MT04445RGGA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !5_1DWZBI_NJ3_3^M4*V=!B^>67T 4?
MY_*ML/&]1'5@X<U>*\_R-NBBBO9/J HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M*\G_ !\+^%7ZH2?\?"_A5^A@%%%%( HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ JK9_\ 'V_T/\ZM55L_^/M_H?YT= -&BBBI
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH HVG
M_(2?ZM6K65:?\A)_JU:M.6X(****D84444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)8D\GOUQ] *TJR=KZ&\;VU"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH I:Q_P @2_\ ^O:3_P!!->,?!?\ UFM?2#_V>O9]8_Y E_\
M]>TG_H)KQCX+_P"LUKZ0?^SUK#X68S^.)ZQ1110:&=K/_'FG_70?R-8=;FL_
M\>:?]=!_(UAUY.,_BGSV9?QWZ(****Y3SPHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KI]*A\
MFP3(Y?YC7/6L)N+F.,#J>?IWKK0 H '05W8*&KD>OE5*\G4?H+1117HGMA11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 5Y/^/A?PJ_5"3_CX7\*OT, HHHI %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5;/_C[?
MZ'^=6JJV?_'V_P!#_.CH!HT445(!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% %&T_Y"3_5JU:RK3_D)/\ 5JU:<MP04445(PHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_/\ WUC\*\2\>RMXA^*5W;0DG=<QV48 R01A#]?FS7TA!"EO;QPQ_<C4(OT
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !114]I;-=7"Q#H>I]!32;=D5&+DU%;LU=$MMJ-<,.6X7Z5L
M4V-%CC5%&%48%.KVJ5-0BHGU6'HJC34$%%%%:&P4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% %>3_CX7\*OU0D_X^%_"K]# ****0!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !56S_X^W^A_G5JJMG_Q]O\ 0_SH
MZ :-%%%2 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!1M/^0D_U:M6LJT_Y"3_ %:M6G+<$%%%%2,**** "BBB@ HHHH ****
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MKF&^%W@QY3(=$3<3G GE _(-BNOHIIM;"<4]T4-+T73-$MS!IEC!:QL<L(D
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH HVG_ "$G^K5JUE6G_(2?ZM6K3EN""BBBI&%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% %+6/^0)?_ /7M)_Z":\8^
M"_\ K-:^D'_L]>SZQ_R!+_\ Z]I/_037C'P7_P!9K7T@_P#9ZUA\+,9_'$]8
MHHHH-#.UG_CS3_KH/Y&L.MS6?^/-/^N@_D:PZ\G&?Q3Y[,OX[]$%%%%<IYX4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 445+!;2W+[(D)/<]A32;=D.,7)V1$ 2< 9-;FFZ5LQ-<+\W54/;ZU9L=,
MCM0&?#R^O8?2K]>A0PO+[TSV\'E_)[]7?L%%%%=QZP4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 5Y/\ CX7\*OU0D_X^%_"K]# ****0!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !56S_P"/M_H?
MYU:JK9_\?;_0_P Z.@&C1114@%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 4;3_D)/]6K5K*M/^0D_U:M6G+<$%%%%2,**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *6L?\@2__ .O:3_T$
MUXQ\%_\ 6:U](/\ V>O9]8_Y E__ ->TG_H)KQCX+_ZS6OI!_P"SUK#X68S^
M.)ZQ1110:&=K/_'FG_70?R-8=;FL_P#'FG_70?R-8=>3C/XI\]F7\=^B"BBB
MN4\\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** ">@S3
MQ#*W2-S]%-.S&DWL,HJTFG7;](&_'BK,6B7#_P"L94'YFKC1J2V1M##5I_#%
MF93XXI)FVQH6/H!6]#HEO'S(6D/OP*T(XDB7;&BJ/85TPP<G\3L=U+*ZDM:C
ML8UKHC'#7#8_V16S%#'"@2-0JCTI]%=M.C"G\*/6HX:G17N(****U-PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *\G_'POX5?JA)_Q\+^%
M7Z& 4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "JMG_Q]O]#_ #JU56S_ ./M_H?YT= -&BBBI **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH HVG_(2?ZM6K65:?\A)_JU:
MM.6X(****D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M4M8_Y E__P!>TG_H)KQCX+_ZS6OI!_[/7L^L?\@2_P#^O:3_ -!->,?!?_6:
MU](/_9ZUA\+,9_'$]8HHHH- HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ IDGW1]:?3)/NCZT 6(_]6OTIU-C_ -6OTIU(
M84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 5Y/^/A?PJ_5"3_ (^%_"K]# ****0!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !56S_ ./M_H?YU:JK9_\ 'V_T/\Z.@&C1
M114@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M4;3_ )"3_5JU:RK3_D)/]6K5IRW!!1114C"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **CGC,L+H#@L,9K/_LN3_GH
MM-) :E%9?]ER?\]%H_LN3_GHM.R[B-2BLO\ LN3_ )Z+1_9<G_/1:++N!J45
ME_V7)_ST6C^RY/\ GHM%EW U**R_[+D_YZ+1_9<G_/1:++N!J45E_P!ER?\
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ME_V7)_ST6C^RY/\ GHM%EW U**R_[+D_YZ+1_9<G_/1:++N!J45E_P!ER?\
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M5]*/*^E $E%1^5]*/*^E $E%1^5]*/*^E $E%1^5]*/*^E $E%1^5]*/*^E
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MW_OBC[&_]\46 N453^QO_?%'V-_[XHL!<HJG]C?^^*/L;_WQ18"Y15/[&_\
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MEW =:?\ (2?ZM6K618KMOMI/W<BM>B6X(****D84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 4M8_Y E__P!>TG_H)KQCX+_ZS6OI!_[/
M7L^L?\@2_P#^O:3_ -!->,?!?_6:U](/_9ZUA\+,9_'$]8HHHH- HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDGW1]:?
M3)/NCZT 6(_]6OTIU-C_ -6OTIU(84444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 5Y/^/A?PJ_5"3_ (^%_"K]# ****0!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !56S_
M ./M_H?YU:JK9_\ 'V_T/\Z.@&C1114@%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 4;3_ )"3_5JU:RK3_D)/]6K5IRW!!111
M4C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH HVG_ "$G^K5JUE6G_(2?ZM6K3EN""BBBI&%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% %+6/^0)?_ /7M)_Z":\8^
M"_\ K-:^D'_L]>SZQ_R!+_\ Z]I/_037C'P7_P!9K7T@_P#9ZUA\+,9_'$]8
MHHHH- JIJ?\ R#I?P_F*MU4U/_D'2_A_,5G6_AR]&8XC^#/T?Y'.T445X9\H
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !2JQ4Y4D'VI**8R_;ZK-%A9/WB^_6M:WO(;D?(WS?W3UKFJ
M56*L&4D$="*Z:6*G#1ZH[J&85:6DM4=916/9ZJ00EP<CL_\ C6NK!E!4@@]Q
M7I4ZL:BO$]NAB(5HW@Q:***T-PHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F2?='UI],D^Z/K0!8C_
M -6OTIU-C_U:_2G4AA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!7D_X^%_"K]4)/^/A?PJ_0P"BBBD 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 55L_^/M_H?YU:JK9_
M\?;_ $/\Z.@&C1114@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 4;3_D)/]6K5K*M/^0D_P!6K5IRW!!1114C"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"EK'_($O_\ KVD_]!->,?!?
M_6:U](/_ &>O9]8_Y E__P!>TG_H)KQCX+_ZS6OI!_[/6L/A9C/XXGK%%%%!
MH%5-3_Y!TOX?S%6ZJ:G_ ,@Z7\/YBLZW\.7HS'$?P9^C_(YVBBBO#/E HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!7D_X^%_"K]4)
M/^/A?PJ_0P"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 55L_^/M_H?YU:JK9_P#'V_T/\Z.@&C1114@%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 4;3_D)/\ 5JU:RK3_
M )"3_5JU:<MP04445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAA1110!\LZGXL\1QZK>(GB#5559W 47D@ &X\=:J_P#"7>)O^ABU;_P-D_\
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M(V*]"0 .*TFHKX3*FYOXBS11169J%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!2UC_D"7__ %[2?^@FO&/@O_K-:^D'_L]>SZQ_R!+_ /Z]
MI/\ T$UXQ\%_]9K7T@_]GK6'PLQG\<3UBBBB@T"JFI_\@Z7\/YBK=5-3_P"0
M=+^'\Q6=;^'+T9CB/X,_1_D<[1117AGR@4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %7]-O#!)Y;G]VWZ&J%%7";A+F1I2JRI34XG6T5GZ7=>=#Y3'YT_45H5[5.
M:G%21]31JQJP4X]0HHHJS0**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *9)]T?6GTR3[H^M %B/_5K]*=38_\ 5K]*
M=2&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% %>3_ (^%_"K]4)/^/A?PJ_0P"BBBD 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 55L_\ C[?Z'^=6JJV?_'V_T/\ .CH!
MHT445(!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=@Q'Q(^D_!?B?0+7P7H\%QKFF0S1VJ*\<EW&K*<=""<@UMOXR\,1H6;Q#I1
M_NW<;'\@:^4:*'238*NTK6/;?B=\0]&O/#4VC:3<K>3W14221_<C0-D\]R2H
M&/0Y]*\4CC>:1(XT9Y'(5549+$] !ZUIZ#X;U3Q->-:Z5;B:50&?,BJ%7.,G
M)Z5[+X&^$R:#>PZKK%PEQ>Q'=%#%GRXV[,2<%B/I@>_6G>--6)M*J[G?:!IQ
MTCP[IVG-@O;6T<3D=V"@$_GFM&BBN8[4K!1110 4444 %%%% !1110 4444
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M!LG_ ,57UA5#6=8L]!TJXU*_D\NWA7)QU8]E [DG@5,9V5K&DZ3;O>Q\O?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@"EK'_($O_\ KVD_]!->,?!?_6:U](/_ &>O9]8_Y E__P!>TG_H)KQC
MX+_ZS6OI!_[/6L/A9C/XXGK%%%%!H%5-3_Y!TOX?S%6ZJ:G_ ,@Z7\/YBLZW
M\.7HS'$?P9^C_(YVBBBO#/E HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** );
M:8V\ZR#L>?I73JP= RG((R*Y.MS2)_,MS&3RAX^E=V"J6ER/J>KEE:TW2?4T
M:***](]P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *9)]T?6GTR3[H^M %B/_ %:_2G4V/_5K]*=2&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>3_CX7\*O
MU0D_X^%_"K]# ****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !56S_X^W^A_G5JJMG_ ,?;_0_SHZ :-%%%2 4444 %%%%
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M'_1?^OE?ZU]25\M_#[_D?]%_Z^5_K7U)65;<VP_PL^3_ !=_R.NO?]A&X_\
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M.M;29[1K'AO1]?MWAU*PAG#?QE<.#C (8<@\U\K:K:)8:Q>V<<HECM[B2)9
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M>0@<=/G'/TKW/XR?\B!)_P!?,7]:Y#X.>#IYM1'B6]B9+:$%;0,,>8YR"WT
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M &Q_]')5OX=_\D_T7_KW_J:J?%;_ ))KJ_\ VQ_]')6:^/YFS_A_(\'\#_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *N:9-Y5ZH[/\ *:IT
MJL4=6'4'(JX2Y9*1I2FZ<U-=#K**:C!XU<=& (IU>Z?6IWU"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F2?='UI]
M,D^Z/K0!8C_U:_2G4V/_ %:_2G4AA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!7D_P"/A?PJ_5"3_CX7\*OT, HHHI %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5;/_
M (^W^A_G5JJMG_Q]O]#_ #HZ :-%%%2 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!1M/^0D_U:M6LJT_Y"3_5JU:<MP04445(
MPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *X;XJ>']4\2>&+:STFU^T7"7JRLGF*F%"."<L0.K"NYHII
MV=Q27,K,^?\ PK\-O%NF^*]*O;O2?+MX+I))'^TQ':H.2<!LFOH"BBG*3EN3
M""@K(*\-\=?"K5I?$DMWX<L$FLKD>8T:R1QB%^Z@,PX[C'KCM7N5%$9.+T"<
M%-69X)X/^'/BO2O%^EWU[I7E6T$X>1_M$3;1] Q->]T442DY;A""@K(^>_$?
MPT\77_B?5KRVTC?;W%[-+$_VF(;E9R0<%LC@]Z]0^%^@ZEX=\*/9:K;?9[@W
M3R!-ZO\ *0H!RI([&NTHIN;:L*-)1=T>=?%CP?J/B>QTZ72;47%W;2,K)YBH
M=C#.<L0."H_/ZUYC!\)_&+7$:S:04B+ .PN83M&>3]^OI.BG&HTK"E1C)W8R
M&&.W@C@B7;'&H11G. !@5X/XP^'/BO5?%^J7UEI7FVT\Y>-_M$2[A]"P->]T
M5,9.+NBIP4U9GGGPG\,ZQX9TW48=7M/LSS3*T8\Q'R ,'[I-=-XSTZZU;P?J
M=A91>;<SP[8TW!=QR.Y(%;M%#DV[C44H\I\T?\*I\:_] 7_R:A_^+KW[PG8W
M.F>$M*L;R/R[F"V1)$W [6 Y&1P:V:*<IN6Y,*2@[H*R?$OA^U\3Z#<:7=_*
MLHRD@7)C<=&'^>02.]:U%0G8MJ^C/FI_A1XT5V4:.& . PNH<'WY;-=]X,L/
M'?AWPQJFDS:.['R6;3W%W#^[E;@C[_3)W=N0?6O5Z*T=1O1F<:*B[IGS2?A5
MXV9BS:,23R2;J'G_ ,?KVOX=>')O#'@^WLKN/R[R1WFN$W!L,3@#(X^Z%[UU
M=%*51R5F.%*,'=!1114&ARWQ!\-OXG\)7-G;Q+)>H1+;9P/F!Y&3TR,CKWKQ
M'_A5/C7_ * O_DU#_P#%U]+T5<:CBK(SG2C-W9C>%!JJ^&+&/6X##J,4?ERJ
M75LX. <J2.1@ULT45#+2LK!1110,^<=0^%WC*?4KJ:/1]R/,[*?M,(R"21_'
M7L7PXT:_T'P9;6&IP>1=))(S)O5L L2.5)%=915RFY*S,X4E%W1YC\6/!6J^
M)9M-N]&M/M$\2O%,OF(GR\%?O$=]WYUP&F_"?Q4^JV:W^DF.S:=!.XN8CMCW
M#<<!\],]*^C:*:J-*PI48R=V%?/?B/X:>+K_ ,3ZM>6VD;[>XO9I8G^TQ#<K
M.2#@MD<'O7T)14QDX[%3@I[G#?"OP_JGAOPQ<V>K6OV>X>]:54\Q7RI1 #E2
M1U4UW-%%)N[N5%<JL@JKJ<,EQI5Y!$NZ22!T49QDE2!5JBD,^:/^%4^-?^@+
M_P"34/\ \77OWA.QN=,\):58WD?EW,%LB2)N!VL!R,C@ULT5<IN6YG"DH.Z,
M+QGIUUJW@_4["RB\VYGAVQIN"[CD=R0*\%_X53XU_P"@+_Y-0_\ Q=?2]%$9
MN.B"=)3=V8WA.QN=,\):58WD?EW,%LB2)N!VL!R,C@ULT45#U+2LK&3XE\/V
MOB?0;C2[OY5E&4D"Y,;CHP_SR"1WKP!_A1XT5V4:.& . PNH<'WY;-?2M%7&
M;CL1.E&>K/.?A=IOBOP_;3:1KFFM'8#,EO+]HC?RV)^9,*Q.#G/L<^M>C445
M+=W<J,>56"BBBD4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ/6NIHHYG:P<D;WMJ8?BKPK8^+]+BT_4);B**.83 V[*K;@K+W!XPQK"\/\
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M **** "BBB@ HHHH **** "BBB@ HHHH I:Q_P @2_\ ^O:3_P!!->,?!?\
MUFM?2#_V>O9]8_Y E_\ ]>TG_H)KQCX+_P"LUKZ0?^SUK#X68S^.)ZQ1110:
M!534_P#D'2_A_,5;JIJ?_(.E_#^8K.M_#EZ,QQ'\&?H_R.=HHHKPSY0****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH Z2P??8PGT7'Y<59JCI)S8CV8U
M>KW*+O3B_(^KPTN:C%^2"BBBM#8**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ IDGW1]:?3)/NCZT 6(_P#5K]*=38_]6OTI
MU(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 5Y/^/A?PJ_5"3_CX7\*OT, HHHI %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %5;/_C[?Z'^=6JJV?_'V_P!#_.CH!HT4
M45(!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %
M&T_Y"3_5JU:RK3_D)/\ 5JU:<MP04445(PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH W=&_P"/-O\ ?/\ (5H50T@8L1[L:OU[=#^%$^IP
MG\"/H%%%%:G0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4R3[H^M/IDGW1]: +$?\ JU^E.IL?^K7Z4ZD,**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *\G_'POX5?J
MA)_Q\+^%7Z& 4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "JMG_Q]O]#_ #JU56S_ ./M_H?YT= -&BBBI **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH HVG_(2?ZM6K65:
M?\A)_JU:M.6X(****D84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% %&_UG2]*9%U'4K.S:0$H+B=
M8RP'7&XC-.L-6TW55=M.U"TO!'@.;>99-N>F=I.*\&^,5X^H>/Q91Y8VT$<*
MH,_>;Y_S.\?D*U?@7=-%K>KV)X\RW20J1SE&Q_[/6OL_=N8JK[_*>X4445D;
M#)IHK>"2>>1(HHU+O([!550,DDGH *S(?%/AZXGC@@U[2Y99&")&EY&S,Q.
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$0]1G\^:M4V)!'$B#HJ@4ZO>@N6*1];2CRP4>R"BBBJ+"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *9)]T?6GTR3[H^M %
MB/\ U:_2G4V/_5K]*=2&%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% %>3_CX7\*OU0D_X^%_"K]# ****0!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !56S_X^W^A_G5JJ
MMG_Q]O\ 0_SHZ :-%%%2 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!1M/^0D_U:M6LJT_Y"3_ %:M6G+<$%%%%2,**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWJNJRJSF.$1"1N<L[9//K\OZ^]-\<:4G@OX8Z7H*E#=WMQYUTX(^8JN6 [D
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKC_ 'C+3_$>@V< N474H(ECG@=L.648+ =P<9XZ=ZU/$?BW1_"]E)/?W<8E
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MP 1CUW$C\*]H^(NH_P!F> M7F$@1Y(?(3)Y)<A3CWP2?PKR3X2^'KC6_%O\
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M+?(/T8_E2@]'(JHM8Q1]#4445B= 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 4M8_P"0)?\ _7M)_P"@FO&/@O\ ZS6OI!_[/7L^L?\ ($O_ /KVD_\ 037C
M'P7_ -9K7T@_]GK6'PLQG\<3UBBBB@T"JFI_\@Z7\/YBK=5-3_Y!TOX?S%9U
MOX<O1F.(_@S]'^1SM%%%>&?*!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 /
MAB,TRQKU8UU$<8BC5%'"C%9VDVNQ//8?,W"_2M.O5PE+ECS/=GT&78?V<.=[
MO\@HHHKK/1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "F2?='UI],D^Z/K0!8C_U:_2G4V/\ U:_2G4AA1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!7D_X^%_
M"K]4)/\ CX7\*OT, HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %5;/\ X^W^A_G5JJMG_P ?;_0_SHZ :-%%%2 4444
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MC 7GV]J](HJ%)IW-)14E9E'1K :5H=AI_P O^C6Z1$IT)50":O444B@HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH 1E5U*L 5(P01P164WA;P\\IE?0=+:0G)<V<9.?7.*UJ*+BLF
M,AABMXEB@B2*->B(H4#\!3Z**!A1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 4M8_P"0)?\ _7M)_P"@FO&/@O\ ZS6OI!_[/7L^
ML?\ ($O_ /KVD_\ 037C'P7_ -9K7T@_]GK6'PLQG\<3UBBBB@T"JFI_\@Z7
M\/YBK=5-3_Y!TOX?S%9UOX<O1F.(_@S]'^1SM%%%>&?*!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5;L+,W,P+#]VOWO?VJ*VMGN90B].Y]*Z."%+>(1H.!^M=>
M&H>T?,]CT,#A'5ESR^%?B/ "@ # %+117JGT(4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,D^Z/K3Z9)]T?
M6@"Q'_JU^E.IL?\ JU^E.I#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@"O)_Q\+^%7ZH2?\ 'POX5?H8!1112 **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *JV?\ Q]O]
M#_.K55;/_C[?Z'^='0#1HHHJ0"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** *-I_P A)_JU:M95I_R$G^K5JTY;@@HHHJ1A1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!2UC_D"7_P#U[2?^
M@FO&/@O_ *S6OI!_[/7L^L?\@2__ .O:3_T$UXQ\%_\ 6:U](/\ V>M8?"S&
M?QQ/6****#0*J:G_ ,@Z7\/YBK=5-3_Y!TOX?S%9UOX<O1F.(_@S]'^1SM%%
M%>&?*!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !4]K:R74FU!A1U;L*LV>F/.0\N4C_4U
MM1Q)"@2-0JBNRAA7/WI:(]+"X"53WJFB_,9;V\=M&$0?4]S4U%%>FDDK(]Z,
M5%<L=@HHHIC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ IDGW1]:?3)/NCZT 6(_]6OTIU-C_P!6OTIU(844
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5
MY/\ CX7\*OU0D_X^%_"K]# ****0!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !56S_P"/M_H?YU:JK9_\?;_0_P Z.@&C1114
M@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4;3
M_D)/]6K5K*M/^0D_U:M6G+<$%%%%2,**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** *6L?\@2__ .O:3_T$UXQ\%_\ 6:U](/\ V>O9]8_Y
M E__ ->TG_H)KQCX+_ZS6OI!_P"SUK#X68S^.)ZQ1110:!534_\ D'2_A_,5
M;JIJ?_(.E_#^8K.M_#EZ,QQ'\&?H_P CG:***\,^4"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***4(QZ*3]!3'82B
MI5MIW^["Y_X#4R:9=.?]7M_WC5*G.6R-(T:DOABRI16M'HO_ #UE_!15Z&QM
MX.5C!/JW)KHA@ZDM]#KIY;6E\6ABV]A/<<A=J_WFK7M=-AMR&/SOZGM5RBNV
MEA80UW9ZE# 4J6N["BBBN@[0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDGW1]:?3)/NCZT
M6(_]6OTIU-C_ -6OTIU(84444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 5Y/^/A?PJ_5"3_ (^%_"K]# ****0!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !56S_ ./M_H?Y
MU:JK9_\ 'V_T/\Z.@&C1114@%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 4;3_ )"3_5JU:RK3_D)/]6K5IRW!!1114C"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"EK'_ "!+_P#Z]I/_
M $$UXQ\%_P#6:U](/_9Z]GUC_D"7_P#U[2?^@FO&/@O_ *S6OI!_[/6L/A9C
M/XXGK%%%%!H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %,D^Z/K3Z9)]T?6@"Q'_JU^E.IL?^K7Z4ZD,**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *\G_ !\+^%7Z
MH2?\?"_A5^A@%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ JK9_\ 'V_T/\ZM55L_^/M_H?YT= -&BBBI **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH HVG_(2?ZM6K65:?
M\A)_JU:M.6X(****D84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^^_Z4?V7%_??]*- U+'VNW_YZK^='VNW_P">J_G5?^RXO[[_ *4?V7%_??\
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M *4?V7%_??\ 2C0-2Q]KM_\ GJOYT?:[?_GJOYU7_LN+^^_Z4?V7%_??]*-
MU+'VNW_YZK^='VNW_P">J_G5?^RXO[[_ *4?V7%_??\ 2C0-2Q]KM_\ GJOY
MT?:[?_GJOYU7_LN+^^_Z4?V7%_??]*- U+'VNW_YZK^='VNW_P">J_G5?^RX
MO[[_ *4?V7%_??\ 2C0-2Q]KM_\ GJOYT?:[?_GJOYU7_LN+^^_Z4?V7%_??
M]*- U+'VNW_YZK^='VNW_P">J_G5?^RXO[[_ *4?V7%_??\ 2C0-2Q]KM_\
MGJOYT?:[?_GJOYU7_LN+^^_Z4?V7%_??]*- U+'VNW_YZK^='VNW_P">J_G5
M?^RXO[[_ *4?V7%_??\ 2C0-2Q]KM_\ GJOYT?:[?_GJOYU7_LN+^^_Z4?V7
M%_??]*- U+'VNW_YZK^='VNW_P">J_G5?^RXO[[_ *4?V7%_??\ 2C0-2Q]K
MM_\ GJOYT?:[?_GJOYU7_LN+^^_Z4?V7%_??]*- U+'VNW_YZK^='VNW_P">
MJ_G5?^RXO[[_ *4?V7%_??\ 2C0-2Q]KM_\ GJOYT?:[?_GJOYU7_LN+^^_Z
M4?V7%_??]*- U+'VNW_YZK^='VNW_P">J_G5?^RXO[[_ *4?V7%_??\ 2C0-
M2Q]KM_\ GJOYT?:[?_GJOYU7_LN+^^_Z4?V7%_??]*- U+'VNW_YZK^='VNW
M_P">J_G5?^RXO[[_ *4?V7%_??\ 2C0-2Q]KM_\ GJOYT?:[?_GJOYU7_LN+
M^^_Z4?V7%_??]*- U+'VNW_YZK^='VNW_P">J_G5?^RXO[[_ *4?V7%_??\
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M *4?V7%_??\ 2C0-2Q]KM_\ GJOYT?:[?_GJOYU7_LN+^^_Z4?V7%_??]*-
MU+'VNW_YZK^='VNW_P">J_G5?^RXO[[_ *4?V7%_??\ 2C0-2Q]KM_\ GJOY
MT?:[?_GJOYU7_LN+^^_Z4?V7%_??]*- U+'VNW_YZK^='VNW_P">J_G5?^RX
MO[[_ *4?V7%_??\ 2C0-2Q]KM_\ GJOYT?:[?_GJOYU7_LN+^^_Z4?V7%_??
M]*- U+'VNW_YZK^='VNW_P">J_G5?^RXO[[_ *4?V7%_??\ 2C0-2Q]KM_\
MGJOYT?:[?_GJOYU7_LN+^^_Z4?V7%_??]*- U+'VNW_YZK^='VNW_P">J_G5
M?^RXO[[_ *4?V7%_??\ 2C0-2Q]KM_\ GJOYT?:[?_GJOYU7_LN+^^_Z4?V7
M%_??]*- U+'VNW_YZK^='VNW_P">J_G5?^RXO[[_ *4?V7%_??\ 2C0-2Q]K
MM_\ GJOYT?:[?_GJOYU7_LN+^^_Z4?V7%_??]*- U+'VNW_YZK^='VNW_P">
MJ_G5?^RXO[[_ *4?V7%_??\ 2C0-2Q]KM_\ GJOYT?:[?_GJOYU7_LN+^^_Z
M4?V7%_??]*- U+'VNW_YZK^='VNW_P">J_G5?^RXO[[_ *4?V7%_??\ 2C0-
M2Q]KM_\ GJOYT?:[?_GJOYU7_LN+^^_Z4?V7%_??]*- U+'VNW_YZK^='VNW
M_P">J_G5?^RXO[[_ *4?V7%_??\ 2C0-2Q]KM_\ GJOYT?:[?_GJOYU7_LN+
M^^_Z4?V7%_??]*- U+'VNW_YZK^='VNW_P">J_G5?^RXO[[_ *4?V7%_??\
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M *4?V7%_??\ 2C0-2Q]KM_\ GJOYT?:[?_GJOYU7_LN+^^_Z4?V7%_??]*-
MU+'VNW_YZK^='VNW_P">J_G5?^RXO[[_ *4?V7%_??\ 2C0-2Q]KM_\ GJOY
MT?:[?_GJOYU7_LN+^^_Z4?V7%_??]*- U+'VNW_YZK^='VNW_P">J_G5?^RX
MO[[_ *4?V7%_??\ 2C0-2Q]KM_\ GJOYT?:[?_GJOYU7_LN+^^_Z4?V7%_??
M]*- U+'VNW_YZK^='VNW_P">J_G5?^RXO[[_ *4?V7%_??\ 2C0-2Q]KM_\
MGJOYT?:[?_GJOYU7_LN+^^_Z4?V7%_??]*- U+'VNW_YZK^='VNW_P">J_G5
M?^RXO[[_ *4?V7%_??\ 2C0-2Q]KM_\ GJOYT?:[?_GJOYU7_LN+^^_Z4?V7
M%_??]*- U+'VNW_YZK^='VNW_P">J_G5?^RXO[[_ *4?V7%_??\ 2C0-2Q]K
MM_\ GJOYT?:[?_GJOYU7_LN+^^_Z4?V7%_??]*- U+'VNW_YZK^='VNW_P">
MJ_G5?^RXO[[_ *4?V7%_??\ 2C0-2Q]KM_\ GJOYT?:[?_GJOYU7_LN+^^_Z
M4?V7%_??]*- U+'VNW_YZK^='VNW_P">J_G5?^RXO[[_ *4?V7%_??\ 2C0-
M2Q]KM_\ GJOYT?:[?_GJOYU7_LN+^^_Z4?V7%_??]*- U+'VNW_YZK^='VNW
M_P">J_G5?^RXO[[_ *4?V7%_??\ 2C0-2Q]KM_\ GJOYT?:[?_GJOYU7_LN+
M^^_Z4?V7%_??]*- U+'VNW_YZK^='VNW_P">J_G5?^RXO[[_ *4?V7%_??\
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M55'4DJ<"O*OA3HVI:.^K'4;.:V\T1;/,7&[&_./S%>H7UDEKI]S<(S%HHF<
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M+ZT;E]:;Y8]31Y8]30 [<OK1N7UIOECU-'ECU- #MR^M&Y?6F^6/4T>6/4T
M.W+ZT;E]:;Y8]31Y8]30 [<OK1N7UIOECU-'ECU- #MR^M,<@C@TOECU-(RA
M10!-'(@C4%AG%/\ ,3^\*B2!60$D\T[[.OJ:6@#_ #$_O"CS$_O"F?9U]31]
MG7U-+08_S$_O"CS$_O"F?9U]31]G7U-&@#_,3^\*/,3^\*9]G7U-'V=?4T:
M/\Q/[PH\Q/[PIGV=?4T?9U]31H _S$_O"CS$_O"F?9U]31]G7U-&@#_,3^\*
M/,3^\*9]G7U-'V=?4T: /\Q/[PH\Q/[PIGV=?4T?9U]31H _S$_O"CS$_O"F
M?9U]31]G7U-&@#_,3^\*/,3^\*9]G7U-'V=?4T: /\Q/[PH\Q/[PIGV=?4T?
M9U]31H _S$_O"CS$_O"F?9U]31]G7U-&@#_,3^\*/,3^\*9]G7U-'V=?4T:
M/\Q/[PH\Q/[PIGV=?4T?9U]31H _S$_O"CS$_O"F?9U]31]G7U-&@#_,3^\*
M/,3^\*9]G7U-'V=?4T: /\Q/[PH\Q/[PIGV=?4T?9U]31H _S$_O"CS$_O"F
M?9U]31]G7U-&@#_,3^\*/,3^\*9]G7U-'V=?4T: /\Q/[PH\Q/[PIGV=?4T?
M9U]31H _S$_O"CS$_O"F?9U]31]G7U-&@#_,3^\*/,3^\*9]G7U-'V=?4T:
M/\Q/[PH\Q/[PIGV=?4T?9U]31H _S$_O"CS$_O"F?9U]31]G7U-&@#_,3^\*
M/,3^\*9]G7U-'V=?4T: /\Q/[PH\Q/[PIGV=?4T?9U]31H _S$_O"CS$_O"F
M?9U]31]G7U-&@#_,3^\*/,3^\*9]G7U-'V=?4T: /\Q/[PH\Q/[PIGV=?4T?
M9U]31H _S$_O"CS$_O"F?9U]31]G7U-&@#_,3^\*/,3^\*9]G7U-'V=?4T:
M/\Q/[PH\Q/[PIGV=?4T?9U]31H _S$_O"CS$_O"F?9U]31]G7U-&@#_,3^\*
M/,3^\*9]G7U-'V=?4T: /\Q/[PH\Q/[PIGV=?4T?9U]31H!'(P,RD'CBKGGQ
M?WQ5)XPLH4$X-6?L:?WFINPB3SXO[XH\^+^^*C^QI_>:C[&G]YJ6@R3SXO[X
MH\^+^^*C^QI_>:C[&G]YJ- )//B_OBCSXO[XJ/[&G]YJ/L:?WFHT D\^+^^*
M//B_OBH_L:?WFH^QI_>:C0"3SXO[XH\^+^^*C^QI_>:C[&G]YJ- )//B_OBC
MSXO[XJ/[&G]YJ/L:?WFHT D\^+^^*//B_OBH_L:?WFH^QI_>:C0"3SXO[XH\
M^+^^*C^QI_>:C[&G]YJ- )//B_OBCSXO[XJ/[&G]YJ/L:?WFHT D\^+^^*//
MB_OBH_L:?WFH^QI_>:C0"3SXO[XH\^+^^*C^QI_>:C[&G]YJ- )//B_OBCSX
MO[XJ/[&G]YJ/L:?WFHT D\^+^^*//B_OBH_L:?WFH^QI_>:C0"3SXO[XH\^+
M^^*C^QI_>:C[&G]YJ- )//B_OBCSXO[XJ/[&G]YJ/L:?WFHT D\^+^^*//B_
MOBH_L:?WFH^QI_>:C0"3SXO[XH\^+^^*C^QI_>:C[&G]YJ- )//B_OBCSXO[
MXJ/[&G]YJ/L:?WFHT D\^+^^*//B_OBH_L:?WFH^QI_>:C0"3SXO[XH\^+^^
M*C^QI_>:C[&G]YJ- )//B_OBCSXO[XJ/[&G]YJ/L:?WFHT D\^+^^*//B_OB
MH_L:?WFH^QI_>:C0"3SXO[XH\^+^^*C^QI_>:C[&G]YJ- )//B_OBCSXO[XJ
M/[&G]YJ/L:?WFHT D\^+^^*//B_OBH_L:?WFH^QI_>:C0"3SXO[XH\^+^^*C
M^QI_>:C[&G]YJ- )//B_OBCSXO[XJ/[&G]YJ/L:?WFHT D\^+^^*//B_OBH_
ML:?WFH^QI_>:C0"3SXO[XH\^+^^*C^QI_>:C[&G]YJ- )//B_OBCSXO[XJ/[
M&G]YJ/L:?WFHT D\^+^^*//B_OBH_L:?WFH^QI_>:C0"3SXO[XH\^+^^*C^Q
MI_>:C[&G]YJ- )//B_OBCSXO[XJ/[&G]YJ/L:?WFHT D\^+^^*//B_OBH_L:
M?WFH^QI_>:C0"3SXO[XJO:R(ERS,P (/)J3[&G]YJA@A66=D)( !Z4:"-#[3
M#_ST6C[3#_ST6H?[/C_OO^E']GQ_WW_2IT&3?:8?^>BT?:8?^>BU#_9\?]]_
MTH_L^/\ OO\ I1H!-]IA_P">BT?:8?\ GHM0_P!GQ_WW_2C^SX_[[_I1H!-]
MIA_YZ+1]IA_YZ+4/]GQ_WW_2C^SX_P"^_P"E&@$WVF'_ )Z+1]IA_P">BU#_
M &?'_??]*/[/C_OO^E&@$WVF'_GHM'VF'_GHM0_V?'_??]*/[/C_ +[_ *4:
M 3?:8?\ GHM'VF'_ )Z+4/\ 9\?]]_TH_L^/^^_Z4: 3?:8?^>BT?:8?^>BU
M#_9\?]]_TH_L^/\ OO\ I1H!-]IA_P">BT?:8?\ GHM0_P!GQ_WW_2C^SX_[
M[_I1H!-]IA_YZ+1]IA_YZ+4/]GQ_WW_2C^SX_P"^_P"E&@$WVF'_ )Z+1]IA
M_P">BU#_ &?'_??]*/[/C_OO^E&@$WVF'_GHM'VF'_GHM0_V?'_??]*/[/C_
M +[_ *4: 3?:8?\ GHM'VF'_ )Z+4/\ 9\?]]_TH_L^/^^_Z4: 3?:8?^>BT
M?:8?^>BU#_9\?]]_TH_L^/\ OO\ I1H!-]IA_P">BT?:8?\ GHM0_P!GQ_WW
M_2C^SX_[[_I1H!-]IA_YZ+1]IA_YZ+4/]GQ_WW_2C^SX_P"^_P"E&@$WVF'_
M )Z+1]IA_P">BU#_ &?'_??]*/[/C_OO^E&@$WVF'_GHM'VF'_GHM0_V?'_?
M?]*/[/C_ +[_ *4: 3?:8?\ GHM'VF'_ )Z+4/\ 9\?]]_TH_L^/^^_Z4: 3
M?:8?^>BT?:8?^>BU#_9\?]]_TH_L^/\ OO\ I1H!-]IA_P">BT?:8?\ GHM0
M_P!GQ_WW_2C^SX_[[_I1H!-]IA_YZ+1]IA_YZ+4/]GQ_WW_2C^SX_P"^_P"E
M&@$WVF'_ )Z+1]IA_P">BU#_ &?'_??]*/[/C_OO^E&@$WVF'_GHM'VF'_GH
MM0_V?'_??]*/[/C_ +[_ *4: 3?:8?\ GHM'VF'_ )Z+4/\ 9\?]]_TH_L^/
M^^_Z4: 3?:8?^>BT?:8?^>BU#_9\?]]_TH_L^/\ OO\ I1H!-]IA_P">BT?:
M8?\ GHM0_P!GQ_WW_2C^SX_[[_I1H!-]IA_YZ+1]IA_YZ+4/]GQ_WW_2C^SX
M_P"^_P"E&@$WVF'_ )Z+1]IA_P">BU#_ &?'_??]*/[/C_OO^E&@$WVF'_GH
MM'VF'_GHM0_V?'_??]*/[/C_ +[_ *4: 3?:8?\ GHM'VF'_ )Z+4/\ 9\?]
M]_TH_L^/^^_Z4: 3?:8?^>BT?:8?^>BU#_9\?]]_TH_L^/\ OO\ I1H!-]IA
M_P">BT?:8?\ GHM0_P!GQ_WW_2C^SX_[[_I1H!-]IA_YZ+1]IA_YZ+4/]GQ_
MWW_2C^SX_P"^_P"E&@#+,@ZBQ!X.[%:M9-DH6_*C^'(%:U$MP04445(PHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH I:Q_P @2_\ ^O:3
M_P!!->,?!?\ UFM?2#_V>O9]8_Y E_\ ]>TG_H)KQCX+_P"LUKZ0?^SUK#X6
M8S^.)ZQ1110:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !3)/NCZT^F2?='UH L1_ZM?I3J;'_JU^E.I#"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O)_P ?"_A5
M^J$G_'POX5?H8!1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *JV?_ !]O]#_.K55;/_C[?Z'^='0#1HHHJ0"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *-I_R$G^K5JUE6
MG_(2?ZM6K3EN""BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8/[5G_*CI_M5O_S\1?\ ?8H^U6__ #\1?]]BN8HH^O2[!_:L_P"5'3_:K?\
MY^(O^^Q1]JM_^?B+_OL5S%%'UZ78/[5G_*CI_M5O_P _$7_?8H^U6_\ S\1?
M]]BN8HH^O2[!_:L_Y4=/]JM_^?B+_OL4?:K?_GXB_P"^Q7,44?7I=@_M6?\
M*CJ1/">DJ'Z,*>&4]"#^-<G2ABIR"1]*I8Y]8E+-GUC^)UE%<REY<1_=E;\3
MFK<6LRKQ(BO].#6L<;3>^AT0S.C+XKHVZ*IPZG;2X!;8WHU7 01D'(KIC.,E
M>+.Z%6%17@[A1115%A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !3)/NCZT^F2?='UH L1_P"K7Z4ZFQ_ZM?I3
MJ0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH KR?\?"_A5^J$G_'POX5?H8!1112 **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *JV?_'V_T/\ .K55;/\ X^W^A_G1T T:
M***D HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M"C:?\A)_JU:M95I_R$G^K5JTY;@@HHHJ1A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4R3[H^M/IDGW1]: +$?^K7Z4ZFQ_ZM?I3J0PHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH KR?\ 'POX5?JA)_Q\
M+^%7Z& 4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "JMG_P ?;_0_SJU56S_X^W^A_G1T T:***D HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"C:?\A)_JU:M95I_R$G^K
M5JTY;@@HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!2UC_D"7_\ U[2?^@FO&/@O_K-:^D'_ +/7L^L?\@2__P"O:3_T$UXQ\%_]
M9K7T@_\ 9ZUA\+,9_'$]8HHHH- JIJ?_ "#I?P_F*MU4U/\ Y!TOX?S%9UOX
M<O1F.(_@S]'^1SM%%%>&?*!1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ JK9_\?;_ $/\ZM55L_\ C[?Z
M'^='0#1HHHJ0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %W3KS[-+M8_NVZ^WO7
M0 Y&17)5N:5=>;%Y+'YTZ>XKOP=;7V;^1Z^6XFS]C+Y&C1117HGM!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)/NCZT^F2?='UH
M L1_ZM?I3J;'_JU^E.I#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@"O)_P ?"_A5^J$G_'POX5?H8!1112 **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *JV?_ !]O]#_.
MK55;/_C[?Z'^='0#1HHHJ0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** *-I_R$G^K5JUE6G_(2?ZM6K3EN""BBBI&%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMVC;S_P)OR^E3.-Y(NG.T&CS/PMIW]K>*]*L2"4FND#[3@[,Y;'X U8\<?\
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MO_(8OO\ KXD_]"-?4?@^].H>#='NFQN>TC#8]0,']17RYJO_ "&+[_KXD_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"C:?\
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M_D?]%_Z^5_K7U)7RW\/O^1_T7_KY7^M?4E95MS;#_"SY/\7?\CKKW_81N/\
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M\R_TJJOPD4/C*GQP_P"1*L_^PBG_ *+DKQKPC_R.N@_]A&W_ /1BU[+\</\
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M%;_DFNK_ /;'_P!')2:2FDBE*4J;<CP'PC_R.N@_]A&W_P#1BU]85\G^$?\
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MKX)T7QE'J":A=7D5Q;%"J6[HN4;//S*<\C]1ZUZG\3/"#^*_#RFT7.H63&2
M?WP1\R=<#. <^JCUKY^L-0U;PMK1GM9);._MV*.K+R.Q5E/4>QK6+YHV6YA4
M7+4NUH>TO\$O"\<;22:AJJHH)9FFB  '<GRZYFV\*?"N[=5C\5WJEL8\V5(Q
MSZEHABL#6OBMXDUS1WTR9K6"*5-DSV\95Y%[@DL<9[X ZD=*J^ _!5UXNU=,
MHR:9 X-U,> 1UV*?[Q'Y=?3(E)*\F-RBW:"/HK0-/L]+T"RLM/G:>SBB'DRE
MPV]3R#D  YSU%?*>J_\ (8OO^OB3_P!"-?7JJJ*%4 *!@ #@"OD+5?\ D,7W
M_7Q)_P"A&E1W96(T2/I?X=_\D_T7_KW_ *FJGQ6_Y)KJ_P#VQ_\ 1R5;^'?_
M "3_ $7_ *]_ZFJGQ6_Y)KJ__;'_ -')6:^/YFK_ (?R/!_ _P#R/6A_]?L7
M_H0KZ<UG_D!:A_U[2?\ H)KYC\#_ /(]:'_U^Q?^A"OIS6?^0%J'_7M)_P"@
MFKJ[HRH?"SY$KZHNM4_L3X?G4@,M;Z>KH/5M@V_KBOE>OJQ],36O JZ:Y %S
MIZQ!C_"2@P?P.#^%55Z$T+ZV/ES=<:IJ0,LS27-S*-TDK$EF8]2?J:]WTCX+
M>'K.%3J4EQ?S8&[YS&F>^ O/YFO"]2TV^T34Y;&^A>WNH&PRGMZ$'N.X(KLK
M7XP^*[;319^9:3.%VK<RQ%I1QCKG!/N0:J:D_A(IN*;YT.^+6DZ5HGB*RLM*
MM8K:,6@=TC]2[<D]2<"NE^ W_,P?]NW_ +5KS36+'7)[2/Q%JXF9=0D(2><_
M-+@#D#^[C ';'2O0?@5?1Q:IK%BQ423Q1RKEN3L+ @#O]_\ 2E)>Y8J#_>W/
M;J***YCL"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *6L?\@2__P"O:3_T
M$UXQ\%_]9K7T@_\ 9Z]GUC_D"7__ %[2?^@FO&/@O_K-:^D'_L]:P^%F,_CB
M>L4444&@54U/_D'2_A_,5;JIJ?\ R#I?P_F*SK?PY>C,<1_!GZ/\CG:***\,
M^4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +VDR^7
M>!>SC%;]<K$YBF1Q_"P-=4#D CO7IX*5XN/8]W*ZEZ;AV"BBBNT]0**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDGW1]:?3)/NCZT 6(_]
M6OTIU-C_ -6OTIU(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 5Y/^/A?PJ_5"3_ (^%_"K]# ****0!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !56S_ ./M_H?YU:JK
M9_\ 'V_T/\Z.@&C1114@%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 4;3_ )"3_5JU:RK3_D)/]6K5IRW!!1114C"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX(>(1<1F>]TLQ!AO"S29*YYQ^[ZXKWJBA5&E9!*E&3NQJ(D<:QQJJHH 55&
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M;>*6.Z68FX9E7:$=>P/.6%<)X<^$'B#2/$FG:C<7FF-#;7"2NL<LA8@')QE
M,_C7M5%"FTK!*G%N["O";[X(ZZ^H7+V=YI:VK2L80\D@8)D[<@(0#C'>O=J*
M49..PYP4]S@OAKX%N_!L>H/J$EI+<7)0*]NS-A%SQ\RC')_0>E:OC_PW>>*O
M##:98R01S&9)-T[$+@9ST!/Z5U%%',[W&H)1Y3PFR^"OB.VO[>=[W2BL4JN0
M)9,X!!_YYU[M111*3EN*$%#8\H\>_#'6O%/BB34[&ZL(X&B1 L\CAL@<]$(_
M6N8_X4?XF_Y_M)_[^R?_ !NO?J*I5))6)=&+=V> _P#"C_$W_/\ :3_W]D_^
M-U:M?@7J[LOVO5[&)<\F%7D('XA:]THH]K(7L(''>%?AKH7A:5;J-'N[Y3E;
MBXP2G&/E X'ZGWKL:**AMO<U44E9'F_Q'\"Z_P",M2M&LKJPBLK:(A4GE<,7
M)^8X"D= H_ US_AGX.:OIOB6POM3NM.EM+>42ND4CLS%>5X* ?> SSTS7M%%
M4IM*Q#I1;YF%%%%0:!7E7C_X6ZCXF\3-JNEW-G$LL2B9;AV!+KQD;5/&T+^5
M>JT4XR<7=$RBI*S/(?!GPR\3^%?%%KJ9OM-:!<I<1QS29>,]1C8,]B,GJ!7K
MU%%.4G+5A&"BK(****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M22V*E_I6G:HB)J%A:W:H<HMQ"L@4^HR#BH;/P_HNG7 N+'2+"UG ($D%LB,
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M HHHH **** "BBB@ HHHH **** *6L?\@2__ .O:3_T$UXQ\%_\ 6:U](/\
MV>O9]8_Y E__ ->TG_H)KQCX+_ZS6OI!_P"SUK#X68S^.)ZQ1110:!534_\
MD'2_A_,5;JIJ?_(.E_#^8K.M_#EZ,QQ'\&?H_P CG:***\,^4"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NHM6WVL3>J"N7KH]..
M;"(^Q'ZUW8%^^T>KE3_>27D6J***](]P**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ IDGW1]:?3)/NCZT 6(_\ 5K]*=38_]6OTIU(84444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5Y/
M^/A?PJ_5"3_CX7\*OT, HHHI %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %5;/_C[?Z'^=6JJV?\ Q]O]#_.CH!HT445(!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %&T_Y"3_
M %:M6LJT_P"0D_U:M6G+<$%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** *6L?\@2_P#^O:3_ -!->,?!?_6:U](/_9Z]GUC_ ) E
M_P#]>TG_ *":\8^"_P#K-:^D'_L]:P^%F,_CB>L4444&@54U/_D'2_A_,5;J
MIJ?_ "#I?P_F*SK?PY>C,<1_!GZ/\CG:***\,^4"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "NBTS_D'Q?C_,USM=)8+ML81_LYKM
MP*]]^AZ>5+]ZWY?JBS1117IGO!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %,D^Z/K3Z9)]T?6@"Q'_ *M?I3J;'_JU^E.I#"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O)_Q\+^%7
MZH2?\?"_A5^A@%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% %+6/\ D"7_ /U[2?\ H)KQCX+_ .LUKZ0?^SU[/K'_ "!+_P#Z
M]I/_ $$UXQ\%_P#6:U](/_9ZUA\+,9_'$]8HHHH- JIJ?_(.E_#^8JW534_^
M0=+^'\Q6=;^'+T9CB/X,_1_D<[1117AGR@4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5U4*>7 B>B@5S=I'YMW$G^UDUT]>C@8Z.1
M[650TE/Y!1117>>N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4R3[H^M/IDGW1]: +$?\ JU^E.IL?^K7Z4ZD,**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *\G_'POX5?JA)_Q\+^%
M7Z& 4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "JMG_Q]O]#_ #JU56S_ ./M_H?YT= -&BBBI **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH HVG_(2?ZM6K65:?\A)_JU:
MM.6X(****D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%5-5OAIFCWM^PR+6WDF(]=JD_TH ^=-1QX
MG^+LD?F%X[C4Q$''_/-6"Y'_  %:WOC'H[:/XJL]>L]R&[ 8L!PLT>.?Q&W\
M0:S?A#9/J'Q!BN64,+6*2=R1W(VC\<O7KOQ(T#_A(/!=Y%''ONK<?:(,#)W+
MU ^JY'XBNB4N621R1CS0;-?PSK<7B+PY8ZI'M!GC!D53PCCAE_ YIWB2_P#[
M+\,ZG?;]C06TCHW^UM.W]<5Y=\#]>8F_T"5QM ^U0 ]>RN/_ $$X^M=1\8-0
M:R\ 31+C-W/'!R,\<N?_ $"LG&T[&RG>GS'G'P7T_P"U>.&NB/EL[9Y <9^9
ML(![<,WY5[CXBU$:3X;U+4,X-O;2.O.,L%.T9[9.!7G'P+T[R]*U74FC&9IE
M@1R.<*,G'M\P_+VK>^+^HBQ\ SP!PKWDT<*\G)&=QQCV7!^M5/6=B:?NT[GD
M7P^TIM2NM;(0%8M(N<$C.&9=H_'DG\*Z_P"!-X%N]9LCU>.*5?;:6!_]"'Y5
M?^!FG*-'U>_= PGF6WYP>%7)'_CXKFOA)(VF?$FXL#_RTAFMR#GJI#?G\GZU
M<G?F1G!<O*SZ KC?B7XJ/A?PNYMY=FH79,5M@\K_ 'G'T!_,BNP=TCC:21E5
M%!+,QP !W)KYXU">?XI?$N.WMV<6.[8AY&RW4_,^#T)Z_4@5E"-W=F]65E9;
MLRHM-;1_A[-J\BLL^KS"T@.<8@4[G;\655^@/KSZQ\%M/^R^"7NBOS7ET[AL
M8RJX4#WY#?G7"_&2>&'7M.T6TC$5KIUH D:C 4L>@_!5KV7P?IYTOP=I%FP"
MO':H7 '1B,M^I-7-^[ZF5.-IV['!?'/4C%H^EZ:K,#<3-,P!XP@P,_B_Z>U:
MGP8T];7P0;O;\]Y<N^<?PK\@'YJWYUY]\9]1^U^-Q:!LK96Z1D;<89OG//?A
MEKV[PMI_]E>%-*LLY:*U0,<_Q8R?U)I2T@D5'6JWV->BBBLC<^8?'%I_PC?Q
M'OQ8GRO)N$N82J[0A8+(,8Z $XX]*^FK>=+JVBN(\[)4#KD<X(R*^:OB?<?;
M/B/JICW,%:.)1CG*HH(_/-?2-A ;;3K6 @@Q1(A!.>@ K6ILCGH_%(G9E12S
M$!0,DD\ 5\V^+-7N?B'X]CMK LT#2"VLT/0+GES]3EL^F/2O3OB[XJ.B^'AI
M=K(5O=0!4D?P0_Q'/J?N_0GTK$^"GA<);S^)+E#ND)@M,_W1]]O?)^7_ ("U
M$/=7,QU'SR4$;?Q"\/6NG?"1]/M%"Q:=Y3H,#YCO 8GW.YB?>LGX$W1?2]8M
M-QVQ31RA>P+*1_[)^E>@>,+07W@W6;<@DM9RE0/[P4D?J!7CWP0NUB\77ELS
M >?9L5]V5E./R)_*A:P82]VHCWRBBBLC<*\Z^-&HBT\$+: _->7*(1G'RKER
M??E5_.O1:\0^.FHB35-*TU7'[F%YG4$]7( SV_@/Y^]735Y(SJNT&<K%I3?\
M*CN-1* ;M73#8Y*K&P_++_I7L/PDO!=?#RQ3^*WDDB)_X&6'Z,*PKC1Q#^SX
M+?9\QM$N\\$_-(),]/0X^G%+\#+PR>'=2LSTANA(/^!J!_[)^M7)WB_4R@N6
M:7D>J5XW\:/%+%H?#%G)G.V6\5>2>A1#^C8_W:].\2Z[;^&O#]WJER1B%/D3
M^^YX51]3^F3VKQOX8:%-XL\7W/B+55\Z&VD,IW\AYVY4<]EZ^V%J8*WO,NJV
M_<74YOQAIY\/6FDZ 5*S1P?;+OYNLTG;'^RJJ/S]>?HKPWI_]E>&=,L-NUH+
M6-'&,?-M&XX^N:^?;AF\5?%T\%DN-3"?,/\ EDC <C_<7I7MOQ#\1-X:\'W5
MU$S+<S?Z/;L.JNP//X $_454[NR(I67-(Y3Q]\6#HUW+I&A+')>1$K/<N,K$
MPZJH[L.Y/ Z8/;SA=<^(&M*]Y;WFO3QY)9[3S!&/7[F .E;'PL\#P^)[Z;5=
M3!DL+60#RSG$TG7!/< 8)'?([5] HB1QK'&JJB@!548  [ 4-QAHD"C*I[S=
MD?.V@?%#Q+X?U$1:I+-?6ZL%F@NO]8H QPQY!^O7%?0&F:E:ZOIMOJ%E+YEM
M.F]&QC(^G8]J\\^,WARUNO#?]NI$BWEFZ*\HZO$QV[3ZX9E(].?6D^"%]+/X
M6O;1SE;:ZS'QT#*#C\P3^-*5I1YD5!RC/D9V?BKQ38>$M':_O268_+# I^:5
M_0>@]3V_('PB_P#'WC/Q3?LEC<7D7=;;30P(&?\ 9^8]0,_2G^.-4NO&_P 0
M_L-D2\:S"RM$;[HYP6..Q;)SZ8STKWCPUX;L/"^CQ:?81@ <R2D?-*_=C_GC
MI3T@M=Q>]4DTG9(\,TGX@^,/">J+'JYO9XCCS;74%8.5]5+?,#C\.>0:I>,-
M03QA\1R;64O;W,L%O;D<X4A1V]R3CWKW7QSH=KKWA+4(+F,,\4+S0. -R2*"
M003ZXP?8FO"_A9IXU#XA:=N&4M]\[?\  5.W_P >*U46FG(B<9)J%]&?2L:+
M%&L:#"J H'H!7B=SX_\ $VH_$IM&TW5E@L'OQ;(([>-P$#;2P)4D]">O?TKV
M'6+]=*T6^U!BH%M \OS=,JI.*\'^#UC)J/CXW\A)-K#),S'NS?)_[.3^%9P2
MLVS6JW=11]"USWCG6Y?#W@[4-1MY$CN40)"6 /SL0H(!ZD9SCVYXKH:\J^.6
MHM!H&FZ<O'VJX:1O<1CI^;@_A4P5Y)%U':+9;^$WB/Q!XF74[G6-0^T0P%(X
MD\F-/F.23\JCL!^=9/QUU';;:1IBY^=WN'YXX&U>/^!-73?"+3OL/P_M9#G=
M=RR7!!&,<[1]>$!_&O,OB[=MJ?Q#-G"=[6\45NJY&-Q^;'_C]:12=30RDVJ6
MO4]8^%]A]@^'VF*?O3*T[?\  F)'Z8K#^(7Q0'ARX?2=(1)=24 RRN,I!G!Q
MC^)L?@,CKT'H=A9QZ?IUK91?ZNWA2)>.R@ ?RKSK_A4>C6WB :QJ6KRW-N9F
MFEBO H\UCD_,X(!YY/'.#4)Q;;9<E)12B>9KKWQ!UYOM%M=Z[< YYLED5>O/
M$8 J:S\?^-O#5V([RZNWP1OM]10L3CMEOF'X&O?&\2^'+15B;6]*A51M5#=1
MJ !V SVKSSXK^*?#6J>%6L;74+:\OA,KQ"'Y]N#\QW#@<9[\UHI7=K&4H<JO
MS:G>>$/$]OXM\/1:G GEON,<\6<^7(,9&>XP01[$5Y/\1_'^O6WBG5-&T_4?
M*T]4$#(L2$G*#?\ ,5W Y)'![<5T?P,@*^&]3GP</=A,Y_NH#_[-5KXUW_V;
MP;#:#[UU=*I_W5!8_J%J4DIV+DW*G>YXEH?B#5/#=Z]YI-U]GN'C,3/Y:OE2
M02,,".JBOI+P/J-_?>"+#4M9N1)<S(\LDK*J +N.T\  #;BN<^"VG?9?!<EX
MV=UY<LXR,?*N%'UY#5#\9_$4FF:!;Z3;2!9=09O-P>1$N,CVR2.?8BG-\TN5
M$TUR1YFSG/&7QBO)[B6Q\-L(+925-X5S))[J#PHZ\]>AXKE3J7Q#GA%^+CQ&
M8/O"5/.$>,^WR]:[OX2^ [8V,?B35(5EED)^R1. 55>F\CU)SC/3&>XQZ_0Y
M1CHD-0E-<TF>$>#/B]J-I>Q6?B&475E(P7[2PQ)#[G ^8?K[\8KW965U#*05
M(R"#P17AOQK\/6EA?V6L6D*Q->%UN O 9Q@AL>I!.?IZFO2OAO>R7_P]T>>4
ML7$3198Y)".R#]%%*:32DBJ;DI.#./\ BIXXUSP_K]EI^BWP@W6_F2J(DD))
M8@#YE./N]O6LWQ;\2-:GEB\/>'Y'FNT1([F[M4W22R@8=4 ' W=Q^''7E/B'
M<3:S\3+Z*T1VE$Z6L*+]XLH"X'U;/YU[IX/\)67A+1HK6"*)KME'VFY"_-*W
MUZ[1V']2:;Y8I-HA<TY-)Z'!?"=_%-UX@O\ ^VKW5#;VL(W07CN3YC'"\/SC
M"MT[XKU^BBLY.[N;PCRJP4445)04444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7(?$7Q9=>$/#\-]8QV\EQ+<K"$G4E<;6). 0>P_.NOJI?Z5IVJ(B:A86MV
MJ'*+<0K(%/J,@XIJU]123:T/G/7/B=XG\06[VDEU':02G#1VH,8(QC!8DG![
MC.*]1^&GP\C\.0KK%])#<:C/'^[,3!TA1@#\I[L>Y'&.!P23D?$KX:Z5;:#<
M:UHML+2:V^>:&,DI(F0"0"?E(Z\>AXS1\$-=NKFVU#1IY"\-L%E@W$DH"2&4
M>V<''J3ZUM)IP]TYXIJI:>IV_P 0M0&F^ M8FW[6> PKCKESLX_[ZKS/X&:?
MYNMZIJ+*<06ZPJ<#&7;/YX3]:Z+XX:AY'ABQL58!KFZWD9'*HISQ]67G_&K'
MP5TXVO@R6\8'-Y<LRG'55 7^8:I6E,IZU4NQP?PQWZ3\5FT\[D)^T6S+T^[E
ML'\4_2OH2OGNZ1M)^/2KC!?54;CTE(/\GKV#QUXF7PKX7N+Y&7[4_P"[ME;!
MS(>AQW Z_A145V@I/EB[]#RWXK^(9O$?B6V\,:6#,EM-L*H<^;<'C'_ <D?4
MM4/Q)T^+PMX6\/\ AB AF!>ZN74$"23 7=S]6'T K3^#?A=[R\G\4W^7VLR6
MQ?YB[G[[DGTSC/J3Z5S7Q8O3JGQ$N+>'+FW2.V4 ]6QD@?BQ%6OB45T,Y7Y7
M-]3USX66'V'X>Z;G[\^^=O\ @3''_CNVNRJKIMDFG:59V,8PEM D*\YX50.O
MX5:K!N[N=459)!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4M8_Y E__ ->T
MG_H)KQCX+_ZS6OI!_P"SU[/K'_($O_\ KVD_]!->,?!?_6:U](/_ &>M8?"S
M&?QQ/6****#0*J:G_P @Z7\/YBK=5-3_ .0=+^'\Q6=;^'+T9CB/X,_1_D<[
M1117AGR@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
MJ:-#F5YB.%&!]:V:K6$'V>T1",,>3]:LU[6'AR4TCZC!TO945%[A1116QTA1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,D^Z/K3Z9)]T?6
M@"Q'_JU^E.IL?^K7Z4ZD,**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** *\G_'POX5?JA)_Q\+^%7Z& 4444@"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JMG_Q]O\ 0_SJ
MU56S_P"/M_H?YT= -&BBBI **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH HVG_(2?ZM6K65:?\ (2?ZM6K3EN""BBBI&%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7%_%:_%C\/=0'\=P4@3\6!/\ XZ&KM*\A^.NH[;'2-,5Q^\D>X=<?
MW1M4Y_X$U5!7DB*CM!D7P*TWY-7U1E.24MT;'']YAG\4KV.N&^$>G_8?A]:2
M$8:[EDG88QWVCZ\*#^-=S3F[R8J2M!'SAJ4'_"O?BNDL8VVL-RLR8'_+!_O
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MLNKRVM+BXDE)\B"&,NR1+]T8&>W)]R:N06_Q%M8$@MX?%,,,8VI'&MPJJ/0
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MDK\MG;22[N< G" ?7#'KZ&NL^.TTBZ7H\ 8^6\TCLN>"54 '_P >/YTWX%6
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 4M8_P"0)?\ _7M)_P"@FO&/@O\ ZS6OI!_[
M/7L^L?\ ($O_ /KVD_\ 037C'P7_ -9K7T@_]GK6'PLQG\<3UBBBB@T"JFI_
M\@Z7\/YBK=5-3_Y!TOX?S%9UOX<O1F.(_@S]'^1SM%%%>&?*!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %7--MO/N@6&43DU452[!5&2>
M*Z2SMA;6ZI_$>6/O73AJ7/.[V1W8##^UJ7>R+%%%%>N?1A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !3)/NCZT^F2?='UH L1_P"K
M7Z4ZFQ_ZM?I3J0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH KR?\?"_A5^J$G_'POX5?H8!1112 **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *JV?_'V_T/\ .K55;/\
MX^W^A_G1T T:***D HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@"C:?\A)_JU:M95I_R$G^K5JTY;@@HHHJ1A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<$,LIFDCC56D(P7(&">IZ]>IJ:BBD44]6LI-2T>]L8I_L[W,#PB8+N*;@1N
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!2UC_ ) E_P#]>TG_
M *":\8^"_P#K-:^D'_L]>SZQ_P @2_\ ^O:3_P!!->,?!?\ UFM?2#_V>M8?
M"S&?QQ/6****#0*J:G_R#I?P_F*MU4U/_D'2_A_,5G6_AR]&8XC^#/T?Y'.T
M445X9\H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !116EIVG^:1-
M,OR#[H/>M*=.527*C6C1E5GRQ)]*LMH%Q(/F/W1Z>]:E'2BO9ITU3CRH^GH4
M8T8*$0HHHJS4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *9)]T?6GTR3[H^M %B/_ %:_2G4V/_5K]*=2&%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>3_CX7\*OU0D_X^%_
M"K]# ****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !56S_X^W^A_G5JJMG_ ,?;_0_SHZ :-%%%2 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!1M/^0D_P!6K5K*M/\ D)/]
M6K5IRW!!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M HJ6&WEN'VQJ2?7L*VK/34M\/)AY/T%;TJ$JCTV.K#X2I7>FW<J6&F%L2SC
MZA?7ZUL@ # Z445ZM*E&FK(^@H8>%"/+$****T-PHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *9)]T?6GTR3[H^M %B/_5K]
M*=38_P#5K]*=2&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% %>3_CX7\*OU0D_P"/A?PJ_0P"BBBD 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 55L_P#C[?Z'^=6JJV?_
M !]O]#_.CH!HT445(!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% %&T_P"0D_U:M6LJT_Y"3_5JU:<MP04445(PHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS+S_ )X_^/#_ !H]C4_E?W!]7K?R/[F5**M_V9>?\\?_ !X?XT?V9>?\\?\
MQX?XT>QJ?RO[@^KUOY']S*E%6_[,O/\ GC_X\/\ &C^S+S_GC_X\/\:/8U/Y
M7]P?5ZW\C^YE2BK?]F7G_/'_ ,>'^-']F7G_ #Q_\>'^-'L:G\K^X/J];^1_
M<RI15O\ LR\_YX_^/#_&C^S+S_GC_P"/#_&CV-3^5_<'U>M_(_N94HJW_9EY
M_P \?_'A_C1_9EY_SQ_\>'^-'L:G\K^X/J];^1_<RI15O^S+S_GC_P"/#_&C
M^S+S_GC_ ./#_&CV-3^5_<'U>M_(_N94HJW_ &9>?\\?_'A_C1_9EY_SQ_\
M'A_C1[&I_*_N#ZO6_D?W,J45;_LR\_YX_P#CP_QH_LR\_P">/_CP_P :/8U/
MY7]P?5ZW\C^YE2BK?]F7G_/'_P >'^-']F7G_/'_ ,>'^-'L:G\K^X/J];^1
M_<RI15O^S+S_ )X_^/#_ !H_LR\_YX_^/#_&CV-3^5_<'U>M_(_N94HJW_9E
MY_SQ_P#'A_C1_9EY_P \?_'A_C1[&I_*_N#ZO6_D?W,J45;_ +,O/^>/_CP_
MQH_LR\_YX_\ CP_QH]C4_E?W!]7K?R/[F5**M_V9>?\ /'_QX?XT?V9>?\\?
M_'A_C1[&I_*_N#ZM6_D?W,J45=&E79_@4?5A4BZ/<'[S(OXYJE0J/[)2PE=_
M99G45L1Z*H_UDI/^Z*MQZ=:Q=(@Q]6YK6.#J/?0Z(9;6EOH8,5M-/_JXR1Z]
MJT[?1P,-.V3_ '5K4  & ,4M=5/!PCK+4]"CEM*&LM6-CC2) J*%4=A3J**Z
MTK:(]%))604444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4R3[H^M/IDGW1]: +$?^K7Z4ZFQ_ZM?I3J0PHHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH KR?\
M'POX5?JA)_Q\+^%7Z& 4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "JMG_P ?;_0_SJU56S_X^W^A_G1T T:***D HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"C:?\A)_J
MU:M95I_R$G^K5JTY;@@HHHJ1A1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!2UC_D"7_\ U[2?^@FO&/@O_K-:^D'_ +/7L^L?\@2__P"O
M:3_T$UXQ\%_]9K7T@_\ 9ZUA\+,9_'$]8HHHH- HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDGW1]:?3)/NCZT 6(_\
M5K]*=38_]6OTIU(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 5Y/^/A?PJ_5"3_CX7\*OT, HHHI %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %5;/_C[?Z'^=6JJV?\
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M_*O,_P"V]1_Y^3_WR/\ "C^V]1_Y^3_WR/\ "CV <YZ9_:4'H_Y4?VE!Z/\
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M#T?\J/[2@]'_ "KS/^V]1_Y^3_WR/\*/[;U'_GY/_?(_PH]@'.>F?VE!Z/\
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M;U'_ )^3_P!\C_"C^V]1_P"?D_\ ?(_PH]@'.>F?VE!Z/^5']I0>C_E7F?\
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M_/R?^^1_A1[ .<],_M*#T?\ *C^TH/1_RKS/^V]1_P"?D_\ ?(_PH_MO4?\
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M\*/8!SGIG]I0>C_E1_:4'H_Y5YG_ &WJ/_/R?^^1_A1_;>H_\_)_[Y'^%'L
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MS![UPO\ ;>H_\_)_[Y'^%']MZC_S\G_OD?X4>R8<YW7F#WH\P>]<+_;>H_\
M/R?^^1_A1_;>H_\ /R?^^1_A1[)ASG=>8/>CS![UPO\ ;>H_\_)_[Y'^%']M
MZC_S\G_OD?X4>R8<YW7F#WH\P>]<+_;>H_\ /R?^^1_A1_;>H_\ /R?^^1_A
M1[)ASG=>8/>CS![UPO\ ;>H_\_)_[Y'^%']MZC_S\G_OD?X4>R8<YW7F#WH\
MP>]<+_;>H_\ /R?^^1_A1_;>H_\ /R?^^1_A1[)ASG=>8/>CS![UPO\ ;>H_
M\_)_[Y'^%']MZC_S\G_OD?X4>R8<YW7F#WH\P>]<+_;>H_\ /R?^^1_A1_;>
MH_\ /R?^^1_A1[)ASG=>8/>CS![UPO\ ;>H_\_)_[Y'^%']MZC_S\G_OD?X4
M>R8<YW7F#WH\P>]<+_;>H_\ /R?^^1_A1_;>H_\ /R?^^1_A1[)ASG=>8/>C
MS![UPO\ ;>H_\_)_[Y'^%']MZC_S\G_OD?X4>R8<YW7F#WH\P>]<+_;>H_\
M/R?^^1_A1_;>H_\ /R?^^1_A1[)ASG=>8/>CS![UPO\ ;>H_\_)_[Y'^%']M
MZC_S\G_OD?X4>R8<YW7F#WH\P>]<+_;>H_\ /R?^^1_A1_;>H_\ /R?^^1_A
M1[)ASG=>8/>CS![UPO\ ;>H_\_)_[Y'^%']MZC_S\G_OD?X4>R8<YW7F#WH\
MP>]<+_;>H_\ /R?^^1_A1_;>H_\ /R?^^1_A1[)ASG=>8/>CS![UPO\ ;>H_
M\_)_[Y'^%']MZC_S\G_OD?X4>R8<YW7F#WH\P>]<+_;>H_\ /R?^^1_A1_;>
MH_\ /R?^^1_A1[)ASG=>8/>CS![UPO\ ;>H_\_)_[Y'^%']MZC_S\G_OD?X4
M>R8<YW7F#WH\P>]<+_;>H_\ /R?^^1_A1_;>H_\ /R?^^1_A1[)ASG=>8/>C
MS![UPO\ ;>H_\_)_[Y'^%']MZC_S\G_OD?X4>R8<YW7F#WH\P>]<+_;>H_\
M/R?^^1_A1_;>H_\ /R?^^1_A1[)ASG=>8/>CS![UPO\ ;>H_\_)_[Y'^%']M
MZC_S\G_OD?X4>R8<YW7F#WH\P>]<+_;>H_\ /R?^^1_A1_;>H_\ /R?^^1_A
M1[)ASG=>8/>CS![UPO\ ;>H_\_)_[Y'^%']MZC_S\G_OD?X4>R8<YW7F#WH\
MP>]<+_;>H_\ /R?^^1_A1_;>H_\ /R?^^1_A1[)ASG=>8/>CS![UPO\ ;>H_
M\_)_[Y'^%']MZC_S\G_OD?X4>R8<YW7F#WH\P>]<+_;>H_\ /R?^^1_A1_;>
MH_\ /R?^^1_A1[)ASG=>8/>CS![UPO\ ;>H_\_)_[Y'^%']MZC_S\G_OD?X4
M>R8<YW7F#WH\P>]<+_;>H_\ /R?^^1_A1_;>H_\ /R?^^1_A1[)ASG=>8/>C
MS![UPO\ ;>H_\_)_[Y'^%']MZC_S\G_OD?X4>R8<YW7F#WH\P>]<+_;>H_\
M/R?^^1_A1_;>H_\ /R?^^1_A1[)ASG=>8/>CS![UPO\ ;>H_\_)_[Y'^%']M
MZC_S\G_OD?X4>R8<YW7F#WH\P>]<+_;>H_\ /R?^^1_A1_;>H_\ /R?^^1_A
M1[)ASG=>8/>CS![UPO\ ;>H_\_)_[Y'^%']MZC_S\G_OD?X4>R8<YW7F#WH\
MP>]<+_;>H_\ /R?^^1_A1_;>H_\ /R?^^1_A1[)ASG=>8/>CS![UPO\ ;>H_
M\_)_[Y'^%']MZC_S\G_OD?X4>R8<YW7F#WH\P>]<+_;>H_\ /R?^^1_A1_;>
MH_\ /R?^^1_A1[)ASG=>8/>CS![UPO\ ;>H_\_)_[Y'^%']MZC_S\G_OD?X4
M>R8<YW7F#WH\P>]<+_;>H_\ /R?^^1_A1_;>H_\ /R?^^1_A1[)ASG=>8/>C
MS![UPO\ ;>H_\_)_[Y'^%']MZC_S\G_OD?X4>R8<YW7F#WH\P>]<+_;>H_\
M/R?^^1_A1_;>H_\ /R?^^1_A1[)ASG=>8/>FNP8<5P_]MZC_ ,_)_P"^1_A0
M-<U(?\O)_P"^5_PH]DPYT=ZDRJ@!SQ2^>GO7 _VWJ)_Y>3_WRO\ A1_;>H_\
M_)_[Y'^%'L6'.=]YZ>]'GI[UP/\ ;>H_\_)_[Y'^%']MZC_S\G_OD?X4>Q8<
MYWWGI[T>>GO7 _VWJ/\ S\G_ +Y'^%']MZC_ ,_)_P"^1_A1[%ASG?>>GO1Y
MZ>]<#_;>H_\ /R?^^1_A1_;>H_\ /R?^^1_A1[%ASG?>>GO1YZ>]<#_;>H_\
M_)_[Y'^%']MZC_S\G_OD?X4>Q8<YWWGI[T>>GO7 _P!MZC_S\G_OD?X4?VWJ
M/_/R?^^1_A1[%ASG?>>GO1YZ>]<#_;>H_P#/R?\ OD?X4?VWJ/\ S\G_ +Y'
M^%'L6'.=]YZ>]'GI[UP/]MZC_P _)_[Y'^%']MZC_P _)_[Y'^%'L6'.=]YZ
M>]'GI[UP/]MZC_S\G_OD?X4?VWJ/_/R?^^1_A1[%ASG?>>GO1YZ>]<#_ &WJ
M/_/R?^^1_A1_;>H_\_)_[Y'^%'L6'.=]YZ>]'GI[UP/]MZC_ ,_)_P"^1_A1
M_;>H_P#/R?\ OD?X4>Q8<YWWGI[T>>GO7 _VWJ/_ #\G_OD?X4?VWJ/_ #\G
M_OD?X4>Q8<YWWGI[T>>GO7 _VWJ/_/R?^^1_A1_;>H_\_)_[Y'^%'L6'.=]Y
MZ>]'GI[UP/\ ;>H_\_)_[Y'^%']MZC_S\G_OD?X4>Q8<YWWGI[T>>GO7 _VW
MJ/\ S\G_ +Y'^%']MZC_ ,_)_P"^1_A1[%ASG?>>GO1YZ>]<#_;>H_\ /R?^
M^1_A1_;>H_\ /R?^^1_A1[%ASG?>>GO1YZ>]<#_;>H_\_)_[Y'^%']MZC_S\
MG_OD?X4>Q8<YWWGI[T>>GO7 _P!MZC_S\G_OD?X4?VWJ/_/R?^^1_A1[%ASG
M?>>GO1YZ>]<#_;>H_P#/R?\ OD?X4?VWJ/\ S\G_ +Y'^%'L6'.=]YZ>]'GI
M[UP/]MZC_P _)_[Y'^%']MZC_P _)_[Y'^%'L6'.=]YZ>]'GI[UP/]MZC_S\
MG_OD?X4?VWJ/_/R?^^1_A1[%ASG?>>GO1YZ>]<#_ &WJ/_/R?^^1_A1_;>H_
M\_)_[Y'^%'L6'.=]YZ>]'GI[UP/]MZC_ ,_)_P"^1_A1_;>H_P#/R?\ OD?X
M4>Q8<YWWGI[T>>GO7 _VWJ/_ #\G_OD?X4?VWJ/_ #\G_OD?X4>Q8<YWWGI[
MT>>GO7 _VWJ/_/R?^^1_A1_;>H_\_)_[Y'^%'L6'.=]YZ>]'GI[UP/\ ;>H_
M\_)_[Y'^%']MZC_S\G_OD?X4>Q8<YWWGI[T>>GO7 _VWJ/\ S\G_ +Y'^%']
MMZC_ ,_)_P"^1_A1[%ASG?>>GO1YZ>]<#_;>H_\ /R?^^1_A1_;>H_\ /R?^
M^1_A1[%ASG?>>GO1YZ>]<#_;>H_\_)_[Y'^%']MZC_S\G_OD?X4>Q8<YWWGI
M[T>>GO7 _P!MZC_S\G_OD?X4?VWJ/_/R?^^1_A1[%ASG?>>GO1YZ>]<#_;>H
M_P#/R?\ OD?X4?VWJ/\ S\G_ +Y'^%'L6'.=]YZ>]'GI[UP/]MZC_P _)_[Y
M'^%']MZC_P _)_[Y'^%'L6'.=]YZ>]'GI[UP/]MZC_S\G_OD?X4?VWJ/_/R?
M^^1_A1[%ASG?>>GO1YZ>]<#_ &WJ/_/R?^^1_A1_;>H_\_)_[Y'^%'L6'.=]
MYZ>]'GI[UP/]MZC_ ,_)_P"^1_A1_;>H_P#/R?\ OD?X4>Q8<YW+N&E##.!B
MK7VN/T;\J\\&N:D!C[2?^^%_PH_MO4?^?D_]\C_"CV+#G/0_M<?HWY4?:X_1
MORKSS^V]1_Y^3_WR/\*/[;U'_GY/_?(_PI>Q8<YZ']KC]&_*C[7'Z-^5>>?V
MWJ/_ #\G_OD?X4?VWJ/_ #\G_OD?X4>Q8<YZ']KC]&_*C[7'Z-^5>>?VWJ/_
M #\G_OD?X4?VWJ/_ #\G_OD?X4>Q8<YZ']KC]&_*C[7'Z-^5>>?VWJ/_ #\G
M_OD?X4?VWJ/_ #\G_OD?X4>Q8<YZ']KC]&_*C[7'Z-^5>>?VWJ/_ #\G_OD?
MX4?VWJ/_ #\G_OD?X4>Q8<YZ']KC]&_*C[7'Z-^5>>?VWJ/_ #\G_OD?X4?V
MWJ/_ #\G_OD?X4>Q8<YZ']KC]&_*C[7'Z-^5>>?VWJ/_ #\G_OD?X4?VWJ/_
M #\G_OD?X4>Q8<YZ']KC]&_*C[7'Z-^5>>?VWJ/_ #\G_OD?X4?VWJ/_ #\G
M_OD?X4>Q8<YZ']KC]&_*C[7'Z-^5>>?VWJ/_ #\G_OD?X4?VWJ/_ #\G_OD?
MX4>Q8<YZ']KC]&_*C[7'Z-^5>>?VWJ/_ #\G_OD?X4?VWJ/_ #\G_OD?X4>Q
M8<YZ']KC]&_*C[7'Z-^5>>?VWJ/_ #\G_OD?X4?VWJ/_ #\G_OD?X4>Q8<YZ
M']KC]&_*C[7'Z-^5>>?VWJ/_ #\G_OD?X4?VWJ/_ #\G_OD?X4>Q8<YZ']KC
M]&_*C[7'Z-^5>>?VWJ/_ #\G_OD?X4?VWJ/_ #\G_OD?X4>Q8<YZ']KC]&_*
MC[7'Z-^5>>?VWJ/_ #\G_OD?X4?VWJ/_ #\G_OD?X4>Q8<YZ']KC]&_*C[7'
MZ-^5>>?VWJ/_ #\G_OD?X4?VWJ/_ #\G_OD?X4>Q8<YZ']KC]&_*C[7'Z-^5
M>>?VWJ/_ #\G_OD?X4?VWJ/_ #\G_OD?X4>Q8<YZ']KC]&_*C[7'Z-^5>>?V
MWJ/_ #\G_OD?X4?VWJ/_ #\G_OD?X4>Q8<YZ']KC]&_*C[7'Z-^5>>?VWJ/_
M #\G_OD?X4?VWJ/_ #\G_OD?X4>Q8<YZ']KC]&_*C[7'Z-^5>>?VWJ/_ #\G
M_OD?X4?VWJ/_ #\G_OD?X4>Q8<YZ']KC]&_*C[7'Z-^5>>?VWJ/_ #\G_OD?
MX4?VWJ/_ #\G_OD?X4>Q8<YZ']KC]&_*C[7'Z-^5>>?VWJ/_ #\G_OD?X4?V
MWJ/_ #\G_OD?X4>Q8<YZ']KC]&_*C[7'Z-^5>>?VWJ/_ #\G_OD?X4?VWJ/_
M #\G_OD?X4>Q8<YZ']KC]&_*C[7'Z-^5>>?VWJ/_ #\G_OD?X4?VWJ/_ #\G
M_OD?X4>Q8<YZ']KC]&_*C[7'Z-^5>>?VWJ/_ #\G_OD?X4?VWJ/_ #\G_OD?
MX4>Q8<YZ']KC]&_*C[7'Z-^5>>?VWJ/_ #\G_OD?X4?VWJ/_ #\G_OD?X4>Q
M8<YZ']KC]&_*C[7'Z-^5>>?VWJ/_ #\G_OD?X4?VWJ/_ #\G_OD?X4>Q8<YZ
M']KC]&_*C[7'Z-^5>>?VWJ/_ #\G_OD?X4?VWJ/_ #\G_OD?X4>Q8<YZ']KC
M]&_*C[7'Z-^5>>?VWJ/_ #\G_OD?X4?VWJ/_ #\G_OD?X4>Q8<YZ']KC]&_*
MC[7'Z-^5>>?VWJ/_ #\G_OD?X4?VWJ/_ #\G_OD?X4>Q8<YZ']KC]&_*C[7'
MZ-^5>>?VWJ/_ #\G_OD?X4?VWJ/_ #\G_OD?X4>Q8<YZ']KC]&_*C[7'Z-^5
M>>?VWJ/_ #\G_OD?X4?VWJ/_ #\G_OD?X4>Q8<YZ']KC]&_*C[7'Z-^5>>?V
MWJ/_ #\G_OD?X4?VWJ/_ #\G_OD?X4>Q8<YZ']KC]&_*C[7'Z-^5>>?VWJ/_
M #\G_OD?X4?VWJ/_ #\G_OD?X4>Q8<YZ']KC]&_*C[7'Z-^5>>?VWJ/_ #\G
M_OD?X4?VWJ/_ #\G_OD?X4>Q8<YZ']KC]&_*H+>98IV=LX(/2N#_ +;U'_GY
M/_?(_P *#KFI$8^TG_OA?\*?L6'.>C_;X?1ORH^WP^C?E7G']MZC_P _)_[Y
M'^%']MZC_P _)_[Y'^%+V##G/1_M\/HWY4?;X?1ORKSC^V]1_P"?D_\ ?(_P
MH_MO4?\ GY/_ 'R/\*/8,.<]'^WP^C?E1]OA]&_*O./[;U'_ )^3_P!\C_"C
M^V]1_P"?D_\ ?(_PH]@PYST?[?#Z-^5'V^'T;\J\X_MO4?\ GY/_ 'R/\*/[
M;U'_ )^3_P!\C_"CV##G/1_M\/HWY4?;X?1ORKSC^V]1_P"?D_\ ?(_PH_MO
M4?\ GY/_ 'R/\*/8,.<]'^WP^C?E1]OA]&_*O./[;U'_ )^3_P!\C_"C^V]1
M_P"?D_\ ?(_PH]@PYST?[?#Z-^5'V^'T;\J\X_MO4?\ GY/_ 'R/\*/[;U'_
M )^3_P!\C_"CV##G/1_M\/HWY4?;X?1ORKSC^V]1_P"?D_\ ?(_PH_MO4?\
MGY/_ 'R/\*/8,.<]'^WP^C?E1]OA]&_*O./[;U'_ )^3_P!\C_"C^V]1_P"?
MD_\ ?(_PH]@PYST?[?#Z-^5'V^'T;\J\X_MO4?\ GY/_ 'R/\*/[;U'_ )^3
M_P!\C_"CV##G/1_M\/HWY4?;X?1ORKSC^V]1_P"?D_\ ?(_PH_MO4?\ GY/_
M 'R/\*/8,.<]'^WP^C?E1]OA]&_*O./[;U'_ )^3_P!\C_"C^V]1_P"?D_\
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MI+W39+BX;?*LQ0-C&!M7T^IKI*PFK.Q:V"BBBI&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!B^+/\ D6;S_@'_ *&M
M>8UZ=XL_Y%F\_P" ?^AK7F-==#X3*>X4445N0%%%206\]S)Y=O#)*^,[8U+'
M'T% $=%7?['U/_H'7G_?AO\ "JLL4D$C1RQM'(O57&"/PI73 91113 **M1Z
M9J$T:R16-RZ-R&6)B#^.*;/87EJ@>XM)X5)P&DC*@GTYI706*]%%%, HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHJ[_ &/J?_0.O/\ OPW^%)M("E14UQ:7-H5%S;RPEN@D0KG\ZAI@%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%/AAEN)1%#&\DC=
M$122?P%6O['U/_H'7G_?AO\ "E=("E13Y8I()&CEC:.1>JN,$?A3*8!1110
M4444 %%%% !1110 4444 %%%% !1110 445=&D:F0"-.NR#T(@;_  I-I 4J
M*N_V/J?_ $#KS_OPW^%']CZG_P! Z\_[\-_A1S(+%*BKC:5J*_>T^Z'UA;_"
MJKH\;E)%9&'56&"*+I@-HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\M_Z"M=/7!4^-F\=@HHHJ!A1110 4444 %%%% !1110 4444 %%%% !1110
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M):&SA2.088DECZ\=/:M(4YQEIL2Y)HYNBBBNDS"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9;?]=O\ V4UP551^ 4]S4\-@'Q%9 G \S/Z&O5*\?L+G['J%M<G.(I%<A>I
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M6YZW7GWCF0MK,*9^58!Q[DG_ .M7H->=>-O^0^/^N*_S-<E#XS2>QSE==X"
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M@_RK==5=&1AE6&"/45"E*F[#LI(\8HI7 #L%;<H/!QC(I*[C$**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_0BG:EXIOM4LFM9XK=8V()**P/!SW)IJC)2OT$YIHPZ];T?_ ) EA_U[1_\
MH(KR2NBMO&>HVMK#;I#:E(D5%+*V2 ,<_-6E6#DE8F+2-OQY_P @RV_Z[?\
MLIK@JU]6\17>LP1PW$<"JC;@8U(.<8[DUD55.+C&S"3NPKO?"6O1SVJ:=<R!
M9XAMB+'&]>P'N*X*BG."FK,2=CV66&.>)HI45XV&&5AD&L!_!6DM+O'GJO\
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M2B6*-I)1TDE.XCZ=OQQ6I<7$-K TT\BQQKU9C@"N+F\>S,A$%A&C]B\A8?D
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M (3K4_\ GA9_]\-_\57/7=P;N[EN&1$:5BS*F<9/7&2:NE"4;W%)IGJ.@_\
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MSZ3?]\&BZ"Q5HJU_9M]_SZ3?]\&C^S;[_GTF_P"^#1=!8JT5:_LV^_Y])O\
MO@T?V;??\^DW_?!HN@L5:*M?V;??\^DW_?!J&6WF@QYT,D>[IO4C/YT70$=%
M%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ]!\"_\ ($F_Z^6_]!6NGKF/ O\ R!)O
M^OEO_05KIZX*GQLWCL%%%%0,**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@!DT,5Q$8IHTDC;JCJ"#^!JK_8^F?\ 0.L_
M^_"_X5=HIW: I?V/IG_0.L_^_"_X4?V/IG_0.L_^_"_X5=HHYF*Q2_L?3/\
MH'6?_?A?\*/['TS_ *!UG_WX7_"KM%',PL4O['TS_H'6?_?A?\*/['TS_H'6
M?_?A?\*NT4<S"Q2_L?3/^@=9_P#?A?\ "C^Q],_Z!UG_ -^%_P *NT4<S"Q2
M_L?3/^@=9_\ ?A?\*/['TS_H'6?_ 'X7_"KM%',PL4O['TS_ *!UG_WX7_"C
M^Q],_P"@=9_]^%_PJ[11S,+%+^Q],_Z!UG_WX7_"C^Q],_Z!UG_WX7_"KM%'
M,PL4O['TS_H'6?\ WX7_  H_L?3/^@=9_P#?A?\ "KM%',PL4O['TS_H'6?_
M 'X7_"C^Q],_Z!UG_P!^%_PJ[11S,+%+^Q],_P"@=9_]^%_PH_L?3/\ H'6?
M_?A?\*NT4<S"Q2_L?3/^@=9_]^%_PH_L?3/^@=9_]^%_PJ[11S,+%+^Q],_Z
M!UG_ -^%_P */['TS_H'6?\ WX7_  J[11S,+%+^Q],_Z!UG_P!^%_PH_L?3
M/^@=9_\ ?A?\*NT4<S"Q2_L?3/\ H'6?_?A?\*/['TS_ *!UG_WX7_"KM%',
MPL4O['TS_H'6?_?A?\*/['TS_H'6?_?A?\*NT4<S"Q2_L?3/^@=9_P#?A?\
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M?*W_ ._2_P"%']FV/_/E;_\ ?I?\*LT4786*W]FV/_/E;_\ ?I?\*/[-L?\
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M_2_X59HHNPL5O[-L?^?*W_[]+_A1_9MC_P ^5O\ ]^E_PJS11=A8K?V;8_\
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M_P *MT4786*G]E:=_P ^%K_WY7_"C^RM._Y\+7_ORO\ A5NBB["Q4_LK3O\
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M]I_WY7_"KE%%V%BG_9.F_P#0/M/^_*_X4?V3IO\ T#[3_ORO^%7**+L+%/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@"EK'_($O_\ KVD_]!->,?!?_6:U](/_ &>O9]8_Y E__P!>TG_H
M)KQCX+_ZS6OI!_[/6L/A9C/XXGK%%%%!H%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %,D^Z/K3Z9)]T?6@"Q'_JU^E.IL
M?^K7Z4ZD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** *\G_'POX5?JA)_Q\+^%7Z& 4444@"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "JMG_Q]O\ 0_SJU56S_P"/M_H?
MYT= -&BBBI **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH HVG_(2?ZM6K65:?\ (2?ZM6K3EN""BBBI&%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MIA4G*+5MCZFHHHK(W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"EK'_($O\ _KVD_P#0
M37C'P7_UFM?2#_V>O9]8_P"0)?\ _7M)_P"@FO&/@O\ ZS6OI!_[/6L/A9C/
MXXGK%%%%!H%%%5-3_P"0=+^'\Q4SERQ<NQ%2?)!S[(MT5R5%</U_^[^/_ /*
M_M;^Y^/_  #K:*Y*BCZ__=_'_@!_:W]S\?\ @'6T5R5%'U_^[^/_   _M;^Y
M^/\ P#K:*Y*BCZ__ '?Q_P" ']K?W/Q_X!UM%<E11]?_ +OX_P# #^UO[GX_
M\ ZVBN2HH^O_ -W\?^ ']K?W/Q_X!UM%<E11]?\ [OX_\ /[6_N?C_P#K:*Y
M*BCZ_P#W?Q_X ?VM_<_'_@'6T5R5%'U_^[^/_ #^UO[GX_\  .MHKDJ*/K_]
MW\?^ ']K?W/Q_P" =;17)44?7_[OX_\  #^UO[GX_P# .MHKDJ*/K_\ =_'_
M ( ?VM_<_'_@'6T5R5%'U_\ N_C_ , /[6_N?C_P#K:*Y*BCZ_\ W?Q_X ?V
MM_<_'_@'6T5R5%'U_P#N_C_P _M;^Y^/_ .MHKDJ*/K_ /=_'_@!_:W]S\?^
M =;17)AV'1B/H:D6YG3[LSC_ (%36.76)2S:/6/XG445SR:G=)U<-]15J+6N
MTL7XJ:UCC*;WT-X9E0EOH:]%5X;ZWGX209]#P:L5TQDI*Z9VPG&:O%W"BBBF
M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %,D^Z/K3Z9)]T?6@"Q'_JU^E.IL?^K7Z4ZD,**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *\G_'POX5?JA)_
MQ\+^%7Z& 4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "JMG_Q]O\ 0_SJU56S_P"/M_H?YT= -&BBBI **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH HVG_(2?ZM6K65:?\
M(2?ZM6K3EN""BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MNMK!JSL=2=U<^-J^J?#K,GP\TIE)##2H2"#R#Y0KY6KZP\(_\B5H/_8.M_\
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M\\]>,5/\5O\ DI6K_P#;'_T2E=K\#]#MWM[_ %V6(-.DOV:%S@[/E!;'H3N
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MS=HIL<B2H'1@RGN*=7>G?5'KIIJZ"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *9)]T?6GTR3[H^M %B/\ U:_2G4V/
M_5K]*=2&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% %>3_CX7\*OU0D_X^%_"K]# ****0!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !56S_X^W^A_G5JJMG_Q]O\ 0_SH
MZ :-%%%2 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!1M/^0D_U:M6LJT_Y"3_ %:M6G+<$%%%%2,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO-/CA
M_P B59_]A%/_ $7)3BKNQ,I<JN>ET5\;H[1NKHQ5E.0P."#ZU]/^ /%:>+/#
M45S(Z_;H,172\#YP/O8'9AS]<CM5SI\JN9TZJF['4T45Y-\=?^0/I'_7P_\
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M@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4R3[H^
MM/IDGW1]: +$?^K7Z4ZFQ_ZM?I3J0PHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH KR?\ 'POX5?JA)_Q\+^%7Z& 4444@
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JMG
M_P ?;_0_SJU56S_X^W^A_G1T T:***D HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@"C:?\A)_JU:M95I_R$G^K5JTY;@@HHHJ1
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5YI\</^1*L_P#L(I_Z+DKTNO-/CA_R)5G_ -A%/_1<E5#X
MD9U?@9X#75?#_P 5OX4\313NQ^PW&(KI?]D]&^JGGZ9'>L?P_IJ:QX@L--DD
M:-+J=8BZCE<G&:BU?2[G1-7NM-O$*3V\A1@1U]"/8C!'L:ZG9Z'$KKWD?74<
MD<T22Q.KQNH974Y# ]"#W%>4?'7_ ) ^D?\ 7P__ *"*D^#?B[[=IS^'KR0?
M:+4;K8D_?B[K]5/Z'VJ/XZ_\@?2/^OA__017/&/+.QUSDI4VT>:?#[_D?]%_
MZ^5_K7U)7RW\/O\ D?\ 1?\ KY7^M?4E.MN3A_A9\G^+O^1UU[_L(W'_ *,:
MLUK61;"*\_Y9R2O$/8J%/_LP_*M+Q=_R.NO?]A&X_P#1C5M6NE&Y^#U]J QF
MUU93G!)P8U4CVY=?RK:]DCGM=L[/X%:H-FK:0[\@K<QKGK_"Y_\ 0*]A=TCC
M:21E5%!+,QP !W)KYJ^%NJMI?C^P^95CN]UM)DXR&^Z/^^@M>W?$75!I/@/5
M9@1OEB^SH/>3Y>/< D_A6-2/O>ITTI>YZ'S9K&HOJ^M7NHR*%:ZG>4J.@W$G
M%1ZA92:=?S6<P82PML<,,$'N"*O>%M._M;Q7I5B02DUT@?:<'9G+8_ &K'CC
M_D>M<_Z_9?\ T(UO?6QRVTN>H_ K_D#ZO_U\)_Z":[+XB?\ )/\ 6O\ KW_J
M*XWX%?\ ('U?_KX3_P!!-=E\1/\ DG^M?]>_]17/+XSKA_"/EVOI/P7X8T"Z
M\%Z//<:'IDTTEJC/)):1LS''4DC)-?-E>_>$_B1X3TSPEI5C>:MY=S!;(DB?
M9Y3M8#D9"X-:U;VT,:#2;N=E_P (CX9_Z%W2?_ */_XFN!^)WP_T.#PU<ZUI
MMK'8W-KM9DA&V.52P!&WH",Y!'T^G1O\6/!:(675V<C^%;67)_-17!_$3XH6
M&NZ&^C:,DK1SLIGGD7;\H.=JCKR0ISZ<=^,X*=S:I*GRL\FKZR\+7LFI>$])
MO)69I9K2)I&;JS;1D_GFOE.TM)[Z\AM+6)I9YG$<:+U9B< 5];:/IZZ3HMCI
MR$$6L"0[O7:H&?QQFJK;(SP^[+M<9\4=>70_!-VJN1<WW^BQ 8S\P^8_3;GG
MU(KLZ^?OC+K[:EXJ32XV4V^G)MX.<R. 6_(;1CL0:SIJ\C:K+EB>>6MM+>7<
M-K A>::18XU'4L3@#\S23PR6T\D$RE)8V*.I[$'!%>@_!K1?[1\8M?R)F'3X
MC)DKD>8WRJ/RW$?[M5_BYH*Z/XR>YB4B#4%^T#IC?DAQ^>#_ ,"KHYO>Y3DY
M'R<QZQ\+M?.N^"K832A[JS/V:7UPOW"?^ XY[D&NTKYZ^#FO?V7XN.G2?ZG4
MD\O.>DBY*G_T(?\  A7T+7/4C:1UTI<T0HHHJ#0***HZU=_8-"U&\R1]GMI)
M<CJ-JD_TH ^=/B3XED\1^+KG:?\ 1+-FM[=?4 _,WXGGZ8]*E^'/@?\ X3#5
M9)+IF33;3:9BO!D)Z(#^!R>P^HKBJ^CO@_:+;?#VUE4#-S-+*V/4,4_D@KIF
M^6.AQ4USSNSKM-T?3=(@6'3K&"V11@"- #C.>3U/-9/B?P1HWBBREBN;6.*Z
M8$QW<: 2(WKG^(>H/Z=:Z.BN>[O<['%-6/D'5-.GTC5;K3KD 36TK1MCH2#U
M%>X?!B_U!]#NM,O;>X2*W826TDD; %6SD GC@C./]HUZ*-.L1=O=BSMQ<R$%
MYA$N]B  ,MC)P /RJS6DJG,K6,H4>65[GG_QD_Y$"3_KYB_K7SM7T3\9/^1
MD_Z^8OZU\[5I2^$QK_&?8\DD<,3RRNJ1HI9G8X"@=23V%?._Q)^($OB:_?3M
M/E*Z-"WRXR#<,/XF]L]!^/7I?^)WQ&&NLVB:1(?[.C?]].I(^T,.P_V!^I /
M;GS&E3A;5CK5;^ZC6\.^'=0\3ZM'IVG1;G;EW;[L2]V8]A_/I7TYX<\.:?X7
MTF/3]/CPHYDD;[TK=V8^O\JSO .CZ+I7A6U?13YL5T@EDN67#RM_M>F.1M[?
MF3U%9U)\SL:TJ:BK]0KS;Q_\3Y?"VH/I-A8B2\$:N9YF^1=WHHY/YBO2:\8\
M>>!==\5?$*9[&VV6ODQ!KJ8[8QQS@]2?IFE!*^I55R4?=/+-1U+4O$.J/=WL
MTMW=RGW)]=JCL/0"J%?1>B_#S2_"/AV_F %UJ1M9 ]TZ_=^5N$'\(P<>I_2O
MG2NB,E+8Y)P<;7/IWX9?\DZT?_KF_P#Z,:NLKD_AE_R3K1_^N;_^C&KK*Y9;
ML[8?"BM?Z?::I926=];QW%O("K1N,@_X'W'-?.WQ#\(:1X9U!O[*UB"8,^&L
M6?=- 2,\D=OK@\CKUKO?BSX\GTD#P_I4ICNI8]UU,O6-#T53V)'4]AC'7CQ&
MWM[F_NE@MH9;BXD/RQQJ7=CUX Y-;4HM:G/6FF^6VIUW@?XB:AX0E%O(&N]*
M8DO;$X*$]60]C[=#['FOH'0?$.F>)-/6\TRY65.-Z='C)&=K#L:^='^&OC".
MU%PVASE#V5T9_P#OD'=^E8^C:WJ?AS4EO--N9+>=#A@.C#NK#N/8TY04M43"
MI*&DMCZWHKE_ WC.W\9:.TZH(;V#"W,(Z*3T8?[)P<?0CMD]16#5G9G6FFKH
M****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N5\
M6> M-\8W-M-J-W?QBW0K''!(H49.2<%3R<#\A7544TVM4)I-69QGAGX9:'X6
MU<:G9S7LUPL;(HN)%*KGJ1M4<XR/Q-=G110VWN"BEH@JAK>CVNOZ-<Z7>[OL
M]PNUBF-PY!!&01D$ ]*OT4AO4\T_X4?X9_Y_M6_[^Q__ !NNXU+18=6\/2Z-
M=W%P\4L(BDFRHD;&/FSC&3CTQ[5IT53DWN2H16R/-/\ A1_AG_G^U;_O['_\
M;H_X4?X9_P"?[5O^_L?_ ,;KTNBGSR[D^RAV/-/^%'^&?^?[5O\ O['_ /&Z
MMZ5\(/#^D:M:ZC;WFIM-;2K*BR2QE20<C.$!Q^->@44N>7<?LX=@KBO$/PM\
M-:_-)<^0]C=R9+2VIVAF]2IROUP 3D\UVM%)-K8IQ3W/'7^ R%OW?B-E'HUE
MG_V<5H:;\#]&MY%?4-1NKP <HBB)6/OU./QKU*BJ]I+N1[*'8J:9I=CH]BEE
MIUK';6Z=$C&!GU/J?<UA^+? VG>,FM?[1N[V);8-L2W=%&6QDG*G)X%=/14I
MM.Y;BFK&1X:\.6/A71TTS3S*T2NSEY6!=F)ZG  ]!P.@H\2^'K;Q1H[Z7>7%
MS#;NZLYMV"LV#D Y!&,X/3L*UZ*+N]PLK6/.;7X+>&K6[AN/M6IR^5(K^7)+
M'M;!S@X0'!]B*]&HHH<F]Q1BH[!1112*/-Y_@GX9FGDE%UJ<8=BVR.6,*N3T
M V=*['PUX>M_"^CII=I<W,]O&[-']H92R9.2!M4<9R?Q-:]%4Y-[DJ$4[I'F
MG_"C_#/_ #_:M_W]C_\ C==G<>&[.Y\)CPX\DXLQ;);;PP\S:H !SC&>!VK8
MHH<F]P4(K9'FG_"C_#/_ #_:M_W]C_\ C='_  H_PS_S_:M_W]C_ /C=>ET4
M^>7<GV4.QYI_PH_PS_S_ &K?]_8__C==%X3\!:7X-FNI=.N+R5KE55_M#JP
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MHTFEWLDT<$C*Q:%@&R#D=01^E<OH_P (] T35[74[:[U)YK9Q(BR21E2??"
M_K7?44*32L@<(MW:"N7\4^ =#\6XEO87AO%&%NH"%?'H>H8?49]"*ZBBA-K8
M;2:LSQUO@/&924\1.(\\*;,$X^N_^E=5X7^%FA>&KJ*]8RWU]'RDL^ J-ZJH
MZ'ZD^HQ7<453G)]2%2@G=(*XOQ+\,=%\4ZP^IWUU?QSLBH5@D0+@=.J$_K7:
M45*;6Q;BGHSGO"?@W3O!UM<P:?-=2K<.'<W#*Q! QQA170T44-WW!))60444
M4AC71)(VCD561@0RL,@@]B*\ZUSX-:!J<S3V$TVFR,V2D8#Q>^%/(_/'M7H]
M%-2:V)E%2W/'8_@,@D!D\1LR=PME@G\=Y_E78^%?AKH7A:5;J-'N[Y3E;BXP
M2G&/E X'ZGWKL:*;G)[L2IP3ND%%%%26%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!2UC_D"7__ %[2
M?^@FO&/@O_K-:^D'_L]>SZQ_R!+_ /Z]I/\ T$UXQ\%_]9K7T@_]GK6'PLQG
M\<3UBBBB@T"JFI_\@Z7\/YBK=5-3_P"0=+^'\Q6=;^'+T9CB/X,_1_D<[111
M7AGR@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %S3[PVTN&
M/[MNOM[UT(((!'0UR5;>DW7F1^0Y^9/N^XKOP=:S]F_D>OEN)L_92^1I4445
MZ)[04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4R3[
MH^M/IDGW1]: +$?^K7Z4ZFQ_ZM?I3J0PHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH KR?\?"_A5^J$G_'POX5?H8!1112
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *JV
M?_'V_P!#_.K55;/_ (^W^A_G1T T:***D HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@"C:?\A)_JU:M95I_P A)_JU:M.6X(**
M**D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %>:?'#_ )$JS_["*?\ HN2O2Z\T^.'_ ")5G_V$4_\
M1<E5#XD9U?@9Y!X'_P"1ZT/_ *_8O_0A7JOQD\(_;M.3Q#9QC[1:C;<@#[\7
M9OJI_0^U>5>!_P#D>M#_ .OV+_T(5]421QS1/%*BO&ZE61AD,#U!'<5K4ERR
M3,:,5*#3/D72-4N=$U>UU*S<I/;R!U(/7U!]B,@^QKU'XKZU:^(?!GA[5+1O
MW4\KDKGE&VC<I]P<BN'\=^%G\)^)9K-58V<G[VU<G.8SV)]0<C\,]ZPSJ%RV
MF#3FD+6RR^<J'^%L8)'U&,_05I92M)&5W%.+-OX??\C_ *+_ -?*_P!:^I*^
M6_A]_P C_HO_ %\K_6OJ2L:VYOA_A9\G^+O^1UU[_L(W'_HQJ]0^&FG?VM\)
M-?L!G=/<3HN!D[O)CQQ]<5Y?XN_Y'77O^PC<?^C&KV7X'_\ (E7G_81?_P!%
MQUI/X#.DKS:/!K:X>TNX;F/'F1.LBY]0<BO7OC+K\=[H&@V]NYV7J_;2HZ;=
MHV\_\";\OI7F_C#3#H_C#5K';M6.Y<QC_88[E_\ '2*HW^J76I0V4=S(76SM
MQ;Q>R!F8?^A8_"J:NTR%+E3B=U\%M.%WXTDO&QBSMF=?]YL+_(M7+^./^1ZU
MS_K]E_\ 0C7K'P.T[R/#FH:@3S=7 C Q_"@ZY^KG\J\M^(/_ "/^M?\ 7RW]
M*E.\V5)6IH]+^!7_ "!]7_Z^$_\ 0379?$3_ ))_K7_7O_45QOP*_P"0/J__
M %\)_P"@FNR^(G_)/]:_Z]_ZBLI?&;P_A'R[6G'X;UV:T%W%HNHO;,F\3+:N
M4*^N[&,>]9E?5'@3_D1-$_Z]$_E6TY<J.>G#G=CY8=&C=D=2K*<%2,$'TK:\
M+^&IO%.JC3[>]L[:4\C[3(5+#N%&/F/M_P#7KVKXG^ H_$.G/JNG6_\ Q-X%
MR0G6X0?PD=V Z?EZ8^>T=HW5T8JRG(8'!!]:<9<RT%.')+4^CO!OPPTOPK,E
M]-*;[4E!Q*Z[4CS_ '5YP>V2?RKNJ\\^%WCK_A)-,_LS4)LZK:K]YCS/'V;W
M8=#^![G'H=<T[WU.RGR\ONE'6=4@T71KO4KDCRK:(R$$XW$=!^)P/QKY*N[J
M:^O)KNXD:2:9R[NQR22<FO;OC;KZVVC6NAQ,WFW;B:7!X$:] ?7+8/\ P#Z5
MX76U)65SFKRO*Q]'?"70ETCP3!<NFVXU _:')&#MZ(/IMY_X%47Q?T)=5\&/
M>I'NN=.;SD(Z[#@./IC!_P" U\[44_9OFYKA[5<O+8EM[B:TNHKFWD:.:%Q)
M&Z]58'((_&OK+P_K$.OZ#9:I!PES&&Q_=;HP_ @C\*^2*]K^"&OF6TO=!GD&
M82)[=21DJ?O@?0X/XTJL;JX4)6E;N>L7EW!864]Y<OLM[>-I97P3M51DG Y/
M [5R?_"UO!7_ $&O_)6;_P"(K<\4PRW'A'6H((WEEDL)T2-%+,S&-@  .I)K
MYE_X1'Q-_P!"[JW_ (!2?_$UG""EN;59RB]$>_?\+6\%?]!K_P E9O\ XBK.
MHZWIWB7X?Z[=:1<?:8#97$6[8R?-Y9XPP![BOGC_ (1'Q-_T+NK?^ 4G_P 3
M7MWPLT>Y@\!76GZI97%L9KB56BGC,;%&51G!'UJI0C%71,*DI.S1\\5],_"V
M59OAQI)&,J)%(!S@B1O_ -?XU\WZC8S:9J5U87 Q-;2M$X]U.#_*O:/@EKT$
MND76A2.JW,,IGB4GET8#./H1_P"/"KJJ\3.@[3LSUBBBD9E12S$!0,DD\ 5S
M'8+17SSK_P 4-<C\8ZA=:-J;"P\SRX8F4/&RK@;@#TR1G(P>:](^&WCC5?&0
MO_M]C;1);;,30;E#%L_+@D]AZ_SJW3:5S*-6,G8;\9/^1 D_Z^8OZU\[5]$_
M&3_D0)/^OF+^M?.U;4OA,*_QFAHNBW_B#5(M.TZ$RSR'\%'=F/8"I?$6@7?A
MG7+C2[T R1$%74?+(IY##V_KD=J^D/!O@VP\'Z6(( );N0 W%R1S(?0>BCL/
MZUS7Q?\ "7]L:'_;5J@^V:<A,F!R\/4C/^SRW_?5)5;RMT&Z%H7ZG*?!WQD;
M"^_X1R]D_P!&N6+6K$_<E./E^C?S^M>Z5\<1R/#(DD;LDB$,K*<%2.A!]:^F
MOA[XMC\5^&XY)'']H6P$5VF>=W9_HP&?KD=JFK'JBZ$[^ZSK:***Q.@HZS_R
M M0_Z]I/_037R)7UWK/_ " M0_Z]I/\ T$U\B5O1ZG+B-T?3OPR_Y)UH_P#U
MS?\ ]&-765R?PR_Y)UH__7-__1C5UE8RW9T0^%'R3XBU)]7\1ZCJ#N&,]P[@
MCIMS\H'L!@5[+\%_#EO:Z"^O2('NKMF2-BO,<:D@@'W(.?H*\.OK5[+4+FT<
M,KP2M&P88(*DCG\J^DOA;-'-\.=*V,"4$B,,\@B1N#^A_$5O5TCH<M%7G=G8
M5XE\;/#D%K<6>OV\81KEC!<8'#.!E6^I (_ 5[;7EWQRNHD\+Z=:%OWTMZ)%
M7U548$_FZ_G65-^\=%9)P=SSWX4:LVE^/;.,MB*\5K:0>N1E?_'@M?2=?+/@
M&$S^/=$1>HNE?\%^;^E?4U56W(P[]T****R-PHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH I:Q_R!+_\ Z]I/_037C'P7
M_P!9K7T@_P#9Z]GUC_D"7_\ U[2?^@FO&/@O_K-:^D'_ +/6L/A9C/XXGK%%
M%%!H%5-3_P"0=+^'\Q5NJFI_\@Z7\/YBLZW\.7HS'$?P9^C_ ".=HHHKPSY0
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J2"5H)DD7JIJ.
MBFFT[H:;B[HZM'62-74Y5AD4ZLW1Y]\#1$\H<CZ5I5[E*?/!2/JZ%55::GW"
MBBBK-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F2?='UI
M],D^Z/K0!8C_ -6OTIU-C_U:_2G4AA1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!7D_X^%_"K]4)/^/A?PJ_0P"BBBD 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 55L_^
M/M_H?YU:JK9_\?;_ $/\Z.@&C1114@%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 4;3_D)/]6K5K*M/^0D_P!6K5IRW!!1114C
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KS3XX?\B59_P#813_T7)7I=<A\1O"M]XO\/6^GZ?+;Q2QW
M2S$W#,J[0CKV!YRPJH.TD143<6D>">!_^1ZT/_K]B_\ 0A7U57BOASX0>(-(
M\2:=J-Q>:8T-M<)*ZQRR%B <G&4 S^->U5=5IO0BA%Q3N<E\1/"8\5^&9(H5
M_P!/MLRVQ]3W7\1Q]<5\R$%6*L""."#VK[(KR;QQ\);S7?$4FJ:-<6<"W W3
MQW#LO[SN5VJ>",'ZY]:=.=M&36IMZH\T^'W_ "/^B_\ 7RO]:^I*\8\+_"/7
M]$\3Z?J=S=Z:\-M,)'6.20L1[90#]:]GJ:K3>A5"+BG<^3_%W_(ZZ]_V$;C_
M -&-7M/P315\#S$#EKZ0GZ[4']*YC7?@[XAU/Q#J6H07FEK%=74LR!Y9 P5G
M+#.$/.#7H?P]\,7OA/PV^G7\MO),;AI=T#,5P0H[@'/'I5SDG&R(I0DIW:/*
M_C7IOV7QA!>J%"WELI) P2RG:<^O&VO-:^DOB3X)NO&6GV*6$MO%=6LK'-PS
M!=C#GD G.0O:O/(/@AXA%Q&9[W2S$&&\+-)DKGG'[OKBG":Y=2*E.3D[(]8\
M!Z<VE>!='M&X;[.)&'H7)<C\VKY]^(/_ "/^M?\ 7RW]*^HD1(XUCC5510 J
MJ,  =@*\:\4?"/7];\3ZAJ=M=Z:D-S,9$6220,![X0C]:BG)<S;-:L&XI(O?
M K_D#ZO_ -?"?^@FNR^(G_)/]:_Z]_ZBL[X;>#=1\'6%]!J$UK*UQ*KH;=F8
M  8YRHKH/%6DSZYX7U#3+5XTGN8MB-*2%!R.N 3^E*37/<J*:IV/DZOJCP)_
MR(FB?]>B?RKR+_A1_B;_ )_M)_[^R?\ QNO:?#6FS:-X:T[3;AHVFMH%C=HR
M2I(';(!Q^%55DFM#.A"46[HU:^?OBUX,&AZL-8L8@NGWKG>B+Q#+CD?1N2/?
M(XXKZ!JCK&DVFN:3<Z9?(7MKA-K@'!'.01[@@$?2LX2Y7<VJ0YU8^4]$UBZT
M'6;74[-L36[A@">&'=3[$9!^M?5>BZM;:[H]KJ=FVZ"X3<OL>A!]P01^%>)/
M\#O$8=@E_I17/!,D@)'TV5UGA?P3XR\-Z#J^E)?:4\5Y"P@(FDS#*1M+#Y/[
MOZA?>M:G++9F-)3@[-:'EGC_ %YO$7C&^NPX:")S!;D9QY:D@$9]>3^-=5\'
M/"MOJ]]?:IJ5C#<V4">3&D\8=&D."3@\$A?7^\*B_P"%'^)O^?[2?^_LG_QN
MO7?!'AP^%?"UMIDIC:X4L\[QDE6<GJ,@=L#H.E$YI1LA4Z<G.\D6/^$1\,_]
M"[I/_@%'_P#$T?\ "(^&?^A=TG_P"C_^)K9HK&[.GE78\(^,OABTTB\T[4=-
MLX;6VG0PR1P1JB!U.0< =2"?^^:XCPAKI\-^*;'4^3'$^V4 ]488;]#G\!7T
M?XS\/'Q1X6N]+1D2>0!H7<D!74@C. >.W3O7D'_"C_$W_/\ :3_W]D_^-UM"
M:<;,YJE.2G>*/?5974,I!4C((/!%+6/X5L=2TSPU96.K30S7ENGEM)$[,K*"
M=O+ '.,#\*V*P9TK8****!GD'Q=\"SWDC>)=,B,CJ@%[&O)(48$@'L!@^P!]
M37CEE>W.G7L-Y9S/#<0MNCD0X*FOL*O/_$WPDT/7IFN;-FTRZ<Y9H4#1L><D
MID<\]B*VA4LK,YZE%M\T3CM-^.>HP6PCU+2(+N4  213&'/J2,,,GVP/:L+Q
M7\5-9\36+6"116%FXQ*D+$M)[%CV]@![YK5G^!NO+(1;ZGILB>LA=#^04_SJ
MS8? O47D3^T=7M8DS\PMT:0X]MVW_/K5?NUJ0U5:L>6V5E<ZC>PV=G"\UQ,V
MV.-!DL:^H?!7AI/"GAFWTX-OF),L[X',C 9_ 8 _"H_"O@;1?"41-C"9+IAA
M[J;#2$>@./E'L/;.:Z6LZD^;1&M*ER:O<\_^,G_(@2?]?,7]:^=J^H?'_AN\
M\5>&&TRQD@CF,R2;IV(7 SGH"?TKRG_A1_B;_G^TG_O[)_\ &ZNG)):F=:$G
M*Z1[]2,JNI5@"I&""."*6BL#J/F+XA>%#X3\3201 FQN!YMLQ[+W4^X/'TP>
M]5?!/BF;PEXBBOU#/;-^[N(@V-Z'^HZCZ>]>_>//"$?C#0#:HR1WT+;[:5\[
M5;N#CL1Q^1[5Y5_PH_Q-_P _VD_]_9/_ (W71&:<;2.2=.497B>]6\\5U;17
M$$BR0RH'C=3D,I&01[8J2N1^'^A:_P"&M'?2]9N;2XAC;-L\$CLR ]4.Y1QG
MD?4^U==6#5F=47=791UG_D!:A_U[2?\ H)KY$K[ U"W>[TVZMHRH>6%XU+=
M2".:\*_X4?XF_P"?[2?^_LG_ ,;K6E)*]S"O%R:L>I?#+_DG6C_]<W_]&-76
M5A^#]&N/#_A2PTJ[>)Y[=65VB)*G+$\$@'OZ5N5E+=FT5:*/GSXO^&)-)\2M
MJ\*_Z'J)W$C^"4#YA^/WOQ/I5'X??$&;P?<O;7*//I4[;GC4_-$W]Y?ZCO@5
M]"ZKI5EK6FS:?J$"S6TPPRG]"#V([&O%==^">K6UP[Z)=0WEL3\L<S;)5'N<
M;3]>/I6T9IKED83IRC+F@=Y-\7O!\5IYR7T\TF,^0ELX?ITRP"Y_&O$_&GB^
MZ\8ZR+R:/R8(EV00!L[%[Y/<D_T]*T?^%4>--^W^QQC.-WVJ''U^]FNJ\/?!
M&Y:>.?7[V)(0<M;6Y+,P]"W&/PS]::Y(ZW)E[2>C1'\%?#,DVHS>(KB-EA@4
MQ6Q9?O.>&8?09'XU[?4%G9V]A9Q6EI"D-O$H6.-!@**GK&4N9W.B$.6-@HHH
MJ2PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JNIS26
M^E7D\3;9(X'=3C."%)%6JHZS_P @+4/^O:3_ -!-"$]CYV_X6MXU_P"@U_Y*
MP_\ Q%'_  M;QK_T&O\ R5A_^(KC:^A/#GPT\(W_ (8TF\N=(WW%Q90RRO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH KR?\?"_A5^J$G_'POX5?H8!1112 **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *JV?_'V_P!#_.K55;/_ (^W^A_G1T T
M:***D HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@"C:?\A)_JU:M95I_P A)_JU:M.6X(****D84444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4U/_ )!TOX?S%6ZJ:G_R#I?P_F*SK?PY>C,<1_!GZ/\ (YVBBBO#/E HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KH].;?81'T&*Y
MRM[2&S98]&(KLP3_ 'EO(]+*Y6K->1?HHHKU#WPHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "F2?='UI],D^Z/K0!8C_P!6OTIU-C_U:_2G
M4AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!7D_X^%_"K]4)/^/A?PJ_0P"BBBD 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 55L_^/M_H?YU:JK9_P#'V_T/\Z.@&C11
M14@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4
M;3_D)/\ 5JU:RK3_ )"3_5JU:<MP04445(PHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUYX@T73K@V]]J]A:S@ F.>Y1& /0X)S5]'22-9(V5D8 JRG((/<&@+CJ***
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MZS_R M0_Z]I/_035ZJ.L_P#("U#_ *]I/_030A/8^1*^L/"/_(E:#_V#K?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% %+6/^0)?_P#7M)_Z":\8^"_^LUKZ0?\ L]>SZQ_R
M!+__ *]I/_037C'P7_UFM?2#_P!GK6'PLQG\<3UBBBB@T"JFI_\ (.E_#^8J
MW534_P#D'2_A_,5G6_AR]&8XC^#/T?Y'.T445X9\H%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %;FC?\ 'F__ %T/\A6'6]I Q8Y]
M6)KKP?\ %/0RQ?O_ )%^BBBO5/H0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "F2?='UI],D^Z/K0!8C_U:_2G4V/\ U:_2G4AA1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!7D_X^%_
M"K]4)/\ CX7\*OT, HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %5;/\ X^W^A_G5JJMG_P ?;_0_SHZ :-%%%2 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*9)]T?6GTR3[H^M %B/_ %:_2G4V/_5K]*=2&%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% %>3_CX7\*OU0D_X^%_"K]#
M ****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !56S_X^W^A_G5JJMG_ ,?;_0_SHZ :-%%%2 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!1M/^0D_P!6K5K*M/\ D)/]6K5I
MRW!!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KA/B]>/:_#^Y1'*FXFCB..XSN(_\ ':[NO._C
M2I;P(I X6\C)^F&']:J'Q(BI\#.>^!6FI_Q-]49<N-ENAQT'+-_[)^5>RUY/
M\"IT;1M6MP1O2X1R,]F7 _\ 037K%.I\3%1^!!116-XE\3Z?X4TP7^HF0QM(
M(U2( NQ/H"1G Y-0E<MNVK-FN.^*6H_V=\/M1VNRR7 6W3:<9W$;A_WR&K6\
M-^+-*\5VTT^EO,RPL%D\R)DP3TY/!_ \<9ZBO/?CKJ(6PTG3%;F25[AU]-HV
MJ?\ QYORJX+WDF14DN1M'F/AOQ1<^%UOYK!%%]<PB!)VY\I2<L0/7A<?2J-]
MI>J06<&J7UM.L%Z6:*>4']Z>I.3SSG.3UKTCX9?#6WU:VBU_6E66S?/V:UR?
MG()&Y_;(X'?OQP?4?&'AJ'Q/X6N=+VJLFT/;-@?)(OW<>@ZJ?8FM742D<\:4
MI1NRO\/]>M=?\(6<UM%% T"""6", *CJ.P'0'J/K745\X_#GQ)/X/\7O87^8
M;6XD^S74;\>5(#@-]0<@^Q-?1U93C9G12GS1"BBBH-#A/B_?FR^']Q$,9NYH
MX,GMSO/Z)6/\#M.\CP[J.H'(-S<B,#'\*+US]78?A67\=K\&71M/7JHDG?\
M'"K_ ":N]^&^G_V=\/\ 2(R@5I8O/8\9;>2P)Q[$?D*UVI^I@M:OH=57(^*_
M'MEX<N8]-MX7U#6)L".SAZ@G[NX]LG''7GI6_K>IQZ-H=]J4O*VT+28_O$#@
M?B<#\:\7^#]JVM^-;_6;]O/GAC,NYP"3*[?>]N-W3UJ8Q5FV7.3345U-OQ#\
M.?$/C".36=3?3K+4Q$?+L[:(DO@?*KR%L;NV>1^'3.\"?$J^TC45\/\ BAI3
M&K>2DTP/F0/G[KYY([9[?3I[;7A?QOT:*UUJPU>)0K7L;1S8[LF,'_OD@?\
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ML[B&XMWSMEA<.K8.#@C@\@BBPKHFHHHH&%%%% !1110 4444 %%%% !1110
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M44 %%%% !1110 4444 %,D^Z/K3Z9)]T?6@"Q'_JU^E.IL?^K7Z4ZD,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *\G_
M !\+^%7ZH2?\?"_A5^A@%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ JK9_\ 'V_T/\ZM55L_^/M_H?YT= -&BBBI ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP%KF_=-LEU( #CN%'\(_/ZT+EAJM6-\]31JR+O@SPW%X5\,VVFK@S?ZRX?\
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MYQ[([VBBBLS8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW=O?RGROWF(;NUDRN\<X[$<#H1R,]>:]QF^(G@S39!9'6+=/*Q&$@B=T4#C
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH HVG_ "$G^K5JUE6G_(2?ZM6K3EN""BBBI&%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%07M[;:=9RWEY.D%O$NYY)#@*
M*\0\5?$75_&-_P#V%X6@N%MI<QGRU_>W Y!)_NIC],Y/:JC%R(G-1-[XC?%"
M"TMYM&T"=9;IP4N+I.5B'0JIZ%O<<#Z]$^$O@.ZTN0^(-6@,,[IMM86^\JL.
M7([$CC!YZU?\"_"FTT/R=2UH)=ZCC<L! ,4!_P#9F'KT';H#7I55*22Y8D1@
MY/FF8WBW56T7PGJFHHRK)#;MY98X <\+_P"/$5\X^%?"&N>*9I8]*CV0@;)I
MY&*1CH=I(Z]C@ U]3T4HSY5H5.GSM-L\4;X$70M"R:]";G'$9MB$S_O;L_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *JV?_'V_P!#_.K55;/_ (^W^A_G1T T:***
MD HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"C:
M?\A)_JU:M95I_P A)_JU:M.6X(****D84444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>JLBSXKNUT7P3JD\($8@LV2(9X4D;5_4BO(/@E8?:/%UU>'[MM:G'^\S #]
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !56S_P"/M_H?YU:JK9_\?;_0_P Z.@&C1114@%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 4;3_D)/]6K5K*M/^0D_U:M6
MG+<$%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *
M6L?\@2__ .O:3_T$UXQ\%_\ 6:U](/\ V>O9]8_Y E__ ->TG_H)KQCX+_ZS
M6OI!_P"SUK#X68S^.)ZQ1110:!534_\ D'2_A_,5;JIJ?_(.E_#^8K.M_#EZ
M,QQ'\&?H_P CG:***\,^4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BG!&/12?H*>MM._P!V
M%S_P&FHM[%*,GLB*BKB:9=.>8]OU-6XM%[RR_@HK6.'J2V1T0P=>>T3(JU;Z
M?/<<A=B_WFK;AL;>#E(QGU/)JQ773P76;.^CE?6J_N*=KIT-OAC\[^IJY117
M;&$8*T4>K3IPIKE@K(****HL**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ IDGW1]:?3)/NCZT 6(_\ 5K]*=38_]6OT
MIU(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 5Y/^/A?PJ_5"3_CX7\*OT, HHHI %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %5;/_C[?Z'^=6JJV?\ Q]O]#_.CH!HT
M445(!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^UV__/5?SH^UV_\ SU7\Z+@345#]KM_^>J_G1]KM_P#GJOYT7 FHJ'[7;_\
M/5?SH^UV_P#SU7\Z+@345#]KM_\ GJOYT?:[?_GJOYT7 FHJ'[7;_P#/5?SH
M^UV__/5?SHN!-3)/NCZTS[7;_P#/5?SI//BEX1PQ'/%%P+D?^K7Z4ZH4F14
M.<BG>>GO^5*PR2BH_/3W_*CST]_RHL!)14?GI[_E1YZ>_P"5%@)**C\]/?\
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MHL!)14?GI[_E1YZ>_P"5%@)**C\]/?\ *CST]_RHL!)14?GI[_E1YZ>_Y46
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MVN+W_*BP$]%0?:XO?\J/M<7O^5%@)Z*@^UQ>_P"5'VN+W_*BP$]%0?:XO?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY$/_ #R3_OD4>1#_ ,\D_P"^14E% $?D0_\ /)/^^11Y$/\ SR3_ +Y%244
M1^1#_P \D_[Y%'D0_P#/)/\ OD5)10!'Y$/_ #R3_OD4>1#_ ,\D_P"^14E%
M $?D0_\ /)/^^11Y$/\ SR3_ +Y%244 1^1#_P \D_[Y%'D0_P#/)/\ OD5)
M10!'Y$/_ #R3_OD4>1#_ ,\D_P"^14E% $?D0_\ /)/^^11Y$/\ SR3_ +Y%
M244 1^1#_P \D_[Y%'D0_P#/)/\ OD5)10!'Y$/_ #R3_OD4>1#_ ,\D_P"^
M14E% $?D0_\ /)/^^11Y$/\ SR3_ +Y%244 1^1#_P \D_[Y%'D0_P#/)/\
MOD5)10!'Y$/_ #R3_OD4>1#_ ,\D_P"^14E% $?D0_\ /)/^^11Y$/\ SR3_
M +Y%244 1^1#_P \D_[Y%'D0_P#/)/\ OD5)10!'Y$/_ #R3_OD4>1#_ ,\D
M_P"^14E% $?D0_\ /)/^^11Y$/\ SR3_ +Y%244 1^1#_P \D_[Y%'D0_P#/
M)/\ OD5)10!'Y$/_ #R3_OD4>1#_ ,\D_P"^14E% $?D0_\ /)/^^11Y$/\
MSR3_ +Y%244 1^1#_P \D_[Y%'D0_P#/)/\ OD5)10!'Y$/_ #R3_OD4>1#_
M ,\D_P"^14E% $?D0_\ /)/^^11Y$/\ SR3_ +Y%244 1^1#_P \D_[Y%'D0
M_P#/)/\ OD5)10!'Y$/_ #R3_OD4>1#_ ,\D_P"^14E% $?D0_\ /)/^^11Y
M$/\ SR3_ +Y%244 1^1#_P \D_[Y%'D0_P#/)/\ OD5)10!'Y$/_ #R3_OD4
M>1#_ ,\D_P"^14E% $?D0_\ /)/^^11Y$/\ SR3_ +Y%244 1^1#_P \D_[Y
M%'D0_P#/)/\ OD5)10!'Y$/_ #R3_OD4>1#_ ,\D_P"^14E% $?D0_\ /)/^
M^11Y$/\ SR3_ +Y%244 1^1#_P \D_[Y%'D0_P#/)/\ OD5)10!'Y$/_ #R3
M_OD4>1#_ ,\D_P"^14E% $?D0_\ /)/^^11Y$/\ SR3_ +Y%244 1^1#_P \
MD_[Y%'D0_P#/)/\ OD5)10!'Y$/_ #R3_OD4>1#_ ,\D_P"^14E% $?D0_\
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MS]34M%%P(OLT/]S]31]FA_N?J:EHHN!%]FA_N?J:/LT/]S]34M%%P(OLT/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4R3[H^M/IDGW1]: +$?\ JU^E.IL?^K7Z4ZD,**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *\G_'PO
MX5?JA)_Q\+^%7Z& 4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "JMG_Q]O]#_ #JU56S_ ./M_H?YT= -&BBBI **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH HVG_(2?ZM6
MK65:?\A)_JU:M.6X(****D84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA_*SIZ*YC[5<?\_$O_?9H^U7'_/Q+_WV:/KT>P?VK#^5G3T5S'VJX_Y^)?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH HVG_ "$G^K5JUE6G_(2?ZM6K3EN""BBBI&%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% %+6/^0)?_ /7M)_Z":\8^
M"_\ K-:^D'_L]>SZQ_R!+_\ Z]I/_037C'P7_P!9K7T@_P#9ZUA\+,9_'$]8
MHHHH- JIJ?\ R#I?P_F*MU4U/_D'2_A_,5G6_AR]&8XC^#/T?Y'.T445X9\H
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 JL5.5)!]15^WU6:+"R#S%]^M9]%7"
MI*#O%FM.M.D[P=CIK>\AN1\C?-_=/6IZY-6*L&4D$="*U;/52"$N.G]__&O0
MHXQ2TGH>QALRC/W:NC[]#7HI%8,H92"#T(I:[3U HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F2?='UI],D^Z/K0!8
MC_U:_2G4V/\ U:_2G4AA1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!7D_X^%_"K]4)/\ CX7\*OT, HHHI %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5;/\ X^W^A_G5
MJJMG_P ?;_0_SHZ :-%%%2 4444 %%%% !1110 4444 %%%% !1110 4444
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M7,?&3_D0)/\ KYB_K7SM1"FI*X5*K@[6/LA65U#*05(R"#P12U7L/^0=;?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ***JZG-);Z5>3Q-MDC@=U.,X(4D4 6J*^:/^%K>-?^@U
M_P"2L/\ \11_PM;QK_T&O_)6'_XBM?8R,/K$3Z7HKYKB^+/C.-]S:JD@_NO:
MQ8_10:[+PE\9Y+B]CLO$D,$:2':MY$"H0_[:\\>XQCT[TG2DAJO%NQ[%12*R
MNH92"I&00>"*6LS8**** "BBB@ HHHH **PO&>HW6D^#]3O[*7RKF"'=&^T-
MM.1V((KP[3_BCXRGU*UADUC<CS(K#[-",@D _P %7&#DKHSG4479GT=1114&
M@445XO\ $GQWXET#QA+8:9J7D6RPQL$\B-N2.>64FJC%R=D3.:@KL]HHKSSX
M3^)M8\3:;J,VKW?VEX9E6,^6B8!&3]T"O0Z35G8(R4E=!1112*"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **X#XK>)-6\-:)8W&D7?V:66YV.
MWEH^5VDX^8'TKD?AUX^\3:[XTM-/U+4_/M9$D+1^1&N2$)'*J#U%6H-JYFZB
M4N4]MHHHJ#0**** "BBB@ HHKP3QA\1O%>E>+]4L;+5?*MH)RD:?9XFVCZE2
M:J,7+8B<U!79[W17S1_PM;QK_P!!K_R5A_\ B*4?%?QJ&!.L@@=C:P\_^.5?
ML9&?UB)]+45X5HWQNU6WE"ZQ907<)/+PCRY /Y']/K7LVCZS8:]ID6H:;.)K
M:3.& (((Z@@\@U$H..YI"I&6Q?HHKYH_X6MXU_Z#7_DK#_\ $4XP<MA3J*&Y
M]+T5F>'+N>_\,:3>7+[[BXLH997P!N9D!)P.!R>U:=0:)W"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** *6L?\ ($O_ /KVD_\ 037C'P7_ -9K7T@_]GKV
M?6/^0)?_ /7M)_Z":\8^"_\ K-:^D'_L]:P^%F,_CB>L4444&@54U/\ Y!TO
MX?S%6ZJ:G_R#I?P_F*SK?PY>C,<1_!GZ/\CG:***\,^4"BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@"O)_Q\+^%7ZH2?\?"_A5^A@%%%%(
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JK9_
M\?;_ $/\ZM55L_\ C[?Z'^='0#1HHHJ0"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** *-I_R$G^K5JUE6G_ "$G^K5JTY;@@HHH
MJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M +Y!I_CC_D>M<_Z_9?\ T(UO?6QRVTN>H_ K_D#ZO_U\)_Z":[+XB?\ )/\
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M%6*KV'_(.MO^N2?R%6*YCL"BBB@#YH^*W_)2M7_[8_\ HE*W_@;_ ,C1J/\
MUY'_ -#6L#XK?\E*U?\ [8_^B4I?AQXML/!^LW=YJ$-S+'-;^4HMU5B#N!YR
MPXXKJ:O XDTJMWW/I:JU[I]GJ-NT%[:PW$3 @I*@88_&O/?^%X>&?^?'5O\
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MJ47&-F%%%%0:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-LMO9WLEC=N([E$A9EVYQOX_N]<^F:;A%J\1*I-2M-'T91116)T!7RW\0?\
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M,Y':NJK%JSL="::N@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** *6L?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>3_CX7\*OU0D_X^%_"
MK]# ****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !56S_X^W^A_G5JJMG_Q]O\ 0_SHZ :-%%%2 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!1M/^0D_U:M6LJT_Y"3_ %:M
M6G+<$%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "O-/CA_R)5G_ -A%/_1<E>EUYI\</^1*L_\
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M&3_D0)/^OF+^M?.U%+X0K_&?8-A_R#K;_KDG\A5BJ]A_R#K;_KDG\A5BN8[
MHHHH ^:/BM_R4K5_^V/_ *)2L'0O#FJ^);J2VTBU^TS1IYCKYBIA<@9RQ'<B
MM[XK?\E*U?\ [8_^B4K?^!O_ "-&H_\ 7D?_ $-:ZKVA<X>7FJ6?<XK6?!OB
M'P_"9M3TJ:"$$ RC#H">F64D"L08W#<2!W(&:^P[FV@O+66VN8DE@E4H\;C(
M8'J"*^9_B!X/D\(^(&BC!.GW.9+1S_=XRA]UR![C![TH5.;1E5:7)JMCOO _
MPQ\+ZC:0:K)JAUA>"8D'E(K=PZ_>X/J1G'0@UZ['''#$D42*D:*%5%& H'0
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MN&*^P**J2=Q4)-JS"BBBLC<**** "BBB@ HHHH **** "BBB@ HHHH ****
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M&VT+0[O5M/U25TMEWM#<("2N0.&&.?PY]J\[\.7DUAXETVZ@<K)'<QD$>FX
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M8?9GA?QT0#Q#I<G.3:D?DY_QJQ\"/^0CK7_7*+^;5#\=/^0[I7_7LW_H53?
MC_D(ZU_URB_FU/\ Y=D_\OCVRBBBL#J/'?C-X2O;NXA\0V4+31QPB&Y5.67!
M)#8].<'\/<UY1I6N:KHDQETR_N+5C][RG(#?4=#^-?16N_$OPYX>U*73KR:X
M:ZAQYD<<!.TD @9. <@@\<<UGV.E^"/B5ITVH0Z5Y;)*8GD"B&4, #D[3R""
M.N?TK>,VH^\M#FG!2E>+U//--^-/B6T*K>1V=\G\1>/RW/T*X _(UZ7X1^)V
MC^*KA+(H]EJ# E8)6!#X'\+<9/7C /%<IK_P4L;>PNKO2]5G0PQM((KE0X.
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M4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *EMIC;W"2#L>
M?I45%--IW149.+4ET.L5@ZAE.01D&EK.TB?S+<QD\H>/I6C7N4Y\\5(^JHU5
M5IJ:ZA1115FH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3
M)/NCZT^F2?='UH L1_ZM?I3J;'_JU^E.I#"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@"O)_Q\+^%7ZH2?\?"_A5^A@%%
M%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MJK9_\?;_ $/\ZM55L_\ C[?Z'^='0#1HHHJ0"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** *-I_R$G^K5JUE6G_ "$G^K5JTY;@
M@HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5YI\</\ D2K/_L(I_P"BY*]+KF?''A'_ (3/18=.
M^W?8_+N%G\SRO,SA67&-P_O=?:JB[.[(J)N+2/GOP/\ \CUH?_7[%_Z$*^JJ
M\JT/X,?V-KMCJ?\ ;_G?99EE\O['MW8.<9WG'Y5ZK55)*3T(HP<4[G.^-?#$
M/BSPW/8,%%PO[RVD/\$@Z?@>0?K[5\NW%O-:7,EO<1/%-$Q1XW&"I'4$5]B5
MYWXQ^%%KXIULZI!J/]GRR(!,HM_,$C#HWWA@XP/P^M.G.VC%6IN6JW/'_A]_
MR/\ HO\ U\K_ %KZDKRWP_\ !S^PM?LM4_M[S_LLHD\K['MW>V=YQ^5>I4JD
MDWH.C%Q6I\G^+O\ D==>_P"PC<?^C&KVKX* #P-*0 ";V0GW^5*S=7^"O]JZ
MU?ZC_P )!Y7VNXDG\O['NV;F+8SY@SC/6NU\%>%?^$/T)M,^V_:\S-+YGE>7
MU &,9/IZU4YIQLB*=.2G=GE/QOT[[/XGL;\9VW5ML/'&Y#SS]&6O+Z^GO'7@
MF/QKI]K;F]^QRV\I=9?*\S((P5QD>QSGM7$P? E([B.23Q")$5@60V.-P!Z?
MZRJA42C9DU*4G)M(]#\%:<-)\%Z19C&5ME=L?WF^9OU8U\\_$'_D?]:_Z^6_
MI7U)7EOB#X.?V[K][JG]O>1]JE,GE?8]VWVSO&?RJ*<DFVS6K!N*42#X%?\
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MM%%8MW.A*RL@HHHH&%%%% !1110 4444 %%%% !1110 4444 4M8_P"0)?\
M_7M)_P"@FO&/@O\ ZS6OI!_[/7L^L?\ ($O_ /KVD_\ 037C'P7_ -9K7T@_
M]GK6'PLQG\<3UBBBB@T"JFI_\@Z7\/YBK=5-3_Y!TOX?S%9UOX<O1F.(_@S]
M'^1SM%%%>&?*!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% %S3)C%>J.S_*:Z&N41BCJPZ@YKJ48.BN.C#->E@9WBXGN954O"4.PZBB
MBNX]4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDGW1]:?
M3)/NCZT 6(_]6OTIU-C_ -6OTIU(84444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 5Y/^/A?PJ_5"3_ (^%_"K]# ****0!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !56S_
M ./M_H?YU:JK9_\ 'V_T/\Z.@&C1114@%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 4;3_ )"3_5JU:RK3_D)/]6K5IRW!!111
M4C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"EK'_ "!+
M_P#Z]I/_ $$UXQ\%_P#6:U](/_9Z]GUC_D"7_P#U[2?^@FO&/@O_ *S6OI!_
M[/6L/A9C/XXGK%%%%!H%5-3_ .0=+^'\Q5NJFI_\@Z7\/YBLZW\.7HS'$?P9
M^C_(YVBBBO#/E HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KH]/;?81'T&*YRM[2&S8X]&(KLP3_>6\CTLKE:LUY%^BBBO4/?"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *9)]T?6GTR3[H^M %
MB/\ U:_2G4V/_5K]*=2&%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% %>3_CX7\*OU0D_X^%_"K]# ****0!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !56S_X^W^A_G5JJ
MMG_Q]O\ 0_SHZ :-%%%2 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!1M/^0D_U:M6LJT_Y"3_ %:M6G+<$%%%%2,**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% %+6/^0)?_P#7M)_Z":\8^"_^LUKZ0?\
ML]>SZQ_R!+__ *]I/_037C'P7_UFM?2#_P!GK6'PLQG\<3UBBBB@T"JFI_\
M(.E_#^8JW534_P#D'2_A_,5G6_AR]&8XC^#/T?Y'.T445X9\H%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %;FC?\ 'FW_ %T/\A6'
M6]I Q99]7)KKP?\ %/0RS^/\B_1117JGT(4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !3)/NCZT^F2?='UH L1_ZM?I3J;'_JU^E.I#"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O)
M_P ?"_A5^J$G_'POX5?H8!1112 **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *JV?_ !]O]#_.K55;/_C[?Z'^='0#1HHHJ0"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *-I_R$
MG^K5JUE6G_(2?ZM6K3EN""BBBI&%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\]_&:^-YXY6T3)
M^R6R1[0<_,V7Z>N&7\J/ MW-X'^)LFCWTNV*60V<K#[I.?W;?0G'T#&LSY/%
M'Q<_BD@N=4^I,2O_ /$BNG^-FB_8M9L->ME*&Y7RY74X_>)C:WUV\?\  *Z>
MT3CUNZBZ,]PHK!\&Z^/$OA6QU(D&9DV3X&,2+PW'H3S]#4OBV_72_".K7A8J
M8[5]I']XC"_J17/;6QUW5KG@6C@>*OBW%(1OCN=2:?;NS^[5B^,\<;5Q7TM7
MS_\ !2P%SXRGNFZ6MJQ7_>8A?Y%J]G\6Z@-+\(ZM>9PT=J^P_P"V1A?U(K2I
M\21C1TBY,^?-(4^*OBG#)EF6[U)IS@9^0,7QSVVCOT%?3E?/OP6T_P"U>-9+
MIE&VTM7<' .&8A1^A;G_ !KZ"HJ[V"@O=N%%%%9&YY5\<[\PZ!IFGAL&XN6E
M(&>0BXQZ8RX_(5A> ?A=I?B;PO'JNI7-_%)+*XC$#(J[%..ZG)R&YJG\;=0%
MSXNMK-3E;6U&X>CL23^FVO8/!6G_ -F>"M'M=H5EM4=P .&8;FZ>['FMFW&"
ML<Z2G4=SDO\ A1_AG_G^U;_O['_\;J.?X&Z T#"WU+4XY3]UI&C=1]0%&?S%
M>GU7OK^TTVTDN[VXCM[>,9:21L ?Y]*CGEW-/9P['S)-#J/P\\<JID!GL9E;
M<AXEC///LRGD>]?4,;K+&LB'*L P/J#7S!XGU.7QQX[EEL(V87,JP6J%>=HP
MH)QZ\D^F:^GH8UAACB4DJBA1GK@"JJ]+[F=#=VV/ _C9J'VGQC;V:D[;2U4$
M'^^Q+']-M=1I/P7T&\T:QN;J\U-;B:WCDE6.6/:'*@D#*=,YKSK6?^*J^*5Q
M$KEDN]1$"N>/D#! ?^^17TY3DW%)(5.*G)MGFG_"C_#/_/\ :M_W]C_^-UQW
MCCX4+X:T235]/OY+B" KYT4R , 2!D$=>2.,=*]\KS7XO^*+.Q\-RZ&DB27U
MX5#1 Y,<8(;<?3. !GU]J4)R;+J4X*+=BA\$-=GNM/O]&GD9TM"LL&3]U6)W
M*/;(!_$UT7Q0\6/X8\->7:/LU"^)BA8$@HH'SN/<9 'NP/:N6^!>E.EMJNK.
M"%D9;>,YZX^9OYK^M>F:OX<T?7P@U73X+HH"$9QRH/7!'(Z4I64P@I.G9'A'
M@GX:7WC&%]3O+I[2Q9CLE*;WG;/S8R>@.<L>_'/..OU?X&V/V-VT;4[E;E1E
M4N]K*YYXRH&WMSS7J6FZ;::1IT-A80B&UA&V.,,3@9SU))/6L_7?%>B^&[:2
M;4KZ-&3@0J=TC'&0 HYY]^.>2*'4DWH"I04?>/%/A5KE[H/C5=&F+BWNW:":
M$G(24=& ]<C:?8^PKZ%KYU\!V=SXJ^*/]JK#MA2Z>_G8#Y4RQ91U[L0/S/.#
M7T515W"A?E"BBBLS8\1^.NH;]5TG31TB@><\==[;1_Z ?SKT'X9V']G_  ^T
MI"FUYHS.WOO8L#_WR5KQ?XE7+:O\2K^*'G;)';)G Y"@'_Q[-?1]I;1V=G!:
MQ9\N&-8USUP!@?RK6>D$C"GK4DR:BO#?BMXIU.#QNFG:=JUY8Q001I*(+AT&
M]LMD@$#[K+46N>.O$GBVZ;1_"4=\;&%-IEB4F>8 8W.W\(./;.>>N E3=KE.
MLDVCW>BOEO5_"?BSPV!JFHV=S;88?Z2DRN58Y RRL<>G_P"NO8_A1XONO$NB
M3VNHS>;?6+*ID/WI(VSM)]2,$9^F>3DDH65TPA5N^5JQVFL7RZ9HE]?LVT6]
MN\N?HI->$_!FP:\\</>,-PM+=Y-Q/(9OE'Z%J]-^+&HG3_A]>JK[7NG2W4Y'
M<Y8>^55A7D7@WQ>/".AZD;&'S]9OY4BA4KD1JH/S8ZDDM@#N1[<U!/E=B*DE
MSJ_0^DZ*^;;SP?\ $'Q 'OKZPOK@D;S]HE56''9&8$?0#\*M_#WQ9JWAOQ9!
MHU]+,+2XN!!/;SG_ %4A.T-SRI!QGU[]J7L]-&-5M;-6/H>N6\6> M,\93VT
MNHW5]']F5E1+>10O)&3AE// _(5U-> ZCXBUK6?BT^GVNLWUO9OJ*VPCM[F1
M4"*0A( ..0I)]R:F";>A=222LT>XZ1I=OHND6NFVF_R+:,1H7.6..Y/J>M?/
MEHH\4_&564>;%-J;288XS$A+?^@I7O\ K^H?V5X>U&_WA6M[:212<?>"D@<\
M9SBOF7PIXA;PWJ\VIQPF>]\ATML\@2,0-S=R,%N!U./>KIIV;,ZS2:1]5T5\
MWZCX4^(?B0-J>H:??7 )+!9I%4KST6-B"HYZ 5)X'^(.J>%]6CL=2FFFTTOY
M4T,[$M;\X++GD8YRO0\]^:7L]-&/VVNJL?1E8GBGPQ9^+=*33KZ>ZAA642YM
MW"EB 0 <@@CG/U K:5E=0RD%2,@@\$5X?\7?%.JV?BV.PTW4[NTC@MEWBVN'
MCW.Q)YP1VVU$$V]#2I)1CJ>K>%O"UAX1TI]/T]YWB>4S,T[!F+$ =@!T4=J\
MK^.>IF35-+TM7.V&%IW4'@EC@9'J I_[Z]Z[/QD-<L/AK:VNEG4[C5&$$3RV
MWF//D#<S$CYAG:03[X[XKP*_.L7^K"#43?7&I;A#Y=QO>;.>$PWS9R>GO6E.
M-WS,QJRM'E2/IGP-8?V9X'T>U*[&%LKLOHS_ #G]6-=!7C7PO@\8-XKSK;:[
M'8PVSLJWIF$;-D*!AN"<$G'M[5T7Q'^(_P#PBP&F:8(Y=5D3<S,,K IZ$CNW
M< _4\8!AQ;E9&D9I0NST.BOF"#2_&GCIVNDCO]17D>;+)MC'? +$+^ J.>R\
M7>!+B*:1+W326.QU;,;-C!&02I.!TJO9=+D^WZVT/J.BN.^'OC9?&.DN9T6/
M4;;"W"+PK9SAE]CC\#6GXVU)](\%ZM>Q2F*5+=ECD4X*NWRJ1[Y85GRN]C52
M3CS(WJ*^>?#?Q!U31=!U*YN-2N]0U&Z=(+**YF:58\<NY!/^TH'J?7!JA<^#
M?'FKW":I>V%_)-.X7SIG^=<^JYW*HSZ8%:>S[LR]MIHCZ5HJO8VJV.GVUHC,
MRP1+$&8Y)"@#))[\58K(W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH Y+XAZ_J>@Z#"=%C\W4KJX6&)%C\QL8))"]^@'0_>%>86'PV\
M8>+[X7WB&XDM4;DR73;Y,>BH#\OT.*]\JIJEX-.TF]OB 1;0/-@]#M4G^E7&
M;2LC.5-2=V]#YIT[1[.X^)<&D6ADEL5U$1*S8+/&K\D_4 G^G:OJ&OGOX-V+
M7_CMKUR?]$MY)2=O5FPF/;AF/X5]"555ZV(H+W6R&[N4L[*>ZDQLAC:1LG'
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MJ[+"/WR:YY068*.I.!74Q((XD0=% %=V!C[S9ZN50O.4O(?1117I'N!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %,D^Z/K3Z9)]T?6@"Q'
M_JU^E.IL?^K7Z4ZD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** *\G_'POX5?JA)_Q\+^%7Z& 4444@"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JMG_Q]O\ 0_SJU56S
M_P"/M_H?YT= -&BBBI **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH HVG_(2?ZM6K65:?\ (2?ZM6K3EN""BBBI&%%%% !1110
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M5_\ 9J[[X=VZVWP_T6-.AM_,Z=V)8_J:+VI^H6YJOH=/7@'QKTV"S\6V]W"
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% %+6/\ D"7_ /U[2?\ H)KQCX+_ .LUKZ0?^SU[/K'_
M "!+_P#Z]I/_ $$UXQ\%_P#6:U](/_9ZUA\+,9_'$]8HHHH- JIJ?_(.E_#^
M8JW534_^0=+^'\Q6=;^'+T9CB/X,_1_D<[1117AGR@4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!:TZ+S;U!V7YC^%='69H\.V%YB.
M6.!]*TZ]?"0Y:=^Y]'EU+DHW?74****Z3N"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *9)]T?6GTR3[H^M %B/_5K]*=38_P#5K]*=2&%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %
M>3_CX7\*OU0D_P"/A?PJ_0P"BBBD 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 55L_P#C[?Z'^=6JJV?_ !]O]#_.CH!HT445
M(!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %&T
M_P"0D_U:M6LJT_Y"3_5JU:<MP04445(PHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\;^.NH_+I&F*[=
M7N)$SQV53C_ONO9*Y#Q3\.=)\7ZG'?ZA=Z@DD<0B5()$50 2>A0\Y)[U4&D[
MLBHG*-D1?"FP%C\/=//\=P7G?\6('_CH6NTJMI]E%INFVMA 6,-M"D,>XY.U
M0 ,^^!5FDW=W*BK)(\T^,^@'4?#,6JQ+F73GR^!R8W(!_([3],UXI>ZA=:[-
MIL,C%I(+>.RCR>-JDA1^1'ZU]77UG!J-A/97*!X)XVCD4]P1@UPVF?![P]I>
MJ6FH0W>IO+:S),BR2QE2RD$9P@.,CUK2$TE9F%2DY2NCN[2VCL[."UBSY<,:
MQKGK@# _E7S=\4]0&H?$+4=IREOL@7_@*C=_X\6KZ7KSN^^#7A[4-0N;V>^U
M7S;B5I7Q-'C<Q)/5/4TJ<DG=EU8.2LBA8_&;PM8:?;6<=CJWEV\2Q+B"(<*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %+6/^0)?
M_P#7M)_Z":\8^"_^LUKZ0?\ L]>SZQ_R!+__ *]I/_037C'P7_UFM?2#_P!G
MK6'PLQG\<3UBBBB@T"JFI_\ (.E_#^8JW534_P#D'2_A_,5G6_AR]&8XC^#/
MT?Y'.T445X9\H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4^&)IIEC7JQQ3*VM)M-B>>X^9ON^PK6C3=2:1T8:@ZU11Z=31C18HU11@*,"
MG445[:5M#ZE))604444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4R3[H^M/IDGW1]: +$?\ JU^E.IL?^K7Z4ZD,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *\G_'POX5?JA)_Q
M\+^%7Z& 4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "JMG_Q]O]#_ #JU56S_ ./M_H?YT= -&BBBI **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH HVG_(2?ZM6K65:?\A)
M_JU:M.6X(****D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 4M8_Y E__P!>TG_H)KQCX+_ZS6OI!_[/7L^L?\@2_P#^O:3_ -!->,?!
M?_6:U](/_9ZUA\+,9_'$]8HHHH- JIJ?_(.E_#^8JW534_\ D'2_A_,5G6_A
MR]&8XC^#/T?Y'.T445X9\H%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !114UK;/=2A$Z=SZ"FDY.R*C%R:C'<ET^S-U-EA^[4_-[^U=" %  & *9
M!"EO$(T' _6I*]FA15*-NI]+A,,J$+=7N%%%%;'4%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %,D^Z/K3Z9)]T?6@"Q'_ *M?I3J;
M'_JU^E.I#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@"O)_Q\+^%7ZH2?\?"_A5^A@%%%%( HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ JK9_\?;_0_P ZM55L_P#C[?Z'
M^='0#1HHHJ0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** *-I_R$G^K5JUE6G_(2?ZM6K3EN""BBBI&%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% %+6/^0)?_\ 7M)_Z":\8^"_^LUKZ0?^
MSU[/K'_($O\ _KVD_P#037C'P7_UFM?2#_V>M8?"S&?QQ/6****#0*J:G_R#
MI?P_F*MU4U/_ )!TOX?S%9UOX<O1F.(_@S]'^1SM%%%>&?*!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !116A9Z8\Q#RY2/T[FKA3E-VB:TJ4ZLN6"*UK
M:274FU!A1U;L*Z&WMX[:((@^I[FG1Q)"@2-0JCTI]>K0PZI*_4^@PF#C05WK
M(****Z#L"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ IDGW1]:?3)/NCZT 6(_P#5K]*=38_]6OTIU(84444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5Y/^/A?PJ_5"3_CX
M7\*OT, HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %5;/_C[?Z'^=6JJV?_'V_P!#_.CH!HT445(!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% %&T_Y"3_5JU:RK3_D)/\
M5JU:<MP04445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "JMG_P ?;_0_SJU56S_X^W^A_G1T
M T:***D HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM1RL+FC16=_:O_3'_P >_P#K4?VK_P!,?_'O_K4<K"YHT5G?VK_TQ_\ 'O\
MZU']J_\ 3'_Q[_ZU'*PN:-%9W]J_],?_ ![_ .M1_:O_ $Q_\>_^M1RL+FC1
M6=_:O_3'_P >_P#K4?VK_P!,?_'O_K4<K"YHT5G?VK_TQ_\ 'O\ ZU']J_\
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M\>_^M1RL+FC16=_:O_3'_P >_P#K4?VK_P!,?_'O_K4<K"YHT5G?VK_TQ_\
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MM1RL+FC16=_:O_3'_P >_P#K4?VK_P!,?_'O_K4<K"YHT5G?VK_TQ_\ 'O\
MZU']J_\ 3'_Q[_ZU'*PN:-%9W]J_],?_ ![_ .M1_:O_ $Q_\>_^M1RL+FC1
M6=_:O_3'_P >_P#K4?VK_P!,?_'O_K4<K"YHT5G?VK_TQ_\ 'O\ ZU']J_\
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M\>_^M1RL+FC16=_:O_3'_P >_P#K4?VK_P!,?_'O_K4<K"YHT5G?VK_TQ_\
M'O\ ZU']J_\ 3'_Q[_ZU'*PN:-%9W]J_],?_ ![_ .M1_:O_ $Q_\>_^M1RL
M+FC16=_:O_3'_P >_P#K4?VK_P!,?_'O_K4<K"YHT5G?VK_TQ_\ 'O\ ZU']
MJ_\ 3'_Q[_ZU'*PN:-%9W]J_],?_ ![_ .M1_:O_ $Q_\>_^M1RL+FC16=_:
MO_3'_P >_P#K4?VK_P!,?_'O_K4<K"YHT5G?VK_TQ_\ 'O\ ZU']J_\ 3'_Q
M[_ZU'*PN:-%9W]J_],?_ ![_ .M1_:O_ $Q_\>_^M1RL+FC16=_:O_3'_P >
M_P#K4?VK_P!,?_'O_K4<K"YHT5G?VK_TQ_\ 'O\ ZU']J_\ 3'_Q[_ZU'*PN
M:-%9W]J_],?_ ![_ .M1_:O_ $Q_\>_^M1RL+FC16=_:O_3'_P >_P#K4?VK
M_P!,?_'O_K4<K"YHT5G?VK_TQ_\ 'O\ ZU']J_\ 3'_Q[_ZU'*PN:-%9W]J_
M],?_ ![_ .M1_:O_ $Q_\>_^M1RL+FC16=_:O_3'_P >_P#K4?VK_P!,?_'O
M_K4<K"YHT5G?VK_TQ_\ 'O\ ZU']J_\ 3'_Q[_ZU'*PN:-%9W]J_],?_ ![_
M .M1_:O_ $Q_\>_^M1RL+FC16=_:O_3'_P >_P#K4?VK_P!,?_'O_K4<K"YH
MT5G?VK_TQ_\ 'O\ ZU']J_\ 3'_Q[_ZU'*PN:-%9W]J_],?_ ![_ .M1_:O_
M $Q_\>_^M1RL+FC16=_:O_3'_P >_P#K4?VK_P!,?_'O_K4<K"YHT5G?VK_T
MQ_\ 'O\ ZU']J_\ 3'_Q[_ZU'*PN:-%9W]J_],?_ ![_ .M1_:O_ $Q_\>_^
MM1RL+FC16=_:O_3'_P >_P#K4?VK_P!,?_'O_K4<K"YHT5G?VK_TQ_\ 'O\
MZU']J_\ 3'_Q[_ZU'*PN:-%9W]J_],?_ ![_ .M1_:O_ $Q_\>_^M1RL+FC1
M6=_:O_3'_P >_P#K4?VK_P!,?_'O_K4<K"YHT5G?VK_TQ_\ 'O\ ZU']J_\
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MA<M455^V_P#3/]:/MO\ TS_6BS"Y:HJK]M_Z9_K1]M_Z9_K19A<M455^V_\
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MFOY4>5'_ ,\U_*GT4 ,\J/\ YYK^5'E1_P#/-?RI]% #/*C_ .>:_E1Y4?\
MSS7\J?10 SRH_P#GFOY4>5'_ ,\U_*GT4 ,\J/\ YYK^5'E1_P#/-?RI]% #
M/*C_ .>:_E1Y4?\ SS7\J?10 SRH_P#GFOY4>5'_ ,\U_*GT4 ,\J/\ YYK^
M5'E1_P#/-?RI]% #/*C_ .>:_E1Y4?\ SS7\J?10 SRH_P#GFOY4>5'_ ,\U
M_*GT4 ,\J/\ YYK^5'E1_P#/-?RI]% #/*C_ .>:_E1Y4?\ SS7\J?10 SRH
M_P#GFOY4>5'_ ,\U_*GT4 ,\J/\ YYK^5'E1_P#/-?RI]% #/*C_ .>:_E1Y
M4?\ SS7\J?10 SRH_P#GFOY4>5'_ ,\U_*GT4 ,\J/\ YYK^5'E1_P#/-?RI
M]% #/*C_ .>:_E1Y4?\ SS7\J?10 SRH_P#GFOY4>5'_ ,\U_*GT4 ,\J/\
MYYK^5'E1_P#/-?RI]% #/*C_ .>:_E1Y4?\ SS7\J?10 SRH_P#GFOY4>5'_
M ,\U_*GT4 ,\J/\ YYK^5'E1_P#/-?RI]% #/*C_ .>:_E1Y4?\ SS7\J?10
M SRH_P#GFOY4>5'_ ,\U_*GT4 ,\J/\ YYK^5'E1_P#/-?RI]% #/*C_ .>:
M_E1Y4?\ SS7\J?10 SRH_P#GFOY4>5'_ ,\U_*GT4 ,\J/\ YYK^5'E1_P#/
M-?RI]% #/*C_ .>:_E1Y4?\ SS7\J?10 SRH_P#GFOY4>5'_ ,\U_*GT4 ,\
MJ/\ YYK^5'E1_P#/-?RI]% #/*C_ .>:_E1Y4?\ SS7\J?10 SRH_P#GFOY4
M>5'_ ,\U_*GT4 ,\J/\ YYK^5'E1_P#/-?RI]% #/*C_ .>:_E1Y4?\ SS7\
MJ?10 SRH_P#GFOY4>5'_ ,\U_*GT4 ,\J/\ YYK^5'E1_P#/-?RI]% #/*C_
M .>:_E1Y4?\ SS7\J?10 SRH_P#GFOY4>5'_ ,\U_*GT4 ,\J/\ YYK^5'E1
M_P#/-?RI]% #/*C_ .>:_E1Y4?\ SS7\J?10 SRH_P#GFOY4>5'_ ,\U_*GT
M4 ,\J/\ YYK^5'E1_P#/-?RI]% #/*C_ .>:_E1Y4?\ SS7\J?10 SRH_P#G
MFOY4>5'_ ,\U_*GT4 ,\J/\ YYK^5'E1_P#/-?RI]% #/*C_ .>:_E1Y4?\
MSS7\J?10 SRH_P#GFOY4>5'_ ,\U_*GT4 ,\J/\ YYK^5'E1_P#/-?RI]% #
M/*C_ .>:_E1Y4?\ SS7\J?10 SRH_P#GFOY4>5'_ ,\U_*GT4 ,\J/\ YYK^
M5'E1_P#/-?RI]% #/*C_ .>:_E1Y4?\ SS7\J?10 SRH_P#GFOY4>5'_ ,\U
M_*GT4 ,\J/\ YYK^5'E1_P#/-?RI]% #/*C_ .>:_E1Y4?\ SS7\J?10 SRH
M_P#GFOY4>5'_ ,\U_*GT4 ,\J/\ YYK^5'E1_P#/-?RI]% #/*C_ .>:_E1Y
M4?\ SS7\J?10 SRH_P#GFOY4>5'_ ,\U_*GT4 ,\J/\ YYK^5'E1_P#/-?RI
M]% #/*C_ .>:_E1Y4?\ SS7\J?10 SRH_P#GFOY4>5'_ ,\U_*GT4 ,\J/\
MYYK^5'E1_P#/-?RI]% #/*C_ .>:_E1Y4?\ SS7\J?10 SRH_P#GFOY4>5'_
M ,\U_*GT4 ,\J/\ YYK^5'E1_P#/-?RI]% #/*C_ .>:_E1Y4?\ SS7\J?10
M SRH_P#GFOY4>5'_ ,\U_*GT4 ,\J/\ YYK^5'E1_P#/-?RI]% #/*C_ .>:
M_E1Y4?\ SS7\J?10 SRH_P#GFOY4>5'_ ,\U_*GT4 ,\J/\ YYK^5'E1_P#/
M-?RI]% #/*C_ .>:_E1Y4?\ SS7\J?10 SRH_P#GFOY4>5'_ ,\U_*GT4 ,\
MJ/\ YYK^5'E1_P#/-?RI]% #/*C_ .>:_E1Y4?\ SS7\J?10 SRH_P#GFOY4
M>5'_ ,\U_*GT4 ,\J/\ YYK^5'E1_P#/-?RI]% #/*C_ .>:_E1Y4?\ SS7\
MJ?10 SRH_P#GFOY4>5'_ ,\U_*GT4 ,\J/\ YYK^5'E1_P#/-?RI]% #/*C_
M .>:_E1Y4?\ SS7\J?10 SRH_P#GFOY4>5'_ ,\U_*GT4 ,\J/\ YYK^5'E1
M_P#/-?RI]% #/*C_ .>:_E1Y4?\ SS7\J?10 SRH_P#GFOY4>5'_ ,\U_*GT
M4 4=615T:^95 86\A! Y!VFO'_@_=W-V^L?:;B:;:(=OF.6Q]_IFO8=8_P"0
M)?\ _7M)_P"@FO&/@O\ ZS6OI!_[/6L/A9C/XXGK&!Z48'I110:!@>E&!Z44
M4 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&
M!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !
M@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E
M%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I
M1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110
M 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'
MI110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!
MZ48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E,D'%/
MIDGW1]: )XU!C7@=*=M7^Z/RI(_]6OTIU(8FU?[H_*C:O]T?E2T4 )M7^Z/R
MHVK_ '1^5+10 FU?[H_*C:O]T?E2T4 )M7^Z/RHVK_='Y4M% ";5_NC\J-J_
MW1^5+10 FU?[H_*C:O\ ='Y4M% ";5_NC\J-J_W1^5+10 FU?[H_*C:O]T?E
M2T4 )M7^Z/RHVK_='Y4M% ";5_NC\J-J_P!T?E2T4 )M7^Z/RHVK_='Y4M%
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MIU% #=B_W1^5&Q?[H_*G44 -V+_='Y4;%_NC\J=10 W8O]T?E1L7^Z/RIU%
M#=B_W1^5&Q?[H_*G44 -V+_='Y4;%_NC\J=10 W8O]T?E1L7^Z/RIU% #=B_
MW1^5&Q?[H_*G44 -V+_='Y4;%_NC\J=10 W8O]T?E1L7^Z/RIU% #=B_W1^5
M&Q?[H_*G44 -V+_='Y4;%_NC\J=10 W8O]T?E1L7^Z/RIU% #=B_W1^5&Q?[
MH_*G44 -V+_='Y4;%_NC\J=10 W8O]T?E1L7^Z/RIU% #=B_W1^5&Q?[H_*G
M44 -V+_='Y4;%_NC\J=10 W8O]T?E1L7^Z/RIU% #=B_W1^5&Q?[H_*G44 -
MV+_='Y4;%_NC\J=10 W8O]T?E1L7^Z/RIU% #=B_W1^5&Q?[H_*G44 -V+_=
M'Y4;%_NC\J=10 W8O]T?E5:T4&Z8$ C!X/UJW56S_P"/M_H?YT= +_EI_<7\
MJ/+3^XOY4ZBI ;Y:?W%_*CRT_N+^5.HH ;Y:?W%_*CRT_N+^5.HH ;Y:?W%_
M*CRT_N+^5.HH ;Y:?W%_*CRT_N+^5.HH ;Y:?W%_*CRT_N+^5.HH ;Y:?W%_
M*CRT_N+^5.HH ;Y:?W%_*CRT_N+^5.HH ;Y:?W%_*CRT_N+^5.HH ;Y:?W%_
M*CRT_N+^5.HH ;Y:?W%_*CRT_N+^5.HH ;Y:?W%_*CRT_N+^5.HH ;Y:?W%_
M*CRT_N+^5.HH ;Y:?W%_*CRT_N+^5.HH ;Y:?W%_*CRT_N+^5.HH ;Y:?W%_
M*CRT_N+^5.HH ;Y:?W%_*CRT_N+^5.HH ;Y:?W%_*CRT_N+^5.HH ;Y:?W%_
M*CRT_N+^5.HH ;Y:?W%_*CRT_N+^5.HH ;Y:?W%_*CRT_N+^5.HH ;Y:?W%_
M*CRT_N+^5.HH ;Y:?W%_*CRT_N+^5.HH ;Y:?W%_*CRT_N+^5.HH ;Y:?W%_
M*CRT_N+^5.HH ;Y:?W%_*CRT_N+^5.HH ;Y:?W%_*CRT_N+^5.HH ;Y:?W%_
M*CRT_N+^5.HH ;Y:?W%_*CRT_N+^5.HH ;Y:?W%_*CRT_N+^5.HH ;Y:?W%_
M*CRT_N+^5.HH ;Y:?W%_*CRT_N+^5.HH ;Y:?W%_*CRT_N+^5.HH ;Y:?W%_
M*CRT_N+^5.HH HV8QJ+CW:M6LJT_Y"3_ %:M6G+<$%%%%2,**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=%5/[3L_^>W_ (Z?\*/[3L_^>W_CI_PH]M3_ )E]X?6*/\Z^]%NBJG]IV?\
MSV_\=/\ A1_:=G_SV_\ '3_A1[:G_,OO#ZQ1_G7WHMT54_M.S_Y[?^.G_"C^
MT[/_ )[?^.G_  H]M3_F7WA]8H_SK[T6Z*J?VG9_\]O_ !T_X4?VG9_\]O\
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M[T6Z*JC4;0_\MA^(-2+=V[_=F0_C352#V:*5:F]I+[R:BD# ]"#2U9H%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4R3[H^M/IDGW1]: +$?^K7Z4ZFQ_ZM?I3J0PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH KR?\ 'POX
M5?JA)_Q\+^%7Z& 4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "JMG_P ?;_0_SJU56S_X^W^A_G1T T:***D HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"C:?\A)_JU:M9
M5I_R$G^K5JTY;@@HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!2UC_D"7_\ U[2?^@FO&/@O_K-:^D'_ +/7L^L?\@2__P"O:3_T
M$UXQ\%_]9K7T@_\ 9ZUA\+,9_'$]8HHHH- JIJ?_ "#I?P_F*MU4U/\ Y!TO
MX?S%9UOX<O1F.(_@S]'^1SM%%%>&?*!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 Y79#
ME6(^AJS%J5U%_P M-P]&&:J45<9RC\+-(59P^%V-J'68VXE0H?4<BM"*:.9=
MT;AA[&N5IT<CQ-NC8J?4&NJGC)KXM3OHYG4CI45T=7161:ZN<A;@<?WQ6JCK
M(H9&#*>XKOIU85%[K/7HXBG65X,=1116AN%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4R3[H^M/IDGW1]: +$?^K7Z
M4ZFQ_P"K7Z4ZD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** *\G_'POX5?JA)_P ?"_A5^A@%%%%( HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JK9_P#'V_T/\ZM55L_^
M/M_H?YT= -&BBBI **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH HVG_ "$G^K5JUE6G_(2?ZM6K3EN""BBBI&%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% %+6/^0)?_ /7M)_Z":\8^"_\
MK-:^D'_L]>SZQ_R!+_\ Z]I/_037C'P7_P!9K7T@_P#9ZUA\+,9_'$]8HHHH
M- JIJ?\ R#I?P_F*MU4U/_D'2_A_,5G6_AR]&8XC^#/T?Y'.T445X9\H%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %3VUW+:ON0\=U/0U!151DXNZ*C.4
M'S1=F=+:WD=TF5X8=5/:K%<I'(\3AT8JP[BN@L;Y;I,'B0=1ZUZ>'Q*G[LMS
MWL'CE5]R?Q?F6Z***ZST0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *9)]T?6GTR3[H^M %B/_5K]*=38_\ 5K]*=2&%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>3_
M (^%_"K]4)/^/A?PJ_0P"BBBD 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 55L_\ C[?Z'^=6JJV?_'V_T/\ .CH!HT445(!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %&T_Y"
M3_5JU:RK3_D)/]6K5IRW!!1114C"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K#\5>*K'PAI<6H:A%<2
MQ23"$"W56;<59NY'&%-;E>:?'#_D2K/_ +"*?^BY*J*N[$S;46T*GQO\,LZJ
M;/55!."QACP/?A\UZ1')'-$DL3J\;J&5U.0P/0@]Q7QQ7NGP;\7?;M.?P]>2
M#[1:C=;$G[\7=?JI_0^U:3II*Z,:59R=I'JM<]XL\9:=X.MK:?4(;J5;ARB"
MW56((&><L*Z&O)OCK_R!](_Z^'_]!%9P5W9FM23C%M&WH_Q<T#6]7M=,MK34
MDFN7$:-)'&%!]\.3^E=]7RW\/O\ D?\ 1?\ KY7^M?4E54BHO0FC-R5V>>ZC
M\8O#VF:I=Z?/9ZHTMK,\+E(HRI96*G&7'&15;_A>'AG_ )\=6_[]1_\ QRO&
MO%W_ ".NO?\ 81N/_1C5C5JJ4;&#KSN?7VE:C!J^E6FHVP<0W,2RH'&& (S@
M^]6Z\^^#FJ?;_!"VK2%I+*9HL-U"GYE_#DC\*]!KGDK.QU1?-%,Y+Q7\0]'\
M'W\-EJ$-Y+-+%YH%NBL N2.<L.X/Y5@_\+P\,_\ /CJW_?J/_P".5Y9\2M1_
MM/Q_JL@&%AE^S@9S]P;3^H)KE*WC25M3FE6DF['U1X3\9:=XQMKF?3X;J);=
MPCBX55))&>,,:TM9U:#0]'NM3NDD>"V3>ZQ %B/;) _6O-?@5_R!]7_Z^$_]
M!-=E\1/^2?ZU_P!>_P#45DXI2L;QDW#F.;_X7AX9_P"?'5O^_4?_ ,<H_P"%
MX>&?^?'5O^_4?_QRO :ZJP^&_BS4[""^L])\RVG0/&_VB(;E/0X+9%:NG!;G
M.JU1['JG_"\/#/\ SXZM_P!^H_\ XY5JV^,OA.=U$C7MN#C+2P9 ^NTFO*?^
M%4^-?^@+_P"34/\ \76#K7AS6/#TRQ:MI\UJ7SL9@"K8ZX89!_ T<D'L-U:B
MU:/J?2M8T[6[,7>F7D5S">-T9Z'T(ZC\:O5\J>$O%-YX3UR*^MG8PE@MS"#Q
M+'GD?7K@]C^-?4]O/%=6T5Q"X>*5 Z,.ZD9!_*LIPY6;TZG.B2BBJ>K:C%I&
MD7FHSX\NVA:4@G&<#.,^IZ?C4&AR6O\ Q6\/^'M9GTNXAOIYX,"1K=$9 2,X
MR7'(SS2^'_BIH'B/6H-*M8+^&>?=L:XC0*2 3C(8\X!KYWU&^FU/4KJ_N#F:
MYE:5S[L<G^=&G7]QI>HVU_:OLN+>19(S[@YY]1[5T>R5CC]O*_D?8%%5-,U"
M#5M+M=0MF#0W,2R+@YP",X^HZ5;KG.P**** "BBB@ K"\0>,="\,(/[3OD25
MONP(-\A_X".@]S@5@_$KQY_PB5@EI8E3JURNZ/(!$29Y<COG! ^A],'YVN;J
M>]N9+FZF>:>1MSR2-EF/J36L*?-JS"I6Y=%N>T7?QVLD<BST*XF7/6:=8SCZ
M -4</QXA9OW_ (>D1?5+L,?U05Q6C_"SQ5K$*SBR2SA;!5KM]A(]=H!;\Q5K
M4O@_XKT^!I8XK6]"J6*VLI+<>@8*2?89J^6GL9\]7<]9\/?$_P -^(9EMTG>
MSN6P%BNP%W'T# D'IZBNRKXXDC>&1XY$9)$)5E88*D=01ZU[=\(?&\VHHWA[
M4YWEN(EWVDKG)9!U0GKD=1[9]!4SIV5T73K7=I'K-%%<KX]\7Q^$- -P@#WT
MY,=JA&1NQRQ]A_4>M9)7=D;MI*[-+7O%.C>&K?S=5OHX21E(A\TC_11R?KT]
M37G]]\=-.BD(L-&N;A1T::58L_@ U>,:CJ-YJU])>W]S)<7,GWI'.2?3\*ZC
M0_A?XGUVVCN8[:.UMY.4DNW*9&,@@ $X/'.*W5.*7O'*ZTY.T3N+?X[VS/BY
MT"6-?6.Z#G\BHKN_#?CK0?%1\O3[HK<XW&VF79)COQT/X$UXEK'PF\4Z1:R7
M/D07D<8RWV20LP'KM(!/X"N*BED@E66&1XY$.5=&((/J"*/9QDM ]K.+]X^Q
MJ*X;X8^,W\5:&\-XV=2LL+,V,>8ISM?Z\$'W&>XKN:P:L[,ZHR4E=!6/XE\2
MV'A31VU+4?,,0=8U2( N['L 2!T!/7H#6Q7A?QMU_P"U:U:Z'$1Y=FGFRX/6
M1QP"/9<'_@5.$>9V)J2Y8W.I_P"%X>&?^?'5O^_4?_QRN]T?5;;7-(M=3LRQ
MM[F,.H<88>H/N#D'Z5\B5[A\$-?-QIM[H4TH+6Q\^W4]=C'Y@/8-@_5ZTG32
M5T8TJKE*S/6:***Q.D*X77?BSX9T69K>.674)U!R+0!D!]"Q('Y9K%^,?BZX
MTNS@T&QE>*:[0R7#KP?*R1M!Z\D'/L,=S7BFG:=>:M?1V5A;27%S)]V-!DGU
M_"MH4TU=G/4JM/EB>NO\>4#?N_#C,/5KW'_LAK0TWXX:-<2*FH:==68(Y=&$
MJJ??H<?A7&P_!7Q3+;^8\FG0O_SR>=BW_CJD?K7,>(_!VM^%70:I:[(I"1'-
M&P='/ID=#['!JN6F]$0YU5JSZ=TK6-.URR6[TR\BN8&_B0\CV(Z@^QYJ]7RK
MX/\ %-UX3UZ&^A=S;LP6YA4\2QYY&#QD=C_]>OJ>*5)X4EC8-&ZAE8=P>0:R
MG#E9O3J<Z.<\7>.-,\&?8_[1@NY?M>_9]G16QMVYSN8?WA7-?\+P\,_\^.K?
M]^H__CE8WQY_YE__ +>?_:5>16-E<:E?065I'YEQ.XCC3<!N8\ 9/ K2%.+C
M=F52K*,K(]V_X7AX9_Y\=6_[]1__ !RC_A>'AG_GQU;_ +]1_P#QRO,_^%4^
M-?\ H"_^34/_ ,71_P *I\:_] 7_ ,FH?_BZ?)3[D^TJ]OP/3/\ A>'AG_GQ
MU;_OU'_\<KL?"_B>R\6:2VHV$5Q'")3%MG50V0 >Q(QSZUX%_P *I\:_] 7_
M ,FH?_BZ]C^%^@ZEX=\*/9:K;?9[@W3R!-ZO\I"@'*DCL:B<8I:&E.4V_>1V
ME%%%9&X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>_X1OQ;8:DPS"K[)A_TS8;6/X Y^H%?1FO\ AZ'4O!5WH-NF$^RB*W48&&0
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MV?\ Q]O]#_.K55;/_C[?Z'^='0#1HHHJ0"BBB@ HHHH **** "BBB@ HHHH
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M,TWS-7U34V52((5A4D\Y<Y.!]$_6N'\=H8_'>M@XR;MSQ[G/]:]H^#FF_8O
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5'6?\
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M"G)QP>0.HKL:B;O(UI*T4@HHHJ#0**** "BBB@ HHHH **** "BBB@ HHHH
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M 4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "JMG_Q]O\ 0_SJU56S_P"/M_H?YT= -&BBBI **** "BBB@ HHHH ****
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MZU]25RVG_#GPII6H07UEI7E7,#;XW^T2MM/T+$5U-*I)2>@4H."LSY/\7?\
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MSLF0, <8R,]#R>1S6D*CCH8U*2GKU/ES1_&/B'08Q'IFJSP1 Y$9PZ9QC[K
MBK=]\1/%NHPM%<:Y<!&&"(0L61]4 KV.]^#OA*ZD+Q17=IG^&"?@>_S!JK0_
M!/PO')N>XU.4?W7F0#]$!K3VD-S+V51:7/G\DLQ9B23R2>]=SX1^%^L^(YDG
MNXWL-.X+2RKAW&>0BGOUY/'UKVW1_ OAG0I5FL-)@6=3E9I,R.I]06)P?IBN
MBJ95>Q4</_,%97B+P_9>)]&FTR_5O*?YE=3AHV'1A[BM6BL=CI:OHSY9\4^"
M=8\)W3)>0&2U)/EW48RC#.!G^Z>G!_6L:QU*_P!,D,EA>W-I(>"T$K1D_B#7
MUY+%'/&T<L:R1MPRN,@_A7,WGPX\(7S;I="ME.<_N2T0_)"*W57N<TL.[^ZS
MYJO=4U#4G#W]]<W3#HT\S.?U-7_#?A75O%5^+;3;=F52/-G;B.('NQ_IU..!
M7T):_#7P?:2!X]#@8@Y_>N\@_)F(KIX+>&U@6&WACAB3A4C4*H^@%#JKHA+#
MN_O,RO"_ANS\*Z%#IEF2P4EY)6&#*YZL?R ]@ *\N^..NK+<V&A1-GRLW,X_
MVB,(/RW?F*]JKF-4^'OA?6M2FU#4-,,]U,09)#<2C.  . P X %9QDE*[-IP
M;CRQ/GGP=H7_  D?BNPTQ@WDR2;IBO:-1EN>W QGU(KZL5510J@!0,  < 5@
M:)X'\.>';YKW2M-%O<-&8RYFD?Y202,,Q Z#FN@HJ3YGH*E3Y%J%07MI%J%A
M<V4X)AN(FBD Z[6!!_0U/14&I\A:MILVCZO=Z;<%3+;2M$Q7HV#C(]CUKV+X
M(:_Y^GWN@S2DO;G[1;J<GY&.' [ !L'ZN:[;5O 'AC7-2EU#4=+$UW+@/)Y\
MB;L  <*P'0"ET?P%X:T#44O],TTP7* J'^T2MP1@\,Q%;2J*4;'/"E*,KHY3
MXL>!)]=ABUG28#+J$($<T*#F6/L1ZL/U!]@*\'(>&4@ADD0X(/!4C^1K['KG
MM<\#^'/$,AEU#3(VG/)FC)C<_4KC/XYI0J65F.I1YG='@-G\2/%]A (8-;F*
M   2QI(0 ,#EE)K,UGQ1KGB C^U-2GN5!R$)P@/LHP/TKVJ7X)>&)'W+<ZI&
M/[J3)C]4)JS9_!SPG:RJ\D=Y=!?X9Y^#]=H%7[2"U,_95'HV>%^'?#FH^*-5
MCL-.A+,>9)#]R)?[S'L/Y]J^H]#TBWT'1+/2[7_56T80'&-QZLQ]R23^-3:?
MIECI-H+73[2&U@'.R% H)QC)QU/ Y/-6JRG/F-J=/D/&_CS_ ,R__P!O/_M*
MO'H)YK6=)[>5XIHV#))&Q5E(Z$$<@U]6:]X4T3Q/]G_MBR^T_9]WE?O73;NQ
MG[I&?NCKZ5C?\*I\%?\ 0%_\FIO_ (NKA42C9F=2C*4KH\!_X2[Q-_T,6K?^
M!LG_ ,51_P )=XF_Z&+5O_ V3_XJO?O^%4^"O^@+_P"34W_Q='_"J?!7_0%_
M\FIO_BZKVD>Q/L9]SP'_ (2[Q-_T,6K?^!LG_P 57KOP7U;4M5M-8;4=0N[P
MQO$$-Q,TFW(;.-Q.*Z'_ (53X*_Z O\ Y-3?_%UM:#X7T;PRDZ:/9_9EG(,@
M\UWW$9Q]XG'4U,IQ:LD7"E.,KMFQ1116)T!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "F2?='UI],D^Z/K0!8C_P!6
MOTIU-C_U:_2G4AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!7D_X^%_"K]4)/^/A?PJ_0P"BBBD 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 55L_^/M_H?YU:JK9_P#'
MV_T/\Z.@&C1114@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 4;3_D)/\ 5JU:RK3_ )"3_5JU:<MP04445(PHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH:E<""UC(#.5+<D@#@ D\GL*O5X-\6/$4WB#Q+%X=T]_,M[1\.J\AI^02?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>3_ (^%
M_"K]4)/^/A?PJ_0P"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 55L_\ C[?Z'^=6JJV?_'V_T/\ .CH!HT445(!1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!R7Q#D\0?V##:^&DN&O[FX5
M"T P4CP226/"\[1DD=?K7 :'\%]1O;C[7XEU 1ACN>*%_,E8_P"TYX'X9KVR
MJ&N:@-*T'4+\NJ&WMWD4MTR%) _/%7&;2LC.5--WD?.FC:?9ZE\5;:SL(,6
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O)_Q\+^%7ZH2?\
M'POX5?H8!1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *JV?\ Q]O]#_.K55;/_C[?Z'^='0#1HHHJ0"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *-I_P A)_JU:M95I_R$
MG^K5JTY;@@HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5P?Q@E:/X>W*C.))XE.#VW9_I7>5Q_Q
M0TYM2^'^HI&CO+"%G0(,GY6&>/\ =W54?B1$_A9Q?P'@7;KEP?O9A0>P^<G^
MGY5[)7@_P2UN*RU^]TJ=U07T:M%NSS(F?E'U5F/_  &O>*JK\1-%^XCP_P"(
M'Q&\1Z3XTOM/TG4?L]K;A$"^1&^6V@DY92>IQ^%<Q_PM;QK_ -!K_P E8?\
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MB@ HHHH **** "BBB@ HHHH ***L6=N;FY5,?+U;Z548N3LBH0<Y**W9KZ7
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M?YT= -&BBBI **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH I:Q_P @2_\ ^O:3_P!!
M->,?!?\ UFM?2#_V>O9]8_Y E_\ ]>TG_H)KQCX+_P"LUKZ0?^SUK#X68S^.
M)ZQ1110:!534_P#D'2_A_,5;JIJ?_(.E_#^8K.M_#EZ,QQ'\&?H_R.=HHHKP
MSY0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ ZUT.G6OV:W
MRP_>/RWM[52TJRW$7$@X'W!Z^];->EA*-OWDCV\NPO*O:R^04445W'K!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)/NCZT^F2?=
M'UH L1_ZM?I3J;'_ *M?I3J0PHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH KR?\?"_A5^J$G_ !\+^%7Z& 4444@"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JMG_ ,?;
M_0_SJU56S_X^W^A_G1T T:***D HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@"C:?\ (2?ZM6K65:?\A)_JU:M.6X(****D8444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4M8_Y E_\ ]>TG
M_H)KQCX+_P"LUKZ0?^SU[/K'_($O_P#KVD_]!->,?!?_ %FM?2#_ -GK6'PL
MQG\<3UBBBB@T"JFI_P#(.E_#^8JW534_^0=+^'\Q6=;^'+T9CB/X,_1_D<[1
M117AGR@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %7M/L#<OOD!$
M0_6GV.FM,1),"(^P[FMM5"J%4  = *[L/AG+WI['JX+ N;52IMV[@ %  & *
M6BBO2/<"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ IDGW1]:?3)/NCZT 6(_]6OTIU-C_P!6OTIU(84444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 5Y/\ CX7\*OU0D_X^
M%_"K]# ****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !56S_P"/M_H?YU:JK9_\?;_0_P Z.@&C1114@%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 4;3_D)/]6K5K*M/^0D_
MU:M6G+<$%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** *6L?\@2__ .O:3_T$UXQ\%_\ 6:U](/\ V>O9]8_Y E__ ->TG_H)KQCX
M+_ZS6OI!_P"SUK#X68S^.)ZQ1110:!534_\ D'2_A_,5;JIJ?_(.E_#^8K.M
M_#EZ,QQ'\&?H_P CG:***\,^4"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **DB
M@EF.(T+?2M*WT<G#7#8']U?\:UIT9S^%&]+#5:K]Q&9%%),^V-2Q]JV;/2UA
M(>;#/V'85=BAC@7;&@45)7H4<)&&LM6>SALOA3]Z>K_ ****ZST0HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F2?='
MUI],D^Z/K0!8C_U:_2G4V/\ U:_2G4AA1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!7D_X^%_"K]4)/\ CX7\*OT, HHH
MI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5
M;/\ X^W^A_G5JJMG_P ?;_0_SHZ :-%%%2 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!1M/\ D)/]6K5K*M/^0D_U:M6G+<$%
M%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *6L?\
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MS+S_ )X_^/#_ !KHJ*/J5/NP_LNCW?X?Y'._V9>?\\?_ !X?XT?V9>?\\?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %,D^Z/K3Z9)]T?6@"Q'_ *M?I3J;'_JU^E.I#"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O)_Q\
M+^%7ZH2?\?"_A5^A@%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ JK9_\?;_0_P ZM55L_P#C[?Z'^='0#1HHHJ0"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *-I_R$G^K
M5JUE6G_(2?ZM6K3EN""BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 45E>);V^T_P -W]WID/G7L41:*,(7R?\
M=')KR'_A8/Q)_P"@-)_X+9*J,&R)5%'1GN=%>&?\+!^)/_0&D_\ !;)1_P +
M!^)/_0&D_P#!;)5>S9/MHGN=%>&?\+!^)/\ T!I/_!;)1_PL'XD_] :3_P %
MLE'LV'MHGN=%>&?\+!^)/_0&D_\ !;)1_P +!^)/_0&D_P#!;)1[-A[:)[G1
M7AG_  L'XD_] :3_ ,%LE'_"P?B3_P! :3_P6R4>S8>VB>YT5X9_PL'XD_\
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M\+!^)/\ T!I/_!;)1_PL'XD_] :3_P %LE'LV'MHGN=%>&?\+!^)/_0&D_\
M!;)1_P +!^)/_0&D_P#!;)1[-A[:)[G17AG_  L'XD_] :3_ ,%LE'_"P?B3
M_P! :3_P6R4>S8>VB>YT5X9_PL'XD_\ 0&D_\%LE'_"P?B3_ - :3_P6R4>S
M8>VB>YT5X9_PL'XD_P#0&D_\%LE'_"P?B3_T!I/_  6R4>S8>VB>YT5X9_PL
M'XD_] :3_P %LE'_  L'XD_] :3_ ,%LE'LV'MHGN=%>&?\ "P?B3_T!I/\
MP6R4?\+!^)/_ $!I/_!;)1[-A[:)[G17AG_"P?B3_P! :3_P6R4?\+!^)/\
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M - :3_P6R4?\+!^)/_0&D_\ !;)1[-A[:)[G17AG_"P?B3_T!I/_  6R4?\
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M4?\ "P?B3_T!I/\ P6R4>S8>VB>YT5X9_P +!^)/_0&D_P#!;)1_PL'XD_\
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M\+!^)/\ T!I/_!;)1[-A[:)[G17AG_"P?B3_ - :3_P6R4?\+!^)/_0&D_\
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M>VB>YT5X9_PL'XD_] :3_P %LE'_  L'XD_] :3_ ,%LE'LV'MHGN=%>&?\
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M4<H>U1[!17C_ /PF?Q#_ .@+-_X+I*/^$S^(?_0%F_\ !=)1RA[5'L%%>/\
M_"9_$/\ Z LW_@NDH_X3/XA_] 6;_P %TE'*'M4>P45X_P#\)G\0_P#H"S?^
M"Z2C_A,_B'_T!9O_  724<H>U1[!17C_ /PF?Q#_ .@+-_X+I*/^$S^(?_0%
MF_\ !=)1RA[5'L%%>/\ _"9_$/\ Z LW_@NDH_X3/XA_] 6;_P %TE'*'M4>
MP45X_P#\)G\0_P#H"S?^"Z2C_A,_B'_T!9O_  724<H>U1[!17C_ /PF?Q#_
M .@+-_X+I*/^$S^(?_0%F_\ !=)1RA[5'L%%>/\ _"9_$/\ Z LW_@NDH_X3
M/XA_] 6;_P %TE'*'M4>P45X_P#\)G\0_P#H"S?^"Z2C_A,_B'_T!9O_  72
M4<H>U1[!17C_ /PF?Q#_ .@+-_X+I*/^$S^(?_0%F_\ !=)1RA[5'L%%>/\
M_"9_$/\ Z LW_@NDH_X3/XA_] 6;_P %TE'*'M4>P45X_P#\)G\0_P#H"S?^
M"Z2C_A,_B'_T!9O_  724<H>U1[!17C_ /PF?Q#_ .@+-_X+I*/^$S^(?_0%
MF_\ !=)1RA[5'L%%>/\ _"9_$/\ Z LW_@NDH_X3/XA_] 6;_P %TE'*'M4>
MP45X_P#\)G\0_P#H"S?^"Z2C_A,_B'_T!9O_  724<H>U1[!17C_ /PF?Q#_
M .@+-_X+I*/^$S^(?_0%F_\ !=)1RA[5'L%%>/\ _"9_$/\ Z LW_@NDH_X3
M/XA_] 6;_P %TE'*'M4>P45X_P#\)G\0_P#H"S?^"Z2C_A,_B'_T!9O_  72
M4<H>U1[!17C_ /PF?Q#_ .@+-_X+I*/^$S^(?_0%F_\ !=)1RA[5'L%%>/\
M_"9_$/\ Z LW_@NDH_X3/XA_] 6;_P %TE'*'M4>P45X_P#\)G\0_P#H"S?^
M"Z2C_A,_B'_T!9O_  724<H>U1[!17C_ /PF?Q#_ .@+-_X+I*/^$S^(?_0%
MF_\ !=)1RA[5'L%%>/\ _"9_$/\ Z LW_@NDH_X3/XA_] 6;_P %TE'*'M4>
MP45X_P#\)G\0_P#H"S?^"Z2C_A,_B'_T!9O_  724<H>U1[!17C_ /PF?Q#_
M .@+-_X+I*/^$S^(?_0%F_\ !=)1RA[5'L%%>/\ _"9_$/\ Z LW_@NDH_X3
M/XA_] 6;_P %TE'*'M4>P45X_P#\)G\0_P#H"S?^"Z2C_A,_B'_T!9O_  72
M4<H>U1[!17C_ /PF?Q#_ .@+-_X+I*/^$S^(?_0%F_\ !=)1RA[5'L%%>/\
M_"9_$/\ Z LW_@NDH_X3/XA_] 6;_P %TE'*'M4>P45X_P#\)G\0_P#H"S?^
M"Z2C_A,_B'_T!9O_  724<H>U1[!17C_ /PF?Q#_ .@+-_X+I*/^$S^(?_0%
MF_\ !=)1RA[5'L%%>/\ _"9_$/\ Z LW_@NDH_X3/XA_] 6;_P %TE'*'M4>
MP45X_P#\)G\0_P#H"S?^"Z2C_A,_B'_T!9O_  724<H>U1[!17C_ /PF?Q#_
M .@+-_X+I*/^$S^(?_0%F_\ !=)1RA[5'L%%>/\ _"9_$/\ Z LW_@NDH_X3
M/XA_] 6;_P %TE'*'M4>P45X_P#\)G\0_P#H"S?^"Z2C_A,_B'_T!9O_  72
M4<H>U1[!17C_ /PF?Q#_ .@+-_X+I*/^$S^(?_0%F_\ !=)1RA[5'L%%>/\
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M_H"R_P#@NDH_X3?XB_\ 0%E_\%TE'(P]M$]EHKQK_A-_B+_T!9?_  724?\
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M/:J*\5_X3KXC?] :7_P724?\)U\1O^@-+_X+I*.1A[:)[517BO\ PG7Q&_Z
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M $!I?_!=)1_PG7Q&_P"@-+_X+I*.1A[:)[517BO_  G7Q&_Z TO_ (+I*/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4453U34[?2-/DO;G=Y<>,A "Q). !F@"Y16-H?B:Q\0-,MJLR-
M" 2LH )!SR,$^GZBMF@ HK-UO6[;0;)+JZ25T>01@1 $Y()[D>E6-.OXM3T^
M&]A5UCE&Y0X (YQSB@"U1110 45F:MK^G:*J_;;@*[#*QJ-S$>N/3W-88^(V
MC;L>1>X]?+7_ .*H Z^BLS2_$&F:QQ9W2O( "8V!5A^!Z_A6G0 4444 %%%%
M !1110 444R65((7FE;;'&I9F] .30 ^BN=TCQGINLZ@EE!%<QRN"5,JJ <#
M..&/:NBH **** "BBB@ HHHH **** "BBB@ HHHH **KR7UK%>PV;SH+F8$Q
MQ9^8@ DG'IP?RJQ0 4444 %%%% !1110 4444 %%8^N^)+/P_P#9_M<<[^?N
MV^4H.-N,YR1ZBM:*02Q)(N0'4,,^] #J**AN[E+.RGNI Q2&-I&"]2 ,G'Y4
M 345EZ'KUKK\$LUK',BQMM(E !SC/8FM2@ HHHH ***AN[E+.RGNI Q2&-I&
M"]2 ,G'Y4 345EZ'KUKK\$LUK',BQMM(E !SC/8FM2@ HHHH **:[I'&SNP5
M%!+,QP !W-1VEW;WULMS:RB6%B0KCH<$@_J#0!-1110 4444 %%%% !1110
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M[2^M;])'M)TF2-S&S(<C< #C/?J*L4 %%%% !15/5=2ATC39;ZX61HHL;A&
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M 'PG_P 50!V%%<I!\0M$F<*XNH03C=)&,#WX)KIX)XKF!)H9%DB<;E93D$4
M24444 %%%% !1110 445BV7B>RO];GTF**X$\+.K,RKM.TX.#G/Z4 ;5%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%8NA^)[+7Y9H[6*X0Q*&;S54=?3!-;5 !1110 453U74H=(TV6^N%D:*+&X1
M@%N2!QDCUIND:M!K6GK>6R2)&S%0)  >/H30!>HHHH **Q-%\466NW4UO:Q7
M"/$NYC*J@'G'&":VZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **K7%_:6L\,,\Z)+,VV.,GYF/L/ZU9H **** "BBB@ HHHH **** "BBB@
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M.<D>_P"5 &W1573;^'5-/AO;?=Y4HRH;&1S@@X]Q5J@ HHHH **** "BBB@
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MADNXYG$I*KY2@XQZY(H UJ*X_P#X6/H__/M??]\)_P#%4#XCZ/G_ (][X?\
M;-/_ (J@#L**R-(\2Z9K3F.TG/F@9\MUVMCU'K6O0 4444 %%%% !1110 44
M44 %%%% !1110 4456CO[26]DLXYT>XC7<\:G)4=.?3Z4 6:*** "BBB@ HH
MHH ***S]8UBWT2Q^V7*2O'O"8C )R?J10!H45@Z+XMT[7;QK6V2XCE5"_P"]
M50" 1TP3ZUO4 %%,EE2"%YI6VQQJ69O0#DUSFG>.=,U/4(;.&"[625MJET4
M?7#4 =-1110 45AVWBO3KS73I-OYLDH+#S0H\LD#)P<Y[$=*W* "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *\_P#B)J$DL]GI$!R6_>NH[DG"
MC^?YBN_9@JEF(  R2>U>;>' ?$/CJ?4I,M#"6E4,>@Z(/PZ_A0 TQIX/\=0
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M/5I+CQ;XR_LD2&*UMG9"/3;]YOJ>@_#WKJAX*T 6_D_8<\8WF1MV?7.?_K4
M;=M=07D"S6TR2Q-T9&R*@U+5;+2+=;B^F\J)G"!MI;G!.. ?0UP>G/+X1\9_
MV9YY:QN&488]FX4GC@@]:V/B/_R+UO\ ]?:_^@/0!LW7BC1;)86GOE7SHQ*@
M",25(R"0!D?C6A9WMMJ%N+BTF2:(G&Y3WKCO"7A;3[O1(K[4(OM,T_0.3A%!
MV@#GVK1\1:/>+X<CTG0;<+#N^=?-P=F2<98]R?7M[T 7;CQ=H-K*8Y-2B+#K
MY:LX_-014MCXDT?4I1%:W\3R'HC90GZ!@,UEZ1X(TJVL(A>VPGNBH,C.QP#Z
M  XXKG/&WA^ST46MYIRM!OD(9 Q(!'(([CO^E 'IE><?#3_C^O\ _KFO\S7=
MZ3,]SHUC/*<R26\;L?4E037"?#3_ (_K_P#ZYK_,T >CT457OY)8=.N981F5
M(F9!C/S '% %74/$&DZ7)Y=Y?11R=T&68=^0,D5%9>)]%U"=8;:_1I7.%5E9
M23[9 KAO!MAI6L75U)JT@GNV8%(Y'(W9ZMU^8Y[5N>(_ ]K/8B31[41W2,/D
M5\!U)YZG&1U_/KQ0!VE5+[5+#3(]][=Q0C&0&;D_0=3^%5-.DN].\,)+J:@W
M%M S2!6!R%SCGUP!7$>'=*?Q?JMSJ6JRM)#&0"@)&XGHH]% ]* .RM_%^@W,
MJQ1:BF]C@;T9!^9 %;=<IK/@C2Y]+E%C;>1=1J6C9"3N('W2"><_G_67P3)J
M8TEK;4[>>,PD")IE()0]N?3'Y$4 <]\-/^/Z_P#^N:_S->BNZ1QL[L%102S,
M<  =S7G7PT_X_K__ *YK_,U)XQO;K5_$4'AZW;RXPRA\YPS, <GV /\ .@#I
MI?&/A^*4QMJ2%@<91'8?F!BM2RO[348?.L[B.9.Y0YQ]?2L:V\$Z%!;")[3S
MFQAI'=MS'UX/'X5RM_"W@?Q/!+:2O]BG +1LV25S\P/';L: /1+Z^M]-LY+N
M[D\N"/&YMI.,D <#GJ15"7Q1HL-E!=R7RK#/GRSL;+8.#\N,]1Z55\:L&\'7
MK*001&01W_>+7-^"/#EEJ=A)?:@AG"N8HHV)VJ!R3^9/Z^M '=:?JEEJL)EL
M;A)D!P=O!'U!Y%5]0\0:3I4GEWE]'')W099A]0,D=:R=?D@\)>&IAI4/D-/-
MM7:2=K,.6YSV7^597A/PA:7FGIJ>J*UQ)/EDC9B !GJ<<DG^M '4V'B31]2E
M$5K?QO(> C H3] P&?PK5KA_$_@NQ33)K[3(C!/ N\QJQ*NHZ]>A YX]/>M/
MP3K4VKZ.RW+%[BW;8SGJP[$^_;\* -?4-9T[2L?;;R*%FY"DY8CUP.<<=:I6
M_B[0;J41Q:BFXD ;T9.3[D"N&T.*RUKQ1=MK\V9"3MC=RH9L],]L#H,UU.M^
M"=-N-,E_LZT6&\0;HMK$;C_=.3CF@#JZYS3O^$:_X22Y^P_\A7=)YO\ K.N?
MFZ_+U]*G\)VFHV&AK:ZDJK)$Y$8#!ODX(R1[Y_#%<IX<_P"2DZC_ -=+C_T.
M@#T.:>*VA::>5(HE^\[L% ^I-8I\9^'PX3^T5R3C_5OC\\8KFOB)<2MJ-A9R
M2M'9LN]L#C.[!..^!_.N@L_"OAF>S1K>UBGB9?\ 6"5F)X]<\&@#<L[VVU"W
M%Q:3)-$3C<I[TMS=V]G&)+JXB@C)QNE<*,^F37'Z!X;U/0O%4K0KG2W#*79P
M2RXRO'7(.!T]:W_$6B?V_IJV?VCR-L@DW[-W0$8QD>M &G!/#<PK-;RQRQ-]
MUXV#*>W!%25GZ)IG]C:/!8>=YWE;OGV[<Y8GID^M:% $5U<Q6=K+<S-MBB4N
MQ]A7F5C;WGCO7Y)KN4QVL."P7^!2>%7W..OL?I7:>-':/PC?LAP2$7\"Z@_H
M:SOAU D?A^68#YY9SN/L  !_/\Z -BV\+Z):1;$TVW?U,J"0G\6S7->+?!]I
M#I[ZCID7DO -TD:YPR]R/0CKZ8%=Y10!S_@[4KO4=#'VY9//A<Q[W4@N.QSW
M/;\.>M<KJ'_)5D_Z[P_^@+7I5>7ZW=167Q+>ZG;;%%)$[$#/ C6@#T74M2M=
M)L7N[N39&O;NQ[ #N:\ZCCU+Q]K/F29AL(3CCE8U]!ZL?7^F!67XAUJ[\07'
MVQXI$L8F\N)?X5)YY/3<0/TKU#P[)I\FAVS:8H2WV_=[JW<-[YH N6-C;Z;9
MQVMK&(XD& !W]SZFLCQ+XI@\/(B>4TUS("43. !ZDUOU5ETZSGO8KR6W1[B(
M8C=N=OTH \?UR'5I'BU+5596O"QC#\'"X_A[#GBO8[/_ (\;?_KFO\JX;XF_
M\PO_ +:_^R5W-G_QXV__ %S7^5 $]%%% %74K%-2TVXLI#M69"N[^Z>Q_ \U
MGZ)K$EP[:=J*^3JD ^=3TE']]?4']*KOK-[JNJ2V&BA$B@.V>^D7<JM_=4<9
M/^?>L[Q#H&KFU744U9KBYL\R)F!(V [X*_R- '46FEV-C//-:VT<4D[;I&4?
M>/\ 3\*MUF>']4_MC1+:\.T2,N) #T8'!^GK^-:= !17/^)_#'_"1_9?],^S
M^1O_ .66_=NQ[C'2N?\ ^%9?]1?_ ,EO_LZ /0**\_\ ^%9?]1?_ ,EO_LZZ
MOP]HW]@Z9]C^T>?\Y??LV]?;)H U:HZQJ4>DZ5<7LF#Y:_*I_B;L/SJ]7(_$
M5V3PY$JG >Y56]QM8_S H Y[0-&N/&.HSZGJDS&!6VL%X+'&0H] ,C_)S7=1
M^&M$BA,2Z7:E?5HPQ_,\U5\%P)!X4L]HYD#.Q]26/],#\*WZ /.?%WA=-)$6
MJZ0'B"R*&C0D[&[,IZCG]2*[+P]?SZEH=M<W*,DY7$@9"N2#C/X]>..:U**
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MU[5S7PX_Y%ZX_P"OMO\ T!*Y^Z^SZI\09H=;G*VR2-&BLQ48'W5SV!Z__KH
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M)QW4Y_+WH ]!U+5;+2+=;B^F\J)G"!MI;G!.. ?0U4NO%&BV2PM/?*OG1B5
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MAY$L+GSFC +#RV7 /U J6_U;3]+4->W<4.[H&/)^@')I+#1]/TMI&LK5(3(
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MB+P187-E-<:=!]GNT!<)'G;)WQM[>V,5)X!U"[NM(DM[I9"+<KY4C@_,A!P
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M;IK:348Q*IVGY6(!_P![&/UK7$B&,2!U,9&[=GC'KFN?M?!.AP6<<,UH)Y%
MWRLS L?7@\?2L+QQJ5U>:I;^'[0E1(4W\XWLQ^4'V'!__50!T<WC#0()3&^I
M1EAW1&<?F 16E8ZE9:G#YME<QS(.NT\CZCJ/QK%LO ^B6ML(YK;[3)CYI)&(
M)/L >*YC6[%O!.N6M_IDC"WFSF)FSP"-RGU&",=Z .K\;_\ (H7W_;/_ -&+
M5/PSJMCI/@O3I+ZY2%7,@7.23^\;H!S5GQC*D_@J[FB;='(L3*WJ"ZD5S7@W
MPK!J=J-1U$-)""4AA)(! ZGZ9)X'?- '9V'B31]2E$5K?QO(> C H3] P&?P
MK5K@_%O@^RM]-DU#38_L[P#<\88D,/49/!%;O@[5GU;0(WF??<0L8I&)Y..A
M/X$?CF@"W'XBTF6ZNK9;Q1+:AFF#*RA IP>2,=33++Q1HNH7(M[:_1I6.%5E
M9<GVR!FO/(=-&K^/;RQ>1TADNYC+M[J&+8_$@5Z+:>&M'L+N*ZM;)(IHLA'#
M-QD8/?GB@"]=WEM80&>[GCAB'&YVQD^@]3[5D)XS\/O($&HJ"3CF-P/S(Q7&
M6D,WCKQ/,]S+(EG$"P4'E4S@*/<]S[&NQF\$Z#+;F%;+RCCB1)&W#\23G\<T
M ;L4L<\2RPR))&PRKH<@CV(I)IXK:%IIY4BB7[SNP4#ZDUYYX<N;KPWXMDT*
M:1GMI)-H';)&5<>F1C/_ -:I/B)<2MJ-A9R2M'9LN]L#C.[!..^!_.@#I3XS
M\/APG]HKDG'^K?'YXQ6O9WMMJ%N+BTF2:(G&Y3WK#L_"OAF>S1K>UBGB9?\
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MZKPKJ#ZGX<M+B5MTH4HY.<DJ<9.>I( /XUQ/BOQ0GB$0:=ID4K1[P22O,C=
M .O?_.*[SP_IATC0[6R;!D1<R$?WB<GZ]<?A0!IT45S_ (G\,?\ "1_9?],^
MS^1O_P"66_=NQ[C'2@#H**\__P"%9?\ 47_\EO\ [.C_ (5E_P!1?_R6_P#L
MZ /0**RO#VC?V#IGV/[1Y_SE]^S;U]LFM6@"KJ?_ ""KS_K@_P#Z":XGX9?\
MQ3_ME_[/7;:G_P @J\_ZX/\ ^@FN)^&7_,4_[9?^ST =C<ZUI]GJ,.GSW&RZ
MGP8X]C'=DD#D#'4&J][XGT73IC#<ZA&L@X94!<J?0[0<'V-<7X^:9?%ED;=F
M6;[.FQE."&WOC%='8>!-'M[14NX3=3GEY6=AD^P!&!^M &WI^K6&JQE[*ZCF
M Z@'!'U!Y%9/B_6+.RTBZLI;@QW-Q PC0*QW \=0,#\:Y%K/_A%O'UI%;2,(
M))$QO_N.=I!/?'//M78>+M-L[C1+N\F@5[B& ^6YZK0!SW@77M,T[2WL[NY\
MNXENB43RV.054#D#'4&O0'=(XV=V"HH)9F.  .YK@_ 6CZ?>Z2]W<VJ2SQ71
M".V>,*I'ZFHO&-[=:OXB@\/6[>7&&4/G.&9@#D^P!_G0!TTOC'P_%*8VU)"P
M.,HCL/S Q6I97]IJ,/G6=Q',G<H<X^OI6-;>"="@MA$]IYS8PTCNVYCZ\'C\
M*Y6_A;P/XG@EM)7^Q3@%HV;)*Y^8'CMV- '6>-_^10OO^V?_ *,6H/ /_(JQ
M?]='_G4WC5@W@Z]92""(R"._[Q:A\ _\BK%_UT?^= '/^'/^2DZC_P!=+C_T
M.O1Z\X\.?\E)U'_KI<?^AU=\?ZM<*]OHMME3<*'D(/+ D@+],@Y_"@#?N/%V
M@VLIBDU*,L.OEJSC\U!%7[#5K#5$+65U'-CJ%/(^H/-8FF>!M(M+-%NK<75Q
MCYY&8XSZ >GZUSGB/2?^$1U&UU/2)&BC=BIC+9P?3GJI'KF@#TJJ&H:WIFE_
M\?M[%$W]S.6_[Y'-5M1UM;?PM)J\ # PJ\8ST+8 S]":Y'PGX;CU\3:OJ[/<
M!Y"%0L1O/<DCMZ >E '7V7BC1=0N%@MK]&E8X565D)/MN J36M8L])LR;NX,
M+2JRQD*QRV/8<5SOB;P99G3&N=*MFBNH>1'%EO,&>F/7N,?_ *KEC:2:OX73
M^WK)S=6RN%,X()P.&_+ Y]* .8\"ZWIVC?;_ +?<>3YOE[/D9LXW9Z ^HKOM
M0U[3-*2![VY\I9P3&?+9MP&,] <=17"> =(L-5_M#[=;)-Y?E[-V>,[L]/H*
MN?$Q0JZ4J@  2@ =ON4 =^CK(BNIRK $'VJCJ>MZ=HWE?;[CR?-SL^1FSC&>
M@/J*LV?_ !XV_P#US7^5<-\3?^87_P!M?_9* .^1UD174Y5@"#[5GZAX@TG2
MY/+O+Z*.3N@RS#OR!DBG2&Z&@_Z"H:Z-N!%D@ -C@\^G6N6\.^!T"2W&NP&2
MX9SMC:3( _O$J>2?>@#=A\8:!<2!$U*,$_\ /1&0?FP K;5@RAE(((R".]<9
MXH\(Z3#HES=VEO\ 9YX$W HQPPSR"#[9JS\/;B6X\-LLKEA#.T:9.<+M4X_4
MT 8=U_R5E?\ KI'_ .BA7H]><77_ "5E?^ND?_HH5Z/0 5YGXCC27XCVL<B*
MZ/+;JRL,@@D9!%>F5YCXGGCMOB';W$S;8HI('=L9P 02>* .^_L'1_\ H$V/
M_@.G^%9VL>$=+O["5;>R@@N0O[IXD"8;MD# /IS2_P#";^'?^@A_Y!D_^)K+
MUKQ_IZ64T6F-)-<.NU)-A55SWYYR/I0!2^&^H2M)=Z>S$QA1*@.?EYP<?F*[
M!M=TU=6.EM<@7@&3&4;CY=WWL8Z<]:YCX=Z1);V\^IS*5\\!(@1@E1R3]"<8
M^E87B.U:]^(<MHDAC,\D49<=@R*#^A- '=Q>+="FN1;IJ,?F$X&58*3_ +Q&
M/UK6FGBMH6FGE2*)?O.[!0/J363;>$M$M7@DCLAYL#*Z2%VW;AT)YY_E7':J
M]SXL\9G2A*T=I;R,F/[H7[S?4D8'U% '6GQIX>#[/[17.<?ZI\?GMQ6Q;75O
M>0+/;31S1-T=&R*Q5\%: MMY)LMW&#(9&W$^N<__ %JY*/S_  3XO2V25WL9
M]I(./G0G&2/[P.?R]Z /0=2U6RTBW6XOIO*B9P@;:6YP3C@'T-5[SQ%I-A%!
M)<WJQK.@DC&UB2IZ' &1^-8?Q'_Y%ZW_ .OM?_0'JKX7\)6]Y81ZEJZM<23(
M/+1V("H  I/KP!CMC% '4Z=KVEZJY2RO8Y7 SLY5L?0X-:-><^+O"\6CQ)J^
MD[X%C<;T5C\ASPP/4<X'XBNNTW6UNO"RZM( Q2!GE5?[R@[OIT_6@"[?ZG9:
M9$);VYC@4]-QY;Z#J>O:L^#Q?H%Q*(X]10,3@;T9!^; "N.\/Z6WC'5[K4]5
M<M"C#,:DC)/11Z*!^-=/?^!]%NK1HX+;[/, =DB.>#VSG.10!TBL&4,I!!&0
M1WJA=:WIUEJ,%A<7&RZGV^6FQCNW' Y P.17*^ M5G$]SHMU)N, )BR>F#AE
M'MT_6LSXA[_^$GM/+)#_ &9-I'4'>^* .TE\6:%#=-;2:C&)5.T_*Q /^]C'
MZUPGCK5[#5KRT:QN!,(D97(4C!S[CFNRM?!.AP6<<,UH)Y% WRLS L?7@\?2
MN0\?:99Z=?6GV2!8O-1F?:3R<T =O'XMT.6WFGCO2T4 !D;R7^7)P/X?6M#3
M]1M-4M1<V4WFPDE=VTCD>Q&:H/X9TQ+"\MK2U2 W,1C8@G\#^!YKF/A[=/:W
MM_H\_P KJ=X4GHRG:P_E^5 '?LRHA=V"JHR23@ 50TS6]/UD2FPN/.$6-_R,
MN,YQU ]#6?XSU Z?X9N2I(DGQ I _O=?_'0U1^"-,.G>'8GD4"6Y/G-P,@'[
MHS].?Q- &TFI6,EU]E2]MFN 2/)$JE\CJ,9SVJU7,6OA#[+XJ;6_MV[,DDGD
M^5C[P(QNW=L^E=/0 5YKX]_Y&ZP_ZX1_^C&KTJO-/'[!/%=DS'"BWC)/_ VH
M ]&N;F"SMI+FYD6.&,99VZ 5YK?7VH^.M76SLU:*QC.0&Z*/[[^_H/\ ZYJK
MXH\0W'B&1UM8Y!IUL=V0#R2<!F].N!]:[7P1)IS^'HA8H$D7BX4G+;_4^Q[>
MU &KI&D6NBV*VMJO'5W/WG/J:YCQYX@FM!'I5D[+-,NZ5D/S!<X"C'<X/X?6
MNVKS"Y(O_B>%E&56Y5=IZ?(!_A0!O:%X#LK6W2;4T^T7+ $QD_)'[<=3[]*V
MKGPOHEW%L?3;=/0Q((R/Q7%:]% 'EFH65YX%UZ&YM92]K*3LR?OJ.J,/49Z_
MC]/3;2ZBO;2*Z@;=%*H93]?ZUS?Q"CW^&=W_ #SG1OYC^M2^ YVF\*PJP'[I
MW0>XSG^M '*>"[2VO/%5]'=6\4Z"*1@LJ!@#O7G!^M>@?V#H_P#T";'_ ,!T
M_P *\MT;7?\ A']=N[O[-]HWAX]N_9C+ YS@^E=%_P +-_ZA'_DS_P#84 :W
MB/PGI,VE75Q!:QVUQ#$TBM"-H.T9P5''.*H?#6[DDL;ZT8YCA='3VW9R/_'?
MUK.O?$NN^*+=[+3=->."0A7:/+'![%^  >?3^>>K\): V@Z6R3%3=3-OE*G(
M'HOX<_F: -^BBHKF'[1:30;MOF(R;L9QD8H EHKS_P#X5E_U%_\ R6_^SH_X
M5E_U%_\ R6_^SH ] HKC]$\"_P!C:Q!?_P!H^=Y6[Y/(VYRI'7<?6NPH *\X
M\.?\E)U'_KI<?^AUZ/7F>BW,%G\0-5N;F18X8WN"SMT WT >B7M[;:=:O<W<
MRQ0IU8_YYJOIFM:?K D-A,TPC^\WE.H'XD"N$87_ (]UHA2\.EP-P2/NC^KD
M?E_/T.QL;?3;..UM8Q'$@P ._N?4T )>ZA::=#YMY<QP(> 7;&3[>M9(\:^'
MBV/[1&?^N,G_ ,36+=>%M1UOQ;+<:JI73EW",K(,E1]U1W&<Y/'K6W)X,T"2
M$Q_8%7C 978,/?.?YT :]I>6U_ )[2>.:(\;D;.#Z'T/M5?4M:T_2#"+ZX\H
MS9$?R,V<8ST!]17">#_-TOQK=Z8DI>']Y&V?XMIX;'KQ^IJU\33@Z41U_>_^
MR4 =7J'B32-*N/(O+U8Y< E K,1]< XJQI^KZ?JJLUC=1S;?O <,/J#S7/:)
MX+L_L8N=7B-U>S_O)/,8_*3SCZ\\Y[U@>)=%;PIJ-KJNE.T<)? 4DG8V/NY[
M@C/ZT >DSSQVUO+<3-MBB0N[8S@ 9)XK/C\1:3)IK:@MZHM5?RS(RLOS>@!&
M3^%,U&Z2^\(7EU%]R:QD<<],H37!^#O#W]N,TMZ[FPMG^6+) =SC(_(#..>E
M '=6OBS0KR988=1CWL< .K)D_5@*V:Y#7? VG3Z<[Z;!Y%U&N5"DD28_A()Z
MGUH^'^KR7VE2V<\F^2U("$GG8>@_ @CZ8H ZB[O+:P@,]W/'#$.-SMC)]!ZG
MVK'/C7P\&Q_:(S_UQD_^)K'U?PWJ>O>*UDO5*:6GRHRR*2% Z8ZY)[XXS[5L
MMX-T!H3'_9ZJ",;@[;A^.: -6RU"TU&'S;.YCG0<$HV<'W]*LUYGX>A;1_B&
M^FP2L8"TB$$]5"EES[C KTR@ J.:>*VA::>5(HE^\[L% ^I-25YIJKW/BSQF
M=*$K1VEO(R8_NA?O-]21@?44 =:?&GAX/L_M%<YQ_JGQ^>W%;%M=6]Y L]M-
M'-$W1T;(K%7P5H"VWDFRW<8,AD;<3ZYS_P#6KDH_/\$^+TMDE=[&?:2#CYT)
MQDC^\#G\O>@#T'4M5LM(MUN+Z;RHF<(&VEN<$XX!]#5>\\1:381027-ZL:SH
M)(QM8DJ>AP!D?C6'\1_^1>M_^OM?_0'JKX7\)6]Y81ZEJZM<23(/+1V("H
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MN)&D;'7 &30!377=-?5CI:7(:]!(,81CC R><8Z>]<3=?\E97_KI'_Z*%6?
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M3:W]NW9DDD\GRL?>!&-V[MGTKIZ "BBB@ HHHH **** "BBB@ HHHH ****
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M_P!=C_Z#73Z#_P B]IG_ %Z1?^@"N8^)7_(+LO\ KL?_ $&NGT'_ )%[3/\
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M^/\ OZ*ZKPYHJZ%I"6F\/(6,DK#H6/I[8 'X5YONU"+QKJ-QIB&2YAN9I/+
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M3U8CMZ >Y]J .UK/U[_D7M3_ .O27_T UH5GZ]_R+VI_]>DO_H!H YCX:_\
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M#HJ@]N.30!Z/1110!Y_\3?\ F%_]M?\ V2NVTS_D%6?_ %P3_P!!%<3\3?\
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MC.?K0/B01#L;2G^T@8(\SC/Y9H I_$7Y]<L8U/S^3VZC+'%=9XS_ .12O_\
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M66"!KK3Y>I .&'. 3SM8<T >EU@W.LV&LZ#JBZ=<><RVLF<(PVY4XZBN9O\
MQO>:U;/I^DZ;*)IAM9@=[!3UP /U[<_6ND\): VA:65GP;J=M\N#D+Z+[XY_
M,T <)X6\.R:]'<F/4GM3"5RJH6SG//WAZ5T/_"O;G_H/R_\ ?D__ !=9]SIV
MJ>"=9>_L(C<V#@@_+D!2?NMCH0<8/_UQ5N;XBRSPM%9:6XNFX7<^X+[X R:
M+.A^%;;3/$,5R-=BN9XBP: * Q)4CGYB>.O3M6=XW /C3301D&*+_P!&-6EX
M*\-7-G.^K:BK+<2 A(V^\,]6/N?2LWQM_P CKIG_ %SB_P#1C4 >CUY9XEM&
MN_B$UL9C#Y[Q(L@&=N54>W>O4ZY'QKX:GU58]0L26NH$VF,=74'/'N,GZ_S
M*?\ PKVY_P"@_+_WY/\ \75:[\!QQ!!>>)%0,?D\Z/&3[9>GV_Q#N;2,0:GI
MCFX3Y68'821ZJ1P:I?9-4\<ZS'<3V[6MC&,!B#A5SG )^\Q]: .D\30"V^'L
MENLHE6*&!!(.CX9!G\:L^"F5O"5CMQQO!'H=[4WQG&L7@N\C0;401*H] '6N
M1T'5]4\,Z='.]DUSIES\X8$CRSD@\\@'CH>M '?Z\Z)X>U)G("_9I!R<9RI
M%<S\-8W&F7LA^XTP4<]PO/\ ,5EZEKVJ>,0FG:;8O% Q!D.<YYXW-C 7_"NY
MT+2(]$TF*R1@S#+2.!C<QZG^GX4 <5X= /Q)U'(Z2W&/^^C7H%ZC26%PB9W-
M$P&.N<&O/_#G_)2=1_ZZ7'_H=>CT >>_#*11)J<9/SL(V ]0-V?YBO0J\YU/
M2=3\+:\^KZ7$9K5R2RJ"0H)Y5AZ9Q@_X58D^)!>(K;Z6WVC' :3< ?P&3^E
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MHH \_P#^+B?Y^ST?\7$_S]GKT"B@#*\/?VM_9G_$Z_X^]Y_N?=[?=XK5HHH
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M4 8_B^1];\66&AQ@[(V&\@9.6P2?H% /YUZ JJB!$4*JC  & !7G_@"UDO\
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M]Z0]@1_"/;\,5Z'0!YKX"_Y&Z_\ ^N$G_HQ:]$N[.WOK9[>ZA26)Q@JXS_\
MJ/O7G?@+_D;K_P#ZX2?^C%KTJ@#RJZ2\\#>)%:!V>U?YE4M_K(\\J?<>OTKT
M^TNH;VTBNH&W12J&4^QK-\2Z(FNZ3)!@"=/GA8]F]/H>G_ZJY#P%K;VEZ^BW
M1VH[$Q!OX9.Z_CC\_K0!Z/45SYOV2;R/]=L;R^GWL<=>.M2T4 >?_P#%Q/\
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M"_\ $%N=.TG3Y4:8%9"#N8KW XX'J:ZKPKH']@Z88Y"K7,IWRLO0>B_A_4T
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M3/J<C)_$UQ?@ZWFU7Q#9),2T.GH74$?=PQ('UW-G\/:N^\6_\BKJ'_7,?S%
M&%X+N6LO!%_=(H9H7ED /0D(#_2N5T/Q(NE:E<:C<69O+N;.)&FV[<]?X3S7
M:?#K_D6Y/^OEO_05KK: /+];\=?VSH\]A_9WD^;M^?S]V,,#TVCTJ7PCXL^P
M1V>C_8M_FW 3S?-QC>P'3';/K75^-_\ D4+[_MG_ .C%J#P#_P BK%_UT?\
MG0!6^(__ "+UO_U]K_Z ]:WA+_D5=/\ ^N9_F:R?B/\ \B];_P#7VO\ Z ]:
MWA+_ )%73_\ KF?YF@"GXL\+Q:Q:/<V\:K?QC*L!CS /X3ZG'2LKP)XDEG?^
MR+V0LZ@F!VZD#JI^@Y'_ .JN[KS7QQI#Z5JL6LV68UEDW,5_@E'.?QZ_7- '
MI5%9GA_6$UO2(KQ<"3[DJCHKCJ/Y'\:TZ .?\3_\)%_HO]@?[?G?ZOVV_?\
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M?Q&X\1QB=-KJDD8#$9XZOG&0:>/B01$4?2F%R!C DXS],9_"H_#^B:CK6O\
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M><>'/^2DZC_UTN/_ $.@"GXEM&N_B$UL9C#Y[Q(L@&=N54>W>MG_ (5[<_\
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M^5(P:XE;?*1T!QP!]*YO7M&U+0M?.OZ2AFC=S)(@7<4)^]D=U//(Z>W!H ]
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M-A*&-I;A7:-7P7)ZG..#C@<''/K5B'XD1V\$<,6BA8XU"(HN>@ P!]VO0Z*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** ,7Q0U\VC26MA://-=?N"1C"*P.2?PX_&
MKNDV/]F:3:V6[<88PK$=">_ZYJ[10 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %<Q%:7NH^-OM\]LUO:V"-%"S?\M2<C(]L$_I73T4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 <?\ $?\ Y%ZW_P"OM?\ T!ZV?"__ "+&G?\ 7$5;U+2K+5[=;>^A
M\V)7#A=Q7G!&>"/4U-:VL-E:QVUNFR&-=J+DG ^IH FHHHH **** "BBB@ H
MHHH 9+(D,3RR'"(I9CCH!UKAO%/C*RO-*DL-*FDEEN,*SB-E 4]1S@Y/3IT)
MKNG19$9&&58$$>U95IX6T6QNA<V]@BS*<JQ9FVGU )(% "^&])_L;0[>U88F
M(WS?[YZC\.GX5K444 <Q%:7NH^-OM\]LUO:V"-%"S?\ +4G(R/;!/Z5T]%%
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M(&HWUEJ=HEK>7$"M"21%*R@G)]#0!Z#117GWP_U&^O=3NTNKRXG5800)968
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MVGEAD\Y1OC<J<<]Q0!TM%8?@^>:Y\+64UQ+)+*V_<\C%F/SL.2:W* "BBB@
MHHHH ***XSXA7MW96EBUI=30%G8,8I"N>!UQ0!V=%4])=Y-'L7=BSM;QEF8Y
M))4<FKE !1110 4444 %%%9?B'5CHFC37JQ"1U(5%)P,DXR?:@#4HK)\,W]Q
MJGAZUO+I@TTI?<0,#AV X^@%9&HV/B"3QC!<6SW TP/&7"W 5,#&[Y=W/Y4
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M&IOI?AV>2)VCGE(BC9>"">ISVX!YKDO ^IZC=>(Q#=7UU,GE.=DLS,,\=B:
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M]8>9AT1+Q\G_ +Z % 'H=%<!X6\4Z@-7&D:N69V)17D&'1QV/KFN_H ****
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MLTK<D MC '3/'4T =91110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 <?\ $?\ Y%ZW_P"OM?\ T!ZY
M74-(ET[2-)UZQ+(61/,V\;''1OQQS[_6NJ^(_P#R+UO_ -?:_P#H#UJ:#:Q7
MO@VSMIT#12VX5@?2@"SH&L1ZYI,5X@"O]V5!_"XZC^1_&N(^)7_(5L_^N!_]
M"-0:=<3^"?%4EI<EC92D*S," 4)XD'N/\14WQ(8-J=DRD$&#(([_ #&@#TNO
M-?AK_P A6\_ZX#_T(5Z57FOPU_Y"MY_UP'_H0H ]*HHHH \UU_\ Y*99?]=[
M?^8KTJO+?%UK]M\=I:;]GGF&/=C.W=@9QWZUHM\,CM.W5P3C@&WQ_P"S4 =S
M>7]II\)EN[B.% "<NV,X]!W_  KSCPOG5/B!+?VZ$0!YICG@A6! S[Y85BRZ
M2FD:T+/7$F2+/+VY'*]F7(Y'^>M>L:-IFG:;8H--C412J'\P')D&."3_ )ZT
M 8WQ!_Y%C_MNG]:M>"/^10L?^VG_ *,:JOQ!_P"18_[;I_6N9T3_ (3/^QX/
M[)_X\?F\O_4_WCG[W/7/6@#U"O+O&;)<>-88[/F<".-MO_/3/'Z%:OR0?$"Y
M7RY'9%/=7A0_FO-:'AGP7)IUX-1U.5);D9*1K\P4GN2>IZ_SR: .@UG0[778
M(X;MI@B-N C?'.,9/^>]6K2VATZPBMHOEA@0*"<= .I_F:L5B>(_#J^(8K>)
M[IH%B8M\J[MV1]: .3\>:I;ZK=V>G6#?:98V.[ROF!8X 48ZFN_L8'M=/MK=
MV#/%$J,P[D "O-M1T+4O!=Q'J=E.DT0;;YC1C*Y[$'/7D9'Z5Z%HVIIK&DV]
M\@V^8OS+_=8<$?G0!?K'\2:[_P (_IT=W]F^T;Y1'MW[,9!.<X/I6Q5/4M5L
MM(MUN+Z;RHF<(&VEN<$XX!]#0!Q?_"S?^H1_Y,__ &%'_"S?^H1_Y,__ &%=
M!_PF_AW_ *"'_D&3_P")H_X3?P[_ -!#_P @R?\ Q- #_#/B/_A(H;B3[)]G
M\E@N/,WYS^ K=JAIFLV&L)(]A/YRQD!CL9<$_4"K] &?KW_(O:G_ ->DO_H!
MKS'2]!_M;PO>W,(_TJUEW* /OK@9']1_]>O3M>_Y%[4_^O27_P! -<Q\-?\
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M$Z*.K$] *XJVUGQCX@+W&FI';VP.!\J;3[9;)/X5-\3)G6VTZ 'Y'=W(]U
M_P#0C77Z1;1V>CV=O']U(5'UXY/YT ><>)-9U5]-&D:U:^7=I(LJRKC#KAAV
MX[]O2NZ\)?\ (JZ?_P!<S_,UE?$6V270(K@K^\AF&#Z @@C^7Y4ZTN3:?#+S
MESN%HZ@@X()) /X9H J:IXQO[S4VTOP[;K+("5,V-V2.Z]@/<\5!/>^.=*B^
MUW*I<0KRZA$; ]]N#CWK#\+>);;P]'<&2S:::4CYU8#"CM^== WQ*M64JVF2
M$$8(,@Y_2@#I/#VOP:_8>=&-DR8$T?\ =/M[&M>O+_ EYM\53)$NR&X1\)Z
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MECS]UO\ #TK595="CJ&5A@@C((KG8=!M/#&E:E<V,EQN^SNS;W!Y4$CH!R*
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M,]3GK0!T?AO7DU_3/M&P1S(VR5 > V.H]C_CZ5S>K>+KS1_&-S!+*TEA$HQ
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M0"MWQ3?7&F^'+N[M)/+GCV;6V@XRZ@\'CH37(>-O^1UTS_KG%_Z,:NG\;_\
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M/X#/XUS7@]#K7BG4=<E&0A/E!B25+9 _)1C\: $^)O\ S"_^VO\ [)7<V?\
MQXV__7-?Y5PWQ-_YA?\ VU_]DKJKS6+?1-#M[RY25X]J)B, G)'N10!K55U/
M_D%7G_7!_P#T$US/_"Q]'_Y]K[_OA/\ XJM:'6+?6_#=Y>6R2I'Y<B8D !R%
M]B: .9^&7_,4_P"V7_L]>@5Y_P##+_F*?]LO_9Z] H P/&6G+J'AJY.T>9;C
MSD/IMZ_IFLWX=7K3Z+-:MS]GE^7G^%N<?GG\ZZ'7G6/P_J+.0!]FD')QG*D
M5R7PS!\C4F[%HQ^C4 =[17(R?$32(I7C:VOLJ2IPB=O^!5<TCQEIVLZ@ME;0
MW2R,"P,BJ!P,]F- %/Q+XMN+#45TG2[<37K !F8$[21P .YY!ST^O:@X^("Q
MF7>G SY8$)/\OZUOWJ>'-%U(:G=F&"\;)#;F+-G@G:.OUQ6?-\1-'C5O*BNI
M6QQA  3]2?Z4 1^%_%UUJ&HMI>J0JET-P5E7;DKU5AZ\'IZ5L>)?$$?A_3A-
ML\RXD)6&,]"?4^PKA] OEU+XC17BQ&)9GD8(3G'[MJZ?QWHUSJNF02VD;2RV
M[DF->I4CG'J>!0!F07'CO4H5NH#%!#*-R+MC'!Z8#9./K5G0_%E^NL_V/KL"
MQW#/M63[N&[ @<'/8CU[UFZ=\0;FQB2UU&P\QHP%+JVQL#U4CKT]*W;/4?"_
MB'58+K:/[17;Y8FW*V5Y'0[2?S_E0!-XVU6]TC1H;BQF\J5KA4+;0W&UCCD'
MT%8<?B+Q)KPCCT2+8L,:B:=U3YWP-W7@<YX'U]AH?$?_ )%ZW_Z^U_\ 0'K;
M\-6D5EX<L(XE W0K(Q]689)_6@#DD\5Z]H&H);^((!+$_.Y54-C/52O!^GTZ
M5W\4L<\*31,'CD4,K#H0>0:Y[QU:QW'A:XD=07@970^AW ']":;X)F-]X2CB
MG 94+P_5?_U'% &1<^+=8UG4I++PY;KL0G]Z0"6 /7YN%!]#S_*H[NZ\=Z9"
M;JX9984!+[4C8*!W. #BMLZCX8\*O/%"Z12N09(HBTAR.W<#OQQ6??\ Q"TR
M2VDAM[6YE:12GS *,$$>I_E0!L>%O$0\06+N\8CN82!*J_=.>A'?'!K \1>*
MM0T?Q7Y*S%K)%1FA"+\W'(W$9%,^&7_,4_[9?^SU3\1P)<_$:VAD4-&\D"L#
MW'&10!IV\_CJ\EBN5$45O*X_=LJ813W(/S8'US7+^(DUQ=6MAJ\J/=E!Y14+
MP-QQ]T8ZYKV&O./'W_(T:=_UR3_T,T =7X<37T2X_MV5'8E?*VA>!SG[H'M7
M/7/BW6-9U*2R\.6Z[$)_>D E@#U^;A0?0\_RKNY(UEC:-QN1P58>H-<V=1\,
M>%7GBA=(I7(,D41:0Y';N!WXXH Q+NZ\=Z9";JX9984!+[4C8*!W. #BNC\+
M>(AX@L7=XQ'<PD"55^Z<]".^.#6/?_$+3)+:2&WM;F5I%*?, HP01ZG^55?A
ME_S%/^V7_L] &#XN36EO(O[8D5R=WD[=O"Y_V17?>'8_$:2SG7)D=-H\H*$Z
M]_NBN8^)?_']8?\ 7-OYBNT\17)M/#NH3+G<(&4$'!!(P#^&: .:U3QC?WFI
MMI?AVW660$J9L;LD=U[ >YXJ">]\<Z5%]KN52XA7EU"(V![[<''O6'X6\2VW
MAZ.X,EFTTTI'SJP&%';\ZZ!OB5:LI5M,D((P09!S^E '2>'M?@U^P\Z,;)DP
M)H_[I]O8U0\8>(KOP^EHUI' YF+AO-4G&,=,$>M<KX$O-OBJ9(EV0W"/A/0
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M@BNVT?5(=9TN&^A4J'R&0G)5AP1_GMBN(\1>-[+5M)N+"UM)_P!Z!\\F!C#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ''_$?_D7K?\
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M[C^8(_E6)XKT"Q\/Z9:00-YMS+(S/(Y&X@#@ =AS0!Z'H/\ R+VF?]>D7_H
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M -=8/Z5Z/7-WWA3[9XGAUG[;L\MT;R?*SG;[Y_I724 ><:)_R4Z\_P"NL_\
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M:-"VI6L1:9 \D++N7KD @Y]OQK#TGP)8Z?=K=7,[WDRG<N]=JY]2.<_G75T
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M-OO"GVSQ/#K/VW9Y;HWD^5G.WWS_ $KI* ,7_A$M!_Z!L7YG_&C_ (1+0?\
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M\NT1HXPV0 JD D^QR3S]/2N\M] T:QC_ '6G6JA1]]T#$#_>.357Q#X6L_$
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M ,C=8?\ 7"/_ -&-7I5<UKWA+^V]7@O_ +;Y/E(J;/*W9PQ/7(]: .EHHHH
M*Q_%&EG5O#]S;HNZ91YD77[R\X'U&1^-;%% 'CTFJRZAX9TW1(B6G6Y9=@'W
MAQLR?JQ'X5ZOIMDNG:9;6:=(8PF?4XY/XFO//"VG07OC:YN;52UC:R/(C=N2
M0@_F1]*]-H \XUO_ )*=9_\ 76#^E>CUS=]X4^V>)X=9^V[/+=&\GRLYV^^?
MZ5TE 'G&M_\ )3K/_KK!_2MWX@_\BQ_VW3^M37WA3[9XGAUG[;L\MT;R?*SG
M;[Y_I5_Q#HW]O:9]C^T>1\X??LW=/;(H K^#/^12L/\ =;_T-JI?$'_D6/\
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M$\K?N93G<3N')XS]*U_$.C?V]IGV/[1Y'SA]^S=T]LB@"OX,_P"12L/]UO\
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MQ/X8_P"$C^R_Z9]G\C?_ ,LM^[=CW&.E;L,?DP1QYSL4+GUP* *7]@Z/_P!
MFQ_\!T_PI;NUM[31;R*V@BAC\F0[(T"C.T]A5^HKF'[1:30;MOF(R;L9QD8H
M X3X9?\ ,4_[9?\ L]=])(D2%Y'5$'5F. *X'_A67_47_P#);_[.E'PR&>=7
M)'M;?_94 /\ &_B>VEL3I=A,D[RD>:\9W*%ZX![DFM[PAI;Z3X>ABF5EFE)F
MD5OX2>@_(#\<U#HW@K3-(G2Y)DN;A#E6DQM4^H7U^N:Z2@"@=#TAF+-I5B2>
M23;IS^E26^E:=:2B6VL+6&0<!XX54_F!5NB@#RG2H(-?\;7 U>7JSD1EL!V!
MP$!ST _E7HG]GZ-I4'VC[)9VT<(!\TQJ-N.ASUSTK)UWP19ZQ=M=QS-:SO\
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M'=I;_:4;YX O!7L<'.:R_&NAZ+::/+>)!';W991'Y1VASD C;TZ9/3M4U_\
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MP/ESD]S^E9OA?Q4-?DN+2^2"*;_EG$ ?G7'(YZG^E=4JA5"J  !@ =JY;6/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XWQ'X2
MO+G51J^CSK%=<%D)VY8<;@?IC@UV5% '!M_PL"6,Q%40$8,@,0/Z'C\*U?#'
MA/\ L65[R[F6>^D!!8<JN3S@GDD^M=/10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% $=P)#;2B$XEV'8>.&QQUKSZ7P_XMUVYC@U>?9:JP);>F
MW [A5ZGD]17HM% $<$,=M;QP0KMBC4(BYZ # %2444 9UGHMG9:E=:A$KFYN
M3\[NV<#T'H.!^5:-%% !1110 4444 %<9XCM?%MUJ,T.G.W]GOM"[7C0CY0#
MD_>ZYKLZ* ,7PQH*Z!I?DLRO<2'=,ZDX)[ 9[ 5M444 %%%% !1110 4444
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MPKE=P7C:PSR1ZBM/0;6:RT*RMKA-DT<05UR#@_45HT4 %%%% !1110 4444
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M'J-Q(- 'H%%,AFCN((YHF#1R*'1AW!&0:Y/6O'$=I>&PTNV^V76[9D9*AO0
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M_7RW_H*T 9.O^(-?B\6SZ7IEU@%D6*/RX^I13U8>I/4T_P#XN)_G[/574/\
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MZ5JUQ)HCW^L6PL&C+;PP(^4=\'D?3G]:YM_'.IZA<M'H>DF5%_BD5G)'J0I
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ME%<+!X[O;&\6WU[3#;[N=\:LI YYVMG(SZ'UZUVT$\5S DT,BR1.-RLIR"*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 V2*.:-HY45T8896&0?PI'B
MCEV^8BOM8,NX9P1T(]Z?10!5U/\ Y!5Y_P!<'_\ 037&?#/_ %.I?[T?_LU=
MGJ?_ ""KS_K@_P#Z":XSX9_ZG4O]Z/\ ]FH S_$EA+X4\1P:MIXVP2N7"#@
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MCQ;XF;0(;=;98I+F5LE).<)@\\$$<XQ]#0!S_P 0YY(;;3-.,SR%4+R,W\9
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MT_C?_D4+[_MG_P"C%JC\/;.&+0#=*@\Z:1@SXYP. /I_C5[QO_R*%]_VS_\
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M!<77Q#F@M)?*N'>)8Y-Q7:?+7G(Y%:;^%_&*QLPUPN0"0JWDN3[#(Q5?4/\
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M /0Q7H] 'F_P\_=:_J$ ^Z(C^C ?UJW\3/\ 4Z;_ +TG_LM5? /_ "-&H_\
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MF&-3U8L,'\@2?PK+^'=F\&A2W#C N)25XZJ!C/YYH R/ /\ R-&H_P#7)_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@"&\A:XLIX4(#21L@)Z9(Q7/\
M@_P[=^'TNUNY(',Q0KY3$XQGKD#UKIJ* "N7\6>%#KWE3VC117:?*S29 =??
M /(^G>NHHH Q?"VCW&B:/]CN7B>3S&?,9)&#CU J'Q'X5MM?59 WD7:# E"Y
MW#T8=ZZ"B@#@1X5\6+$;==<3R,;0//DSCTZ?UK;\-^$;?0F-Q+)]HO6&/,*X
M">H7_'^7-='10!5U'3[?5;&6SNDW12#G!P0>Q'N*XA/ ^NZ?,XTS6%BA8Y.)
M'C)],@ @FO0:* .$N/ $KZ9+_I:7.IS2*S3SE@ .X'4DY[G]*ZW1K*33M&M+
M.9D:2&,*Q0Y!/MFKU% ')^$/#%[H%S<R74MNXE0*OE,QZ'OD"M[6;*34=&N[
M.%D62:,JI<X /OBKU% &#X2T2YT'2I;6Z>)W><R Q$D8*J.X'I4GBG1[C6]'
M^QVSQ))YBOF0D# SZ UM44 9OA_3Y=*T.VLIV1I8@0Q0DCEB>,@>M8.M>"%N
MKXW^E7/V.Y+;B!D+N]01R#7844 <#+X1\37X6'4-:C>WW L!([<?3 !KK-%T
M2TT*R^SVJDECF21OO.??^@K2HH Y/Q%X8O=7\0V>H6\MNL4*(K"1F#'#ECC
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MD?%WAG4O$%[;O;3VR00QD!968'<3R> >P7\JRHO"'BR")8H=;2.-1A42ZE
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <UXITD3;
M=6_M>?3S:QD%HUR,9[8(.3G'7TK@=.DOI;X1SZG-81ZEAC<8XDP2.<$=]W]?
M6O5M5TJUUFQ-I=JQC)# J<%2.XJO?>'=,U"UM;::WQ#:D&-4.,#T^AH K_\
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MHD,T=Q!'-$P:.10Z,.X(R#7G=U_R5E?^ND?_ **% &O\1_\ D7K?_K[7_P!
M>MGPO_R+&G?]<16-\1_^1>M_^OM?_0'K9\+_ /(L:=_UQ% &O37=(XV=V"HH
M)9F.  .YIU</\1M2>*SM=.B;'GDO(!U*CH/H2?TH O7/Q!T2WF,:"YG _CBC
M&T_]]$&L/QKK-EK6AV<]E+O"SD,IX93M/45U.A^&=/TW384DLXGN2@,SR*')
M;N,^F?2N/\>>'[;39(+^RB$44S%)$4856QD8';(SQ[4 =[H/_(O:9_UZ1?\
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M1Z=,C+@QQJH8#Z#D50\,>&+S0-2NY&NHWLY5(2-2<G#?*3QUQG\Z .JHHHH
MQ]6\3Z5HLGE74Y:?KY48W,/KV'XUD+\1M&9L&"]4>IC7^C4W2/!31ZK<WVM-
M!>,YW(O+#<3DE@1],#GJ:W-1T?1IK-X[NUM8HV&WS-JH5/LW8T 7+#4+34[4
M7-E,LT))&X9&".Q!Y'XUG:QXFLM%O8+6YBN'>894QJ"!SCG)%<G\-I'74;^
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M=]*LOLL:. Z^4J9..ORFK6N*%\.:DJ@ "TE  [?(:YGX:_\ (+O?^NP_]!H
MWF\2V*:^^CNLJ3HNYI&"B,#9OSG.>GM69-\0]%BF**MU* <;TC&#[\D']*Y?
MQ#9?VC\19;/<4$TD2%AU \M<_I7>CPQHRV/V0:?!LVXWE 7^N[KF@"2W\0Z5
M<Z8VH)>(MNGWR_RE3Z$>O\^V:Q1\1-%,H0QW84_QF,8'_CV?TKD?#.BIJ7B.
M;3IW8VD):62,,0)-AVC_ -"_(FN\UGPYI4FAW21V%O$\<+-&Z1A65@,CD<_7
MUH V;2[M[^UCN;642PR#*N._.*JZIK>GZ-$)+VX6,M]U!RS?0#^?2N7^&MP[
MZ=>VY)*1RJRCTW#G_P!!JU>^$;C5/%7]H:A-%+8C@0AF#!0.%Z=,\GGN: $/
MQ&T;=CR+W'KY:_\ Q5;NDZ[I^MQLUE-N9/OHPPR_A_A3Y-(TH6[))86:PA?F
M!B4 #\N*X#0HH;+XD_9[)P;8O*J[3D;=A.,^QQ^5 &IX]UVU^RS:-Y<WVG*/
MNP-F.O7.?TH\&>)[*.QL-$,5Q]I+,NX*NSEF;KG/0^E:'CV"$>')IO*3S3(@
MW[1NQGUJ7P1;6_\ PB]C/Y$7G?O/WFP;OOL.O7I0!NWU_:Z;;-<WDZ0Q#C<W
M<^@'4GV%<TWQ%T99"HBO& _C$:X/YMFN?UN8^(?&ZZ=<W ALK=RF2P 4 98Y
M]3C'Y5V<-KX:@MQ D>F>7Z,4;/U)Z_C0!<TO6+'6;<S64XD"X#J1AD/H15ZO
M,+QK;PMXQMI],N UE*%,B1MN 4G#+UYZ9&?:O3Z "J&MWPT[1;R[)P8XCMYQ
M\QX'ZD5?KCOB'=,-,M+"-=TEU-P/4+CC\V6@";X?V7V;P[Y[(0]S(7R>ZC@?
MR/YUU=5["U6RT^WM5  AC5/EZ<#%6* $9@JEF(  R2>U<S>^/-$LYC$KS7)'
M!:! 5!^I(S]1D52^(FJ2VNG06,+;1=%C(0>=JXX^A)_2K/A[2=!TW38O.DLI
MKIU#2/*R$@GL,] .E %[2?%VDZQ.((97BG;[L<R[2WTQD?K6[7GOC33=)6S7
M4M-DMHKF-QN6W8?,#WP#P0>];EMJ5QJO@&6ZC<BZ^S.K-WW*"#^) _6@!^H>
M.-&T^X> R2SR(<,($R ?3)('Y4EAXYT6_F$1DDMF;H;A0H_,$@5R_@B?P_%'
M*NH^0MX7^5[D#;MQV)X!Z_F*Z'Q#X5M->LX9M*%I%,&XE3A'3O\ =!R: -O6
M-8M]$L?MERDKQ[PF(P"<GZD5YGX=\06FD>(;S4+B.9HID=5$:@L,N&&<D=A7
MIUC8O'I-O::@8[J2-0K,RY!QT//M7!>#K>&?QEJ4<L,<B".4A74$#]XO:@#J
M]5US21H%KJ5]9/<6D[KY<;Q(Y!()!()QT![]ZU=+GM[K2[:>TB\FW= 8X]H7
M:/3 X%<S\155/#=LB*%5;I0 !@ ;'K:\+_\ (L:=_P!<10!5L_&>DW=C<WA,
MT$-N5#><H!8MG 4 G)X-5(_B)HKS!&2[C4GEVC&!^1)_2N/\%Z+!K.JNMT"T
M$">84'1SG !]NM=EXLT#33X>N9X;*"&6!-Z/%&$/'8X'(H U=1\1Z7IMC'=S
M7*NDH!B6,AFD'J!Z>]9EKX_T2YG$3&>WSP'F0!?T)Q6%X$T*VU.WDO[]!<)"
M_DPQ2'*K_$>/JWTY/%6_'VBV$&D17MM:Q02I*$8QH%#*0>H'N!0!W58FK>+-
M)T>4PSSF2<=8H1N*_7L/IG-+X:N)KKPG92!@9O)*J7Z97*C/Y5DZ#X*%G>W%
MWK!@O97.4)RPR>2S!AU_.@!T?Q%T9W"M%>(/[S1K@?DQKIK*]MM1M4N;2998
M7Z,/\\5EZYH^CRZ7,+BVM8?D;RY-JH5;!Q@_AT]JYWX9.QCU.,GY%,3 >YW9
M_D* ,/QGKMKK=[!]FCF3R R-Y@ R<]L$UZ!H?B>RU^6:.UBN$,2AF\U5'7TP
M37'_ !&@A@O;$0Q)&&C8G8H&3D>E=Y=FWTC3;N[AMX8_+B:0A5"[B 2 <?YY
MH @U?Q'IFBX6[G_>D9$,8W.?P[?CBLF#XA:+-*$=;J$$_?DC&!^1)KG/"=G9
MZOJ%UJNMSPNP?(CF8 .QY)(/8<<=*Z^_T_PWJ%HUO)_9Z9!"/&R*R'U!'\J
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M/R-=U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU':^'M9\3:PM_KJ&WMUXV8VD@<[0.H'/4T =WI\4,.FVL5NS/"D*+&S=2H
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M;1S:,_'G/&R[?H6X%95IH&HZ+XOLWD@N+J-75Y+B.%F7+#GGGH2: .H\??\
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MCK'@VP<V,QNVG5Y88X6RORN#\O) Z=?6NB\.120>';"*:-XY%B 9'&"#[@T
M<9\-/^/Z_P#^N:_S-=AXH_Y%C4?^N)KF/A[I][97EZUU9W$ :-0IEB9<\GID
M5U7B.*2?P[?Q0QO)(T1"H@R2?8"@##^''_(O7'_7VW_H"5-\0?\ D6/^VZ?U
MH\ 6ES9Z%/'=6\L#FY9@LJ%21M7G!^E2^.;6XN_#OE6T$LTGG*=D:%CCGL*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ K%\6_P#(JZA_US'\Q6U3)H8KB)HIHTDC
M;AD=00?J#0!ROPZ_Y%N3_KY;_P!!6NMJ&VM+>SC,=K;Q01DYVQ(%&?7 J:@
MKSC3/^2J3?\ 767_ -!->CU673K)+HW26=NMR229A$H<YZ\XS0!9HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KSC6_P#DIUG_ -=8/Z5Z/59].LI;
MH74EG;O<*01*T2EQCISC- %FBBB@ HHHH **** "L/7?%5CH$R0W,<TDLB;U
M$8&.N.<FMRJUSIUC>.'NK*WG8# :6)6('XCWH X?X<6TSW-_?N"(V C#'^)B
M<G'TX_,5Z#38XTB0)&BH@Z*HP!3J "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y#7/'5MITEU906TY
MO(R4#,%" XX;J<]N,4_P'H[66E/?W"G[1>'<"W4)V_,Y/N,5T,FEZ?+/Y\EC
M;/-G/F-"I;\\9JW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
-%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>nmra-20240331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-05-07T10:26:54.6764+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.neumoratx.com/20240331" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2023" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nmra="http://www.neumoratx.com/20240331" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage" id="DocumentCoverPage">
        <link:definition>100000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" id="StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
        <link:definition>100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" id="StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited">
        <link:definition>100040 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" id="StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>100050 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidity" id="DisclosureOrganizationAndLiquidity">
        <link:definition>100060 - Disclosure - Organization and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation1" id="DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation1">
        <link:definition>100070 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecurities1" id="DisclosureCashEquivalentsAndMarketableSecurities1">
        <link:definition>100080 - Disclosure - Cash Equivalents and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>100090 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponents" id="DisclosureBalanceSheetComponents">
        <link:definition>100100 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssets" id="DisclosureAcquisitionsOfAssets">
        <link:definition>100110 - Disclosure - Acquisitions of Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>100120 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreements" id="DisclosureStrategicLicenseAndResearchAndCollaborationAgreements">
        <link:definition>100130 - Disclosure - Strategic License and Research and Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquity1" id="DisclosureStockholdersEquity1">
        <link:definition>100140 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosurePreferredStockWarrants" id="DisclosurePreferredStockWarrants">
        <link:definition>100150 - Disclosure - Preferred Stock Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensation" id="DisclosureStockbasedCompensation">
        <link:definition>100160 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>100170 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>100180 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>100190 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies">
        <link:definition>100200 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables" id="DisclosureCashEquivalentsAndMarketableSecuritiesTables">
        <link:definition>100210 - Disclosure - Cash Equivalents and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>100220 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsTables" id="DisclosureBalanceSheetComponentsTables">
        <link:definition>100230 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100240 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>100250 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationTables" id="DisclosureStockbasedCompensationTables">
        <link:definition>100260 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>100270 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>100280 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails" id="DisclosureOrganizationAndLiquidityAdditionalInformationDetails">
        <link:definition>100290 - Disclosure - Organization and Liquidity - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme" id="DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme">
        <link:definition>100300 - Disclosure - Cash Equivalents and Marketable Securities - Summary of Amortized Cost and Fair Value of Cash Equivalents and Marketable Securities by Major Investment Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesByContractualMaturityDetails" id="DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesByContractualMaturityDetails">
        <link:definition>100310 - Disclosure - Cash Equivalents and Marketable Securities - Summary of Marketable Securities by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100320 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100330 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>100340 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsParentheticalDetails" id="DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsParentheticalDetails">
        <link:definition>100350 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails" id="DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails">
        <link:definition>100360 - Disclosure - Balance Sheet Components - Schedule of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesParentheticalDetails" id="DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesParentheticalDetails">
        <link:definition>100370 - Disclosure - Balance Sheet Components - Schedule of Accrued Liabilities (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails" id="DisclosureAcquisitionsOfAssetsAdditionalInformationDetails">
        <link:definition>100380 - Disclosure - Acquisitions of Assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails" id="DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails">
        <link:definition>100390 - Disclosure - Strategic License and Research and Collaboration Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>100400 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails" id="DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails">
        <link:definition>100410 - Disclosure - Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" id="DisclosureStockbasedCompensationAdditionalInformationDetail">
        <link:definition>100420 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails" id="DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails">
        <link:definition>100430 - Disclosure - Stock-Based Compensation - Summary of Fair Value of Stock Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail" id="DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail">
        <link:definition>100440 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail" id="DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail">
        <link:definition>100450 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedDetails" id="DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedDetails">
        <link:definition>100460 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense Recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100470 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetails" id="DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetails">
        <link:definition>100480 - Disclosure - Income Taxes - Summary of Reconciliation of Federal Income Tax Rate and Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" id="DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>100490 - Disclosure - Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsDetails" id="DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsDetails">
        <link:definition>100500 - Disclosure - Income Taxes - Summary of NOL and Tax Credit Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsParentheticalDetails" id="DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsParentheticalDetails">
        <link:definition>100510 - Disclosure - Income Taxes - Summary of NOL and Tax Credit Carryforwards (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfUnrecognizedTaxBenefitsDetails" id="DisclosureIncomeTaxesSummaryOfReconciliationOfUnrecognizedTaxBenefitsDetails">
        <link:definition>100520 - Disclosure - Income Taxes - Summary of Reconciliation of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails" id="DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails">
        <link:definition>100530 - Disclosure - Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar" id="DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar">
        <link:definition>100540 - Disclosure - Net Loss Per Share - Summary of Outstanding Potentially Dilutive Common Stock Equivalents were Excluded from Computation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100550 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage" xlink:href="nmra-20240331.xsd#DocumentCoverPage" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="nmra-20240331.xsd#StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="nmra-20240331.xsd#StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:href="nmra-20240331.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" xlink:href="nmra-20240331.xsd#StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="nmra-20240331.xsd#StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidity" xlink:href="nmra-20240331.xsd#DisclosureOrganizationAndLiquidity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation1" xlink:href="nmra-20240331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecurities1" xlink:href="nmra-20240331.xsd#DisclosureCashEquivalentsAndMarketableSecurities1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="nmra-20240331.xsd#DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponents" xlink:href="nmra-20240331.xsd#DisclosureBalanceSheetComponents" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssets" xlink:href="nmra-20240331.xsd#DisclosureAcquisitionsOfAssets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="nmra-20240331.xsd#DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreements" xlink:href="nmra-20240331.xsd#DisclosureStrategicLicenseAndResearchAndCollaborationAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquity1" xlink:href="nmra-20240331.xsd#DisclosureStockholdersEquity1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosurePreferredStockWarrants" xlink:href="nmra-20240331.xsd#DisclosurePreferredStockWarrants" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensation" xlink:href="nmra-20240331.xsd#DisclosureStockbasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxes" xlink:href="nmra-20240331.xsd#DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShare" xlink:href="nmra-20240331.xsd#DisclosureNetLossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:href="nmra-20240331.xsd#DisclosureRelatedPartyTransactions" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" xlink:href="nmra-20240331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables" xlink:href="nmra-20240331.xsd#DisclosureCashEquivalentsAndMarketableSecuritiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="nmra-20240331.xsd#DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsTables" xlink:href="nmra-20240331.xsd#DisclosureBalanceSheetComponentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="nmra-20240331.xsd#DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityTables" xlink:href="nmra-20240331.xsd#DisclosureStockholdersEquityTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationTables" xlink:href="nmra-20240331.xsd#DisclosureStockbasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="nmra-20240331.xsd#DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="nmra-20240331.xsd#DisclosureNetLossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails" xlink:href="nmra-20240331.xsd#DisclosureOrganizationAndLiquidityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme" xlink:href="nmra-20240331.xsd#DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesByContractualMaturityDetails" xlink:href="nmra-20240331.xsd#DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesByContractualMaturityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="nmra-20240331.xsd#DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="nmra-20240331.xsd#DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="nmra-20240331.xsd#DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsParentheticalDetails" xlink:href="nmra-20240331.xsd#DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails" xlink:href="nmra-20240331.xsd#DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesParentheticalDetails" xlink:href="nmra-20240331.xsd#DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails" xlink:href="nmra-20240331.xsd#DisclosureAcquisitionsOfAssetsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails" xlink:href="nmra-20240331.xsd#DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="nmra-20240331.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails" xlink:href="nmra-20240331.xsd#DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" xlink:href="nmra-20240331.xsd#DisclosureStockbasedCompensationAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails" xlink:href="nmra-20240331.xsd#DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail" xlink:href="nmra-20240331.xsd#DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail" xlink:href="nmra-20240331.xsd#DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedDetails" xlink:href="nmra-20240331.xsd#DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="nmra-20240331.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetails" xlink:href="nmra-20240331.xsd#DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="nmra-20240331.xsd#DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsDetails" xlink:href="nmra-20240331.xsd#DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsParentheticalDetails" xlink:href="nmra-20240331.xsd#DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:href="nmra-20240331.xsd#DisclosureIncomeTaxesSummaryOfReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:href="nmra-20240331.xsd#DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar" xlink:href="nmra-20240331.xsd#DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="nmra-20240331.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PreferredStockWarrantsHeldByRelatedParty" xlink:label="nmra_PreferredStockWarrantsHeldByRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_EarlyExerciseLiabilityCurrentPortion" xlink:label="nmra_EarlyExerciseLiabilityCurrentPortion"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember" xlink:label="nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_RelatedPartyTransactionObligationWithRelatedParty" xlink:label="nmra_RelatedPartyTransactionObligationWithRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_CollaborationAgreementNonRefundableQuarterlyPayments" xlink:label="nmra_CollaborationAgreementNonRefundableQuarterlyPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SharesReservedForIssuanceUnderThePlansMember" xlink:label="nmra_SharesReservedForIssuanceUnderThePlansMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ContingentConsiderationMilestonePaymentSettledInCash" xlink:label="nmra_ContingentConsiderationMilestonePaymentSettledInCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AdvisorsMember" xlink:label="nmra_AdvisorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet" xlink:label="nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_DevelopmentMilestonesMember" xlink:label="nmra_DevelopmentMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_LiquidityMember" xlink:label="nmra_LiquidityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities" xlink:label="nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AlairionCarveoutPlanMember" xlink:label="nmra_AlairionCarveoutPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_NumberOfLicenseAgreements" xlink:label="nmra_NumberOfLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PercentageOfFutureTaxableIncomeOffsettingByNol" xlink:label="nmra_PercentageOfFutureTaxableIncomeOffsettingByNol"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SeriesA1ConvertiblePreferredStockMember" xlink:label="nmra_SeriesA1ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ResearchAgreementExpiryDate" xlink:label="nmra_ResearchAgreementExpiryDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AmgenResearchAndCollaborationAgreementMember" xlink:label="nmra_AmgenResearchAndCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SeriesA2ConvertiblePreferredStockMember" xlink:label="nmra_SeriesA2ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="nmra_EmergingGrowthCompanyStatusPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_OrganizationAndLiquidityLineItems" xlink:label="nmra_OrganizationAndLiquidityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SummaryOfFairValueOfStockOptionsTableTextBlock" xlink:label="nmra_SummaryOfFairValueOfStockOptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_CollaborationAgreementTerm" xlink:label="nmra_CollaborationAgreementTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AccruedClinicalTrialAndPreclinicalCosts" xlink:label="nmra_AccruedClinicalTrialAndPreclinicalCosts"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PrepaidResearchAndDevelopmentCosts" xlink:label="nmra_PrepaidResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_FederalPostDecember312017Member" xlink:label="nmra_FederalPostDecember312017Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_BlackthornTherapeuticsIncMember" xlink:label="nmra_BlackthornTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="nmra_TwoThousandTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_RestrictedCommonStockMember" xlink:label="nmra_RestrictedCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember" xlink:label="nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_MarketableSecuritiesMember" xlink:label="nmra_MarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember" xlink:label="nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ResearchAndCollaborationAgreementQuarterlyPayments" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_FederalPreJanuary12018Member" xlink:label="nmra_FederalPreJanuary12018Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AlairionIncMember" xlink:label="nmra_AlairionIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_MassachusettsMember" xlink:label="nmra_MassachusettsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_EarlyExerciseLiabilityNetOfCurrentPortion" xlink:label="nmra_EarlyExerciseLiabilityNetOfCurrentPortion"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_MilestonePaymentDueDescription" xlink:label="nmra_MilestonePaymentDueDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AlairionMergerAgreementMember" xlink:label="nmra_AlairionMergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_DeferredTaxAssetsInCapitalizedLicenseAgreements" xlink:label="nmra_DeferredTaxAssetsInCapitalizedLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AcquiredInProcessResearchAndDevelopment" xlink:label="nmra_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PreferredStockWarrantsMember" xlink:label="nmra_PreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SharesIssuedUponAchievementOfMilestone" xlink:label="nmra_SharesIssuedUponAchievementOfMilestone"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_TwoThousandAndFifteenTsriLicenseAgreementMember" xlink:label="nmra_TwoThousandAndFifteenTsriLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_NoncashOperatingLeaseExpense" xlink:label="nmra_NoncashOperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_NavacaprantMember" xlink:label="nmra_NavacaprantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AwardsWithPerformanceConditionsMember" xlink:label="nmra_AwardsWithPerformanceConditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_DeferredTaxAssetsTaxCreditCarryforwardsTable" xlink:label="nmra_DeferredTaxAssetsTaxCreditCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SeriesBConvertiblePreferredStockMember" xlink:label="nmra_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" xlink:label="nmra_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SyllableLifeSciencesIncMember" xlink:label="nmra_SyllableLifeSciencesIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_DeferredTaxAssetsTaxCreditCarryforwardsLineItems" xlink:label="nmra_DeferredTaxAssetsTaxCreditCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_OfferingExpenses" xlink:label="nmra_OfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_DeferredOfferingCostsPolicyTextBlock" xlink:label="nmra_DeferredOfferingCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_MilestonePayments" xlink:label="nmra_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PerformanceConditionsMember" xlink:label="nmra_PerformanceConditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_EffectiveIncomeTaxRateReconciliationStateRateAdjustments" xlink:label="nmra_EffectiveIncomeTaxRateReconciliationStateRateAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock" xlink:label="nmra_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AwardModificationMember" xlink:label="nmra_AwardModificationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:label="us-gaap_InvestmentIncomeAmortizationOfDiscount"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_CaseTwoMember" xlink:label="nmra_CaseTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AmgenIncLicensesMember" xlink:label="nmra_AmgenIncLicensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AchievementOfSpecifiedCommercializationEventsMember" xlink:label="nmra_AchievementOfSpecifiedCommercializationEventsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PerformanceRestrictedStockMember" xlink:label="nmra_PerformanceRestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_RepurchaseOfUnvestedEarlyExercisedStockOptions" xlink:label="nmra_RepurchaseOfUnvestedEarlyExercisedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_CaseOneMember" xlink:label="nmra_CaseOneMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ServiceConditionsMember" xlink:label="nmra_ServiceConditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions" xlink:label="nmra_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember" xlink:label="nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ServicesAgreementMember" xlink:label="nmra_ServicesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_CollaborationAgreementTerminationDescription" xlink:label="nmra_CollaborationAgreementTerminationDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AmgenIncMember" xlink:label="nmra_AmgenIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="nmra_TwoThousandTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember" xlink:label="nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AdditionalSharesOfCapitalStockMember" xlink:label="nmra_AdditionalSharesOfCapitalStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms" xlink:label="nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_RepurchaseOfUnvestedEarlyExercisedShares" xlink:label="nmra_RepurchaseOfUnvestedEarlyExercisedShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AcquisitionDateFairValueOfSharesTransferred" xlink:label="nmra_AcquisitionDateFairValueOfSharesTransferred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_UpfrontCashPayment" xlink:label="nmra_UpfrontCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SupplementalInformationOnTheCompanysOperatingLeasesTableTextBlock" xlink:label="nmra_SupplementalInformationOnTheCompanysOperatingLeasesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PaymentsForExecutionOfAgreement" xlink:label="nmra_PaymentsForExecutionOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_CommercialMilestonePayments" xlink:label="nmra_CommercialMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="nmra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ConvertiblePreferredStockPolicyPolicyTextBlock" xlink:label="nmra_ConvertiblePreferredStockPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_FundsReceivedUponExecutionOfAgreement" xlink:label="nmra_FundsReceivedUponExecutionOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_EarlyExerciseOfEmployeeStockOptionsMember" xlink:label="nmra_EarlyExerciseOfEmployeeStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SalesBasedMilestonesMember" xlink:label="nmra_SalesBasedMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_VanderbiltSponsoredResearchAgreementMember" xlink:label="nmra_VanderbiltSponsoredResearchAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_BlackthornCarveoutPlanMember" xlink:label="nmra_BlackthornCarveoutPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ParkinsonsResearchVenturesFundingAgreementMember" xlink:label="nmra_ParkinsonsResearchVenturesFundingAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ScheduleOfOrganizationAndLiquidityTable" xlink:label="nmra_ScheduleOfOrganizationAndLiquidityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="nmra_CashEquivalentsAndMarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember" xlink:label="nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SharesReservedForFutureIssuanceUnderThePlansMember" xlink:label="nmra_SharesReservedForFutureIssuanceUnderThePlansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_CommercialMilestonePaymentMember" xlink:label="nmra_CommercialMilestonePaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_DevelopmentAndRegulatoryApprovalMilestonesMember" xlink:label="nmra_DevelopmentAndRegulatoryApprovalMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_VanderbiltLicenseMember" xlink:label="nmra_VanderbiltLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SyllableMergerAgreementMember" xlink:label="nmra_SyllableMergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ContingentConsiderationMilestonePayment" xlink:label="nmra_ContingentConsiderationMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_EffectiveIncomeTaxRateReconciliationMilestonePaymentsPercent" xlink:label="nmra_EffectiveIncomeTaxRateReconciliationMilestonePaymentsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AchievementOfSpecifiedDevelopmentEventsMember" xlink:label="nmra_AchievementOfSpecifiedDevelopmentEventsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_StockPurchaseRightMember" xlink:label="nmra_StockPurchaseRightMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_MilestonesAchieved" xlink:label="nmra_MilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AccruedResearchAndDevelopmentServicesDueToRelatedParty" xlink:label="nmra_AccruedResearchAndDevelopmentServicesDueToRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AccruedResearchAndDevelopmentServices" xlink:label="nmra_AccruedResearchAndDevelopmentServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_MaximumAdditionalFinancingInEquitySecurities" xlink:label="nmra_MaximumAdditionalFinancingInEquitySecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_VanderbiltIprDAssetsMember" xlink:label="nmra_VanderbiltIprDAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="nmra_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ShareBasedCompensationAwardTrancheFourMember" xlink:label="nmra_ShareBasedCompensationAwardTrancheFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PreferredStockExercisePricePerShare" xlink:label="nmra_PreferredStockExercisePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_UpfrontConsiderationTransferredShares" xlink:label="nmra_UpfrontConsiderationTransferredShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="nmra_DeferredTaxAssetsOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_Nmra511Member" xlink:label="nmra_Nmra511Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_NumberOfMilestoneAchieved" xlink:label="nmra_NumberOfMilestoneAchieved"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetAssetValuePerShare" xlink:label="us-gaap_NetAssetValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone" xlink:label="nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_RisksAndUncertaintiesPolicyTextBlock" xlink:label="nmra_RisksAndUncertaintiesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_UnderwritingDiscountsAndCommissions" xlink:label="nmra_UnderwritingDiscountsAndCommissions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AcquiredInProcessResearchAndDevelopedExpense" xlink:label="nmra_AcquiredInProcessResearchAndDevelopedExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_BlackthornMergerAgreementMember" xlink:label="nmra_BlackthornMergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_DevelopmentAndRegulatoryMilestonePayments" xlink:label="nmra_DevelopmentAndRegulatoryMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_MaximumRepaymentAmountAgreedToPay" xlink:label="nmra_MaximumRepaymentAmountAgreedToPay"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_MarketAwardMember" xlink:label="nmra_MarketAwardMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue" xlink:label="nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term, Outstanding (Years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, in Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalties due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Royalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of Series B convertible preferred stock, issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance / Offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments for deferred offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share based compensation forfeited under unvested plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation granted under plan vested period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PreferredStockWarrantsHeldByRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock warrants held by related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PreferredStockWarrantsHeldByRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Warrants Held By Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PreferredStockWarrantsHeldByRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock warrants held by related party.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Restricted Stock Awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EarlyExerciseLiabilityCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Early exercise liability, current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EarlyExerciseLiabilityCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Early Exercise Liability Current Portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EarlyExerciseLiabilityCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Early exercise liability, current portion.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Stock Options (With Performance Conditions to Be Established)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance stock options (with performance conditions to be established) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance stock options (with performance conditions to be established).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_RelatedPartyTransactionObligationWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party transaction obligation with related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_RelatedPartyTransactionObligationWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Obligation with Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_RelatedPartyTransactionObligationWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party transaction obligation with related party.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CollaborationAgreementNonRefundableQuarterlyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement non-refundable quarterly payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CollaborationAgreementNonRefundableQuarterlyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Non-refundable Quarterly Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CollaborationAgreementNonRefundableQuarterlyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement non-refundable quarterly payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesReservedForIssuanceUnderThePlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Reserved for Issuance Under the Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesReservedForIssuanceUnderThePlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Reserved for Issuance under the Plans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesReservedForIssuanceUnderThePlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares reserved for issuance under the plans.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ContingentConsiderationMilestonePaymentSettledInCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration, milestone payment settled in cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ContingentConsiderationMilestonePaymentSettledInCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration, Milestone Payment Settled in Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ContingentConsiderationMilestonePaymentSettledInCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent consideration, milestone payment settled in cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split conversion ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, Outstanding Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, Outstanding Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets less valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AdvisorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advisors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AdvisorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Advisors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AdvisorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Advisors.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at Ending (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at Beginning (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares reserved for potential future issuances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisitions of Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Fixed assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Expired, Outstanding Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expired, Outstanding Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross increases based on tax positions related to prior years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued based on volume weighted average price per share prior to date milestone was met.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Based on Volume Weighted Average Price Per Share Prior to Date Milestone Was Met</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued based on volume weighted average price per share prior to date milestone was met</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Limitations on Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits, Expiration Years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DevelopmentMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DevelopmentMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DevelopmentMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_LiquidityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_LiquidityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_LiquidityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities, current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: Operating lease liabilities, current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funds provided for preclinical research and development activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funds Provided For Pre-clinical Research And Development Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funds provided for pre-clinical research and development activities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AlairionCarveoutPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Alairion Carveout Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AlairionCarveoutPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Alairion Carveout Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AlairionCarveoutPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Alairion Carveout Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total assets measured at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NumberOfLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of license agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NumberOfLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NumberOfLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of license agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PercentageOfFutureTaxableIncomeOffsettingByNol_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of future taxable income offsetting by NOL.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PercentageOfFutureTaxableIncomeOffsettingByNol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Future Taxable Income Offsetting By NOL</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PercentageOfFutureTaxableIncomeOffsettingByNol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of future taxable income offsetting by NOL carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SeriesA1ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series A-1 Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SeriesA1ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SeriesA1ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A-1 convertible preferred stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SeriesA1ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-1 convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options vested in period incremental expense resulted in modification.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total incremental expense resulted in modification</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement By Share-Based Payment Award Options Vested in Period Incremental Expense Resulted in Modification</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation related</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ResearchAgreementExpiryDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research agreement expiry date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ResearchAgreementExpiryDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Agreement Expiry Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ResearchAgreementExpiryDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research agreement expiry date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AmgenResearchAndCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amgen Research and Collaboration Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AmgenResearchAndCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amgen Research And Collaboration Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AmgenResearchAndCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amgen research and collaboration agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SeriesA2ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series A-2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SeriesA2ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-2 Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SeriesA2ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A-2 Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SeriesA2ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-2 Convertible Preferred Stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emerging Growth Company Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Emerging Growth Company Status [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Emerging growth company status.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investment Income, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Executives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Executive Officer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_OrganizationAndLiquidityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization and Liquidity [Line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_OrganizationAndLiquidityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and Liquidity [Line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SummaryOfFairValueOfStockOptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of fair value of stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SummaryOfFairValueOfStockOptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Fair Value of Stock Options [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SummaryOfFairValueOfStockOptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value of Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CollaborationAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of the agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CollaborationAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CollaborationAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding and unvested, Shares at ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding and unvested, Shares at beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares or restricted stock remained outstanding and unvested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AccruedClinicalTrialAndPreclinicalCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical trial and preclinical costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AccruedClinicalTrialAndPreclinicalCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Trial and Preclinical Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AccruedClinicalTrialAndPreclinicalCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical trial and preclinical costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PrepaidResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid research and development costs ($9.4 million and $6.3 million from related party in 2024 and 2023, respectively)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PrepaidResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Prepaid research and development costs from related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PrepaidResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Research and Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PrepaidResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid research and development costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_FederalPostDecember312017Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal (Post-December 31, 2017).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_FederalPostDecember312017Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Federal (Post-December 31, 2017) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">California Franchise Tax Board [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Amortized Cost and Fair Value of Cash Equivalents and Marketable Securities by Major Investment Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Marketable Securities by Contractual Maturity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_BlackthornTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BlackThorn Therapeutics, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_BlackthornTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">BlackThorn Therapeutics, Inc. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_BlackthornTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">BlackThorn Therapeutics, Inc. member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Three Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_RestrictedCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_RestrictedCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_RestrictedCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Options and Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option and and Restricted Stock Units Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock option and and restricted stock units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible preferred stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Early Exercised Stock Options Subject to Future Vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Early exercised stock options subject to future vesting [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Early exercised stock options subject to future vesting.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and collaboration agreement quarterly payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Collaboration Agreement Quarterly Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research And Collaboration Agreement Quarterly Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other noncash expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Noncash Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and collaboration agreement quarterly payments for first two year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Collaboration Agreement Quarterly Payments For First Two Years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and collaboration agreement quarterly payments for first two years.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Income (Loss), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_FederalPreJanuary12018Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal (Pre-January 1, 2018).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_FederalPreJanuary12018Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Federal (Pre-January 1, 2018) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration deemed due or payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Contingent Consideration, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Asset Acquisition, Contingent Consideration, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AlairionIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Alairion, Inc</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AlairionIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Alairion, Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AlairionIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Alairion, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Massachusetts.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Massachusetts [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Massachusetts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EarlyExerciseLiabilityNetOfCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Early exercise liability, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EarlyExerciseLiabilityNetOfCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Early Exercise Liability Net Of Current Portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EarlyExerciseLiabilityNetOfCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Early exercise liability, net of current portion.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MilestonePaymentDueDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment due description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MilestonePaymentDueDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Due Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MilestonePaymentDueDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment due description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AlairionMergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Alairion Merger Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AlairionMergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Alairion Merger Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AlairionMergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Alairion Merger Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DeferredTaxAssetsInCapitalizedLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets in capitalized license agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DeferredTaxAssetsInCapitalizedLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets In Capitalized License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DeferredTaxAssetsInCapitalizedLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized license agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AcquiredInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired in-process research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AcquiredInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquired in-process research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AcquiredInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquired in-process research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options granted to purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax law change</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate Intrinsic Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross increases based on tax positions related to current year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expense, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price to public, per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred stock warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, outstanding stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesIssuedUponAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued upon achievement of milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesIssuedUponAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares issued upon achievement of milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesIssuedUponAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued upon achievement of milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TwoThousandAndFifteenTsriLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015 TSRI License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TwoThousandAndFifteenTsriLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Fifteen TSRI License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TwoThousandAndFifteenTsriLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and fifteen TSRI license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stockholders' equity (deficit):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NoncashOperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-cash operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NoncashOperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash operating lease expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate grant-date fair value of options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NavacaprantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">navacaprant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NavacaprantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Navacaprant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NavacaprantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Navacaprant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Maturity of the Company's Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AwardsWithPerformanceConditionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Awards with Performance Conditions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AwardsWithPerformanceConditionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Awards with Performance Conditions [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AwardsWithPerformanceConditionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Awards with performance conditions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DeferredTaxAssetsTaxCreditCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets tax credit carryforwards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DeferredTaxAssetsTaxCreditCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based payment, milestones achieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Milestones Achieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award milestones achieved.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series B</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series b convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock warrant liability policy text block.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Warrant Liability [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock Warrant Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Cash and Cash Equivalents [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Commitments and contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SyllableLifeSciencesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Syllable Life Sciences, Inc</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SyllableLifeSciencesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Syllable Life Sciences, Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SyllableLifeSciencesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Syllable Life Sciences, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested, outstanding stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">After one year through two years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">After one year through [two] years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities After One Through Two Years Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale securities debt maturities after one through two years fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">All Award Types</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">All Award Types</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DeferredTaxAssetsTaxCreditCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets tax credit carryforwards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DeferredTaxAssetsTaxCreditCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_OfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_OfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Offering Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_OfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Offering expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards, Limitations on Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NOLs, Expiration Years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance of unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance of unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross increases based on tax positions related to acquired entities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PerformanceConditionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Conditions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PerformanceConditionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Conditions [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PerformanceConditionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance conditions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EffectiveIncomeTaxRateReconciliationStateRateAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation state rate adjustments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EffectiveIncomeTaxRateReconciliationStateRateAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State Rate Adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EffectiveIncomeTaxRateReconciliationStateRateAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State rate adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options grant date fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement By Share-Based Payment Award Options Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unaudited Interim Condensed Consolidated Financial Statements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unaudited Interim Condensed Consolidated Financial Statements [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unaudited interim condensed consolidated financial statements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable, Outstanding Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Recurring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AwardModificationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Modification</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AwardModificationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Modification [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AwardModificationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Award modification.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Consideration Transferred, Contingent Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents, and marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised, Outstanding Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercised, Outstanding Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeAmortizationOfDiscount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net accretion of investments in marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeAmortizationOfDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Amortization of Discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CaseTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Case Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CaseTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Case Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CaseTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Case two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Within one year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Liabilities, Convertible Preferred Stock, and Stockholders' Equity (Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AmgenIncLicensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amgen Inc. Licenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AmgenIncLicensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amgen Inc. Licenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AmgenIncLicensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amgen Inc. Licenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AchievementOfSpecifiedCommercializationEventsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Achievement of Specified Commercialization Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AchievementOfSpecifiedCommercializationEventsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Achievement of Specified Commercialization Events [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AchievementOfSpecifiedCommercializationEventsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Achievement of specified commercialization events.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Granted, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested shares repurchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash paid for acquisition of assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire in Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PerformanceRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Restricted Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PerformanceRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PerformanceRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance restricted stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_RepurchaseOfUnvestedEarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of unvested early exercised stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_RepurchaseOfUnvestedEarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase of unvested early exercised stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_RepurchaseOfUnvestedEarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repurchase of unvested early exercised stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CaseOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Case One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CaseOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Case One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CaseOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Case one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ServiceConditionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Service Conditions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ServiceConditionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Service Conditions [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ServiceConditionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Service conditions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration payable in cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Businesses, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Receivables, Net, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Receivables, Net, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Tax Credit Carryforwards [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of NOL and Tax Credit Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested, Weighted Average Grant Date Fair Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Vesting of restricted stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeiture of restricted stock subject to repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation uncertain tax positions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Uncertain Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Restricted Stock (With Performance Conditions to Be Established)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance restricted stock (with performance conditions to be established) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance restricted stock (with performance conditions to be established).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accumulated other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset acquisition compensation recognized and paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income (Expense), Nonoperating, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining service period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Strategic License and Research and Collaboration Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Services Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Services Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Services agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible preferred stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at Ending (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at Beginning (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Organization and Liquidity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies and Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reconciliation of Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net change in cash and cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and collaboration agreement quarterly payments for third year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Collaboration Agreement Quarterly Payments For Third Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and collaboration agreement quarterly payments for third year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental disclosure of noncash investing and financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Canceled and forfeited, Outstanding Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options, cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Canceled and forfeited, Outstanding Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Outstanding Potentially Dilutive Common Stock Equivalents were Excluded from Computation of Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized loss on investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Realized loss on investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average common shares outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CollaborationAgreementTerminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement termination description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CollaborationAgreementTerminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Termination Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CollaborationAgreementTerminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement termination description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses and Related Prepaid Assets and Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AmgenIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amgen Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AmgenIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amgen Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AmgenIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amgen Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of cash and restricted cash:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Reserved for Options and Restricted Stock Units Issued Under the Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Reserved For Options And Restricted Stock UnitsIssued UnderThe Plans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares reserved for options and restricted stock unitsissued underthe plans.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of earnings per share amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AdditionalSharesOfCapitalStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Shares of Capital Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AdditionalSharesOfCapitalStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Shares of Capital Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AdditionalSharesOfCapitalStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional shares of capital stock member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Deferred Tax Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of clinical and preclinical neuroscience programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Clinical And Preclinical Neuroscience Programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of clinical and preclinical neuroscience programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_RepurchaseOfUnvestedEarlyExercisedShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of unvested early exercised shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_RepurchaseOfUnvestedEarlyExercisedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Of Unvested Early Exercised Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_RepurchaseOfUnvestedEarlyExercisedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repurchase of unvested early exercised shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation Expense Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AcquisitionDateFairValueOfSharesTransferred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition date fair value of shares transferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AcquisitionDateFairValueOfSharesTransferred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquisition Date Fair Value of Shares Transferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AcquisitionDateFairValueOfSharesTransferred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquisition date fair value of shares transferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_UpfrontCashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront cash payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_UpfrontCashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Cash Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_UpfrontCashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront cash payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SupplementalInformationOnTheCompanysOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Supplemental information on the company's operating leases.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SupplementalInformationOnTheCompanysOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Information on the Company's Operating Leases [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SupplementalInformationOnTheCompanysOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Information on the Company's Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PaymentsForExecutionOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments for execution of agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PaymentsForExecutionOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Execution Of Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PaymentsForExecutionOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments for execution of agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CommercialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CommercialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CommercialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial milestone payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities operating lease right of use assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Operating Lease Right Of Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, Weighted Average Grant Date Fair Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation, term of plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements Not Yet Adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock warrants, issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ConvertiblePreferredStockPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock, policy policy text block.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ConvertiblePreferredStockPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ConvertiblePreferredStockPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax law change</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_FundsReceivedUponExecutionOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funds received upon execution of agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_FundsReceivedUponExecutionOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funds Received Upon Execution Of Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_FundsReceivedUponExecutionOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funds received upon execution of agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Canceled and forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EarlyExerciseOfEmployeeStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Early Exercise of Employee Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EarlyExerciseOfEmployeeStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Early Exercise of Employee Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EarlyExerciseOfEmployeeStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Early exercise of employee stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SalesBasedMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales-based Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SalesBasedMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Based Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SalesBasedMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales-based milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of convertible preferred stock automatically converted into shares of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Converted shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits, Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Short-term marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_VanderbiltSponsoredResearchAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vanderbilt Research Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_VanderbiltSponsoredResearchAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vanderbilt Sponsored Research Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_VanderbiltSponsoredResearchAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vanderbilt sponsored research agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_BlackthornCarveoutPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BlackThorn Carveout Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_BlackthornCarveoutPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">BlackThorn Carveout Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_BlackthornCarveoutPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">BlackThorn Carveout Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ParkinsonsResearchVenturesFundingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Parkinson's Research Ventures Funding Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ParkinsonsResearchVenturesFundingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Parkinsons Research Ventures Funding Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ParkinsonsResearchVenturesFundingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Parkinsons research ventures funding agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ScheduleOfOrganizationAndLiquidityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Organization And Liquidity [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ScheduleOfOrganizationAndLiquidityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of organization and liquidity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CashEquivalentsAndMarketableSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents and Marketable Securities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CashEquivalentsAndMarketableSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents and marketable securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized (loss/gain) on marketable debt securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Related Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Employee Share Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Employee Share Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty three employee share purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents and Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding and unvested, Weighted Average Grant Date Fair Value Per Share at ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding and unvested, Weighted Average Grant Date Fair Value Per Share at beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock sold in initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options granted, exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Certificates of Deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Certificates of Deposit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Commercial Paper</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesReservedForFutureIssuanceUnderThePlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares reserved for future issuance under the plans.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesReservedForFutureIssuanceUnderThePlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares reserved for future issuance under the plans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesReservedForFutureIssuanceUnderThePlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Reserved for Future Issuance Under the Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CommercialMilestonePaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Milestone Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CommercialMilestonePaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Milestone Payment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CommercialMilestonePaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial milestone payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S Government and Agency Debt Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Short-Term Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DevelopmentAndRegulatoryApprovalMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and Regulatory Approval Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DevelopmentAndRegulatoryApprovalMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development and Regulatory Approval Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DevelopmentAndRegulatoryApprovalMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and regulatory approval milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_VanderbiltLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vanderbilt License</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_VanderbiltLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vanderbilt License [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_VanderbiltLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vanderbilt License.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SyllableMergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Syllable Merger Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SyllableMergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Syllable Merger Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SyllableMergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Syllable Merger Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ContingentConsiderationMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration, milestone payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ContingentConsiderationMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration, Milestone Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ContingentConsiderationMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent consideration, milestone payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EffectiveIncomeTaxRateReconciliationMilestonePaymentsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation, milestone payments, percent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EffectiveIncomeTaxRateReconciliationMilestonePaymentsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Milestone payments, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EffectiveIncomeTaxRateReconciliationMilestonePaymentsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation and amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at Ending</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at Beginning</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible preferred stock, $0.0001 par value; 50,000 and 820,349 shares authorized as of December 31, 2023 and December 31, 2022, respectively; no and 104,417 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AchievementOfSpecifiedDevelopmentEventsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Achievement of Specified Development Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AchievementOfSpecifiedDevelopmentEventsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Achievement of Specified Development Events [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AchievementOfSpecifiedDevelopmentEventsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Achievement of specified development events.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_StockPurchaseRightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Purchase Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_StockPurchaseRightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Purchase Right [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_StockPurchaseRightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock purchase right.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestones achieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestones Achieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestones achieved.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AccruedResearchAndDevelopmentServicesDueToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development services due to related party.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AccruedResearchAndDevelopmentServicesDueToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research and Development Services Due to Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AccruedResearchAndDevelopmentServicesDueToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development services due to related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AccruedResearchAndDevelopmentServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AccruedResearchAndDevelopmentServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research and Development Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AccruedResearchAndDevelopmentServices_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development services.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MaximumAdditionalFinancingInEquitySecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum additional financing in equity securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MaximumAdditionalFinancingInEquitySecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum additional financing in equity securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration by Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_VanderbiltIprDAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vanderbilt IPR&amp;D Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_VanderbiltIprDAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vanderbilt IPR&amp;D Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_VanderbiltIprDAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vanderbilt IPR&amp;D Assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Common Stock Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of common stock reserved for future issuance [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of common stock reserved for future issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ShareBasedCompensationAwardTrancheFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Based Compensation Award Tranche Four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ShareBasedCompensationAwardTrancheFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Award Tranche Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ShareBasedCompensationAwardTrancheFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Market Based Tranches</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited and canceled, Weighted Average Grant Date Fair Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PreferredStockExercisePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock warrants, exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PreferredStockExercisePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Exercise Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PreferredStockExercisePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock exercise price per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_UpfrontConsiderationTransferredShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront consideration transferred shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_UpfrontConsiderationTransferredShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Consideration Transferred Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_UpfrontConsiderationTransferredShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront consideration transferred shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisitions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets operating lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination and Asset Acquisition [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Prepaid Expense, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_Nmra511Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NMRA-511</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_Nmra511Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">NMRA-511 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_Nmra511Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">NMRA-511.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Long-term marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NumberOfMilestoneAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of milestone achieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NumberOfMilestoneAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Milestone Achieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NumberOfMilestoneAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of milestone achieved.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetAssetValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net asset value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetAssetValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Asset Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetAssetValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Net Asset Value Per Share, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetAssetValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Net Asset Value Per Share, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited and canceled, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Other Assets [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash and cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total cash and cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available-for-Sale Securities, Debt Maturities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fund eligible to receive upon completion of certain development milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fund Eligible To Receive Upon Completion Of Certain Development Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fund eligible to receive upon completion of certain development milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment included in accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risks and Uncertainties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Risks and Uncertainties [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Risks and uncertainties.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at Ending</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at Beginning</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts and commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies and Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts and commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Discounts And Commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting discounts and commissions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average common shares outstanding, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reconciliation of Federal Income Tax Rate and Effective Income Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective income tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AcquiredInProcessResearchAndDevelopedExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquired in-process research and developed expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AcquiredInProcessResearchAndDevelopedExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquired in-process Research and Developed Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AcquiredInProcessResearchAndDevelopedExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired in-process research and developed expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Amortized Cost, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grants vest percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_BlackthornMergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BlackThorn Merger Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_BlackthornMergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">BlackThorn Merger Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_BlackthornMergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">BlackThorn Merger Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DevelopmentAndRegulatoryMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and regulatory milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DevelopmentAndRegulatoryMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development And Regulatory Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DevelopmentAndRegulatoryMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and regulatory milestone payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Exercise Price Per Share, Outstanding, end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Exercise Price Per Share, Outstanding, beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Computation of Basic and Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MaximumRepaymentAmountAgreedToPay_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum repayment amount agreed to pay.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MaximumRepaymentAmountAgreedToPay_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Repayment Amount Agreed To Pay</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MaximumRepaymentAmountAgreedToPay_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum repayment amount agreed to pay.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MarketAwardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Market Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MarketAwardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Market Award [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MarketAwardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Market award.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Vested, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation and benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents and restricted cash at end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents and restricted cash at beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sales and maturities of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Fair Value Of Available For Sale Debt Securities Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated fair value of available for sale debt securities fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NOLs, Carryforwards</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_PreferredStockWarrantsHeldByRelatedParty" xlink:to="nmra_PreferredStockWarrantsHeldByRelatedParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_EarlyExerciseLiabilityCurrentPortion" xlink:to="nmra_EarlyExerciseLiabilityCurrentPortion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember" xlink:to="nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_RelatedPartyTransactionObligationWithRelatedParty" xlink:to="nmra_RelatedPartyTransactionObligationWithRelatedParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_CollaborationAgreementNonRefundableQuarterlyPayments" xlink:to="nmra_CollaborationAgreementNonRefundableQuarterlyPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_SharesReservedForIssuanceUnderThePlansMember" xlink:to="nmra_SharesReservedForIssuanceUnderThePlansMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ContingentConsiderationMilestonePaymentSettledInCash" xlink:to="nmra_ContingentConsiderationMilestonePaymentSettledInCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AdvisorsMember" xlink:to="nmra_AdvisorsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet" xlink:to="nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_DevelopmentMilestonesMember" xlink:to="nmra_DevelopmentMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_LiquidityMember" xlink:to="nmra_LiquidityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities" xlink:to="nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AlairionCarveoutPlanMember" xlink:to="nmra_AlairionCarveoutPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_NumberOfLicenseAgreements" xlink:to="nmra_NumberOfLicenseAgreements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_PercentageOfFutureTaxableIncomeOffsettingByNol" xlink:to="nmra_PercentageOfFutureTaxableIncomeOffsettingByNol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_SeriesA1ConvertiblePreferredStockMember" xlink:to="nmra_SeriesA1ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification" xlink:to="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ResearchAgreementExpiryDate" xlink:to="nmra_ResearchAgreementExpiryDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AmgenResearchAndCollaborationAgreementMember" xlink:to="nmra_AmgenResearchAndCollaborationAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_SeriesA2ConvertiblePreferredStockMember" xlink:to="nmra_SeriesA2ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:to="nmra_EmergingGrowthCompanyStatusPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="nmra_OrganizationAndLiquidityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_SummaryOfFairValueOfStockOptionsTableTextBlock" xlink:to="nmra_SummaryOfFairValueOfStockOptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_CollaborationAgreementTerm" xlink:to="nmra_CollaborationAgreementTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AccruedClinicalTrialAndPreclinicalCosts" xlink:to="nmra_AccruedClinicalTrialAndPreclinicalCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_PrepaidResearchAndDevelopmentCosts" xlink:to="nmra_PrepaidResearchAndDevelopmentCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_FederalPostDecember312017Member" xlink:to="nmra_FederalPostDecember312017Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:to="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_BlackthornTherapeuticsIncMember" xlink:to="nmra_BlackthornTherapeuticsIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:to="nmra_TwoThousandTwentyThreeEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_RestrictedCommonStockMember" xlink:to="nmra_RestrictedCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember" xlink:to="nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_MarketableSecuritiesMember" xlink:to="nmra_MarketableSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember" xlink:to="nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ResearchAndCollaborationAgreementQuarterlyPayments" xlink:to="nmra_ResearchAndCollaborationAgreementQuarterlyPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears" xlink:to="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_FederalPreJanuary12018Member" xlink:to="nmra_FederalPreJanuary12018Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AlairionIncMember" xlink:to="nmra_AlairionIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_MassachusettsMember" xlink:to="nmra_MassachusettsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_EarlyExerciseLiabilityNetOfCurrentPortion" xlink:to="nmra_EarlyExerciseLiabilityNetOfCurrentPortion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_MilestonePaymentDueDescription" xlink:to="nmra_MilestonePaymentDueDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AlairionMergerAgreementMember" xlink:to="nmra_AlairionMergerAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_DeferredTaxAssetsInCapitalizedLicenseAgreements" xlink:to="nmra_DeferredTaxAssetsInCapitalizedLicenseAgreements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AcquiredInProcessResearchAndDevelopment" xlink:to="nmra_AcquiredInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_PreferredStockWarrantsMember" xlink:to="nmra_PreferredStockWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_SharesIssuedUponAchievementOfMilestone" xlink:to="nmra_SharesIssuedUponAchievementOfMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_TwoThousandAndFifteenTsriLicenseAgreementMember" xlink:to="nmra_TwoThousandAndFifteenTsriLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_NoncashOperatingLeaseExpense" xlink:to="nmra_NoncashOperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_NavacaprantMember" xlink:to="nmra_NavacaprantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AwardsWithPerformanceConditionsMember" xlink:to="nmra_AwardsWithPerformanceConditionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_DeferredTaxAssetsTaxCreditCarryforwardsTable" xlink:to="nmra_DeferredTaxAssetsTaxCreditCarryforwardsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved" xlink:to="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_SeriesBConvertiblePreferredStockMember" xlink:to="nmra_SeriesBConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" xlink:to="nmra_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_SyllableLifeSciencesIncMember" xlink:to="nmra_SyllableLifeSciencesIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:to="nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_DeferredTaxAssetsTaxCreditCarryforwardsLineItems" xlink:to="nmra_DeferredTaxAssetsTaxCreditCarryforwardsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_OfferingExpenses" xlink:to="nmra_OfferingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_DeferredOfferingCostsPolicyTextBlock" xlink:to="nmra_DeferredOfferingCostsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_MilestonePayments" xlink:to="nmra_MilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_PerformanceConditionsMember" xlink:to="nmra_PerformanceConditionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_EffectiveIncomeTaxRateReconciliationStateRateAdjustments" xlink:to="nmra_EffectiveIncomeTaxRateReconciliationStateRateAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" xlink:to="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock" xlink:to="nmra_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AwardModificationMember" xlink:to="nmra_AwardModificationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:to="us-gaap_InvestmentIncomeAmortizationOfDiscount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_CaseTwoMember" xlink:to="nmra_CaseTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AmgenIncLicensesMember" xlink:to="nmra_AmgenIncLicensesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AchievementOfSpecifiedCommercializationEventsMember" xlink:to="nmra_AchievementOfSpecifiedCommercializationEventsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_PerformanceRestrictedStockMember" xlink:to="nmra_PerformanceRestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_RepurchaseOfUnvestedEarlyExercisedStockOptions" xlink:to="nmra_RepurchaseOfUnvestedEarlyExercisedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_CaseOneMember" xlink:to="nmra_CaseOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ServiceConditionsMember" xlink:to="nmra_ServiceConditionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:to="us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions" xlink:to="nmra_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember" xlink:to="nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ServicesAgreementMember" xlink:to="nmra_ServicesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityTableTextBlock" xlink:to="us-gaap_TemporaryEquityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear" xlink:to="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_CollaborationAgreementTerminationDescription" xlink:to="nmra_CollaborationAgreementTerminationDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AmgenIncMember" xlink:to="nmra_AmgenIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="us-gaap_ContingentConsiderationTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_TwoThousandTwentyEquityIncentivePlanMember" xlink:to="nmra_TwoThousandTwentyEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember" xlink:to="nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AdditionalSharesOfCapitalStockMember" xlink:to="nmra_AdditionalSharesOfCapitalStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms" xlink:to="nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_RepurchaseOfUnvestedEarlyExercisedShares" xlink:to="nmra_RepurchaseOfUnvestedEarlyExercisedShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AcquisitionDateFairValueOfSharesTransferred" xlink:to="nmra_AcquisitionDateFairValueOfSharesTransferred_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_UpfrontCashPayment" xlink:to="nmra_UpfrontCashPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_SupplementalInformationOnTheCompanysOperatingLeasesTableTextBlock" xlink:to="nmra_SupplementalInformationOnTheCompanysOperatingLeasesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_PaymentsForExecutionOfAgreement" xlink:to="nmra_PaymentsForExecutionOfAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_CommercialMilestonePayments" xlink:to="nmra_CommercialMilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:to="nmra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ConvertiblePreferredStockPolicyPolicyTextBlock" xlink:to="nmra_ConvertiblePreferredStockPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_FundsReceivedUponExecutionOfAgreement" xlink:to="nmra_FundsReceivedUponExecutionOfAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_EarlyExerciseOfEmployeeStockOptionsMember" xlink:to="nmra_EarlyExerciseOfEmployeeStockOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_SalesBasedMilestonesMember" xlink:to="nmra_SalesBasedMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_VanderbiltSponsoredResearchAgreementMember" xlink:to="nmra_VanderbiltSponsoredResearchAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_BlackthornCarveoutPlanMember" xlink:to="nmra_BlackthornCarveoutPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ParkinsonsResearchVenturesFundingAgreementMember" xlink:to="nmra_ParkinsonsResearchVenturesFundingAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ScheduleOfOrganizationAndLiquidityTable" xlink:to="nmra_ScheduleOfOrganizationAndLiquidityTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="nmra_CashEquivalentsAndMarketableSecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember" xlink:to="nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_SharesReservedForFutureIssuanceUnderThePlansMember" xlink:to="nmra_SharesReservedForFutureIssuanceUnderThePlansMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_CommercialMilestonePaymentMember" xlink:to="nmra_CommercialMilestonePaymentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_DevelopmentAndRegulatoryApprovalMilestonesMember" xlink:to="nmra_DevelopmentAndRegulatoryApprovalMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_VanderbiltLicenseMember" xlink:to="nmra_VanderbiltLicenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_SyllableMergerAgreementMember" xlink:to="nmra_SyllableMergerAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ContingentConsiderationMilestonePayment" xlink:to="nmra_ContingentConsiderationMilestonePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_EffectiveIncomeTaxRateReconciliationMilestonePaymentsPercent" xlink:to="nmra_EffectiveIncomeTaxRateReconciliationMilestonePaymentsPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AchievementOfSpecifiedDevelopmentEventsMember" xlink:to="nmra_AchievementOfSpecifiedDevelopmentEventsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_StockPurchaseRightMember" xlink:to="nmra_StockPurchaseRightMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_MilestonesAchieved" xlink:to="nmra_MilestonesAchieved_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AccruedResearchAndDevelopmentServicesDueToRelatedParty" xlink:to="nmra_AccruedResearchAndDevelopmentServicesDueToRelatedParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AccruedResearchAndDevelopmentServices" xlink:to="nmra_AccruedResearchAndDevelopmentServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_MaximumAdditionalFinancingInEquitySecurities" xlink:to="nmra_MaximumAdditionalFinancingInEquitySecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_VanderbiltIprDAssetsMember" xlink:to="nmra_VanderbiltIprDAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="nmra_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ShareBasedCompensationAwardTrancheFourMember" xlink:to="nmra_ShareBasedCompensationAwardTrancheFourMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_PreferredStockExercisePricePerShare" xlink:to="nmra_PreferredStockExercisePricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_UpfrontConsiderationTransferredShares" xlink:to="nmra_UpfrontConsiderationTransferredShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="nmra_DeferredTaxAssetsOperatingLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_Nmra511Member" xlink:to="nmra_Nmra511Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_NumberOfMilestoneAchieved" xlink:to="nmra_NumberOfMilestoneAchieved_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetAssetValuePerShare" xlink:to="us-gaap_NetAssetValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone" xlink:to="nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_RisksAndUncertaintiesPolicyTextBlock" xlink:to="nmra_RisksAndUncertaintiesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_UnderwritingDiscountsAndCommissions" xlink:to="nmra_UnderwritingDiscountsAndCommissions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AcquiredInProcessResearchAndDevelopedExpense" xlink:to="nmra_AcquiredInProcessResearchAndDevelopedExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_BlackthornMergerAgreementMember" xlink:to="nmra_BlackthornMergerAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_DevelopmentAndRegulatoryMilestonePayments" xlink:to="nmra_DevelopmentAndRegulatoryMilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_MaximumRepaymentAmountAgreedToPay" xlink:to="nmra_MaximumRepaymentAmountAgreedToPay_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_MarketAwardMember" xlink:to="nmra_MarketAwardMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue" xlink:to="nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_EarlyExerciseLiabilityCurrentPortion" xlink:label="nmra_EarlyExerciseLiabilityCurrentPortion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_EarlyExerciseLiabilityNetOfCurrentPortion" xlink:label="nmra_EarlyExerciseLiabilityNetOfCurrentPortion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="nmra_EarlyExerciseLiabilityCurrentPortion" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="nmra_EarlyExerciseLiabilityNetOfCurrentPortion" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AcquiredInProcessResearchAndDevelopment" xlink:label="nmra_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="nmra_AcquiredInProcessResearchAndDevelopment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_RepurchaseOfUnvestedEarlyExercisedStockOptions" xlink:label="nmra_RepurchaseOfUnvestedEarlyExercisedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_11"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_12"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_13"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_14"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nmra_RepurchaseOfUnvestedEarlyExercisedStockOptions" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_12" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_13" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_14" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_NoncashOperatingLeaseExpense" xlink:label="nmra_NoncashOperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_RepurchaseOfUnvestedEarlyExercisedShares" xlink:label="nmra_RepurchaseOfUnvestedEarlyExercisedShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:label="us-gaap_InvestmentIncomeAmortizationOfDiscount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="nmra_NoncashOperatingLeaseExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nmra_RepurchaseOfUnvestedEarlyExercisedShares" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InvestmentIncomeAmortizationOfDiscount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnInvestments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecurities1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="nmra_CashEquivalentsAndMarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquity1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosurePreferredStockWarrants" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock" xlink:label="nmra_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_RisksAndUncertaintiesPolicyTextBlock" xlink:label="nmra_RisksAndUncertaintiesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_DeferredOfferingCostsPolicyTextBlock" xlink:label="nmra_DeferredOfferingCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" xlink:label="nmra_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ConvertiblePreferredStockPolicyPolicyTextBlock" xlink:label="nmra_ConvertiblePreferredStockPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="nmra_EmergingGrowthCompanyStatusPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nmra_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nmra_RisksAndUncertaintiesPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nmra_DeferredOfferingCostsPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nmra_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nmra_ConvertiblePreferredStockPolicyPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nmra_EmergingGrowthCompanyStatusPolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="nmra_CashEquivalentsAndMarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfOtherAssetsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SupplementalInformationOnTheCompanysOperatingLeasesTableTextBlock" xlink:label="nmra_SupplementalInformationOnTheCompanysOperatingLeasesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="nmra_SupplementalInformationOnTheCompanysOperatingLeasesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="nmra_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_TemporaryEquityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="nmra_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SummaryOfFairValueOfStockOptionsTableTextBlock" xlink:label="nmra_SummaryOfFairValueOfStockOptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="nmra_SummaryOfFairValueOfStockOptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_OrganizationAndLiquidityLineItems" xlink:label="nmra_OrganizationAndLiquidityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms" xlink:label="nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ScheduleOfOrganizationAndLiquidityTable" xlink:label="nmra_ScheduleOfOrganizationAndLiquidityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_LiquidityMember" xlink:label="nmra_LiquidityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_UnderwritingDiscountsAndCommissions" xlink:label="nmra_UnderwritingDiscountsAndCommissions"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_OfferingExpenses" xlink:label="nmra_OfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="nmra_ScheduleOfOrganizationAndLiquidityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_ScheduleOfOrganizationAndLiquidityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="nmra_OrganizationAndLiquidityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nmra_LiquidityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_ScheduleOfOrganizationAndLiquidityTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="nmra_UnderwritingDiscountsAndCommissions" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="nmra_OfferingExpenses" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_MarketableSecuritiesMember" xlink:label="nmra_MarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="nmra_MarketableSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_CashAndCashEquivalentsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesByContractualMaturityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue" xlink:label="nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetAssetValuePerShare" xlink:label="us-gaap_NetAssetValuePerShare"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_NetAssetValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PrepaidResearchAndDevelopmentCosts" xlink:label="nmra_PrepaidResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="nmra_PrepaidResearchAndDevelopmentCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PrepaidResearchAndDevelopmentCosts" xlink:label="nmra_PrepaidResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nmra_PrepaidResearchAndDevelopmentCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AccruedResearchAndDevelopmentServices" xlink:label="nmra_AccruedResearchAndDevelopmentServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AccruedClinicalTrialAndPreclinicalCosts" xlink:label="nmra_AccruedClinicalTrialAndPreclinicalCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="nmra_AccruedResearchAndDevelopmentServices" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="nmra_AccruedClinicalTrialAndPreclinicalCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AccruedResearchAndDevelopmentServicesDueToRelatedParty" xlink:label="nmra_AccruedResearchAndDevelopmentServicesDueToRelatedParty"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="nmra_AccruedResearchAndDevelopmentServicesDueToRelatedParty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_BlackthornMergerAgreementMember" xlink:label="nmra_BlackthornMergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SeriesA2ConvertiblePreferredStockMember" xlink:label="nmra_SeriesA2ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_CaseOneMember" xlink:label="nmra_CaseOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_DevelopmentAndRegulatoryApprovalMilestonesMember" xlink:label="nmra_DevelopmentAndRegulatoryApprovalMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_BlackthornTherapeuticsIncMember" xlink:label="nmra_BlackthornTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_BlackthornCarveoutPlanMember" xlink:label="nmra_BlackthornCarveoutPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_CaseTwoMember" xlink:label="nmra_CaseTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ContingentConsiderationMilestonePayment" xlink:label="nmra_ContingentConsiderationMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_DevelopmentMilestonesMember" xlink:label="nmra_DevelopmentMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_NavacaprantMember" xlink:label="nmra_NavacaprantMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SyllableMergerAgreementMember" xlink:label="nmra_SyllableMergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_MilestonePaymentDueDescription" xlink:label="nmra_MilestonePaymentDueDescription"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SalesBasedMilestonesMember" xlink:label="nmra_SalesBasedMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_Nmra511Member" xlink:label="nmra_Nmra511Member"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AlairionMergerAgreementMember" xlink:label="nmra_AlairionMergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ContingentConsiderationMilestonePaymentSettledInCash" xlink:label="nmra_ContingentConsiderationMilestonePaymentSettledInCash"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AchievementOfSpecifiedDevelopmentEventsMember" xlink:label="nmra_AchievementOfSpecifiedDevelopmentEventsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SyllableLifeSciencesIncMember" xlink:label="nmra_SyllableLifeSciencesIncMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AlairionCarveoutPlanMember" xlink:label="nmra_AlairionCarveoutPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_NumberOfMilestoneAchieved" xlink:label="nmra_NumberOfMilestoneAchieved"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AchievementOfSpecifiedCommercializationEventsMember" xlink:label="nmra_AchievementOfSpecifiedCommercializationEventsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AlairionIncMember" xlink:label="nmra_AlairionIncMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AmgenIncLicensesMember" xlink:label="nmra_AmgenIncLicensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_CommercialMilestonePaymentMember" xlink:label="nmra_CommercialMilestonePaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AmgenIncMember" xlink:label="nmra_AmgenIncMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_VanderbiltLicenseMember" xlink:label="nmra_VanderbiltLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_VanderbiltIprDAssetsMember" xlink:label="nmra_VanderbiltIprDAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_NumberOfLicenseAgreements" xlink:label="nmra_NumberOfLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_UpfrontConsiderationTransferredShares" xlink:label="nmra_UpfrontConsiderationTransferredShares"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AcquisitionDateFairValueOfSharesTransferred" xlink:label="nmra_AcquisitionDateFairValueOfSharesTransferred"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_UpfrontCashPayment" xlink:label="nmra_UpfrontCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AcquiredInProcessResearchAndDevelopment" xlink:label="nmra_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet" xlink:label="nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AcquiredInProcessResearchAndDevelopedExpense" xlink:label="nmra_AcquiredInProcessResearchAndDevelopedExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_BlackthornMergerAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nmra_SeriesA2ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nmra_CaseOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nmra_DevelopmentAndRegulatoryApprovalMilestonesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="nmra_BlackthornTherapeuticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_BlackthornCarveoutPlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nmra_CaseTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_ContingentConsiderationMilestonePayment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nmra_DevelopmentMilestonesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="nmra_NavacaprantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_SyllableMergerAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_MilestonePaymentDueDescription" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nmra_SalesBasedMilestonesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="nmra_Nmra511Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_AlairionMergerAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_ContingentConsiderationMilestonePaymentSettledInCash" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nmra_AchievementOfSpecifiedDevelopmentEventsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="nmra_SyllableLifeSciencesIncMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_AlairionCarveoutPlanMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_NumberOfMilestoneAchieved" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nmra_AchievementOfSpecifiedCommercializationEventsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="nmra_AlairionIncMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_AmgenIncLicensesMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ProductOrServiceAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nmra_CommercialMilestonePaymentMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="nmra_AmgenIncMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_VanderbiltLicenseMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="nmra_VanderbiltIprDAssetsMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_NumberOfLicenseAgreements" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_UpfrontConsiderationTransferredShares" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_AcquisitionDateFairValueOfSharesTransferred" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_UpfrontCashPayment" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_AcquiredInProcessResearchAndDevelopment" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_AcquiredInProcessResearchAndDevelopedExpense" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_TwoThousandAndFifteenTsriLicenseAgreementMember" xlink:label="nmra_TwoThousandAndFifteenTsriLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_DevelopmentAndRegulatoryMilestonePayments" xlink:label="nmra_DevelopmentAndRegulatoryMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AmgenResearchAndCollaborationAgreementMember" xlink:label="nmra_AmgenResearchAndCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_CommercialMilestonePayments" xlink:label="nmra_CommercialMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_VanderbiltSponsoredResearchAgreementMember" xlink:label="nmra_VanderbiltSponsoredResearchAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_MilestonesAchieved" xlink:label="nmra_MilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ParkinsonsResearchVenturesFundingAgreementMember" xlink:label="nmra_ParkinsonsResearchVenturesFundingAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_MilestonePayments" xlink:label="nmra_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_CollaborationAgreementTerm" xlink:label="nmra_CollaborationAgreementTerm"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_CollaborationAgreementTerminationDescription" xlink:label="nmra_CollaborationAgreementTerminationDescription"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_CollaborationAgreementNonRefundableQuarterlyPayments" xlink:label="nmra_CollaborationAgreementNonRefundableQuarterlyPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ResearchAndCollaborationAgreementQuarterlyPayments" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPayments"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ResearchAgreementExpiryDate" xlink:label="nmra_ResearchAgreementExpiryDate"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities" xlink:label="nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_FundsReceivedUponExecutionOfAgreement" xlink:label="nmra_FundsReceivedUponExecutionOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PaymentsForExecutionOfAgreement" xlink:label="nmra_PaymentsForExecutionOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone" xlink:label="nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_MaximumRepaymentAmountAgreedToPay" xlink:label="nmra_MaximumRepaymentAmountAgreedToPay"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_TwoThousandAndFifteenTsriLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_DevelopmentAndRegulatoryMilestonePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccountsPayableMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_AmgenResearchAndCollaborationAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_CommercialMilestonePayments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_VanderbiltSponsoredResearchAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_MilestonesAchieved" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_ParkinsonsResearchVenturesFundingAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_MilestonePayments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_CollaborationAgreementTerm" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_CollaborationAgreementTerminationDescription" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_CollaborationAgreementNonRefundableQuarterlyPayments" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_ResearchAndCollaborationAgreementQuarterlyPayments" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_ResearchAgreementExpiryDate" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_FundsReceivedUponExecutionOfAgreement" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_PaymentsForExecutionOfAgreement" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_MaximumRepaymentAmountAgreedToPay" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AmgenResearchAndCollaborationAgreementMember" xlink:label="nmra_AmgenResearchAndCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ServiceConditionsMember" xlink:label="nmra_ServiceConditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_BlackthornMergerAgreementMember" xlink:label="nmra_BlackthornMergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PerformanceConditionsMember" xlink:label="nmra_PerformanceConditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AdditionalSharesOfCapitalStockMember" xlink:label="nmra_AdditionalSharesOfCapitalStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_MaximumAdditionalFinancingInEquitySecurities" xlink:label="nmra_MaximumAdditionalFinancingInEquitySecurities"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SharesIssuedUponAchievementOfMilestone" xlink:label="nmra_SharesIssuedUponAchievementOfMilestone"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_MilestonesAchieved" xlink:label="nmra_MilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_AmgenResearchAndCollaborationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="nmra_ServiceConditionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_BlackthornMergerAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_VestingAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="nmra_PerformanceConditionsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="nmra_AdditionalSharesOfCapitalStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nmra_MaximumAdditionalFinancingInEquitySecurities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nmra_SharesIssuedUponAchievementOfMilestone" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nmra_MilestonesAchieved" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember" xlink:label="nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SharesReservedForIssuanceUnderThePlansMember" xlink:label="nmra_SharesReservedForIssuanceUnderThePlansMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SharesReservedForFutureIssuanceUnderThePlansMember" xlink:label="nmra_SharesReservedForFutureIssuanceUnderThePlansMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_SharesReservedForIssuanceUnderThePlansMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_SharesReservedForFutureIssuanceUnderThePlansMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="nmra_TwoThousandTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AdvisorsMember" xlink:label="nmra_AdvisorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="nmra_TwoThousandTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_RestrictedCommonStockMember" xlink:label="nmra_RestrictedCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember" xlink:label="nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ShareBasedCompensationAwardTrancheFourMember" xlink:label="nmra_ShareBasedCompensationAwardTrancheFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_EarlyExerciseOfEmployeeStockOptionsMember" xlink:label="nmra_EarlyExerciseOfEmployeeStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_MarketAwardMember" xlink:label="nmra_MarketAwardMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AwardsWithPerformanceConditionsMember" xlink:label="nmra_AwardsWithPerformanceConditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AwardModificationMember" xlink:label="nmra_AwardModificationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_StockPurchaseRightMember" xlink:label="nmra_StockPurchaseRightMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ServicesAgreementMember" xlink:label="nmra_ServicesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PerformanceRestrictedStockMember" xlink:label="nmra_PerformanceRestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ExecutiveOfficerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="nmra_TwoThousandTwentyThreeEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="nmra_AdvisorsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="nmra_TwoThousandTwentyEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="nmra_RestrictedCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="nmra_ShareBasedCompensationAwardTrancheFourMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_EarlyExerciseOfEmployeeStockOptionsMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_MarketAwardMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_AwardsWithPerformanceConditionsMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_AwardModificationMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_StockPurchaseRightMember" order="8.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_ServicesAgreementMember" order="9.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="10.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_PerformanceRestrictedStockMember" order="11.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockOptionMember" order="12.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="13.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_EffectiveIncomeTaxRateReconciliationMilestonePaymentsPercent" xlink:label="nmra_EffectiveIncomeTaxRateReconciliationMilestonePaymentsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_EffectiveIncomeTaxRateReconciliationStateRateAdjustments" xlink:label="nmra_EffectiveIncomeTaxRateReconciliationStateRateAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions" xlink:label="nmra_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="nmra_EffectiveIncomeTaxRateReconciliationMilestonePaymentsPercent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="nmra_EffectiveIncomeTaxRateReconciliationStateRateAdjustments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="nmra_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="nmra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_DeferredTaxAssetsInCapitalizedLicenseAgreements" xlink:label="nmra_DeferredTaxAssetsInCapitalizedLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="nmra_DeferredTaxAssetsOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="nmra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="nmra_DeferredTaxAssetsInCapitalizedLicenseAgreements" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="nmra_DeferredTaxAssetsOperatingLeaseLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_DeferredTaxAssetsTaxCreditCarryforwardsTable" xlink:label="nmra_DeferredTaxAssetsTaxCreditCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_DeferredTaxAssetsTaxCreditCarryforwardsLineItems" xlink:label="nmra_DeferredTaxAssetsTaxCreditCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_FederalPostDecember312017Member" xlink:label="nmra_FederalPostDecember312017Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_FederalPreJanuary12018Member" xlink:label="nmra_FederalPreJanuary12018Member"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_MassachusettsMember" xlink:label="nmra_MassachusettsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_DeferredTaxAssetsTaxCreditCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_DeferredTaxAssetsTaxCreditCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="nmra_FederalPostDecember312017Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_CaliforniaFranchiseTaxBoardMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:to="nmra_DeferredTaxAssetsTaxCreditCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_DeferredTaxAssetsTaxCreditCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_DeferredTaxAssetsTaxCreditCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="nmra_FederalPreJanuary12018Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="nmra_MassachusettsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_DeferredTaxAssetsTaxCreditCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_DeferredTaxAssetsTaxCreditCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_DeferredTaxAssetsTaxCreditCarryforwardsTable" xlink:to="nmra_DeferredTaxAssetsTaxCreditCarryforwardsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_DeferredTaxAssetsTaxCreditCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_DeferredTaxAssetsTaxCreditCarryforwardsTable" xlink:label="nmra_DeferredTaxAssetsTaxCreditCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_DeferredTaxAssetsTaxCreditCarryforwardsLineItems" xlink:label="nmra_DeferredTaxAssetsTaxCreditCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PercentageOfFutureTaxableIncomeOffsettingByNol" xlink:label="nmra_PercentageOfFutureTaxableIncomeOffsettingByNol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_DeferredTaxAssetsTaxCreditCarryforwardsTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_DeferredTaxAssetsTaxCreditCarryforwardsLineItems" xlink:to="nmra_PercentageOfFutureTaxableIncomeOffsettingByNol" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:to="nmra_DeferredTaxAssetsTaxCreditCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_DeferredTaxAssetsTaxCreditCarryforwardsTable" xlink:to="nmra_DeferredTaxAssetsTaxCreditCarryforwardsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PreferredStockWarrantsMember" xlink:label="nmra_PreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember" xlink:label="nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember" xlink:label="nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember" xlink:label="nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember" xlink:label="nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="nmra_PreferredStockWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AmgenResearchAndCollaborationAgreementMember" xlink:label="nmra_AmgenResearchAndCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SeriesBConvertiblePreferredStockMember" xlink:label="nmra_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SeriesA1ConvertiblePreferredStockMember" xlink:label="nmra_SeriesA1ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PreferredStockWarrantsHeldByRelatedParty" xlink:label="nmra_PreferredStockWarrantsHeldByRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PreferredStockExercisePricePerShare" xlink:label="nmra_PreferredStockExercisePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_RelatedPartyTransactionObligationWithRelatedParty" xlink:label="nmra_RelatedPartyTransactionObligationWithRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_MaximumAdditionalFinancingInEquitySecurities" xlink:label="nmra_MaximumAdditionalFinancingInEquitySecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_AmgenResearchAndCollaborationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nmra_SeriesBConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nmra_SeriesA1ConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nmra_PreferredStockWarrantsHeldByRelatedParty" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nmra_PreferredStockExercisePricePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nmra_RelatedPartyTransactionObligationWithRelatedParty" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nmra_MaximumAdditionalFinancingInEquitySecurities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_RepurchaseOfUnvestedEarlyExercisedStockOptions" xlink:label="nmra_RepurchaseOfUnvestedEarlyExercisedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nmra_RepurchaseOfUnvestedEarlyExercisedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ScheduleOfOrganizationAndLiquidityTable" xlink:label="nmra_ScheduleOfOrganizationAndLiquidityTable"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_OrganizationAndLiquidityLineItems" xlink:label="nmra_OrganizationAndLiquidityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms" xlink:label="nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_LiquidityMember" xlink:label="nmra_LiquidityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_UnderwritingDiscountsAndCommissions" xlink:label="nmra_UnderwritingDiscountsAndCommissions"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_OfferingExpenses" xlink:label="nmra_OfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="nmra_ScheduleOfOrganizationAndLiquidityTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nmra_ScheduleOfOrganizationAndLiquidityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="nmra_OrganizationAndLiquidityLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nmra_LiquidityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nmra_ScheduleOfOrganizationAndLiquidityTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="nmra_UnderwritingDiscountsAndCommissions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="nmra_OfferingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_MarketableSecuritiesMember" xlink:label="nmra_MarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="nmra_MarketableSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PrepaidResearchAndDevelopmentCosts" xlink:label="nmra_PrepaidResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nmra_PrepaidResearchAndDevelopmentCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_BlackthornMergerAgreementMember" xlink:label="nmra_BlackthornMergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SeriesA2ConvertiblePreferredStockMember" xlink:label="nmra_SeriesA2ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_CaseOneMember" xlink:label="nmra_CaseOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_DevelopmentAndRegulatoryApprovalMilestonesMember" xlink:label="nmra_DevelopmentAndRegulatoryApprovalMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_BlackthornTherapeuticsIncMember" xlink:label="nmra_BlackthornTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_BlackthornCarveoutPlanMember" xlink:label="nmra_BlackthornCarveoutPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_CaseTwoMember" xlink:label="nmra_CaseTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ContingentConsiderationMilestonePayment" xlink:label="nmra_ContingentConsiderationMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_DevelopmentMilestonesMember" xlink:label="nmra_DevelopmentMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_NavacaprantMember" xlink:label="nmra_NavacaprantMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SyllableMergerAgreementMember" xlink:label="nmra_SyllableMergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_MilestonePaymentDueDescription" xlink:label="nmra_MilestonePaymentDueDescription"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SalesBasedMilestonesMember" xlink:label="nmra_SalesBasedMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_Nmra511Member" xlink:label="nmra_Nmra511Member"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AlairionMergerAgreementMember" xlink:label="nmra_AlairionMergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ContingentConsiderationMilestonePaymentSettledInCash" xlink:label="nmra_ContingentConsiderationMilestonePaymentSettledInCash"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AchievementOfSpecifiedDevelopmentEventsMember" xlink:label="nmra_AchievementOfSpecifiedDevelopmentEventsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SyllableLifeSciencesIncMember" xlink:label="nmra_SyllableLifeSciencesIncMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AlairionCarveoutPlanMember" xlink:label="nmra_AlairionCarveoutPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_NumberOfMilestoneAchieved" xlink:label="nmra_NumberOfMilestoneAchieved"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AchievementOfSpecifiedCommercializationEventsMember" xlink:label="nmra_AchievementOfSpecifiedCommercializationEventsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AlairionIncMember" xlink:label="nmra_AlairionIncMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AmgenIncLicensesMember" xlink:label="nmra_AmgenIncLicensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_CommercialMilestonePaymentMember" xlink:label="nmra_CommercialMilestonePaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AmgenIncMember" xlink:label="nmra_AmgenIncMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_VanderbiltLicenseMember" xlink:label="nmra_VanderbiltLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_VanderbiltIprDAssetsMember" xlink:label="nmra_VanderbiltIprDAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_NumberOfLicenseAgreements" xlink:label="nmra_NumberOfLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_UpfrontConsiderationTransferredShares" xlink:label="nmra_UpfrontConsiderationTransferredShares"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AcquisitionDateFairValueOfSharesTransferred" xlink:label="nmra_AcquisitionDateFairValueOfSharesTransferred"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_UpfrontCashPayment" xlink:label="nmra_UpfrontCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AcquiredInProcessResearchAndDevelopment" xlink:label="nmra_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet" xlink:label="nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AcquiredInProcessResearchAndDevelopedExpense" xlink:label="nmra_AcquiredInProcessResearchAndDevelopedExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_BlackthornMergerAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nmra_SeriesA2ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nmra_CaseOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nmra_DevelopmentAndRegulatoryApprovalMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="nmra_BlackthornTherapeuticsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_BlackthornCarveoutPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nmra_CaseTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_ContingentConsiderationMilestonePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nmra_DevelopmentMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="nmra_NavacaprantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_SyllableMergerAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_MilestonePaymentDueDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nmra_SalesBasedMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="nmra_Nmra511Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_AlairionMergerAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_ContingentConsiderationMilestonePaymentSettledInCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nmra_AchievementOfSpecifiedDevelopmentEventsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="nmra_SyllableLifeSciencesIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_AlairionCarveoutPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_NumberOfMilestoneAchieved" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nmra_AchievementOfSpecifiedCommercializationEventsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="nmra_AlairionIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_AmgenIncLicensesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nmra_CommercialMilestonePaymentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="nmra_AmgenIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_VanderbiltLicenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="nmra_VanderbiltIprDAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_NumberOfLicenseAgreements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_UpfrontConsiderationTransferredShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_AcquisitionDateFairValueOfSharesTransferred" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_UpfrontCashPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_AcquiredInProcessResearchAndDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_AcquiredInProcessResearchAndDevelopedExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_TwoThousandAndFifteenTsriLicenseAgreementMember" xlink:label="nmra_TwoThousandAndFifteenTsriLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_DevelopmentAndRegulatoryMilestonePayments" xlink:label="nmra_DevelopmentAndRegulatoryMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AmgenResearchAndCollaborationAgreementMember" xlink:label="nmra_AmgenResearchAndCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_CommercialMilestonePayments" xlink:label="nmra_CommercialMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_VanderbiltSponsoredResearchAgreementMember" xlink:label="nmra_VanderbiltSponsoredResearchAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_MilestonesAchieved" xlink:label="nmra_MilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ParkinsonsResearchVenturesFundingAgreementMember" xlink:label="nmra_ParkinsonsResearchVenturesFundingAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_MilestonePayments" xlink:label="nmra_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_CollaborationAgreementTerm" xlink:label="nmra_CollaborationAgreementTerm"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_CollaborationAgreementTerminationDescription" xlink:label="nmra_CollaborationAgreementTerminationDescription"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_CollaborationAgreementNonRefundableQuarterlyPayments" xlink:label="nmra_CollaborationAgreementNonRefundableQuarterlyPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ResearchAndCollaborationAgreementQuarterlyPayments" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPayments"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ResearchAgreementExpiryDate" xlink:label="nmra_ResearchAgreementExpiryDate"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities" xlink:label="nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_FundsReceivedUponExecutionOfAgreement" xlink:label="nmra_FundsReceivedUponExecutionOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PaymentsForExecutionOfAgreement" xlink:label="nmra_PaymentsForExecutionOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone" xlink:label="nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_MaximumRepaymentAmountAgreedToPay" xlink:label="nmra_MaximumRepaymentAmountAgreedToPay"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_TwoThousandAndFifteenTsriLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_DevelopmentAndRegulatoryMilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccountsPayableMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_AmgenResearchAndCollaborationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_CommercialMilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_VanderbiltSponsoredResearchAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_MilestonesAchieved" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_ParkinsonsResearchVenturesFundingAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_MilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_CollaborationAgreementTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_CollaborationAgreementTerminationDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_CollaborationAgreementNonRefundableQuarterlyPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_ResearchAndCollaborationAgreementQuarterlyPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_ResearchAgreementExpiryDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_FundsReceivedUponExecutionOfAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_PaymentsForExecutionOfAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_MaximumRepaymentAmountAgreedToPay" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AmgenResearchAndCollaborationAgreementMember" xlink:label="nmra_AmgenResearchAndCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ServiceConditionsMember" xlink:label="nmra_ServiceConditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_BlackthornMergerAgreementMember" xlink:label="nmra_BlackthornMergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PerformanceConditionsMember" xlink:label="nmra_PerformanceConditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AdditionalSharesOfCapitalStockMember" xlink:label="nmra_AdditionalSharesOfCapitalStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_MaximumAdditionalFinancingInEquitySecurities" xlink:label="nmra_MaximumAdditionalFinancingInEquitySecurities"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SharesIssuedUponAchievementOfMilestone" xlink:label="nmra_SharesIssuedUponAchievementOfMilestone"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_MilestonesAchieved" xlink:label="nmra_MilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_AmgenResearchAndCollaborationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="nmra_ServiceConditionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_BlackthornMergerAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="nmra_PerformanceConditionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="nmra_AdditionalSharesOfCapitalStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nmra_MaximumAdditionalFinancingInEquitySecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nmra_SharesIssuedUponAchievementOfMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nmra_MilestonesAchieved" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember" xlink:label="nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SharesReservedForIssuanceUnderThePlansMember" xlink:label="nmra_SharesReservedForIssuanceUnderThePlansMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SharesReservedForFutureIssuanceUnderThePlansMember" xlink:label="nmra_SharesReservedForFutureIssuanceUnderThePlansMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_SharesReservedForIssuanceUnderThePlansMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_SharesReservedForFutureIssuanceUnderThePlansMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="nmra_TwoThousandTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_EarlyExerciseOfEmployeeStockOptionsMember" xlink:label="nmra_EarlyExerciseOfEmployeeStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AdvisorsMember" xlink:label="nmra_AdvisorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="nmra_TwoThousandTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_RestrictedCommonStockMember" xlink:label="nmra_RestrictedCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_MarketAwardMember" xlink:label="nmra_MarketAwardMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember" xlink:label="nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AwardsWithPerformanceConditionsMember" xlink:label="nmra_AwardsWithPerformanceConditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ShareBasedCompensationAwardTrancheFourMember" xlink:label="nmra_ShareBasedCompensationAwardTrancheFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AwardModificationMember" xlink:label="nmra_AwardModificationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_StockPurchaseRightMember" xlink:label="nmra_StockPurchaseRightMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ServicesAgreementMember" xlink:label="nmra_ServicesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PerformanceRestrictedStockMember" xlink:label="nmra_PerformanceRestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ExecutiveOfficerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nmra_TwoThousandTwentyThreeEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_EarlyExerciseOfEmployeeStockOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="nmra_AdvisorsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nmra_TwoThousandTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="nmra_RestrictedCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_MarketAwardMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_AwardsWithPerformanceConditionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="nmra_ShareBasedCompensationAwardTrancheFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_AwardModificationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_StockPurchaseRightMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_ServicesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_PerformanceRestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsDetails">
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_DeferredTaxAssetsTaxCreditCarryforwardsLineItems" xlink:label="nmra_DeferredTaxAssetsTaxCreditCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_DeferredTaxAssetsTaxCreditCarryforwardsTable" xlink:label="nmra_DeferredTaxAssetsTaxCreditCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_FederalPostDecember312017Member" xlink:label="nmra_FederalPostDecember312017Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_FederalPreJanuary12018Member" xlink:label="nmra_FederalPreJanuary12018Member"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_MassachusettsMember" xlink:label="nmra_MassachusettsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nmra_DeferredTaxAssetsTaxCreditCarryforwardsLineItems" xlink:to="nmra_DeferredTaxAssetsTaxCreditCarryforwardsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nmra_DeferredTaxAssetsTaxCreditCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_DeferredTaxAssetsTaxCreditCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="nmra_FederalPostDecember312017Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_CaliforniaFranchiseTaxBoardMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nmra_DeferredTaxAssetsTaxCreditCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_DeferredTaxAssetsTaxCreditCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="nmra_FederalPreJanuary12018Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="nmra_MassachusettsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nmra_DeferredTaxAssetsTaxCreditCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_DeferredTaxAssetsTaxCreditCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_DeferredTaxAssetsTaxCreditCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_DeferredTaxAssetsTaxCreditCarryforwardsLineItems" xlink:label="nmra_DeferredTaxAssetsTaxCreditCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_DeferredTaxAssetsTaxCreditCarryforwardsTable" xlink:label="nmra_DeferredTaxAssetsTaxCreditCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PercentageOfFutureTaxableIncomeOffsettingByNol" xlink:label="nmra_PercentageOfFutureTaxableIncomeOffsettingByNol"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nmra_DeferredTaxAssetsTaxCreditCarryforwardsLineItems" xlink:to="nmra_DeferredTaxAssetsTaxCreditCarryforwardsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nmra_DeferredTaxAssetsTaxCreditCarryforwardsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_DeferredTaxAssetsTaxCreditCarryforwardsLineItems" xlink:to="nmra_PercentageOfFutureTaxableIncomeOffsettingByNol" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PreferredStockWarrantsMember" xlink:label="nmra_PreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember" xlink:label="nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember" xlink:label="nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember" xlink:label="nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember" xlink:label="nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="nmra_PreferredStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AmgenResearchAndCollaborationAgreementMember" xlink:label="nmra_AmgenResearchAndCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SeriesBConvertiblePreferredStockMember" xlink:label="nmra_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_SeriesA1ConvertiblePreferredStockMember" xlink:label="nmra_SeriesA1ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PreferredStockWarrantsHeldByRelatedParty" xlink:label="nmra_PreferredStockWarrantsHeldByRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PreferredStockExercisePricePerShare" xlink:label="nmra_PreferredStockExercisePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_RelatedPartyTransactionObligationWithRelatedParty" xlink:label="nmra_RelatedPartyTransactionObligationWithRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_MaximumAdditionalFinancingInEquitySecurities" xlink:label="nmra_MaximumAdditionalFinancingInEquitySecurities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_AmgenResearchAndCollaborationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nmra_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nmra_SeriesA1ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nmra_PreferredStockWarrantsHeldByRelatedParty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nmra_PreferredStockExercisePricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nmra_RelatedPartyTransactionObligationWithRelatedParty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nmra_MaximumAdditionalFinancingInEquitySecurities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="nmra_EarlyExerciseLiabilityNetOfCurrentPortion" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="nmra_EarlyExerciseLiabilityCurrentPortion" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_EarlyExerciseLiabilityNetOfCurrentPortion" xlink:label="nmra_EarlyExerciseLiabilityNetOfCurrentPortion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_EarlyExerciseLiabilityCurrentPortion" xlink:label="nmra_EarlyExerciseLiabilityCurrentPortion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="nmra_AcquiredInProcessResearchAndDevelopment" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AcquiredInProcessResearchAndDevelopment" xlink:label="nmra_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nmra_NoncashOperatingLeaseExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="nmra_RepurchaseOfUnvestedEarlyExercisedShares" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnInvestments" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InvestmentIncomeAmortizationOfDiscount" order="13" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="14" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_NoncashOperatingLeaseExpense" xlink:label="nmra_NoncashOperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_RepurchaseOfUnvestedEarlyExercisedShares" xlink:label="nmra_RepurchaseOfUnvestedEarlyExercisedShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:label="us-gaap_InvestmentIncomeAmortizationOfDiscount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesByContractualMaturityDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue" xlink:to="nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue" xlink:label="nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="nmra_PrepaidResearchAndDevelopmentCosts" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_PrepaidResearchAndDevelopmentCosts" xlink:label="nmra_PrepaidResearchAndDevelopmentCosts"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="nmra_AccruedClinicalTrialAndPreclinicalCosts" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="nmra_AccruedResearchAndDevelopmentServices" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AccruedClinicalTrialAndPreclinicalCosts" xlink:label="nmra_AccruedClinicalTrialAndPreclinicalCosts"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_AccruedResearchAndDevelopmentServices" xlink:label="nmra_AccruedResearchAndDevelopmentServices"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="nmra_EffectiveIncomeTaxRateReconciliationMilestonePaymentsPercent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="nmra_EffectiveIncomeTaxRateReconciliationStateRateAdjustments" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="nmra_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="8" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_EffectiveIncomeTaxRateReconciliationMilestonePaymentsPercent" xlink:label="nmra_EffectiveIncomeTaxRateReconciliationMilestonePaymentsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_EffectiveIncomeTaxRateReconciliationStateRateAdjustments" xlink:label="nmra_EffectiveIncomeTaxRateReconciliationStateRateAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions" xlink:label="nmra_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="nmra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="nmra_DeferredTaxAssetsInCapitalizedLicenseAgreements" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="nmra_DeferredTaxAssetsOperatingLeaseLiabilities" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="nmra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_DeferredTaxAssetsInCapitalizedLicenseAgreements" xlink:label="nmra_DeferredTaxAssetsInCapitalizedLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20240331.xsd#nmra_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="nmra_DeferredTaxAssetsOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="nmra_SupplementalInformationOnTheCompanysOperatingLeasesTableTextBlock" name="SupplementalInformationOnTheCompanysOperatingLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_ResearchAndCollaborationAgreementQuarterlyPayments" name="ResearchAndCollaborationAgreementQuarterlyPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_AdditionalSharesOfCapitalStockMember" name="AdditionalSharesOfCapitalStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_SharesIssuedUponAchievementOfMilestone" name="SharesIssuedUponAchievementOfMilestone" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember" name="EarlyExercisedStockOptionsSubjectToFutureVestingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_LiquidityMember" name="LiquidityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_Nmra511Member" name="Nmra511Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears" name="ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_SharesReservedForFutureIssuanceUnderThePlansMember" name="SharesReservedForFutureIssuanceUnderThePlansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_CollaborationAgreementTerm" name="CollaborationAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_DeferredTaxAssetsInCapitalizedLicenseAgreements" name="DeferredTaxAssetsInCapitalizedLicenseAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_SeriesA1ConvertiblePreferredStockMember" name="SeriesA1ConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_PreferredStockWarrantsHeldByRelatedParty" name="PreferredStockWarrantsHeldByRelatedParty" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="nmra_VanderbiltLicenseMember" name="VanderbiltLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_AchievementOfSpecifiedCommercializationEventsMember" name="AchievementOfSpecifiedCommercializationEventsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_MarketAwardMember" name="MarketAwardMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_RestrictedCommonStockMember" name="RestrictedCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_AccruedResearchAndDevelopmentServicesDueToRelatedParty" name="AccruedResearchAndDevelopmentServicesDueToRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_CommercialMilestonePayments" name="CommercialMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_AchievementOfSpecifiedDevelopmentEventsMember" name="AchievementOfSpecifiedDevelopmentEventsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_VanderbiltIprDAssetsMember" name="VanderbiltIprDAssetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_DeferredTaxAssetsOperatingLeaseLiabilities" name="DeferredTaxAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_EffectiveIncomeTaxRateReconciliationStateRateAdjustments" name="EffectiveIncomeTaxRateReconciliationStateRateAdjustments" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_MassachusettsMember" name="MassachusettsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_DeferredTaxAssetsTaxCreditCarryforwardsLineItems" name="DeferredTaxAssetsTaxCreditCarryforwardsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear" name="ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_PreferredStockExercisePricePerShare" name="PreferredStockExercisePricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="nmra_RelatedPartyTransactionObligationWithRelatedParty" name="RelatedPartyTransactionObligationWithRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_EarlyExerciseOfEmployeeStockOptionsMember" name="EarlyExerciseOfEmployeeStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_MaximumRepaymentAmountAgreedToPay" name="MaximumRepaymentAmountAgreedToPay" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_TwoThousandTwentyEquityIncentivePlanMember" name="TwoThousandTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_UnderwritingDiscountsAndCommissions" name="UnderwritingDiscountsAndCommissions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_TwoThousandAndFifteenTsriLicenseAgreementMember" name="TwoThousandAndFifteenTsriLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_EmergingGrowthCompanyStatusPolicyTextBlock" name="EmergingGrowthCompanyStatusPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_AwardModificationMember" name="AwardModificationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_AcquisitionDateFairValueOfSharesTransferred" name="AcquisitionDateFairValueOfSharesTransferred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_ResearchAgreementExpiryDate" name="ResearchAgreementExpiryDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_DeferredTaxAssetsTaxCreditCarryforwardsTable" name="DeferredTaxAssetsTaxCreditCarryforwardsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember" name="PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_UpfrontConsiderationTransferredShares" name="UpfrontConsiderationTransferredShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_MaximumAdditionalFinancingInEquitySecurities" name="MaximumAdditionalFinancingInEquitySecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_AlairionMergerAgreementMember" name="AlairionMergerAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_PaymentsForExecutionOfAgreement" name="PaymentsForExecutionOfAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_AwardsWithPerformanceConditionsMember" name="AwardsWithPerformanceConditionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_AlairionCarveoutPlanMember" name="AlairionCarveoutPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_PercentageOfFutureTaxableIncomeOffsettingByNol" name="PercentageOfFutureTaxableIncomeOffsettingByNol" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_DeferredOfferingCostsPolicyTextBlock" name="DeferredOfferingCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_PerformanceRestrictedStockMember" name="PerformanceRestrictedStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_AccruedResearchAndDevelopmentServices" name="AccruedResearchAndDevelopmentServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_ParkinsonsResearchVenturesFundingAgreementMember" name="ParkinsonsResearchVenturesFundingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_RisksAndUncertaintiesPolicyTextBlock" name="RisksAndUncertaintiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_MilestonesAchieved" name="MilestonesAchieved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_UpfrontCashPayment" name="UpfrontCashPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_CashEquivalentsAndMarketableSecuritiesAbstract" name="CashEquivalentsAndMarketableSecuritiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_ContingentConsiderationMilestonePaymentSettledInCash" name="ContingentConsiderationMilestonePaymentSettledInCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_BlackthornCarveoutPlanMember" name="BlackthornCarveoutPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_RepurchaseOfUnvestedEarlyExercisedShares" name="RepurchaseOfUnvestedEarlyExercisedShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_FederalPostDecember312017Member" name="FederalPostDecember312017Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_DevelopmentAndRegulatoryApprovalMilestonesMember" name="DevelopmentAndRegulatoryApprovalMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_SummaryOfFairValueOfStockOptionsTableTextBlock" name="SummaryOfFairValueOfStockOptionsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_SalesBasedMilestonesMember" name="SalesBasedMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_NumberOfMilestoneAchieved" name="NumberOfMilestoneAchieved" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_EarlyExerciseLiabilityNetOfCurrentPortion" name="EarlyExerciseLiabilityNetOfCurrentPortion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_AdvisorsMember" name="AdvisorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_NavacaprantMember" name="NavacaprantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_SyllableLifeSciencesIncMember" name="SyllableLifeSciencesIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_ServicesAgreementMember" name="ServicesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember" name="SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_AmgenResearchAndCollaborationAgreementMember" name="AmgenResearchAndCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_BlackthornMergerAgreementMember" name="BlackthornMergerAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_OfferingExpenses" name="OfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_PreferredStockWarrantsMember" name="PreferredStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_TwoThousandTwentyThreeEquityIncentivePlanMember" name="TwoThousandTwentyThreeEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_MilestonePayments" name="MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_CollaborationAgreementTerminationDescription" name="CollaborationAgreementTerminationDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_RepurchaseOfUnvestedEarlyExercisedStockOptions" name="RepurchaseOfUnvestedEarlyExercisedStockOptions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_EffectiveIncomeTaxRateReconciliationMilestonePaymentsPercent" name="EffectiveIncomeTaxRateReconciliationMilestonePaymentsPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_ServiceConditionsMember" name="ServiceConditionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_AmgenIncMember" name="AmgenIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_SharesReservedForIssuanceUnderThePlansMember" name="SharesReservedForIssuanceUnderThePlansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_ContingentConsiderationMilestonePayment" name="ContingentConsiderationMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember" name="EmployeeStockOptionAndAndRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_VanderbiltSponsoredResearchAgreementMember" name="VanderbiltSponsoredResearchAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_CaseOneMember" name="CaseOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_AcquiredInProcessResearchAndDevelopedExpense" name="AcquiredInProcessResearchAndDevelopedExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_AcquiredInProcessResearchAndDevelopment" name="AcquiredInProcessResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_ConvertiblePreferredStockPolicyPolicyTextBlock" name="ConvertiblePreferredStockPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_FederalPreJanuary12018Member" name="FederalPreJanuary12018Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms" name="NumberOfClinicalAndPreclinicalNeurosciencePrograms" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="nmra_DevelopmentMilestonesMember" name="DevelopmentMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_CaseTwoMember" name="CaseTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_NumberOfLicenseAgreements" name="NumberOfLicenseAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_PerformanceConditionsMember" name="PerformanceConditionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_DevelopmentAndRegulatoryMilestonePayments" name="DevelopmentAndRegulatoryMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_MarketableSecuritiesMember" name="MarketableSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_CollaborationAgreementNonRefundableQuarterlyPayments" name="CollaborationAgreementNonRefundableQuarterlyPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_AmgenIncLicensesMember" name="AmgenIncLicensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet" name="SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities" name="FundsProvidedForPreClinicalResearchAndDevelopmentActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_StockPurchaseRightMember" name="StockPurchaseRightMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_PrepaidResearchAndDevelopmentCosts" name="PrepaidResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_MilestonePaymentDueDescription" name="MilestonePaymentDueDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember" name="PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" name="ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone" name="FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_EarlyExerciseLiabilityCurrentPortion" name="EarlyExerciseLiabilityCurrentPortion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_ShareBasedCompensationAwardTrancheFourMember" name="ShareBasedCompensationAwardTrancheFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_ScheduleOfOrganizationAndLiquidityTable" name="ScheduleOfOrganizationAndLiquidityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_BlackthornTherapeuticsIncMember" name="BlackthornTherapeuticsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_OrganizationAndLiquidityLineItems" name="OrganizationAndLiquidityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_NoncashOperatingLeaseExpense" name="NoncashOperatingLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember" name="TwoThousandTwentyThreeEmployeeSharePurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions" name="EffectiveIncomeTaxRateReconciliationUncertainTaxPositions" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_AlairionIncMember" name="AlairionIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue" name="EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_SyllableMergerAgreementMember" name="SyllableMergerAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock" name="UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_CommercialMilestonePaymentMember" name="CommercialMilestonePaymentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_AccruedClinicalTrialAndPreclinicalCosts" name="AccruedClinicalTrialAndPreclinicalCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_SeriesA2ConvertiblePreferredStockMember" name="SeriesA2ConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_FundsReceivedUponExecutionOfAgreement" name="FundsReceivedUponExecutionOfAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687690926016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>May 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001885522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEUMORA THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-41802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-4367680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">490 Arsenal Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Watertown<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">760-0900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NMRA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,523,997<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687600344256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 182,927<span></span>
</td>
<td class="nump">$ 374,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term marketable securities</a></td>
<td class="nump">239,788<span></span>
</td>
<td class="nump">79,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">20,070<span></span>
</td>
<td class="nump">24,297<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">442,785<span></span>
</td>
<td class="nump">478,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable securities</a></td>
<td class="nump">302<span></span>
</td>
<td class="nump">9,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,635<span></span>
</td>
<td class="nump">1,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">4,276<span></span>
</td>
<td class="nump">5,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">450,211<span></span>
</td>
<td class="nump">496,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,492<span></span>
</td>
<td class="nump">337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">19,493<span></span>
</td>
<td class="nump">21,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_EarlyExerciseLiabilityCurrentPortion', window );">Early exercise liability, current portion</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">3,491<span></span>
</td>
<td class="nump">3,378<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">24,609<span></span>
</td>
<td class="nump">25,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">938<span></span>
</td>
<td class="nump">1,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_EarlyExerciseLiabilityNetOfCurrentPortion', window );">Early exercise liability, net of current portion</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">25,669<span></span>
</td>
<td class="nump">27,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,181,829<span></span>
</td>
<td class="nump">1,172,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(148)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(757,155)<span></span>
</td>
<td class="num">(703,434)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">424,542<span></span>
</td>
<td class="nump">469,076<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 450,211<span></span>
</td>
<td class="nump">$ 496,195<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_EarlyExerciseLiabilityCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Early exercise liability, current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_EarlyExerciseLiabilityCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_EarlyExerciseLiabilityNetOfCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Early exercise liability, net of current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_EarlyExerciseLiabilityNetOfCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687682457888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 45,757<span></span>
</td>
<td class="nump">$ 29,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">14,317<span></span>
</td>
<td class="nump">9,683<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">60,074<span></span>
</td>
<td class="nump">39,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(60,074)<span></span>
</td>
<td class="num">(39,168)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">6,365<span></span>
</td>
<td class="nump">3,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">6,353<span></span>
</td>
<td class="nump">3,543<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(53,721)<span></span>
</td>
<td class="num">(35,625)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(72)<span></span>
</td>
<td class="nump">476<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (53,793)<span></span>
</td>
<td class="num">$ (35,149)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (1.22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (1.22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding, basic</a></td>
<td class="nump">157,943<span></span>
</td>
<td class="nump">29,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding, diluted</a></td>
<td class="nump">157,943<span></span>
</td>
<td class="nump">29,277<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687597859920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Beginning at Dec. 31, 2022</a></td>
<td class="num">$ (446,850)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 21,430<span></span>
</td>
<td class="num">$ (774)<span></span>
</td>
<td class="num">$ (467,509)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at Beginning at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 843,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at Beginning (in Shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance at Beginning (in Shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_RepurchaseOfUnvestedEarlyExercisedStockOptions', window );">Repurchase of unvested early exercised stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted common stock</a></td>
<td class="nump">1,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">2,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(35,625)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,625)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Ending at Mar. 31, 2023</a></td>
<td class="num">(477,920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">25,509<span></span>
</td>
<td class="num">(298)<span></span>
</td>
<td class="num">(503,134)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at Ending at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 843,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at Ending (in Shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance at Ending (in Shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Beginning at Dec. 31, 2023</a></td>
<td class="nump">469,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">1,172,570<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="num">(703,434)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at Beginning (in Shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">1,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted common stock</a></td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(72)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">7,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(53,721)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53,721)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Ending at Mar. 31, 2024</a></td>
<td class="nump">$ 424,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 1,181,829<span></span>
</td>
<td class="num">$ (148)<span></span>
</td>
<td class="num">$ (757,155)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at Ending (in Shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_RepurchaseOfUnvestedEarlyExercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repurchase of unvested early exercised stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_RepurchaseOfUnvestedEarlyExercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687599639120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (53,721)<span></span>
</td>
<td class="num">$ (35,625)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">7,373<span></span>
</td>
<td class="nump">2,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_NoncashOperatingLeaseExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">791<span></span>
</td>
<td class="nump">799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeAmortizationOfDiscount', window );">Net accretion of investments in marketable securities</a></td>
<td class="num">(1,147)<span></span>
</td>
<td class="num">(892)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other noncash expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">7,351<span></span>
</td>
<td class="nump">7,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,155<span></span>
</td>
<td class="num">(6,012)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(4,113)<span></span>
</td>
<td class="num">(736)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(802)<span></span>
</td>
<td class="num">(801)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(42,955)<span></span>
</td>
<td class="num">(33,041)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(185,804)<span></span>
</td>
<td class="num">(41,483)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">36,578<span></span>
</td>
<td class="nump">44,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Cash paid for acquisition of assets</a></td>
<td class="num">(775)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(150,001)<span></span>
</td>
<td class="nump">2,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">1,845<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_RepurchaseOfUnvestedEarlyExercisedShares', window );">Repurchase of unvested early exercised shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(491)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments for deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,845<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents and restricted cash</a></td>
<td class="num">(191,111)<span></span>
</td>
<td class="num">(30,123)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents and restricted cash at beginning of year</a></td>
<td class="nump">375,251<span></span>
</td>
<td class="nump">242,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents and restricted cash at end of year</a></td>
<td class="nump">184,140<span></span>
</td>
<td class="nump">212,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract', window );"><strong>Components of cash and restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">182,927<span></span>
</td>
<td class="nump">210,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Total cash and cash equivalents and restricted cash</a></td>
<td class="nump">$ 184,140<span></span>
</td>
<td class="nump">$ 212,083<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_NoncashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_NoncashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_RepurchaseOfUnvestedEarlyExercisedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repurchase of unvested early exercised shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_RepurchaseOfUnvestedEarlyExercisedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeAmortizationOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion of purchase discount on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeAmortizationOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687599399792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Liquidity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Liquidity</a></td>
<td class="text"><p id="organization_and_liquidity" style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.	</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Organization and Liquidity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Description of Business</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Neumora Therapeutics, Inc. (the Company), was originally incorporated in the State of Delaware in November 2019, and is headquartered in Watertown, Massachusetts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. The Company&#8217;s therapeutic pipeline currently consists of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">seven</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, the Company has devoted a significant portion of its financial resources and efforts to building its organization, acquiring technologies and companies, executing clinical and preclinical studies, conducting research and development, identifying and developing potential product candidates, building its precision neuroscience tools, organizing and staffing the Company, business planning, establishing, maintaining and protecting its intellectual property portfolio, raising capital and providing general and administrative support for these operations. The Company has not generated revenue from the sale of products.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s most advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of major depressive disorder (MDD) and other neuropsychiatric diseases. In 2023, the Company initiated a Phase 3 program called the KOASTAL program evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company anticipates releasing topline results from the KOASTAL-1 study in the fourth quarter of 2024 and topline results from the KOASTAL-2 and KOASTAL-3 studies in the first half of 2025. We also expect to initiate a Phase 2 study for navacaprant in bipolar depression in the second quarter of 2024 and anticipate releasing results from that study in 2025.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reverse Stock Split</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 8, 2023, the Company&#8217;s board of directors approved an amended and restated certificate of incorporation to effect a reverse split of shares of the Company&#8217;s common stock and convertible preferred stock on a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_fc1674b5-31ae-4580-a05a-09485f8e145a;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7.8463</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-for-1</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> basis (the &#8220;Reverse Stock Split&#8221;). The par value and authorized shares of the common stock and convertible preferred stock were not adjusted as a result of the Reverse Stock Split. All share data and per share data amounts for all periods presented in the condensed consolidated financial statements and notes thereto have been retrospectively adjusted to reflect the effect of the Reverse Stock Split.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Initial Public Offering</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 19, 2023, the Company completed its initial public offering (IPO), pursuant to which it issued and sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14,710,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock at a price to the public of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, resulting in net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">226.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, after deducting underwriting discounts and commissions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and other offering expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Upon the closing of the IPO, the Company&#8217;s outstanding convertible preferred stock automatically converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">104,417,415</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock (see Note 9).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the completion of its IPO, on September 19, 2023, the Company&#8217;s certificate of incorporation was amended and restated to authorize </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">700,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of preferred stock, par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has incurred net losses and negative cash flows from operations since inception and as of March 31, 2024, had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">757.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. As of March 31, 2024, the Company had cash, cash equivalents and marketable securities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">423.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which are available to fund future operations. The Company believes that its existing cash, cash equivalents and marketable securities as of March 31, 2024 will be sufficient to support operations for at least the next 12 months from the date these condensed consolidated financial statements are issued.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company expects to incur additional losses in the future as it continues its research and development efforts, advances its product candidates through preclinical and clinical development, enhances its precision</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">neuroscience approach and programs, expands its product pipeline, seeks regulatory approval, prepares for commercialization, as well as hires additional personnel, protects its intellectual property and grows its business. The Company will need to raise additional capital to support its continuing operations and pursue its long-term business plan, including to complete the development and commercialization of its product candidates, if approved. Such activities are subject to significant risks and uncertainties, including clinical failure which can impact the Company&#8217;s ability to secure additional funding. The Company expects to finance its cash needs through a combination of public or private equity offerings or debt financings or other capital sources, which may include strategic collaborations or other arrangements with third parties, or other sources of financing. However, there is no guarantee that any of these financing or opportunities will be executed or realized on favorable terms, if at all, and some could be dilutive to existing stockholders.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687599138928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies and Basis of Presentation</a></td>
<td class="text"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.	Summary of Significant Accounting Policies and Basis of Presentation</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis of Presentation and Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting. The condensed consolidated financial statements include all accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unaudited Interim Condensed Consolidated Financial Statements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The condensed consolidated balance sheet as of March 31, 2024, condensed consolidated statements of operations and comprehensive loss, statement of stockholders&#8217; equity (deficit), and the condensed consolidated statements of cash flows</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the three months ended March 31, 2024 and 2023, and related notes to condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for the fair statement of the Company&#8217;s consolidated financial position, results of operations and cash flows for the periods presented. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2023 included herein was derived from the audited consolidated financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements as of and for the year ended December 31, 2023 included in the Company&#8217;s Annual Form 10-K.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. These estimates form the basis for judgments the Company makes about the carrying values of assets and liabilities that are not readily apparent from other sources. The Company bases its estimates and judgments on historical experience and on various other assumptions that the Company believes are reasonable under the circumstances. These estimates are based on management&#8217;s knowledge about current events and expectations about actions the Company may undertake in the future. These judgments, estimates and assumptions are used for, but not limited to, accrued research and development expenses, accounting for acquisitions of assets, fair value of certain assets and liabilities, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the fair value of the Company&#8217;s convertible preferred stock, the fair value of the Company&#8217;s common stock,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock-based compensation, the measurement of right-of-use assets and lease liabilities and related incremental borrowing rate, and uncertain tax positions and the valuation allowance for net deferred tax assets. Actual results may differ from the Company&#8217;s estimates.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks and Uncertainties</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to certain risks and uncertainties, including, but not limited to, changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: successfully develop, manufacture, and market any approved products; obtain regulatory approval from the U.S. Food and Drug Administration or foreign regulatory agencies prior to commercial sales; new technological innovations; dependence on key personnel, protection of intellectual property; compliance with governmental regulations; uncertainty of market acceptance of any approved products; product liability; and the need to obtain additional financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Marketable Securities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company invests its excess cash in marketable debt securities with high credit ratings including but not limited to money market funds, securities issued by the U.S. government and its agencies, commercial paper, certificates of deposit, and corporate debt securities that are accounted for as available-for-sale and carried at fair value. Marketable securities are classified as short-term or long-term based on the maturity date and their availability to meet current operating requirements. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income in the condensed consolidated statements of operations and comprehensive loss. Realized gains and losses on marketable securities, if any, are included in other income (expense), net. The cost of securities sold is determined based on the trade date using the specific identification method.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company periodically assesses its available-for-sale debt securities for impairment. For debt securities in an unrealized loss position, this assessment first considers the Company&#8217;s intent to sell, or whether it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of these criteria are met, the debt security&#8217;s amortized cost basis is written down to fair value within other income (expense), net. For debt securities in an unrealized loss position that do not meet the aforementioned criteria, the Company assesses whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and any adverse conditions specifically related to the security is considered, among other factors. If this assessment indicates that a credit loss may exist, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses will be recorded in other income (expense), net, limited by the amount that the fair value is less than the amortized cost basis. Any additional impairment not recorded through an allowance for credit losses is recognized in other comprehensive income (loss). Changes in the allowance for credit losses are recorded as provision for (or reversal of) credit loss expense. Losses are charged against the allowance when management believes the un-collectability of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met. These changes are recorded in other income (expense), net.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The Company measures fair value by maximizing the use of observable inputs, where available, and minimizing the use of unobservable inputs when measuring fair value. Financial assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized in the fair value hierarchy based upon the lowest level of input that is significant to the fair value as follows:</span></p><p style="margin-left:36pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></p><p style="margin-left:36pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2&#8212;Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></p><p style="margin-left:36pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value of the instrument.</span></p></div><div style="font-size:11pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and Development Expenses and Related Prepaid Assets and Accrued Liabilities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development expenses primarily consist of internal research and development expense, including personnel-related expenses (such as salaries, benefits and noncash stock-based compensation) and other expenses, including laboratory supplies and other non-capital equipment utilized for in-house research, research and consulting expenses, software development costs, license fees and allocated expenses, including facilities costs and depreciation and amortization; external research and development expenses incurred under arrangements with vendors conducting research and development services on its behalf, such as contract research organizations (CROs), preclinical testing organizations and contract manufacturing organizations (CMOs). Costs to develop the Company&#8217;s platform information technologies are recorded as research and development expense unless the criteria to be capitalized as internal-use software costs is met. Payments made prior to the receipt of goods or services to be used in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">research and development are capitalized, evaluated for current or long-term classification, and included in prepaid expenses and other current assets or other assets in the condensed consolidated balance sheets based on when the goods are received or the services are expected to be received or consumed, and recognized in research and development expenses when they are realized.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is required to estimate expenses resulting from its obligations under contracts with vendors, service providers and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in cash flows that do not match the periods over which materials or services are provided. The Company estimates and records accrued expenses for the related research and development activities based on the level of services performed but not yet invoiced pursuant to agreements established with its service providers, according to the progress of preclinical studies, clinical trials or related activities, and discussions with applicable personnel and service providers as to the progress or state of consummation of goods and services.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the course of a clinical trial, the rate of expense recognition is adjusted if actual results differ from the Company&#8217;s estimates. The Company estimates accrued expenses as of each balance sheet date in its condensed consolidated financial statements based on the facts and circumstances known at that time. The clinical trial accrual is dependent in part upon the timely and accurate reporting of CROs, CMOs and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its estimate may vary from the actual results. To date, the Company has not experienced material differences between its accrued expenses and actual expenses.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss includes net loss and certain changes in stockholders&#8217; equity (deficit) that are excluded from net loss, such as unrealized losses on the Company&#8217;s available-for-sale marketable securities.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging Growth Company Status</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent Accounting Pronouncements Not Yet Adopted</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(ASU 2023-09), which requires issuers to make additional discloses on an annual basis related to specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis, disclose additional information about income taxes paid as well as other disaggregated disclosures. ASU 2023-09 will be effective for the Company as of January 1, 2025 for annual periods. The Company is evaluating the impact of this ASU on its condensed consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (ASU 2023-07), which requires issuers to make additional disclosures with respect to segment expenses, including required disclosure on an annual and interim basis for significant segment expenses and other segment items. ASU 2023-07 also permits the disclosure of more than one measure of a segment&#8217;s profit or loss. ASU 2023-07 will be effective for the Company as of January 1, 2024 for annual periods and as of January 1, 2025 for interim periods. The Company is evaluating the impact of this ASU on its condensed consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687596168240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_CashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash Equivalents and Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash Equivalents and Marketable Securities</a></td>
<td class="text"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.	Cash Equivalents and Marketable Securities</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables summarize the amortized cost and fair value of the Company&#8217;s cash equivalents and marketable securities by major investment category for the periods indicated:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.38%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gain</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Loss</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">142,817</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">142,817</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">142,817</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">142,817</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69,612</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69,577</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificates of deposit</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,669</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,671</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency debt securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122,660</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122,552</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,297</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,290</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total marketable securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">240,238</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">157</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">240,090</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents and marketable securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">383,055</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">157</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">382,907</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.38%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gain</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Loss</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">306,801</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">306,801</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,455</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,461</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency debt securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,998</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,992</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">362,254</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">362,254</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47,534</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47,547</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency debt securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,515</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,424</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,816</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,818</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total marketable securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,865</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,789</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents and marketable securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">452,119</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">452,043</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s marketable securities by contractual maturity were (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:76.28%;"></td>
         <td style="width:2%;"></td>
         <td style="width:1%;"></td>
         <td style="width:19.72%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Within one year</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">239,788</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">After one year through two years</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">302</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total marketable securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">240,090</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, the Company has not realized any material gains or losses on its marketable securities, including any impairment charges on its securities related to expected credit losses. As of March 31, 2024, the aggregate difference between the amortized cost and fair value of each security in an unrealized loss position was de minimis. Since any provision for expected credit losses for a security held is limited to the amount the fair value is less than its amortized cost, no allowance for expected credit loss was deemed necessary at March 31, 2024 (see Note 4).</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_CashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_CashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687596335152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4.	Fair Value Measurements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The carrying amounts of the Company&#8217;s financial instruments, including prepaid expenses and other current assets, accounts payable, accrued liabilities and the current portion of operating lease liabilities approximate fair value due to the short-term nature of those instruments.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables summarize the Company&#8217;s assets and liabilities measured at fair value on a recurring basis by level within the valuation hierarchy:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.38%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">142,817</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">142,817</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69,577</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69,577</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificates of deposit</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,671</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,671</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency debt securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">115,062</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,490</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122,552</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,290</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,290</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at fair value</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">257,879</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">125,028</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">382,907</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.38%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">306,801</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">306,801</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90,008</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90,008</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency debt securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,473</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,943</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,416</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,818</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,818</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at fair value</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">326,274</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">125,769</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">452,043</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds are highly liquid and actively traded marketable securities that generally transact at a stable $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> net asset value representing its estimated fair value. The Company estimates the fair value of its commercial paper, certificates of deposit, U.S. government and agency debt securities, and corporate debt securities by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data, and other observable inputs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//820/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687599634736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5.	Balance Sheet Components</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid Expenses and Other Current Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:60.692%;"></td>
         <td style="width:1.2%;"></td>
         <td style="width:1%;"></td>
         <td style="width:15.603%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.7%;"></td>
         <td style="width:1%;"></td>
         <td style="width:16.802999999999997%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31,</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid research and development costs ($</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.4</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;million and $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><br/>&#160;&#160;&#160;&#160;million from related party in 2024 and 2023, respectively)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,603</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,085</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid other</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,561</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,273</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other receivables</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">906</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">939</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,070</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,297</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued Liabilities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued liabilities consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:63.473%;"></td>
         <td style="width:1.86%;"></td>
         <td style="width:1%;"></td>
         <td style="width:13.943%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.7%;"></td>
         <td style="width:1%;"></td>
         <td style="width:15.023%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31,</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Compensation and benefits</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,660</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,011</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued research and development services ($</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;million and $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;<br/>&#160;&#160;&#160;&#160;&#160;million due to related party in 2024 and 2023, respectively)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,442</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,004</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional services</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">926</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">787</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued clinical trial and preclinical costs</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,923</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,705</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">542</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">750</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued liabilities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,493</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,257</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687596335152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions of Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions of Assets</a></td>
<td class="text"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6.	Acquisitions of Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BlackThorn Therapeutics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2020, the Company entered into an agreement and plan of merger (BlackThorn Merger Agreement) to acquire all of the equity interests of BlackThorn Therapeutics, Inc. (BlackThorn), which became effective in September 2020. The Company acquired BlackThorn for its in-process research and development programs, including an antagonist of the kappa opioid veceptor (navacaprant (NMRA-140)) for the treatment of major depressive disorders and an antagonist of the vasopressin 1a veceptor (NMRA-511) for the treatment of agitation in Alzheimer's disease. The Company also gained access to a cloud-based computational psychiatry and data platform that was being developed to support drug target identification, patient stratification and objective clinical trial endpoints. Both navacaprant and NMRA-511 were exclusively licensed to BlackThorn by The Scripps Research Institute (TSRI). The acquisition was accounted for as an acquisition of assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The BlackThorn Merger Agreement requires the Company to pay the former stockholders of BlackThorn contingent consideration (i) with respect to navacaprant, in the form of development and regulatory approval milestones of up to an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">365.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which includes a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">milestone payment that became due in October 2023 upon dosing the first patient in the Phase 3 clinical trial for navacaprant,</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and sales-based milestones of up to an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">450.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and (ii) with respect to NMRA-511, in the form of development and regulatory approval milestones of up to an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and sales-based milestones of up to an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (BlackThorn Milestones). At the Company&#8217;s sole discretion, the BlackThorn Milestone payments may be settled in cash or shares of the Company, or a combination of both, subject to the provisions of the BlackThorn Merger Agreement, other than one development milestone in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which must be settled in cash. None of the BlackThorn Milestones were subject to liability classification and/or derivative accounting and any such contingent consideration will be recognized when the contingency is resolved, and the consideration becomes payable. The Company settled the Phase 3 navacaprant dosing milestone in December 2023 by issuing </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,072,445</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock based on the volume weighted average price per share prior to the date the milestone was met and paying cash of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to the former stockholders of BlackThorn and participants in the carveout plan (discussed </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">below). As a result, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">60.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in acquired in-process research and developed expenses in the fourth quarter of 2023 related to the BlackThorn Milestones. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ne of the other Blackthorn Milestones have been achieved and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> such amounts were deemed due or payable as of March 31, 2024.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">BlackThorn Carveout Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The BlackThorn Merger Agreement required that the Company establish a carveout plan (the BlackThorn Carveout Plan), pursuant to which each BlackThorn stock option holder as of immediately prior to the closing date was allocated a certain number of units (the BlackThorn Carveout Units) based on the number of shares underlying the outstanding options held by each participant at that time. Each BlackThorn Carveout Unit represents a right to receive a portion of the BlackThorn Milestone payment (the BlackThorn Carveout Payments) upon the later of (i) the achievement of a BlackThorn Milestone and (ii) the vesting of the BlackThorn Carveout Unit.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The BlackThorn Carveout Units vest based on time-based schedules that mirror the vesting schedules for the original option awards held by each participant. As of the closing date in September 2020, a portion of the BlackThorn Carveout Units corresponding to the pre-acquisition service periods were fully vested (Vested Carveout Units). The remainder of the BlackThorn Carveout Units vest subject to the continued service of the participants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Vested Carveout Units represent contingent consideration for the acquisition as they are attributable to pre-acquisition services rendered by the participants and continuing service is not required for the participants to receive future payments upon a BlackThorn Milestone being achieved. The Company recognizes the contingent consideration obligation for the Vested Carveout Units when the contingency is resolved, and the consideration becomes payable. The BlackThorn Carveout Units that were unvested as of the closing date are dependent on the continued service of participants and were deemed to be a compensation arrangement. The Company recognizes compensation starting from the time payment becomes probable over each participant&#8217;s service period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company settled the Phase 3 navacaprant dosing milestone in December 2023. The Company recognized contingent consideration related to Vested Carveout Units, which was included in acquired in-process research and developed expenses in the fourth quarter of 2023 related to the BlackThorn Milestones as described above. In addition, the Company recognized and paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in compensation related to the BlackThorn Carveout Units that were a compensatory arrangement in 2023. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ne of the other BlackThorn Milestones had been achieved and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> such amounts were deemed due or payable as of March 31, 2024.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Syllable Life Sciences, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2020, the</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company entered into an agreement and plan of merger (Syllable Merger Agreement) to acquire all of the outstanding equity of Syllable Life Sciences, Inc. (Syllable). The Company acquired Syllable to gain access the rights granted to Syllable under an exclusive license agreement (as amended, the Harvard License Agreement) with President and Fellows of Harvard College (Harvard) and an associated behavior analysis machine learning and computer vision software tool which Syllable was developing to identify and quantify behavior as an indicator of neurological conditions. The transaction was accounted for as an acquisition of assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The former stockholders of Syllable are entitled to contingent consideration in the form of development milestones of up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (Syllable Milestones). At the Company&#8217;s sole discretion, the Syllable Milestone payments may be settled, in cash or shares equity of the Company, or a combination of both, subject to the provisions of the Syllable Merger Agreement and were not subject to liability classification and/or derivative accounting. Any such contingent consideration will be recognized when the contingency is resolved, and the consideration becomes payable. As of March 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ne of the Syllable Milestones had been achieved and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> such amounts were deemed due or payable.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Alairion, Inc.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2020, the Company entered into an agreement and plan of merger (Alairion Merger Agreement) to acquire all of the outstanding equity of Alairion, Inc. (Alairion). The acquisition of Alairion allowed the Company to expand its program pipeline by gaining rights to two preclinical stage research and development programs focused on the treatment of sleep disorders, an H1 receptor antagonist program (the H1 Program) and a GABA receptor positive allosteric modulator program (the GABA Program). The acquisition also provided the Company with access to a license for software that records sleep and related drug discovery and optimization technology platform. The transaction was accounted for as an acquisition of assets.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The holders of Alairion common stock outstanding as of immediately prior to the closing date received non-transferable rights to future milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">33.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon the achievement of specified development events and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">135.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon the achievement of specified commercialization events related to the H1 Program and the GABA Program (the Alairion Milestones).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Alairion Milestone payments may be settled, at the Company&#8217;s sole discretion, in cash or shares of the Company, or a combination of both, subject to the provisions of the Alairion Merger Agreement. None of the Alairion Milestones were subject to liability classification and/or derivative accounting and any such contingent consideration will be recognized when the contingency is resolved, and the consideration becomes payable. As of March 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ne of the Alairion Milestones have been recognized. In March 2022, the Company paused the active program acquired from Alairion while it assesses pre-IND feedback received from the FDA and continues to consider alternative options for that program.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amgen Inc. Licenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2021, the Company entered into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> license agreements with Amgen Inc. (Amgen) pursuant to which it obtained exclusive, worldwide licenses to develop, manufacture, use, commercialize and distribute products containing compounds that are directed to, in one case, CK1&#948;, and in the other case, glucocerebrosidase (GCase), both for the treatment of neurodegenerative diseases (the Amgen License Agreements) and related know-how and clinical material (collectively, the Amgen IPR&amp;D Assets). The Company accounted for these transactions as acquisitions of assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Concurrently, the Company also executed a research collaboration agreement as well as a stock purchase agreement with Amgen. Both agreements were deemed to be separate transactions and not accounted for as part of the acquisition of assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total upfront consideration transferred to Amgen of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares of the Company's Series A-2 convertible preferred stock, with an acquisition date fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">157.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was allocated to the Amgen IPR&amp;D Assets and expensed in 2021.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under these </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> license agreements, Amgen is eligible to receive contingent consideration up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">360.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in commercial milestone payments per product payable in cash with a compound directed to CK1&#948; and up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">360.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in commercial milestone payments per product payable in cash with a compound directed to GCase, in each case, upon the achievement of certain sales thresholds and single digit royalties on potential future net sales, related to CK1&#948; or GCase (the Amgen Milestones). Such contingent consideration was not subject to liability classification and/or derivative accounting and will be recognized when the contingency is resolved, and the consideration becomes payable. As of March 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ne of the Amgen Milestones had been achieved and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> such amounts were deemed due or payable.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, until a specified period of time following the achievement of the first successful Phase 2 clinical trial for any licensed product, if the Company chooses to sell, transfer, sublicense or divest rights to a licensed product in certain major markets, Amgen has a period of time to enter into an agreement with the Company for such rights. The Company determined that these rights of first negotiation were not freestanding instruments from the Amgen License Agreements and did not meet the definition of a derivative.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Vanderbilt License</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2022, the Company and Vanderbilt University (Vanderbilt) entered into a license agreement (Vanderbilt License Agreement). Pursuant to the Vanderbilt License Agreement, as amended, the Company obtained an exclusive, worldwide royalty-bearing, sublicensable (subject to certain restrictions) license under certain patent rights and a non-exclusive, worldwide, royalty-bearing, sublicensable (subject to certain restrictions) license under certain know-how covering small molecule positive allosteric modulators (PAMs) predominantly of the muscarinic acetylcholine receptor subtype 4 (M4) to develop, manufacture, and commercialize products, processes and services covered by such patent rights or that incorporate or use such know-how, for any and uses (the Vanderbilt IPR&amp;D Assets). Concurrently, the Company also executed a sponsored research agreement (see Note 8) with Vanderbilt. The sponsored research agreement was deemed to be a separate transaction and not accounted for as part of the acquisition of assets. The acquisition of Vanderbilt IPR&amp;D Assets became effective in February 2022.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The licensed patent rights are subject to Vanderbilt&#8217;s right to use the patent rights for research, internal non-commercial use, and educational purposes. The Company intends to develop the PAMs for the treatment of schizophrenia and other neuropsychiatric disorders. The Company has agreed to use commercially reasonable efforts to develop and commercialize licensed products, and to achieve certain development milestones.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company paid Vanderbilt a non-refundable, non-creditable upfront cash payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the Vanderbilt IPR&amp;D Assets, which was immediately recognized as acquired in-process research and development expense in the condensed consolidated statement of operations and comprehensive loss as it was determined to have no alternative future use as of the acquisition date. Under the Vanderbilt License Agreement, Vanderbilt is eligible to receive contingent consideration payable in cash up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">42.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon the achievement of specified development milestones and up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">380.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon the achievement of commercial milestone events as well as tiered royalties at mid-single digit percentages on potential future net sales, subject to specified reductions for the lack of patent coverage, generic entry and payment obligations for third-party licenses (the Vanderbilt Milestones). In addition, the Company is obligated to pay Vanderbilt low-double-digit percentage of sublicense income it receives for sublicenses entered into before the achievement of a specified event. Such contingent consideration was not subject to liability classification and/or derivative accounting and will be recognized when the contingency is resolved, and the consideration becomes payable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> In October 2023, a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million Vanderbilt Milestone was achieved and settled in cash in November 2023 and was recognized in acquired in-process research and developed expenses in the fourth quarter of 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ne of the other Vanderbilt Milestones had been achieved and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> such amounts were deemed due or payable as of March 31, 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the Company also had an exclusive option, exercisable for a specified period of time, to negotiate an exclusive license to certain patent rights conceived or developed by Vanderbilt in the course of carrying out the sponsored research pursuant to a sponsored research agreement the between the Company and Vanderbilt, which was entered into at the same time as the Vanderbilt License Agreement. The Company determined that the right to negotiate was not a freestanding instrument from the Vanderbilt License Agreement and did not meet the definition of a derivativ</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e. The Company exercised the above disclosed exclusive option and the parties executed an agreement in December 2023 pursuant to which the Company licensed certain patent rights in return for a payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million that was recognized in acquired in-process research and developed expenses in the fourth quarter of 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687596409856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7.	Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indemnification</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors&#8217; and officers&#8217; insurance.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other Commitments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has various manufacturing, clinical, research and other contracts with vendors in the conduct of the normal course of its business. Such contracts are generally terminable with advanced written notice and payment for any products or services received by the Company through the effective time of termination and any non-cancelable and non-refundable obligations incurred by the vendor at the effective time of the termination. In the case of terminating a clinical trial agreement at a particular site, the Company would also be obligated to provide continued support for appropriate medical procedures at that site until completion or termination.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687596241648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Strategic License and Research and Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Strategic License and Research and Collaboration Agreements</a></td>
<td class="text"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8.	Strategic License and Research and Collaboration Agreements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2015 TSRI License Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the acquisition of BlackThorn (see Note 6), the Company gained certain exclusive rights to intellectual property related to Kappa Opioid Receptor and V1aR Receptor Antagonist programs as well as an oxytocin receptors positive allosteric modulator program (collectively, the TSRI Programs) under a license agreement between BlackThorn and TSRI originally entered into in November 2015 (as amended, the 2015 TSRI License Agreement). The technology licensed under the 2015 TSRI License Agreement is used in the Company&#8217;s navacaprant and NMRA-511 research and development programs.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:18pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the 2015 TSRI License Agreement, the Company is obligated, among other things, to pay TSRI (i) a nominal annual license fee due and payable on the first day of each calendar year and after the fourth anniversary creditable against any royalties due for such calendar year, (ii) development and regulatory milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in aggregate for the first product from each TSRI Program, which are contingent upon achieving specific development and regulatory milestone events, (iii) commercial milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in aggregate for each occurrence, which are contingent upon achieving specified commercialization milestone events, (iv) tiered low-single digit royalties on future net sales of each royalty-bearing product and (v) a percentage ranging from the mid-single digits to sub teen double digits of any sublicensing revenues the Company receives. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2023, the Phase 3 navacaprant dosing milestone was met and the Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to TSRI, which was recognized in acquired in-process research and developed expenses in the fourth quarter of 2023. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ne of the other milestones have</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> been achieved and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> royalties were due under the 2015 TSRI License Agreement as of March 31, 2024.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Collaboration Agreement with Amgen</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2021, and concurrently with the Amgen License Agreements (see Note 6), the Company entered into a research collaboration agreement with Amgen (Amgen Collaboration Agreement) to collectively discover drug targets, biomarkers, and other insights associated with central nervous system (CNS) diseases utilizing Amgen&#8217;s deCODE genetics and human data research capabilities. The Company received exclusive rights under intellectual property generated in the collaboration to exploit therapeutic compounds and diagnostics for use with therapeutics in the CNS field and Amgen received exclusive rights to exploit therapeutic</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compounds and diagnostics for use with therapeutics outside of the CNS field. The agreement is governed by the Joint Research Committee (JRC), which is made up of equal representatives from each of the Company and Amgen to manage the progress and direction of research and development activities. All decisions made by the JRC shall be by consensus with each party having one vote, and if the JRC cannot reach a consensus, the dispute shall be referred to each company&#8217;s executive officers. If the executive officers fail to reach a consensus, the Company will have final decision-making authority provided that the matter does not relate to the approval of, or any material change to, a project, decisions to acquire rights from a third party, decisions or activities that are in conflict with Amgen&#8217;s database usage or data access rights, or the approval of external costs and expenses relating to certain new data generation activities or certain new dataset acquisitions, as such matters require mutual agreement.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In return for Amgen performing research and development activities under the agreement, the Company is committed to making non-refundable, non-creditable quarterly payments over the first two years totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and for the third year $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Additionally, the Company will reimburse Amgen for certain direct, out-of-pocket external costs and expenses that are incurred in the performance of the activities under the Amgen Collaboration Agreement.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term of the agreement is up to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, although it will terminate after three years if the Company and Amgen do not mutually agree upon a compensation structure for years four and five. If the parties do not reach an agreement at least 30 days prior to the end of year three, the Amgen Collaboration Agreement will automatically terminate upon its third anniversary. Further, either party can terminate the Amgen Collaboration Agreement upon material uncured breach or bankruptcy by the other party, in which case all amounts that have become due through the date of termination are non-refundable.</span></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:18pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amgen also has an exclusive option to negotiate, and the right of first negotiation, to obtain exclusive, worldwide licenses to research, develop, commercialize, and otherwise exploit up to two therapeutic compounds or any pharmaceutical product containing such therapeutic compound arising from the collaboration. That right exists with respect to each compound for a certain period of time following positive Phase 2 results for that compound. The Company determined that these rights were not freestanding instruments from the Amgen Collaboration Agreement and did not meet the definition of a derivative. Upon execution of the Amgen Collaboration Agreement in September 2021, the Company was obligated to start paying Amgen non-refundable quarterly payments. As of March 31, 2024 and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> December 31, 2023, the related prepaid research and development costs included in the condensed consolidated balance sheets were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, within prepaid expenses and other current assets. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> research and development expense was incurred during the three months ended March 31, 2024. The Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of related research and development expenses during the three months ended March 31, 2023.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sponsored Research Agreement with Vanderbilt</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2022, concurrently with the Vanderbilt License Agreement (see Note 6), the Company entered into a sponsored research agreement with Vanderbilt (Vanderbilt Research Agreement), pursuant to which Vanderbilt agreed to provide the Company research services to develop a M4 PAM back-up program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In return for Vanderbilt performing research and development activities under the agreement, the Company agreed to make quarterly payments for research up to a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million on an annual basis. The term of the agreement ended in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In addition, the Company also had an exclusive option to negotiate an exclusive license to certain patent rights conceived or developed by Vanderbilt in the course of carrying out the sponsored research (see Note 6).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Parkinson's Research Ventures Funding Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2024, the Company entered into a research funding agreement with Parkinson's Research Ventures Limited (PRV), pursuant to which PRV agreed to provide the Company funding up to a total of &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in two tranches to carry out preclinical research and development activities related to the Company&#8217;s NLPR3 program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The first tranche of &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was due upon execution of the agreement and was received in March 2024, for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company is eligible to receive the second tranche of &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon the completion of certain development milestones. The Company concluded the funding arrangement was an obligation to perform services and the funding received is recognized as a contra-R&amp;D expense as project costs are incurred. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> costs were incurred during the three months ended March 31, 2024. Upon achievement of certain development, regulatory or commercial trigger events, the Company agreed to pay PRV in aggregate an amount equal to no more than four times the funding provided by PRV i.e., a maximum repayment amount of up to &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The trigger event payments meet the derivative scope exception under Accounting Standards Codification (ASC) 815 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivatives and Hedging,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and therefore do not need to be bifurcated and separately accounted for.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687599399792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9.	Stockholders&#8217; Equity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preferred Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subsequent to the IPO, the Company's board of directors has the authority to issue up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of preferred stock in one or more series with rights, preferences and privileges to be determined. There are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of preferred stock issued and outstanding as of March 31, 2024.</span></p><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stock outstanding in the condensed consolidated balance sheet and condensed consolidated statement of stockholders&#8217; equity as of March 31, 2024 includes </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">447,931</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of restricted stock that vest based on service conditions and are subject to the Company&#8217;s right of repurchase upon termination of services and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">637,240</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of restricted stock that vest based on performance conditions (see Note 10). </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stock reserved for future issuance consisted of the following:</span></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:78.02%;"></td>
         <td style="width:1.7%;"></td>
         <td style="width:1%;"></td>
         <td style="width:18.28%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares reserved for options and restricted stock units issued under the plans</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,084</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares reserved for future issuance under the plans</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,965</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,049</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the Company may be required to issue additional shares of its capital stock if certain milestone conditions are met pursuant to the contingent consideration associated with the Company&#8217;s acquisitions of assets (see Note 6). In December 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,072,445</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock were issued related to BlackThorn Merger Agreement upon achievement of the Phase 3 navacaprant dosing milestone that was met in October 2023. As of March 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares have been reserved for potential future issuances as no other BlackThorn Milestones have been achieved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687596382416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10.	Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 Equity Incentive Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2023, the Company adopted the 2023 Equity Incentive Plan (the 2023 Plan) that became effective in connection with the Company&#8217;s IPO. The 2023 Plan provides for the grant of stock options, restricted stock awards, restricted stock unit awards, and other stock-based awards to employees, directors, and non-employee service providers of the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Awards granted under the 2023 Plan expire no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of grant. The price of stock options shall not be less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the estimated fair value on the date of grant and typically vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period although may be granted with different vesting terms. The 2023 Plan initially reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">16,373,061</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock for the issuance of future awards and provides for an automatic annual increase in the number of shares of common stock reserved for future issuance under the 2023 Plan.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 Employee Share Purchase Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2023, the Company adopted the 2023 Employee Share Purchase Plan (the 2023 ESPP) that became effective in connection with the Company&#8217;s IPO. The 2023 ESPP initially reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,526,984</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock for the issuance of future awards and provides for an automatic annual increase in the number of shares of common stock reserved for future issuance under the 2023 ESPP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2020 Equity Incentive Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2020, the Company adopted the 2020 Equity Incentive Plan (the 2020 Plan) that provides for the grant of stock options, restricted stock awards, restricted stock unit awards, and other stock-based awards to employees, directors, and non-employee service providers of the Company. The 2020 Plan was suspended in connection with the Company&#8217;s IPO and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> further grants will be made under the 2020 Plan. The 2020 Plan continues to govern the terms and conditions of outstanding awards granted under the 2020 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2015 Equity Incentive Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon the closing of the BlackThorn acquisition in September 2020, the Company assumed BlackThorn&#8217;s 2015 Equity Incentive Plan (the 2015 Plan, and collectively with the 2020 Plan and 2023 Plan, the Plans), pursuant to which outstanding stock options previously granted under the 2015 Plan converted into stock options to purchase common stock of the Company, which remain subject to the terms and conditions of the 2015 Plan. The 2015 Plan was suspended in connection with the closing of the acquisition of BlackThorn in September 2020.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock Option Activity</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:41.692%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:13.877%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.42%;"></td>
         <td style="width:1%;"></td>
         <td style="width:10.058%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:11.418%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.42%;"></td>
         <td style="width:1%;"></td>
         <td style="width:10.118%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding<br/>Stock Options</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price Per<br/>Share</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (years)</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic <br/>Value</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands, except per share amounts and years)</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,783</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.39</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.7</span></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">146,966</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,841</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17.43</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">525</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.51</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Canceled and forfeited</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">884</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.93</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expired</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.37</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of March 31, 2024</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,130</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.60</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.8</span></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90,736</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested as of March 31, 2024</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,667</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.43</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.6</span></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,256</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable as of March 31, 2024</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,659</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.44</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.6</span></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,145</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The stock option activity table above excludes options granted to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">446,068</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock that were originally granted with market conditions to one of the Company&#8217;s executives.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted Stock Activity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s Plans allow for the grant of restricted common stock and restricted stock units to certain employees, executives, non-employee scientific advisors, and third-party service providers. The restrictions lapse over time primarily according to service-based vesting conditions of each award. In the event of a voluntary or involuntary termination of the holder&#8217;s continuous provision of services to the Company, any unvested portion of the restricted stock award is automatically forfeited.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company&#8217;s restricted stock activity:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:45.46%;"></td>
         <td style="width:1.06%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.74%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.28%;"></td>
         <td style="width:1%;"></td>
         <td style="width:11.64%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.86%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.16%;"></td>
         <td style="width:1%;"></td>
         <td style="width:10.8%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares of<br/>Restricted<br/>Common<br/>Stock</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value<br/>Per Share</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares of<br/>Restricted<br/>Stock<br/>Units</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average Grant<br/>Date Fair<br/>Value Per<br/>Share</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands, except per share amounts)</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding and unvested as of December 31, 2023</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">840</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.11</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">353</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17.00</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,165</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18.07</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">190</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.26</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited and canceled</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18.07</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding and unvested as of March 31, 2024</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">650</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.81</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,508</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17.83</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The restricted stock activity table above excludes </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">254,896</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of restricted common stock issued to certain of the Company&#8217;s scientific advisors which vest based on the achievement of certain performance conditions to be separately defined and approved by the Company&#8217;s board of directors. As the performance conditions had not been determined as of March 31, 2024, the criteria for establishing a grant date, and accordingly a measurement date, were not met as of that date.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Award with Market and Performance Conditions</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2021, the Company granted stock options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">446,068</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock to one of its executive officers with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.52</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share that contained both market and service conditions (the Market Award). Subject to the holder&#8217;s continued service, the Market Award provided for vesting in four equal tranches once the Company&#8217;s stock price exceeded certain thresholds. The original grant-date fair value of the Market Award of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was determined using a Monte Carlo simulation model using an expected volatility of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and risk-free rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2022, the Company amended the terms of the Market Award such that the award would vest in three modified tranches. One tranche of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">223,034</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock options was based on a performance condition and two tranches of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">111,517</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock options each were based on revised Company stock price thresholds and/or vesting schedules, subject to the holder&#8217;s continued service. The modification resulting in a performance-based tranche was determined to be a probable-to-improbable modification and the modification resulting in two revised market-based tranches were determined to be probable-to-probable modifications. The modification resulted in $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in total incremental expense.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2023, the Company amended the terms such that vesting schedule for the two tranches of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">111,517</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock options each that were based on the Company stock price thresholds would instead vest monthly over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, subject to the holder&#8217;s continued service. The modification of the two market-based tranches were deemed to be probable-to-probable modifications. The modification resulted in $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in total incremental expense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The unrecognized original grant-date fair value, together with incremental expense, is recognized as compensation for each tranche over the requisite service period. For the three months ended March 31, 2024 stock-based compensation related to the tranches was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, including expense related to the performance-based tranche for which the condition was met upon completion o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">f the Company's IPO. For the three months ended March 31, 2023, stock-based compensation related to the market-based tranches was not material and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> expense was recognized for the performance-based tranche as the performance condition was not probable of being met.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Awards with Performance Conditions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2020, the Company approved grants of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">700,965</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock options and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">892,136</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of restricted common stock to certain of the Company&#8217;s scientific advisors, which vest based on the achievement of performance conditions to be determined and continued service to the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, the Company&#8217;s board of directors established performance conditions for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">401,462</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock options, such that the criteria for establishing a grant date, and accordingly a measurement date, were met for these performance stock options and the remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">299,503</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock options with performance conditions to be established were cancelled in July 2023 because certain of the Company&#8217;s scientific advisors were terminated. Further, as of March 31, 2024, the performance conditions for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">382,344</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restricted </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">common stock were established,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">254,896</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of restricted common stock with performance conditions to be established were cancelled in July 2023 because the consulting agreements with certain of the Company&#8217;s scientific advisors were terminated, and the performance conditions for the remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">254,896</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of restricted common stock have yet to be established.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-Based Compensation</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes total stock-based compensation included in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.734%;"></td>
         <td style="width:1.64%;"></td>
         <td style="width:1%;"></td>
         <td style="width:12.082%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.5%;"></td>
         <td style="width:1%;"></td>
         <td style="width:13.043000000000001%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,812</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,403</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,561</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">792</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,373</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,195</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, there was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">89.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">28.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of unrecognized stock-based compensation related to stock options and restricted stock outstanding, respectively, including stock options and restricted common stock for which achievement of milestones was not probable, which were expected to be recognized over a weighted-average remaining service period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years and</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.4</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687682598048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11.	Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the computation of basic and diluted net loss per share:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:58.352%;"></td>
         <td style="width:1.94%;"></td>
         <td style="width:1%;"></td>
         <td style="width:16.323%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.94%;"></td>
         <td style="width:1%;"></td>
         <td style="width:17.442999999999998%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands, except per share amounts)</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Numerator:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,721</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,625</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Denominator:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">157,943</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,277</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.34</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.22</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following outstanding potentially dilutive common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;"></td>
         <td style="width:1.16%;"></td>
         <td style="width:1%;"></td>
         <td style="width:13.357%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.16%;"></td>
         <td style="width:1%;"></td>
         <td style="width:13.357%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31,</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible preferred stock</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104,417</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock options and restricted stock units</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,084</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,777</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Performance stock options (with performance conditions to be established)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">300</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Early exercised stock options subject to future vesting</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted stock awards</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">650</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,314</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Performance restricted stock (with performance conditions to be established)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">255</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">510</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,044</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117,434</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687603109296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12.	Related Party Transactions</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024 and December 31, 2023, the Company was obligated to pay Amgen $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, under the Amgen Collaboration Agreement, which was recorded within current liabilities on the condensed consolidated balance sheets. As of March 31, 2024 and December 31, 2023, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, related to amounts prepayable to Amgen were recorded as prepaid expenses and other current assets on the condensed consolidated balance sheets. During the three months ended March 31, 2024 and 2023, the Company recorded </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">nil</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, of research and development expenses with Amgen.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687600523568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis of Presentation and Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting. The condensed consolidated financial statements include all accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock', window );">Unaudited Interim Condensed Consolidated Financial Statements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unaudited Interim Condensed Consolidated Financial Statements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The condensed consolidated balance sheet as of March 31, 2024, condensed consolidated statements of operations and comprehensive loss, statement of stockholders&#8217; equity (deficit), and the condensed consolidated statements of cash flows</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the three months ended March 31, 2024 and 2023, and related notes to condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for the fair statement of the Company&#8217;s consolidated financial position, results of operations and cash flows for the periods presented. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2023 included herein was derived from the audited consolidated financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements as of and for the year ended December 31, 2023 included in the Company&#8217;s Annual Form 10-K.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. These estimates form the basis for judgments the Company makes about the carrying values of assets and liabilities that are not readily apparent from other sources. The Company bases its estimates and judgments on historical experience and on various other assumptions that the Company believes are reasonable under the circumstances. These estimates are based on management&#8217;s knowledge about current events and expectations about actions the Company may undertake in the future. These judgments, estimates and assumptions are used for, but not limited to, accrued research and development expenses, accounting for acquisitions of assets, fair value of certain assets and liabilities, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the fair value of the Company&#8217;s convertible preferred stock, the fair value of the Company&#8217;s common stock,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock-based compensation, the measurement of right-of-use assets and lease liabilities and related incremental borrowing rate, and uncertain tax positions and the valuation allowance for net deferred tax assets. Actual results may differ from the Company&#8217;s estimates.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks and Uncertainties</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to certain risks and uncertainties, including, but not limited to, changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: successfully develop, manufacture, and market any approved products; obtain regulatory approval from the U.S. Food and Drug Administration or foreign regulatory agencies prior to commercial sales; new technological innovations; dependence on key personnel, protection of intellectual property; compliance with governmental regulations; uncertainty of market acceptance of any approved products; product liability; and the need to obtain additional financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Marketable Securities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company invests its excess cash in marketable debt securities with high credit ratings including but not limited to money market funds, securities issued by the U.S. government and its agencies, commercial paper, certificates of deposit, and corporate debt securities that are accounted for as available-for-sale and carried at fair value. Marketable securities are classified as short-term or long-term based on the maturity date and their availability to meet current operating requirements. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income in the condensed consolidated statements of operations and comprehensive loss. Realized gains and losses on marketable securities, if any, are included in other income (expense), net. The cost of securities sold is determined based on the trade date using the specific identification method.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company periodically assesses its available-for-sale debt securities for impairment. For debt securities in an unrealized loss position, this assessment first considers the Company&#8217;s intent to sell, or whether it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of these criteria are met, the debt security&#8217;s amortized cost basis is written down to fair value within other income (expense), net. For debt securities in an unrealized loss position that do not meet the aforementioned criteria, the Company assesses whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and any adverse conditions specifically related to the security is considered, among other factors. If this assessment indicates that a credit loss may exist, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses will be recorded in other income (expense), net, limited by the amount that the fair value is less than the amortized cost basis. Any additional impairment not recorded through an allowance for credit losses is recognized in other comprehensive income (loss). Changes in the allowance for credit losses are recorded as provision for (or reversal of) credit loss expense. Losses are charged against the allowance when management believes the un-collectability of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met. These changes are recorded in other income (expense), net.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The Company measures fair value by maximizing the use of observable inputs, where available, and minimizing the use of unobservable inputs when measuring fair value. Financial assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized in the fair value hierarchy based upon the lowest level of input that is significant to the fair value as follows:</span></p><p style="margin-left:36pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></p><p style="margin-left:36pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2&#8212;Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></p><p style="margin-left:36pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value of the instrument.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses and Related Prepaid Assets and Accrued Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and Development Expenses and Related Prepaid Assets and Accrued Liabilities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development expenses primarily consist of internal research and development expense, including personnel-related expenses (such as salaries, benefits and noncash stock-based compensation) and other expenses, including laboratory supplies and other non-capital equipment utilized for in-house research, research and consulting expenses, software development costs, license fees and allocated expenses, including facilities costs and depreciation and amortization; external research and development expenses incurred under arrangements with vendors conducting research and development services on its behalf, such as contract research organizations (CROs), preclinical testing organizations and contract manufacturing organizations (CMOs). Costs to develop the Company&#8217;s platform information technologies are recorded as research and development expense unless the criteria to be capitalized as internal-use software costs is met. Payments made prior to the receipt of goods or services to be used in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">research and development are capitalized, evaluated for current or long-term classification, and included in prepaid expenses and other current assets or other assets in the condensed consolidated balance sheets based on when the goods are received or the services are expected to be received or consumed, and recognized in research and development expenses when they are realized.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is required to estimate expenses resulting from its obligations under contracts with vendors, service providers and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in cash flows that do not match the periods over which materials or services are provided. The Company estimates and records accrued expenses for the related research and development activities based on the level of services performed but not yet invoiced pursuant to agreements established with its service providers, according to the progress of preclinical studies, clinical trials or related activities, and discussions with applicable personnel and service providers as to the progress or state of consummation of goods and services.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the course of a clinical trial, the rate of expense recognition is adjusted if actual results differ from the Company&#8217;s estimates. The Company estimates accrued expenses as of each balance sheet date in its condensed consolidated financial statements based on the facts and circumstances known at that time. The clinical trial accrual is dependent in part upon the timely and accurate reporting of CROs, CMOs and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its estimate may vary from the actual results. To date, the Company has not experienced material differences between its accrued expenses and actual expenses.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss includes net loss and certain changes in stockholders&#8217; equity (deficit) that are excluded from net loss, such as unrealized losses on the Company&#8217;s available-for-sale marketable securities.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_EmergingGrowthCompanyStatusPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging Growth Company Status</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent Accounting Pronouncements Not Yet Adopted</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(ASU 2023-09), which requires issuers to make additional discloses on an annual basis related to specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis, disclose additional information about income taxes paid as well as other disaggregated disclosures. ASU 2023-09 will be effective for the Company as of January 1, 2025 for annual periods. The Company is evaluating the impact of this ASU on its condensed consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (ASU 2023-07), which requires issuers to make additional disclosures with respect to segment expenses, including required disclosure on an annual and interim basis for significant segment expenses and other segment items. ASU 2023-07 also permits the disclosure of more than one measure of a segment&#8217;s profit or loss. ASU 2023-07 will be effective for the Company as of January 1, 2024 for annual periods and as of January 1, 2025 for interim periods. The Company is evaluating the impact of this ASU on its condensed consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_EmergingGrowthCompanyStatusPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Emerging growth company status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_EmergingGrowthCompanyStatusPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unaudited interim condensed consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687690946032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_CashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash Equivalents and Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Amortized Cost and Fair Value of Cash Equivalents and Marketable Securities by Major Investment Category</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables summarize the amortized cost and fair value of the Company&#8217;s cash equivalents and marketable securities by major investment category for the periods indicated:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.38%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gain</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Loss</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">142,817</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">142,817</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">142,817</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">142,817</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69,612</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69,577</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificates of deposit</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,669</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,671</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency debt securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122,660</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122,552</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,297</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,290</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total marketable securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">240,238</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">157</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">240,090</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents and marketable securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">383,055</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">157</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">382,907</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.38%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gain</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Loss</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">306,801</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">306,801</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,455</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,461</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency debt securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,998</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,992</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">362,254</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">362,254</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47,534</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47,547</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency debt securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,515</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,424</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,816</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,818</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total marketable securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,865</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,789</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents and marketable securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">452,119</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">452,043</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of Marketable Securities by Contractual Maturity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s marketable securities by contractual maturity were (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:76.28%;"></td>
         <td style="width:2%;"></td>
         <td style="width:1%;"></td>
         <td style="width:19.72%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Within one year</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">239,788</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">After one year through two years</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">302</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total marketable securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">240,090</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_CashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_CashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687599914928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables summarize the Company&#8217;s assets and liabilities measured at fair value on a recurring basis by level within the valuation hierarchy:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.38%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">142,817</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">142,817</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69,577</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69,577</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificates of deposit</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,671</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,671</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency debt securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">115,062</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,490</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122,552</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,290</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,290</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at fair value</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">257,879</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">125,028</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">382,907</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.38%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.22%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.184000000000001%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">306,801</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">306,801</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90,008</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90,008</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency debt securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,473</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,943</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,416</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,818</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,818</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at fair value</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">326,274</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">125,769</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">452,043</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687596361136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid Expenses and Other Current Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:60.692%;"></td>
         <td style="width:1.2%;"></td>
         <td style="width:1%;"></td>
         <td style="width:15.603%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.7%;"></td>
         <td style="width:1%;"></td>
         <td style="width:16.802999999999997%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31,</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid research and development costs ($</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.4</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;million and $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><br/>&#160;&#160;&#160;&#160;million from related party in 2024 and 2023, respectively)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,603</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,085</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid other</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,561</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,273</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other receivables</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">906</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">939</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,070</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,297</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued Liabilities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued liabilities consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:63.473%;"></td>
         <td style="width:1.86%;"></td>
         <td style="width:1%;"></td>
         <td style="width:13.943%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.7%;"></td>
         <td style="width:1%;"></td>
         <td style="width:15.023%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31,</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Compensation and benefits</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,660</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,011</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued research and development services ($</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;million and $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;<br/>&#160;&#160;&#160;&#160;&#160;million due to related party in 2024 and 2023, respectively)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,442</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,004</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional services</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">926</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">787</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued clinical trial and preclinical costs</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,923</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,705</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">542</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">750</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued liabilities</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,493</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,257</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687596426960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Schedule of Common Stock Reserved for Future Issuance</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stock reserved for future issuance consisted of the following:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:78.02%;"></td>
         <td style="width:1.7%;"></td>
         <td style="width:1%;"></td>
         <td style="width:18.28%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares reserved for options and restricted stock units issued under the plans</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,084</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares reserved for future issuance under the plans</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,965</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,049</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687599616496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock Option Activity</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:41.692%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:13.877%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.42%;"></td>
         <td style="width:1%;"></td>
         <td style="width:10.058%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:11.418%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.42%;"></td>
         <td style="width:1%;"></td>
         <td style="width:10.118%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding<br/>Stock Options</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price Per<br/>Share</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (years)</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic <br/>Value</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands, except per share amounts and years)</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,783</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.39</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.7</span></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">146,966</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,841</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17.43</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">525</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.51</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Canceled and forfeited</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">884</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.93</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expired</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.37</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of March 31, 2024</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,130</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.60</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.8</span></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90,736</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested as of March 31, 2024</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,667</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.43</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.6</span></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,256</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable as of March 31, 2024</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,659</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.44</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.6</span></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,145</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Activity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company&#8217;s restricted stock activity:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:45.46%;"></td>
         <td style="width:1.06%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.74%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.28%;"></td>
         <td style="width:1%;"></td>
         <td style="width:11.64%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.86%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.16%;"></td>
         <td style="width:1%;"></td>
         <td style="width:10.8%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares of<br/>Restricted<br/>Common<br/>Stock</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value<br/>Per Share</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares of<br/>Restricted<br/>Stock<br/>Units</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average Grant<br/>Date Fair<br/>Value Per<br/>Share</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands, except per share amounts)</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding and unvested as of December 31, 2023</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">840</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.11</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">353</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17.00</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,165</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18.07</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">190</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.26</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited and canceled</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18.07</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding and unvested as of March 31, 2024</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">650</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.81</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,508</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17.83</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Expense Recognized</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes total stock-based compensation included in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.734%;"></td>
         <td style="width:1.64%;"></td>
         <td style="width:1%;"></td>
         <td style="width:12.082%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.5%;"></td>
         <td style="width:1%;"></td>
         <td style="width:13.043000000000001%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,812</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,403</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,561</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">792</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,373</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,195</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687600518640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Computation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the computation of basic and diluted net loss per share:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:58.352%;"></td>
         <td style="width:1.94%;"></td>
         <td style="width:1%;"></td>
         <td style="width:16.323%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.94%;"></td>
         <td style="width:1%;"></td>
         <td style="width:17.442999999999998%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands, except per share amounts)</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Numerator:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,721</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,625</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Denominator:</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">157,943</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,277</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.34</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.22</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Outstanding Potentially Dilutive Common Stock Equivalents were Excluded from Computation of Diluted Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following outstanding potentially dilutive common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;"></td>
         <td style="width:1.16%;"></td>
         <td style="width:1%;"></td>
         <td style="width:13.357%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1.16%;"></td>
         <td style="width:1%;"></td>
         <td style="width:13.357%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31,</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible preferred stock</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104,417</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock options and restricted stock units</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,084</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,777</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Performance stock options (with performance conditions to be established)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">300</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Early exercised stock options subject to future vesting</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted stock awards</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">650</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,314</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Performance restricted stock (with performance conditions to be established)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">255</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">510</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,044</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117,434</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687598540032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Liquidity - Additional information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 19, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>Program</div>
</th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 20, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_OrganizationAndLiquidityLineItems', window );"><strong>Organization and Liquidity [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms', window );">Number of clinical and preclinical neuroscience programs | Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7.8463-for-1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (757,155)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (703,434)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">374,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_OrganizationAndLiquidityLineItems', window );"><strong>Organization and Liquidity [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Common stock sold in initial public offering | shares</a></td>
<td class="nump">14,710,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price to public, per share | $ / shares</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering</a></td>
<td class="nump">$ 226,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_UnderwritingDiscountsAndCommissions', window );">Underwriting discounts and commissions</a></td>
<td class="nump">17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_OfferingExpenses', window );">Offering expenses</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized | shares</a></td>
<td class="nump">700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized | shares</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of convertible preferred stock automatically converted into shares of common stock | shares</a></td>
<td class="nump">104,417,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nmra_LiquidityMember', window );">Liquidity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_OrganizationAndLiquidityLineItems', window );"><strong>Organization and Liquidity [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">757,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 423,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of clinical and preclinical neuroscience programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_OfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_OfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_OrganizationAndLiquidityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization and Liquidity [Line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_OrganizationAndLiquidityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_UnderwritingDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underwriting discounts and commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_UnderwritingDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nmra_LiquidityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nmra_LiquidityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687599036432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Summary of Amortized Cost and Fair Value of Cash Equivalents and Marketable Securities by Major Investment Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 383,055<span></span>
</td>
<td class="nump">$ 452,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gain</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Loss</a></td>
<td class="num">(157)<span></span>
</td>
<td class="num">(102)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">382,907<span></span>
</td>
<td class="nump">452,043<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">142,817<span></span>
</td>
<td class="nump">362,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">142,817<span></span>
</td>
<td class="nump">362,254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">142,817<span></span>
</td>
<td class="nump">306,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">142,817<span></span>
</td>
<td class="nump">306,801<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents | U.S Government and Agency Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Loss</a></td>
<td class="num">(108)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">122,552<span></span>
</td>
<td class="nump">12,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gain</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Loss</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">11,671<span></span>
</td>
<td class="nump">42,461<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=nmra_MarketableSecuritiesMember', window );">Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">240,238<span></span>
</td>
<td class="nump">89,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gain</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Loss</a></td>
<td class="num">(157)<span></span>
</td>
<td class="num">(96)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">240,090<span></span>
</td>
<td class="nump">89,789<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=nmra_MarketableSecuritiesMember', window );">Marketable Securities | U.S Government and Agency Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">122,660<span></span>
</td>
<td class="nump">37,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=nmra_MarketableSecuritiesMember', window );">Marketable Securities | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">36,297<span></span>
</td>
<td class="nump">4,816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gain</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Loss</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">36,290<span></span>
</td>
<td class="nump">4,818<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=nmra_MarketableSecuritiesMember', window );">Marketable Securities | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">69,612<span></span>
</td>
<td class="nump">47,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gain</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Loss</a></td>
<td class="num">(36)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">69,577<span></span>
</td>
<td class="nump">$ 47,547<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=nmra_MarketableSecuritiesMember', window );">Marketable Securities | Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 11,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=nmra_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=nmra_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687596456544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Summary of Marketable Securities by Contractual Maturity (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Available-for-Sale Securities, Debt Maturities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Within one year</a></td>
<td class="nump">$ 239,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue', window );">After one year through two years</a></td>
<td class="nump">302<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue', window );">Total marketable securities</a></td>
<td class="nump">$ 240,090<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available for sale securities debt maturities after one through two years fair value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value of available for sale debt securities fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687597792608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">$ 382,907<span></span>
</td>
<td class="nump">$ 452,043<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">257,879<span></span>
</td>
<td class="nump">326,274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">125,028<span></span>
</td>
<td class="nump">125,769<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">142,817<span></span>
</td>
<td class="nump">306,801<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">142,817<span></span>
</td>
<td class="nump">306,801<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S Government and Agency Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">122,552<span></span>
</td>
<td class="nump">50,416<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S Government and Agency Debt Securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">115,062<span></span>
</td>
<td class="nump">19,473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S Government and Agency Debt Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">7,490<span></span>
</td>
<td class="nump">30,943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S Government and Agency Debt Securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">36,290<span></span>
</td>
<td class="nump">4,818<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate Debt Securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate Debt Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">36,290<span></span>
</td>
<td class="nump">4,818<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate Debt Securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">11,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Certificates of Deposit | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Certificates of Deposit | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">11,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">69,577<span></span>
</td>
<td class="nump">90,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">69,577<span></span>
</td>
<td class="nump">90,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687599121648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetAssetValuePerShare', window );">Net asset value per share</a></td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetAssetValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net asset value per share or per unit of investments in certain entities that calculate net asset value per share. Includes, but is not limited to, by unit, membership interest, or other ownership interest. Investment includes, but is not limited to, investment in certain hedge funds, venture capital funds, private equity funds, real estate partnerships or funds. Excludes fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 54B<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482134/820-10-35-54B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 59<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482134/820-10-35-59<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6A<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480737/946-205-50-7<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480737/946-205-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetAssetValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687595480544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_PrepaidResearchAndDevelopmentCosts', window );">Prepaid research and development costs ($9.4 million and $6.3 million from related party in 2024 and 2023, respectively)</a></td>
<td class="nump">$ 14,603<span></span>
</td>
<td class="nump">$ 19,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid other</a></td>
<td class="nump">4,561<span></span>
</td>
<td class="nump">4,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">906<span></span>
</td>
<td class="nump">939<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 20,070<span></span>
</td>
<td class="nump">$ 24,297<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_PrepaidResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_PrepaidResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687599109680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Parenthetical) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_PrepaidResearchAndDevelopmentCosts', window );">Prepaid research and development costs from related party</a></td>
<td class="nump">$ 14,603<span></span>
</td>
<td class="nump">$ 19,085<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_PrepaidResearchAndDevelopmentCosts', window );">Prepaid research and development costs from related party</a></td>
<td class="nump">$ 9,400<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_PrepaidResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_PrepaidResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687706738464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and benefits</a></td>
<td class="nump">$ 4,660<span></span>
</td>
<td class="nump">$ 10,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_AccruedResearchAndDevelopmentServices', window );">Accrued research and development services</a></td>
<td class="nump">7,442<span></span>
</td>
<td class="nump">5,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional services</a></td>
<td class="nump">926<span></span>
</td>
<td class="nump">787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_AccruedClinicalTrialAndPreclinicalCosts', window );">Accrued clinical trial and preclinical costs</a></td>
<td class="nump">5,923<span></span>
</td>
<td class="nump">4,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">542<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 19,493<span></span>
</td>
<td class="nump">$ 21,257<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_AccruedClinicalTrialAndPreclinicalCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trial and preclinical costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_AccruedClinicalTrialAndPreclinicalCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_AccruedResearchAndDevelopmentServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_AccruedResearchAndDevelopmentServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687599287760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued Liabilities (Parenthetical) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_AccruedResearchAndDevelopmentServicesDueToRelatedParty', window );">Accrued research and development services due to related party</a></td>
<td class="nump">$ 6.3<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_AccruedResearchAndDevelopmentServicesDueToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development services due to related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_AccruedResearchAndDevelopmentServicesDueToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687589719376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions of Assets - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>Agreements </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>Milestones</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=nmra_AmgenIncMember', window );">Amgen Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_NumberOfLicenseAgreements', window );">Number of license agreements | Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=nmra_VanderbiltIprDAssetsMember', window );">Vanderbilt IPR&amp;D Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Contingent consideration deemed due or payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_BlackthornMergerAgreementMember', window );">BlackThorn Merger Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_ContingentConsiderationMilestonePaymentSettledInCash', window );">Contingent consideration, milestone payment settled in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_NumberOfMilestoneAchieved', window );">Number of milestone achieved | Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_BlackthornMergerAgreementMember', window );">BlackThorn Merger Agreement | BlackThorn Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Contingent consideration deemed due or payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Contingent consideration payable in cash</a></td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_AcquiredInProcessResearchAndDevelopedExpense', window );">Acquired in-process research and developed expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_BlackthornMergerAgreementMember', window );">BlackThorn Merger Agreement | BlackThorn Therapeutics, Inc. | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet', window );">Shares issued based on volume weighted average price per share prior to date milestone was met | shares</a></td>
<td class="nump">6,072,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_BlackthornMergerAgreementMember', window );">BlackThorn Merger Agreement | navacaprant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_MilestonePaymentDueDescription', window );">Milestone payment due description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">milestone payment that became due in October 2023 upon dosing the first patient in the Phase 3 clinical trial for navacaprant,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_BlackthornMergerAgreementMember', window );">BlackThorn Merger Agreement | navacaprant | Maximum | Development and Regulatory Approval Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_BlackthornMergerAgreementMember', window );">BlackThorn Merger Agreement | navacaprant | Maximum | Sales-based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_BlackthornMergerAgreementMember', window );">BlackThorn Merger Agreement | NMRA-511 | Maximum | Development and Regulatory Approval Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_BlackthornMergerAgreementMember', window );">BlackThorn Merger Agreement | NMRA-511 | Maximum | Sales-based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_BlackthornCarveoutPlanMember', window );">BlackThorn Carveout Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_NumberOfMilestoneAchieved', window );">Number of milestone achieved | Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Contingent consideration deemed due or payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable', window );">Asset acquisition compensation recognized and paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_SyllableMergerAgreementMember', window );">Syllable Merger Agreement | Syllable Life Sciences, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_NumberOfMilestoneAchieved', window );">Number of milestone achieved | Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Contingent consideration deemed due or payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_SyllableMergerAgreementMember', window );">Syllable Merger Agreement | Syllable Life Sciences, Inc | Maximum | Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_AlairionMergerAgreementMember', window );">Alairion Merger Agreement | Alairion, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_NumberOfMilestoneAchieved', window );">Number of milestone achieved | Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_AlairionMergerAgreementMember', window );">Alairion Merger Agreement | Alairion, Inc | Achievement of Specified Commercialization Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_ContingentConsiderationMilestonePayment', window );">Contingent consideration, milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_AlairionMergerAgreementMember', window );">Alairion Merger Agreement | Alairion, Inc | Maximum | Achievement of Specified Development Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_ContingentConsiderationMilestonePayment', window );">Contingent consideration, milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_AmgenIncLicensesMember', window );">Amgen Inc. Licenses | Amgen Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_NumberOfMilestoneAchieved', window );">Number of milestone achieved | Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Contingent consideration deemed due or payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_AmgenIncLicensesMember', window );">Amgen Inc. Licenses | Amgen Inc. | Series A-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_UpfrontConsiderationTransferredShares', window );">Upfront consideration transferred shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_AcquisitionDateFairValueOfSharesTransferred', window );">Acquisition date fair value of shares transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 157,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_AmgenIncLicensesMember', window );">Amgen Inc. Licenses | Amgen Inc. | Maximum | Case One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Contingent consideration payable in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_AmgenIncLicensesMember', window );">Amgen Inc. Licenses | Amgen Inc. | Maximum | Commercial Milestone Payment | Case Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Contingent consideration payable in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 360,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_VanderbiltLicenseMember', window );">Vanderbilt License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_ContingentConsiderationMilestonePaymentSettledInCash', window );">Contingent consideration, milestone payment settled in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_NumberOfMilestoneAchieved', window );">Number of milestone achieved | Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_VanderbiltLicenseMember', window );">Vanderbilt License | Maximum | Achievement of Specified Development Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Contingent consideration payable in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_VanderbiltLicenseMember', window );">Vanderbilt License | Maximum | Achievement of Specified Commercialization Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Contingent consideration payable in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_VanderbiltLicenseMember', window );">Vanderbilt License | Vanderbilt IPR&amp;D Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_UpfrontCashPayment', window );">Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_AcquiredInProcessResearchAndDevelopedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired in-process research and developed expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_AcquiredInProcessResearchAndDevelopedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired in-process research and development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_AcquisitionDateFairValueOfSharesTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquisition date fair value of shares transferred</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_AcquisitionDateFairValueOfSharesTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_ContingentConsiderationMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration, milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_ContingentConsiderationMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_ContingentConsiderationMilestonePaymentSettledInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration, milestone payment settled in cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_ContingentConsiderationMilestonePaymentSettledInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_MilestonePaymentDueDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment due description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_MilestonePaymentDueDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_NumberOfLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_NumberOfLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_NumberOfMilestoneAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of milestone achieved.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_NumberOfMilestoneAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued based on volume weighted average price per share prior to date milestone was met.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_UpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront cash payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_UpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_UpfrontConsiderationTransferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront consideration transferred shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_UpfrontConsiderationTransferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=nmra_AmgenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=nmra_AmgenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=nmra_VanderbiltIprDAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=nmra_VanderbiltIprDAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmra_BlackthornMergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmra_BlackthornMergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=nmra_BlackthornTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=nmra_BlackthornTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=nmra_NavacaprantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=nmra_NavacaprantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=nmra_DevelopmentAndRegulatoryApprovalMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=nmra_DevelopmentAndRegulatoryApprovalMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=nmra_SalesBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=nmra_SalesBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=nmra_Nmra511Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=nmra_Nmra511Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmra_BlackthornCarveoutPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmra_BlackthornCarveoutPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmra_SyllableMergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmra_SyllableMergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=nmra_SyllableLifeSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=nmra_SyllableLifeSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=nmra_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=nmra_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmra_AlairionMergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmra_AlairionMergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=nmra_AlairionIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=nmra_AlairionIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=nmra_AchievementOfSpecifiedCommercializationEventsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=nmra_AchievementOfSpecifiedCommercializationEventsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=nmra_AchievementOfSpecifiedDevelopmentEventsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=nmra_AchievementOfSpecifiedDevelopmentEventsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmra_AmgenIncLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmra_AmgenIncLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nmra_SeriesA2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nmra_SeriesA2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nmra_CaseOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nmra_CaseOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=nmra_CommercialMilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=nmra_CommercialMilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nmra_CaseTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nmra_CaseTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmra_VanderbiltLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmra_VanderbiltLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687597842176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Strategic License and Research and Collaboration Agreements - Additional Information (Details)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,070,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,297,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,757,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,485,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_TwoThousandAndFifteenTsriLicenseAgreementMember', window );">2015 TSRI License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_MilestonesAchieved', window );">Milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_MilestonePayments', window );">Milestone Payments</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Accrued Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_TwoThousandAndFifteenTsriLicenseAgreementMember', window );">2015 TSRI License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_DevelopmentAndRegulatoryMilestonePayments', window );">Development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_CommercialMilestonePayments', window );">Commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_AmgenResearchAndCollaborationAgreementMember', window );">Amgen Research and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_CollaborationAgreementTerminationDescription', window );">Collaboration agreement termination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The term of the agreement is up to five years, although it will terminate after three years if the Company and Amgen do not mutually agree upon a compensation structure for years four and five. If the parties do not reach an agreement at least 30 days prior to the end of year three, the Amgen Collaboration Agreement will automatically terminate upon its third anniversary. Further, either party can terminate the Amgen Collaboration Agreement upon material uncured breach or bankruptcy by the other party, in which case all amounts that have become due through the date of termination are non-refundable.<span></span>
</td>
<td class="text">The term of the agreement is up to five years, although it will terminate after three years if the Company and Amgen do not mutually agree upon a compensation structure for years four and five. If the parties do not reach an agreement at least 30 days prior to the end of year three, the Amgen Collaboration Agreement will automatically terminate upon its third anniversary. Further, either party can terminate the Amgen Collaboration Agreement upon material uncured breach or bankruptcy by the other party, in which case all amounts that have become due through the date of termination are non-refundable.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears', window );">Research and collaboration agreement quarterly payments for first two year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_AmgenResearchAndCollaborationAgreementMember', window );">Amgen Research and Collaboration Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear', window );">Research and collaboration agreement quarterly payments for third year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_AmgenResearchAndCollaborationAgreementMember', window );">Amgen Research and Collaboration Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_CollaborationAgreementTerm', window );">Term of the agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_VanderbiltSponsoredResearchAgreementMember', window );">Vanderbilt Research Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_ResearchAndCollaborationAgreementQuarterlyPayments', window );">Research and collaboration agreement quarterly payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_ResearchAgreementExpiryDate', window );">Research agreement expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023-09<span></span>
</td>
<td class="text">2023-09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_ParkinsonsResearchVenturesFundingAgreementMember', window );">Parkinson's Research Ventures Funding Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_FundsReceivedUponExecutionOfAgreement', window );">Funds received upon execution of agreement | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_PaymentsForExecutionOfAgreement', window );">Payments for execution of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone', window );">Fund eligible to receive upon completion of certain development milestone | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_MaximumRepaymentAmountAgreedToPay', window );">Maximum repayment amount agreed to pay. | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_ParkinsonsResearchVenturesFundingAgreementMember', window );">Parkinson's Research Ventures Funding Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities', window );">Funds provided for preclinical research and development activities | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_CollaborationAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_CollaborationAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_CollaborationAgreementTerminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement termination description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_CollaborationAgreementTerminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_CommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_CommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_DevelopmentAndRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development and regulatory milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_DevelopmentAndRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fund eligible to receive upon completion of certain development milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funds provided for pre-clinical research and development activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_FundsReceivedUponExecutionOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funds received upon execution of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_FundsReceivedUponExecutionOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_MaximumRepaymentAmountAgreedToPay">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum repayment amount agreed to pay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_MaximumRepaymentAmountAgreedToPay</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_MilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestones achieved.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_MilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_PaymentsForExecutionOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for execution of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_PaymentsForExecutionOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_ResearchAgreementExpiryDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research agreement expiry date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_ResearchAgreementExpiryDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_ResearchAndCollaborationAgreementQuarterlyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Collaboration Agreement Quarterly Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_ResearchAndCollaborationAgreementQuarterlyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and collaboration agreement quarterly payments for first two years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and collaboration agreement quarterly payments for third year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmra_TwoThousandAndFifteenTsriLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmra_TwoThousandAndFifteenTsriLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmra_AmgenResearchAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmra_AmgenResearchAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmra_VanderbiltSponsoredResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmra_VanderbiltSponsoredResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmra_ParkinsonsResearchVenturesFundingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmra_ParkinsonsResearchVenturesFundingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687682585648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 20, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for potential future issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,049,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | BlackThorn Merger Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_SharesIssuedUponAchievementOfMilestone', window );">Shares issued upon achievement of milestone</a></td>
<td class="nump">6,072,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Service Conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">447,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Performance Conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">637,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=nmra_AdditionalSharesOfCapitalStockMember', window );">Additional Shares of Capital Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for potential future issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_SharesIssuedUponAchievementOfMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued upon achievement of milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_SharesIssuedUponAchievementOfMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmra_BlackthornMergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmra_BlackthornMergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=nmra_ServiceConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=nmra_ServiceConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=nmra_PerformanceConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=nmra_PerformanceConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=nmra_AdditionalSharesOfCapitalStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=nmra_AdditionalSharesOfCapitalStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687599251440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance (Details)<br> shares in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">37,049<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember', window );">Shares Reserved for Options and Restricted Stock Units Issued Under the Plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">17,084<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nmra_SharesReservedForFutureIssuanceUnderThePlansMember', window );">Shares Reserved for Future Issuance Under the Plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">19,965<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nmra_SharesReservedForFutureIssuanceUnderThePlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nmra_SharesReservedForFutureIssuanceUnderThePlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687588794800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,049,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,373,000<span></span>
</td>
<td class="nump">$ 2,195,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember', window );">Executives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Stock options granted to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">446,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nmra_AdvisorsMember', window );">Advisors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Share based compensation forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nmra_MarketAwardMember', window );">Market Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based compensation granted under plan vested period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification', window );">Total incremental expense resulted in modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nmra_MarketAwardMember', window );">Market Award | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,517<span></span>
</td>
<td class="nump">223,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nmra_MarketAwardMember', window );">Market Award | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,517<span></span>
</td>
<td class="nump">111,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nmra_MarketAwardMember', window );">Market Award | Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nmra_MarketAwardMember', window );">Market Award | Executives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Stock options granted, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nmra_MarketAwardMember', window );">Market Award | Executives | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">446,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nmra_AwardsWithPerformanceConditionsMember', window );">Awards with Performance Conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">401,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Stock options, cancelled</a></td>
<td class="nump">299,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nmra_AwardsWithPerformanceConditionsMember', window );">Awards with Performance Conditions | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nmra_AwardsWithPerformanceConditionsMember', window );">Awards with Performance Conditions | Restricted Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">382,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">892,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Stock options, cancelled</a></td>
<td class="nump">254,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Share based compensation forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Unvested shares repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares or restricted stock remained outstanding and unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">840,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nmra_TwoThousandTwentyThreeEquityIncentivePlanMember', window );">2023 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share based compensation, term of plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based compensation granted under plan vested period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,373,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nmra_TwoThousandTwentyThreeEquityIncentivePlanMember', window );">2023 Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Grants vest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nmra_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember', window );">2023 Employee Share Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,526,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options vested in period incremental expense resulted in modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nmra_AdvisorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nmra_AdvisorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nmra_MarketAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nmra_MarketAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nmra_AwardsWithPerformanceConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nmra_AwardsWithPerformanceConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=nmra_RestrictedCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=nmra_RestrictedCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nmra_TwoThousandTwentyThreeEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nmra_TwoThousandTwentyThreeEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nmra_TwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nmra_TwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687683143296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Detail) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance, Outstanding Stock Options</a></td>
<td class="nump">13,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, outstanding stock options</a></td>
<td class="nump">2,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised, Outstanding Stock Options</a></td>
<td class="num">(525)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled and forfeited, Outstanding Stock Options</a></td>
<td class="num">(884)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired, Outstanding Stock Options</a></td>
<td class="num">(85)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance, Outstanding Stock Options</a></td>
<td class="nump">15,130<span></span>
</td>
<td class="nump">13,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested, outstanding stock options</a></td>
<td class="nump">3,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, Outstanding Stock Options</a></td>
<td class="nump">3,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Outstanding, beginning of period</a></td>
<td class="nump">$ 6.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Granted</a></td>
<td class="nump">17.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Exercised</a></td>
<td class="nump">3.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Canceled and forfeited</a></td>
<td class="nump">5.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Expired</a></td>
<td class="nump">3.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Outstanding, end of period</a></td>
<td class="nump">8.6<span></span>
</td>
<td class="nump">$ 6.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Vested</a></td>
<td class="nump">4.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Exercisable</a></td>
<td class="nump">$ 4.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term, Outstanding (Years)</a></td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Vested</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 90,736<span></span>
</td>
<td class="nump">$ 146,966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested</a></td>
<td class="nump">34,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 34,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687600545744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Restricted Stock Activity (Detail)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and unvested, Shares at beginning balance | shares</a></td>
<td class="nump">840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, Shares | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested, Shares | shares</a></td>
<td class="num">(190)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited and canceled, Shares | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and unvested, Shares at ending balance | shares</a></td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding and unvested, Weighted Average Grant Date Fair Value Per Share at beginning balance | $ / shares</a></td>
<td class="nump">$ 6.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted Average Grant Date Fair Value Per Share | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, Weighted Average Grant Date Fair Value Per Share | $ / shares</a></td>
<td class="nump">0.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited and canceled, Weighted Average Grant Date Fair Value Per Share | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding and unvested, Weighted Average Grant Date Fair Value Per Share at ending balance | $ / shares</a></td>
<td class="nump">$ 7.81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and unvested, Shares at beginning balance | shares</a></td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, Shares | shares</a></td>
<td class="nump">1,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested, Shares | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited and canceled, Shares | shares</a></td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and unvested, Shares at ending balance | shares</a></td>
<td class="nump">1,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding and unvested, Weighted Average Grant Date Fair Value Per Share at beginning balance | $ / shares</a></td>
<td class="nump">$ 17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted Average Grant Date Fair Value Per Share | $ / shares</a></td>
<td class="nump">18.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, Weighted Average Grant Date Fair Value Per Share | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited and canceled, Weighted Average Grant Date Fair Value Per Share | $ / shares</a></td>
<td class="nump">18.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding and unvested, Weighted Average Grant Date Fair Value Per Share at ending balance | $ / shares</a></td>
<td class="nump">$ 17.83<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687603373456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-Based Compensation Expense Recognized (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 7,373<span></span>
</td>
<td class="nump">$ 2,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">2,812<span></span>
</td>
<td class="nump">1,403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 4,561<span></span>
</td>
<td class="nump">$ 792<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687603095008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (53,721)<span></span>
</td>
<td class="num">$ (35,625)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic</a></td>
<td class="nump">157,943<span></span>
</td>
<td class="nump">29,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted</a></td>
<td class="nump">157,943<span></span>
</td>
<td class="nump">29,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (1.22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (1.22)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687682639360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summary of Outstanding Potentially Dilutive Common Stock Equivalents were Excluded from Computation of Diluted Net Loss Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount</a></td>
<td class="nump">18,044<span></span>
</td>
<td class="nump">117,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">104,417<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember', window );">Common Stock Options and Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount</a></td>
<td class="nump">17,084<span></span>
</td>
<td class="nump">9,777<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember', window );">Performance Stock Options (With Performance Conditions to Be Established)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember', window );">Early Exercised Stock Options Subject to Future Vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount</a></td>
<td class="nump">650<span></span>
</td>
<td class="nump">2,314<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember', window );">Performance Restricted Stock (With Performance Conditions to Be Established)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount</a></td>
<td class="nump">255<span></span>
</td>
<td class="nump">510<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140687603151424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid research and development costs</a></td>
<td class="nump">$ 20,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">45,757<span></span>
</td>
<td class="nump">$ 29,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_AmgenResearchAndCollaborationAgreementMember', window );">Amgen Research and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_RelatedPartyTransactionObligationWithRelatedParty', window );">Related party transaction obligation with related party</a></td>
<td class="nump">6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid research and development costs</a></td>
<td class="nump">9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_RelatedPartyTransactionObligationWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party transaction obligation with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_RelatedPartyTransactionObligationWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmra_AmgenResearchAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmra_AmgenResearchAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>55
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MG(5<F@?@_EP(O3TQ/U#]]X3A?U!+ P04    "  P@*=8L#4WP5D%  #5%@
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M#^EX07RJL!\O\N_8AJVP#V_])MCS8J/] HH]%T D)!N1J]Q\L+=?.$E/U-L
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M,V I""V OR\Y5_L'_8'N7Q"+'U!+ P04    "  P@*=88?P0S.\&   $-@
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M4 *H8_@GO;'Z.:E#?&T#0/T-P'=I6/;_RQCMO[1W9T=?SID=D[V3K9RKV_+
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M6H-16U7LF/3S3R\6\]-7G@3U$1"M;A7%%WSBZ$2<#@.@'J3#O1Z2S. &=BG
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M\):$$<<T'UVL+6W1L&!+K=JB!+M53D Y]\.CR7IY>R[APMTV]SU[^Z\"E,)
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M<PDU*]#Z6A'1?L(.A@^PY;]02P,$%     @ ,("G6%L30)&$!0  <@T  !@
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M</K#@.(&1/ZT>:D<V)56=Z3'!2$3:/:E55[&4%P,!R/L:40M*JZ/%!/&M*Z
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MGL85_5E1R[23^/Z7?+"M@__)\=B07* :L@DEBWK:G_;LE!8WZ'ZA/-RE<AR
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M5_SK6DG8F![ ]TN-NAW^H WB_V/@V?\#4$L#!!0    ( #" IUB[RRC\]P0
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M]WHBSI/R :4T5K6JEGF0/E@1.Q+.-\IBCD7MD@]X;\4J!8"'<)$W +67=B<
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M F$/+H 0NL% 95!>00B#BLZD?_'!K/L=>^!OV$'NRE!>DH-=6V,OD.L(3M/
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M_,/)CG2.]D-T-?_>9>8B1F#^<VDT_$0+\/W<H0.D#W1 ]P.HT_\"4$L#!!0
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MESGNGZ2= =ZO%3)N-BY >Z-=_ M02P,$%     @ ,("G6-G$68)?#   #R@
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MPYI>.S3>@=;76KO=Q&\PO)^+/U!+ P04    "  P@*=8,G'Y]0X5   +0P
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M2Y_<2"O3KB$%)0=H!B=B5W,+;3#T0PPY$&8J3N6,<E4!*7<(XZHF2T98D91
MZO5XYR'< _:9!&O/Z9@5P!=0U#:X:XF8-,PIGA YL;&5ZCX#![4<DSL+@$/_
MU4/5NQ>%G8E\I+BV77B)6(@6P^GOG;4UT_NI&Q;%=4W%IT&#)3!)9JG-8DQI
M05$:^J%2'T##L@-2F<NI3%%A_X(L>5/TNEJVMK$+CN^F;6E[/N,+.M8:L 1V
M3]M\UEL 0 K:K6Y*G*+WG4,2#:!6 Q /!Z!']&*_?<&>3>X9.Q,+$D#7>I_,
M>@HO,LO82GD@<N/6!:]GT#0I1?]3C .T;W#A5K,I!4&KNF:]0KZB;#0>#GC>
M#]'S?CCH>;\RNYS,4EMDRN^^@<S8P2@,N]YG['M8H-0=IO4BX\6UGO6%2Q18
M]DL*H@5%1!(!@B =W24'G/ _E"!Z&S0QIVR(*CL1-93F /BWR4R3>F/G)9AA
MF9O?6I%]E!P?N*':"\(A>X/CE;[&[PBGT:,'IXF(Q^=#7]10*%!WRC20P"E]
M< HC]Y49E8H ?'V6ILZ*3-H9=1"N&@KIQ!G6<$G0]:<4/59PM<:V"_DE(A'.
M6*H'A2T7(,'^:"_/$MLE"Q5E4< E/J @*PFT93PA"(W0*4GG7YP>72_B&<L!
MQ3D7OT$ LB("; K=*T-H*J#53H<GM7&^7\;P63@OB\W2$/XP;E1T<!%%-H</
M[4I_ 2T_LFUS5GS4JN%3+LA!?5:G!]H)Q)O0$*4-#@4EJRIG52"HY_/8XZ:3
M$@D[U*PBR4R(Q'J-(]<:.C4ME["97BG(UEJ4.CAHBMLCA"%AN(4A&7@3AFA7
MNE^&^CAXK-3,"*[ Y3A90-P3UKJK8JC5$!W30:;( ]U#,T!VI/C9!4E"?EG'
MHE]R%P<;LV?.34=2X-8*VF.3L 1*E^+*45@O8?>;I1;Q]A 7F1J UV?=P/UI
M?\0.=DQZOC%-(Q4T&W4=Z(CLA'.D:60M='(0-3CJLU3&=L^%TUGQ\[S0AO<7
M%$#YNR(JR.AL!B1Y08ZY=++R?((HCK&AM^BD16TW+;C,4"QBYI=LZO'J\$T*
MR_+B6,"=#D@"RJ$WP*,_63GN90?;"9J0XU9((M@UXWU)44MP2^BG^+@?7*L+
MG1["*K:#?.%LG\6^1^8B/.C[8 \2([*]Z.T&:8BM8"SGDC-V0'&TF,MO"7@>
MS"5KH .&9YPSMI(&^.0>L2'F>(P>/)"]*@!^OT.D:5PT<UV78 X;[QQ\_L!!
M?"LM9II<> SJ];UQ7C"^LY>56ZD+&%MNTH&K+ .DO,,5.>6D SUWZ1B3-KLC
M-L__-_(Q4MV^+<L= ?#A?4[9K8S&5I;" ,937PS19<0>'E)(?R;A^WU&MX]S
M*LC8>"+F2Y'4-TL\7_VRL\-B^:7S&,=+%BWO$P\SSFKA:%AS<E;<I!*&V3Q
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M6A%0PPOT?&YM'W[!!O'O7[S^7U!+ P04    "  P@*=8)^YE(G@$  !$#
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M WDF7! D!^[H(Q+;A.9]B=="AB9>7R/G:F9/K4LY?%^:?9T'9%4\2)@/"0N
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MX<4%\OR:L7R_4Q30?).X^ ]02P,$%     @ ,("G6-Y U?$A!P  R#   !D
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MS43C GA_KC5M)ZZ/VU<X_0-02P,$%     @ ,("G6"#1%D15!P  B$8  !D
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MIIK;J0F,K-P!?R\-7A=N6."%#LHFX/N%E&83V#NC^XN0_@)02P,$%     @
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MV>M.G_>CR' !$A:"8)J*3G<J.CU,1>2&;JNK,WTB.MT;-CC3_1'N)V.HH?)
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M$&5W(YH=.*G.&\DQ89.R- JM#/U,LC0RO2HDST#I-^3S=<W,+?E EIC\K.9
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M3=-K)D96KM%<2H-MRPT+_$\ 93>@/9?2W$UL[^K^/)*_4$L#!!0    ( #"
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M33!/!3/%P_O3,1H1D0G/L#HD-?Z>DEE^LH0OR*M1EP]Z#&0*(5^RY"\^/[X
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M_NQ$BW6Z2SX76HLH/5P!"T":!GA_(83>G9@!B@\MX_\ 4$L#!!0    ( #"
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M]>I!MK-B6C#?V;N/UJD':X+0B\99K6=%N3EP)5U0S3_-BPAY*:Y]:@GB^D(
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M#<_'WY>/DYVW]XZS@W]1BU]02P,$%     @ ,("G6"[2^,"N 0  RAH  !,
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MCD'ZZO-1.^V,LE]ZA^O]T';5S<.Q;KG^CK_.^*1_80X!DD."Y$A <MR Y)B
MY+@%R7$'DN,>) <?HP1!(2I'02I'82I'@2I'H2I'P2I'X2I' 2M'(:M (:M
M(:M (:M (:M (:M (:M (:M (:M (:M (:M$(:M$(:M$(:M$(:M$(:M$(:M$
M(:M$(:M$(:M$(6N"0M8$A:P)"ED3%+(F_TG6=ZU7?_UWI5WC6I7-T9]UO[#F
MGU!+ 0(4 Q0    ( #" IU@'04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ ,("G6+"F%M'O    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ ,("G6)E<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    "  P@*=8'?[DP P&  "J(   &
M        @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ ,("G6+ U-\%9!0  U18  !@              ("!4 X  'AL+W=O<FMS
M:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( #" IU@5(<&*;00  (X0   8
M              " @=\3  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"
M% ,4    "  P@*=88?P0S.\&   $-@  &               @(&"&   >&PO
M=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ ,("G6+^22FB7!@
MCAT  !@              ("!IQ\  'AL+W=O<FMS:&5E=',O<VAE970U+GAM
M;%!+ 0(4 Q0    ( #" IU@[=[DUMPH  %X:   8              " @70F
M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  P@*=8'R<M
MQ%\4  #(/0  &               @(%A,0  >&PO=V]R:W-H965T<R]S:&5E
M=#<N>&UL4$L! A0#%     @ ,("G6!B8F& A!0  C T  !@
M ("!]D4  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( #"
MIUA;$T"1A 4  '(-   8              " @4U+  !X;"]W;W)K<VAE971S
M+W-H965T.2YX;6Q02P$"% ,4    "  P@*=8T7(.=5(#  #"!P  &0
M        @($'40  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0
M   ( #" IU@5-A+S4Q(  &]    9              " @9!4  !X;"]W;W)K
M<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ ,("G6+O+*/SW!   V@L
M !D              ("!&F<  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q0
M2P$"% ,4    "  P@*=8&L4A27D-   ,)0  &0              @(%(;
M>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( #" IU@%BA'?
MH@0  -T*   9              " @?AY  !X;"]W;W)K<VAE971S+W-H965T
M,30N>&UL4$L! A0#%     @ ,("G6-G$68)?#   #R@  !D
M ("!T7X  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  P
M@*=83$,3<MD#  "U"   &0              @(%GBP  >&PO=V]R:W-H965T
M<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( #" IUB9\;)H_P(  $L'   9
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M970R,2YX;6Q02P$"% ,4    "  P@*=8]DEN)90"  #'!0  &0
M    @($VM   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (
M #" IU@15^'58P0   (+   9              " @0&W  !X;"]W;W)K<VAE
M971S+W-H965T,C,N>&UL4$L! A0#%     @ ,("G6)H[>K(3!   R D  !D
M             ("!F[L  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"
M% ,4    "  P@*=8/,B1EQX'  "?.   &0              @('EOP  >&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( #" IUC>0-7Q(0<
M ,@P   9              " @3K'  !X;"]W;W)K<VAE971S+W-H965T,C8N
M>&UL4$L! A0#%     @ ,("G6([XIQYV @  D04  !D              ("!
MDLX  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  P@*=8
M(-$61%4'  "(1@  &0              @($_T0  >&PO=V]R:W-H965T<R]S
M:&5E=#(X+GAM;%!+ 0(4 Q0    ( #" IUCR/>5$"P(  #$$   9
M      " @<O8  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%
M  @ ,("G6!*#27OR @  K <  !D              ("!#=L  'AL+W=O<FMS
M:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  P@*=8]N^R_;8"   N"
M&0              @($VW@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+
M 0(4 Q0    ( #" IUB%!XPE^@(  'P(   9              " @2/A  !X
M;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ ,("G6"UX-E)A
M @  : 4  !D              ("!5.0  'AL+W=O<FMS:&5E=',O<VAE970S
M,RYX;6Q02P$"% ,4    "  P@*=8XRCF!R42  #H(0$ &0
M@('LY@  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( #"
MIUB"XD*\A@H  )5J   9              " @4CY  !X;"]W;W)K<VAE971S
M+W-H965T,S4N>&UL4$L! A0#%     @ ,("G6$.L,[I=!   EQD  !D
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M=#0P+GAM;%!+ 0(4 Q0    ( #" IU@HQE5T(P,  +<+   9
M  " @1,D 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @
M,("G6/0N0W$0 P  L D  !D              ("!;2<! 'AL+W=O<FMS:&5E
M=',O<VAE970T,BYX;6Q02P$"% ,4    "  P@*=873K[E9P$  !T&0  &0
M            @(&T*@$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4
M Q0    ( #" IUA>%TD'C ,  +0.   9              " @8<O 0!X;"]W
M;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ ,("G6#=!ME5E P
ML!8   T              ( !2C,! 'AL+W-T>6QE<RYX;6Q02P$"% ,4
M"  P@*=8EXJ[',     3 @  "P              @ ':-@$ 7W)E;',O+G)E
M;'-02P$"% ,4    "  P@*=83IF<JN@#  #7'0  #P              @ '#
M-P$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ ,("G6$<<8+FD 0  FQH
M !H              ( !V#L! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ ,("G6"[2^,"N 0  RAH  !,              ( !M#T!
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #0 -  C#@  DS\!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>221</ContextCount>
  <ElementCount>244</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>80</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Disclosure - Organization and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidity</Role>
      <ShortName>Organization and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation1</Role>
      <ShortName>Summary of Significant Accounting Policies and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Cash Equivalents and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecurities1</Role>
      <ShortName>Cash Equivalents and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Acquisitions of Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssets</Role>
      <ShortName>Acquisitions of Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Strategic License and Research and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreements</Role>
      <ShortName>Strategic License and Research and Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquity1</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation1</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Cash Equivalents and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables</Role>
      <ShortName>Cash Equivalents and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecurities1</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponents</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquity1</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Organization and Liquidity - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails</Role>
      <ShortName>Organization and Liquidity - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Cash Equivalents and Marketable Securities - Summary of Amortized Cost and Fair Value of Cash Equivalents and Marketable Securities by Major Investment Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Summary of Amortized Cost and Fair Value of Cash Equivalents and Marketable Securities by Major Investment Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Cash Equivalents and Marketable Securities - Summary of Marketable Securities by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesByContractualMaturityDetails</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Summary of Marketable Securities by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsParentheticalDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Balance Sheet Components - Schedule of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Balance Sheet Components - Schedule of Accrued Liabilities (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesParentheticalDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued Liabilities (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Acquisitions of Assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails</Role>
      <ShortName>Acquisitions of Assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Strategic License and Research and Collaboration Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails</Role>
      <ShortName>Strategic License and Research and Collaboration Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Restricted Stock Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-Based Compensation Expense Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Net Loss Per Share - Summary of Outstanding Potentially Dilutive Common Stock Equivalents were Excluded from Computation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar</Role>
      <ShortName>Net Loss Per Share - Summary of Outstanding Potentially Dilutive Common Stock Equivalents were Excluded from Computation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="nmra-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 -  nmra-20240331.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="nmra-20240331.htm">nmra-20240331.htm</File>
    <File>nmra-20240331.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img235846496_0.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="475">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>62
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "nmra-20240331.htm": {
   "nsprefix": "nmra",
   "nsuri": "http://www.neumoratx.com/20240331",
   "dts": {
    "inline": {
     "local": [
      "nmra-20240331.htm"
     ]
    },
    "schema": {
     "local": [
      "nmra-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "keyStandard": 196,
   "keyCustom": 48,
   "axisStandard": 20,
   "axisCustom": 0,
   "memberStandard": 29,
   "memberCustom": 44,
   "hidden": {
    "total": 7,
    "http://fasb.org/us-gaap/2023": 3,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 221,
   "entityCount": 1,
   "segmentCount": 80,
   "elementCount": 549,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 475,
    "http://xbrl.sec.gov/dei/2023": 31
   },
   "report": {
    "R1": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage",
     "longName": "100000 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_6a59c933-f461-45be-9258-2eeefba9dd39",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6a59c933-f461-45be-9258-2eeefba9dd39",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
     "longName": "100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
     "longName": "100040 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_d4c8d898-2127-41b5-99f4-5fed585e8a39",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d4c8d898-2127-41b5-99f4-5fed585e8a39",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
     "longName": "100050 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidity",
     "longName": "100060 - Disclosure - Organization and Liquidity",
     "shortName": "Organization and Liquidity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation1",
     "longName": "100070 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation",
     "shortName": "Summary of Significant Accounting Policies and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecurities1",
     "longName": "100080 - Disclosure - Cash Equivalents and Marketable Securities",
     "shortName": "Cash Equivalents and Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurements",
     "longName": "100090 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponents",
     "longName": "100100 - Disclosure - Balance Sheet Components",
     "shortName": "Balance Sheet Components",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssets",
     "longName": "100110 - Disclosure - Acquisitions of Assets",
     "shortName": "Acquisitions of Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "longName": "100120 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreements",
     "longName": "100130 - Disclosure - Strategic License and Research and Collaboration Agreements",
     "shortName": "Strategic License and Research and Collaboration Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquity1",
     "longName": "100140 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensation",
     "longName": "100160 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShare",
     "longName": "100180 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactions",
     "longName": "100190 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies",
     "longName": "100200 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation (Policies)",
     "shortName": "Summary of Significant Accounting Policies and Basis of Presentation (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables",
     "longName": "100210 - Disclosure - Cash Equivalents and Marketable Securities (Tables)",
     "shortName": "Cash Equivalents and Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "longName": "100220 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsTables",
     "longName": "100230 - Disclosure - Balance Sheet Components (Tables)",
     "shortName": "Balance Sheet Components (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityTables",
     "longName": "100250 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "nmra:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "nmra:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationTables",
     "longName": "100260 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareTables",
     "longName": "100280 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails",
     "longName": "100290 - Disclosure - Organization and Liquidity - Additional information (Details)",
     "shortName": "Organization and Liquidity - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_6a59c933-f461-45be-9258-2eeefba9dd39",
      "name": "nmra:NumberOfClinicalAndPreclinicalNeurosciencePrograms",
      "unitRef": "U_Program",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6a59c933-f461-45be-9258-2eeefba9dd39",
      "name": "nmra:NumberOfClinicalAndPreclinicalNeurosciencePrograms",
      "unitRef": "U_Program",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme",
     "longName": "100300 - Disclosure - Cash Equivalents and Marketable Securities - Summary of Amortized Cost and Fair Value of Cash Equivalents and Marketable Securities by Major Investment Category (Details)",
     "shortName": "Cash Equivalents and Marketable Securities - Summary of Amortized Cost and Fair Value of Cash Equivalents and Marketable Securities by Major Investment Category (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_6a59c933-f461-45be-9258-2eeefba9dd39",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6a59c933-f461-45be-9258-2eeefba9dd39",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesByContractualMaturityDetails",
     "longName": "100310 - Disclosure - Cash Equivalents and Marketable Securities - Summary of Marketable Securities by Contractual Maturity (Details)",
     "shortName": "Cash Equivalents and Marketable Securities - Summary of Marketable Securities by Contractual Maturity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_6a59c933-f461-45be-9258-2eeefba9dd39",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6a59c933-f461-45be-9258-2eeefba9dd39",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "100320 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_5ea749b2-350e-4a76-be5d-6ec287b9f397",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5ea749b2-350e-4a76-be5d-6ec287b9f397",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "longName": "100330 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_6a59c933-f461-45be-9258-2eeefba9dd39",
      "name": "us-gaap:NetAssetValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6a59c933-f461-45be-9258-2eeefba9dd39",
      "name": "us-gaap:NetAssetValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "longName": "100340 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_6a59c933-f461-45be-9258-2eeefba9dd39",
      "name": "nmra:PrepaidResearchAndDevelopmentCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6a59c933-f461-45be-9258-2eeefba9dd39",
      "name": "us-gaap:OtherPrepaidExpenseCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsParentheticalDetails",
     "longName": "100350 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Parenthetical) (Details)",
     "shortName": "Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_6a59c933-f461-45be-9258-2eeefba9dd39",
      "name": "nmra:PrepaidResearchAndDevelopmentCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7da00584-584d-4a38-a226-8df0e7c5789c",
      "name": "nmra:PrepaidResearchAndDevelopmentCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails",
     "longName": "100360 - Disclosure - Balance Sheet Components - Schedule of Accrued Liabilities (Details)",
     "shortName": "Balance Sheet Components - Schedule of Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_6a59c933-f461-45be-9258-2eeefba9dd39",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6a59c933-f461-45be-9258-2eeefba9dd39",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesParentheticalDetails",
     "longName": "100370 - Disclosure - Balance Sheet Components - Schedule of Accrued Liabilities (Parenthetical) (Details)",
     "shortName": "Balance Sheet Components - Schedule of Accrued Liabilities (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_6a59c933-f461-45be-9258-2eeefba9dd39",
      "name": "nmra:AccruedResearchAndDevelopmentServicesDueToRelatedParty",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6a59c933-f461-45be-9258-2eeefba9dd39",
      "name": "nmra:AccruedResearchAndDevelopmentServicesDueToRelatedParty",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails",
     "longName": "100380 - Disclosure - Acquisitions of Assets - Additional Information (Details)",
     "shortName": "Acquisitions of Assets - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_57949529-090f-4b07-8503-88af5ca1f576",
      "name": "nmra:NumberOfLicenseAgreements",
      "unitRef": "U_Agreements",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57949529-090f-4b07-8503-88af5ca1f576",
      "name": "nmra:NumberOfLicenseAgreements",
      "unitRef": "U_Agreements",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails",
     "longName": "100390 - Disclosure - Strategic License and Research and Collaboration Agreements - Additional Information (Details)",
     "shortName": "Strategic License and Research and Collaboration Agreements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_6a59c933-f461-45be-9258-2eeefba9dd39",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_10a4bee1-f023-4318-b204-afcaf55d14c2",
      "name": "nmra:MilestonesAchieved",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
     "longName": "100400 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_eae3f164-5e78-4151-9e37-d2d160340f1e",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6a59c933-f461-45be-9258-2eeefba9dd39",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails",
     "longName": "100410 - Disclosure - Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance (Details)",
     "shortName": "Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_6a59c933-f461-45be-9258-2eeefba9dd39",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c76761b1-4f4c-4b1c-9b56-2a77a0b656cd",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
     "longName": "100420 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_6a59c933-f461-45be-9258-2eeefba9dd39",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_93cb25ef-3bf9-4722-9f0f-76e81b2a808d",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail",
     "longName": "100440 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail",
     "longName": "100450 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Detail)",
     "shortName": "Stock-Based Compensation - Summary of Restricted Stock Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_345bf6ed-eb39-4b95-8e9c-d73a88a49e29",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b8b16692-cbc0-4367-b249-644373e8d0f7",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedDetails",
     "longName": "100460 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense Recognized (Details)",
     "shortName": "Stock-Based Compensation - Summary of Stock-Based Compensation Expense Recognized (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9d7f8b41-ab55-4cad-89a8-122b00ff6bb3",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails",
     "longName": "100530 - Disclosure - Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R43": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar",
     "longName": "100540 - Disclosure - Net Loss Per Share - Summary of Outstanding Potentially Dilutive Common Stock Equivalents were Excluded from Computation of Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Summary of Outstanding Potentially Dilutive Common Stock Equivalents were Excluded from Computation of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_387b8b88-6529-413e-9474-299a471851cb",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "longName": "100550 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_6a59c933-f461-45be-9258-2eeefba9dd39",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockSharesOutstanding",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_24425110-363c-4304-86c3-338011263481",
      "name": "nmra:RelatedPartyTransactionObligationWithRelatedParty",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20240331.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r650"
     ]
    },
    "us-gaap_AccountsPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable [Member]",
        "documentation": "Obligations incurred and payable to vendors for goods and services received."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "nmra_AccruedClinicalTrialAndPreclinicalCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "AccruedClinicalTrialAndPreclinicalCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued clinical trial and preclinical costs",
        "label": "Accrued Clinical Trial and Preclinical Costs",
        "documentation": "Accrued clinical trial and preclinical costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accrued liabilities",
        "verboseLabel": "Accrued liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional services",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "nmra_AccruedResearchAndDevelopmentServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "AccruedResearchAndDevelopmentServices",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development services",
        "label": "Accrued Research and Development Services",
        "documentation": "Accrued research and development services."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_AccruedResearchAndDevelopmentServicesDueToRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "AccruedResearchAndDevelopmentServicesDueToRelatedParty",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development services due to related party.",
        "label": "Accrued Research and Development Services Due to Related Party",
        "terseLabel": "Accrued research and development services due to related party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties due",
        "label": "Accrued Royalties",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r86",
      "r147",
      "r484",
      "r507",
      "r508"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r13",
      "r33",
      "r392",
      "r395",
      "r419",
      "r503",
      "r504",
      "r694",
      "r695",
      "r696",
      "r701",
      "r702",
      "r703"
     ]
    },
    "nmra_AchievementOfSpecifiedCommercializationEventsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "AchievementOfSpecifiedCommercializationEventsMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Achievement of Specified Commercialization Events",
        "label": "Achievement of Specified Commercialization Events [Member]",
        "documentation": "Achievement of specified commercialization events."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_AchievementOfSpecifiedDevelopmentEventsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "AchievementOfSpecifiedDevelopmentEventsMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Achievement of Specified Development Events",
        "label": "Achievement of Specified Development Events [Member]",
        "documentation": "Achievement of specified development events."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_AcquiredInProcessResearchAndDevelopedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "AcquiredInProcessResearchAndDevelopedExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired in-process research and developed expense.",
        "label": "Acquired in-process Research and Developed Expense",
        "terseLabel": "Acquired in-process research and developed expense"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_AcquiredInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "AcquiredInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired in-process research and development",
        "label": "Acquired in-process research and development",
        "documentation": "Acquired in-process research and development"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_AcquisitionDateFairValueOfSharesTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "AcquisitionDateFairValueOfSharesTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition date fair value of shares transferred",
        "label": "Acquisition Date Fair Value of Shares Transferred",
        "documentation": "Acquisition date fair value of shares transferred"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r342",
      "r343",
      "r523",
      "r701",
      "r702",
      "r703",
      "r763",
      "r783"
     ]
    },
    "nmra_AdditionalSharesOfCapitalStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "AdditionalSharesOfCapitalStockMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Shares of Capital Stock",
        "label": "Additional Shares of Capital Stock [Member]",
        "documentation": "Additional shares of capital stock member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_AdvisorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "AdvisorsMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advisors",
        "label": "Advisors [Member]",
        "documentation": "Advisors."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_AlairionCarveoutPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "AlairionCarveoutPlanMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alairion Carveout Plan",
        "label": "Alairion Carveout Plan [Member]",
        "documentation": "Alairion Carveout Plan."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_AlairionIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "AlairionIncMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alairion, Inc",
        "label": "Alairion, Inc [Member]",
        "documentation": "Alairion, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_AlairionMergerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "AlairionMergerAgreementMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alairion Merger Agreement",
        "label": "Alairion Merger Agreement [Member]",
        "documentation": "Alairion Merger Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total stock-based compensation",
        "terseLabel": "Share based compensation recognized",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r349"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_AmgenIncLicensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "AmgenIncLicensesMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amgen Inc. Licenses",
        "label": "Amgen Inc. Licenses [Member]",
        "documentation": "Amgen Inc. Licenses."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_AmgenIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "AmgenIncMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amgen Inc.",
        "label": "Amgen Inc [Member]",
        "documentation": "Amgen Inc."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_AmgenResearchAndCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "AmgenResearchAndCollaborationAgreementMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amgen Research and Collaboration Agreement",
        "label": "Amgen Research And Collaboration Agreement [Member]",
        "documentation": "Amgen research and collaboration agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share amount",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration",
        "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration",
        "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r760",
      "r761",
      "r762"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable",
        "terseLabel": "Asset acquisition compensation recognized and paid",
        "documentation": "Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r760",
      "r761",
      "r762"
     ]
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration deemed due or payable",
        "label": "Asset Acquisition, Contingent Consideration, Liability",
        "totalLabel": "Asset Acquisition, Contingent Consideration, Liability, Total",
        "documentation": "Amount of liability recognized from contingent consideration in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r143",
      "r165",
      "r198",
      "r208",
      "r210",
      "r245",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r385",
      "r389",
      "r409",
      "r479",
      "r562",
      "r650",
      "r663",
      "r722",
      "r723",
      "r768"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r148",
      "r165",
      "r245",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r385",
      "r389",
      "r409",
      "r650",
      "r722",
      "r723",
      "r768"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total assets measured at fair value",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Assets, Fair Value Disclosure, Total",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r668",
      "r670",
      "r671"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r668",
      "r670",
      "r671"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r668",
      "r670",
      "r671"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Debt Securities, Available-for-Sale, Amortized Cost, Total",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r253",
      "r478"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gain",
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain",
        "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross Unrealized Loss",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss",
        "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Available-for-Sale Securities, Debt Maturities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesByContractualMaturityDetails": {
       "parentTag": "nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesByContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "After one year through two years",
        "terseLabel": "After one year through [two] years",
        "label": "Available For Sale Securities Debt Maturities After One Through Two Years Fair Value",
        "documentation": "Available for sale securities debt maturities after one through two years fair value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesByContractualMaturityDetails": {
       "parentTag": "nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesByContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Within one year",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r476"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total marketable securities",
        "terseLabel": "Estimated Fair Value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r253",
      "r472",
      "r708"
     ]
    },
    "nmra_AwardModificationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "AwardModificationMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Modification",
        "label": "Award Modification [Member]",
        "documentation": "Award modification."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335"
     ]
    },
    "nmra_AwardsWithPerformanceConditionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "AwardsWithPerformanceConditionsMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards with Performance Conditions",
        "label": "Awards with Performance Conditions [Member]",
        "documentation": "Awards with performance conditions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65"
     ]
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Consolidation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies and Basis of Presentation",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "nmra_BlackthornCarveoutPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "BlackthornCarveoutPlanMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BlackThorn Carveout Plan",
        "label": "BlackThorn Carveout Plan [Member]",
        "documentation": "BlackThorn Carveout Plan."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_BlackthornMergerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "BlackthornMergerAgreementMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BlackThorn Merger Agreement",
        "label": "BlackThorn Merger Agreement [Member]",
        "documentation": "BlackThorn Merger Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_BlackthornTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "BlackthornTherapeuticsIncMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BlackThorn Therapeutics, Inc.",
        "label": "BlackThorn Therapeutics, Inc. [Member]",
        "documentation": "BlackThorn Therapeutics, Inc. member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r642",
      "r643"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r380",
      "r642",
      "r643"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions of Assets",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r381"
     ]
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions",
        "label": "Business Combinations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_CaliforniaFranchiseTaxBoardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CaliforniaFranchiseTaxBoardMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "California Franchise Tax Board [Member]",
        "terseLabel": "California",
        "documentation": "Designated tax department of the government of the state of California."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of property and equipment included in accounts payable",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r41"
     ]
    },
    "nmra_CaseOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "CaseOneMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Case One",
        "label": "Case One [Member]",
        "documentation": "Case one."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_CaseTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "CaseTwoMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Case Two",
        "label": "Case Two [Member]",
        "documentation": "Case two."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r141",
      "r628"
     ]
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsLineItems",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r117"
     ]
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecurities1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents and Marketable Securities",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents, and marketable securities",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and cash equivalents and restricted cash at end of year",
        "periodStartLabel": "Cash and cash equivalents and restricted cash at beginning of year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r97",
      "r163"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash and cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r97"
     ]
    },
    "nmra_CashEquivalentsAndMarketableSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "CashEquivalentsAndMarketableSecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents and Marketable Securities [Abstract]",
        "documentation": "Cash equivalents and marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents",
        "label": "Cash Equivalents [Member]",
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certificates of Deposit",
        "label": "Certificates of Deposit [Member]",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r657",
      "r658",
      "r659",
      "r660"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r144",
      "r145",
      "r146",
      "r165",
      "r185",
      "r186",
      "r188",
      "r190",
      "r196",
      "r197",
      "r245",
      "r265",
      "r267",
      "r268",
      "r269",
      "r272",
      "r273",
      "r277",
      "r278",
      "r281",
      "r284",
      "r292",
      "r409",
      "r513",
      "r514",
      "r515",
      "r516",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r550",
      "r571",
      "r593",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r678",
      "r699",
      "r704"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r196",
      "r277",
      "r278",
      "r279",
      "r281",
      "r284",
      "r290",
      "r292",
      "r513",
      "r514",
      "r515",
      "r516",
      "r637",
      "r678",
      "r699"
     ]
    },
    "nmra_CollaborationAgreementNonRefundableQuarterlyPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "CollaborationAgreementNonRefundableQuarterlyPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement non-refundable quarterly payments",
        "label": "Collaboration Agreement Non-refundable Quarterly Payments",
        "documentation": "Collaboration agreement non-refundable quarterly payments."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_CollaborationAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "CollaborationAgreementTerm",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of the agreement",
        "label": "Collaboration Agreement Term",
        "documentation": "Collaboration agreement term."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_CollaborationAgreementTerminationDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "CollaborationAgreementTerminationDescription",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement termination description",
        "label": "Collaboration Agreement Termination Description",
        "documentation": "Collaboration agreement termination description."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Strategic License and Research and Collaboration Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r127",
      "r135"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "nmra_CommercialMilestonePaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "CommercialMilestonePaymentMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Milestone Payment",
        "label": "Commercial Milestone Payment [Member]",
        "documentation": "Commercial milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_CommercialMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "CommercialMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial milestone payments",
        "label": "Commercial Milestone Payments",
        "documentation": "Commercial milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commercial Paper",
        "terseLabel": "Commercial Paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r657",
      "r658",
      "r659",
      "r660"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r71",
      "r480",
      "r549"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r259",
      "r260",
      "r624",
      "r719"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares reserved for potential future issuances",
        "terseLabel": "Common stock reserved for future issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r653",
      "r654",
      "r655",
      "r657",
      "r658",
      "r659",
      "r660",
      "r701",
      "r702",
      "r763",
      "r782",
      "r783"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r550"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r80",
      "r550",
      "r568",
      "r783",
      "r784"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r482",
      "r650"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r152",
      "r154",
      "r159",
      "r473",
      "r493"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Loss",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r129"
     ]
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentConsiderationByTypeAxis",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Consideration by Type [Axis]",
        "documentation": "Information by type of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_ContingentConsiderationMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "ContingentConsiderationMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration, milestone payment",
        "label": "Contingent Consideration, Milestone Payment",
        "documentation": "Contingent consideration, milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_ContingentConsiderationMilestonePaymentSettledInCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "ContingentConsiderationMilestonePaymentSettledInCash",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration, milestone payment settled in cash",
        "label": "Contingent Consideration, Milestone Payment Settled in Cash",
        "documentation": "Contingent consideration, milestone payment settled in cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentConsiderationTypeDomain",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Consideration Type [Domain]",
        "documentation": "Description of contingent payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar",
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock",
        "label": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r281",
      "r657",
      "r658",
      "r659",
      "r660"
     ]
    },
    "nmra_ConvertiblePreferredStockPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "ConvertiblePreferredStockPolicyPolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible preferred stock, policy policy text block.",
        "label": "Convertible Preferred Stock, Policy [Policy Text Block]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of convertible preferred stock automatically converted into shares of common stock",
        "verboseLabel": "Converted shares",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r51",
      "r79",
      "r107",
      "r287"
     ]
    },
    "nmra_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible preferred stock warrant liability policy text block.",
        "label": "Convertible Preferred Stock Warrant Liability [Policy Text Block]",
        "terseLabel": "Convertible Preferred Stock Warrant Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Debt Securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r639",
      "r641",
      "r781"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Total deferred tax liabilities",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r119",
      "r366"
     ]
    },
    "nmra_DeferredOfferingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "DeferredOfferingCostsPolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Offering Costs",
        "label": "Deferred Offering Costs [Policy Text Block]",
        "documentation": "Deferred offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "nmra_DeferredTaxAssetsInCapitalizedLicenseAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "DeferredTaxAssetsInCapitalizedLicenseAgreements",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets in capitalized license agreements.",
        "label": "Deferred Tax Assets In Capitalized License Agreements",
        "terseLabel": "Capitalized license agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized research and development expense",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r757"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets less valuation allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "nmra_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets operating lease liabilities.",
        "label": "Deferred Tax Assets Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating losses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r757"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r757"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_DeferredTaxAssetsTaxCreditCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsLineItems",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r757"
     ]
    },
    "nmra_DeferredTaxAssetsTaxCreditCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsTable",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Compensation related",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r757"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "terseLabel": "Less: valuation allowance",
        "negatedLabel": "Less: valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "nmra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities operating lease right of use assets.",
        "label": "Deferred Tax Liabilities Operating Lease Right Of Use Assets",
        "terseLabel": "Operating lease right-of-use assets",
        "negatedLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "terseLabel": "Fixed assets",
        "negatedLabel": "Fixed assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r757"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "verboseLabel": "Depreciation and amortization expense",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r199"
     ]
    },
    "nmra_DevelopmentAndRegulatoryApprovalMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "DevelopmentAndRegulatoryApprovalMilestonesMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development and Regulatory Approval Milestones",
        "label": "Development and Regulatory Approval Milestones [Member]",
        "documentation": "Development and regulatory approval milestones."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_DevelopmentAndRegulatoryMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "DevelopmentAndRegulatoryMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development and regulatory milestone payments",
        "label": "Development And Regulatory Milestone Payments",
        "documentation": "Development and regulatory milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_DevelopmentMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "DevelopmentMilestonesMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development Milestones",
        "label": "Development Milestones [Member]",
        "documentation": "Development milestones."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r306",
      "r337",
      "r338",
      "r340",
      "r645"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r668",
      "r670",
      "r671"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r668",
      "r670",
      "r671",
      "r673"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_EarlyExerciseLiabilityCurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "EarlyExerciseLiabilityCurrentPortion",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Early exercise liability, current portion",
        "label": "Early Exercise Liability Current Portion",
        "documentation": "Early exercise liability, current portion."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_EarlyExerciseLiabilityNetOfCurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "EarlyExerciseLiabilityNetOfCurrentPortion",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Early exercise liability, net of current portion",
        "label": "Early Exercise Liability Net Of Current Portion",
        "documentation": "Early exercise liability, net of current portion."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_EarlyExerciseOfEmployeeStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "EarlyExerciseOfEmployeeStockOptionsMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Early Exercise of Employee Stock Options",
        "label": "Early Exercise of Employee Stock Options [Member]",
        "documentation": "Early exercise of employee stock options."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "EarlyExercisedStockOptionsSubjectToFutureVestingMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Early Exercised Stock Options Subject to Future Vesting",
        "label": "Early exercised stock options subject to future vesting [Member]",
        "documentation": "Early exercised stock options subject to future vesting."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, basic",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r183",
      "r185",
      "r188",
      "r189",
      "r190",
      "r194",
      "r400",
      "r401",
      "r474",
      "r494",
      "r629"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, diluted",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r185",
      "r188",
      "r189",
      "r190",
      "r194",
      "r400",
      "r401",
      "r474",
      "r494",
      "r629"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r191",
      "r192",
      "r193"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate",
        "totalLabel": "Effective income tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal income taxes",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r358",
      "r376"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r758"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Tax law change",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r754"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Permanent differences",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r758"
     ]
    },
    "nmra_EffectiveIncomeTaxRateReconciliationMilestonePaymentsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "EffectiveIncomeTaxRateReconciliationMilestonePaymentsPercent",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation, milestone payments, percent.",
        "label": "Effective Income Tax Rate Reconciliation, Milestone payments, Percent",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income taxes, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r758"
     ]
    },
    "nmra_EffectiveIncomeTaxRateReconciliationStateRateAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "EffectiveIncomeTaxRateReconciliationStateRateAdjustments",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation state rate adjustments.",
        "label": "Effective Income Tax Rate Reconciliation State Rate Adjustments",
        "terseLabel": "State rate adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Research and development tax credits",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r758"
     ]
    },
    "nmra_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "EffectiveIncomeTaxRateReconciliationUncertainTaxPositions",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation uncertain tax positions.",
        "label": "Effective Income Tax Rate Reconciliation Uncertain Tax Positions",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_EmergingGrowthCompanyStatusPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "EmergingGrowthCompanyStatusPolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Emerging Growth Company Status",
        "label": "Emerging Growth Company Status [Policy Text Block]",
        "documentation": "Emerging growth company status."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation and benefits",
        "label": "Employee-related Liabilities, Current",
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized stock-based compensation",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining service period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "EmployeeStockOptionAndAndRestrictedStockUnitsMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Options and Restricted Stock Units",
        "label": "Employee Stock Option and and Restricted Stock Units Member",
        "documentation": "Employee stock option and and restricted stock units."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option",
        "verboseLabel": "Common Stock Options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r137",
      "r156",
      "r157",
      "r158",
      "r169",
      "r170",
      "r171",
      "r173",
      "r179",
      "r181",
      "r195",
      "r246",
      "r247",
      "r293",
      "r341",
      "r342",
      "r343",
      "r372",
      "r373",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r399",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r419",
      "r503",
      "r504",
      "r505",
      "r523",
      "r593"
     ]
    },
    "nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesByContractualMaturityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesByContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total marketable securities",
        "label": "Estimated Fair Value Of Available For Sale Debt Securities Fair Value",
        "documentation": "Estimated fair value of available for sale debt securities fair value."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ExecutiveOfficerMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executives",
        "label": "Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r407"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r407"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r404",
      "r431",
      "r432",
      "r433",
      "r635",
      "r636",
      "r639",
      "r640",
      "r641"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r406",
      "r408"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r295",
      "r300",
      "r404",
      "r431",
      "r639",
      "r640",
      "r641"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r295",
      "r300",
      "r404",
      "r432",
      "r635",
      "r636",
      "r639",
      "r640",
      "r641"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r404",
      "r433",
      "r635",
      "r636",
      "r639",
      "r640",
      "r641"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]",
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r431",
      "r432",
      "r433",
      "r635",
      "r636",
      "r639",
      "r640",
      "r641"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r408"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r20"
     ]
    },
    "nmra_FederalPostDecember312017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "FederalPostDecember312017Member",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal (Post-December 31, 2017).",
        "label": "Federal (Post-December 31, 2017) [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_FederalPreJanuary12018Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "FederalPreJanuary12018Member",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal (Pre-January 1, 2018).",
        "label": "Federal (Pre-January 1, 2018) [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r275",
      "r290",
      "r397",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r492",
      "r634",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r712",
      "r713",
      "r714",
      "r715"
     ]
    },
    "nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fund eligible to receive upon completion of certain development milestone",
        "label": "Fund Eligible To Receive Upon Completion Of Certain Development Milestone",
        "documentation": "Fund eligible to receive upon completion of certain development milestone."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "FundsProvidedForPreClinicalResearchAndDevelopmentActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Funds provided for preclinical research and development activities",
        "label": "Funds Provided For Pre-clinical Research And Development Activities",
        "documentation": "Funds provided for pre-clinical research and development activities."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_FundsReceivedUponExecutionOfAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "FundsReceivedUponExecutionOfAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Funds received upon execution of agreement",
        "label": "Funds Received Upon Execution Of Agreement",
        "documentation": "Funds received upon execution of agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gain (Loss) on Investments, Total",
        "label": "Gain (Loss) on Investments",
        "terseLabel": "Realized loss on investments",
        "negatedLabel": "Realized loss on investments",
        "documentation": "Amount of realized and unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r677"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "totalLabel": "General and Administrative Expense, Total",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r573"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial Public Offering",
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r102"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r87",
      "r121",
      "r198",
      "r207",
      "r209",
      "r211",
      "r475",
      "r489",
      "r631"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r578"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r578"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Domain]",
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r352",
      "r359",
      "r363",
      "r370",
      "r374",
      "r377",
      "r378",
      "r379",
      "r518"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense",
        "negatedLabel": "Provision for income taxes",
        "verboseLabel": "Provision for income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r134",
      "r180",
      "r181",
      "r200",
      "r357",
      "r375",
      "r495"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r355",
      "r356",
      "r363",
      "r364",
      "r369",
      "r371",
      "r512"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Tax law change",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r358"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities",
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total",
        "terseLabel": "Accrued liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r679",
      "r697"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest income",
        "documentation": "The net amount of nonoperating interest income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeAmortizationOfDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeAmortizationOfDiscount",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net accretion of investments in marketable securities",
        "label": "Investment Income, Amortization of Discount",
        "documentation": "Amount of accretion of purchase discount on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Net",
        "totalLabel": "Investment Income, Net, Total",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r94"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r601",
      "r603",
      "r605",
      "r608",
      "r609",
      "r610",
      "r611",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r655"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r601",
      "r603",
      "r605",
      "r608",
      "r609",
      "r610",
      "r611",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r655"
     ]
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Marketable Securities by Contractual Maturity",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Summary of Maturity of the Company's Operating Lease Liabilities",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r165",
      "r245",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r386",
      "r389",
      "r390",
      "r409",
      "r548",
      "r630",
      "r663",
      "r722",
      "r768",
      "r769"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r120",
      "r486",
      "r650",
      "r700",
      "r716",
      "r764"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders' Equity",
        "verboseLabel": "Liabilities, Convertible Preferred Stock, and Stockholders' Equity (Deficit)",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r140",
      "r165",
      "r245",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r386",
      "r389",
      "r390",
      "r409",
      "r650",
      "r722",
      "r768",
      "r769"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_LiquidityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "LiquidityMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidity",
        "label": "Liquidity [Member]",
        "documentation": "Liquidity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_MarketAwardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "MarketAwardMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market Award",
        "label": "Market Award [Member]",
        "documentation": "Market award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "verboseLabel": "Short-term marketable securities",
        "label": "Marketable Securities, Current",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "nmra_MarketableSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "MarketableSecuritiesMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Marketable securities [Member]",
        "documentation": "Marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Long-term marketable securities",
        "label": "Marketable Securities, Noncurrent",
        "documentation": "Amount of investment in marketable security, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "nmra_MassachusettsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "MassachusettsMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Massachusetts.",
        "label": "Massachusetts [Member]",
        "terseLabel": "Massachusetts"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_MaximumAdditionalFinancingInEquitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "MaximumAdditionalFinancingInEquitySecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum additional financing in equity securities",
        "documentation": "Maximum additional financing in equity securities."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsParentheticalDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r302",
      "r458",
      "r502",
      "r540",
      "r541",
      "r602",
      "r604",
      "r606",
      "r607",
      "r612",
      "r625",
      "r626",
      "r633",
      "r637",
      "r644",
      "r652",
      "r724",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775"
     ]
    },
    "nmra_MaximumRepaymentAmountAgreedToPay": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "MaximumRepaymentAmountAgreedToPay",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum repayment amount agreed to pay.",
        "label": "Maximum Repayment Amount Agreed To Pay",
        "documentation": "Maximum repayment amount agreed to pay."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_MilestonePaymentDueDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "MilestonePaymentDueDescription",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment due description",
        "label": "Milestone Payment Due Description",
        "documentation": "Milestone payment due description."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_MilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "MilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments",
        "label": "Milestone Payments",
        "documentation": "Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_MilestonesAchieved": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "MilestonesAchieved",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestones achieved",
        "label": "Milestones Achieved",
        "documentation": "Milestones achieved."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r302",
      "r458",
      "r502",
      "r540",
      "r541",
      "r602",
      "r604",
      "r606",
      "r607",
      "r612",
      "r625",
      "r626",
      "r633",
      "r637",
      "r644",
      "r652",
      "r724",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money Market Funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "nmra_NavacaprantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "NavacaprantMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "navacaprant",
        "label": "Navacaprant [Member]",
        "documentation": "Navacaprant."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetAssetValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetAssetValuePerShare",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net asset value per share",
        "label": "Net Asset Value Per Share",
        "periodEndLabel": "Net Asset Value Per Share, Ending Balance",
        "periodStartLabel": "Net Asset Value Per Share, Beginning Balance",
        "documentation": "Net asset value per share or per unit of investments in certain entities that calculate net asset value per share. Includes, but is not limited to, by unit, membership interest, or other ownership interest. Investment includes, but is not limited to, investment in certain hedge funds, venture capital funds, private equity funds, real estate partnerships or funds. Excludes fair value disclosure."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3",
      "r19",
      "r526",
      "r533",
      "r534",
      "r552",
      "r568",
      "r618",
      "r663"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r99"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss",
        "totalLabel": "Net loss",
        "terseLabel": "Net Income (Loss)",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r99",
      "r122",
      "r138",
      "r151",
      "r153",
      "r158",
      "r165",
      "r172",
      "r174",
      "r175",
      "r176",
      "r177",
      "r180",
      "r181",
      "r187",
      "r198",
      "r207",
      "r209",
      "r211",
      "r245",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r401",
      "r409",
      "r491",
      "r570",
      "r591",
      "r592",
      "r631",
      "r661",
      "r722"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements Not Yet Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_Nmra511Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "Nmra511Member",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NMRA-511",
        "label": "NMRA-511 [Member]",
        "documentation": "NMRA-511."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of noncash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_NoncashOperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "NoncashOperatingLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash operating lease expense",
        "documentation": "Noncash operating lease expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "NumberOfClinicalAndPreclinicalNeurosciencePrograms",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of clinical and preclinical neuroscience programs",
        "label": "Number Of Clinical And Preclinical Neuroscience Programs",
        "documentation": "Number of clinical and preclinical neuroscience programs"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_NumberOfLicenseAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "NumberOfLicenseAgreements",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of license agreements",
        "label": "Number of License Agreements",
        "documentation": "Number of license agreements."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_NumberOfMilestoneAchieved": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "NumberOfMilestoneAchieved",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of milestone achieved",
        "label": "Number of Milestone Achieved",
        "documentation": "Number of milestone achieved."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_OfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "OfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering expenses",
        "label": "Offering Expenses",
        "documentation": "Offering expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating Income (Loss), Total",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r207",
      "r209",
      "r211",
      "r631"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liabilities, current portion",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Less: Operating lease liabilities, current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liabilities, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "NOLs, Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLimitationsOnUse",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards, Limitations on Use",
        "terseLabel": "NOLs, Expiration Years",
        "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_OrganizationAndLiquidityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "OrganizationAndLiquidityLineItems",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Liquidity [Line items]",
        "documentation": "Organization and Liquidity [Line items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Organization and Liquidity",
        "terseLabel": "Summary of Significant Accounting Policies and Basis of Presentation",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r115",
      "r509",
      "r510"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "totalLabel": "Total other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss):",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on marketable securities",
        "verboseLabel": "Unrealized (loss/gain) on marketable debt securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r150",
      "r244"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other noncash expenses",
        "label": "Other Noncash Income (Expense)",
        "totalLabel": "Other Noncash Income (Expense), Total",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expense, net",
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid other",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r692",
      "r717"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other Receivables, Net, Current",
        "totalLabel": "Other Receivables, Net, Current, Total",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_ParkinsonsResearchVenturesFundingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "ParkinsonsResearchVenturesFundingAgreementMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Parkinson's Research Ventures Funding Agreement",
        "label": "Parkinsons Research Ventures Funding Agreement [Member]",
        "documentation": "Parkinsons research ventures funding agreement."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_PaymentsForExecutionOfAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "PaymentsForExecutionOfAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for execution of agreement",
        "label": "Payments For Execution Of Agreement",
        "documentation": "Payments for execution of agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of Series B convertible preferred stock, issuance costs",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Issuance / Offering costs",
        "negatedLabel": "Payments for deferred offering costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration payable in cash",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r382"
     ]
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cash paid for acquisition of assets",
        "label": "Payments to Acquire in Process Research and Development",
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "nmra_PercentageOfFutureTaxableIncomeOffsettingByNol": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "PercentageOfFutureTaxableIncomeOffsettingByNol",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of future taxable income offsetting by NOL.",
        "label": "Percentage of Future Taxable Income Offsetting By NOL",
        "terseLabel": "Percentage of future taxable income offsetting by NOL carryforward"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_PerformanceConditionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "PerformanceConditionsMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Conditions",
        "label": "Performance Conditions [Member]",
        "documentation": "Performance conditions."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_PerformanceRestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "PerformanceRestrictedStockMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Restricted Stock",
        "label": "Performance Restricted Stock [Member]",
        "documentation": "Performance restricted stock."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Restricted Stock (With Performance Conditions to Be Established)",
        "label": "Performance restricted stock (with performance conditions to be established) [Member]",
        "documentation": "Performance restricted stock (with performance conditions to be established)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Stock Options",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Stock Options (With Performance Conditions to Be Established)",
        "label": "Performance stock options (with performance conditions to be established) [Member]",
        "documentation": "Performance stock options (with performance conditions to be established)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752"
     ]
    },
    "nmra_PreferredStockExercisePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "PreferredStockExercisePricePerShare",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock warrants, exercise price",
        "label": "Preferred Stock Exercise Price Per Share",
        "documentation": "Preferred stock exercise price per share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r277"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r550"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock warrants, issued",
        "terseLabel": "Preferred stock, issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r277"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r550",
      "r568",
      "r783",
      "r784"
     ]
    },
    "us-gaap_PreferredStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosurePreferredStockWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock Warrants",
        "label": "Preferred Stock [Text Block]",
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "nmra_PreferredStockWarrantsHeldByRelatedParty": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "PreferredStockWarrantsHeldByRelatedParty",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock warrants held by related party",
        "label": "Preferred Stock Warrants Held By Related Party",
        "documentation": "Preferred stock warrants held by related party."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_PreferredStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "PreferredStockWarrantsMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock Warrants",
        "label": "Preferred stock warrants [Member]",
        "documentation": "Preferred stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total prepaid expenses and other current assets",
        "terseLabel": "Prepaid research and development costs",
        "verboseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_PrepaidResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "PrepaidResearchAndDevelopmentCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid research and development costs ($9.4 million and $6.3 million from related party in 2024 and 2023, respectively)",
        "verboseLabel": "Prepaid research and development costs from related party",
        "label": "Prepaid Research and Development Costs",
        "documentation": "Prepaid research and development costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts and commissions",
        "terseLabel": "Proceeds from initial public offering",
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from issuance of convertible preferred stock",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of convertible preferred stock, net of issuance costs",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales and maturities of marketable securities",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r18"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r212",
      "r459",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r627",
      "r638",
      "r651",
      "r680",
      "r720",
      "r721",
      "r725",
      "r780"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r212",
      "r459",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r627",
      "r638",
      "r651",
      "r680",
      "r720",
      "r721",
      "r725",
      "r780"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r151",
      "r153",
      "r161",
      "r165",
      "r172",
      "r180",
      "r181",
      "r198",
      "r207",
      "r209",
      "r211",
      "r245",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r384",
      "r387",
      "r388",
      "r401",
      "r409",
      "r475",
      "r490",
      "r522",
      "r570",
      "r591",
      "r592",
      "r631",
      "r648",
      "r649",
      "r662",
      "r696",
      "r722"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Total property and equipment",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r477",
      "r488",
      "r650"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r130",
      "r133",
      "r487"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsParentheticalDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r294",
      "r302",
      "r332",
      "r333",
      "r334",
      "r434",
      "r458",
      "r502",
      "r540",
      "r541",
      "r602",
      "r604",
      "r606",
      "r607",
      "r612",
      "r625",
      "r626",
      "r633",
      "r637",
      "r644",
      "r652",
      "r655",
      "r718",
      "r724",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsParentheticalDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r294",
      "r302",
      "r332",
      "r333",
      "r334",
      "r434",
      "r458",
      "r502",
      "r540",
      "r541",
      "r602",
      "r604",
      "r606",
      "r607",
      "r612",
      "r625",
      "r626",
      "r633",
      "r637",
      "r644",
      "r652",
      "r655",
      "r718",
      "r724",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r423",
      "r424",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r567",
      "r569",
      "r600"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r168",
      "r423",
      "r424",
      "r425",
      "r426",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r567",
      "r569",
      "r600"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsParentheticalDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r575",
      "r578"
     ]
    },
    "nmra_RelatedPartyTransactionObligationWithRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "RelatedPartyTransactionObligationWithRelatedParty",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party transaction obligation with related party",
        "label": "Related Party Transaction Obligation with Related Party",
        "documentation": "Related party transaction obligation with related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r423",
      "r424",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r567",
      "r569",
      "r600",
      "r767"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r421",
      "r422",
      "r424",
      "r427",
      "r519",
      "r520",
      "r521",
      "r576",
      "r577",
      "r578",
      "r597",
      "r599"
     ]
    },
    "nmra_RepurchaseOfUnvestedEarlyExercisedShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "RepurchaseOfUnvestedEarlyExercisedShares",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchase of unvested early exercised shares",
        "label": "Repurchase Of Unvested Early Exercised Shares",
        "documentation": "Repurchase of unvested early exercised shares"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_RepurchaseOfUnvestedEarlyExercisedStockOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "RepurchaseOfUnvestedEarlyExercisedStockOptions",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchase of unvested early exercised stock options",
        "label": "Repurchase of unvested early exercised stock options",
        "documentation": "Repurchase of unvested early exercised stock options."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_ResearchAgreementExpiryDate": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "ResearchAgreementExpiryDate",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research agreement expiry date.",
        "label": "Research Agreement Expiry Date",
        "terseLabel": "Research agreement expiry date"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_ResearchAndCollaborationAgreementQuarterlyPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "ResearchAndCollaborationAgreementQuarterlyPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and collaboration agreement quarterly payments",
        "label": "Research And Collaboration Agreement Quarterly Payments",
        "documentation": "Research And Collaboration Agreement Quarterly Payments"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and collaboration agreement quarterly payments for first two year",
        "label": "Research And Collaboration Agreement Quarterly Payments For First Two Years",
        "documentation": "Research and collaboration agreement quarterly payments for first two years."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and collaboration agreement quarterly payments for third year",
        "label": "Research And Collaboration Agreement Quarterly Payments For Third Year",
        "documentation": "Research and collaboration agreement quarterly payments for third year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development expenses",
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "totalLabel": "Research and Development Expense, Total",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r351",
      "r776"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses and Related Prepaid Assets and Accrued Liabilities",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and Development",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash",
        "totalLabel": "Restricted Cash, Total",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r689",
      "r698",
      "r777",
      "r779"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cash and cash equivalents and restricted cash",
        "terseLabel": "Total cash and cash equivalents and restricted cash",
        "label": "Restricted Cash and Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r117",
      "r141",
      "r163",
      "r481"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsAbstract",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of cash and restricted cash:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted cash",
        "label": "Restricted Cash, Current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r689",
      "r698"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted cash",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r690",
      "r698"
     ]
    },
    "nmra_RestrictedCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "RestrictedCommonStockMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Common Stock",
        "label": "Restricted Common Stock [Member]",
        "documentation": "Restricted common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted Common Stock",
        "terseLabel": "Restricted Stock",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted Stock Units",
        "terseLabel": "Unvested Restricted Stock Awards",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r109",
      "r485",
      "r506",
      "r508",
      "r517",
      "r551",
      "r650"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r169",
      "r170",
      "r171",
      "r173",
      "r179",
      "r181",
      "r246",
      "r247",
      "r341",
      "r342",
      "r343",
      "r372",
      "r373",
      "r391",
      "r393",
      "r394",
      "r396",
      "r399",
      "r503",
      "r505",
      "r523",
      "r783"
     ]
    },
    "nmra_RisksAndUncertaintiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risks and Uncertainties",
        "label": "Risks and Uncertainties [Policy Text Block]",
        "documentation": "Risks and uncertainties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock sold in initial public offering",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price to public, per share",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_SalesBasedMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "SalesBasedMilestonesMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales-based Milestones",
        "label": "Sales Based Milestones [Member]",
        "documentation": "Sales-based milestones."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Outstanding Potentially Dilutive Common Stock Equivalents were Excluded from Computation of Diluted Net Loss Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Amortized Cost and Fair Value of Cash Equivalents and Marketable Securities by Major Investment Category",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r380"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "nmra_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Stock Reserved for Future Issuance",
        "label": "Schedule of common stock reserved for future issuance [Table Text Block]",
        "documentation": "Schedule of common stock reserved for future issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Summary of Deferred Tax Assets and Liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Computation of Basic and Diluted Net Loss Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Reconciliation of Federal Income Tax Rate and Effective Income Tax Rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock-Based Compensation Expense Recognized",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404"
     ]
    },
    "nmra_ScheduleOfOrganizationAndLiquidityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "ScheduleOfOrganizationAndLiquidityTable",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Organization And Liquidity [Table]",
        "documentation": "Schedule of organization and liquidity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOtherAssetsTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Assets [Table Text Block]",
        "terseLabel": "Schedule of Other assets",
        "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsParentheticalDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r69",
      "r574",
      "r575",
      "r578"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305",
      "r307",
      "r308",
      "r309",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Restricted Stock Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r56"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r53",
      "r54",
      "r106",
      "r108",
      "r109",
      "r144",
      "r145",
      "r146",
      "r196",
      "r277",
      "r278",
      "r279",
      "r281",
      "r284",
      "r290",
      "r292",
      "r513",
      "r514",
      "r515",
      "r516",
      "r637",
      "r678",
      "r699"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Summary of Reconciliation of Unrecognized Tax Benefits",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r755"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r213",
      "r632"
     ]
    },
    "nmra_SeriesA1ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "SeriesA1ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Series A-1 Convertible Preferred Stock",
        "terseLabel": "Series A-1",
        "label": "Series A-1 convertible preferred stock [Member]",
        "documentation": "Series A-1 convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_SeriesA2ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "SeriesA2ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Series A-2",
        "terseLabel": "Series A-2 Convertible Preferred Stock",
        "label": "Series A-2 Convertible Preferred Stock [Member]",
        "documentation": "Series A-2 Convertible Preferred Stock."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_SeriesBConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "SeriesBConvertiblePreferredStockMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Series B",
        "terseLabel": "Series B Convertible Preferred Stock",
        "label": "Series B Convertible Preferred Stock [Member]",
        "documentation": "Series b convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_ServiceConditionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "ServiceConditionsMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service Conditions",
        "label": "Service Conditions [Member]",
        "documentation": "Service conditions."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_ServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "ServicesAgreementMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Services Agreement",
        "label": "Services Agreement [Member]",
        "documentation": "Services agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share based compensation forfeited under unvested plan",
        "terseLabel": "Share based compensation granted under plan vested period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited and canceled, Shares",
        "terseLabel": "Share based compensation forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited and canceled, Weighted Average Grant Date Fair Value Per Share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted, Shares",
        "terseLabel": "Unvested shares repurchased",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted, Weighted Average Grant Date Fair Value Per Share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Outstanding and unvested, Shares at ending balance",
        "periodStartLabel": "Outstanding and unvested, Shares at beginning balance",
        "terseLabel": "Shares or restricted stock remained outstanding and unvested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Outstanding and unvested, Weighted Average Grant Date Fair Value Per Share at ending balance",
        "periodStartLabel": "Outstanding and unvested, Weighted Average Grant Date Fair Value Per Share at beginning balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested, Shares",
        "terseLabel": "Vested, Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested, Weighted Average Grant Date Fair Value Per Share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options granted, exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305",
      "r307",
      "r308",
      "r309",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335"
     ]
    },
    "nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based payment, milestones achieved",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Milestones Achieved",
        "documentation": "Share based compensation arrangement by share based payment award milestones achieved."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, Outstanding Stock Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price Per Share, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expired, Outstanding Stock Options",
        "terseLabel": "Expired, Outstanding Stock Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Canceled and forfeited, Outstanding Stock Options",
        "verboseLabel": "Stock options, cancelled",
        "terseLabel": "Canceled and forfeited, Outstanding Stock Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options grant date fair value.",
        "terseLabel": "Grant date fair value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award Options Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted, outstanding stock options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Outstanding",
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Ending balance, Outstanding Stock Options",
        "periodStartLabel": "Beginning balance, Outstanding Stock Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted-Average Exercise Price Per Share, Outstanding, end of period",
        "periodStartLabel": "Weighted-Average Exercise Price Per Share, Outstanding, beginning of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested, outstanding stock options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price Per Share, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options vested in period incremental expense resulted in modification.",
        "terseLabel": "Total incremental expense resulted in modification",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award Options Vested in Period Incremental Expense Resulted in Modification"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options granted to purchase",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award",
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Award Types",
        "label": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price Per Share, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price Per Share, Expired",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price Per Share, Canceled and forfeited",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price Per Share, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "nmra_ShareBasedCompensationAwardTrancheFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "ShareBasedCompensationAwardTrancheFourMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Award Tranche Four.",
        "label": "Share Based Compensation Award Tranche Four [Member]",
        "terseLabel": "Market Based Tranches"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche One",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche Three",
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche Two",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r310",
      "r329",
      "r330",
      "r331",
      "r332",
      "r335",
      "r344",
      "r345",
      "r346",
      "r347"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation, term of plan",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Remaining Contractual Term, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Remaining Contractual Term, Outstanding (Years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Remaining Contractual Term, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Aggregate grant-date fair value of options",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grants vest percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued based on volume weighted average price per share prior to date milestone was met.",
        "label": "Shares Issued Based on Volume Weighted Average Price Per Share Prior to Date Milestone Was Met",
        "terseLabel": "Shares issued based on volume weighted average price per share prior to date milestone was met"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_SharesIssuedUponAchievementOfMilestone": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "SharesIssuedUponAchievementOfMilestone",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued upon achievement of milestone.",
        "label": "Shares issued upon achievement of milestone",
        "terseLabel": "Shares issued upon achievement of milestone"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance at Ending (in Shares)",
        "periodStartLabel": "Balance at Beginning (in Shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_SharesReservedForFutureIssuanceUnderThePlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "SharesReservedForFutureIssuanceUnderThePlansMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares reserved for future issuance under the plans.",
        "label": "Shares reserved for future issuance under the plans [Member]",
        "terseLabel": "Shares Reserved for Future Issuance Under the Plans"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_SharesReservedForIssuanceUnderThePlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "SharesReservedForIssuanceUnderThePlansMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Reserved for Issuance Under the Plans",
        "label": "Shares Reserved for Issuance under the Plans [Member]",
        "documentation": "Shares reserved for issuance under the plans."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Reserved for Options and Restricted Stock Units Issued Under the Plans",
        "label": "Shares Reserved For Options And Restricted Stock UnitsIssued UnderThe Plans [Member]",
        "documentation": "Shares reserved for options and restricted stock unitsissued underthe plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r144",
      "r145",
      "r146",
      "r165",
      "r185",
      "r186",
      "r188",
      "r190",
      "r196",
      "r197",
      "r245",
      "r265",
      "r267",
      "r268",
      "r269",
      "r272",
      "r273",
      "r277",
      "r278",
      "r281",
      "r284",
      "r292",
      "r409",
      "r513",
      "r514",
      "r515",
      "r516",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r550",
      "r571",
      "r593",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r678",
      "r699",
      "r704"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r31",
      "r137",
      "r156",
      "r157",
      "r158",
      "r169",
      "r170",
      "r171",
      "r173",
      "r179",
      "r181",
      "r195",
      "r246",
      "r247",
      "r293",
      "r341",
      "r342",
      "r343",
      "r372",
      "r373",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r399",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r419",
      "r503",
      "r504",
      "r505",
      "r523",
      "r593"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r195",
      "r459",
      "r511",
      "r534",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r550",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r569",
      "r572",
      "r573",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r593",
      "r656"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r195",
      "r459",
      "r511",
      "r534",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r550",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r569",
      "r572",
      "r573",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r593",
      "r656"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vesting of restricted stock",
        "terseLabel": "Forfeiture of restricted stock subject to repurchase",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "totalLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r79",
      "r80",
      "r109"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail",
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised, Outstanding Stock Options",
        "verboseLabel": "Exercised, Outstanding Stock Options",
        "terseLabel": "Issuance of common stock upon exercise of stock options, shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r79",
      "r80",
      "r109",
      "r316"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of restricted common stock",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "totalLabel": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r109"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r31",
      "r109"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "nmra_StockPurchaseRightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "StockPurchaseRightMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Purchase Right",
        "label": "Stock Purchase Right [Member]",
        "documentation": "Stock purchase right."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "periodEndLabel": "Balance at Ending",
        "periodStartLabel": "Balance at Beginning",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r83",
      "r84",
      "r101",
      "r552",
      "r568",
      "r594",
      "r595",
      "r650",
      "r663",
      "r700",
      "r716",
      "r764",
      "r783"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity:",
        "verboseLabel": "Stockholders' equity (deficit):",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r164",
      "r276",
      "r278",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r291",
      "r293",
      "r398",
      "r596",
      "r598",
      "r623"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split conversion ratio",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_SummaryOfFairValueOfStockOptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "SummaryOfFairValueOfStockOptionsTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of fair value of stock options.",
        "label": "Summary of Fair Value of Stock Options [Table Text Block]",
        "terseLabel": "Summary of Fair Value of Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfTaxCreditCarryforwardsTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Tax Credit Carryforwards [Table Text Block]",
        "terseLabel": "Summary of NOL and Tax Credit Carryforwards",
        "documentation": "Tabular disclosure of tax credit carryforwards available to reduce future taxable income, including amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureBalanceSheetComponents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Components",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "nmra_SupplementalInformationOnTheCompanysOperatingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "SupplementalInformationOnTheCompanysOperatingLeasesTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental information on the company's operating leases.",
        "label": "Supplemental Information on the Company's Operating Leases [Table Text Block]",
        "terseLabel": "Supplemental Information on the Company's Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_SyllableLifeSciencesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "SyllableLifeSciencesIncMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Syllable Life Sciences, Inc",
        "label": "Syllable Life Sciences, Inc [Member]",
        "documentation": "Syllable Life Sciences, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_SyllableMergerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "SyllableMergerAgreementMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Syllable Merger Agreement",
        "label": "Syllable Merger Agreement [Member]",
        "documentation": "Syllable Merger Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credits, Carryforwards",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_TaxCreditCarryforwardLimitationsOnUse": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardLimitationsOnUse",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Limitations on Use",
        "terseLabel": "Tax credits, Expiration Years",
        "documentation": "Description of the limitation related to use of the tax credit carryforward."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfNolAndTaxCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, Carrying Value",
        "periodEndLabel": "Balance at Ending",
        "periodStartLabel": "Balance at Beginning",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "verboseLabel": "Convertible preferred stock, $0.0001 par value; 50,000 and 820,349 shares authorized as of December 31, 2023 and December 31, 2022, respectively; no and 104,417 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r267",
      "r268",
      "r269",
      "r272",
      "r273",
      "r348",
      "r483"
     ]
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Convertible preferred stock, par value",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r47"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, Shares Authorized",
        "label": "Temporary Equity, Shares Authorized",
        "verboseLabel": "Convertible preferred stock, shares authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, Shares Issued",
        "label": "Temporary Equity, Shares Issued",
        "verboseLabel": "Convertible preferred stock, shares issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares outstanding",
        "verboseLabel": "Convertible preferred stock, Shares Outstanding",
        "periodEndLabel": "Balance at Ending (in Shares)",
        "periodStartLabel": "Balance at Beginning (in Shares)",
        "label": "Temporary Equity, Shares Outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Convertible Preferred Stock",
        "label": "Temporary Equity [Table Text Block]",
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r47"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r706",
      "r766"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r275",
      "r290",
      "r397",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r492",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r712",
      "r713",
      "r714",
      "r715"
     ]
    },
    "nmra_TwoThousandAndFifteenTsriLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "TwoThousandAndFifteenTsriLicenseAgreementMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2015 TSRI License Agreement",
        "label": "Two Thousand And Fifteen TSRI License Agreement [Member]",
        "documentation": "Two thousand and fifteen TSRI license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_TwoThousandTwentyEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "TwoThousandTwentyEquityIncentivePlanMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Equity Incentive Plan",
        "label": "Two Thousand Twenty Equity Incentive Plan [Member]",
        "documentation": "Two thousand twenty equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "TwoThousandTwentyThreeEmployeeSharePurchasePlanMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Employee Share Purchase Plan",
        "label": "Two Thousand Twenty Three Employee Share Purchase Plan [Member]",
        "documentation": "Two thousand twenty three employee share purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_TwoThousandTwentyThreeEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "TwoThousandTwentyThreeEquityIncentivePlanMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Equity Incentive Plan",
        "label": "Two Thousand Twenty Three Equity Incentive Plan [Member]",
        "documentation": "Two Thousand Twenty Three Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentAgenciesShorttermDebtSecuritiesMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amortized Cost",
        "terseLabel": "U.S Government and Agency Debt Securities",
        "label": "US Government Agencies Short-Term Debt Securities [Member]",
        "documentation": "Debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae) which have maturities of one year or less. Excludes US Treasury securities and debt issued by Government-sponsored Enterprises (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae)."
       }
      }
     },
     "auth_ref": [
      "r657",
      "r658",
      "r659",
      "r660",
      "r778"
     ]
    },
    "nmra_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unaudited Interim Condensed Consolidated Financial Statements",
        "label": "Unaudited Interim Condensed Consolidated Financial Statements [Policy Text Block]",
        "documentation": "Unaudited interim condensed consolidated financial statements."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_UnderwritingDiscountsAndCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "UnderwritingDiscountsAndCommissions",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriting discounts and commissions",
        "label": "Underwriting Discounts And Commissions",
        "documentation": "Underwriting discounts and commissions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodStartLabel": "Beginning balance of unrecognized tax benefits",
        "periodEndLabel": "Ending balance of unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r360"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Acquisition",
        "terseLabel": "Gross increases based on tax positions related to acquired entities",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from acquisitions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Gross increases based on tax positions related to current year",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Gross increases based on tax positions related to prior years",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "nmra_UpfrontCashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "UpfrontCashPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront cash payment",
        "label": "Upfront Cash Payment",
        "documentation": "Upfront cash payment."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_UpfrontConsiderationTransferredShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "UpfrontConsiderationTransferredShares",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront consideration transferred shares",
        "label": "Upfront Consideration Transferred Shares",
        "documentation": "Upfront consideration transferred shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r46",
      "r126",
      "r128",
      "r131",
      "r132"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "nmra_VanderbiltIprDAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "VanderbiltIprDAssetsMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vanderbilt IPR&amp;D Assets",
        "label": "Vanderbilt IPR&amp;D Assets [Member]",
        "documentation": "Vanderbilt IPR&amp;D Assets."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_VanderbiltLicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "VanderbiltLicenseMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vanderbilt License",
        "label": "Vanderbilt License [Member]",
        "documentation": "Vanderbilt License."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_VanderbiltSponsoredResearchAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20240331",
     "localname": "VanderbiltSponsoredResearchAgreementMember",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vanderbilt Research Agreement",
        "label": "Vanderbilt Sponsored Research Agreement [Member]",
        "documentation": "Vanderbilt sponsored research agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average common shares outstanding, diluted",
        "terseLabel": "Weighted-average shares outstanding, diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r190"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.neumoratx.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.neumoratx.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average common shares outstanding, basic",
        "terseLabel": "Weighted-average shares outstanding, basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r190"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482134/820-10-35-54B"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "59",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482134/820-10-35-59"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481047/942-405-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(19)",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(27)",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)-(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//820/tableOfContent"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-15"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//210/tableOfContent"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>63
<FILENAME>0000950170-24-054448-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-054448-xbrl.zip
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M)O*S$@(R,C)*"LK+%RY<%KG*>E7D__K ?0*H22F5J4\("3B <]0$A-0$N'8
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MT)?_=>5?:HDB<('E_^52EE_5/!32>7#\\\KLO]0B0-3#E_'K4L>?M2@%_MF
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M:&^>DL3"O7 ,0VLN__,J;!"(':FN&PV5J$RU9ELL^.6)ZGLDP$R1R)#C/<J
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MS'<L14R!GRE*KN!4TV1!P=^!]B)>Z$5H:CMA4,B.\>3JZ'V;;*HZQ7V'=<%
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MSZ6[U1.G$8YGW*P9FFF>C5GXWDRG'TC>QK:=I.\?\8%KKT%-K=EB3+(IWK0
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MC]&_G2;][4ZY!MPS?KL*)31!U^SZ^CX$YWE]D*2>#63*= ZTU\5(9$[1:E-
MOT-6N9!'-P2U'9C'4(R=>*OI:B/+TM5AIKSSL2$W;(#,?@BXJHJ.PD+<.OY5
MIT.JIAZB?PF4/D_/NTF-PP'V@XM2I(>V2C#YRZ0!3'/V'B8S5TJ>]2]I; >X
M& F>OSX=(5;_7D$2TLZ83#32)D 1,];I%'\1)FO%^.9[@+N3'%K2$BR@6K8L
MO#0)8V:;"<_>*KFUC_SY^6Y;,'U;J])3_N*/[Z@("4S?)B@/L#P4=U5<P_Y?
MV<AP=B0H#!KI)T>?^(.MULZRT7WWR:=/O@FO,:YS;=9K"$S$$0Y@0GJK(;=D
M'O:%&3EJYOF4$Y)\ESS!A&^JO1QC=_Y;FBA-,]Q-\RSK3K=]_FQN<=][V6\W
MNANP'D061@-IE6&>7_BCT$#.;GR S&:-5B.Y^8G$'6()#YFI/>U!/]7;J.E=
M"OE7T.1W_%O'W*3WRX^R(T%%54O=DXW99C-&B8.VX7Y_D>PEPF1]] "$+/C=
M#@7S7(C>??/.7YMD2=K_/I#F! <(OG5T![L0CON+:L 5[?W:S?Q0%7T/*?/5
MB^[!E_"M%A0Q3.BSP8J"DP0%6?6A["[!R16I<1-#:E$W93)%:*G\?1$>KOL2
M;KTN5\L]1R0VD\+-2FS[NY^''?"TI8][@BZMFJ+@,49RA5]Q@#OIZU?WL+7"
MG':L.YWZFT=?EX@G(556T^5@\X;F!DL![]=< _FA&\0" L1>1XC(832O/U/;
M%,\C*_88*T+?)Y\5,?T;W#!$ !,ZJF?._7=),%7Y9ZG-AB^P5'':;UMTZ_&Q
MR65(:ZS\/\V";F<V.UWZ6T%+F'67@[P-G5JL7N3%@*I8R/LU_-#T#S=CQ@DU
M8XSW11>80&6:[^QA'95ID[VE.M=#>85?:KHAG7V (\2.<0M\AW1OCNAO&C>%
MP9>?IA@>XH_83Z!1SW3/"#_R4D=G9W.QH7P4&9GLLCTQE=OZR=.<TFIMM_3$
MF:M7.RE$I!$S\U2C]QZK0(<I-K$B:%/AOI)[HV'EZ[I_%\\C0DI9P=E4%J?B
MVP14%^45W.OWZVSN[(I,7^S<K%X7 2.H<(!^^X8Q+.<V36U\YV>+R4/&0([.
M-_[XT+^O"VP5-)JTTG^(2K%8E]@N4=?63-5GE+ES-EDL-[D>G^R_ A*N8/G0
M";K1-/=J,W3>D1LF.^9QV,&&@<D^S566C_,I6)ABSTY@/9)A3:B_I?O\];)4
MU/NEE%=6$?;<L66;H?'S&#'DO?QT-_VE:J<MJ1E[&U:39) XL8+?^2C5V2A#
MO$Q,P<(\K7?MGM)S:7.;C[<SW*@WH>*HKFKX$247/AS,]A48X/,"X'%^N[.O
MNAOA &//&*^QD*Z,Z(RGUFI<?0H]4(*WJQEH/K<QS;Z-.')G=DX"L;LGP>*,
M;P^,LY#7/61>45U5OYW9KQNI.@49RN4?F)_=#1"'<Z.L>_3\M/-B9, "+^X,
MU7R]6Q#!1#K)\ 7Q%JEI?7(6(7A=4RTC3:P+@7TO8KUT9R<SGER<S6ZY%0D*
MBMJ2;>Q=V-VYOX<3XG_K%DQM[WL\ZU.DER09JM1X?<]O"@<0QL>N=5SKM"?#
MTSO^?H<L@'  N^FDJV^@;7_N?W3&ZG]79WC_.R?\XRVF0$,Q7#>/[T2^R,<S
MYD;]P+[U,;GQ%<6&&D_]#U]!ZFL"%<A;+'KDOLBHCC23]2V=F5?=&O!KJB2E
M):!;R43<[C4/3<*!V\ "R(H%9-V8<G4TG*;_ZVE\\:SA3/]##]4?DF$#5YR,
M%?:0KE04(P:[8_(OL5#2)[H0,6+'-7 FN4R/-NY]I%0Q.QBZ&,%*EGAPO)6.
M8F1 =V/)#DS9PD0CAV:57\=ZBTM5T^.),<95!O,%-Z_B $;%.X/850^L'7<=
M$M'51BO;:-!2PJC1_(90J)CB2>P7/JD;I1R7_@\))=(T-2]O3>JTG0&9J6&8
MHU*6*DJ6]_@I*^#I#8#QJW#G_U-R_,?.)1!7:9TD<T,7#H"O[Q4R.N6N^ZO^
M<T?J4_&?\:@$ [H5"^<%F /C)R=B&ZC#])9"U;'NI^_UKX')GS \,>2K?].'
MOE/3Z)CO^O4Q#A#NVZK6#Q7=S85FM[-[Z2.Z]3&JGUIX#M<%6+U'4WZN!IYO
M*R#HRQ !]'9D=L9W)]G3AH<BQ_G-E"YUB[>V[SF;T$'^XN, 3HS7:LU\7][!
M[L@_Y* DPSL8*$VI>C]".*4O;]U;Q@O1>:9#8Y7EZFP1^)O[34N0W\IC8B]J
M:6!D(=H3>372KQBE,>UVEJCQ[4BW4DOF34C_D +1<K8"/??88>7WFOJ$O[L6
M80\0K@,'@7D+"+P2/_,Q7G9^O4YW7^BE32DIR:04-BD1K$?YHE<E_?VAB<KD
M!G38EU9'+4.?@N6XURN\5_WAK)>O9FW+9.Z3>>/[]Y]X*1A:XU<Q01%%%&6>
MJ.:#D$?2SZA&Q 3?FZ!^/CKHN\4=A4CWT:<%;7V%D?4#OS<>K,Y3 7N#7=1E
M%Z;>"/P+>"Q\&;O*=OC\'CK4U*^#6;I(_+]OX)\200NY(]&(8K6Y$5CA$=!:
M!0*T$N/Y-0P;M"]!B]^RPWO8V>6ML*[CZ#FZOX!.56]HG4R2/BM42(Z3^B/]
M>O2SO,*?:TU5SJ3)9%[\U?XP(44,BSGD7-(^HRR)C_68R858<4YPDJH3O[$2
M_@&)C2^=JZL[S  +*51'WY'NI LY%(=GN8V2HJ%=HB1@L*NKE<8)6_G@<<AA
MM!BK/XGRH=MH3.J#XO3*1+HB=$%]HBD.T*[F B%]E\.]2$CQW%X@$T@DI9[O
M56ZTH]$'/G!\EW*B)%%X=I?NR4-I 1*Z$^-EPZ-P/W ..O/2@Y+-T;EQ_E>+
M1?]D#N9A1<O.[XK0WUV!OY^^7V$(!Z2GB5P(?S&G\,K&0Q$8-Z,4HI:&YMVJ
M#)3!%6;1ATNSG::Q!="=R#.3!QB9B5;IHCZ$R+C1+D]3BNW'5YK.R1^\ #YG
M4E=KK>0*?SIJZEI4E7(HB9Q>?&,1$7TE3G?C#5>X%:2+GK>"5!'X+T$ZH>%1
M([XS(NJ2LE5DUTXY+ESF2G2>X<341]%US_WJU08H:#<E=9G$SU%GVKQ]MB=.
M"786GQUX(R^+L:_\3S^U+F6^UH\*R+NWD:(QUZKA;<*2LB"@>'!H\\6B@5ZO
MLZQB-.]T;[M.6F3Z"O];);,>:%O>[K=SQR,.[W;&&0+QX[EW=\_Z3J!;D?ME
M[.7[;KW_\:(0!/,Z6M/N"._>F=.+7==B*A-C*FC:&2V#_)COR+$5K2I@H_#0
M0</7T*<'O+6TXK*M+8:&8*E>TEV2%K?^0G\Y5QR P$^4K:^(O4. (FR&:@6X
MY/*JO^CU0T8M76,B)!@'B#G3XX,7).E^%35<J!Y67E0ND58Z] UX?8-G:0DN
MTI.SMB9\ZT1XH#CVF>#R",2>VZ3QA3RS::GG5$/.RNU_8=\:O!,":,>&WS1D
M;P,'4+YHX^XUIH<J5"L@:NO<&Z(%ZC8^A=1^]H;?15U@H.FC-WZP'2.BADXX
MJ9%^]^?49ETE#:.W*NRO6:0PR:T)MD:9<4E),*ZF_65D"MH)&T9_2\3XYC@
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M83U:U(I7'S$*#%!YKO=N(<OKRBM/K*CAO#/=S_IN-UN/GUXO5Y+K0AZ#A="
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ML%NRI**OI476.*P_903LE"0J/TFH)0ZU7=BAFE,L=S>^+F1KJ7#/E=<D&L
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M$V/_X)3K&)^BKT9R@"$2\]\">1:@IQ>CD+UM"%+6:,B'TD)?L-#VT]3,)I=
M7;!L]&,.U492X%A=(KOC_6.';8SS<[OUW_'2/G]' [JF+D@.\K5UH"C)N75(
M,@-@,".$X^&/O#4!2, D<47^C)6ND$>T\JN5&9.H*_X[[UF/BB8G<2HJ@F;P
MV,DYV.VRL"*L]-DK9Q?5E;3^TQ^[ VVUO;9EF*3CV:!@J/1J_%[^;5M" Q?
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MXN_Q_>RXIK)%N@/15U>W5E!W$(V<146'5!<M%U. >AOGO(W#U+M<1!,F7I_
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MP!_"0<)Y>!JD)V)8X.[V3)<<5(-Q1D+ MQ9-GQ7)O:NLB>(Q&:CSD'8AE09
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MHTI=S[,Y';'U\;LS56)(-B))\]#)WW_[I^R#C;A96]WZ$NH0HZ]:]CE$7JO
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M9P^;>$+G.']>=J6AG7ILZ>G_Q=Y[1D6U;&N@2U$044%R!B6#@ A(ID5V$T1
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MN>_?DZA%,R,WR^&SHF7:/E<WUP6/<^]T4;-IRB?-P#W.!%)3D_.?7JJ28 E
M<:5)30>;#MHW\U!?LU6]A04X"<;/A<_P3&?74MXM+^F1JJM54[*5?=CA\_"U
MBZ63],&SJF4^4X?BCV(4OK4V\SWH+BQPB(M]2W-&>=HQDEC@"RZ,L &=/D@
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M[S<"*G8QS_!=I93O8 'E831'=K(AV"X#PCQ-E[(INF"BJRK5+E/@C+R6,YM
MU*1GE6,1]UBC]K[94/[\%58OA2<J,O3$S25>W.:,]".25 (50_M=\>NZI J4
M/.]'NW5XSOE]M&*-P'3L9R][#)?C$DVYH\$&9 LBTC6]6QGTB.54I0^/BFEW
M4C#TVX9,(T@-Q=^N>DS"BB/W?4,>+CEK"3X<J&=^N>O7&O7JBJ"WK"_\BQ_J
M\B%Q"'R7&>=O(0)0O5@Z99U^0?OT+5>7 *?C6L%<OBP;VDY)._%VIJT $YZH
M_6[HY0&_9HS@S@<K7<NM@MI^:#]'Q*.[H&J#,'P[!,.]55TORH%GPY*:::NX
M3I"5N$@I\]'$H:/',F1D^#J"7H!5[6;JRT^:Y$\X&0 &?X/ES_N"::H)YOO2
M8 +U7J<[YZJ*ZGT*W=I7H F>Q,CY=D3;B6S:5-O@IFW)Q?DO1MT$EOLL(VL7
M[;$ ?:DKJ&1_TX0%_%'YT(S><TD]+78]-.]XA 7I=K#IQ2QSOHC(Z4+1[8/F
M;2PPRO5@P!]!-Y#UV1G" %T@3H6.M&"!E9NU*?=VV+8#^L_VCP0F)IL6".5U
M!@M9P[T$-C^.Y*"=L,!;Z0@<,<2XR0BVQW_^I1TJL%W/"RYN4\[W_+TI#?CB
M&Y"!\4X&D;TY=\5A'/TJV_L24L6%J*GZ#Z55@;,XQI5T^;L$=<?Y5KKH:_.Z
MF^"'85+>JSZ&K&.&_FV1NETFUH>=OA'4[8,LG_"*&-ZL&FGLC#^RNQ:>GN,1
MTF^@(-5XN>'KFEC5F!R,L5.,T:0 %:NSXYSYHC9&44_^/-W+O2*)BYH'RXSI
MN1 441OMBYBQZ*5P(>?,.YM5.ID'W(1/I#KR&EX'*E;L&,2>E&VF%8_?>XB_
MI!E"0XC'8K>,Y[)L-#?%BVS)TMK!QR7S)#;/FI@2'J?/;41\Y,K*Z4PDG@&]
M<9FBK(=-;>E:"P4VU]YJJXV UR8F*+)\.ID9Z;^TRFK!:ID;<DY+XZW,UE4/
M^%R\.P^$?,W.K!C,]K;2&._^;-13,8!$@=F4R=\=QX9[20Y:N##T8Z!"XK=(
M%V,S;M#.A)V&%L\<W^N$"=UY1O&=H:-@8<4(]D@I;I&;1$ZL^ !R2Z)HO4?%
M;XI.-9"1K[Z4ZM%*U*M?GK\*BRBB[IE\1KRJ0S6L+:Z5(ISP64C[[B[%$YD+
MUR>@ D;Q*6B[0:L^XZ'];]8[B'B\5\H'+!?(]MM>;L56/\]C/QY=UAA?9Z0>
M\GT0J^>$AMP6XVQT\Q4/MVOS),)U.]6Y,\*Q54TGHOLLE>/>3""GQLV/3*WT
MVJ)3=U .\Q(UKX1KS&Y4!3V0LY'EGIF)>/>LLN>HZ&0DZ64U>U!J(T2NN-2'
M;9WU\K4=S)$ZB+;;OGK(W.K!79?@WGD,C^OP<HN>(ZU77+O$^M"S%PS/0NPB
M,'T<P&'380%I_SZ#0QN5?8)T]]R)P9*N8"/':3<"@#L8A>_T/*PZ]?J0G4U9
M+D#G_.3:=3]*&NG9,-"D<!M*%E%=X.>QLC'OZV[V3;#E3F)*);/O->F4L?S+
M?=6"F=L22L_*BV9L2%?NIB^K];^ G3M*D].E\$HC1,P;\K?P,QF]'*LKCX#:
M[JZZ\-U48S'=V'!53]TWF&?)@!9H$[>'XCTN3>S1[>>;#7 4$&]OUN1N#+B
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M'1MK_-+7&FC7N?7%;6?EHC/T8BV_?464*VR-4@G*V6:N'[H _Q!8B,?X$?[
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M:?RSG,@-UB>GOK>AT@=<[6XZ67*.!U4'%],&J88C#/4^%S?=(0@#2]Z6NNH
M(MWFLY1F,H^]ZT*F/\$17:YCD,)G<L]6GL47; >Z('F_NR*1Z<,NB6?Z-$=2
MQS70'>)EHZBY.MF'_;7"+NZYNF?%S5*)EHSJG0U\21ZY]T19&3UYV*M,C#\I
M)5))>R$K8!ZR=G.;E(0'F^HZJ0T^C"*U$='O.I)\"1>N0Y2UHU89Q5'N+GDZ
M^KJNVITU<7.BL[&GTI/.8D\HBNE8" A8X@Y@3HPU.G'<G>NVR95,I!YZO8YT
M5;=F%)V(,CNU269NWEXC8L0"]RSBL(#_;LT.%K@T.YK88+7,I,H7^1I^/T&'
METXJ##:+%MA1O;_#MJ8SI\_3>8TES..9[ JU'=PX9,1.?4 _)C4M^S)7_BJ]
M%6M(-HSPA;$WL*7\JKML!WYO(%^/Z)+I(&Q!*&*6I2>)(^H C_%U;_)4\[MW
M+E(W8;N7I"7U2[T-7+T4!H8EDI9WN4$);@0!M2;)J&)*JSL+'R)<%&VX-R,(
M*K>DFECBK$GU8<(LO!\:P!2-ZTQ40E?)M*L'^*R$.>)&OUCW(6C4/8MG,.\B
M;9ZEL3%TG\!F#U1AXNP)LS6\.O*2D499%NZRI0KW6"DM2<F?.RV/U]^I%=D)
M&S 8YMT?#V6<&U;Z<,%.2#TH8,YULOFMU'%&)X]1ZZG"U(C471AL:8E(0M?:
MVD0A*4BI-LR6_%IJW-Y5C?FP:"O[OM5JD[9]"T0\JR^%M9N/KUWX(^(R-LI#
M^@SJ+;<TCZ%Y)C*4[TB[7BOER58&N<!D1Q:]BSUWYA5;@ #03EL!T>PKJSA6
M#.:E#;!Z10H&W632:F391=2Y'H5^@"!HQ[DN*B^\)G%EL<O+:LO(\C?+()_K
M<47IN[MDNI(.SQVN67P8TY6),2,J.A<F)CEB:L#?S'3,$0,]&(:<71F!9)D[
MZX%#8JO]/^N/RQ^E.C3NG\#-/T/([OH=470Y:D>M,3$(H4R?#^R_VDHA"&)[
M#XX(5\Z;RNB7%EDY<LAU2X3;9>1 NS2A8E3KWG2[^/"2V*?N.D8C4G(PV-@2
M49=.OE6:XI-HV=0W]M2,KVF_[(@$W4+SI#*HG(@MO!9'E%^\6.SFQ.Q51KFB
M;\833ZY]-0FMV2LIDYT.M[FX?ZUCE\9:73A4\W$1:Z#H#&WSD+3HZG"U7U/&
MJOK4>(K5WI@-CTMU_D#$09LV:WD17RII78]6<I$DSYP[A'(E1;TTP%7C56BD
M2=,5H/O23)C;\*22%I=$3E(RC/-_^OS8S_V0/_&WP^F$:*O?F&GR%L@ "^@M
M\.0@9[O?M_2K@V0,=>1/6_JZ&'+0H6Z<R74L*_?_A7CM9UWL_V%0R.OBG KE
MI]_?L1;\]>PF22*B(_H@\#5TX4$O=(/!!@LD#]>K%N1*LF"!FUI^6.#).O2,
MLJS.*J(K<#)>>(&)8?/MV,L*0X;G,=(),I>A#[W*U@]P_]TBUUTI/XUU4.29
MKP?4SBS$H:0B>4C!$)2B1,L.G2J8@XPU<^)P=[0A#G9(#)O>57:"GAIC@93(
M6NCL+7;(FQ.'L C6;J]$?7[,5Z.F'7V,8GX!%K"$[MMK1:'ZHD&S@HT>.)%8
M\G$B/:6#GE&7[?.W)FAYLC3J1;?EE#I4YW*O#[D4JGN&]=NZTVOW&%W' A$C
M,EB@,+0!$Z)W8MQ&>\6+#;FX%,7R>F_0\FW(QA,9C6,8M\>#N>1XOZ(]C@!'
MUS(L0#)F%F6$,*'?D(F3:6SD8*@2;5S.*G@6-6,=8.6+R%KCD19SYNSZZ#1>
MREA_,!^W''!@<\VPKC[#E%74*H=]H.ALJ)HQ^F[L'*ZEE>R<C'4J.SFX\\W3
M7FBC/LM^3J2-3HEH)4*11>YH=CIHH\PB7LF3;VOQR=O7E6$W265&W\$S<:S7
MOT:FK/7,!C-M=ACQ*AJ/WW;6XO7S;LUJ5V@Z6:H-OH\:S1ZKEL\;:W,G?O44
MPF>48'>DNL S5IJGU:4W\'10Z'C8PBQ ,W#MTH:\G>YC^S4;L-Q1L&3P/"CX
MA8C2;+SB@U]@Q8:;HK=4N0,3WS>U2_&$(?F]\]&F+BR$]5^?GCMO=KC%>JC)
MT+,"8G9 VPE%H=8-7@E6&GWVDX:UR:]<=(]MEM!)0CD]9;4(J(S4997.937I
M6<@YUJSHO'JE_S":H=M&$T5G?(AOQ:)1166>ZE\]UGEC0_K194S9@G.%'CS
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MSY)W8;W\7>)R).-T4&IS\SH$/X!=:%=H)+1,=H4<'+V)!= VEI3GH44QI%B
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M @* "[ SS&CCWC8$95O/$RP,>_LV9*C])IE"B-1@05D7:\)KFSACL3:J#@7
M/%ZG<O(5H[3@J+$@@<4Y_ U#/LK&J0>.9-.V$R?;N?)O3.ESNN:U9#_NQ[5.
M,1;;Y+2*HP[U*I!#;JJ%NYV$7Q#C!2Z?-!T?Y2OZZ]7_M"G[6IW:? %5^V"'
M +N^TJTVEUL5D^3N%I=)MR7A(,A[!(TC\(.!"69+]Q)$?.D,7#2HD76O^'86
MC=5@ERMXH2-@0>=*KUKYC_T-1WM?,'IPT+O>:TM4$[? [!AIU8R8UXRDQZYJ
MQ8QQ,!/2A"OS^1^?PI^DA5MXS @S6VNW[,,#[J.8LQ1-7CFZ/+K]S*R]E8O"
M&" TE1Y^Q98O+T<+D$/-%'XM,RW:A8,E)G)M"A=RDY!L4=W6GRJ;>K>K^/ ]
M/@UHEQ'F0]&?U61&)(@,C=F]$DN""86;I.5H1&U*9Q)\7Q(3W.]L;:"K"M\5
MRJBMAUXQKWZS;:>I]EZ\)G++()E<HV)V)3LSC5]@CF0CA66X+SSG#6N(Z*?E
M0-EC=6$"5,*A7J,/)93WL?O1?CMZLJ MZ)"H\5N]<["5TIOGJ32V4(G]M18&
M@J=55(*AY\DM25DI7V0;]XG7-N5/\C!L2,LT5[@6;<SV:=' 2KZI7@UG$4VS
MZ*?#?A">00RYX[?3*@^AJ3%A$*$G:%B,P4V\/]D%<B<%Q#VT,!CG%^&JZB"\
M-S-^#S&.>7(NA_8$X4+4,>ON!A$<10+*XU:;(!Q%DM&@<P2SICU+E#_8^SW5
M@35"L,6 Q*C&NL<2J%SCW!M(012NPA(CCFX&/D.H_-XW-W>S(J$XF3I'YJL;
M ZPI46CMID=AG]B3T RM13[([3Y4WO [+]I6R>'THF&;J!OOUJR.36:B9RX2
M&F5,EV=7!_U-2@@/?\C-[P65BZOOJ:8<:NC8?G5+8BD.(.K57F)W[89+I479
MO!&6473$;TFY-8P"FHE_A0GT%O>Q?>Y8B/D@A!_*OA0\AWO4JH84=$CUIR7=
MK+G+>Q7NW\Z1"^N0QA\A-33+\R09XOEJ^:A/=K&)=R!V8XWS@B@"PF<]DIVJ
M4!# +JN7 LY D0P5V&H9J*BG8 36OLFC8DQV)=F 4A+EXZY^30D//KRS5N+4
M7BXK+_/:#Q'/J?2]MDSJEY0B$KR1_76-K: MIYV+Y:V(7(OXC:>C.TZBBN@7
M Q41\CXKH3DG(#8I(9#NUG$RZTU'N9IAGI2GOBN/19\^>2E><@W-B29/2AP-
MD[EGZI;UDP@380$#)P4X)FSRDPFOCXUM6%K>+#,+?AI"&[OYA'HU,RV(]?1:
MNYQQ2L'7UOP-05V;5OFBF0X3Y]#W3<#GOOQ(,!X60 AJ!1VB\R!SN+ +^</=
M@)Q#H.@9:>QZ099V^U=+YP1/HAV*? Y"*J9B3=5TH4XA\C[PLY*QLLDRM-25
MA*E7@2_.;WF03HQ^XR#^0<+2@"0SXVZVONG@X:KR- &/ _C!#*-9/X^;?&H@
M 0)/1_K0[3^6K;YE9#^EH6:S8\NJ=RG3K.[.TP]X=OW'SQP@-R_5$2S)^C_"
M LBE<]LR9+([XS:@O ^)Q24,LK823C?7Q)P6BA=AA ;:G'X.C0T5+$<QCCXC
MQ))<T</.'IHM^OG]^6[I)H%(FKR\C?.4T&6[8#5'ZK5[VE?LFBB,+C;K'1J,
M]J]6S=(@RI/;%J*H'&T<,F):BIO9T,.!G1<"QU=$<H>J']USG2YNV@)>.[II
M!ZX9V;4]9DE8Z0TO[J96]2KQQY0W+JA<L\20E*0,JR2L:J]&]YJ\_=9&C]=!
M;M]N-ZB^/%6<YO^B1E+UQU2SER5WP8CB?;(["LRO6O%'-$8T/OTKPXTCP2T5
M$K>&5H:/SFSO!2N$MLWPE=IRYDT0/TRK9,]UL'/0N)L\Q"\FF3KM&BU=-63'
M$L^]^WCWM3S1XZ)7OI(,&LZ%K"!?0[I@C4B[\C<Y1/SWO1IWDMV5?EI22%:W
MC*+%&G:][*:';O4H#X_3M:]5+_LCNGSXW_/A2;EUN!\+_!A4>%Q!%QR[QK&@
M$C2EXK?'5C.\5A>KL'0PO4,<"NAW;0F>&7OW6:"/<>MYC=OM&Y\F=DCQWI]T
M,1_E':E.V\ZG196(#6/((8&0M0LM+*"Q& M U!Q96[\K*PN<XFN_*Q.FZ,1$
MY*@^*!WM$<RK-K$LIKF_)H_PSJ%,S=:?D[G_]L.3RG>:4S2)-2D.'5]P$]T.
M62OMB&Y!S%@J"^*JIDZ&5.-#IN7+!(T%SB,O5IV+'&1/BW QW3WZO6 45:9K
MQPW78Z"(H$\(R]B*YKX<5Q0)@1^2<*5Q00YI@8&4VUU< +$ .KAB6HY"P8>W
M(2ZO%\NA@;J&M999>D:;[F4?LUI>^9]U1UW?=$A* O"OI^5:&A&@Q#.LQFI"
M!74_14T_*TGK83%3Y.CJO\78<+Q.KC; =&)?OTVN)J/P2A\6C&%<QSRL\]U3
MC=WE2(7VW+3]5ALGW/PMQ1_6.ZXC\VAJ0HDU?T!\V)ODM8A6EG6V[B9MR0".
M2/CW,/(1O_563BE?UU"3MMEE;Y=[F1;,0?[S4Z:]]SVD21HR2]M+^7P3(SQ)
M0=A\]TK3QNAUM!6$T%-LR!,($5B%V7O<CY99>5CU[N55R25"X<6:*<[JY'P5
M%KN?14[4537 CS=<+ 7* GR?A=%1;.)1+V:FO?\?[;1WE/R8@4ZA?-AF2C9P
MBI?VD3\ED_L\'JRE4$VIN[X[E)DA0HODHR=#&K(0D)!<8:;V8?>NJ)E*ZJZP
M&#W4:C;-?Z=H2D76]6@.;]&2G^2# =G@#CZP5PBC.>CJN,#HDSJ3^:-',7LF
M]9O;_+61<W\&E9&$O?5<Q^A-J<S+>SB->Q"4Y21!93?ZU+TR)&DX,Y8\((08
M-HJK8=,_$Z\%3^5:-4C4D29UFN=9$3M^6ZX<)M+VIMAHO/H.M+UW72%'GEHQ
MN[OJ$N]%V3?X5A7Z&IQF?S7,:1$+H) TJ0^9^69:E0AT<J_U<E^:\9EMR*ZH
M#.P?H]-S;7LK%4+_6H33YSWHCMZ(\S,V 8H^ML>*,N1:!/+_=. -IGKK^>"9
MZ5*#9>9;'C4=+& J#PL0@Z*/Y4YR<8\Q,Q;@I?:MW5$J>  S:G2V#-G+!96#
M,6[ B\UP+:I'[/E8P XNCDV1PYRG7VA"UB)QP6OVRJN_^O_5_Z_^?_7_G^P/
M_(_*<=0['QP93,SH^7.:?8QV=@P--:^"7G851]T=;]_3VMJYPULAGNB\>PJ:
M+;B3YL(?96N9'$,^P#\%Y9^*-UG_ZI8R@OL!G'.D6)0S_C?VWC,JJF9;%&T%
M08E*!H$&B1)%)(<&D2P@*#DJ*#E'R2 Y"@A(;'*&EIQS!LDYYYRZB0TTW9<O
MG+OW/N_M=]][X]SSG7V//^88M;IJSJJNM6JFJIK3N!(@&F*<<""=<""&GY&P
MZ::\Z?8&[5>COZZ1$=C!P^1$)+_H.E .4 F\JKQZ6U W5"DV-[88?X!VW5RL
M$* D*7[N<[,T&5F!?XBLT.#X]?SK^>^?Z?]P4A9-QCCXE(X6>51XV9^EIY/D
M%31; N=O3*Y-D%M[<C^=V955/6=!M5<CYR,W0Y.ASVK-0@I_+T9611YZ5FCZ
M][]3U?^]^#N%C)\<6AD%-[\5,P\RK\'%)._M)HC5?R\"?R=<CAWW#WU(?M>I
ME%3]O2@])WT!TF)KVRA@@?Q>%/V]YT^DOP;Q7WP0!3,H0/?<#?[)'[U(XB#?
M=2G4#KH,")G0:85DWV2 MA(0V\@1X,E/I*-PT<=9EOCSH%L99WR2>?W*:XC[
M<J2OI5Y2Y8\&#EXFD9>;7H("&J0F!?JS=,C/X,'(@T>W.O;0EC3KW0-B^3]Q
M_B2[8:";D?\G#JA"&G$"2J$LPJY0Y?PWG'_K*M;'Z=^-Q<'N!\?(N^8_D(!_
M=!6A=N_7\/Z;#4_^SX1/96SZCLA]C_W$J0QM7RSFC*S_BH$A_B^@*7@4X.!%
M*($CV)@[JT+"3G9"]4P)\S!*:US9[4'6A8 V,&"18,PZK;%BU+T^B%+V\4W.
MV\I FN4J7,=WR@I5%^C1O^6ME/C_LE4C8"FQ,N1WIO#2;6^ 7M9>R#JJX[AD
M;<_?@#6[VE=(VZ1X1:7TE<]# D4 &66J@JPD[QR!K 61LB2M/Y&RV+W_:# V
M=\5+6F5]]+%@+N'@2S#O ]WG[?R]*@_V1BM,TBAJ ]-=),2A/\OELTSWK.G[
MB)=^.M/CM93R Q4;7+'F,T(>-ZW*LON&,*?]P]M^;9)I&!<N>_8$+ G@[@U%
M?F:Z.68^_G#[Y<BB .XA'D2 (4;.RW7P14_FG[5/3]^@"7]OWHKV6GH2^6==
M[H@8SM^0_JWV%\E?)'^1_*]%\LV$X:N1HY1'JG&++^^3T1SPK.O?AQQQ+FE<
M?YR_>(PNY+Z#?3"(6&.*\&WTTD !OC*@ #=NMT32$F&1OBC '@\D"W@M8H[O
M_WUH+7@73NT;AB\N+XGA:^"*]4SD'CN=8$:<$U9F/M-=;ZM6GVWFEE-BTMEB
M%&!KE?-Z7_F\T.L2'HJ\)A:&'4I7!#K(_],61/;=-6XRSJ]J?N] V:-@">GY
M! 5HZ@2:5:, X*#FHU)I8;? 7S1^T?A%XQ>-7S3^<VDDT0 <<OY&A.>PN&?5
MY9:&4JI(^ZQ$'7M7@:%.WLZ.TG3S C!6/>)P6BIM7F+L>A5\WJ]_>1GXAP0
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M74QJL4YQ8=$%8OO-3[M_%/C&'CTQX]<:D1[VPG8XR46(C$EX7+8K3@L N0E
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M=\5VVQOMZC@[B]%T)@Y.Y]QTI02,Z5D'*-^3 I*C*:]<59M#EHX5'+VN#5&
MS.@F\Q!-6KN16C66/IE3&E_00YGL^T]I)_)66.D6>)K#ZZS >;*6.3N0O&[R
M6>.3#KGNIJ78,D'[+J^WTW")SLE4KC'ZQHJJ&F])IK@]9K*%L.5'K<N1@PW2
MBG#950]Y*06I%Y5!,O5KU8DJ93_V;<-PKJ/T:E<*7T%)VR7CSMG+M5LNU)GQ
MV6FWK%R-#R&Y1(I<\@K=BF^MCJ='8=+A+[P>B!7GO7Y]_)1+N^OYT5%$.QTY
MS]:QNTN00A!"^( 4R*WKO8BP  TV@)7'.1&2Q;+.=@,B&^/)=V)Z^;$RAVT
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MG#)7P+R=Q_T2-Q4XU8>Z5X$*XU9+RJI]#_HNK3R> 5C!.LGJP8B19D?'6X;
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M_Z]$QFK+ML503U-VU^#V:0TZEBC1$UILGRDC",#,)900[GQY"?Z$' %HZ"$
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MUCW&;F2/&MW]=?WIU")QN2"U(7Z-\"Z.#>E:O>\UX94/<5HW$18^Y"C*P,V
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MFHJ+N?.-VZ%6@D_47A$UHGC[+@9IYC95;^1/(SB49Q6+Y3I?4[MA3?_=AB$
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M&XJ: W'>4U\0Z189P>/R\;?XYI%HV<I'\SC8D;G:=O7WB/T,09S@8B%6:(L
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MW-Q#\?C;H]1N*1Q)4Y5WMB+PEV"71ZU 8Y 71^($8,([PFRCI7W(O7FR6VE
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M6GWU))OR[)23"MU<9:6G^GSA2PJS//5OM]Y>M+SFW5$P+#][^XIQI>T;F>O
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M"G2XI/T6N$_%H\R#=Z=(]<84TQL=V4K-U*^N9KO1"8_7AUI%$P"_F1GX(6H
M^;T?@G4HLPUU332Z^"+Z1N V5_!;\U<&>8=8WUV$T-=> 3&M#GQ77^YWT4K;
M(U'RVQU+=*,4?+Z'FJ@T&OJ":&?3%%-/&):'\@(!Z [-(0 ^2<0ZBKJ%;$)0
MZ(\WGM2Q_))B]^I#4I-<,W87<978$F4:IG:Y5Z?0IUF)]:I9V$V&#A73[)RJ
MQV1F=KW-*W@/"%%XJ.W;T12E>RM*42NH#^QN7/TV8:GU?K0.#)5N\GZUJOPU
MUS$[=GMSLJ[+JCU#D\/M22MSB=037D7W2^AM(<9J>A:7VT>@(Z4R! BK4(I2
M+8Y_!K-.]B?Q/]J9(['9!;9)OR4,[V FJ:*JYJ)3S"%.& *@6(G_UKO!XX7D
MV;B87,$77Q')8([4+=))H">Z."-9 H!@@^R>T'4.>J!9JY\6ZN5H/9W%\>+:
MN,'XN%P1%W8BP(*AV,Z-]!1JG[^;!BO1*WK']B:=YIK*<G38718&.WT"<!;G
MG;4$O^3F3P :, WET5^NO]!;>&Q4<8T"FO3-%&]ZD.4GLKK/FZ4AI6/C:?[6
MAQ-2IS%[GQ^^;I1_F+FQB,OR$<P0$Z14UMV%'E;,@+"1>B#,$@\Q#<1(0\/D
M1BB"XY)<J%2DS"Q_]JX>_^E.'U&SBI9@2C>'(XTPU_-NVUFK#:^2=FX66;57
MWPLQ?U+PM9>_BA>S>M5$K'YLC#^H^5P90  *93$:4@;#'RND"NI:HQ>G(\KE
MGK_<XM4)Q+LCI)7?B+-:#(1,1KY])5_8:^K)<)N=,L#PW, \JB@8$QWA;65E
MH5@ONK]!RXET.ED?4?&B6?^4D:1F7X:YJ:-J<C*"N08R(X/^A(<4PH^.B$V1
M/M>HL?I</Y9>(-LC.+KW?)19R,;(!Z_2%F&5;N8=1$96(#III@1%^99%L$>.
M:^-3X(QL?P'83)]"Z1%KZ+1Z4U9U2E>PND$HZ70T<M_ <DTR$L:-$AW.]Y#U
M?4]:/D\ :JS2T2/)K>XS5@82M\P$U? [C&%-9-@ZO/,\1LEOMI-9L[#?&@O.
M)K-.T:&YZA \O7M$S%_V$*FFT#'MWF"MBWQZ!O4!4%.V,6TG8SOUG3TJ9;D[
M-]24GMB;=U23H"X8TJ*<4Y/L*]:1_&H;\V^?!A]-3^.I=]LLRYUB'58YO%^^
M_*AP'L9/4M.EM!EGC)>NI&F$D^W%W\3(\0>Y.Y.+?3KP,>ID-R_@\?((?>"T
MHGV5Z01*,\GN1I!$U;OP$Y[O@MG%MH=W,\.#]\KN1JX<%?-7L[FE4EY!?Z:G
M\VJGE\6FQUT@%6Z_B[4#3]\L_IL^E++O].B[;H)3<F]T&@YBR)B[5N)?O?G,
MOO1U*6(([.>$//D-='$UW#',DG1Q#GNGPL'B%]L-YP?PO]>E@FCB>G"DMA62
M?,T[JG$\RR?4I"0PV;A:W_<^@ H'/]B9\D]@&.(4O[[B*A0KF&1KDV"S8E;D
MI-&A=$:.EN$]^S-<DW[??CJ1_%%=CZG3[;".$PA>M?].K]7JO,\XD6^HHVQU
M6U"17GJ$;CH8HGNHU2!.,^#%E]YI!;&ZF7B/[+[:0DO9S.N5[C25;SM2-.5,
M-\3H]CSRR_U5SX6]?S0-/?PTZ[Q^@+SHK"SR^CSG/41B9K"/%[P)X25<-;19
M:9[D<Z!27E#L0J\@TGR.-XJU5*73>8JZ&F2XJM4YR\ATM30J2G-QA(;;[BZC
MC ] 0N'&Z%X'?1+U0;'\??FC+4A] A/R6W(_-Y?UYAY5G/\5 /\$Y'K.PSP"
M;FNY[,-AZ7+-_-7F.MVL0E!57NW)Z2L[_B:PAR>64NU$AE[IZEMZ&"P?,0RY
MQ,@L,"GPVS@VW:_=S^V60-O/&EWE+X].'[K;9,*9/Q'^/#YO^Q7M$BGL ZJ;
M+C/2>].L-7@,QJF9=F\&=,CH!#HZ2ZR)Y49$-L="O%!]-5M?D9[(_-8^HGK4
MZ:.]":N&L2>BR%OF0J(;<R3'9^<+U/U9%X*G?;\=J0\N&X(>=\/,'U$WA.7:
M9:N;#P\-^% ^MSUM(27+?"1^HG:367^H.T%XRR5EIM-G(W90^FNX=#3]NV_K
M[$KV4R3FM.(?EZ4TMQHWD=Q9J7HZ"NGC>K6N#%G65T0^L]=$%)K:B64NE@WZ
MJR^L+YC!%-%K/Y@,,[X:1&0RU$U81B*3>4V*\VS'9E6ANU,L'Z1&I:3"GSJ[
MM(K$Z+GI2B39JKVRUX?7P2G7=%U#;Y16]_)L&%^4O1 Q]H"-Q8Y7FOT9 7#1
MC]A/<T0%R7M+UBS.LIAYWADT*8%'1-F(B1M#SJ$@)%:M,T@:;4LU\_7EQMLU
MW2TU&?>_!R]M(3)2_47>L;PQI:2"JO3O&DN?19Q"Q=09*,N7AZ])^'TOW&?)
MOA,=RXUN1E%*\'K+.&2TZD5%Z5)@46*KHXOGV[5SK5/DC*,DD]\YT#*]O;:-
M#/%A+E9DIZ2LY2WJ#\_N2TQ0 >Z3CH=3SFQRM"3V[W52FQ9 CU2^:AYML2 N
M@C5:LD9!OEZ2LYY?]A7HH"+8 [4W>1F;"DQIPZ9':NK]!F.W->)BV*41=?&,
M>T:,HPI%P8(/QUOJB^\;(C<N'5[; _^'/IR)+=NWG%A0$BY\(KCD\DPNJZA[
MR+K(B6%-K<:@\YTRM92V)B_$^IMF^19JZ5R(3H=4@%N_[Y<B"EUK)M:M([P,
MC@9?K849ZH_:@;S&\B%&W:9D2\N^[;$]#9VF"5>0HU;W")<^[7U#RJ">(N>J
M&V4SY2'C2P*PS@#'\,I/H2\1 ":/*9Q3P*'8$W3C%TL,/"B'M6\W:ZTTNO9B
MJZW--ILMKV3P*_=:4+PUEJ;7F8N]3]M 1KFB@%=4ZG0#%]/ZF2ZA$[&IQ*J4
M4!YC2I.BTB15:<)J$MN&518!& /A&**FQ8DO"1MZ1 "^AB#QP;J8*[,&\9T$
MH'Y#=;1KTBHH8+NX\1R-64.Z$C"_1?9C*->O4M)V=N.J^RZC*EL2\O6D3$&8
MAKIL<KCL] F]/I\U82O6+EAJUISET>UJY;]E0O)!XVYO)V I6&8"<%/3EYBX
MK$%P5XLZO(B<-^RD,N8P"#.D,6/QO&0K-(@$5:G:_/2DJ$V*CK;TYS>4$N2.
MR*N</ (@$K&JD.0#-?IWW3$DS\=."=]GZ)>9%8C9ZJ9%6Q. 6Y32!""7R-$^
M"WB#C1YX@;<&JY[/5=V>77O<__GUK5L+T0,#ZM9B<K34NP8:!BV?<XX[@OY-
M4?#<;=_Q#"F;SS9FP)(]B97&29V534Y>)"D/*A4K$$:AX2\E7K9Q\Z@UIM7Q
MJ$34\]JRU5"2AGI(=UK=++6'UX2''Y6*'N.-?\0F:NY_.A1!_;?UV1=.0MF2
M?_;6;K]"@^A.YC;P 8<#F;^?.1/ZRJ)'BOKZSZ;+/Z#RVU$(5NQ_GGJ8QE5[
MFDI%]>[_1,\8@A\]0W1$&G#<6S4"(-5J&&/X E6/?YP%/CJ;A@\*SP1=YLO:
MXJN9"UEX+W.-K\*.6EH.RZXG4K;.8UQ9[!!1>SU<D/$# W1X"XR%Z8)P/HT$
MX,NY$31\A@<M[27;-W:;_VCV>0#.'\^")6O99^XM1^2$"M"T=\"<MB"!-U!&
M 5Q[;/O9:0>NEW+M&3Z3UZ^T, ]#I_$/B+P2]",="R#R2BD[ G!!5(^86W4'
M7CT?TP3W>JP&^3I51P!>WQ=OP&C9HX;P#S$R."\P_@T'DZ%.TI?NV C1OID#
M+ S#@_-"["$R./ZZ-RA%SZX>RWD(;IS:?K VM7^IE #TA,B/NA  DM14X R7
M5,XP9C-$&[),?MCK5H&7,?#$UPF!,/>R2K8&H\MC:J8NOKK'(I1SW[CL?@CS
M,S#7U"^#G2/,)+DCH%HNM?5JSK*^B;J4C3)VY&08A0S^@6%5A7Z_-.SSU"JK
M+8:KHNT4PYD;<J=0]T$A7F4SULI'](VZ9E^V-_QG%#;OT\O5.XZ]<4?8HMLS
MO0-JP2::-Q56!D5/8#EVF'R^R,SIJ(<LAF0H]4^%35\MWIZ:DK2F-8]UUQ0
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MH[BU#3:-O8C.(3S(A #H+Q =H[61[%#GU%DB_TH<)F;ZPI!=/:U> 6H?YE_
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M;R?PKXPG\]--#S[]ZY$L#/#D;]46JOYV(C+RBXB.,ROG_WT[_Q>7IQ))/WH
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M5KD$L?D_FNI[*N%6?#P+"SOW-OUE0J*T";]+WY.B&_@3:M(!.N'=!J%PF;$
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M=R0_O3)/LH!9##CKY%O$W=HH_5UE&0L@U=\IVW1MS QE[LP/9@Z+ ='-)Z[
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M?"W19<>BA[.87]TBF,IUSKJ'+\@CZ':\1Y7>/^V,\6 [A[]%P#O3[T+ \JK
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M7J#;PZ(*SRU74RJ8#JQ#%S2K1P+,0H9\K2^*XTBM!;@P,'L?F](BPS'*=["
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M\ HL""XE",TWD$H*G/HHI'R'L"!"'N?!DHM4!$XOHP2,:E2H[S35=$RU^LZ
M\Y/N1DO:'>BM6)1>EA&::,H Z5RX/0+_;C&'D9/SM QH9MXV)9%]BEOJ,"_2
MY\H"6*W50+,>7XYM1% %'JEE-U9*]/_EXKY_$T.T=MG29K9O8H,%W.!X8$#_
ME4EG[ 74?+["F:K;NRW%LL1:39E/B^Z7DW(/Q])B&!3QV8H@%PLP]X$_J$QS
MF&EL;BHOPP(DYI)7.P>9'B*.6"^;IM]<W&$>RL$"@HBP "T^C"(6<-:OC2+,
MO%$E9#%-K3]NUMY(O-V8Y[=< VZ^7\=\#R#IVDC=[+-YM=<_LS\XLK3+2U-
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MT/5C7@\W[R'G8E%3->CG9?6U*-O"F1RX=+M1ME#0<VL1@8H'U#A?\C.Z. *
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M <NW>QAL*&S55%$1W>,#VZ+RWU>\5HIA6]FS"^,+XU>3!&3=:V4X) C W+O
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MCP;'X0 'Y,.8/;\?[/@CI7.!S%WYT_^OK3\XL@P^];'' <1N_>#)GTGU1Q+
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MPG,OP?OF>^DJ!F?3ID;6_I;/7^ (_7?X?JSMQTY4Q=\,D;W[Q"Q)'WXV53]
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M]^+%-PZV#?/SG1]4/Z_PLFF'2)"7(%]*AM>Z/D?13<!JGM[#&@Y?1#5@I;3
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M<";UF]0'U2,_Z(U"C&UB-[<835*?AI8]?Q$8+$589 -%?G$CQP$>ZF%B8G&
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M%4G.6.D_<<C< &N)CFER(\6P8NDK^K #A]:%;\ZVHFK>(M570N$5(55K)M#
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M/<SO]U8?_@T_0]/_OC7T\\RTG_@O@],2N'NQ!@= F(/V*?1YMPW.3(KV?7
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M]D*N%G!AYH(6:#O*)0;KQZ.# ^ ;X0!SZ3O.F)#RH[,/;T'[ANJJTK?&V>J
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M@QBN2MM\/254W^@V$8@+ZF/2QV2SSW] M*<I*7 #O&]Z?GR#R6Q8[1LD);>
MZ4X,K#?SAX%/-,XAR$MT=D5RKWL70FFP]@P<C-+(-$#P*P6O&XT_2I'2T8]1
M:YC\MIZ%LT%[516QY+(E4302MX!L1%FNAOVN]@Y5909Y'HD"OXIL+Y.U/=J9
MSJ!-51QSU#OQR\Y68;V.R_R0X1>O0^A+C]0/URO_M-JJW3T=;9]G&)[WFN:4
MI5!W6-#55X?+3K)JT5;E+:N@^)+M0_'1#*5'NCH6E3( QMKSNJ "!M:N)L^T
M&7X'!_I72IX$=X 9]D$PL4Z+WTYFDQZ1GQM:PXXBJ*LW>Q>_)P1W!SR504X7
M3.BD^+(:""]XF)F0P*M-KJW#>&O>]#[L$.L+L' F!N)";\[L%_B/WXV[7T?N
M)\WCMCBP@M\)F;+M^7Y&UA6Y%1J+[AZQ"4I</HY0/5HUT=.3(OF<PK*W)/[%
M1]. #D>,3>PR%!_QY5'[B@A>#P/V]?W>^L<"D7[+9X6PIW?>>Y%T!*%Z?&,[
MAO#=1^XQ*/1R3(!]+A38=4 [2FA<37^KWU2:L!K?4COUWK0K<09S5^Q )=N+
MK1+P,NLL>A\NOAP\AYSQCEE7_A$6^_HE= 3K!0Z:QGCY*\6Q!QR=#G+)VQ.=
MOH!4K2TIQ L=$?N<,TZ>YR<6R97LZC5%5UO1A75'(BZ*2A@<=?&-WS0J"-IF
MUP>K;,>Q1(CPG4CAZKX65.'(Q*H"K?+!1FX(#330=Z$89:&G)^; :A71^T<A
MH@MX)F +1-!AA!R% :5!2%+>G8S.DZ6]!_/^?>SZ1D@+>JOT[\9"&V7Z:'FJ
MY7,X!_JS?4[3V""*:[Q6IN2Z[)5-^ B[,16R8-]H"^-MCR*/D8B$/SQY#\TX
M#JJ5Q;)S#M&"UU3GKZ:1/T)<_F2%EQ=)L3EW&->8^5-/M$'7]:JY");FFXA=
MOIBF,?4;GEY =!'I1='\/VGC^DE<LV>?NJ1OX]T"&!9-I6QHDR^ 8>Z'+S;*
M:CM5?](_S IBA=-0[('HSRUMSJ*YGN@FUALK9V['-F'(G7SA-R=A6_RY5.GM
M#E^O"TBT<*2L9^U \SOK3=/OZ B[Y##@AL4D</_(](9PV@^F]/):(\+Q_*Z6
MUO R "F51O);QMD$$WMQ"3J8\&H$G0GI@5O-1<MP1AS^4?2:V,* Z!<E(]?W
MVM&1,?5H9N\VX#V$3UYTZ$7(L'F-$?:I>3+SA5%L=]!2XP9$BK6<B,NV^@NB
M:]ULY(O[KMS.=-63W5U&D#:"1-.HX*,TM4??\;E?W\A%P#=!<AP7GBP5[!U)
M<&?C#;9"&]PI;*WR<_60RR.?//-+?0EK('C-?M=ZK,Q=X^Y(_NSC03\_"=([
M>X':\0']_;);-0D;1H6]3R82$F:NGK<5PCA082D<-[X<)Y#$_;U8+%!?>#9H
M.AO$Y5%'R;1F ?PW]/!O-M7T?W$+B >5@:;;SRE.#LD]"96Z8W-15&L!6-,=
MOM)4M%L_"$?GLEM<C7M+"QCN<3!/S2,&NTBSK.#$WYZA#Q<^@)CM-VDYW1/>
ME=24F<\'<OC+CT*D142C<Q?*-BX57L0K7;(^FY6^9"ND/I,X@Y#'B*6\B!&V
MCNO3U:7AT7B&5V:[(TLW*:WN/=6DVY"B>P<LR!5BM,[!D>?'']1&]OB3'W%)
MJ1%[SX&2^^L>,)_H07<:)>MNT/%4^KKZFU35DL9E&UJ7,6FI MNAX(NIT>X-
MKW>99%=;-3;9C3$3I?_J7<R_V]%,7C.65#?LHLT'DP@9&?33OTO#VGRU 'ZY
M5LN92=L('WTX;T1A:;,97J'[A:!"YI[,J<EVIK_=&-^["%Y'_-(C0->OR"U%
M#0C34^2[R79Z%%<]G'W>SD!G]*UINV#)I\T!4(M+GY/V<(#0=%^M:2CZR=C]
MFQRE!N_)NJND]2'MG4"CKR1M0,G=%JM:\4-)#?F=0I%HO!Y*?5&]E,2R.74R
M)3:7OKRZ"F94P;R,@LLR+ <E= L SM7?W,3> J*G@[["!N0(XQ]UX 7G@EB-
MCS^U/;%#4ARXV"63V=':FQE;.HPIRNC&2OLR"D I9(<U$6]52RUNS@)PS:Q2
M M,=+.F:H4X/7Y0B%IY_O",.L(Y574.SH.1B.SW;S:KF'T,D'9\IZE%(.\D6
ME..M>>\O&(Y03-;H/U"NDN?"BY[8$(S[JE3'O1E+:P<I10SJMKY7K>UB\Z'N
MY!]HSZ0@7_]U+EPB^V9'OV7B?)ELCVF7BBHEY%?!?>K!<QD*/(!U!76^Y'X&
M0[IN;T[^RU>;.-*\8,VQUOU5T5#[?&^^N2M6)OOVNV]SF2VBN[EBW]UUV5-W
M0M1W42[Q_K8<M_8([R<B1[]Q(\.>():,^C0BK[?'=NA .$FY/A3PBGLUMCLR
M/7#[FNRMA?WOD+)M[+L?7'4_KCO3;Y@S^Y[OR/ZM7N\9E26:L4'FE6?=5/N>
M&JI6%21%?/SJ]BD-OG^8,H<HNP6P36.2?!T0*<'%Q"^Y*6PTD*HEZS$*Z4TL
MMT5&*EI0)@L,OZ9WG.NHS%CDSIKT&*'R/EE[JW=_/]6#@W+J=;,"]7H4X;7'
M>;F;:I5D4J7E.Z'4U+!5:O'K7WCGD#+WZ_L._!K!O</L$4LX]\)RJ)G6%ZZG
MJN/#0S@E\B%9)Y[@XKT4AN4?YEXNUI)BCZ@A,D^50%F0[#9Z1 ?*>'6=][<F
MR&Z-.SKG#J+/WW-$VO?3/,46D/8,P>MOZ.!&J$9G;'CW&P3>\%[HO'<4H5?P
M,]3,KZR79&"TL]LO&(&V^G;(Z4;Q"EXTX,%$74MW*-0IFK![64\97XM\%+^D
M%QUQY4IO0=K[#%4R$DCK'6O4COB4-V]B+QG=TWS5G)VRNVA(*D&#LW)RIWS[
M;ZFR#[@3?/7$0.FF[A8PRJ_*O6">&CC)& [/T9NH*5%GJ#E\?O2K[R14]%38
MKX**9D[1OJ]]E0\NALF2]>B[_9@LJ3]%(?]VBN>,@6M=JSUAL#[$U64RUA*[
MD2-(FV;6H#<A=[[UP+_U'\J"9;N!W'"VN=9O#I"]849WK?P3^68>\5Z[]DAI
M=:^U(4]CQ?U-C48<X^Q8COM'/AN7(GNF^/ZX%\KK\,=%I%3$0I9D6(1VKO?C
M]I0T'/VB[!_'-RM):W\K_;'_<B#B;1C!716.C]Q=TEYP*^31B8-85W6JO7B_
M8G-4]*DGNP8,DD6?T<C _;N-<__A#AJGQ9LFWCZ^;N?G5WTO$_#!%PBX12 G
M'=0]%Y@D5+?VCCXF"X]'"85#.YRFV_BCUK;Y).OKK'W*M?!7@SW)2 X]Y:7W
M[6%#!F,MNFM,1(M;(Z\;0[ZA?JNJ/4+FN-S8[ZG1T1D+]M)Q<SZ\;Z/_P25S
MA>1TN=5GNY>?T-#4V^5\9EVWM8J+ 7I7>?#.I_U@.:9H$4TQJ_!$*HI?&05R
M*TYT<]Z#+_FPN@J? QKJ1S0NDB<U=G]?/$[NB;P>DNH@<3'WDBGM7!/8DGND
MV#&LJ"2R=@L@KO5Q=Z+?C<\-8FWX9OB2&M:W01P8BK>'ZX?7JW'U@ V3I[^W
MEZG%\HRJ.NK,;J!I$)]*;6D[E^UH,W) A"ZRO'E-GOJNN7QR;.\>DJSJ.IWS
M4R&6;#F\S^D0)TJ)#O=K5'ZO<$61K%[NI@S +I)$VDEMD6;O(]TD%0]:GR?T
M,R*& DS-S>WSWW196F+).1 <Q@C3WT'[79:D?3/I=5_;*ET*'?!5"JL%DQB%
M"\_O'O[0$-CF"HC((-DT5430]3[PAKZXUNI]U/PY[,@,+^2#A^F%AE,60[5)
M +R^JZYN;<2T_K,2S]@5%6'#G>$QG;C]$#.PV1NFN[5X-?"QN6!1$\-^.NR]
M'&_6Y4W@CVR55])=G]RW!X:;UR&HH+-8) )T@Z.?Z*W?'8_0?R.9]H!MO)0O
MKO3SX<*"Q7H\7IXOY._TFCC"*WM^?TFLHKHY]E>MUMC YYN58F6\";*/2ODV
M(8TB%&K7Z@3(;VW<<$&5XJ6N(A/#J"VS^]^_6HM3TSW;*MDQX9Y"B3E7[2:?
M].:4\G@IKLL09$AE^)XX*P28%!=FZ0 RWP'$L=J,$$$%77F(4_W:8/:(1T\]
M%':R)H",G[9VY\+4U=1P51T9ST=R_ 7*N]9,B6?W?I>/R,BZCRPX.W?!F&\4
MB7R4>GF]],>EC6WO@HN7#5Y,W=N2\@N-5O.))UPA'0:@2HH1/#TM]WYF4)X\
MD_VN?6,?@EB]!;"6@6\^82BHHHHFKNW,6&YJ_H]H!SB3<0VL!>EJI^]J8O3J
M;7G^C_2U6)L[KQ.^JHS(5!Y#@=EU>:+-MHRI'M+ZXP-Q2FRN%!_B =LRDH&Z
MX_Z\L#)(.$J-XR*8AJ>,Y=1$=KC[8W% $[BS=5*:877&0\KX^;)2=7UC[?O1
M&M)[O<JL7Y^2F-P0<VV*]\P,DV^*^$6N 1\8>,MW00I-A'ZQ8(E/5"P+K0>!
MM8-5SG#6VMRF49801#XLM:31O_X]:^W'KQ$D=,\80/33UG"HCD_M#5"-T+_$
M#R0>=>[U'O@LYU2$HX.(8&GO%O!ZBH]5W^]UI5R#M;VHFECE3VS9K6]:43X_
MM!W=-I32^BW+;1[3-?+6,DCYW'V2(A;*YG923W_#/8&F0[UN:FX+?0''Z;7^
M\=FS_@5@O@G'WV/$:C]AV"UN;ZXNP;K<-F%W&A;NL&5<2J*YHY3%( >)+V>)
M[T2_\:)(6M)J#L6A$!^I5[4MCOBE]2I!7>B Z\I:&VX=MC[I1"HM5UQ<>H05
MV0_ =EDO"^#.M&.::V,8K\52L8^TV7BO*/L^!UANO\G[;YK"SI;7>*#\3$_*
MV&F-(TQ:P<$Z>_?N+NL;UACYNUL9FQ<?Y\.V:4:P(?[;,8(GT]ICQU2'%<9S
MQ@&KVSF*MP 39_L=DL]-[/FI*R7V.QBH4&M;9!M[NO$1D[8_$-ZHB##U\LK2
M0>X,N<.YU:R%'6,7L9_*(QBZ8@OR1(3S!KZFBZ[_FAU$/4$$%1KMC2) >FD+
M; .!0\+1IUFZPV-^P7B!Z$:(T63Z^B@D-_J'L<,&UX"S'('/W;;W,&YR^-(7
MG96;*@$$6032Z>TMX"MEUG\MIN9GJQI0*:KW+%QY_?U&7(!*;G-_SIM^5B$I
MP]ZWWS?B=5S5_4-,C6T)Z)Y5:*?1O8'BX1W%G.LF=:_..V2PPTG63/("2HQM
M?47FYVU_UR=9A'*=5%Q#O5X+Q05-$/NN-=@(1WL9:+LY%=CI[_\>I"?A1%I@
MFZP6^C^&J3?53G:-6#H6\#8=V]W94=N.[84L^JO#K&(=O\H7XG]6IF"I#0<3
MB /H'0[WGZ>HCCYWG_=*E<;J,IJJH:OUX]YO5LD&.@M@UQ,6!(O3DT8@Z5:G
M(S?@H- 4OUR=UKJ$ ?"[SGH:0AFAW3V26N_8;G[R&41S-^D>I:BK8?8S%G,^
M;&4YMH=WE9[C:8\U0SX.]XB<C0P0-6(O7(%7GDSH1\\426DDRI"89T=PI^W_
MV5CU?__*CJ%M=,L^\X$/4O]5*0/VDSY6ED;)A3&.4]Y?%B>AL7E>[XH-C&*+
M]C83R\14SH5MLB/.8IW_[*+ZLXOJ_Y NJB%9<5!?HO4MP(P<P\M=]?.F_WW7
M5-0>BO"$!!L3>><8*)T^,$4^@!0>\_(>'VQ5-X5;UO\@=&5UMV3%T1_,P,/\
MZKX\)M)GVL\>F>KJ)=8K>H-"P)R(ZJX$A&&WOJ3%_ _RXR^*U*>L,G17GXZ(
M=!+>-"8_"U6*JS?LD,B@OP7<,?O")-^!NK%?#GR"4$(_!!*G-K_IF/@@%R]-
M;*&Q]O)&@G&=87^;:^SAEJ+(HWYN!O[_I%;]5F]AG@16O7$+^+LRM!__SUO
MU4,(\( %P[[X).&0O[^LU"&,O^(S8\T?P,ITO8IW5E($HQE#/UHS81\'5:+4
MBW:O54NI^,)(+H5.P-WO1DOVZR6'ZI*).J@K:BB+8E8$F-$O2#J;2:*07K/2
MCGR=JTX.8\^]K'G:'ZW7$]1N>^1ZJ/SH=ZV+=4'0Y/L8*!84"^9;_W@GCWK&
MW(_"-[L*X/[5$HB%N#8$ &0GH!&7(Z&2MF,H[-S. 8J-R!''IRJN;ZR7<4@Z
M6\C62%"QR.D;__JSTI5C47M-@Q2E/!3!'UUFD%N *?X?9V<<M+& ^H%3[?O+
MR(CU_[@\;<T?-<74*6L,*6HA#N?X*&RSH6MAST98*GB/-8OB9"A <T7CBE18
M WFFL6F@-S-(TBRN$0$D+LNM3#8==?BLW2UF--_YD1OB!7!G;9,\WY_N_7#,
MYW[=4'ZP[<W'XM#/9HVK'A!B*H9)=$XHEKE+L"WC(A\LZ2,VF/>+&,=^W('?
MREB!U'6I1]'\DA($)04O]FY6Z.GBVDN:,?Q,[\20B_W[\DQVIGR@[16L/8Q/
M6F#MOK'6,N]F'7NL^"DKT =$NES9 2G^P%]VSGV/WX'MH>%PT&C0'I&"LFLK
M$>?$EIY?AA>\P,20B5 A5^DQ'_\&[@1HA$U"XFS0 7EJ@FL,ZA[RWT>+-+LS
MS\\Q575]^OH\(9ZD^2&(:PRAN[(/)+=+3K"K&Q(%.SR@DZ^Z&Q=+'TP"$%B?
MAT_);CC^XO!-J))0]M=>H_-F#2;RTXG@G&!13([G*@[Z",#[B,N&YI@^RO3F
M$QEZ96-!9R+!MV%IMB,GSM(6? L(T5Z!(+%N 1L3RRAC)EBQ/\4MX)DI*B7U
M%A"9=V@^ S&7W1ZB.%K&J5WWRC:VJ8IKZF_I:QWMYSCY< M8UNWUUX-YQ(:<
MT]&<E5@%]VX)YHE5A\1I2%=R?%5B[*V0QH/PATJ;F0=P4]3SO <7+)A%H?'P
M8,7)[0SWHG>'?R&%>I9/V.V7+X@;,+'O8,HQ/2NL]Q3\9%PK66H!,=?V&<%]
M"V#A 9]?<Z"#$W=JM--?6=H3I#,J^8&9]]I/J-LPGA0./&,UN80%LX%79R(4
MB.A&N*HR5E9(3?"+,7#Q_AK=A@&WW]$!N+  +)1,':N$SR8'&@D]*RF!??^-
M& %[2-$(#^D==;Z6GW\)?RH3J*5T5B)YU.P&,9H;<E5T*&.IU<CF$T+$:ZP;
M<_24B5T#H9>.9';&O<GW3ZTEZ%0NKA)+0LLHBX2>\.F-'K?CU(Q4(;3V;H(=
M6QJ82:??$Q*BV=O[(;1PNV+O02-= .<$'P#@C/=]\@SRR7WY 'QW5_0%8/=#
MZ0JA6>J6TT3*%03S0"3WER](_W@@T6\[EM13=?4^:QZT8\!O0[7E%E 1>0O8
M:=@?#N1=& %V&S]_8FD=@Q/.HN6M(%#R $C) 8<H_GTYVL"$&:&?A4@P:IB$
M\-62-S3,-YK%8447D[\CY\B..9<>$')(6MM49_.6#5E+-^_B%;*E4OLP#F!S
M8A%C(_[$DQMT5N;3QNG=NX;/G/QFD3Y",W0VBP;GW2T UQ>$XKP%$-X"1B[*
M;@$@\UO NH?A:P3OZJ"ZZ-Z6U*).R^N6"-HW,&6<TQ-=MXZX@SWVQE7=:5LF
M4G]],Z(,L'WQE6>E0SCKM;32_7$:[I0-^SD4+RQ9;E):)F^O>G%/31J6^ZN(
MS4S>8X6<@RG::$Y-6])._;K "4Z&5D'78CC;+6!"?[#VG*I;XXH# T-^MP!-
M4[X)S9EQ4CCKGA-VMLH*$:T$Q5O:?FQNPN![.PK.R^2!#(8JYGSMV?/W"L(<
M&^M# /HF1X =)7^/_6F(U[]AC#&1Y:]U[IQ 7<ZW8,;9):/=2Q?CV6&8T8OY
M>.5A@A2D_.IRM';/'!\?C;Y.7><"\[KW(3-C:'O618\/7O?RW5M )R_$YR+N
M<.P8WP8@<3)C[AK8R AM(W)#4\%QH5^DY>R+#3=;ZKHKMQDMK(_YUZ0NQ$5J
MXM,<8VQ4QA-_G$=3F'0BE[4J@B_&Y-A;=ABH&3,G([:DGO_+F[#^QAI'Z! I
M('R$]][7M[RS9#P?RA[_S-S>VG$;OBNSGU,Z0FH#1WSJFI[3B2(WZM9]$Q7B
M6#QS\8YD5=T &:%?%YJ, *WSHHO6#._3S=-Q^TF%?WZUWU"51&WB%MNBY/@#
M.5TYW6>0G^R38R?TQO3G[X7.&7>G+1FY _O?PDS1M%.I'Y*0Z;D&*9F=?490
M#$_PJ9 ['!;:4W>0])KB$)&<&K.NL6>D&SV_]@K5JOCBO-RK3TS\])Y9G_3T
MP%Q9]AM[JCJ7 ?:8I37EI&>N]-P/B /@)J%E*/LID?LJ#C7[U.ZK+(>"5U]4
MJ":*?@*NUV,A(MMZ>OH&^5E$>:5.(K^.:\D)XS6NANV*>J"N=L."]M^04JN6
MOZ9-B6MZ4UT$KN)*F-9T/;%/Z ,I3MOJR3H@>T_[GL(754ME[KWGWM,@W"E:
M72::L>7L0(]0,H0JNKIV^U$^;E%:F_Y<,":MP%=)^&+W\KBE*>:A]F7067\_
M8PM21SM^RW(R<L-$">(OG<XGR[13_OD!;Z>S7Q$7Z+5]3HI-V4J\SX9R=K1:
M2TR'K@YAO,H.  *694*]E'U8&R"*GE-+ETEKH@Y;)I5Q)L%A;.C;EJW-6X=$
MBBXQ_\X;<X^4^I[3\#/%/KK8F=@S!.?\YS8PA$/]E()V]/6I3/:\WKB3KL'T
MZYHT4='O^7K#ON9W&\$1RR?J'J!K3-CGQ+=HKRY_88.+11SFV/17U9G)C'O.
M2=R?"%@3@!;)E,RA_[:X_8I+4-G.T=DAYZ<_1DFPEF-DF!D=Z(:Z]CSDWW>@
ME3B&=QV,$"%V;P&/%KG1K9B\]+RH#0?4IV1P"RC7!(D6!DJ"^KQ4,8G "H/S
MQ4Y!3">D&++QS70((]0&JT";\-^HOZ.3$"&$]BV G5OY%E"WC&3?'_\'_OD#
MA;DM/C$7-.]T\_!,'O%!%QC1IC16]>^;5-?A'%#^M5;]@[J8+I5:5Q:3L8J^
M4Y(5;[S,L_[RP76EB*,#%)C8$)O>ZRG^]C<!W&_5G!H% V[[T#;_]W?#^5AL
MUVT?$1.&06JJMK\2$Q-+K=QPYI'40 WREKED[J^"/K:OLK2A)R<PC#=<M]F_
M<,_%%?WIYJLO\NP<^MMCS1-(>^@^2/VAM(7SJ^'S9O-H_@9L] VZ=0^*X@<C
MD]I/,&A8.Y9FS5&IL_V*8%JL3>29)8S'\0X+W<S">L7<_LC-N8DVK'=-RC1L
M3CH^[8E75("!J"8RSN2F<*9GG1]7I":SLRFZ6/D/]/JX/RS1 =TT%3"=L6-D
MFER:VA.K:ZW[2N^%XWI/!OJ<2-*WISME3D49>=3(%'[I,HN2F7P9^D/SO=S>
MVX_HM\ 0ESD.Z'V=<4H9)XU&^PDCGZ0LU8$ 938'E!#"O9P;VOZ@W-^236_T
MF4/-C*'OBVY*KPZZ[S?XU(P%92]M!U.UM@VDFZ@9J8/5P!2[#[H%CWWNT;M?
M08&JE\ H\ FS"H9I"H ,-F2)O25]:DG7#&=^\&;A.F 3^L2XW@\ ]"'!=OMH
M05!?$,>-?\^-7>ZQ<-AG@_QY:=.?"6R,4J,,IY^\:%WVH-CG+&V%D.AQSQ5M
MJ5!6!D6)(;]7X?#.2>&>6,/Q(X-S*D;+0JTJL!8^'8@0S?!D,M(W2[,PQWV(
M*48P$Q82I1#Z?7JO(^!9= >P$+4_W/:P\\1?:=S8)2S)VJD@J>LJ3J?%;=T0
M3&OG\A(6Z6?H81G\P%51@T>CZ.?%BGZF/QELHH)].LSQ/5<U1YQ]0\#F\-O0
MNF=,0=D+%1/\(WH[X+\MZM+!O-"J.$SGQ_PG&#_[[U_(8UK%<.RH "I387^]
M/QRZY!8PSW3S,/&LU7\4;HA6U<,P] ^@,U6=442T !/^GBDN:$,A =UN@0DC
MK0:G&*8328Q:G9$ GEDD+J PM#".4@-Y\\=4$-75-DS([&-"YAU&UXS&ZRHA
MHG[< O#I3.^T;V&(0;W338E)OXD8C YM17+M>0N8JSU(3-<(3]%$D)Y">VT8
M^1F3WXD.VM,5R#2:;N57MG"L\&KWBEX*V4Z+:M[WU'5Q/BB(BXLN]EYK!:X#
MO[!-N$<&N$X)CLUL<F"W**4O@CXC0=X9DYMM!/#TY4\B^HU?!&1J5GA[&AV:
M?^[('2AJ;-G;U*UFC0@G:OB9Y_U#.V4L0A/]^!8 /N1 H_MO ;W[7L:(65N7
M;+6[L>8^%*C1;Z=6<Y0/E7AR'ZK0KP?-7.NG>)O,&T[6#AH#E9N;(JS-KOMR
M+4DY][8QQ/I^QK0OL6J*I^KV6 ;%F/5O%'_!;K(&W8@#)=0FG.N5QLN/(-4K
M:UV,'.JYO/%7^:-/![FW1.KD0$YP(MD;A*V\.;-BSA[+=IUR1?5W=Z485I64
ML,7FH1EN ?U C)9<1J84819-I?ROB^:JVQX*.M' :,Y+='[Q7];7_J_K2Y^8
M@D!;C2! K!TH$@RZ3H5BHJ,2M/.\+6T*M(%;"/KK)-7O_\G%DI(FP2R,9%5%
M]MY'N+?C=8$DNO6FN+EO*.Y $DKV>+75D_41]KR?F7_DC^LHXL&?/GN&4L8J
MACRW\:@\K0^35BCVKM83\QIKB1D*>_?R,(HQ(O+*+^-\SI8)Y[QY1L]8\63I
MYU,<I4_<L49!'X&2IS:Y\5.;[)KA+,X_27]_,IFWAX^HHX>(O/*,;UKXGY":
M/HD!MKQZ-NQ'[S>I]H/?/<*_K%YH1!JT>A]T=R_)\[6QBJME_:GQXO/3AA@
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M9T<;,G2F!;WW^;Z7@G'6C^:B;1Y[$C0YZ MH^QHC+-HQM!7>=-;TI*C?@ZR
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M3V5)T(&B/516W'9TOB-SB. P1B1^F6880*#C>POP;67].6WZ <87+B#!,OH
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MV*<Q[3B)D[$<']ZOI\#FZ;M@/]^]"@QI.!@U7=:,<2LA=T\W#H<S%M\M'\R
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M@C+%ABZ<WOB&>+3YIM;QZY4)*0T?=N27 :E[V%SG*]<G7@.C1EC7T[/IUZ'
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MC&G!T6_I#0UNCA85"<I\@'_>?&(#92!)#M8ZL'0*ZVB2$)>IY>=9(SM.UTB
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MH$(\^L$"PV[:Q7LS<*1-2ZP[O\@ 92H)4JBCN%S(ZQV+)6KG\9 ,!3IM]YF
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ML*?([31N-*Q[0V6W/3>]FSDKWJQ"H/!&W.CG)9@F)%9:!7#/Z62@RM>J7O=
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M>W_&Q8QJZI%;1_J0^*)[8P><?\3OXKKZ=5^>IQ65*K/<AEQA;[#RLN"X_:)
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M?=?0^8?A4B^"Y_QZ;Z'7\S(">47POE06#Y1L>'SH_6E2^LRLH[$1F\%7VG)
MNJFCKZZ_)$3)":8RF&N[I#G.6%$N1_Y8KDU6]!6L-P?2Q(" G9(YPM#7PBX
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M8\%RLK#1TV$X6$\\)CWGB<!]WAZLA9M/>%#U:UMZL!N\AZ6[DM63^S,&U2O
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M<Y7A8F@I-_C!&'C_ML%].+^=^="GM8/H>**JD7L"(@T=S#&['\)>-[R"%\I
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MJ=$YN_:.C1V5*TD1*,;CP)OH".6ACST"*UJVUBN=N(0SM==#""W+CE7D! S
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MZS]Y/[GB4D?0*-^A)_LT[+ZI<RPSTI><M2!7,F.TKJF)XCM)EJ?;/O8T&^$
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MD0?IPC5- TGBW<%*V]T)68IW0@2C(?T*RG,22?5TFIG-38)?^ ?:BEKJ="*
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M(L3#3ZER]7!2/6O[P0A=2$_1SE"3=8Z/78E))-^#LGJ27G1,QE?1 <<]O:F
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M\5 KU0&R+"@XI=;68'SK2;XUFL4>N7U("915:"A++XWHGKQ-BTEWCH;!CMC
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MMG]S>IJL2?'<0UF-5D&]-'T?F3K39=_TY2X\13W1^!#KSJ8<9ZO/-E6H[%6
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M"(O^+]&C/XM7;B?MT=4B$F#C!A)_5VVO9E<K"KC#1P8@XXJ0/9.X)[CH5%A
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M\E5PBL'R:XQ++G^ J3SC[?(MXS#;#N7@.FF+.5-.L5]R/0.@LH2X@-?/O5,
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M9L-I<G.4,_5T&[N'N<O>K?/IL7YI$^^^EV<@1UU8@));B!X3GS9;BO$9E2Q
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M@BK>/44>0S+]3"&A*%FA*X^>;DV5/R>=(<QUC0/_2K&LIT42RUZ[I_(ZBP#
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M?>**6)+NN)GT^4B_%KMKV 4O'C\%=&M@OY>1JR@?_SH/_@N_WJ6,#,]AZU.
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M-EO@ $-1]KX?G&94T[/^DQ@K"DV-QW!?,+;IWA\(G_)Y@><6T&+H1/,)]:!
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MAS^::LI3WT$\&;@(L[A^7LE[B?U4HYOWR%S1<94U^20NAP.H >]#5^IQ )7
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M8=XF(;3FOEI9RLS+S\+2!$#PYTIWW<2$B=.8.8-!IM-#TNR8'Q9O=^5]4"O
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MO5KU /ZM'<,79P5G?61K LPIJ!*=LO(W6PH">#JE_S8EMP>]"5V5C\,VF^,
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MG54B1@OMZ[I,&*$_O'S7M#.(,\2-M$!V"^S8W>4#>^4#>35V@B %*WTHL?O
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M-_R'QLNV@/M7FGZ-;]!Y!-4]-ZHX]$$#C(OTH&7D2&OA-YAQ/\"2G8.1[#;
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MLJ"]VB.I92$EZ)HDS".'"I7FF$L?WD;[RONY,H#0A4AH.1DN;R+XA861:9+
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MU(T&</":%J$V"W@/+M?L^>IP8[Z!>F%K_3P=2LT\=@U%G?NO%_*]O%,AE"Y
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M,VGUT=2!0]<BV0UZ)[9(U\(G)'33]/AC]>,+JD@O./@4\8,9&\+NH"11%6B
M#AHPHB+++-4!BWRWRM_T5WW!A ;X+BZFG,!&F_9&P$B;^FNU!?A^J <CVS2-
M94-NW28#0E9''_Q6A&_A&J@4)Y*L"10I;+OD_'6"ZVC3:0C'^S5[0IZ=:KYN
MZ6M/3G?NU^>@B.5"P.N8Z2)2'@V V?L4.=FJ00^[28IR>DUU!<D]62:V_,BQ
MH=PVHMN\*NFC&9ONK&K#%76/'+-UQ&QQ(';&:8=TN4A3N%O>(@?1G).<5N#I
MY$2+&EL/#>R!\[*[R\(1*,1=SDI(5650Z^GB4C16QJU-<5%D 7-K=,)P7E\
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M]XUEUHZO:)V/;_ 6P#L]$',$ QY,:Y;AJS,NX_*EP_3H"F\>4KK=EB%F9LO
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MX68A,C$"FWJ$DDBK\Q4P-E])"81TM+"T/"'!P0<N3<SDBL7*V(*S?B!Q#OD
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MSC(@BOAY[7B9%A=?VZ?PUA"UW^W^=!N^&<5?7[+W>CU=>]'$O69@I"A@]\+
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M\5;V)3O< 5B/!HZ)WB=BP<DHZ]^N!6@5D#M+PC^\+4QXI!KTG;]=L@Z/4+0
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M>2\V\_2%I< /@CX7Z95+XR@QV\+$;@*)+Z,$1?.?Z5=/BI65!'%K('BI8LD
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M"63]QEO6J31K"VA!&!;^T[R"?A-1HIOD3_.:>$5 YL37*_;KH?MX,+EZ>L@
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M#N"^ H2AJW:A9.O5?4G1\F*VE 682BQ9&*A\"Z%F:UE_7!J9V^D.)MKBM1+
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MJ4XM6,N@,D3E&1*H4P$\)5X2;&I=L?0/.:%MC&.(7:^<O%\?Z<-1*2VS3V*
M^[L1E.&_*(S#+.MP(<]PVM19L306'C?S02<J$P;_EH3T]'_<#J+V*E-E3*8O
MF5B_0QE]N9FU(]44NGH&W9WPSC:Z!W!*;>M:+'QS>[Z4??R <Z!)4P7;!3<
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M9DN_]3+D.5X6*=_)41+N1LGQ[AE)&>C\Z-.5W^))UC@_A7^83+QTD4$"2>3
MBC Y$NAX>(JHP;M$K\&JZ0;?PCZU;<=^'MPWWGE$G3EY%:GX-1Q@U2&!@F8D
M()JJMC>;6>B4;U"G&*/IEM5-&T&(^WDSPG4IZ$(>O?'*]/GH7[PP1E1V(H&6
MT;+H9-.LYI6)Z78!7$SQ/KR&=,,G/G;H[]LO$W)NM<UO5WKP%T@T#Y2'[N,<
MC3/HHYC>\7;)4NQ.M/82H1 6&F5KBQ*.?GBKEBWH[>1T@>T8Z:6I&TFA:6"J
MNJF%[8?IRH/:\@V=@%72]5V9I1G>'I-A,^IGEWG5CV+GR#)AK!+#4\^^CKS*
MH>BI.I2U/1V'L  ;&0FL)IJFRY(I>K4[C2+GD>H-_RCQ*B%-F5!B6/<%O>3;
MLG*'9T*\EROG"3Y[IP593JPBQ BY<=NV)U\H'-QM$Q%E@,64CJCSC5X+3AD"
M.P-SJ(_B=_/2#_:5];%=@7'W+-*K&OGF:9YK4\<=P"3:(!,)SF */P4_H5A?
MII!;0F#]11#\PR@2.#YI.$<=0.\=@W)K,?AFUJL<IN(GW6J)HKL7ABZQI$GL
M6#[I6UE9^H4Q(,Y2:;9R%]-)2ZYFD+9^A/;BY? 1KNQ=T4E@=;+432QU]I$_
MW9 =Q;NO.V=CO8T3$=;10IW'V[LB)):".DF37?J1B@%?-Y=S^> C=Q7'89$2
M(^EW->=:#J@#)IYY>'GV&JY3WQK*SZ,E*6]R34GJZ&L'S@%<O@+;MEF:DD&Q
M_)6X?/2S6P;8DF@VMW:>(CZBK$>MTN" ELZ1 **J\)!G9IU+J"]87S"34\J*
MHNB8092GR8W[*J;=1 +G*PT] QBI@V)J#1'J=IM?WI!%T1J)!L&_4<K?U'G>
M0B[[B>F3LSNAC:-H])NY,$XQ,<-%=Q+Y^#?E#>)1?40:&E+"$S<JK=#'335;
MOX_$E'J[EK]6Y*<,GMB8\=!/^%ZU"$*=[']+/[C]PE&R^8?:-WNFA$PR*HAP
MK3R&J<JC,AD<3J'3"NMG'&%D52#1$021DFS$KNQ>DTQVUA/B 2Y)(J\.[:5$
M;11M"7^[S'V/7-MLL^+2L#819DR*P+7409&K5=0UUWJ.TY-+J FUTO>J(\-8
M$2&JT,XHF0]^Z/Y00=_BAXYX>JH!_<X]]R',55#B\:=&3C-]*;"%[*Q3#_VM
M&,-['X6JCMI_B &V<[\3V%K!.J7Y3J."*%O/.X"JUWFL60Z&:+A::&!XK]02
MQ52^7HN\D\M,;64SL]LJ=@]*YPF ! 2 ]?3]4/_%CVV3$<089"\<:#Z3YLNP
M7KP2IQ'H6^2/K'H>Y^[.2C[5*$!(W,14>AA+:DHU94NCBT?C:U.Q5^$%ET,K
MCV@8SP1*S2<8; ]1VRW;/(7PS\_G7I5$[.S(/;RU7U4>&12&@9J0IH+III#2
M;'AS^E/7U_Y$MBWS<ER\[J!CZBBUMCR*QK&\M#LO#.[.G7[0GO,6Y#?,'I=R
MS[H?Q_HY)3AP,LE&;D5N<U.$:C0Q1\/LZQ=S2WP## PK-'?1'RKN/R<\ZN>$
M4_XVX<>H]/9Y\1Z2@@P+V7Y1>&'#O64.$0XEN%IQ)WK+&KH$>[[I*PDQ"5GY
MUO1G!L&?/=%=XFRD$*4H(^-.?U7AM@/J&X^9Y08>D\%952LA?^CH-N4:!48F
MZT.Z;5IWV*?T^3>:BX0O&VX#8R,\\4^EVZ>L:'UCP]*6 XZ_K5+:YZ@B'@Y8
MIM]MS<I8%*$8C(S<$2F@> [MUMP7FP(?&CV3'9_I\C,_ZC?']>$9V?3 '+;D
M[H24Y!-3M%"D3+98@F;X^58\!:I7N7=AX@T+]%47>'!?1ZFKX"QO,S&VL'ML
M*',O/B/U37)^05I.\8L?XJCH9WQT]*ZK>ZTV"91(("(RZRKQD F]Q/44PC5=
M+/?-2%"&,EST;1'B9?- W8P7]A9 I6KT2Y=:2X=MK#&P0&M6,UYB&^G!B>)=
M<URN&K2E>HS# N_^IGJRA%[RV=$'BX9(0)W!B"E4>\\$U:;O9$J^@H0XDGZ0
M(+C+=6AZ9FJBC;ZZ$GJKLVU=F[D_XY7U.8;?L1!6JV(I:SQ[\P.'=S(/.6OM
M._BHA,"0%DVF$T1,.<3D@+>#?J[$442<(WQ3A/R='$X/*T]M43>!^UBPSX/M
M1B(&X[48XQ/>T)O^\:O.6O7N-;;13!ER^2;R:&IJ'!J3W;9<%E"&A^WC:E_4
MIV:==O4BP%4O';[.?]6;5W12.>7;W/*(FG0:G 3=FBNFQ+\+N;&!MP9^NC""
M2>.__!DO0:-O:0L (* ^3U[VVD<IFF)%W%..QYQ)88FM)=IC']QH3'$3SD.^
MD$3LX0R)5S4_LA&ZM;GNI;-,B-(/>ZI8,V+'<;(<V>_;XSHC^? IY:E0 Z[+
M&&L6I%-5[GP7#^%9MJZR?#XSHJJ'/[OA,$6H^&)+I/\&3Q*>V$@9JPYCZ\[.
MCPGRDYWVKZA5A0(A0C+MD_U?&-]\?;\4HLIS1)WG#LFX:0CSUZS9O]D^1?T
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M'UT*&F_H^Y0LQO"^L[]_%TO-F:JJTDHQ["?,!G]Y<%JVJO39YH[84GRD#[@
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MU2IN35/.:*>&9'",R^V5Q[%//V-O7MWTL4R],@JK*)>,%-P_;U"<#)8J?RX
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MT[;?PCUL;GT@%#_9T+AS0!PODSJQX457H<5EXIW32_R>$%!JD\O% 9T9;CC
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MV'[/BUJ-GJG.91Q0,_P BICKKC4BLX),&3*6?T[IS%MIO.CIV&K&6! D1E5
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M<0H-L3VZ*!>MHM0W$WG62;+#Y^U+.2 2T'@_LT$IRP@LUL42T]7I%=B=0UO
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M^B?"CZ=^.!J@(K]Y)@*+WJ!+@%4>ZP[TL;9?EN*WZ56;AYS0"4%.L93UE*8
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M(EUG0@>']VZ-F49QS?_M^/)3VFI]?$U))$Q3ELBJC\U"GI#L6(;Q@[WC7Z>
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M>USKD,-O,'X9&D/".FL^/*,9EF +0QU ZBH!R4&QEBR*94TWKBO#P<SNSO(
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MK;*F^NOS[@QM:%87S2_!MK/'DY#C29)-PW]N %AC,BUV,]R?Y%RI^;G3E:1
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M\L+"WW*???=U/RYS/#CZZ<M$'I-\W YA5!&F033\"E@VW[@"#G>N?X$_ZQ5
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M]E!M(*.M_+",H;:]DON%^D5HTB4.W,#D[ABXJEG,Z2ZD[)W/:(!AW1(/&!^
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MU=%J8/+TP@_S,4?6J/"UL$PJMR$^(I_4*)2^PPJ1I/"][H\I(D*EL>U++T/
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M/;-BQJ\ P%22W;M&14'>LN8_=:J_RGDW]';-MIL35@/(QVK!C!TL>_YR-?>
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M_*] K A:ODW+<@$M-ZY<J6.2PFO_7:SG(#UFJW-)!T96H2";?VX0?L?A7K0
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MVO\:'.N(N;AL1$=Y"N[II*D$@^'\.,W6T ,-[$3<R@<--0!KZG:)?,K:][;
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MR?@V#,^X+<1?&V::6\Q>]7.:;$$[9_F89KW\%;Z]#%-%O?VSNG=ASUC64O$
MK[^J2=&->?(DQV6Z9#\OM+55[=^9;#X"^G\XTPK[P\C;P#P(Z:WODMU'EH1$
MIUP\0[H/1'S%BSFM7:T3Y<2C;:,G6J<WCOY=Y'!OYFF.,$<QW?8-F_\#GM,T
MK9LIE*,\ O&CSK=&F29*0B,S%3<)W)E3.NIR.?$^QI$#K2@2+;WKW.=6S,GO
M+FW6@&/M4.9M:NZ^DP>+^CE2AVR=>.@H)*R_*OLO+N D2"[9LL$X:&G>3O)I
MUP[B>X2M3RE4=/"?MO?_^R^NA'U1]]B5( N[BQ^?35]!""53JR0DN#)_^(E
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M%A.WPH3:XMU<HSV<.LNL;0CI7 C].Y]9/;ZY*:3W\P/3Z'+C^U\3=Z9H_7P
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MY<ZA#O![!R]A@2-5ZGCC?0^^SQ8\B0RJK#>?1OQJ2@:HTLR%']^]<S(#"7Y
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MW79'[!<D(6PO13D?==W(Z!-N7Z3\+#*>,38\+^ZDIS#AUL'E8Y1CS*LL$CL
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MELB@8Q!(CVW$LO)5-Q@2SHI-<I$$3V4>R:A3/K'[<L;[[DV<%8?[3R) 3)M
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M6L#/_8T<P6'GME'!ZJR(B,.<H9AR^JL^M?-M.0:[UGYCO=WU47;3#H#IGD?
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MQYVSFIV=?+'=A9NYHU)$14N'UQL?K\:WF+'MZQHL*6U/E2T/PM!X%C\,%(G
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MGC:2&Y6C69:K8Y*_Q=],!9K;U!CEEIP"@F=RC\6C!4B!K@WKZ%, ZQSR>5Z
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M_O*7O_SE+W_YRW\/FM/Q_P!02P,$%     @ ,8"G6&/X&N4[#@, !XD? !$
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MEBH*LG]O(TMN6<!A_UNUMLZ)B[ZK12D<6QZ%\U[IY A&J<T'$3HBXP1!@;+
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MCAI9JZS!!I18UUO+WIJQ^+ZXJ)>HJQ*OM3.)(\*4SS'% 5FA,&)*"Q,(9R#
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MK>2Y<;^LE_MEF5F,2BJ9&^+RE,'6$0^T6$A$K5(6.RFD[RW8SA.[6KFO=;F
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M"OH]4E'8G-9!D67)( U79TTV.:O>MAC<&)S7R^"\1,J#?8PT,8*"-+DUA.,
ML0[(CU-:>BW2IC7$IGQD?\!5*H9!R@8Y,:0LV.44>R. Z-H@J!"Y9%%O%>5%
MG;"ART7*D%N&M\.7]J@<V<&ZW) 3C%DI PH:V"O7(2'';':\,AZ33UC$WO+!
M>0ECK3K;IJ[7QS&\J>JN6_+;IAGGU+'/V0*^?]":-==&W Q)II"X152*W,[#
M8F0P7)0&W$K6"DG[%_;[XW;G:06W?($?QT"@;;,BZ_.R;FD\++LK^OPE=XC)
M2C>0C.9#V@5>5GK[*J?4UDV[H]/[:>,[X^P0[\>'.<*N.CWEPX[D_U8V%:=$
M[7S>>S5=P?31]/>YW\\?OHK#ZK <SAMV<F MHEPW[KDAGI]?_<QK<T[C:#RS
MX?/3YD?733IGM%/G<W-IS,Z$>/K\!P?NCN"*A=Y\/G-&/(N#G+_4L^<_./!?
M?_]X:<0I>,"S'QSM8UU]K>WA_#5.'O[@D "C5R[P!OB%7\KO.W#8%6!];+I?
M#Z(-+7H#Q/WV;T7Q"_Q;^.SG^/49D*W,<='7NAH?/2N:T<D Z-JAK;^6PQT[
M'E4OCFS(I4K0(*;1#MX6Y?#%MS*,#G94^_/T<5U^/9@^A]7G*::#E4-T$,\_
M/A#3IYD((#LHOPYW\@SYH2V B*5?G_T[:,Q?CNS7#/_-D1U.O_+M  @$@D]\
MW#FJ(_I6VZ,7[3@A^DG6/9P&['E0#N.+4#9' WL"!"G_BMP ]/ 7"<@/:LI_
MQ1V"CT;=K\D>EH.3G7V@O$WQ/GXK/E6'=O@BK[_;<2I'J*5;P[S._>R1+ZI4
MO.P^ CC,JX1SMO#?@?CMEZ/IBB_,UATO&E5'._CZJ;L7734:58<[A,)W9\XK
MNQ5C_6*1TYE9 +GE=O_7OQ.)7YSN\6CIV\-WW]MMK_+RWEI<6>D.I] ^NS]?
M#:IZY]]Q^^?%3;N]Y6:+S9^5_\'LTX>7<W'%5340IA9TZ#851Z,B5&,@)*>$
M-#\YO=K5@]P-0,;6F%HLBDW?.N;DJD&8/75]RZU_?O]V__6K8F]_=__UWI,\
M@;W7+S]_>KO_]O5>L?O^5?'Z_[[\V^[[O[XN7GYX]^[MWM[;#^_7^ECH+8_E
MOW;W_O;V_5_W/[S?*EZ]+"@6W,P]B,F&6HF+X_\X)0U3.>!:ZG#CZLZ=%A"@
M%Q.2-#V_[4R4FFI0ANF[G6R75W)7#GVOY$3^T$GT%YW>?/CTKICN?78]/S V
M[ 0T@6$U;#7<TK>JQILO+,;D'-7(8&)S'HY#+M?O53E.-QDL J//BHFN_BD+
MY2^_,*V<=EHC*6C.,F01&:XXHL98KH@6Q+MGQ=!F TF(Y<ZKRH^GENI^'"C!
MZ.^GL'3N6'[;X./J\)'GG=P6(_\Q;D9E.EDN2MX6@'[*CO;BPS#^/',$H%D7
MO[1AVA=DO;P> )>\G_P4@3):C4<PY/<8)KHTP7@;KG/R!9^-74=-W&GBD<T.
M2)@RCP[#U].QC\NF=.6@')WL3%^?O@6OA=/[;X?G__'BV?.K'AIY]O27YZ/Z
MTE03Y;V]SKDG_ V6C5P=[9\[[=\H?S!O-1=L"9B4PQ=MDP)O!Y-[!D"Y9%-H
MWWMV_^K8[%!_V8M?JUA\?EOLG1P"&/UEJ['#!C5 -=)5U-4EGA0U#JF@%.*.
M4>2P#]G8G+@121BLED5=_SZV->#_X.13/*KJT;.BK? V^O59"5MLH@?0KP;.
M#@;5R%7?EX!%5Y,&H[A\L0!]?3X*:P\BRSRYOW_>_;3_^M,?_UU\>OWQPZ?]
MXN/G3WN?=]_O%_L?"I"I]T%P+@@K/GPJB/@I_%Q\>%/L_^UU,2-NGXK:NR_W
M\V-B&)][Y*>(#C]DHK26 M5MS3UOJKH8'<3BGU.<*3KG1!&'(8:;1*V;9KV"
M& 227&* V,1HG/VW('1%$+J""=2H&#SS<EG$X&.[G===3,\Y4K 3X!-T"+,<
MY*^A8$_02;0UBL-^W,V['$]0,+*UHFM06H8D9$11<(JXS/U+X)B1]RY:2:+$
M,2SK&MZ4#5"M_X;C?0.?-/TXX.RINXDX+R 3/WXJ\>'31KCKEW!W!\A:B7@G
M!+&,2.0HGS2QMB#8(2^B]8%PZHE=FO)<PW+:X)A>R'>\Q_+=DJ%DF6>W_VGW
M_=[;5H[KJ8AW!PV]5\1[*N*-3O%F*N.ENCHLOIS]*4;5[*\_R.P>RWGEH-&R
MR?%&Q9L2F!S@LXOUSHJ$,.*I"RDW3_<T-WS);22HH0C+I$T4A,1,!>]&.5^W
M44MY,]U>^G'.&!-8N\9T8W]<=_?BV43TIC.^ROKN@V+:&A1ST3/N+4%&<(9X
MP!(GB0-3<3EH\"E^+9M,"T<Y@'"IJ'#CYJ^ZP_>O/[_[\&DW\[=/NQ]??]Y_
M^W)OJWC[_N7V#;C1@[47:^W O"WQ^NGU=^M'10:A'/=T!E2%;8K3XJA%.2S*
M45.\/&BM*S\_-$G#&X*VA$"0&Z7J13=V69.>A84VY'!YJO6Y^VW'OJ.R+?!U
MVO;LTV5JVY>O[M("+NA0W:T_B)G\/-[,YWS>:A9,2,AXX%U<II#[15(4:.2!
MDN0]OK,5KN-\N79?E\97YAQ, (J7U7@XJD]>5B%>UJ*;_,9171WG<99B$[T*
M,5[%@?UF<P3W2IG=0AQLKJ:^7A EM"3.BX24L"!!*6.09J!<4)TH<2P%H_%R
M(&K??G\[R>;HFC$L3;^XZJYT;ETDE=3X1ZPNUQ$@U3_ZHWHG,5TI!K5DI*CJ
MHLJE0HM_C.NR"64;2 ]RT0U,_"[[W%9BD1#P96ZVG*6?[9[KKW98_JO]_>?5
M$Y$U HNWVY^V][:+2?95_8NKG_]VGE(4[ZOM^6?VI*2%&\!X/H'7 B?B0%F6
M0-!SH2@@UL%PH-V6NF03IO3.P10=@=\-H8Y-,_GGCW(8R0K!AAM<[-9-'-I!
M\5_VY('$@?/NUODW8)PC.%J))+4*;D 29%0RB#ICL,=6.NY7=0-TA3>P-X9O
M%Q0OPEU[@0HLVMPPE8&XG(MJ>I /#.88J213##07-DA+O8B7\..'>K_ZMDJ!
M^+^ J=8CF*/'*$ %[2H=LH@#XA'PP+A<O"Q9K)G7PH7E$J%6U/A0?P2-!#CQ
M@RHL[VS36'\P;N)H)M=MH[7<16NA1 2 FH 4R]$HEDMDLB/$1^,P#5@JJY<*
M3Q\K )C!_U<>M>KOZBX*4ZX6\7%LM)65BZ63F\\6VZ,:B$AY!))&_![].!>E
MA8]!.HW-1I2?/3- D")CR W"^H]XUODC\12?6?W_U[]K2M2+IAC%03PZJ(:Q
M&+:FD*T"P&PPSG!16,!+(& A[A0_K<:9')464>>RDSF.CR>@ARY%BBASSE/I
M<S&GN]+0+ #MPDZ61#67< U:J'MSD]UZD3^O*'X@<IFD!&:)78Z\4LDCC5-$
ME$M%X#^CI;CKE>=6JX./&:K[%#^@)$;8_)BJLO&U+<'7=N-D*TM=:I=C;IN*
M>UJVL*A;PAWK&(JC<9UK.(UR[-->5P&D(/0G]W,6$G+8U*X?[=R%CMQIS??F
M7+^%&_1&+GY[-VAO HJ9OL['2:Y]*&[]52X6\YWJ>U(&KB9D\Z5;O3;2;=L?
M-6-Z!'6^*P1T2^'_RC,J_CVU?S![D-.:>SX_4/QE"2>P_E!2VRPEW$"+UV<_
M75S_3[=6=#>P_GAA?1K1UA+$^-T?Y(8>!0A%,"Q\<B8Y_;#IRMPYK69.<L1#
MI4*?2G57J&6&64EMMF828Q'/'>"T80XY1K24QF@OS%W5LHE >T*H:_G8CT/%
M=2'P51ZH\G]N%2!*%<>Y:'#Q/T'8PICD_(&BK62X KW[]&27;?B><ZUS0,<\
M$@JUV&[O+2[\&E3!D5@".(&<]0GQI!1R&L#>4AFXMLX+?>< N D'[QC?\O#D
M_;M/N[?-_MH Z3H!*<<!5$T3D [9QZF#0!:KB+"T6.N(0Z!D6?3\]83KMOD)
ME[R<F2??UL%Y-=-O@OUG\==!Y>R@V(N#Z$=%UT'E5HZK>W(&/*0UZ>TPY$BF
M6+B3PA]$_V=QF OA?#N(;2!<MAS59TD!/Y&?BP/;%*D<Q%#8P0 >YMS5;(KZ
MY[C,AJA15;@X>0'&/+5%L1QIUF5 3BQ2,X:L*:AD*U5^G#,@BS#.Q?S;5V'#
M/K;.!T*+MM1!4_P$XP%0%<T8Y+GFH,J9"=.,P-&!'5U<^S=[?I5YB=V7)WOX
M>:NPPU#\1+L].@!->.[^D8$(WF]?A2_E54S&:<LJMXMH%VF;46%P$>Q)L]T1
MCFM-Y3==V14HK)F-Q@,Z4F9H;LR5D([!HB"YCMYR'OR="WQU#N:7X[J&'7;I
MR9GMC.SHUC4/[@2E_QU7$9YP-Y/FW-N]T]379JS?4)QG^:OY@>*S[ZM>G<99
M*OL#0L7C=D+\&-O(Y!0HZ6$Y&@'M;=ER70VS'#4X*2+(5"?%VRS26-_&+[RR
M(]OE+%_@*F=CS+H[/HWA38[%)(%M/.@"<_?0?O%3%NO4"\KH]N2%T4'9P(KM
M4<YC6S6+Z=9[RCEB\_,*^0)U*1H5-6(NY'0)":*=HPK1Z)UT)GA/EY: <WI7
M^:HF;&+#%S9\85WXPH8XGQ$MH(>V&,!.8F&]!^*<'8ZAI5=UEHCG?EH JJ$Y
M#YI#H.DP1SV5&8'@',+^3[:R^ ^#@<R<S^QK\;6NOHT.IH^W01N([<I"3.6P
M+>_1QK?EB"2*7URUOO8Q>3%][<87KE[?],6L DQ>OF*MTS?+8<=Z"'6(3I6:
M64UF^VEZO=<I^9?H;7-K_[80V_K:4EUD&\OKGE.\?;WO_=HOSWYWM0Z+V48&
M2RGPM"S#WRVK.UT%W'_,IS(+5\!Z[.=SL\OBL9W$*@2/)W%P&Q"ZZ21V-V1F
M R/W06;63#9X^* '2[RSF&$4C!>("^Z1IA@C:P@WAD7O!5M>+;OZ)9" KU5]
M,L='UK[4$@<_>6FI[K)Y.MQ=JX ^%I3<$*?E$B>YD8&>+@A=&<%YE3EF<T(/
M!ROWR( 7)BU7U>N6PD871&['$A%/(B'+L4:*)R9#Y(:))?G"6TC]?=R4P]@T
M2R_5O<3.*VLF[?44[5[/-_T^+K*TB@"YITR-N,@.6$J0YE$"-3(2.4<B<E@D
MX5F(=%DUL*?@^=<6.E]VP-EGJK3!D<T!; [@:1_ K<)JU](GNM*-/6AD0;K&
MAY]KA,P-/"C3O("P-@PLAF)8M5%<XZ;S_\-&NYYM<_I\5'4[U^ D3_ZMA*EA
MVF((RZZR#GE<-JT5:VB'OK2#[,C+A8'SR\W(#H.M0U/DPEIEN"ICGOUD?Y[K
MRO_!F*W;B \Z!.]5H"A@$1!W-E=0C@Q9[RP+(IBDE]0[X/7WL^9#76.YU30?
M6EW\SIW*^3V=L)[F( X&4_PL?@*L:\-KNHK^UP>O3$(5_QN65JPJJO96H-#+
MB+8[1V]ZX:7)I6^,81QQ2A/2H#$@XH2ST5.L]9)\#GL9)N:I#%TD#JQ[T-RV
M(M*=CG=QM6*#XV=L]"P5)TP:RS5M#-N"B3D-4("MVV3G-&/7P-"Q8Z!MY%Y>
M5NG&DZ+917,VPA@X>@WTZ&@ YPF[365]V"TC5Q(;UZ,98M,/*C,A>0].;.;X
M3AXO].^V(9_O[$E!MHK<U73K,L3?U,SWIKGO8/>8$.XW;>P[P/BD"["B40MO
MD1$I5_6G"GX2#%&!G7(62Y(NQ=W'Y&6PEG2-TKA- FE+&$I1<N>%T#JE.?E8
M;3K[7LYFW\M9Z\V'\:@5;$'"?08X5G;#?_[2YK0WSX#9^_(0R/FOS]Z^?W.>
MU@_'ARA4(S1YY=EO1)@M0=F6,6I*>J<;?<!@^FXG&2K\N5S^TPS^TYS^TUS^
MK:(Z.Y8^A^#JY:N;/U0'[L?V>KY4"-VFN59(J,:@R-_Q'&Y=.>_R083R^/2.
M!_$["L#Y6A#.H<#CP^$+X%' @TYV\M-VW(EG!&^+<OAB0ONF4[1O(=!&'\(T
M?7^']AQ.K;/+'-1G@/0U=@XA9-,HUCMV\,V>-#G>>/:0+YT@;.) 3)_.V:$M
M#NI,H_X=T/A+GF217;?C *&:M*S8::6) :@QI]=9#O.OR V ."SCD/;;>':@
M.B^[C\ZRC"S\=R"6#@Z$7E<S?E&8(&MAP+K=WI8,[T^GQ5_;Q<\.0)H$M>)3
M_&KK-LOQ355_@Q_1'U7U9_Z]+4M_> [6%X,#\J/U1)<L;-X>R7,JZ-_';4O#
MP4G1I;GG$E%P-(<%P>COK=1FRV&;X]^>UF!R6LWI:>5W?*R'^5/09 HWB1$
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MQ'2- "<%4%JHZOH0YIFS1)W!:72QWP,\R\D2Y;!K4-8UPCA_1CGV:1+Q/KF
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M(/L(=/)J4(9Y2^RO*#A+CJ\ZIX_ ?^:>TD/A7V_ ;:FGO/MIOWB[W6]<.Y7
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MX:Y7 >(M3VP=J<Z<,8=5O_9['@2NVNC_7.:M]B-AX@ZP_TOY'>YQ^*:V;;9
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M?<^X/SKP<!BBCG'P(_Q^T0S> &L+_^'JO_SGC[;V%P-&AAL*R9[.W!ZT7RX
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M>!O;Q7GF4WHZBG:?Y;R<-&"3P\=\+&E8E[(A6)&/%M:KSMKV_4\__GR.",=
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MX'PTZAX\ ,YE.UH,:+7ZI\O);!$> 4Z2/ZXFH67].>I_$ZC[B@WUSO_L]J^
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M;J<I\BGCKOO7/#EIQ9;L@Y<\]E>WG><YFQ=P!U62'>]!+!U04SNC9M[3=/7
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M*CL55BMKG#&L'B@E.W+GF 3(U09@&@>%K!4*.1R2U@R 5\B#P_0NX^#B+/-
M:B"\(G9%[*,PA+&31A+ND,#6()Y$1(8DAXR7B1JL!)-;AUYV$638<R \!Q=P
MC80??_HXW47Z.'V)Z>-MY-S;R543_SGK?P0N'TXGI19'#:<?1-/1"YHE-HQF
MF=)';P_MO,3^8ZAQHFJ/1T<)J#X4M0(51@6@E\EI,XG%9(SWS.JMLYY6&&\8
M0XE+@KAPH"JIT(C&&).S)@1FCB2VSC3K87'89,BCD:;GM!PWB%#=BN-CCPJV
MAP;;H ('7R(GSKA<Q<_FI'.ED%(:H-92QNEVL!UP63NMD104_!+" &RYXH@:
M8[DB6A#OSC/8?C2"5'&VXFS%V1..O@ME A=>H.BY1%R!K:M3, #$0H;@/>$V
M'!RW7W#T_86)YI[C[Q7"3X1/*H3O$'*)$5@'@32F8"I;"6C+? #+62=%A60N
M;=>@VD%<8M]YZ9KV##Y3M-U%0!X^Y-7:[^#_/IM,^^GV4>BX\?K/OO&Q\U],
MM@M];P?Z[6PZFB]S'E!_>)FGD"]' WL[FG5%(=^V[S/X O]I?CW(ZL#>3.*;
M2;RQN6S+G!1%LMM'?W/G#LC'_J3O^H/^]/;-_"'W)OF7]PI\P?2?WG[S[><N
M(A>4/GC-0Q>8"Z(Y7OY[\(:'+ZC#>FG#>N+6W5WB_47[>0]64YNCXC[!:VD%
M',*R.]TM-6"._/-_?I/[K']VME^4,_%\+/ (&ZV\[U,K+&XT"/<2\/OHX[6+
MXX:17D,Q94]@EA="OETR6 6J"E2[!RI:<6J3?HN-Y?]PXV__G'>7*U#M5H+.
M)9>T2MG]4E8BTT7"EN'I\C'O+5:!JP)7!>Y  I<WA:K 58&K K=;@?MA,NU?
MVVDG97^Q_7'S/W8PBU76JMM[=&0^,[?WP?C<42SP+M'H57_83*]&LXD=ALGC
MLA..F#)'@##S,E:[1IB75\;J_<8QG#<591YG%)V<*)TA>E26/O?U/<,I5Y8^
M[?4]PRE7EC[M]3VY*=>6=0=V<WX:#>-M5UZ@24#26E7@9?:(?*;,_!/-NF=:
MJ2@]0]+"_W#'6.Z*I) 1BNG ;:3.;E6#M\1@YPG2QG#$-7/($$R1CC0I[:B&
MWXZE&@"6/8U)[91:H>T%+&J%MIU"&V!82B+#E >8BE(AE[! +FIIF(Z24+$)
M;=I[FAQ6B)M $:?>(R.]0E@):J*SP2GZ3&?OR^D.]*\X'F5^UY30MQ76*JR]
M@$6ML+;3W@B:&6:(0R$8@WAP'CFE/<(:)\FCXR)NG9/<.ZQ]_='T"FL5UE[F
MHE98VR6L@:'F!$L>>8T=XC(FY+!/2)!<\%IRF?A6>]Y=.*+[/OY='=#GZCI6
MXYXEO6-T?1W'OF\'S8V]B>.J;,Y)W*J.6=4QT9'$>, H&DYS6[%<+B18I*1+
M,BG,2=R*"*@DK#<<(\WA<JZC0#9*T#8D1@R81(,ZEM*GG/;XWBN?GCSO5T [
MP44]44 S0AF5C6:E&,^]O#(X88E$B !GTF#*MLK4*>53 -L8F<@5 L#0R.G@
M$"4N!IH,X;G!^G&4%Y45S"J8U44]#S"SA)J8I$9!)@WVE9+@S<N A$V**8*=
MSL!T8#"K@<TC8OR*9B>XJ">*9N R)L%,1(R9!'ZC!#1+FJ,H-::4*D8#WH>O
MN>=X9O8Q90UG+F97TS@/&\[\_>+#17,Y@FD.K^&;TC/*7L:AOP4N=M/:-*IV
M>=OMLI]M>T3'"2$X.A28HKD$/D5&N01:C.A@<,*8LJT2^"0(*J5"ACL)"BQ0
MY(0"!28"_#\+-YDO+(&_MV IH3UC=.V26'N%5V@]/M8X;6@-0H(KP"6RR95T
M+(<<80PY&6.2.0N";Z5P!2R]9P[\"2TUXHXJ5)J-Q&29(])Q3M399*96X:FX
M6EGCC''U,%V@O$K>.8.1EY:!$<LBTI9ZI(U.P3./(XD'Q^D==H':]_;:4<KB
M472 JGA]U#Q2\?HPK:A)\)%@!G9PSL<R8!'KQ"S2/#$:M E,\GV$&/8<(R^A
M!7J.V/JRDH+I+J+H]"5&T7\;3>V@\1N5WVK$_$3%\BB:&9Z17B-"4<DQ !7'
MH*.<3,BH)!%.DCACB8]N*\]8" &>1K#Y!(M!W-N(#),.!>LE(QCT)-='$CIG
MDO:HX%7!U1A/!=D*LL\$LBIB%R+)( NHR35@I8V,(\RB84DIX=16NF @*C!"
M,!*!.<03N!$6@\/!N#!)8*.LBN>2^WR40E3QM>)KQ=>3#*8++C!F3*$H*$4\
M4 )XG3!* 3-!HI22ZH/C=0VFUV!Z!>YCX)$*W#L#6DNPMBXB;BP&H-41Z: =
MH@F'Y'$@P<A]1!_V74FC1AU>=O.EE]<:Y:=2+3BS^$I>>>V/4LN4URE7ECZ3
M]3W#*5>6/NWU/<,I5Y8^[?4]N2G7.H&U3N#1(="7!A.>W=NM16F?6#!0)NM9
M8L@921&W)" 3:$2121M3%%IBLEUK.QBNX'(<X4HNDD06DX@PP5I8+:T6_$@2
M>;CJ";;OB-K+B9=59#OF1:W(MM-- F.2LB&A1/).@;<,::DQ8DIB)D)@<;O8
M%O;6)D(9BL8IQ(EQR$K!D?:Y@Q3GG!)[+-DS1%58J[#V A:UPMHQ)ZVX&'6(
MQ",?F44\<(:L-Q10,Q*BN$QL.Y-[[S"YPZ25$S3^GBDEI<+E$:UNA<M''G#G
M,3H:+9(<,(XSF9#.*=6$^*B,YIJJK5217?BW^RY2"'XMKP;@8G:U2&$M4EBU
MT/,+8E4^:QV_3* \&(5\D"X'5T4.LTKDA%,Q4FR%V3K]+T12/H$Q[:7PN>,7
M1X92!W,,UA#)-7%?V,AP?Z<D00F1VHVE EI=U',!-.DQQXDC&ST &M,.N?P7
M8)P*/B6G_1:@I1"<E-(CJI-!7%F&#+9P(U8>3'.OA/G"8]\ON*S?R3-^1;,3
M7-07CV:'":4:I7T,7B"K9&YNH#VR-C"DJ0U@N,7HV=;YO[VCXPY#J>8$NR+4
M6&J%R0J3G]\A$DIH90R*EA#$.0D9UA(2BC!#-%A]VRE"N_!B]WW:3O4X/<'=
MH9J.^C)"J.]'XYO1V$YCC9B>R3'QHRG]<MJGPXE*/L8(RH9Q ;HGI[1J'E$R
MB1GG&.>);NHK9X43T8#Q'11#W%*PVL$T1U31I*QAC*MCJ4W'>YJ<926.HQ&?
M6H"CLL99(JOUGB9J.4I" [)B(9'.:15.<:V\P9:;K0 '-8Q*&WDNSJ$0#\$@
MZP4&>'7!*_ MI!7'DE++*JQ66*VP>GRL<2JP>I@XM.9@RE)K4.(2(%<IC8Q3
M!%&KB*"":6:V C9[A^D=QJ'W'88^2EFL=>@J7E>\/@HS& M%H_<>66(BXDY0
MI /6B%'A'7=!4+67 ,.^<XI[FM1VL4>9=/PU ?+CCX"W/5JN[RI!5V/@5=:J
MBGI"60=-N6(R(BQUWK-- EDK'8H^&F-]P#;Y3145A>=,)8N\-0E4%./(2E!1
M/NC HV!)N' D,7!M>EKN._.XRD^U_BMK5&C=C*[@X(CG&,$?,L,D_,6I0<XS
M[Q2AS.BM'&@J2(PB:(2] FA-)B"+?43:*XR]8)Z(YVIMOH6M%%=<K;A:<?7X
M6.-4</5 A2T\C5X2CJ3U.;,:_G))!T0%R%=(1@B\5=AB[SB]RVSLLTP"J6'P
M"M@5L(_"$&9:8,V4139YCKBF CEM!*(V!/A)B)A;5^T^QK#G,+@V/:7-.6+K
MR\H<K[W-UWN;EQH<-9A^$$5'+VB6V#":94H?O3FTY\YC=U/C1+6>T<G0)!02
MP5C$>;3(1<F0\((P$H739$OK:<VM3R8B2H@ MX(QY.!/Y)0)TBFG+3V:@LF"
M]@@YK/H[&FEZ3L-Q@PC5JS@^]JA@>_"CITE)&G!$+#@"+H;7R'%%D<"*<J^2
M!,#=!%MFJ$E:*90"T^!B&(X,P#(27"II>80/QQ-K/VP,YV@DJ0)M!=H*M"<<
M?$^*8DRT1RYQA[@C'EFP@I'E#NQDRJV0X># O<L4=$S/$[F/(OY>(?Q$^*1"
M^.X@-X!!C*VUR'F)$4^YTK6B$C%) %B5#SIN5[K>06!BWUGI@O8P/^S)S*.1
MHEU$Y.%#7JT_SRGX\^PZCOL>/H?^Q_U.Z>^SR;2?;A^%F2NOI_#ZS[[QT52!
M&=XSO<\]?R%A':DZ >-,>8J-01KL%[!IM$.&@HECDK'.$1R3VG9&-0B1TQI)
M00WBA$5DN.*(&F.Y(EH0[S8%[,?AQSB9YK+:D_<#.YGT4S^&[V[?PX,S\\_L
MX"<[S4)V^[V=QM_RXOX&;_QN,/+_^*:)(&4W>:MD/(M[YMA[EO<1R/8%BW'O
M)LA5;-Z/KN&]MZ5TIWH[N7OWHW&W95$ZVL%%+?&:3W$<FU?]83.]&LTF=A@F
MK]<ZWQ^A9'PML;8D8P$.';6V=\;L;#J:PV(>4']XF:>0+T<#>SN:=>53W[;O
M,_@"_VE^/7# P-Y,XIM)O+&YQ-&<%$43MH_^YLXMPX_]2=_U![ \;^8/N?=,
M3'FODA=4_^GM-]]^[B+ZT 7DP0O,A?K2ISSQ?-!=K'#W9NFV$CF>OLG'T#KX
M-*;XZ.;0SYY;<#=!'JL6/K72X4:#<"^]?K)C?]4PTFLHSC7\OIHUCI16NV2>
M Z9GG.8QQ?_3GUZ!E3 :QN8VVMHV^F66Q:QMM789;*!>ZBB2030RA3@5X M9
MEQ //ABI<X.3K1(CT@KC#6.Y+ E!7#CPA:C0\(@8D[,F!&:^+-C0^4'PJ971
M7X;Q_X*$_L7VQ_]C!^#_[&B7CN64P'T?C7^AX85Z\/W+9>I= B!8*!3P/X%.
MEU?-]-.H?%$3]FJ&;<U,?TJ=0M!"@GJ'4N04\6@ELI%FG>,QBYXSGK;J%'Z)
M=AI>C^VC55,1=M!,O[52_MNG4=91DUTK*7;@'<F7+5&UVGFM]7*ZVNYH]J_J
M+O"A59^PUGCI)8J$<,2-,WD7F"#C18@*'#-&MG:!OUCU_3"9@M*9QK!08K^D
MSV?B[-PEX[B'S6$K%1R-5)WGKO#.]KY.=T_TW:09I68].-X#]W*Q4]I<V4DS
M'$V;>4I<D[_,HCSN@WJ^M/TA/&+<#$:3";PQH\KTGFW57M,?^L$L](>7Y2%]
M>$%_7)I!^RN@S_+VE:W8<1QDV&BFHR;^<1-]_MN/8^A/NU=>-/?/P5Y>CN-E
M:9C23RF.X]#'QL7IIQB'[07S0S& ;Y.V)W6",34?,_#DIT8+#^V& R,>PB4
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MOJWP5>'K!2QJA:]=PA?71"1&"7(^2( O@I'VPH YY9Q3+)!(M_J-6,M$TIJ
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M*VN<)7ZJ@"WQ"B,==<Y^!7O2)6$0UT8J&W12?JM(6Q#..<($,M$+L$&#1\:
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M?S*/FFZ.9,,A@^?F3+!L,L$388"KN+VTK#IP/V+1X=0*+2Q'..F >'(4.4U
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MU5'3F9M/]F[Z31Z$0L\ >'P^1Q%J5QB"3&(#2NWL53[6O .O$&P>RZUAA6;
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M_!_P609#_7%3U7/?(O!BE67#_/'MQI-33:M+"9#K"?P?".X.)WOWZ?,_]F9
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M[ 39N!5X+'&[X.6G3Q]W/)]_6TW< JP#NA[;;98XDI@S("UX$.[Z6:URJN0
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MC'_._9P'1-#E1TKS$>=]5'HOX*7N*H"K'O:_C]KO5MK/@_+CT2F2>%'@-LI
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MD D'C:O]G-]OENTVAPK-L@N)TDKYX?) DCWVNOO!UNYNUPH_ZLJAO=U15QY
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M?6;F\;25S<4<R/'DQ\T2D^A'UPR@OR ]#FQOO408>:<@6-$<_$@?)7 T<[8
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M_7!Z-EM<Q/A+50>[0HZK5B;XZ6/ZW/;S5&+Z8;%:KWZ%V_D+QI=_ )[U$.U
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M"U$ ^*[2^ J.F47YMQQ=8X',<(MX=EX(#,5RR1T.?2\O47G+[?UF\A).@H?
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MX,!MIV$9%%X /R7EP/<2<24"L8*U"^_U+Q\_7[2Z@\X;WXN0D?+&4_AM*Q2
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MB^8OM$N4CC$:#%9_OE-.Z$%_"G]\]Q?CUERY^,!MX@-=%Q]P\8&[Q@>>K;
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M#)LA0LSSW7E6UN.4 (H\YO/_$<O5NQ_?P 6BJ]KF-Q0,QJ7R2,7T>'-IH,[
M?HR.DF'H]@^(HI5T).^>_0;R65/F*?&32M@A\"(4<N2J@;?7P,.@,3Y?^'\X
MH"1@J,@F^1-K;U'N:OJ!#8+=<I.T!*,HX5^\$RQ-P\U3R"*G\&">!NPH(R\J
M^Z:%YIY*PV'7>76S#*!7PWY[7,_O[@_;(_.)\6O?(+_6SK,[P/WH.H)R67+
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MO"3!8!6:62\1&05MEU5<KEA$&=R:R IE3ZLG-<\%*)C=D"3%!=%\G %,E8Z
MIK&L"2^U5R15N/\<)0%H)_KYDG:$-D$<M[T/<P0C:B%E<LP;[7?1RZ\7,B$D
MEJ%?2_'QF_/DF),VI=9=Z_PY$.D8T49]""X'\W\X4LFU,<R)#?^Y2V[F'2-[
M5<*5)M2:TDWDS9P3(;>D'(B&U")T4@2HS\W+6*LS=17F@*^GBEPT"SV5;$45
MC.O&"\;]LV"@<%KM#B+0<B@':[:V7$?7< J9D/.%TS<P8I8N"?O-I %B\U&>
ME2L]>8"W>)5BS)QV$R5<-Q2 FAD5&[C!!I*) /Z64+HB)4#QRV$7<0AW(V\L
M-IY=VM'Q*5@7EB:/.,25=*>2EO3 1*ES>2K7RQ7HH&F9UPR<-F;5 6T6(HHW
M4QOKAA#8'YR0-Z(TO6[WG=<,7VU'W22W][:9O/NBB \,WY>?WW<\H7TQ$O_O
M9)I(G<E<*;D[:LY/AAH?7LEEQSHF%P.>QQI.6YJ0RD>N:T2;";J;Y$D@I@4H
ME,I^DM3D\5H"3AC(\W*:*:B%=O$#CAA4/[;XP>0)-0_%B9[.HKP'S+_-IA^J
M.]?C _"!A<43*L66F'HZ\#IUL(+%>_(67*)!@:WSHE!98B],!!T/D!]B$7S[
MNDBSQ#L$FU/8[DTUKE._J)T#[:R !+D8R;V@PD_6G7V4V:7,:OU[V(&AC&_3
M(DR%$);H3\$XZ )(##/AX976ZX(*!0(;!;S7T1O6%93;'5]K)9#Z5GW1$M^Y
MZ3VS(N8ZM(Y>=PE[2=BU4Z[(HVS'=)6+ _WT_=&PBE^:_&"=LRBJ=^%A:54*
M/LYD();2"TN6R=C5B'J$[$_0I1AGF.;:(\')MBJ)7/]6)X#7W;V;F;5LXI,7
MK\5%;C<Y]6#8L:*V^*;74<-%4.W!L-M]\%OH=CKV+=SE:+57>:]ME#9O>=/V
M+@J[D8HI0P;M@(O;,LF!QDVRV$0']N?,J&R-RLQ4"!R]?U6R@+44^1\%6LXS
MT#^TOQ?XQ()R2/Y0H*?\ 4R],2'\@P3*3DU 3WAC4O<S5UBL+K(&L"T".)'T
M69=Q>O.,TY[+.'49IW?-.'VNRLT2%F_@Q50/9LK4J\(P3OL:^9UQSQ\,AA:_
MKB5VL0Q2(=DKY#R8UXJD@;E;Z 2YE"KQRR1XX=^8>\",/-3%114?1HUA*5EZ
MDN;PJM?N;^91X?_G0!GY7)4F*C&@581:99IYM5KTL%+&:V=<:9-4$8! 9%<R
M+0L*9>Y(@;BSB#AH"YZ>.R%!Z*HK8&';J%VPKVPF)<;Q%IBP%JK6#ARKU7D9
MN@D=9;*$*,5#4B@Q>LI-Z4['P'YT>^Q_!8J"6107!\W'<[;8+#!I'^%AD\WZ
MT4Z[3+=%U)RH0>DF0Z+7'ABN1>8-:9>,]CJ\BO9$-(]DV*R3LH-YQP+]B:W.
M[UJARJ&P^*#NVE$5QX*=A6#(TK6(V?.-VPA;:)"1WG\9%<C#48.CLF,$A G&
MJB@TYOB0<<*%D8;"D8-7.]VI?7\*BM020Z8IKC8?-=^WBB2P=+0Y#VV;(UEW
MNWS1'.FQ&T^@^0:P3&K=<\".5RUU3H49/;TGM *-ZLOX?&!SWZ"HA6JLAI4O
M#"!'';^Q0:5.8J7451!LB4KQQ$HE^J/*>N6D&YWKRAQ+9P-0Z0,HXFM/SK%U
M4+ZUXOTE^?S#I&5S4G:5.WXX8=S.#S<PH'0\W%R5VM:4)5Y;M);7A[$H*VVP
M*64XEZ#GP\MU[NG!UJ&GDR#ZP#CZDT:[P]U4E5?81S&)62PH;W/?"$U3BL"1
M=E@!N\=6[[7K$7/O]?O/G_(W?O4<;+)$,X^;0F\^_)$>MM.H 1F+[2>KRAY0
M?D+,@2-WM4K%/B8UV%-E.#.)32#0=+XK@  ?\S1)9-S2>@8E_MLYLJ!/ 5TC
MILYD(N&&<E7J"+:K\@%CJA$L(TR+'KE<Q>E:2DSHOP1MC;2GG9N<ETF@Z$D%
MS-%9C?F^L4Y&5[ULTJ1E*GV #/GG)2;2_4L58J!K+,4L?KT:$%@Z+ZZMAD=+
MUJAS=1 1QVE 1]\ %AX>;EU//:A^0=TRL"S"M+U;(IGS/9\-=?X@ X& 5H;,
M=9I]4^GQ2U"ZHE4L=]^X:?N$2;C)FGSBF"9-9A'2W#>5/;\A:J@;%K<8NM3%
MI?@BOXK(I)E-BFWOO]-KSI765;8;LJNZZS*I4$%1087'+/GFF0!)@(4#&9\:
M,Y'9]0WLNXA4!WMU(MUZAE"$\(_>!G\$(-_R"DX:'&1*H-;O6W6R#(ZMG5,J
MLC;? K,6$&1T/A)"558E^1Y<TY5,1@@ E)58,"WZB6=I9+M,TY RQ+&E6!1(
M2WS@<\?P:6+LIE!Z+0LV\+ )9825]-PBI>KL"0I$5E)V6#5E137\/&I@ ?/(
M.4 %NU7A#I'WP\4LC6*D_S)KU>HG[4:FAX1)W>D:2^IY-J^@I7IOXB;+P@#
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MWJ@]';LK,G+86&CE\,;A#=K9)GG=ZM*BYAHMTR0JTDPW5).YZCYF>Q@O91*
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M\[J6N8]5U"JN1"!6F4@*[_4O'S]?M+J#SANMW;I2UV?5F_H)RD!.@^W<I4O
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M53+<"# ^8K# J5.+71JD(LD*"*VWNL.)9_OP\">@3U]C%'&^X=%#\6F)W:4
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M)8U=-#K]7G!/"Y->KK++[3;&!A:FET5!5<NJQY6&T T)]1XV+6OUTGOV\<#
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M$:(%<1FUQ5_10O/Z57Y!D45JKGTBKD0@5D#]A9TDASI8S#3('-+4Z\ G/\K
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MVT<EI^MN&-@05O6#78.Q@8YEU5^#\Z(C$K[X'H $UU9:N:_DG^'_=<1P;L2
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MZNYRKURE:AA*K6^Z+E$A3P-.5:$&9@*U-Y_5NKVGQU?\$(O@VU?0,Q/L^ 2
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MZJ9F'S*T)D-%2<1;J[=*]NU\I:H#-35/KMI'L#Q9P<N4;*@:E)/[SA07;+3
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M$OT3$ *T]CB6F&]]+FE,/V[<D:>J,1B6 )E9AH8,J"Y8.J=2QNB65_D:A(O
MHC?\FJ8?Y]77H53I<NB:U#_'MU?3ROW]*.#!G0([0'X1KWEF.@!J27T<,%?M
M5;?;\0!!8D1"2L&<X:OR%;&*C5D:.Z<>@]R KWN=[E0?_;>$=O&E8%TBYI$!
M<H6O2"I%_$_:"N!8O_\]\3!,[>)S*@7)E/SE*QY.T_;^.[WFFN4TB=<;[^GV
MS'L2N#?DOV)%*0PZTS9DK8J0'>4U<K4H#:W#Z^G"6)M5:.Y:O\*V]S,Z.N#$
M7:2"7J?7\9L9L[Z'S'1GQGT155O*%M&R7.(H>"JJY-@+"&A5HCN+4C)ALIRY
MR,:A1]\KQR*G2-:_G7Q/RZJ7<K4/**?[5Q&Z"8/V:_[PX=,[;Z$A;^F@?#R=
M9$S!GXHE:.V(G.QT/+KZ?6M7PU;"%""#"MAE*; ,3JH:F7UY@;-*:=W6DD*L
M=3426#0$!>CJ[6MG):]^^?NXHV*-N<JLW<L>[<Q=SD_>D4=1STZUTWF:#%70
M^5+&9J:/BB7(0B>TR5#;O:J)QMGH</^0*K!#_<[2[!O@<DJ:L,F[TT ^.@>8
M"H1D!@_Q+9$'(H^PA0+E;7/),JB-ZUPE4TFJ(=43@X3NC&.U]MF5-]R,_!9I
MDJ*&S1)X-)*E<NZ@&]3WL) CY98]*S#)33:D8L)88%4N&3MCED9&NUUR=G4<
MJV>_)>EU8HB8@;.IQ'!Y*EA)7+RJ2P4-=1L60#0=2Q%J-K2A\S8<AUFI#NC%
MW.$7(WUD]I##D=[$"27$CS9X^[F0PD>XN91PYA)G:1%46%U8U_P,JB!R0T?T
MM_*UZG:0^=5L3?UR3/VP*9_[_]G[UB:WC63+O\+8B(V0(G!U+7F>UQ$;(<OV
MC.]>C1629OT9),$F+!#@X-%MSJ_?RI./RL*#W;)F/&,WOLQ8;!(H%+*RLC)/
MGA-9!0Y#"UO28X<[:6@-K2H_%%5Y;)J]=/7!P$<CBMTE[G M)C Y\CZ$PF$]
MP22>$Z^-&S]D?XT<,)Z9*7)&1IG8>^5@\9*$-P%L-&'IY]URT*F])5CP:D%%
M?30F&KWCN3P73,+Q#FP>UKC"MN@R().V<H3J2):Q7P\&7TL#55<D5PI&6 47
MW'*! J/LV#=VX?/JPBWRQIK#S7?:_X(M?=+2#CL>B-;FL1RD/M7$K( TMR\T
M5XUCT1AQB"96"I,/4H*3^.Z%[,1G])A>"=QUV92\;JR[A@Q*K/E'9CL3Z+C?
M4O'S;L["$4-KWY4EG/!]:42?2PP0@^"(.\O_Q&^Q T$+X.<%(0:.G"3!25LL
MC@>1'D^QZ!JGE[U$S;[-+*8B'<5,B!^.986FKFUX>Y2<U>[Y4[#?.4/)D^%$
MYCX< 26U*>.1(^R5;J1H-.5<HIA^+3@,>KIP4B_/>)L:QZ>^(Q-60+QZOL3H
M^*'7HJYTRA03E])'$6)8D/?@;MT58?WQ".O?K0CK%6']R:2]CR"$C%6PX'?#
M?K#?W+3-73A^<R*1V93T !#<\5_",47(TI[_,;L2%=!E+/N*X\F8.==O6V'P
M1%Y$M^/[&^N3DGY*&WGQ(^EN%Q/^D$@F^E@BM)=(*KQ&0/[Y\RRRUQW#&?WY
M9W_84 @AF0!LK9+4Y&T>@?WX][^QW]-+0"GD^8O/EB_$66Q^_?KNS8#DW<>L
M&^@G_1@8I;D+&Z;^.58R,Y=8IXV1.3'5OGP5#00XL_U*LO%.FN@R(:SL"PEX
MF.V-XP );/(J9H>=M/OFR;=_^>JI3$9!K"$LBQ2;\[B#G[*Z"1+ /UD\FF>;
MOPTY2D+<V._!!J3+GIO@4D+H0R_F6.1[D$;Y!8,E?<KW19+N1%C>E58MM*,=
MA.F)(9*":.1(?62V('?,V;F7IQ#&2O@MTR'4:'NCG^8@*W[S_^6TKVW+JI^)
MY)G&9T\%N82N@=-@4C6#C3@^A$3OWCVQ3?O8 FQH&J0RL<&=2\[IV.RK<RP2
MZ<O!;>(+&?DV"OW@M!Y-.NM]XQUZ$G;S0G4FB[QB<DK0KFJVKA-*"+@07[,%
MK[RM)_I'RH'573H":V7DF90.+2PKP>UHXXPGK]ZU0\FWZY%_=+2'6)^'TFLN
M/MM\-1C(W-EG^"%&R,8H>GNN-ASL+UP&I<%@4+L/F@VSZ>DF3G1I%\2U\&#1
MZESF K1NS@)[>Q^,T0L#ZR2A-W>6XO3A>%+2WF0W16YBWL]=W@V*'D5SR.DJ
M5_5@^D:(S\+YW+URLP;;[OV)T(Z+,U1K\MBR)3'PATG7>"9H7;JAVO5#T"T(
MU[(CP.OH01[-2DY8Y)+%2RNSH71(<IB'_PXOY!PFJ8Q0N; R$#5VC&/7=^K<
M]W\9V18P<6)^C(\+@[GA(W5FY'Y"+QT,I@E&+G*7T28MSO@BKDEE!FWK46%8
MTY=NR8RS0LF&0E6IMK@MP^QI>6>Y'H14>"6. C4.X^+V+,Z>M5<BZ=95;+G
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MHTCR'K'/X&ZC4$SL]L15C<1?4@*8H?F0&L]_0]TG*56K $?W32:EF\NTL/W
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M:D.K#?VO_P.1W B$Z/.;(FW@MQZI1X?X?G?$H3Q!?:N ML"\4]&W&52BDN%
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MW@ JI!\ZI3'6/Y5.8UY-U%\YD%OL[&C#+9?[HD=1-W=KKH2F$;I-:I)\^KZ
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MP.WJA3/G(8533?#6UD;HJ?H0#T]6 .YD0[V3][(ED0!KF++U<\_((Z9"+__
MX2?]!B7Q*<GA)<;O'N?!Q3#J6RJW0Z\WGAW<G9S7J5WLIG =?GN)B<GP-*R6
M$^E>-3D67'QT"7ZJ)64HNBV3C#(.3J8.MR\. NE6TV.$#8W2B:W,OD=?D,&!
M2 ^1\?Y^RPJ/T!)DSS]8REH;*>8M)Y >C:3NRB2O.NW:442=Y'%N7 7W?VSC
MBL]!)XWJXN"#/!&9NC@M%(_:(G]J$2;C1^5<KM[PMJ&SBI/A68+/)PU7D@Z\
MSX>;B#N93+:(JO.V&B%'DWJ=UJL$XI%QXI,K^)HGUK1;-@\7<!V27$GVB##G
M6J/1F1M#(E-&ITVT; Y@Q^'U@@"K=T O7]J;%VHQN4Z?*'DL9>J_7MF@T?A'
MR;$JTF="/ F$6+*%3(W)(9%=(-O-[)24I8L9; $XZQN^0_5658#89GQW4J3B
M)".ZR5L#")4")];M5-2Z+!8XB&?=%SY/">]$R01U;)H\N!TJ&J)I"-QATUZ<
M,>U([(:.E ]*IB_TZ5UMH)H-'=0],"J0_TA#Y?XXO9&UA0EDBSK PK!C-F8^
MXJ(1[CVSH%)K"^=JSZ#)KI>\D@#[T+)EBQ)U;C"SDF>D1'!G%?_9V_K U&_?
ML5.ORT\:8>6=HH$7SRW,@&@!F?;US4YGN"4O>HGN=.<2A&C/<1<F\$R2T QT
M"A?I+?X-'JH@K/GFAV /W=ZXU9454] 7P(A&+.?HC(7-A@!F V/]J"Q<UX6$
MGN6)DJL4_WOUO>M;Y"2/S>U:K2T@U+AUZE2DY=GFRTL:SUZSQN60@B8EE^*6
MM]*87;1R;7J:Q5 _%(O?<L;)]C$_+E80":YF2QHHBQ?CD&,A9L[MV?E=8)F.
M0#O4_&;1U^*042-B8([!9[W(WNSL+D\N+T=DQ>,L*]O&9$AN^K.(7"D(^%)H
MAA5='_R[>P1T$#:,BM"IU@HJO=K0\;"K:7G#[[\"K:8BN*"4^#FIV:1XR&6?
M;;XJNUV(/AP7E7LWT2:5]J)J[L:\Q BE.(6A%5X[0S&= D"*/@SCV@';LDJ!
M0_J'BY/CBD$N5?$#<QR- C(@Q\E=3-Z;H)94U %)[<H*%RDL(*$]_YA(,BDE
MC71Q$K);IE! P>@G#5B*+!J42>S'3R'S'W4?)!QGES6#D\Q&<=Q#F$Q0?!["
MC,?8?2%$1TEL@24'H EVM,'2=F:F70@F?P)G]"\N$[H41;Y%6/@VU>OX:E2*
M>J7]W.^+3@G.*7GV1KK(7DTZ?O_M,X?_](2RS1EGCHHHRC:6HV($:%B,_?%B
MF'Z0BVJBCELS:#,R.6 ZR1'7M,!DEFYFT>:D><!!,)4F1,Z*7BB,OT2)"W(S
M!>I^3.^N2_EN.1'M8AR!S,QP6'9C'8["%SF3OGQRR>2XPUU89H$VQYZVASF_
M4B_X$P-E_V)L]9/AS$V[9SI:>0W??/4R:EVX"'1VWAGY$)X@6,.).RUDOR>"
MW%Y,]D";V.[B@JWQZR-A%^KUZ-3+=,%O=P<MI_/1#O+([\.("M;-Z"R\$CZ.
M.R%I9^!&I+:PBC=OBU4E>YP@?:IB/R8D>A;=6B]NK4R(?<G4XE6ZX:2,2BX^
MC/+<%Q)*P%A8/B:N0;UZ7D_&0%LC[?70ME4?<.7.$\_ !RK^(>:0XAI:JR 1
M&77Z[78-'[7E!5#9/I, X<=2WB2PE_&L+0Y$TC^'GE+=P8(I2A;=15(&[RRW
M>2Z,C2E$>>)C1J #<TJ1[$?.>":XM)N?RJX?]LK&Y0DS.$WJ'%>$6VBFE&<*
MCD9%)9ELOR\8N8 P25O<9NXY]_JD*7O23"W9!+A//IB>N!8X;HNBJ*9'_*9A
M>M^L)/F/FC,S!+!QWU2<--!B)5C;$N.TL/V?3[7R\-"G)*Z:V^9G&-,B=?:_
MX82$;>A?.",,=*:S(5B!I)<UN$N#EHT=WBP-]#\3!;/@5'X^(,SJ:Q^;KY73
MQ/+F;]C="\(X)!G*TR@J(,2JP&[M<VZ)"_%6Q"*$V%:JV-WF3\1A^#_QXF\$
M!;YY\J?_>?,TB7E=X<V!%QS2=^5K7VTYW-(.=%L*Y-&#HX*(WT81O_#WM\5M
M&:[V99.W^\V3;]]^^12IW/Y(^N_,'$CD%N%DC>1OW!>H&5_D,/$79O>36%<V
MDV)_GSFNF-T'8G:?KYC=%;-[%;.[.OG'YN0E(2O<#F#FSE&>)MAEITB(F&15
MD5:)3"[2$,<QQ5;9<Z:M/G^W1E7-F(QS'U]LYL9BQ*X-4P*<F9&42]::_ %0
MHW24M0LRL9LGK]Y^USW-9E(O3$">I?5PR0%+>BHFZ:C/C;-F=7'3Z)%',]^<
M*4M$Z5BX,%( T# 6![&&7^O*3%:F\F(CO3<BXP=-$<@#!B'K-9.*'7A-NQK5
M:E1C=V]V9*8CT@M,XP]B4&[K5A'GD<->36HU*6]2(YU5*5-E EW"?TI+A@!$
M".N&;H3_I);B5HS1\M(=6^7?B'^"\9;+Q4 &BG#+QJBF(IC/) T.I7>K23$!
M/ F-K2:]FC2EUYT5@OG,JL&4[J[01.0PQ OJUTBQ*1BI2V5F%HPUBU2=8$VT
M8425<:RCW3&G.#=<^>_*:25U:8[@DZ5H[5GFZ&?D=%;37TV?11I%W1/J\1NB
MOVU:,MH&#+'AMPRG%^,Y-M5^F=QA-:K5J*)(-E<?* O #E$P&0JTCTC< S#N
M@B",G!U 88?S#L'C"7'$NBH@+)DQ/V ^=D5+O4-;8B%F5'X3H]PQ2S5U+#7Y
MOKIX6AJY47[]5H>2^(FMIS(A/Y$&E6;7H+Q.XC8$#-I5$(:C/C/9:7J!*5$W
M)#A9**7R Z<VUJ6T+J6E URV(5&EHC905ZV!@)DZP[[QTTCB:W^E/-J^S>_H
M)^#&FPFAB79 H%YM$>(*UN0+FT4OP+*>L-NLP=00OEX^'LZKY:Z62Y9;4BP[
M5+W72K5N.U5]O&F;X3QFD%KS5ZL1B9".D)\(803ET;-9!D=KXX[$>*-<N^[)
MW1>>4D6T".;@%A(-&.2B$7H.Z7*91@7VS1L"9S@(O4$S7HV@&0@\IJ ,NNK-
M4.YABW#^V@,[A$/?&F>OJT-0BCNF&>%N).M6X ZK,6AZ5FDZ$ET2I$/828<>
MS2V(2R.[S[:H0^0J-GOUSJ5$_!IPH\5W5^7<"T<EQ7YT&%#S%LZ3U;Q7\PZW
M%(D/[398].>KM:S6$JS%P\R(U^:VY'B3%6<2FT'6M6W.K!X^])+[HN^LUK1:
MD_,]:<_A!%9+41HB1LY525-VV.]$)1?\L(2'-$Y@UUBYNJ_5X.8,#C%3'\R+
M\+746 $*/%7%S*,-C36T-W=YMX'JD/:SLIJG* B$,31)D]M:"5H-T RP(QVN
M22]/<&3GIC3=)[6EJ(A%7=_-GDOU6V+<,CTK"'-T7,5GP@6(L.5]OEK<:G'4
M/'-D&K[$X#0#O8C\8.T<924#'QDT+!2]M!K7:ES^.'"O0?%''* )YR,P(%1.
MK ; ?H4O)MU5E>8'DD#%KMRKR+4%C$KI1M<>6"LDT@W8+CQ3?,FW87C!B_H-
M7CE;IT^P6OQJ\>1.21Z6%$&"I<SB@3B54I'PCY)S=COB3'62>,Q[P%FY/.+K
MT^MYD/WFR:O7WSWU!4<I'OJT_>OO7(8>''"428\ *9?I@8W/#O\+NLEJZJNI
M4^3@:S\<$0PU\;K(J3N*1S%)S$58LCV+J),6 Q.+(_3YN(;U7RP#[*O1S@.2
M'J:KE-S\<EGL:E?Q"!:FW-M,/9T6P+SB4'AQL>PE"@AMTHE#PC$0]6/Z<*+W
M2;7OM%\)N(A11RIN\.W;+[N-P':(J(X[)ZR]53E>IPEGUHBTJ8$DK](+DDA2
MC>I<$>&<!W]4Y_QC29C,#EVU4)F,@J[T/!0B\&/Q**5\DHRNU#0 ,YS'@?$B
ML.%E[,"_(M:&=TRS]#KR\W/K+FAE[3(03KMX#!3J,:T"2)? 4*1,N7D'SO#X
M":M9@MI4^,3EP3LY'.J3TS]- +P>3EO>OV;TOQ,=# ZB9JH",P:[E+]3IOY)
M1H[NRBUFD5=J=)O(&HB'L6:NGSJ#[H L": Q,#-!8))L)5VP(P9;8=$2V2ID
M>+@<UQ$5+'.7$5]YG#_/PY5K88_SY*(?#9*Y;..24LDR&RW:? \:;KH@1<LJ
M"T8*5_GN U<(!4]]&&IED(K<P)/Y?;;YACK*?\R)5B';U!2):W:?G_9,'-[Y
M3L2]A#,AW.@OK]^^E-CFM\^?0YAN9W5.L,8WG5":\C!^#,=&T8 ,D_/J+^]\
M&J-S]M>3G%\K9/CU[5!UGIZ^XMIISIN2C^J!F!7JN&__\I40_^>=R ,2,WG!
M1]@3^P4IU'*A@KFI("+" Q"N\JZ7ZL4N&!"E8&JC%R7SW;P\MV6U>?'9B]^P
M/MZ;(Y')/H^%69JH_WCQN]]A*!#QP"@G0%]S]X=>56]A*,D[D?GOCLU=D4P/
M\N?Y=EOVK&$.8MZF_6 X(+T\=5D2_:M2P\6Z,^M\-=7MR%!H@&-V[8<E[4V3
M@YP4*MDI&6HA[Y+>QV+5<4:/A_0&>03/-B_IQR??5/[S;^_&%K2*GOTT H47
M*X'"2J#PR:)GO]33@:\=\<F=@A2J9LYTAZ:.$>$KH_II$Y= SZ?/0GB3:P3'
MFH\]B_]P3"KTTR-BI7$\_6BD.FQG=[26X]-)65N,:3A!B&_(MK9O\$:6.%HC
MC:AC$5?)CYZO0 >;T2N9Z1,&42;QKN+7%KU0WZ6$H"3G50NIJH'2Y\:_ .BT
MZ&BDP:Z$"SMABRWRJC^B>FI2,!24AV\/1#RZ"Z^T.76DP5[G-XA[X[./8MKM
MT.Z+>HJJFPGKN]TQ!!LZ]Q5&22%';P3+P4?7S:G<R129RH2FOR;S\&@,_75X
M<CIH0%2HIH+.B-? ;'AL_E!$#F^YH.F&6 !)BN_H,%1";89[)LE4<FEY#TZ-
ML4'$>4L@,^7T#Y%1P?0B)SJR\BD5XG!U+<?"*+>BIO5L\U>(5BB_-JN%LUQ=
MHOZ<:FF 3+%K3DZYBG61PEB/Y=G0;Q]_)G__L;^Z,"UN8RN6H*&.$-^/RQ3$
MA:T_7WAAFW#N$)K_/2>4#R'XQFJ%\DK1]:G@A&E=F#!+[L_A(*'YR<\&S1;P
MCY'*.S/4(,/2%S>M$PC",4>I4_>:+G)YKAD>%U,)2'6H)@F*OBNJ@]K"#T5S
M)OFBOU-"Z?VQG,I.Y^)VZ3^%H$V*3#^HW+RX82;AAAOS0EH_)2-QR52,AW2<
M9;"9,=XXS8NJR(WU/SA(.5PF0V%2N:F$W?Q.]&A<W5?6V<5!4!+HU)=9"NEI
M&_>5NB9HSL.:;*$CP^HGB+0Z4D/9-W?U_"\G0N+V#K6OW(H]Z&]T4N[1G,?\
M_<8"I;>#) ICZ)2B6/\D@AVCP_W)$SAP>E"DX*C!#6M"C#'SBZ8?DW;+(HB3
M/;>3(*5[KYG/J!%<,6SHH$AR&##[]J'O&(^)1$42\;"KZ,**)59UV S .)L]
MU\V,&9V>B/GN2>'H1ZMJ(Y&N+^<^]03D^T<2.N+%M-:RU7(=J^A$80 A?;RC
M])NI9WFUN%M3@%FVYRA!F7!ML9C0?B0S$QL4.GG\D>3?K("CJK0B^]NE-_I8
MQ_1STQC?ZP<??+3]%SS<SZ9D$?W)N+TKUK.N%[$L>SA6#9SS(Z+5"2\:SQ8Q
MEYYDTF4U%77.!:9O $/A"#(3/3H;616NV>WR<Q$[YZ=#$/_W]5\1TF*Y%+>4
M2MUS"!7^$*5Y^"=O;4";)Z_>OWVJ7H0<S[XY2U%0T\O/?R,!\[E@1S5[S:\X
MUTB:&-MB1]U 7D6YWOQW7@\$ _C\>48IZQ<J.$V76[Q6C*/S$(-34--/@BT7
M"-'3O'R:184VU 3Q,."B/16H/:$//U;99@*X/O]02,:<K]:87B\Y1GJIM?(
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M3QC#K-OS2ILSXG7YL"^Y59<PJ0?-3QAGH?(9C["<U++!C3NI1#P5JKCEY;$
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M2192R!4!MS&0%K:73)FX"06DC6SM3 9B]@JC%AR7E?02+)1+(-YNI""J&=8
M#Z4@/H)CTS!WZO2L%-X+J?;@+#%W+)BR,]@Q"$S(X8/^<J9O4#QJ<%DW @[W
M+\W@,'_VXN/KOI.8(-)3E%T\_Z8Z832[80]CN8;XJ$XP67I$X@X*2&E_M.#F
MGH3#Z$S@SP-TX,\K%[:#1NBZQ4>L G9U]]C"9FOVVY)T +J)4Q$E808S&&5X
MZFS2*U_PSV[#>J()' &PMP7B#G3).=N>P<&ZMO@Y2*QU6S+DV_30U[Q6=(7?
M%\H-3&(?M%Q<\,EG?V1%V1-X)<RY-->R>B?L6KB<N$%*=:;D3$H+&B 9OK_D
M68D!A;.L]]R:+<H8\5G^*P*NBT/$EM^/HYZUFBCNY&)W0:C3?TFR][$DNMY%
M!5RDC*;,:E/9,B'<4@@@NRY^WVIK<!ZH5I00R)PV6$STRJ:T1@82F=;2Q.C(
M4',6V^"^24K 8Y-V8BNI<NO,X:SGODKIQ@@/1.83MJ;RG*/)5W^B\%O>(&:X
MD&C7NYPE]>2%&D;M^/H :4LY6NYG"-X>3<+@NQE7!%L3K1\)U!CQ.7?&!_5&
M'1-F],W\##8P^EN.7.$2825G3%FY!H?;$MSRK(H$QG,V87Q/WW+L9;+\*^1>
MT;\"K57[QMVQV9R@@X<D&Q.F YB'A2/^T-$4D2 7M>,TS((=OY>+S7 R+%(I
MTN&\]@=M/:,_&@OZLN UYEY7F W.?Y:>H#%5^IWFE:"S"OT+XULQ!D/I6N8>
M7<?C.&'+Z*,ESEZ=>0[]%5Q:!4J3HHC&_I8L<?1DB7$E6<9%]6)0*U(T-C,B
MT4$*[[%43$(((VF3G#QCPOU)_586S&<H/LY>1-D2.NJOH9K9T"F!&*7[6)"@
M+H80#^XXN%"%@6S$+W!N&J:)L^<5,@ ,(SANK,G.2-"2W<IFC=OQ%9X^2_C
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M9@>%!YQ9Y93*K ?3TS%=A6# _HBL;>)U3I$8Q_'4=Q:94K_^ZYBFH2(@&%^
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MHHAGV:AJ'K<SDC4G3X6#(AJZY' ;"Z%FL^&"$QK-QQ*>3@U.[,HWDXI]S=G
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MX/E%#"%^=R080CL,.,Y>?/;\,V[:?".)G3=R)!( VDN" >P1,+ZB>S+_=F0
M%X2?M%>\TJ+3UZH7N7E+_.8[,(#2/ZF)Y FMU4(T4?GN+U^A$0Z*:U @UN.K
M0P=4%Q,LHY^$B#U)7702./"@PIHYCNK3L Z&53+ES[/-2S2G))5V2\J%(>&E
M@0H3.XV8TK9L1N@XI%A*FK=C'1;@S443*> M:HN5I&6%RIGS3(&ELGJ#B4F?
MC_8#;=L<"RRAYY+^*#@H40Z4+G9JPT&34D;AT;Z K KS$2%+&A:QP%6Y348@
M%MTQ9ZA'6%Y\9$#>:VT+7$T5L/X8C4F^T335-G1\. TGX>+I<,J+EKTYA1F
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M.G:M]N4^ M*6.)-R.6LIP2?E@Z#S;I> A4.$J/$Y3F_2PA-*?R6X#VT;!!E
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MZ5'C]@^%<,1-4@MM(%3,>V9U1:QSAS;.:$;JE6Q,9LR[0]< 8IY)7E@O1;8
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MY:ZNW;[&C'OQMU4YV0@,8C[E,ZGF!RG#1R_[J/M3ZCT)]$D0J< ES[M6*H?
M#/P/%=7"/^\1'<O1Q_H"G CAIDBGADM4Q"M5QX/)WY$L%*9NL+X<!S/$.,):
M8$=>V:8[=1M"$8 SWPL;\3,-B)G \^UD%W3S9MIW!2\FN(%> K+1^A.)1Y('
M-BS%]XU=XH&9(_&_LG!Q8M_[P;^^^297E<$IS-^)?7/Z,9#2P_^I\(45WP@U
MH=7QAT$3EISO\S!H\&Z04A6U)4>_<:7BV/E/RDW):H<GH[ 1FBF$\VB[;7A1
M[1$V)WP&*C1-2PQ9::'CS[=M%<V(X9G*%I&2.V"U2VK-SJKHMJHT>L8VU="&
M:=2F,:96#K:4I1*3*>R+?M$XW1FY\OA70+^8LIO92*]+=++;6#?TJW*N*8(O
MZ9LH_6F2$P. TZS.W<A;%8XTO@RRHQICS'-()>!?B@ <Y,I>)J4^^9>2/\#4
M^IWR3$I'7'H+DDY&1X(?TD/\-C+-$LW*!'OVXA/!9R\3K$Q!%'Q(M^WT%3-'
MQ]1)^^";TYY3*BMDD8R4:!;AYD\+9_[SLP51LB!*GBVBQ/-!@F&KE#H:O22Y
MXN9 ^C>-Q'2>O"U!_@KRDXNAX3# V:)Q$9^\/.>3E>Q<KQIS%[$8&V*/CJM?
M%_*U4O+J\X'T ;LL6)!+N$I<PMT);JM4:&6N6L/P40ZG/;THL6%Q\DAQ*C18
MZ7!@5R]A0]\=VJ'1.KP$YPC4U/<7F<^4A6@.77%O-U^H'4MWO]!3XI:WLI+W
MI<,LN)[-OALLD2Y-&T0M,LO8/'S(&#A3;D#PJ?M?41;<9-;!)=^_@E;SK]55
M?*VAM67[$ ?%BQ72AD83R&ST?1S2Y@ LE60 QAZE>2DT\Y!]9IT>D! O3^WB
M6&O(KR\4_Q 7+=P*<-W2[+"F-&W"D+Q#I*S9FM^!^B[#1[A\#LG.@:T8R"L9
MRRJ%J?<@K#B))I2CMJB$8.L ]5$3_ CA>7C-B;;8.OR) %8:1H<%:SD72C2C
M]^T_1VSVK>/XU:7C?>=6 J NEGF*:[=E&I=-S@)*<HM4)A:I8%Q8XFHI("0:
M[/E84<@N2-GLN#D_&XC6>X5)E+K8CW&QC*B@&10I4/9QTZ$3=V*03RPFD.(I
M52^2>F4'6R68UM7J*\G%TC%P>K_8%O<WW8'I"6W,0TQ$*W/6.I1O6)M3.Q*-
M<*[F!N :I)40X7&SX)S8H:1R!89"@S;Q2%)" 6J5JE5)^]>C!(DZFHDTWR9L
M?85'<W6BY$4)OJOK\91P1ET_5V*T?357I79"2@FO#9<JW-C(]+*\^?-0QFC]
MIB.DS/_HWM;^O/)P'&;^"PLS<ZV99_RX%@!NQI%U7RKP<Q 59VK@L=%)W,88
MR^:+*$82%26U];2\@]^2]D [N&AKZWN6+J^OMS?"1)K76OVJ:(URJ.;+"3V7
M@$\L\DU+/U07?S0M. 77AOY_I?V\RA-T$0]D;-8_N1V2OL!']$8R=5[>1P5<
MME7%4A"'BVD?ZEYR<T6')$EV)@T88Z7W8H-RDW5#KU;OPCXCF6A0"5"XD4LB
MQXU@><*+?-N]5.'.(4<E"%8=%C!()P NRW /NVXSYK6N4SPYPEL=>Y@!"3,A
M^.7R*5'2'@4C87=YEGODA<8P)\F]9>])H!L=[1&+O^NC16"S\V;8G\R'/>#(
M*56$V>70OLVUH[%X9)E[DD2'/=3A,O+C]7KH^O7J)D23I+<4;GO?U5MV:10?
M=2GDPWV36M84F="=D8? F*IB,H(C:FSND_HP,][>(UV)6-B_>-<\Q9N1H/'8
MN5'&"8EY6'X&RUJ-<7,3UJ&!]!(3YPF )@X/>MS18!B;+OEJRI+N1,$$G^_$
MP1X4$3#I.-Z*2V,^:7"J$PT>!D[0!>*#IMD1[]VR1A>/X\"-Q./<\'GWC549
MW,$/G!,RCNMVDQGG(][AM 9@;[2:'Y;1(\7M^GS"X_FTL[]VYX_W9=J.M1,L
MPHB*E9>Y<XQQAEPM<;"!U*,--Y@7'@4)0J(C H;=@;N=#DJ?!Y<J3G+VIUZ%
M)%NV>;3I+%?%DE?92 3QBU^8D]#D-&?C?V"-3C?=4")=?S:)X?<82$^E<+RX
M$J&P1#735;?<"^L(2OLF?7^4_C,V[@<VUG SDK80BFX\",)4B5=%,#I$']S&
M%7^G>9@.SUCWS/1\$+2P724FE(!V"0@&6Q-AQL[_M8LR1\Q.[#));SO)XWY?
M#&KCTV3F7. T=YS.ANJ+7C?[ON0T$6[*91\-D!]6H"C/6VJ])D$.N^>,H?P
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M PD>"OCWQ+LJP?Y'WH]ID>[ZD!MW!T<S7I'-D@1Z6#RKI5RM_B0BMT\"%AZ
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M',5+W:FX%W,KTQ>LE<[$D!J@K%0,ZNF4D+_6[.?]Y Q/J',2AV7L^R7A)3D
M9O4$LW><G0V7+QPSXXDRH?K@*@X3!W^ [(2)G\&;>CD<FBB=.=6Q@KJ9"I%%
MW3+\!S^"P]AC*<3FTVOP264"<$K*QW_G71IOT5'&(*T?6&MO-WTL"L#6>^D/
MJ$(+]=W#_R+U;]('CW,IU\T1?$P)E<&@=#!M[VXG/(FN4[(XD^=_6 ONE&NP
M16(F?LMN=D9NG[GBXX-Y<8B,VU*I(+&X>+)3)["R/ 2N-S=26C9^,GP5X$R:
MGMPZ.;T'3XEI\,!FF8K^D==V6H8-16.9YDHYW/T)K%.0?RY<V,N0/ZND"51?
MU?'R&TL)Z3I_&F9C\ G:L#X[%9]K"$5>7N29R8%Q/= 2, 4;;;&[>L]MAWA7
M423FGR.]B3\WPVU[4MT$6?Q'J0;.:@;F[NB"U\K>ZKP.IVK"2F$ZBOX [CB"
MCHEN#*3K)@.J;%)R-@HWVQ[ 8/<>MY,(JD&G)7FS0_3LU:-%16F9@CDRQ0@-
M*PLF2AC5=\GP1GH>BWS1&CRES!3/B\"W6S0!I0!S08#))+F^$8*8^\@H<.RX
MZ^DU(A N.%()IFN/&QJW4##V1FF\,YHTSY$-Y:LI[[:@94M)TSS]-B.J[%]9
M]?1!4NZ,/DYL+E)Q>QZO<!_A;3%#O6.1X,1G)R,1\Y,U(;BY>9CWIEP$*!0;
MC/LAK3K,7Q]KEBB"EM*%BS^1YQ)5%(I/=VDSD&6WPTVJ>EN&%J41?$IWHD\)
M2H4"LW4L+4L].;P"*3+SQBLP7RR$YIZ%H:Q,-B]UE8C+1%4[G:W,3E&6Y%&Q
M&1#;)PG5?/U 3J#G4IGZ>DRP^06I]$0DG00@.()/%8-\GTU"K=QWYE4-Y:P%
M9Z(+'1POC\/5<!W'2VO'RN9EBHZ"O Z^.U78"4=:>!6LZ^4(5R_@>29$B5J]
M<UU#1YWIF;JJA95KCI6KFF5 8_8EQV^6O VA3DKHU1Q/FK,8R("(9+K[ 2?Q
MYOG>\U!"@5H-:F:(X2/5IF/8I' [(?_4TJ^KFE#&&&5VNJ07G$D3Q?PJ9&!T
M[)Z[<4*5GE!$%6O_Z8PN!QX:P=N9:GIAS0\M$U_%D77KI]\?"T#<J]7?$S0<
MWP"/POFU]@S-Y0VL6I5<#>AMGI@844_5))S%XW+ZC/1C$B&O+#:F?XK".^'<
M-NH]+JO>@>5Z"/[G YW[5$=D!4P?EM'7QGZC4C)\"!&!5P$ZL(7[X+C-JH^F
MZN4D-$TTDW^44_XC1;F8$[@E^:&U%'U%USH%'TY5KM.L3.MW3#UML0MQRXG%
ML/R*T)+K(T8:\QW.T^(,FN"XQ4QH!FRHG 8@5_)8>@Z9H'TS$61%1C",E.I0
M^NPB*:>XJO>58H5T8&ZXN"YAW:!\N\N',7-JG"&<!K65808^PR[_-@OF,I:$
M1TC#!CT*,[4Q1%DQ1ZF"XS.Z)0>3-DC=L9XN4.$:2DD/-(0NNV[?=N$AOTL4
MT:+JFAJ6PE==)RG\?<S(\[-'-7>2&=GCB.%2U20D:[*\;"6W^W"@/)LB[_^,
MP9-U(81E0NKCU@Z?; [(ZZ&4QBW*CIA=MQTB+!9HM."2[(E!N2+NA.?\>S=/
M)>*T89/C"**&@K23YD6()*OFN_&2020V+%A]"^BQ(\>^ETY>8<8I,K8)662B
M)RC]-U"6_R,<O1HCW 2O:=Y7/!,Y^1+[H?PY_$8L;\9IEU[:H"' [,[UGN4&
M&<MM8U4'J00?Z BR^D1V3+X>/B(PI6.-FZCB'!)1;A%E@.MNAP])LV8^3""O
M1ZR8]!WX/9^*S87Y!7;3]Q/$@DB11REM"2K8^3F2WPMQ?)38%9.-E4JNOR92
M=:72K\8-6L20\%N)]TC891PR!8T+FEJ9HH98*PCZ6;TB&=OKO*CQ +;^ Y&'
M\G^QT.K 8L?6_>,*2?P3C@RJSX7#XL"UL0>& :]6;U$QK/=#E_%H7([>)H^'
M1ZI ^F;_+CMZW>RI:8J/)9)+/U(T6LG9LJ:@8SQNI1II0SG21__792NK!3+X
M:9#!_[- !A?(X+,ENI_XR,MR.Y1 G(C)\$#Q%PLN*\V1ZH_HG*R=29?"1NNP
M[I&#S(ZA/Q0[J$.>:)RF1?\LUR+"W(XA*K-MB8J?U<XD20U]/JL95)HWX8,'
MM+-<89%:V,/IH+45Y<*VG,G#%BFH<$<3HRLRW']2GXG+*87G2CG3>Q>R6#4P
M8AP2I;P/X562 4!YF^J/<R@@C5Y<?U$RRPD/F]"9)P%&^"SK-M?["V C>[51
MP\KKSTO[<$:"RE@,Z&E!G"2MP9%UR20##&_ U]HX8M+()G^.TDI0 \Z:5Q8H
M^"67J+,L^7>I>,RA-(T-8^K#/:Y7[',5 WA^7_A1>6@>NZMFM/RJ%/N5TN=S
M*49VKE0LTT4(D>>>BO9$-"%M:F6N$K7=_!<>'WF/8>OLTV<6HGKH630H7>R]
M>J/&:1>YLJ1V%>_3M]RMU@1PGZX$5-T,I4$7XXH3Q+^BTKE*?>6->[U2>#NG
M&%@>.Z7D,-HO\:5K)$4Y I \5\1&6-<WL5,C#0/ I]Q:M;N*XJ2Z$G,2(T)-
M^\"23$PL-:4+;GS-LG*00-">&663OBU*'F_LCP\-W#R;$LY[3N"S=%V2>)>"
MN@2>N;CP"@#R4$5YO,+C>%B3Z]/JFSCZ-G(8< ",0YY8NKAZCA\_\UF[:6_K
MK 4U&GK3)M;@8>_JOJ7ZT^E\RYF?<7A-\D^6O,771)S,#L'!B^-DTK-*"0XY
MGHA(R3XE^&IYM#%85DB2==]@,R,>V44Y'U^7<& 2'<S?-H>PJM2PFVK)IN(<
MA0>6$I(DN;YF,168.WGMSD@>+16Q_ NHT<R3!\YBC[:H'05/\HT,$,J/M#*!
M[4&?F8)1"?=1K6ZGO\/\<?TIPH%K$B"YAP/<B;%)F3A\%^BFAJJ!A"DFAQ8L
M R@CGFT(L>3A5BO)=I'F^(_NS(E[&F.::7 _^-C%^F+$%5^.&^[%0:G6S6I*
M8X-3S,G@)8<&J.ZY^[T;59AU2/J#AM,)ST]U0A=:<GM [1O=)H2Q)\'Q:8SE
M6CT(\2)",'9^['#BII-H0HT]D^^4[LIYZ*<IM'!1QB8BLPC^?KXIDW1@UGV\
ML7H38:Y^/8/9X'S]"!C,K_=P\(4UKH6Z8J5YBT> &!S>!25+0G(SL!AAA-:Z
M&2@KPS5A&W-?E*#_S2XU$]^A0M":APT[;G@G:M./"B4Z5, WC8P3;-!L'%S#
M+:J9.+O[,P'9K#,V--;\[9OKNM\BO+6NF32 ;<=CP,?O1M>SXC8P[T8;/DOQ
M)MAF*M26;5!92P'ZEGJ^L=W+J;OOC2*&<LF:$_3NF]OQI -X[*0%KK3+-@X2
MO+P6'PW"MBFVJ+0FDL>K#\RC%0."4PAO@V'(7]13=?VQ.0^2&*UVC<YVM?L]
M>T1_YJJVU!$FAU:$!+"#=AB3]#]IF""S"'%F QP\X_Z,(SQV=J+&/,>F6L?N
M&-)G$!$S9F(F:P?^<0;X^X4PKQR" RX^PSB"MP.\XJTH.TCR;D'%VL?M'[LM
M<B>=!<QI0'VU>N-(_Q0]G^.#\]',! [;34#;^4Q9<EPH4X&*SYNE'C\MKO]W
ME>7ZOABG^7&!B^Y<)N"ZD:/$^Z[?/YM1V&]<PY)D\^HX)AE\/?]OWM *I&7Q
M;R)J:#;C"?^AT-XI#MI*&\=R/8OUL WR77H3<=];XQCGI"&*=*KF8>0ASKUX
M-1T,F=8\J;@K>Y%"^08-<.8L19P8//;Q&M72\$'D ]W0%*/[217V(=A[)7GC
M&!P 86B$#<HA ]Q',XC\92N?@N7K<#@TE.SNY;' GD:W5WZ4-R$X4&ZI:B8[
MB@,#WKWA#+H%YFH3\?$V9C4QA-E7@[.*B;##HPJ.B0XC#N8L@T2U6?0OI]<Z
MRM13D9&5@XP,<?@FPR6-.N[C2TUM!E2,S-\R5W&*,QM3Z4?'Y,V!%='4V@-A
M\_%QQ]7O8/\=I6!Y9359!GK&IN_IOA,F<D]!'F^!&\N2!A\<K$"UQ8+!!-OO
M:)L/%XW^O:9%^C:43]15VI-'\T#+QP7ASO9BQ &^/YD)*DZO6#_AV>0]7RF9
M:WVT@I=-MC3;I\^V/.1E9S"[5+%BW.EP'HB>"]4#<6^?Y/Z $.68W9FNK]K-
MD7#,%-J36V S]_C8:8DQ#Y)U:N5#0\7". *,S4(_E[J)'<BB3<*7:W(>ZC,_
MH?.D/5/%YI.A0'=Q2\0=&>[SKNWVZ94F,P2H@)7(-#T1\:/' HIF(RL9FZ'E
M*H_@@3$%*O.B:;V'\T,&HS'!5)[_9J!R;K%,@)4A2TSYP4X,[0H_QCK/B;IS
M2=JYZV.]->P^UH6FX[1T@;1#["Z&6BCS/^O8*K[==W?=AR8[?'G&F19H#DI6
ML*^8TB9P8/*HQ HH$MD4+(RMDVXQ$E8MOFE6Z]#",JI)6*8M%+%1#ZR\1T^:
M*H>FIM R9+U7JW><&M&"M:4Y228[T3E.]'1*AI5.W"+.O*=XPZ=AR<SM'-N%
M*Q.O&\.V$<IPV&&LF'I"/#0N338WJ/<Q-<*KU5?A>;J[0OO2<S/ZK?C@,;IN
M)F-U7!8>Z5?"2=X<;:;"[=3R[Y))Y-/-%[UX+(2\N6F/-6[_;3AJZHJ7AM[4
MN!\Z:\H!(4]1*G=3V>4:RRDAZ2)%.;WE<(_H0_#LBM5%IAC0M^J>W=W=-Q:?
M1,% *_  4]!L%]#;KQ7T]H?/%M#; GI[MJ W.XS;V$+FOJBB>@W/,U%-!=QZ
MZE_K G3"> ;*,]W;%B.=C#X+\=,HG8<N@3?Y$^7 28V6"QC:Y3* .L[SV6-)
M0'--9^=1RO8A$1(LD_MGQPD"&+T&?P(@HVB@.TF5%PDFW>\M9>/C40:H7F_"
M%J4SC0(5'Y9F4?+E-E//\"FKA&GM_>AS7,.N^$3.S1#' 7LW:E1D!I 03HL0
MG;[LYS,#E-C8==,IY*>C%A8SDUD1J8R4=.%1-$]%Z\BL'WUS3,;!.(*G;";$
MA7CKTIF,=5;N(J#2VAR9.FPWFRD@S>NX@8>=(C,\<6#';6,Q,??359I(BRQ"
MQ#-FB-0G7"W#0Y374!?0[U19=Z3A[&V^'8>AK0TX2+V7?8LBZ.J[#ST5V?CW
MN^-UQQ&G?&#=G.XIHGT[]'7#E<^_A21%V9F0I#!E- =ZAAO5:M*D!A[G5Y*W
M4WHSX>[XQBM_?1V#%H.Y6OUU^NB8X,$ B=Q&=K7LI=B%M!A7SV34]3K<07?4
M5[VO;X>F4%TH2F\EPUX(H[EU0,?"GHI]-,CJEB)F^X]9A+<RWAF\ #^QDN (
MY;0A!Y^:027;O [6'39F\+$@%^AN3U&'GN\RL<1P[U]!_?'SSS[_O**R-:-R
M]*.QTL;N((00[78DSD9R_3_<[KOVY,O1-OC#2]3$AFV^-32Y)(B:O"P_TU8H
MSPL,Z\<IT/,#_JCE=S70R6E99'C,4)&Q[1-[_@6:ET>QC<]GP<_FZ/L+ X>K
MU9<C!03F5T-2<20+_8YBB_!_N6$8;(UAU&RGW[RA%31Z0:Z=5@">-6 L\H?=
M3B+)1U0N,I'4@EA9N"+?,';UYY^]^IR]/O]C6$2YWV_JS8<0 UD%],OO)G_I
MFVL=!61/0^RDX8F5NC-X ?)N.QF\94(Q,G% N!6X;!>FS4O5(KD,%[U%M.48
M7H?_X'1E=XB^"GPK]C4-C)^+@;X7AUA>4S+!"-,AK>@Z6-T-"^/]UWAL5J\J
M<MF_I4E\Q>"'+\&#3Q8U0>=PFTM.U[[M@/(E-[*3@U"AI[,V=^SNR<.'**JF
M0[<>P\K6)V%TW-$-Q+F !$6I7&7?O.'^"3VEC'T/$R \[)1M*UC/>&"\%Z4R
MC$Q'99B^-'U:6"6=9+P["ZPH"8E<S#H*=A\GO8<X5I"& :[I>?D +^->S/%?
MQ-7/4%6G([!Z.M1\9D[D1HH'2CPVF*"C<+Q@XE<Y= <BA T_P4-B0HNCE&EX
M\]32X"@\"J,FKH]S,_D]*BB'5(_HW^QKBDAPW]34/OFN6(]%.#"MN",T="^X
M1^T:\SB[T .&:"D-%,>3,]J5,@V'=0S/B(4XRC+(IX CML,&K 1,S42=Z"T"
M]Z'3.2ZF/ATE6@G)5'C9FBBMFV.S:T_VP[0-1O&LN(@OG'-%0]J'AZ;!T(I^
M$\5](?+F%PSP&@^JX?"Z/?V&'G1,'0G(:CC?R7>8!=T4LS]BL_]"ZLG_SL?)
MGQ+REP28ZCFB$MHSP[PP?'K;1(@BFEB^V$7 >8?(F*;-3*J:3'5JA,N?JR,E
MI>5C2B^9L3]-LO_'](*5ET(<>+VE]]%P(0(-3;WW&)69>)PRJ1+>0AIJ7-N+
M3,7[>N P)G%[)Y()XLHA+^'6F+)/7;>Z"?=&/\JS'K*Q!T8V]<U@"\%9UEF+
MDL.IVWR0P4!NL=IB.GS,0?(;50$@P&MO7)4/5N4T_!QXKB+I''V=G<4%FE5C
MS'V T8ASYQ_*A#^_3&ZCMT>VBDT]-!$!'=+J5K<("DR*\U4#R[F;K&7L$>"8
ME?SXN8W@IP$_Q6:3,X+%/#8-V,C2328E-UMCOB5[ ##=C%LN$BL1.&\ VN_T
M2H.54<NZ.W*D1&=S>QKM!5I_G*9]:6Z L?BPE3C]B$7!,)C\.'VZVX\&4$\1
MA5DQ<1BZ#8.2$1*Z%>8U(0L+!V@K$#871?5U*_7)W4A\DW$<DAGBB9&*OY0)
M4E3I7[%=CVQC4+"@1;WNZP,BZTQUG<;$FFU&)FS4)*4!XR;2PB=:(V&7'</[
MOVEO->KAZ++9WU+4P(,Q,X,2F/>&=L324?VTCNJKI:.Z=%07Y;$'QQ70R;LS
MKLL(I7*C"WVA'/9@@"?GSLP?=VD;-VW*KAN/JY\GLA^/L=CR7$8E<@BXS2+_
M5*_F:O7>)O98L3G%["5$\* 0B4@T25JW)CI=&-6.E*YL 0@;'Z%EX"&7GSQ?
MR['S)6(<H3LL\1.FT;5K7^"V8D"!!^5MQNF+_WVAZV"S)GJ-J,]-B9A4&R;?
MR^(P]#72Y8V!)/(D"HCW-2C1SR'SWUZ[]EYE(]5YY.Q'^K*NG SJVP0[*'AS
ML"G]7C@51\9C&+Y8XBMDJHFL0[)NM:P!RU0U(8GH$!?&*?Z45=*DI58)V\**
MM$4X=GT=)7Y="Y*0I$F>HPUGMX0.'SN_)#\:'M>#:I\,R?T%#= ^9E;VV;00
MWCKR=[8RI7]/DCY!49?H&,.B84+M9/53,)N+TTW2)6/@D:2R[7JII;MN:$9X
M:NVI$([V/-%%'^V0TX2O5H_HRB=PC.P\>4W%1XQ+< PJ4C032( 5[!,"V+09
M9_M#AWO]A'GT)H;82-([@H:%P^)PBRJR9H)Q4BTDZ=8%%\@Y'P_!7_&)8<T
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MO9O4E)AC'K#*,71[T[#4,L,IV=;S?@].ZMN7![1N'O&8:\[';20-0OR9BXF
M?7-"E_6%+=\'.>\PCB;)6$MA .YYB=]F[BL/JN/,9<Q;IMRMT.MRXA@,'*O%
MP#:7U,8,PWYJ4LIZ#]I1V3HV1]I0GXW6IF;;W*DA?M)O@:7L*ZXW#*X(0H%&
M&YPZ F@Y-A2N8CA^:ZJB;GRQ?]Y1W01EX%WD>TOZG9+0>;WJAFZKIP\5I2G
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MY!T,!8?+D.=6J.0P;:USPZYA;JCT+J<%K?'-6T='B)+2*)ZMU4S4>9Z.%8R
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M@BO&Y? >BA $<C*'PZ4 I8QY,#"P4-#J%Y0!5MG# ,;#+5IQY1/TLJIGK<K
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MJ$)?DP2^BSA!&UI#:)G).T&79."1QLJ&*]]YC_=C94.L;-A9BMR ^X"N**7
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M72E%26N&SK<"]()O+6KO2:X_V=JS42U]KH;S!C1BI/.EZ4EKNJ[4XB&N&^
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MXB*[VX^<.0UA.0QY$?*E,K(C^2,9$O'P*BH@CUY\(1=P%)-]ZQ E#+R2<+0
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M) NXE5Y)1X@-\FTJ#;L8F #,J\=%@%<5_+J4?UQYV!;7;B0T,2V9)*W@:=-
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M0EC*/RA"A]T!#-UB]9!@J@/I17Z+@?AQM#K.(,#6BAJH5;J@+!;'>[L3<CU
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M&0DK=7Q053**R_(4VLB_-2-D7R/LJ,97O3!JSI?98=BQ(7^]D]^-86=VAGC
M?)(X[CHCKVQ-26(%BF8-:QH&S[^  B5;J0J#!U_,&U'(V8M#ER:7&YPN5MP3
M>0M(&_N[EXJW;S'R7+J9=S*ERN5NSRWC-D^9 U58P2 W9%&(K\5*HIC<SEG6
MUM2"[@4V?);X 2:J7HCY'7">X7.<N+&_'>K0EI1%4 NU57LY\1G)%91%$FH
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M@A^?E"#)OS!V>>XQ":TZ9;B'>L@3#/+:S[XTVI(6YOD[SV?._'Y9FV!=6&X
MM,;/G/;CFV%]_"\AI/N](S[2!R_6US#82'[FJU _]"PO7)I"*;@3UI'_.Y?/
M6^XT15UB&@U?J940N*)G?U_8LDJU!,('H3%@JIB-<<FN9G]4RGT0\H4FG?%+
M:E(-*7YTCO#I 8H=L@$!'6@*9/)!"/ K<V>#39=36ZW:]CD*XT&0;NAP  J
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M6%X[@)&@SZ!QGP$OAVT45KQV!(Z)44\>8KV@R>D'RI UBZ3X!'OLG1Z5?IG
MLG^2&YT]TT^/P,J&U5W)T6W!66EK?*F\>@&9Q@ A$,L-1=R!T4Z' K8)LP$7
M_(@&XUC6SO=KO".\A.3Q;L,([O,^1;:=[PLZX((?<0KW_PT3TY! 0'R_JP/9
M^\'N 9"1'CSGU?.'"+O+/D3@AASJ0 ^S;RU\ L/D%U\;]UX8C^K<*<NH)6D4
ME-K\&PORD07WE1,EEA<P*_E:&JH=0S,\AJ\>,W+FB/;K*)8]C]C+@;P,XON
M@JM5WD&#51FO^0)E"NT'^E09+_/Q!!C7XNT8Z[K_Z&PA<IG.5_!&G+8PN>#Z
M!S0D$#V<%M(SKT*D$E  */C.@OO0!.D4@#!TPZX[B-OK>FFP(4CLW]BK1"P-
M^)5V<#SWEB)(7:=17_ @-N BA-%/AP2V -3ZDM' AORP8(..>DE_Q?_WIX\?
M^WMGOGYY6OZ 1[)WMGYYHM,XQWK-N*+*9C.W*!&O;ZF'#60)_#;-TM(.7+*:
M)\C/.UW"_8+FEFEY4UP>_YTZ$3[,_I$FL/2]1_+A6$+,V,M&/<,0B%3$HP(P
M>C>A7(:T>@B#W0]09V^QS[\R07;:.*3YO">=4,('\!;CCBL24Y"%JVV.[3$$
M1 L=%*(K"_3@2;!:!J/&KQ)2 .!.@MTR&"'56TNQ,E/<9$0Q)]ZI(;Q$(,")
M%8E"V!4.A9.@A+N%Z'ME8L_K($14(Q2EU$P=F3@@=7S$J8*^R2--1W>=@[I%
M[0G]4F]DL0CC>HUL9I,HV(>$$M:+.4 N OW*C!G5PF8V:+P%>0HPFYJA]TX.
M@C#P0X]_WA78!\:?=P.0J_>\RS\TP?.N7D:*[#GJB1D\Y8ONYRP_=;*LKA&)
ME&7X44J=45.*X6E^&R18:-QAE3EB4&1=O=ATI 49:I&--7YQ@HKS3^B[CC-D
MJ^'<G1\6$J\VQ:D@7SMQXBL0$V+4K@WYGGE-I\GI=?O]X-&@%YM<AF16%J@_
MAKDWAM^0F[)%SL,F,)@^^@^I!D,U(/H8P7] Q=#D'Z,"*F8S 53,X.3RZ##G
M3ZZ?"]]&W*.IX1X*@RX -'QQ$O:WGG[O.KA#R71,P""*CTT()<@,'\]O" T3
M@9/5*2$C3A]^D]4&O$'TO_<! ^CL'QR6EQW\;3;XOX$$S@! )X@+&Y-(7N+J
M4SI1K:Y1"!8 \DX0_4:<!7=IX-[ZWLXCI6.>T 9Y[^CE$ :@'M!*9*OM-8H2
M?&0XR-K<M] KS0A_>X'8QRGN-?G\(L7?)W8L5I<-H#;H%$J:<>Z&."L.^1QS
MLN_BO;U@7U[ IQ?%MQ>K[8)]O01K_.4LF5-Q20VV@T;W7XE1UH>(,!7BK$]T
MQ]5E'PMUZJNDB.0[&WI"E23/3@U).&"$1$[\?NZ-K$8+*5AE)#!A6"(KN6IL
M;#B:;/2%,&9A;"+S9,VK(S'D7/M.'/=(N*!N/#+*1$4-OH9!GNU 3SX++^S_
MH"6QEJR8\\F0D1GJN?&RRLN_94/^V_APM*1<.?F<2Q-L[VGDC7N5)E_#Y.\H
M@<+FO0)B>0%QB(#8Y$@>J/ 4I]<87CH_=:F_R=ELH"1@#,66IX#,&HL';'W9
M\ M^_$7V@<5KFBSP)Q9'?!CA(V,3.]"KAAZ["1-<^C\Y)WQ3ZM0IOPLCY.V"
M4HL;#W<$#<%S_*X>%NTB[FP"M7;\)$8OZVZ28R49A:*]$X D<MF(8]=3 3R7
M>!FX+P%3ZV%C#H@#3\8G4K;TA9.CR5>2,V7JZV@D5IZ$!:DI_Q&[$(D_=WCU
M\=NSAD<, YX\A7[F"VZ'1SP%[03FXBWT7;P(- JH__T?<V/^#U8UQ'XZC%<\
M'XH$TR7-^].1*2VL4OFTA<GYK!/0^,,(ZI,G$(SUA)@.T/?:RL=?\!\ _W3^
MB4F1O;ZBA.I/7=#6R]DH$&#F3P BWVO*U=@_^R=<"?#/# (PUNC6@%XS]TU-
M6F:/&:(RWXHS+"U^BYA59OS:?$/3I&-KFM(L'84;A-SX+@KW&<;]?>#!*^XQ
M?<7*] H>81T0A\LB*OO,8HN_4T#]5W'OB:O%HY]?',CW<1LZ@0^+ )&Z]"F4
M"OD&"AUFG>O%S$9%PDKP8'CP*7"%1F-<.8.]Q#8Q8TZ64E]$9/:%!?O$@GYC
ML9J(6AW[1ZF<8]ZNLSU,WU)4+699M(>WC446HJ$X5*MTF=T "269B80M I T
M?_&* K3U1N? =:8_EI^M_?$2\H$7E8?K25'D-Q S6:FT,K+D(,:\*F+FSPP0
M]$1(\<543 IIG*%8K;8L]07?(^$@.#P%0!:6"?G@BVST20,08R]>;3&?X\R<
MB*7AL[<+O*VWP1MF25UK6=U1?"J&24I)]WLG.@+]W,<6Q=<6V>?(+4*F"8WY
MB9X3;_S,)B.@DW"@B4M3G P**\IIM3>94@M!R85*VPL;UJC2/!:%OH"X?.C%
M,B"9":=*7!435FL%1_=-5#)),H"(&\]/DPS]MD>AFO*S,4_.<5C^1_9:K!6M
M^8!90F9PXO0+4Y,RZL^7;+],<9[O4^"$T$^4:TS=G 7MO&6T&P,FBE<O$FIU
MGH"#IQ/K/I.-IAJ/SQF)NE?A 2C [%%<Y1;<&%)>CN[XK2!O]HI:%L!K3A2L
M+%YF6D([Q4>3 1!W5VGT;4)&K3Y#4,QOZ(+LPLXS21VK$<GCQ/ODY!'=E$5+
M ^@)F%KC/,<<ZZ<LD0*Y'4-G*TIJ]BE,WP\'^C%2S+::C8Y;,!?.N-CJ8Y*>
M"2$!R:4$_/P[&8CKR5)<J^'0:J7-QA0M]V&40(P/5 TC]H!>U&>C+6"X4Z>,
M[62M8*GSHIP7SAW(GTKQ[EI*.@OX)V@)I0+G3&OH%SA(L-X!G!80#V$X_&*9
M#R^R)TI_++!L:@QR!.ONY>+#$ZEX+S$\8.+$VV.-I)^U,:8OMFPLNV?NBR?]
MP4!1'W*%7_G.YE=(P@R^H&B'HN4N0F0;]7<PDJ'7,/2"CKW(!S\EDOQ&:J8!
M<A^8K(HRK2!O[(I$>5HSUAJ?T"[UG22,CGFJ=9:+V6<K\@GF%/TE^PR'"7Q@
M'SI-<OTZI>"3*+[ P3D_GC2EM?I:+=9VNGSYHIYP7[LD9Y0I!IW4C3XD4?RQ
MY$.*+('$ZQD5T H/<,(8@<XPMPPUC?,$# GO5DW*: &05_)-('SN(<UX$LQ:
MJWG)9X=TY>9K#NH]=YX.]^S*T0=+G#:,.<BYDIP(%CS.0./!P+$!*QYU^HWB
M10).IDGN0B*?I$9,^M'%5P)_%L<3%F:?AB$BAR/[7@E<O\:1Z;V-=?R?'N@C
M(N2?B6!(ED'BD? %[YV#A[G]3@$H(-R<VX[UY7_P G2?H'UGW!7N\WQT:C8!
M&H]>.1'U/;'XOS"1!9G)Z"S+L6<*K:^O>@1#LB(2W* 3ZD$<GD[^Q[]Y6/9&
MF[?C [PD>FQOCKI\3')\ORY_FFB;YT1]00[P%JZ@NPC],T7!YMC+_\T-N,A'
M'-T'3EZ27YSOWC[=/R'VBEON(1R-V"?<=8@OVCX7$AM\$66C+QPR_,(AXT-"
M*OYA7!O(X 3Z9=KR@1=T9&K;<0&=#P]^6J157O^&ET\*1O;($(\>?8?8/VXS
MT*,!8=?$J$HG2&HS^%KVC0\+\I4/-+#H]$GF?8+MZ1[9)<@.,,#>D5=,?Y<
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M&T:%N@EU0;$B$$;X/#A8LP1W-8@PP+L+??R%'5;&$6#ZBQ9TQ,^9/YM84]@
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M4KNS^9/,5TU].>#MN'GST#LK<YC;'FMG6J^;>?*XS!E\-=QYVP2A8!U'7M5
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M18DFC)=H1?5[FY>^<E#<&_2:,+,-6#FV"8I6 5J_16&Z>\O2@'-#8MVL,-#
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M9E='\0 RD3OBYZQ@)Y^MSEMN.9.M.KJD17\K""Y#0XI(*K<P;^6M01S>I>#
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ML.4>ZJ@MDR3R7E-2YF,=4NPA"6GMQ[&Y:K-Z,VKW-[<Q->.V+,)_J8+U*I=
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MU83U^R!'/&$Z03/DO^X )@%^*W-\C- !*SXW;(MFT#F!RQ4<UR98:S [PN9
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M,8L0[AX5G73$U"QBO(?@8;-,G"[HV]I".:>HD,ZH7 Z-T%IAP>K !$FH5AX
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MBA<2:W<7P;L&JH1L1RSWUKT\*I3G;9=R4B7-1+27#R[B9&H19CF7QUS?)IA
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MZMS#BD:>5H:%[")B.)2A&V"RNXB@CH$:K=@<.%W(AF?H":R.%6Y_G;EHK'R
MU6RA%8J_N/"^Q1ILHB3J1 IUPG%&Q0^=I984#8:H:(W^(TOC:!V0@*OJUXRC
MDB%B)/]_E\8(N*P$] Y-/(SR3TE0(- M!@W52^B1!\L!^L%^A$(]%VX82;O1
M144B7$O<S,[;/X*,?D=L,BABB^[ DNGAG(<T0:ARYT]O:_$DU'6Y!+3?;6>?
MVCM0\JH,\?OX2SCV:;]_^3.WH-?07D&96A9\0NK(0W(;'*(\B/F1P]P^]H+4
M "((&,!C11_XV39<PI!D9B[R'$:O!8Z*!ZNT?+N9%<"F/(Z]W0O#8E\0+8#H
MC_A,0+!#\FOT5CW>QM])Z?[V3I5D!7*':HP_XZ2"!*Q/V7Z"NBG4QJZ<(EGX
MA=WLLN4R6. .Z;;)MGQIYW,0%ZVLN3K5B\>UE<9Q;<GEIFA8,V\@[6&"AP*&
MNR #^*7)-Y#EY*@P,O/H,8)*([BV:82^.JE?"_P4Z2/(EYO[%&Y A+,0V?+>
MR&&M <*ZD?";14&,7RSZ!Y*AT(I^0PP4%\9=)HTB&C#*T$_-)9.5K8+O#*",
M?<ZB;/>O(LN)V6J5,H2V4^5K;._:8_,I,<$U3\0S*-_0 B\ OI5>$K2ZY_+9
M*-R"*25.\W6_7R Z&S:I1N.SLQU/<YW_#2<Y@O7??\AA <Y_3),<?,_?QT2Q
M^_L/&=CN&_)MU^9<VV6C)/_C.MK7)N<@C@4^7:Y5OFNMXYB-!R/QIQX2FR ^
M1QI++W5-E,8?]RW1S$CE-*=1B/:8U:7)C^O6 C5[]#V!H#(@F,"@MDZXC87X
M4'#M-.UST3.G.;UTM9/ ,[BUWDB@P^4)$E('8A04?IR+'1H9AL4K^+$&1P"*
M."J6#IO+*$AP!UDYH6\H-;'POM1DGRT*[*TNPV#B%/1O4Y<1T'8"!IBJ3>#R
MDXL'1-ZD[3DDDLRR;X UL>Z?'20%EAW=\_4/8A$3D<&?78-A@/7>!"Y_\007
MKHG?!#!_=0680=X"$XC\X@HB^AP+)F#ZU368S+D;3,#WWZ[!-YFSP8B"X)R.
MW'$NR"VZ"J9N!TM/'DI]+L6XA-L@B?Y3QL0GZP\1VEQ$&$=N*49K[L;&9,^Q
MW^7,GQKAZ8@WEE'SB)[KL'!!/3\]8^NNR%1GH;'VB19UK=15\XQ9'^N=I.9<
MQ9TTS_+TF.XM:AJ%05SN<5C]ZQ$4,,W"""2(N\%T"P/ZM >,HM<3FL&\<6S0
MO\Y'!OWC]V><%4R-;.K^.NFTJA07YL3:OT^/&"4RM_V;FYOH0'1M\9JA<XL4
MXI< ,QYA9#^SO;TEG">"*SXCZ?"<M,4->);H.,=%V2>ZAZ<E-WCS_+M#4>?/
MX WG>):ED@YQQ!)*9'I.R[O1W<;EW:W?-=_:M5S KD/9;>+0GC^F>6/;RI@4
M[*!YQF+/.VD"$ SC!).IY*)F$;"'I,$[)-B-< @7%LHKVBEL[E2MV@>L;@;Q
M4_$:1^%RLP&0'4<NWU_S^?^$%%_X#5MSDBW68+$G+B/%#_?[*,M8T<4RW71K
M014"5;H[7>GIMG$AK:X\;XLBWZ40V],8),#KX<(RG@*XA$0]+VVH@C,JT].I
M$O#"#1)T<F0QBMLDV=F]1.WF+?;I0.Q+U:W-)$CUD9S)I6J$!U2E%1BKE.AH
M;R^#C-351?\/RUUOZ!;'MT9^B@,A),?:/:F^UI;V,8!? 0E=.3M'^.6M>3VL
M[E 7XF3]@EA<O@)P_T!\B\0ZR]DFR0&\S0K0:C$_5W.4-4M[&BNI9LFN81EB
M5?84(89E$D-!,?$ZO4AN5#G5*'Q:90L 3]9(BQ>77:0?D>"2:0(B6W4K/$/"
M@.H))-Q\ ;V8>$(N$N$ TO;S)D -P[3+ZQ>&C ]Q1+<(A4U5G@:2JXL'2IX
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ME5;X8'B0\G.(0?GU6P#S($IHN> LJ$>-J5NP+G7*9\2S";:+/=;@":3K58H
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MG"JJ7PMES/OL41$)FL+F_HE63P4,=^B/3VA)[8A+) J%C;@&7;*6^(/:B_G
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M5L%WD-7FA,<4+Q;][1:"=93?!A >-RG$_#8;:4-(]C#X\30I(LOAO_Q^!S8
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M!J+M+B>"D9"";:SW0Q2\1G$9TIJ45]LNC='LLY+BJ$I:NM]'^4F'13N*PY4
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M&3Z\WTTVNW\D:'W[[1N^W_[^]NOHS?"XO+-=X) -[,_]G7/C<+2'_%7:M0<
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ME>@=I,P7>;D*GX#BZL&V-6",8>&6;MH@SI0CVJ+3*+N%9E"+RB5 +.I'GU;
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MG!*0>%D938C)N;D[G,W)*.I>/ZJO?SK;0T,UA.9I#\MR?%<QBEH'\.%!U([
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M_>Y$^?,/O[S?#4P4?OA_4$L#!!0    ( #& IU@3A%RW !X  */E   /
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M'QOS+)$6E3\^)/P$QU5 -/M6.L]&':P=/AB YM0,0TF4?'7/_/#RY<MPBN@
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M$0F%G.C2=!0;<6T4U):$XLU<;I"RLF !NA1F2=J-$3R9$;36P B&-Q#S#UT
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MX858?8&D/J52GU"=_M(^TA]?_0M02P,$%     @ ,8"G6"S.;6JI!0  6R4
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MX=T& &YM<F$M,C R-# S,S$N:'1M4$L! A0#%     @ ,8"G6&V*^NYY/@$
MJ"(3 !$              ( !2^P) &YM<F$M,C R-# S,S$N>'-D4$L! A0#
M%     @ ,8"G6/(HB@X?$@  )YH   \              ( !\RH+ &YM<F$M
M97@Q,%\Q+FAT;5!+ 0(4 Q0    ( #& IU@3A%RW !X  */E   /
M      "  3\]"P!N;7)A+65X,3!?,BYH=&U02P$"% ,4    "  Q@*=8@^/Z
M^M0(  "P/P  #P              @ %L6PL ;FUR82UE>#,Q7S$N:'1M4$L!
M A0#%     @ ,8"G6&HM[V/."   J3\   \              ( !;60+ &YM
M<F$M97@S,5\R+FAT;5!+ 0(4 Q0    ( #& IUA@@)>2I@4  (,E   /
M          "  6AM"P!N;7)A+65X,S)?,2YH=&U02P$"% ,4    "  Q@*=8
M+,YM:JD%  !;)0  #P              @ $[<PL ;FUR82UE>#,R7S(N:'1M
64$L%!@     )  D + (  !%Y"P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>nmra-20240331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nmra="http://www.neumoratx.com/20240331"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nmra-20240331.xsd" xlink:type="simple"/>
    <context id="C_33ed239b-f1e7-4dbe-9413-6d412b79e979">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:MarketAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_eae3f164-5e78-4151-9e37-d2d160340f1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
        </entity>
        <period>
            <instant>2023-09-20</instant>
        </period>
    </context>
    <context id="C_59764801-e98b-441b-813d-c795a4f77342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_65092f10-0d2e-4c03-9fd8-87313bbab41c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_60ca0d63-6992-4ed9-96cd-ba37575ee0f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_8cc2fb07-49d2-42cc-96c7-07529ebadb72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5832b785-c82b-4724-84f7-7e1c54e65756">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_af1ae46a-387b-4cc6-b7c4-deac557cbf45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nmra:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenIncLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0fd1591b-b097-48b9-96e0-c77fef141b7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d4ca77dd-2b7a-4c72-9d67-3f3c267a7400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nmra:LiquidityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_908e2fe1-8e96-4b2a-b94e-f5e7dea5b0a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_2a684aa7-255a-43da-9bf9-acf6d3b4352e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nmra:EmployeeStockOptionAndAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_07471f87-b4eb-4e19-b637-f10364df9c08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d4c8d898-2127-41b5-99f4-5fed585e8a39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a0e6e5ef-74d3-4484-9f60-7605a23196e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:AlairionIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:AchievementOfSpecifiedCommercializationEventsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AlairionMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_51f3d1d1-4794-40b6-9e06-602baca00e1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_03e46424-d2af-4dcd-b68b-3725a6f17401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_997939ff-f371-43ae-8539-1f8d55163ef5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_eeb0b484-a788-4f77-8681-695af51358cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7427bdec-5be3-45d2-91f7-391af97bab20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:AlairionIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AlairionMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_43bd04fb-3740-4cf7-b83c-a9a404955351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_4a935b0c-89b2-44d4-8a74-37a27e755eae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nmra:PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_395f7b48-e0c5-40be-babe-b38226abdb22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:MarketAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_e555a578-5b2d-4468-956c-3321ccffb3aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nmra:AdditionalSharesOfCapitalStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20c204e8-32e7-4a99-afcf-776f05f42ab0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_27e98a1d-ba3b-4cf3-99f9-3fdadc737b90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:SyllableLifeSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:SyllableMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_34c9a333-0792-46d3-8d3d-3200c56c14bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nmra:EarlyExercisedStockOptionsSubjectToFutureVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_15533d05-1a02-4a98-bae1-62dca64d295c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nmra:PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_8d2f7696-8e65-434a-b57a-0fff8a7da606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_a41d013c-1391-41b3-90a7-49ba49d11331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_934561fc-3ca0-4e9c-afc9-cab561a511ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_55f7cf54-c65c-4834-922b-fada916481b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d5479116-b1c4-4d64-a307-24d1e08db08f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:MarketAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_739e5e64-0cd3-46ad-bc1c-ca25045bf637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7a80754f-9ec5-4887-bba9-4311a2728d25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:MarketAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_cc78fb10-fe96-458e-9b51-d23d300acb4b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmra:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_26c72768-5590-4025-8159-fc37393751a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:TwoThousandAndFifteenTsriLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="C_93cb25ef-3bf9-4722-9f0f-76e81b2a808d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_785b6f2c-3814-4a67-a525-c56234244751">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_70e6e56b-1627-4b50-b58c-c7079cb8e79e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_d5bbb135-9ec5-40dc-99e5-5f2b31f645d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_6715b955-aac8-4773-8111-47fd843a4a8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_9e7d5678-cc71-4b15-86ec-dc798d97ec7a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:NavacaprantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:DevelopmentAndRegulatoryApprovalMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_d7ebe7a9-9b3e-43ca-b7d5-0155ac61a792">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_387b8b88-6529-413e-9474-299a471851cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_5eeee25b-8ab1-4a9f-98dc-9fd6387ddc80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:VanderbiltLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="C_e9c77ce3-3b44-4cf6-b432-fc188546ac82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:SyllableLifeSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:DevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:SyllableMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_7642d8ba-9722-4366-8e63-768f192c1673">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4fa032ad-c930-4482-a337-4a8a1b1ede42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_6fcb7871-8d09-408d-8dc0-0412fca292a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:AchievementOfSpecifiedDevelopmentEventsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:VanderbiltLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="C_5ae90723-14e8-439e-81a2-861cd015a4de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_3a1a5b45-cd15-4c5f-8018-f47ae86a02cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e5c437fa-ca9f-4a34-a6dd-cd8d4e53f5bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a69bb320-f60a-431d-9ea6-2f940a271bbb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a19bca81-450f-43b2-9071-1243ab1b452a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e356d7aa-aadb-4a43-9704-349d4130949f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_cf493e6f-190e-4be5-9281-315bbffa2f51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:MarketAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_9a190bc1-8994-483b-9102-8e2f78b28bc1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0311f6e7-f6e3-443f-9af6-6ed78e813333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:VanderbiltLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_884acf9e-2115-4f33-b211-b79d6b7b8a24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a7fa44ea-606a-4dcc-824f-a24a6ed67327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nmra:PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_1c718a38-50b6-430d-81b1-4a6d12e7d922">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_b7c53efd-2f73-4e8f-aeaf-4c1bb51e739b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3492c0b5-ea1d-4cce-912d-8ddfd975d853">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:VanderbiltSponsoredResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_1f06d786-a166-4605-9c3f-8826e794ff47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d76dcd2b-4bbc-41b1-8598-911a369433df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:AwardsWithPerformanceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="C_776fbd65-9035-41d6-b661-57b9c9289144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_05417fea-1510-4361-a4a9-baae7ef69f42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:AwardsWithPerformanceConditionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nmra:RestrictedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_da6c85e3-9c01-4bd3-ae51-498329b996bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">nmra:PerformanceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_aa35f881-a2e4-44a8-bf69-7086dc821033">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_2113c554-0c81-4a7b-979d-5577fd8f2940">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_cb7d09d2-6022-4de5-837f-3706586031b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:TwoThousandAndFifteenTsriLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-11-01</startDate>
            <endDate>2015-11-30</endDate>
        </period>
    </context>
    <context id="C_e06ff9ea-6ac1-463f-a171-26aa417330c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_22d38837-90bd-43aa-9c93-8f13f37f99e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_555b90da-9109-4cae-936b-dac6310ce148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_02b50e0e-46e6-4a57-acee-f328831ee84b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d06cc3be-3868-4b27-8b88-efa3b16b4417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_57949529-090f-4b07-8503-88af5ca1f576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_33dd1233-920e-4439-a019-1de4439f0bdd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_6e7d7080-8e14-4f39-8b8c-749fc8d79976">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:VanderbiltSponsoredResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="C_24425110-363c-4304-86c3-338011263481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenResearchAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_3d2b19e7-2597-4087-9ada-8de5a4121c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_251ee5d8-0c7f-4f9d-a0ce-8c700c53c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_77c53b90-3f1c-4948-9874-3efee2daaf4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_3d8423cb-a654-4705-bc38-351fdb1ead9c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_b7650c04-d7d2-470d-8cdd-f4a7c34c3ee7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_7192706f-bc17-41ba-8cf3-0a9e6b1ad84d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d17d3110-5d3b-4f67-a03a-3459f5097a7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_58d3b1a6-51e2-4cfa-8ee9-64532995d7ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_3e1fdf9f-0c41-49d6-bdc7-817ef4cf3889">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nmra:PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_e8193643-0d56-40a9-b0e8-aa7a9093b9b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_1c88b9f4-137c-4a7d-a570-37859d14341b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_6605667a-124d-429a-9742-9590d104c8b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_a2bb8dd3-a77e-4977-bb71-27730b31dc5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_77008896-6cba-4a73-a7b9-c5a0409529ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c0384758-481a-481e-9efc-b953da92377b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1bb45cba-2398-4df6-8cdb-80b9b69e2e24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_38d1ee4e-868f-457c-9d3a-08007be1e356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenIncLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_d082d3da-55b1-47ee-a8c5-4a74e9aacbc1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_d05c50a8-ba36-4fd1-84d9-0b85ac41d16f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:AchievementOfSpecifiedCommercializationEventsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:VanderbiltLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="C_2dbd3db6-c2fd-461e-bc93-e4f0d0af4663">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_2b466a11-59bd-42da-b1ba-1391e584e43b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_187481d3-58da-4836-be9f-97cca6f7c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_62937b0d-82a4-455d-b20c-613131a128e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fddb666c-28f9-47a3-90ab-b07ceb2c7598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4252d2b2-e04b-48d1-85b6-0e7e74735ae9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenResearchAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_525f8d27-e52b-4d90-aae6-72f3a411fae6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_e25bb6fd-163c-4c2e-a895-464771d27c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_18f69ced-ee72-4bc6-9740-8d6abfc2c287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1b53b7d9-62ee-44e4-a34f-0d741a2336fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_6d6c1116-4ad2-4a9c-88a8-b3a45ef44006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:ParkinsonsResearchVenturesFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_77cfdb28-9e47-4558-b8db-21bed2f9143f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f302022e-1a9e-474c-a0c7-dc6743de3517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_f813a615-5ec3-4225-add3-4edef1f0b0da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:NavacaprantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_310a84d7-31f9-4782-844c-698837e7d4e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_b9e1e62e-8665-4095-88dc-e415a74bf039">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornCarveoutPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8d605d37-23c6-4f30-8d3a-a3a25b1de12d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_00a508a8-d895-4261-b068-9f4d68a32812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_1eca2e79-7a8a-4acf-aa36-a5b1bfaffd3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:MarketAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_29326ae4-2f07-4dd9-ac50-8fbdc7b576a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2a31bc5a-9b88-4b0c-a97e-5b7a3ab157b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_08d37b25-304c-48fb-acac-c44b7eb4f93d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c76761b1-4f4c-4b1c-9b56-2a77a0b656cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_b8b16692-cbc0-4367-b249-644373e8d0f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_014dbf4d-9c71-491e-bae9-913a30763050">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_909c052f-7ffa-437f-92ce-194f4b68b6f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:MarketAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_ba9c409c-cf95-4c6b-a1de-281f2042bc5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_31d52667-94b6-48d2-b574-45d574a0f09b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c27ac2f8-7a27-4804-87d3-3bbc8e87144e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_7a1aaed2-b5ef-4825-a2cb-ef3ae69d40ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:MarketAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_638d684a-75f7-48d0-a1b0-227583ccf014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:VanderbiltIprDAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_77d7002e-e37b-46f4-8b74-d60274250475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-19</instant>
        </period>
    </context>
    <context id="C_b006d350-7cd4-4054-a767-ad0723607854">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nmra:CaseTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:CommercialMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenIncLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_ce5b0975-4f9d-4afa-a419-e3ce04cc3ecb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nmra:EmployeeStockOptionAndAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_0caaf123-e9b7-419b-a654-8ce6c344421a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5ea749b2-350e-4a76-be5d-6ec287b9f397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_f4c941c3-9b74-4cf3-bf81-e52a1de6cb41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_7da00584-584d-4a38-a226-8df0e7c5789c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_44ecaf5c-05ec-4fc1-a4b3-34fd3c08ceb5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a613c3d9-8372-4ff1-9b67-609500a6441a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_a5ae6113-d278-4442-b891-5cdcd2698c04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornCarveoutPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_376fc925-1109-451f-b742-d347b9400872">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmra:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_b52dabe9-8de8-4682-9783-5765240d1d61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:BlackthornTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_fa50bcc6-f909-4f28-9b54-3cce67927d90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_118d5793-6b58-4c11-bd9e-24a1b0197692">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_0a096f27-ed84-4bfd-9a47-aba4b2779d76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_829340ea-2a8e-4dd9-8fc4-4651e162611a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-19</startDate>
            <endDate>2023-09-19</endDate>
        </period>
    </context>
    <context id="C_adde3b8d-d812-4a53-b229-03202c183eb7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_7ee2b185-99f7-4bd5-9ca0-f9d76e4edb87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_aff62d54-a840-4155-a58f-4ca78842f976">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:AwardsWithPerformanceConditionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nmra:RestrictedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_6a59c933-f461-45be-9258-2eeefba9dd39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_a162142f-a9f4-4c93-8b5d-13311233637b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:AwardsWithPerformanceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_f506a8da-d1e3-4763-89af-d777851aeab1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:MarketAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_4a88c6ce-e846-4492-ae0b-e6b735a43fb1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:VanderbiltIprDAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:VanderbiltLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="C_eccfdb09-aec6-4147-bb3a-627442594df7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_04b84919-0f66-4a40-b2c6-b4440e68e095">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_c7dcb4ff-f9ea-4129-bb6e-4ce2d5a96a56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:Nmra511Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:DevelopmentAndRegulatoryApprovalMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_10a4bee1-f023-4318-b204-afcaf55d14c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:TwoThousandAndFifteenTsriLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_241e97c5-2790-4988-bdd5-728453731091">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">nmra:ServiceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_a90b5a54-f1c7-43a2-a245-7aab2d94f07b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_efc6daa1-495e-4af5-8a13-fe64bc5588ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
        </entity>
        <period>
            <instant>2024-05-01</instant>
        </period>
    </context>
    <context id="C_c07a2ba4-b437-458f-928b-576f968fde0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nmra:EarlyExercisedStockOptionsSubjectToFutureVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_0f5b5752-1f37-4791-b9a2-a1fd4665f647">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_3929f877-fd38-4a94-9e5b-54676a4e9e57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9622b93d-0fee-4c35-979b-ac055cc9685e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_39142c7c-f586-4ac5-b162-38a428111720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2ea68049-f744-4490-8038-a161b824989a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:BlackthornTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1ad31ded-f058-420f-adc9-5e78ca23eebb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_79158f11-43a3-45ef-a4fa-baf694b1a1dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c04ac888-4277-45d9-a4b1-48542ea0cbd2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:Nmra511Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:SalesBasedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_9b39dc12-964c-4b06-983f-1dd2a2960d34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e4e3a7e0-9ae1-4a99-a9a2-37ef23ba354a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_99673cd6-c93c-488e-a35a-1c624f6dcd54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_9a1bec7e-9028-4893-9a01-f2631f4b8268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nmra:CaseOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenIncLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_8eca9c19-7868-4c41-b853-b66e96530c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmra:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_5e8a8262-f68c-4d54-b803-90f9002df20b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_43d25bda-98a9-43db-9b57-e1c5583f0e82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:BlackthornTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_bcf2dda4-ea5e-486c-b486-680ccab2876c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_a8941767-b9c2-4978-8d8c-996384d2b743">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:MarketAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_63ea549e-a21c-49a4-aa4c-6bb788b17014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_61a3990c-bdca-4b24-aaa5-3144c2b02eed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenResearchAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_5e016890-9da0-47f3-9793-42aec2feff28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_9e81dd9f-5d49-4381-8c61-747848c7d435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_636c0850-3f38-4c68-923e-8a9192036aec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a2a11bd1-3578-49a9-bc75-aaa978ce9086">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7f5ac940-84de-48e5-ae64-41ee00fc2d79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_222a51e8-068b-4c5a-9701-3a50110c9a80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_98e4cbee-233e-4294-91dc-1bfd8e5796c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenResearchAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_727eaf32-52e9-4c5c-a6c1-0994953c8d5b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:SyllableLifeSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:SyllableMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_b09e08a3-63fc-490c-a2b1-f49e28aca678">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:ParkinsonsResearchVenturesFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_29e92089-1d1d-45de-90cf-b5665e9d2c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenResearchAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_2491722f-cf98-415e-ae66-46193d72f8d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:AwardsWithPerformanceConditionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_3c8b66e7-6cb2-408d-90ae-bc995d83fe8b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenResearchAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_8afd36af-329a-4960-a319-26b63e51bf46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:AwardsWithPerformanceConditionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nmra:RestrictedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="C_52904f82-0764-43ac-8bcb-0b6094dd317b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornCarveoutPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_ba5b5e93-9d73-4a23-8fdd-272f7a933478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3c40c0b1-14e6-4ada-8bd6-1d23c649c6ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_9d7f8b41-ab55-4cad-89a8-122b00ff6bb3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_ba11dd75-605e-4c4e-9798-9cc2968450e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:BlackthornTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d5c12c1d-523a-4e2f-a7e6-1b8c3d85f7ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:AlairionIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:AchievementOfSpecifiedDevelopmentEventsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AlairionMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_28cf5026-31c2-4237-a961-7cf7d3167b00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nmra:AdvisorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_14e89b9f-b5c9-4179-91f4-e162088b136c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:NavacaprantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:SalesBasedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_c407007a-f71b-4362-a5e7-9ede4f3ae224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_3700265e-5b94-44f5-97b6-9328d7c4e21d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_37094d88-e7f6-4b83-a8b8-9f256b675b10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_61fc95eb-f3e2-41fe-a985-6942d28b52ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ec34d5ee-6cf7-4a70-a875-58e1015081f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_8cd94762-0e2e-45f6-a01e-01085a86a854">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4fd44d42-dc78-4882-9e7d-7c2d3d98f539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:VanderbiltLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_42afd269-c212-4524-8ff6-bdd4937462c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmra:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_c58e805b-70de-4471-9304-e335b5edcd5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_96f5c202-287c-4650-8120-d3a9b7c6fa82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenIncLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_5ba84d33-97e9-4add-951a-69e5ffd8a70a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_345bf6ed-eb39-4b95-8e9c-d73a88a49e29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e34b0512-dfda-4a27-98ed-cf663dd4f181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_70fddc6b-c6f5-476e-99bd-8e5dcdebf0ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_dff92dc7-7e5a-4082-a3f9-80aea9d28b77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_0cee2f31-d69c-4bb4-80be-9b786c85fd34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_673045b2-3dfa-4a5c-a957-7ad525519202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_b533a66d-d823-48df-b3a5-6934efcf05e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:SharesReservedForFutureIssuanceUnderThePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_df6fdf4a-265c-48a0-90df-8045faa562ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmra:TwoThousandTwentyThreeEmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Agreements">
        <measure>nmra:Agreements</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Milestones">
        <measure>nmra:Milestones</measure>
    </unit>
    <unit id="U_GBP">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="U_Program">
        <measure>nmra:Program</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_a577262a-b2bf-4067-85e6-ae1d80ff9768">0001885522</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_9b206e6e-5fee-403a-bef2-f31e29027818">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_52b4600f-6913-4e25-9c5f-375cfb09464b">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_8e72c77a-0627-4e13-9d7e-12c8667c6873">false</dei:AmendmentFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      id="F_e748573f-5fcd-435c-b320-b9707be7bc34"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      id="F_92a64cbe-414d-4323-a4eb-a1db34c1b207"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_2dbd3db6-c2fd-461e-bc93-e4f0d0af4663"
      decimals="4"
      id="F_fc1674b5-31ae-4580-a05a-09485f8e145a"
      unitRef="U_pure">0.1274</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:DocumentType
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_3eefbb28-901a-44fb-b701-7a854f905d32">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_bf4f729b-7d77-4b32-b0cd-804f495f5907">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_d1fbf388-1980-4a58-9e1a-d9d297edc3c6">2024-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_786df56e-e542-46e5-a387-ccbea61e60ed">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_b551a316-b249-43db-a4f4-c5eacd142c1a">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_1c2bdf6c-bc2c-495e-a292-06f89e511ecb">001-41802</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_3cd738a9-e020-4ca1-9543-4d060f60d37e">NEUMORA THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_ca83d9df-9c74-46fd-a6c2-d2e4d21fcc0d">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_5861bc5f-75a3-4799-832c-28f21b3fd980">84-4367680</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_850f1ba9-6f21-465e-9d94-65a2bfaf0227">490 Arsenal Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_9bb10ea6-62a7-4661-97f9-2b990c0a6b4c">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_3ea995d3-d278-4c84-9040-7f6fed20ceef">Watertown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_252e805b-3e0d-4ea7-9be9-4fa083c85bd7">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_215dc85d-7342-4a46-9292-ce9b02d067a8">02472</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_e785e839-4387-4f3e-bfe2-23bbc26c86c8">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_e46f6646-0b49-47fc-80fe-246714679865">760-0900</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_93a62a5d-719a-4e2e-893b-b31866998c59">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_0e1a1669-bacf-4f77-b874-a26d48abc58d">NMRA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_40d1009d-8de9-48d5-a07e-06a088e0dd21">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_83ae9c88-2392-4b9f-8eda-d648eca44dc2">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_2bfe97e8-3bd3-4765-ab27-2ecb6b9dcc2d">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_a1cba030-d9c5-454c-8200-a914993ecc53">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_b65aebd5-7d7e-4f5f-a408-74f36de49352">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_45e97e21-84e6-4f96-bb1e-b05f5c3de2cb">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_8ddcc7d2-d05d-4bad-a6e3-acba3d5d9f8e">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_c5c69b49-9934-422f-83de-1b5baec20883">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_efc6daa1-495e-4af5-8a13-fe64bc5588ff"
      decimals="INF"
      id="F_d72e85ca-95f4-4327-9553-250b7ba061fd"
      unitRef="U_shares">159523997</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_6eb7ae7f-57e5-4406-94d8-eaa0f2feb892"
      unitRef="U_USD">182927000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_282e5490-9a55-4c9b-92d6-09d55a88a8d1"
      unitRef="U_USD">374038000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_0bf749a1-f5cc-4d4c-97f4-35016a84b0e9"
      unitRef="U_USD">239788000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_877037ce-959e-4158-b48f-835306c4e7b5"
      unitRef="U_USD">79944000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_e46e67d0-6462-4385-9ab3-95465a06cf54"
      unitRef="U_USD">20070000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_5d646503-c382-4716-92a1-3a0f7f9924bd"
      unitRef="U_USD">24297000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_7c3321b6-3f83-40df-bb11-a71840aad07a"
      unitRef="U_USD">442785000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_61cbb0ed-0096-4219-89b5-cd3e6588e1e0"
      unitRef="U_USD">478279000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_276c4705-982a-4a6d-98bc-fa95e369a228"
      unitRef="U_USD">302000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_44659730-d2f0-44c2-afc0-47dfbda795a8"
      unitRef="U_USD">9845000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_a14f5738-e2d3-42e5-a6b3-c57cc104fbb9"
      unitRef="U_USD">1635000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_96a6f166-acba-44f5-b266-e0f7fe10fac9"
      unitRef="U_USD">1790000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_e80a13f3-f3c3-4cbe-80c7-9170e4a2352e"
      unitRef="U_USD">4276000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_f00fca87-98ab-434a-a2ef-97cb413f79d8"
      unitRef="U_USD">5068000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_22cfa908-8a7f-4d8c-aadc-faa300ba3f57"
      unitRef="U_USD">1213000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_afe8866e-552d-44fb-b3d0-e8dc46992124"
      unitRef="U_USD">1213000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:Assets
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_b2716c90-4e52-4300-9815-cc1cfc76fa2f"
      unitRef="U_USD">450211000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_528fb34b-9d06-4ed5-bdd8-3b99e30f61aa"
      unitRef="U_USD">496195000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_359468e8-7400-40e5-8da4-432d0880b3c1"
      unitRef="U_USD">1492000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_9efbb4c5-f034-41a2-b13a-bc9b726b7f97"
      unitRef="U_USD">337000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_b5db67e3-37b3-4f62-874a-e1d6b63d256a"
      unitRef="U_USD">19493000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_13e3b0d9-7149-44b3-8cca-8b8dc8644424"
      unitRef="U_USD">21257000</us-gaap:AccruedLiabilitiesCurrent>
    <nmra:EarlyExerciseLiabilityCurrentPortion
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_03de554c-0702-43c6-a6a7-a21e0f030d4b"
      unitRef="U_USD">133000</nmra:EarlyExerciseLiabilityCurrentPortion>
    <nmra:EarlyExerciseLiabilityCurrentPortion
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_9a8308a6-b4a0-4ccd-9a73-cdfb84183ecf"
      unitRef="U_USD">139000</nmra:EarlyExerciseLiabilityCurrentPortion>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_a4a9cdad-94d2-4dc8-a803-76af21d49a24"
      unitRef="U_USD">3491000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_57613688-c6ec-40c9-982d-fe95bf8e19bf"
      unitRef="U_USD">3378000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_54160886-b6e6-41ff-81e9-a14cc90a68dd"
      unitRef="U_USD">24609000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_60257557-8c8c-49de-894e-7cf3f458eecf"
      unitRef="U_USD">25111000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_51d5ff34-66bf-487a-bd2e-fe5397fba999"
      unitRef="U_USD">938000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_4326f655-c3de-4ac6-8560-e757401ec2c8"
      unitRef="U_USD">1853000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <nmra:EarlyExerciseLiabilityNetOfCurrentPortion
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_c17d0dfa-5df0-4fd1-9e45-a4c2332f82d7"
      unitRef="U_USD">122000</nmra:EarlyExerciseLiabilityNetOfCurrentPortion>
    <nmra:EarlyExerciseLiabilityNetOfCurrentPortion
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_730bf2b2-53a2-4786-b670-c75fc06f9ef6"
      unitRef="U_USD">155000</nmra:EarlyExerciseLiabilityNetOfCurrentPortion>
    <us-gaap:Liabilities
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_d58fe715-0b77-4039-a68e-d57e2cdb8762"
      unitRef="U_USD">25669000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_c07f7c63-cd45-4f07-b4e4-761b4efcfdbb"
      unitRef="U_USD">27119000</us-gaap:Liabilities>
    <us-gaap:CommonStockValue
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_b4c21445-3d35-4f81-91e7-9bb991ea66fd"
      unitRef="U_USD">16000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_f93cfa06-6771-4a83-aa77-dca106de1dbf"
      unitRef="U_USD">16000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_9fa3acde-6409-4570-8eb2-89899ae68e15"
      unitRef="U_USD">1181829000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_9fc40c2f-fd4a-44c5-bd10-d83c1815d708"
      unitRef="U_USD">1172570000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_215ff3fb-b917-4870-a7c0-3101572e0d33"
      unitRef="U_USD">-148000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_9078dfb7-5d4e-4d1b-bfbe-ed7498159ff7"
      unitRef="U_USD">-76000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_201afc90-08f5-44ba-998e-5dc4166492e1"
      unitRef="U_USD">-757155000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_b7fbb144-66c7-4bf6-8fe2-0f6ddffc5cc2"
      unitRef="U_USD">-703434000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_33613ee1-1611-4ce5-af21-1d3c5a66660b"
      unitRef="U_USD">424542000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_1fb24385-865d-421c-b5a0-1e744952e079"
      unitRef="U_USD">469076000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_6e768d83-0037-42dc-8975-574a228e47c2"
      unitRef="U_USD">450211000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_df9e4bd8-4c64-4460-a230-ac59fac6427f"
      unitRef="U_USD">496195000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_b5718e36-781a-4c8c-9e8f-3d677f1e1455"
      unitRef="U_USD">45757000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_9723076b-5253-4507-95e0-90f60a5b3d48"
      unitRef="U_USD">29485000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_ff833b62-3660-4e57-bb0d-d052081c8f1f"
      unitRef="U_USD">14317000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_b0677a5d-9ca3-43f7-b120-65e8cfcca351"
      unitRef="U_USD">9683000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_635635d8-f506-4562-9297-786610464cff"
      unitRef="U_USD">60074000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_cd5f7517-1d99-4d05-b199-ab07ba709fe4"
      unitRef="U_USD">39168000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_e3498ecd-376f-473b-9803-c08c47418809"
      unitRef="U_USD">-60074000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_22e4e1ff-e2dd-449b-8efd-ed4e935d56e1"
      unitRef="U_USD">-39168000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_ed982cd7-665d-4e5b-b329-c7b7c8f718b5"
      unitRef="U_USD">6365000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_59d74893-e134-4eb0-b5be-83871da88e1b"
      unitRef="U_USD">3569000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_3fe22fa1-f093-434c-905b-145a085db7e6"
      unitRef="U_USD">-12000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_ebbee606-8898-445c-beb5-99d1613e1840"
      unitRef="U_USD">-26000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_a4273e62-14e9-41a9-8434-e04d54b7b7e9"
      unitRef="U_USD">6353000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_28adbd2d-6cb4-4363-8e22-817338fe1be6"
      unitRef="U_USD">3543000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_a69bd2fb-c9b3-4dfa-a5e8-dabfad7843cc"
      unitRef="U_USD">-53721000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_69ebf725-b96d-47a4-aff4-29a9bc58bb78"
      unitRef="U_USD">-35625000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_52c4e30e-e719-494d-bd99-596db94a87fa"
      unitRef="U_USD">-72000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_386eca35-bc91-4e43-830f-0a9d08bfae8f"
      unitRef="U_USD">476000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_b136ccfe-a002-414d-9a6d-25c247b15bf0"
      unitRef="U_USD">-53793000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_206efc8e-4ee0-4542-839c-30feb1641e68"
      unitRef="U_USD">-35149000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="2"
      id="F_f6c94882-f514-4b10-9dfc-5ce9ac5ce6c7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="2"
      id="F_bf12d685-4e92-4ed2-bbeb-3eeae03b61bd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="2"
      id="F_2a529aad-e4b1-40c0-b687-0ea8cc2e1d8d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="2"
      id="F_18d0d3fc-df7a-42ff-b21a-a7970aa5dc98"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_f93f05d8-28ca-4e79-becd-e730ec077440"
      unitRef="U_shares">157943000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_932e4831-62db-4176-8877-385265d66bbb"
      unitRef="U_shares">157943000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_e79b083f-2ed6-4b5e-8349-35699c2f54ab"
      unitRef="U_shares">29277000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_a7b5705b-2388-4c04-9332-086cb089198b"
      unitRef="U_shares">29277000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_a2a11bd1-3578-49a9-bc75-aaa978ce9086"
      decimals="-3"
      id="F_27b8bc53-c94b-464d-8c20-1d6a4d8c12c9"
      unitRef="U_shares">158832000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_a2a11bd1-3578-49a9-bc75-aaa978ce9086"
      decimals="-3"
      id="F_5a3db9dd-f427-449c-9a0e-a82da5212643"
      unitRef="U_USD">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_77008896-6cba-4a73-a7b9-c5a0409529ff"
      decimals="-3"
      id="F_48ba287d-5fce-44ea-829d-e11a9ee217d8"
      unitRef="U_USD">1172570000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3700265e-5b94-44f5-97b6-9328d7c4e21d"
      decimals="-3"
      id="F_699a198a-5ad7-4cb9-9e72-aff688214893"
      unitRef="U_USD">-76000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_62937b0d-82a4-455d-b20c-613131a128e9"
      decimals="-3"
      id="F_068d363b-374a-4e3b-bd4b-1201aff7781b"
      unitRef="U_USD">-703434000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_60351eec-4e89-463b-993f-ca251be2e5a6"
      unitRef="U_USD">469076000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_a2bb8dd3-a77e-4977-bb71-27730b31dc5a"
      decimals="-3"
      id="F_a726b40f-fe6e-4da2-b86d-34c60a7b162a"
      unitRef="U_shares">525000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_65092f10-0d2e-4c03-9fd8-87313bbab41c"
      decimals="-3"
      id="F_69178926-c7a3-4000-91dc-7539a347f2b6"
      unitRef="U_USD">1845000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_c5d2d50a-137a-4e8f-bae2-2556bab89763"
      unitRef="U_USD">1845000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="C_65092f10-0d2e-4c03-9fd8-87313bbab41c"
      decimals="-3"
      id="F_b43afab2-d8c7-40a5-98c5-191a46df79ea"
      unitRef="U_USD">41000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_2411488a-fd0c-46f4-80f0-fcfe622a1e26"
      unitRef="U_USD">41000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_222a51e8-068b-4c5a-9701-3a50110c9a80"
      decimals="-3"
      id="F_96f6a3b8-78dc-4d3f-aea2-186ecda84ede"
      unitRef="U_USD">-72000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_85b29862-eed8-462b-8a05-270896003c8b"
      unitRef="U_USD">-72000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_65092f10-0d2e-4c03-9fd8-87313bbab41c"
      decimals="-3"
      id="F_4b400f4f-c095-488b-a41b-b6a7dc11a38c"
      unitRef="U_USD">7373000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_40a543e7-2c0a-48ec-b87c-5e3eac8c5c56"
      unitRef="U_USD">7373000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="C_58d3b1a6-51e2-4cfa-8ee9-64532995d7ed"
      decimals="-3"
      id="F_88f8f1e3-3115-46fa-be03-4823656ed71a"
      unitRef="U_USD">-53721000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_28bd515f-5c14-4cbf-8930-7e9779fcdeda"
      unitRef="U_USD">-53721000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_04b84919-0f66-4a40-b2c6-b4440e68e095"
      decimals="-3"
      id="F_7a4320b0-d31a-40ab-8383-ea2c0f16fe0a"
      unitRef="U_shares">159357000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_04b84919-0f66-4a40-b2c6-b4440e68e095"
      decimals="-3"
      id="F_f7694db4-95d7-4309-b64d-1b6d8ac549ad"
      unitRef="U_USD">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_673045b2-3dfa-4a5c-a957-7ad525519202"
      decimals="-3"
      id="F_c8d1ca73-7fe1-4cbc-9037-182cff13e068"
      unitRef="U_USD">1181829000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_310a84d7-31f9-4782-844c-698837e7d4e0"
      decimals="-3"
      id="F_774e97d7-8ecd-43ba-acf0-ff3167eb7832"
      unitRef="U_USD">-148000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5e016890-9da0-47f3-9793-42aec2feff28"
      decimals="-3"
      id="F_ea536fe0-2ec3-4448-81cd-caab7878f97b"
      unitRef="U_USD">-757155000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_b5e7382e-a825-42ba-8001-4f03b02b9313"
      unitRef="U_USD">424542000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_636c0850-3f38-4c68-923e-8a9192036aec"
      decimals="-3"
      id="F_5204de70-fa80-4846-9f78-d26089ca0bf8"
      unitRef="U_shares">104417000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_636c0850-3f38-4c68-923e-8a9192036aec"
      decimals="-3"
      id="F_4c5e7698-80b6-407f-b3b7-a1bb20812dad"
      unitRef="U_USD">843687000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_eeb0b484-a788-4f77-8681-695af51358cb"
      decimals="-3"
      id="F_e6b81fb8-d4b3-41cb-b31c-c52760eac7a6"
      unitRef="U_shares">32612000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_eeb0b484-a788-4f77-8681-695af51358cb"
      decimals="-3"
      id="F_34cfc5b8-783d-4e64-9309-afc96aea4107"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_44ecaf5c-05ec-4fc1-a4b3-34fd3c08ceb5"
      decimals="-3"
      id="F_ca014da9-08ac-4398-b8c9-0200582664c5"
      unitRef="U_USD">21430000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_37094d88-e7f6-4b83-a8b8-9f256b675b10"
      decimals="-3"
      id="F_e8a3e825-6f23-4518-b494-b64449c00735"
      unitRef="U_USD">-774000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3a1a5b45-cd15-4c5f-8018-f47ae86a02cb"
      decimals="-3"
      id="F_40d5954e-e40e-4a20-8e8c-2fd042def043"
      unitRef="U_USD">-467509000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d4c8d898-2127-41b5-99f4-5fed585e8a39"
      decimals="-3"
      id="F_4262880a-e6ec-4482-827f-0367acf667bc"
      unitRef="U_USD">-446850000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_70fddc6b-c6f5-476e-99bd-8e5dcdebf0ae"
      decimals="-3"
      id="F_22ca5209-05b6-444d-bc45-20ea9efa9494"
      unitRef="U_shares">219000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_e356d7aa-aadb-4a43-9704-349d4130949f"
      decimals="-3"
      id="F_452c6966-f064-4fda-b1c0-450d454a488a"
      unitRef="U_USD">602000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_b1103069-3f09-438f-b854-817166b5c053"
      unitRef="U_USD">602000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <nmra:RepurchaseOfUnvestedEarlyExercisedStockOptions
      contextRef="C_70fddc6b-c6f5-476e-99bd-8e5dcdebf0ae"
      decimals="-3"
      id="F_a2bc2b15-e512-4b0e-b852-5bfd46d06326"
      unitRef="U_shares">123000</nmra:RepurchaseOfUnvestedEarlyExercisedStockOptions>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="C_e356d7aa-aadb-4a43-9704-349d4130949f"
      decimals="-3"
      id="F_3007542e-51f5-42a3-b5c7-818920e7407c"
      unitRef="U_USD">1282000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_8a159514-9997-4c2c-8fbc-1b5262ce36ae"
      unitRef="U_USD">1282000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_99673cd6-c93c-488e-a35a-1c624f6dcd54"
      decimals="-3"
      id="F_23ad09ba-3818-4e41-a660-1dc96a160111"
      unitRef="U_USD">476000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_df8c8cb7-3f86-4dcd-91c8-fae87dd53494"
      unitRef="U_USD">476000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_e356d7aa-aadb-4a43-9704-349d4130949f"
      decimals="-3"
      id="F_322db808-9e7a-463f-b1aa-b3038faad6c7"
      unitRef="U_USD">2195000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_f30831fd-0cf6-49a2-8976-b396fe8fa2ce"
      unitRef="U_USD">2195000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="C_70e6e56b-1627-4b50-b58c-c7079cb8e79e"
      decimals="-3"
      id="F_69834a17-b928-43de-a527-6b86f2f19fdb"
      unitRef="U_USD">-35625000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_30662a22-28bf-4992-93d6-c4a15ba32e66"
      unitRef="U_USD">-35625000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_60ca0d63-6992-4ed9-96cd-ba37575ee0f4"
      decimals="-3"
      id="F_1defb9b4-6a5f-434e-8dc8-6dfd2c49ca7d"
      unitRef="U_shares">104417000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_60ca0d63-6992-4ed9-96cd-ba37575ee0f4"
      decimals="-3"
      id="F_3379ebb4-5b0c-42ac-b13b-40992e491f88"
      unitRef="U_USD">843687000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_8d2f7696-8e65-434a-b57a-0fff8a7da606"
      decimals="-3"
      id="F_63606504-4f75-4235-ad0f-7acaefc42f92"
      unitRef="U_shares">32708000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_8d2f7696-8e65-434a-b57a-0fff8a7da606"
      decimals="-3"
      id="F_39fd5025-b4de-401f-9947-2751957368e5"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a41d013c-1391-41b3-90a7-49ba49d11331"
      decimals="-3"
      id="F_39ca3604-d455-4377-b9b9-271c28a78eee"
      unitRef="U_USD">25509000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_997939ff-f371-43ae-8539-1f8d55163ef5"
      decimals="-3"
      id="F_be7c52ff-c774-4465-8e48-9b3907bae0ad"
      unitRef="U_USD">-298000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_118d5793-6b58-4c11-bd9e-24a1b0197692"
      decimals="-3"
      id="F_e3598823-e74b-4a8c-948b-96a382ffd438"
      unitRef="U_USD">-503134000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_908e2fe1-8e96-4b2a-b94e-f5e7dea5b0a3"
      decimals="-3"
      id="F_b83aab39-8629-44b2-9862-1d9d6fef003a"
      unitRef="U_USD">-477920000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_9b8d8157-6b17-4ef8-885b-bd1cb8461a5b"
      unitRef="U_USD">-53721000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_3d78900e-827c-47d3-9ce5-48bdc53191d6"
      unitRef="U_USD">-35625000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_8536f477-7369-4d14-940e-3fa561c35898"
      unitRef="U_USD">7373000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_4ecd94f6-42c6-4ca3-900e-714eae4691b1"
      unitRef="U_USD">2195000</us-gaap:ShareBasedCompensation>
    <nmra:NoncashOperatingLeaseExpense
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_d0753ed0-8af9-4734-ae1b-b6bfb4dd92ea"
      unitRef="U_USD">791000</nmra:NoncashOperatingLeaseExpense>
    <nmra:NoncashOperatingLeaseExpense
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_9d1d9be9-6880-4bc6-80b6-7ab8a0963847"
      unitRef="U_USD">799000</nmra:NoncashOperatingLeaseExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_9dc34b5a-2b45-4780-98c5-9c28f614f7ec"
      unitRef="U_USD">158000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_c1fff50e-40ca-4d20-9e4b-f99e38231c69"
      unitRef="U_USD">158000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InvestmentIncomeAmortizationOfDiscount
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_9f2b6eb4-009a-4e35-be44-ce7ca051c8eb"
      unitRef="U_USD">1147000</us-gaap:InvestmentIncomeAmortizationOfDiscount>
    <us-gaap:InvestmentIncomeAmortizationOfDiscount
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_468f6e5d-c0a1-49c0-bb1c-572a7d0a166a"
      unitRef="U_USD">892000</us-gaap:InvestmentIncomeAmortizationOfDiscount>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_d4a0e7e3-9d9d-4f7e-aed9-b4c81c3241de"
      unitRef="U_USD">-15000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_56005fe1-a850-44f2-b3e3-d4f9fa6a090c"
      unitRef="U_USD">-7351000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_9ce7d7bc-a881-465e-b3cd-68413e4e12d6"
      unitRef="U_USD">-7858000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_e4f6f22f-ced8-4329-8653-39158cff2fc5"
      unitRef="U_USD">1155000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_5999b2b5-e8b0-488f-a97a-e34ee2b87a28"
      unitRef="U_USD">-6012000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_45409f82-bc36-461f-8100-4e556a1b4a21"
      unitRef="U_USD">-4113000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_40f4d58f-246f-4e89-8214-bb3b55935de6"
      unitRef="U_USD">-736000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_6ca3fcd8-a6de-4ff3-8ee6-11999838f0bd"
      unitRef="U_USD">-802000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_a5ed4e2f-771b-48c9-9e52-3b4ab7b70ac0"
      unitRef="U_USD">-801000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_ed4b1ed6-aa3e-4bf7-99da-fc3b9ead0951"
      unitRef="U_USD">-42955000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_5ca73c43-e6dd-4748-bd06-6e14836cc526"
      unitRef="U_USD">-33041000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_ab641b2a-a779-477a-b6ac-5414a978adb2"
      unitRef="U_USD">185804000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_22df7074-ce37-44e3-9648-8ac80c4b19e1"
      unitRef="U_USD">41483000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_646fd5af-7404-4661-a56c-fdaaf342a5f5"
      unitRef="U_USD">36578000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_62bfe705-3b47-4a4b-bb03-8f22d404fff0"
      unitRef="U_USD">44336000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_4c25c101-3a5a-4ddd-842a-7907fea3b464"
      unitRef="U_USD">36000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_485a51d1-cd9a-4d60-830e-1b82f54a2eab"
      unitRef="U_USD">775000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_556cf880-71e9-408f-af3e-cee394adf0ed"
      unitRef="U_USD">-150001000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_b0d657aa-d519-4a7b-a4bf-5b962d933ec1"
      unitRef="U_USD">2817000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_9c5b9193-94da-4287-a318-279de8858497"
      unitRef="U_USD">1845000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_28c857e5-dce6-496c-b798-048121124d45"
      unitRef="U_USD">602000</us-gaap:ProceedsFromStockOptionsExercised>
    <nmra:RepurchaseOfUnvestedEarlyExercisedShares
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_a4f97ea5-791d-40ab-a8dd-f06be0d88367"
      unitRef="U_USD">491000</nmra:RepurchaseOfUnvestedEarlyExercisedShares>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_b46de920-9cc2-4067-871b-c809ae0ae5cc"
      unitRef="U_USD">10000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_75dad495-10b2-4d9c-9f05-d30f037ecac9"
      unitRef="U_USD">1845000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_2001704f-e2ef-4d53-8541-ac64cfaed6ac"
      unitRef="U_USD">101000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_ae5bd915-4c0c-43eb-9608-61dd4f91d2a0"
      unitRef="U_USD">-191111000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_72379e6d-0966-47eb-b384-13a9f13181bd"
      unitRef="U_USD">-30123000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_a1c48687-4127-4862-a133-2bc7327f6e0d"
      unitRef="U_USD">375251000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_d4c8d898-2127-41b5-99f4-5fed585e8a39"
      decimals="-3"
      id="F_4e12f8d4-c2ce-4626-9caf-7e5bffb49d27"
      unitRef="U_USD">242206000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_bf0346e2-0ad3-4d92-a48d-af35fad43454"
      unitRef="U_USD">184140000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_908e2fe1-8e96-4b2a-b94e-f5e7dea5b0a3"
      decimals="-3"
      id="F_d028eea1-6cc6-4a80-b60c-2f48feb31301"
      unitRef="U_USD">212083000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_250f4f09-73a9-41c1-944c-93585a42a686"
      unitRef="U_USD">182927000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_908e2fe1-8e96-4b2a-b94e-f5e7dea5b0a3"
      decimals="-3"
      id="F_321fdae6-25ec-44de-8ff4-e0575f5a865f"
      unitRef="U_USD">210870000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_66bcafa4-ead2-415c-943e-1a3dbd63559d"
      unitRef="U_USD">1213000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_908e2fe1-8e96-4b2a-b94e-f5e7dea5b0a3"
      decimals="-3"
      id="F_e484e1ce-9c17-4c57-bec6-f933b6856972"
      unitRef="U_USD">1213000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_e0c579ee-73e8-4241-a0f5-038b83abe583"
      unitRef="U_USD">184140000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_908e2fe1-8e96-4b2a-b94e-f5e7dea5b0a3"
      decimals="-3"
      id="F_84cd1e55-c16d-46cc-9f1e-2e5394d14d86"
      unitRef="U_USD">212083000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_4033c9c8-70eb-479e-a153-7983ee423960">&lt;p id="organization_and_liquidity" style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.	&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Organization and Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Neumora Therapeutics, Inc. (the Company), was originally incorporated in the State of Delaware in November 2019, and is headquartered in Watertown, Massachusetts.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. The Company&#x2019;s therapeutic pipeline currently consists of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;seven&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of March 31, 2024, the Company has devoted a significant portion of its financial resources and efforts to building its organization, acquiring technologies and companies, executing clinical and preclinical studies, conducting research and development, identifying and developing potential product candidates, building its precision neuroscience tools, organizing and staffing the Company, business planning, establishing, maintaining and protecting its intellectual property portfolio, raising capital and providing general and administrative support for these operations. The Company has not generated revenue from the sale of products.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s most advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of major depressive disorder (MDD) and other neuropsychiatric diseases. In 2023, the Company initiated a Phase 3 program called the KOASTAL program evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company anticipates releasing topline results from the KOASTAL-1 study in the fourth quarter of 2024 and topline results from the KOASTAL-2 and KOASTAL-3 studies in the first half of 2025. We also expect to initiate a Phase 2 study for navacaprant in bipolar depression in the second quarter of 2024 and anticipate releasing results from that study in 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On September 8, 2023, the Company&#x2019;s board of directors approved an amended and restated certificate of incorporation to effect a reverse split of shares of the Company&#x2019;s common stock and convertible preferred stock on a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_fc1674b5-31ae-4580-a05a-09485f8e145a;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;7.8463&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;-for-1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; basis (the &#x201c;Reverse Stock Split&#x201d;). The par value and authorized shares of the common stock and convertible preferred stock were not adjusted as a result of the Reverse Stock Split. All share data and per share data amounts for all periods presented in the condensed consolidated financial statements and notes thereto have been retrospectively adjusted to reflect the effect of the Reverse Stock Split.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Initial Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On September 19, 2023, the Company completed its initial public offering (IPO), pursuant to which it issued and sold an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,710,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its common stock at a price to the public of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, resulting in net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;226.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, after deducting underwriting discounts and commissions of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and other offering expenses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. Upon the closing of the IPO, the Company&#x2019;s outstanding convertible preferred stock automatically converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;104,417,415&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock (see Note 9).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the completion of its IPO, on September 19, 2023, the Company&#x2019;s certificate of incorporation was amended and restated to authorize &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;700,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock, par value $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of preferred stock, par value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Liquidity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has incurred net losses and negative cash flows from operations since inception and as of March 31, 2024, had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;757.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. As of March 31, 2024, the Company had cash, cash equivalents and marketable securities of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;423.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which are available to fund future operations. The Company believes that its existing cash, cash equivalents and marketable securities as of March 31, 2024 will be sufficient to support operations for at least the next 12 months from the date these condensed consolidated financial statements are issued.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company expects to incur additional losses in the future as it continues its research and development efforts, advances its product candidates through preclinical and clinical development, enhances its precision&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;neuroscience approach and programs, expands its product pipeline, seeks regulatory approval, prepares for commercialization, as well as hires additional personnel, protects its intellectual property and grows its business. The Company will need to raise additional capital to support its continuing operations and pursue its long-term business plan, including to complete the development and commercialization of its product candidates, if approved. Such activities are subject to significant risks and uncertainties, including clinical failure which can impact the Company&#x2019;s ability to secure additional funding. The Company expects to finance its cash needs through a combination of public or private equity offerings or debt financings or other capital sources, which may include strategic collaborations or other arrangements with third parties, or other sources of financing. However, there is no guarantee that any of these financing or opportunities will be executed or realized on favorable terms, if at all, and some could be dilutive to existing stockholders.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <nmra:NumberOfClinicalAndPreclinicalNeurosciencePrograms
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="INF"
      id="F_24f09f01-5e4e-48fe-82d3-62aad67495e9"
      unitRef="U_Program">7</nmra:NumberOfClinicalAndPreclinicalNeurosciencePrograms>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_94197fa7-7c97-46ab-9f96-0203fbe500ca">7.8463-for-1</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_829340ea-2a8e-4dd9-8fc4-4651e162611a"
      decimals="INF"
      id="F_8bcb8e0e-50ec-48ef-832f-5f1a8209bb18"
      unitRef="U_shares">14710000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_77d7002e-e37b-46f4-8b74-d60274250475"
      decimals="INF"
      id="F_520f903e-8d20-4931-8069-16935da129bb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_829340ea-2a8e-4dd9-8fc4-4651e162611a"
      decimals="-5"
      id="F_5b81032f-4b3e-479c-bd90-75f2844f8044"
      unitRef="U_USD">226500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <nmra:UnderwritingDiscountsAndCommissions
      contextRef="C_829340ea-2a8e-4dd9-8fc4-4651e162611a"
      decimals="-5"
      id="F_65063df7-2c2e-40c9-bf7d-a0c0d7d795d9"
      unitRef="U_USD">17500000</nmra:UnderwritingDiscountsAndCommissions>
    <nmra:OfferingExpenses
      contextRef="C_829340ea-2a8e-4dd9-8fc4-4651e162611a"
      decimals="-5"
      id="F_25dfbf81-cecc-4b3d-98d4-ce121a3b9776"
      unitRef="U_USD">6000000</nmra:OfferingExpenses>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_77d7002e-e37b-46f4-8b74-d60274250475"
      decimals="INF"
      id="F_2848b012-9a46-4f14-98bb-41f2bba7db9d"
      unitRef="U_shares">104417415</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_77d7002e-e37b-46f4-8b74-d60274250475"
      decimals="INF"
      id="F_4bcfa4d2-ebd5-408f-8d99-827afc081d23"
      unitRef="U_shares">700000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_77d7002e-e37b-46f4-8b74-d60274250475"
      decimals="INF"
      id="F_87fb104e-679e-4c67-834b-414e31ab5f19"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_77d7002e-e37b-46f4-8b74-d60274250475"
      decimals="INF"
      id="F_1524b4bb-bc5e-48cd-8ffc-32042ae15bd7"
      unitRef="U_shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_77d7002e-e37b-46f4-8b74-d60274250475"
      decimals="INF"
      id="F_a14428c3-fbfe-410a-b15d-ec9101dc7e22"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_d4ca77dd-2b7a-4c72-9d67-3f3c267a7400"
      decimals="-5"
      id="F_b2fefc21-bea7-4829-8ecb-d04895d9fc8e"
      unitRef="U_USD">757200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_d4ca77dd-2b7a-4c72-9d67-3f3c267a7400"
      decimals="-5"
      id="F_24e1e012-2170-4a25-ab77-eda8f495f4c6"
      unitRef="U_USD">423000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_09d151a9-5506-483a-85ce-843e7ab043f4">&lt;p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.	Summary of Significant Accounting Policies and Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting. The condensed consolidated financial statements include all accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Unaudited Interim Condensed Consolidated Financial Statements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The condensed consolidated balance sheet as of March 31, 2024, condensed consolidated statements of operations and comprehensive loss, statement of stockholders&#x2019; equity (deficit), and the condensed consolidated statements of cash flows&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for the three months ended March 31, 2024 and 2023, and related notes to condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company&#x2019;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for the fair statement of the Company&#x2019;s consolidated financial position, results of operations and cash flows for the periods presented. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2023 included herein was derived from the audited consolidated financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements as of and for the year ended December 31, 2023 included in the Company&#x2019;s Annual Form 10-K.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. These estimates form the basis for judgments the Company makes about the carrying values of assets and liabilities that are not readily apparent from other sources. The Company bases its estimates and judgments on historical experience and on various other assumptions that the Company believes are reasonable under the circumstances. These estimates are based on management&#x2019;s knowledge about current events and expectations about actions the Company may undertake in the future. These judgments, estimates and assumptions are used for, but not limited to, accrued research and development expenses, accounting for acquisitions of assets, fair value of certain assets and liabilities, &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the fair value of the Company&#x2019;s convertible preferred stock, the fair value of the Company&#x2019;s common stock,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; stock-based compensation, the measurement of right-of-use assets and lease liabilities and related incremental borrowing rate, and uncertain tax positions and the valuation allowance for net deferred tax assets. Actual results may differ from the Company&#x2019;s estimates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is subject to certain risks and uncertainties, including, but not limited to, changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: successfully develop, manufacture, and market any approved products; obtain regulatory approval from the U.S. Food and Drug Administration or foreign regulatory agencies prior to commercial sales; new technological innovations; dependence on key personnel, protection of intellectual property; compliance with governmental regulations; uncertainty of market acceptance of any approved products; product liability; and the need to obtain additional financing.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company invests its excess cash in marketable debt securities with high credit ratings including but not limited to money market funds, securities issued by the U.S. government and its agencies, commercial paper, certificates of deposit, and corporate debt securities that are accounted for as available-for-sale and carried at fair value. Marketable securities are classified as short-term or long-term based on the maturity date and their availability to meet current operating requirements. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income in the condensed consolidated statements of operations and comprehensive loss. Realized gains and losses on marketable securities, if any, are included in other income (expense), net. The cost of securities sold is determined based on the trade date using the specific identification method.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company periodically assesses its available-for-sale debt securities for impairment. For debt securities in an unrealized loss position, this assessment first considers the Company&#x2019;s intent to sell, or whether it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of these criteria are met, the debt security&#x2019;s amortized cost basis is written down to fair value within other income (expense), net. For debt securities in an unrealized loss position that do not meet the aforementioned criteria, the Company assesses whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and any adverse conditions specifically related to the security is considered, among other factors. If this assessment indicates that a credit loss may exist, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses will be recorded in other income (expense), net, limited by the amount that the fair value is less than the amortized cost basis. Any additional impairment not recorded through an allowance for credit losses is recognized in other comprehensive income (loss). Changes in the allowance for credit losses are recorded as provision for (or reversal of) credit loss expense. Losses are charged against the allowance when management believes the un-collectability of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met. These changes are recorded in other income (expense), net.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The Company measures fair value by maximizing the use of observable inputs, where available, and minimizing the use of unobservable inputs when measuring fair value. Financial assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized in the fair value hierarchy based upon the lowest level of input that is significant to the fair value as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:36pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1&#x2014;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:36pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2&#x2014;Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:36pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value of the instrument.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:11pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and Development Expenses and Related Prepaid Assets and Accrued Liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Research and development expenses primarily consist of internal research and development expense, including personnel-related expenses (such as salaries, benefits and noncash stock-based compensation) and other expenses, including laboratory supplies and other non-capital equipment utilized for in-house research, research and consulting expenses, software development costs, license fees and allocated expenses, including facilities costs and depreciation and amortization; external research and development expenses incurred under arrangements with vendors conducting research and development services on its behalf, such as contract research organizations (CROs), preclinical testing organizations and contract manufacturing organizations (CMOs). Costs to develop the Company&#x2019;s platform information technologies are recorded as research and development expense unless the criteria to be capitalized as internal-use software costs is met. Payments made prior to the receipt of goods or services to be used in&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;research and development are capitalized, evaluated for current or long-term classification, and included in prepaid expenses and other current assets or other assets in the condensed consolidated balance sheets based on when the goods are received or the services are expected to be received or consumed, and recognized in research and development expenses when they are realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is required to estimate expenses resulting from its obligations under contracts with vendors, service providers and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in cash flows that do not match the periods over which materials or services are provided. The Company estimates and records accrued expenses for the related research and development activities based on the level of services performed but not yet invoiced pursuant to agreements established with its service providers, according to the progress of preclinical studies, clinical trials or related activities, and discussions with applicable personnel and service providers as to the progress or state of consummation of goods and services.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the course of a clinical trial, the rate of expense recognition is adjusted if actual results differ from the Company&#x2019;s estimates. The Company estimates accrued expenses as of each balance sheet date in its condensed consolidated financial statements based on the facts and circumstances known at that time. The clinical trial accrual is dependent in part upon the timely and accurate reporting of CROs, CMOs and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its estimate may vary from the actual results. To date, the Company has not experienced material differences between its accrued expenses and actual expenses.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Comprehensive loss includes net loss and certain changes in stockholders&#x2019; equity (deficit) that are excluded from net loss, such as unrealized losses on the Company&#x2019;s available-for-sale marketable securities.&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(ASU 2023-09), which requires issuers to make additional discloses on an annual basis related to specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis, disclose additional information about income taxes paid as well as other disaggregated disclosures. ASU 2023-09 will be effective for the Company as of January 1, 2025 for annual periods. The Company is evaluating the impact of this ASU on its condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (ASU 2023-07), which requires issuers to make additional disclosures with respect to segment expenses, including required disclosure on an annual and interim basis for significant segment expenses and other segment items. ASU 2023-07 also permits the disclosure of more than one measure of a segment&#x2019;s profit or loss. ASU 2023-07 will be effective for the Company as of January 1, 2024 for annual periods and as of January 1, 2025 for interim periods. The Company is evaluating the impact of this ASU on its condensed consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_26967402-1873-42ae-86cf-ed4d89647c9f">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting. The condensed consolidated financial statements include all accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <nmra:UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_54ebbfef-98bb-4f93-8d77-79361f7fd5b0">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Unaudited Interim Condensed Consolidated Financial Statements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The condensed consolidated balance sheet as of March 31, 2024, condensed consolidated statements of operations and comprehensive loss, statement of stockholders&#x2019; equity (deficit), and the condensed consolidated statements of cash flows&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for the three months ended March 31, 2024 and 2023, and related notes to condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company&#x2019;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for the fair statement of the Company&#x2019;s consolidated financial position, results of operations and cash flows for the periods presented. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2023 included herein was derived from the audited consolidated financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements as of and for the year ended December 31, 2023 included in the Company&#x2019;s Annual Form 10-K.&lt;/span&gt;&lt;/p&gt;</nmra:UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_62247006-92af-4a5f-a2b6-a8b034f2baee">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. These estimates form the basis for judgments the Company makes about the carrying values of assets and liabilities that are not readily apparent from other sources. The Company bases its estimates and judgments on historical experience and on various other assumptions that the Company believes are reasonable under the circumstances. These estimates are based on management&#x2019;s knowledge about current events and expectations about actions the Company may undertake in the future. These judgments, estimates and assumptions are used for, but not limited to, accrued research and development expenses, accounting for acquisitions of assets, fair value of certain assets and liabilities, &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the fair value of the Company&#x2019;s convertible preferred stock, the fair value of the Company&#x2019;s common stock,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; stock-based compensation, the measurement of right-of-use assets and lease liabilities and related incremental borrowing rate, and uncertain tax positions and the valuation allowance for net deferred tax assets. Actual results may differ from the Company&#x2019;s estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <nmra:RisksAndUncertaintiesPolicyTextBlock
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_d40c0aa8-9c99-4c50-b8f2-409c15d78327">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is subject to certain risks and uncertainties, including, but not limited to, changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: successfully develop, manufacture, and market any approved products; obtain regulatory approval from the U.S. Food and Drug Administration or foreign regulatory agencies prior to commercial sales; new technological innovations; dependence on key personnel, protection of intellectual property; compliance with governmental regulations; uncertainty of market acceptance of any approved products; product liability; and the need to obtain additional financing.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</nmra:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_b2927095-d22b-4958-b4eb-1ea5673a41e2">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company invests its excess cash in marketable debt securities with high credit ratings including but not limited to money market funds, securities issued by the U.S. government and its agencies, commercial paper, certificates of deposit, and corporate debt securities that are accounted for as available-for-sale and carried at fair value. Marketable securities are classified as short-term or long-term based on the maturity date and their availability to meet current operating requirements. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income in the condensed consolidated statements of operations and comprehensive loss. Realized gains and losses on marketable securities, if any, are included in other income (expense), net. The cost of securities sold is determined based on the trade date using the specific identification method.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company periodically assesses its available-for-sale debt securities for impairment. For debt securities in an unrealized loss position, this assessment first considers the Company&#x2019;s intent to sell, or whether it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of these criteria are met, the debt security&#x2019;s amortized cost basis is written down to fair value within other income (expense), net. For debt securities in an unrealized loss position that do not meet the aforementioned criteria, the Company assesses whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and any adverse conditions specifically related to the security is considered, among other factors. If this assessment indicates that a credit loss may exist, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses will be recorded in other income (expense), net, limited by the amount that the fair value is less than the amortized cost basis. Any additional impairment not recorded through an allowance for credit losses is recognized in other comprehensive income (loss). Changes in the allowance for credit losses are recorded as provision for (or reversal of) credit loss expense. Losses are charged against the allowance when management believes the un-collectability of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met. These changes are recorded in other income (expense), net.&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_37bfea6e-e431-4637-a16c-462722440f96">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The Company measures fair value by maximizing the use of observable inputs, where available, and minimizing the use of unobservable inputs when measuring fair value. Financial assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized in the fair value hierarchy based upon the lowest level of input that is significant to the fair value as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:36pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1&#x2014;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:36pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2&#x2014;Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:36pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value of the instrument.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_18da1644-1bb9-4ad4-8afc-d529e64dfab2">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and Development Expenses and Related Prepaid Assets and Accrued Liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Research and development expenses primarily consist of internal research and development expense, including personnel-related expenses (such as salaries, benefits and noncash stock-based compensation) and other expenses, including laboratory supplies and other non-capital equipment utilized for in-house research, research and consulting expenses, software development costs, license fees and allocated expenses, including facilities costs and depreciation and amortization; external research and development expenses incurred under arrangements with vendors conducting research and development services on its behalf, such as contract research organizations (CROs), preclinical testing organizations and contract manufacturing organizations (CMOs). Costs to develop the Company&#x2019;s platform information technologies are recorded as research and development expense unless the criteria to be capitalized as internal-use software costs is met. Payments made prior to the receipt of goods or services to be used in&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;research and development are capitalized, evaluated for current or long-term classification, and included in prepaid expenses and other current assets or other assets in the condensed consolidated balance sheets based on when the goods are received or the services are expected to be received or consumed, and recognized in research and development expenses when they are realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is required to estimate expenses resulting from its obligations under contracts with vendors, service providers and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in cash flows that do not match the periods over which materials or services are provided. The Company estimates and records accrued expenses for the related research and development activities based on the level of services performed but not yet invoiced pursuant to agreements established with its service providers, according to the progress of preclinical studies, clinical trials or related activities, and discussions with applicable personnel and service providers as to the progress or state of consummation of goods and services.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the course of a clinical trial, the rate of expense recognition is adjusted if actual results differ from the Company&#x2019;s estimates. The Company estimates accrued expenses as of each balance sheet date in its condensed consolidated financial statements based on the facts and circumstances known at that time. The clinical trial accrual is dependent in part upon the timely and accurate reporting of CROs, CMOs and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its estimate may vary from the actual results. To date, the Company has not experienced material differences between its accrued expenses and actual expenses.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_30b33607-7187-4d3f-8f7c-9cdc7260f148">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Comprehensive loss includes net loss and certain changes in stockholders&#x2019; equity (deficit) that are excluded from net loss, such as unrealized losses on the Company&#x2019;s available-for-sale marketable securities.&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <nmra:EmergingGrowthCompanyStatusPolicyTextBlock
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_9f7a4454-b60d-4999-b5e8-99f85781e62f">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/span&gt;&lt;/p&gt;</nmra:EmergingGrowthCompanyStatusPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_141c308f-03bc-40fa-9d35-d47e00dca518">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(ASU 2023-09), which requires issuers to make additional discloses on an annual basis related to specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis, disclose additional information about income taxes paid as well as other disaggregated disclosures. ASU 2023-09 will be effective for the Company as of January 1, 2025 for annual periods. The Company is evaluating the impact of this ASU on its condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (ASU 2023-07), which requires issuers to make additional disclosures with respect to segment expenses, including required disclosure on an annual and interim basis for significant segment expenses and other segment items. ASU 2023-07 also permits the disclosure of more than one measure of a segment&#x2019;s profit or loss. ASU 2023-07 will be effective for the Company as of January 1, 2024 for annual periods and as of January 1, 2025 for interim periods. The Company is evaluating the impact of this ASU on its condensed consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_67aad6d9-c710-4860-9093-b8abafb426b9">&lt;p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3.	Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables summarize the amortized cost and fair value of the Company&#x2019;s cash equivalents and marketable securities by major investment category for the periods indicated:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;142,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;142,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;142,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;142,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government and agency debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;122,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;122,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;240,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;240,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;383,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;382,907&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;306,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;306,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,455&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government and agency debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;362,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;362,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47,547&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government and agency debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,816&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89,789&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;452,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;452,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s marketable securities by contractual maturity were (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:76.28%;"&gt;&lt;/td&gt;
         &lt;td style="width:2%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:19.72%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Within one year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;239,788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;After one year through two years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;240,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of March 31, 2024, the Company has not realized any material gains or losses on its marketable securities, including any impairment charges on its securities related to expected credit losses. As of March 31, 2024, the aggregate difference between the amortized cost and fair value of each security in an unrealized loss position was de minimis. Since any provision for expected credit losses for a security held is limited to the amount the fair value is less than its amortized cost, no allowance for expected credit loss was deemed necessary at March 31, 2024 (see Note 4).&lt;/span&gt;&lt;/p&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_a3da43b8-a942-4174-8b3c-2c570b2e3270">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables summarize the amortized cost and fair value of the Company&#x2019;s cash equivalents and marketable securities by major investment category for the periods indicated:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;142,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;142,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;142,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;142,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government and agency debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;122,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;122,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;240,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;240,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;383,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;382,907&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;306,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;306,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,455&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government and agency debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;362,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;362,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47,547&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government and agency debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,816&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89,789&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;452,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;452,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_1c718a38-50b6-430d-81b1-4a6d12e7d922"
      decimals="-3"
      id="F_78d3fa5f-248e-4b2b-8afe-3637a31fba85"
      unitRef="U_USD">142817000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_c58e805b-70de-4471-9304-e335b5edcd5f"
      decimals="-3"
      id="F_e3a4d071-d1c6-4a01-9745-9f6179002774"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_c58e805b-70de-4471-9304-e335b5edcd5f"
      decimals="-3"
      id="F_0a77a754-d1b6-41a3-8e93-33077c784a5f"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_1c718a38-50b6-430d-81b1-4a6d12e7d922"
      decimals="-3"
      id="F_6ae9deea-2d2c-44f0-8ce3-668dfa150054"
      unitRef="U_USD">142817000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_59764801-e98b-441b-813d-c795a4f77342"
      decimals="-3"
      id="F_b6b199f0-9479-4ef3-bd42-eb7318f43206"
      unitRef="U_USD">142817000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_b7650c04-d7d2-470d-8cdd-f4a7c34c3ee7"
      decimals="-3"
      id="F_a617533b-7ab0-4f96-8c63-59ed72f8ad2b"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_b7650c04-d7d2-470d-8cdd-f4a7c34c3ee7"
      decimals="-3"
      id="F_7a23cedf-04bf-4811-9852-9ecca9f1c3d5"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_59764801-e98b-441b-813d-c795a4f77342"
      decimals="-3"
      id="F_614d7a5d-729e-48f4-9739-51c4b20fd903"
      unitRef="U_USD">142817000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9622b93d-0fee-4c35-979b-ac055cc9685e"
      decimals="-3"
      id="F_749ab38d-7f82-4bb1-a43f-665d75d13d11"
      unitRef="U_USD">69612000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_f302022e-1a9e-474c-a0c7-dc6743de3517"
      decimals="-3"
      id="F_55824032-4593-4f7a-b929-7de2ebc8ae31"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_f302022e-1a9e-474c-a0c7-dc6743de3517"
      decimals="-3"
      id="F_d60e3630-9ce7-40b5-8a6d-b3ff632ebd14"
      unitRef="U_USD">36000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9622b93d-0fee-4c35-979b-ac055cc9685e"
      decimals="-3"
      id="F_16fc30a1-c252-4ea0-888a-7c960daec083"
      unitRef="U_USD">69577000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_6605667a-124d-429a-9742-9590d104c8b0"
      decimals="-3"
      id="F_23b3cdb9-634d-4ca2-8960-fd697a4438c5"
      unitRef="U_USD">11669000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_3d8423cb-a654-4705-bc38-351fdb1ead9c"
      decimals="-3"
      id="F_0779944b-474c-438d-ab5b-f89f60655c92"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_3d8423cb-a654-4705-bc38-351fdb1ead9c"
      decimals="-3"
      id="F_64ccafdf-922c-4449-83ff-2537a833e735"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_8d605d37-23c6-4f30-8d3a-a3a25b1de12d"
      decimals="-3"
      id="F_936866e0-9ae5-4d2d-b221-2e64e1479240"
      unitRef="U_USD">11671000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_c27ac2f8-7a27-4804-87d3-3bbc8e87144e"
      decimals="-3"
      id="F_fbb6b17b-d7ea-4b55-8f74-c45325d0713a"
      unitRef="U_USD">122660000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_6715b955-aac8-4773-8111-47fd843a4a8d"
      decimals="-3"
      id="F_bc34eecf-2cd6-4a74-80c5-b473eb29577c"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_6715b955-aac8-4773-8111-47fd843a4a8d"
      decimals="-3"
      id="F_03160122-cb85-46d0-bc6c-78b66d1709bb"
      unitRef="U_USD">108000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3c40c0b1-14e6-4ada-8bd6-1d23c649c6ce"
      decimals="-3"
      id="F_2267f6cf-fd8e-414e-84d0-f4c55dcf1962"
      unitRef="U_USD">122552000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_934561fc-3ca0-4e9c-afc9-cab561a511ca"
      decimals="-3"
      id="F_e974460a-65de-4bb9-84f0-2515adc1771f"
      unitRef="U_USD">36297000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_adde3b8d-d812-4a53-b229-03202c183eb7"
      decimals="-3"
      id="F_43fa5ce7-6ffd-4024-a583-c3ab67104162"
      unitRef="U_USD">5000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_adde3b8d-d812-4a53-b229-03202c183eb7"
      decimals="-3"
      id="F_b0168580-24f1-4825-8ad6-a9e6d8c67a3f"
      unitRef="U_USD">12000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_934561fc-3ca0-4e9c-afc9-cab561a511ca"
      decimals="-3"
      id="F_6111472d-ba13-45a4-b298-f36a4589851e"
      unitRef="U_USD">36290000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_c407007a-f71b-4362-a5e7-9ede4f3ae224"
      decimals="-3"
      id="F_24cfe10d-77f4-4bdb-9e30-390005bc30a1"
      unitRef="U_USD">240238000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_3d2b19e7-2597-4087-9ada-8de5a4121c58"
      decimals="-3"
      id="F_4d4a5531-a0fc-4a09-9e8e-5d4328505c17"
      unitRef="U_USD">9000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_3d2b19e7-2597-4087-9ada-8de5a4121c58"
      decimals="-3"
      id="F_0e4bb367-289c-40d7-aa57-b0df883de556"
      unitRef="U_USD">157000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c407007a-f71b-4362-a5e7-9ede4f3ae224"
      decimals="-3"
      id="F_0b69614b-50a9-4f5e-91fb-9c6f2907536b"
      unitRef="U_USD">240090000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_4eb21b69-e87b-425d-b912-4f3ef99cc3a8"
      unitRef="U_USD">383055000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_d7d4290c-3cb5-4da4-a577-77899ca23427"
      unitRef="U_USD">9000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_579d45c5-ec46-4758-8fd9-9456ddcc14ad"
      unitRef="U_USD">157000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_519508d5-8025-4a69-93cd-3c8f72563bfb"
      unitRef="U_USD">382907000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9a190bc1-8994-483b-9102-8e2f78b28bc1"
      decimals="-3"
      id="F_3877e6c3-6ac3-4b33-a587-95738d4ae2ba"
      unitRef="U_USD">306801000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_8cc2fb07-49d2-42cc-96c7-07529ebadb72"
      decimals="-3"
      id="F_3957ff51-89c4-4e67-bf05-be86938e6125"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_8cc2fb07-49d2-42cc-96c7-07529ebadb72"
      decimals="-3"
      id="F_2839391b-dd99-4dbc-b78c-080f64eb45eb"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9a190bc1-8994-483b-9102-8e2f78b28bc1"
      decimals="-3"
      id="F_f51b53fc-c80b-46ef-b0cf-510df8646f42"
      unitRef="U_USD">306801000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_7f5ac940-84de-48e5-ae64-41ee00fc2d79"
      decimals="-3"
      id="F_eb1f34d0-e942-4bde-92da-76bf6f7041e5"
      unitRef="U_USD">42455000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_77cfdb28-9e47-4558-b8db-21bed2f9143f"
      decimals="-3"
      id="F_957973fc-7734-4a05-ae06-5def7069023d"
      unitRef="U_USD">6000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_77cfdb28-9e47-4558-b8db-21bed2f9143f"
      decimals="-3"
      id="F_a129ef68-d6f8-4176-916d-5af73710b83f"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_7f5ac940-84de-48e5-ae64-41ee00fc2d79"
      decimals="-3"
      id="F_940f539e-339f-4866-9f84-e680222732d0"
      unitRef="U_USD">42461000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_31d52667-94b6-48d2-b574-45d574a0f09b"
      decimals="-3"
      id="F_b41110eb-d372-4752-97bf-9f18d90f0023"
      unitRef="U_USD">12998000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_d06cc3be-3868-4b27-8b88-efa3b16b4417"
      decimals="-3"
      id="F_d56f8446-afb2-42cb-b133-b6eef653fc4b"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_d06cc3be-3868-4b27-8b88-efa3b16b4417"
      decimals="-3"
      id="F_c7fcbb90-c6a3-453e-8a2c-898fdc3c0e1e"
      unitRef="U_USD">6000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_31d52667-94b6-48d2-b574-45d574a0f09b"
      decimals="-3"
      id="F_41dce103-af42-4946-8f3a-84f32d89d364"
      unitRef="U_USD">12992000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_555b90da-9109-4cae-936b-dac6310ce148"
      decimals="-3"
      id="F_1572640d-c406-4b6f-97f6-0f61b9a1ceb5"
      unitRef="U_USD">362254000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_d17d3110-5d3b-4f67-a03a-3459f5097a7e"
      decimals="-3"
      id="F_7e0bde1d-c4da-486b-ae34-03e93f775b7f"
      unitRef="U_USD">6000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_d17d3110-5d3b-4f67-a03a-3459f5097a7e"
      decimals="-3"
      id="F_54500337-e522-4d21-aef0-fd0351e66628"
      unitRef="U_USD">6000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_555b90da-9109-4cae-936b-dac6310ce148"
      decimals="-3"
      id="F_5a108abe-49a0-4d8e-8d8b-2f0dfc0d1d96"
      unitRef="U_USD">362254000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_8cd94762-0e2e-45f6-a01e-01085a86a854"
      decimals="-3"
      id="F_e6fac3f3-b962-4a1d-9d2e-e36aefe58601"
      unitRef="U_USD">47534000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_0caaf123-e9b7-419b-a654-8ce6c344421a"
      decimals="-3"
      id="F_599f7adf-f1be-4ca3-8680-376035dd3e3f"
      unitRef="U_USD">17000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_0caaf123-e9b7-419b-a654-8ce6c344421a"
      decimals="-3"
      id="F_bee8de1c-ce3a-4d43-ac92-f1e11746f3b5"
      unitRef="U_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_8cd94762-0e2e-45f6-a01e-01085a86a854"
      decimals="-3"
      id="F_c4eeb2ea-641c-436f-8e1d-11ce79848276"
      unitRef="U_USD">47547000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_55f7cf54-c65c-4834-922b-fada916481b2"
      decimals="-3"
      id="F_f9d24d97-cd6b-4a15-b966-b5b7ee20a594"
      unitRef="U_USD">37515000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_fddb666c-28f9-47a3-90ab-b07ceb2c7598"
      decimals="-3"
      id="F_f6c040f4-aecb-438b-becb-d977dcffb8c4"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_fddb666c-28f9-47a3-90ab-b07ceb2c7598"
      decimals="-3"
      id="F_978cedc5-a76e-488c-aad3-82ad648eec38"
      unitRef="U_USD">91000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_55f7cf54-c65c-4834-922b-fada916481b2"
      decimals="-3"
      id="F_b5758799-ea11-441d-aadf-5713918ffb01"
      unitRef="U_USD">37424000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_ba5b5e93-9d73-4a23-8fdd-272f7a933478"
      decimals="-3"
      id="F_17fceeeb-f345-481d-984e-f9f39bb344f2"
      unitRef="U_USD">4816000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_29326ae4-2f07-4dd9-ac50-8fbdc7b576a5"
      decimals="-3"
      id="F_acc2f2a4-f585-4056-841c-b7487c90a498"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_29326ae4-2f07-4dd9-ac50-8fbdc7b576a5"
      decimals="-3"
      id="F_845e92a9-f467-4778-9b71-2a7152538391"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ba5b5e93-9d73-4a23-8fdd-272f7a933478"
      decimals="-3"
      id="F_0572eccc-a19e-4b52-8d08-325cb4bd5272"
      unitRef="U_USD">4818000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_e5c437fa-ca9f-4a34-a6dd-cd8d4e53f5bd"
      decimals="-3"
      id="F_e824736e-0681-44f5-aa6b-ece99acd0afc"
      unitRef="U_USD">89865000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_251ee5d8-0c7f-4f9d-a0ce-8c700c53c157"
      decimals="-3"
      id="F_80db1c40-80d6-4a30-8429-bc3cb7123984"
      unitRef="U_USD">20000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_251ee5d8-0c7f-4f9d-a0ce-8c700c53c157"
      decimals="-3"
      id="F_bc2ec614-6ac9-4714-bf8d-25fffdf95505"
      unitRef="U_USD">96000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_e5c437fa-ca9f-4a34-a6dd-cd8d4e53f5bd"
      decimals="-3"
      id="F_3850837a-afc4-4825-b895-2add85055e7e"
      unitRef="U_USD">89789000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_98f92f57-5d9a-44ea-be63-5c5131e5b81e"
      unitRef="U_USD">452119000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_3929f877-fd38-4a94-9e5b-54676a4e9e57"
      decimals="-3"
      id="F_bf762d0e-3db1-48c8-b472-50724c7f61e5"
      unitRef="U_USD">26000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_3929f877-fd38-4a94-9e5b-54676a4e9e57"
      decimals="-3"
      id="F_f720018c-bf4b-4b1c-a884-a4bc5124a56d"
      unitRef="U_USD">102000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_d4c70aaa-bc60-4f6f-8726-3619297cd8e6"
      unitRef="U_USD">452043000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_437c2099-824a-4b8b-928c-9f9abb10ef75">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s marketable securities by contractual maturity were (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:76.28%;"&gt;&lt;/td&gt;
         &lt;td style="width:2%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:19.72%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Within one year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;239,788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;After one year through two years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;240,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_2c68e5f9-2e37-425b-9abf-4dcd968b5b71"
      unitRef="U_USD">239788000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <nmra:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_adcd52cb-fe42-4ea6-ae21-45c03ec434f8"
      unitRef="U_USD">302000</nmra:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue>
    <nmra:EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_5aa9c6c6-e114-49b9-8721-9c5de78b5316"
      unitRef="U_USD">240090000</nmra:EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_ab5a781c-1033-4858-ab93-802cd3c40d6c">&lt;p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;4.	Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The carrying amounts of the Company&#x2019;s financial instruments, including prepaid expenses and other current assets, accounts payable, accrued liabilities and the current portion of operating lease liabilities approximate fair value due to the short-term nature of those instruments.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables summarize the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis by level within the valuation hierarchy:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;142,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;142,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government and agency debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;115,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;122,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;257,879&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;125,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;382,907&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;306,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;306,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90,008&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90,008&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government and agency debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,416&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;326,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;125,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;452,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Money market funds are highly liquid and actively traded marketable securities that generally transact at a stable $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; net asset value representing its estimated fair value. The Company estimates the fair value of its commercial paper, certificates of deposit, U.S. government and agency debt securities, and corporate debt securities by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data, and other observable inputs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_d298a54d-315f-48de-903d-80f2bda8d1ba">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables summarize the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis by level within the valuation hierarchy:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;142,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;142,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government and agency debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;115,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;122,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;257,879&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;125,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;382,907&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;306,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;306,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90,008&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90,008&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government and agency debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,416&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;326,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;125,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;452,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e34b0512-dfda-4a27-98ed-cf663dd4f181"
      decimals="-3"
      id="F_ad122b7b-374c-4778-a23e-cca858586d4c"
      unitRef="U_USD">142817000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_20c204e8-32e7-4a99-afcf-776f05f42ab0"
      decimals="-3"
      id="F_a556276e-932b-4905-8a49-65c41463a8d2"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_aa35f881-a2e4-44a8-bf69-7086dc821033"
      decimals="-3"
      id="F_4815f321-bcd6-4910-8c59-cfbbb73d1e21"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e25bb6fd-163c-4c2e-a895-464771d27c28"
      decimals="-3"
      id="F_e370c6c0-41cd-4566-afe4-6b0826538ec9"
      unitRef="U_USD">142817000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_525f8d27-e52b-4d90-aae6-72f3a411fae6"
      decimals="-3"
      id="F_faff5f3e-c59a-463c-b4e3-9c3fff28b477"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_33dd1233-920e-4439-a019-1de4439f0bdd"
      decimals="-3"
      id="F_4c86ec78-ba7a-43b7-a14f-56d1f09f067b"
      unitRef="U_USD">69577000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0cee2f31-d69c-4bb4-80be-9b786c85fd34"
      decimals="-3"
      id="F_430896fb-b3d6-40f7-a7f2-ea5e4417ef80"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5ae90723-14e8-439e-81a2-861cd015a4de"
      decimals="-3"
      id="F_a3c41ff7-3086-432b-b402-6b91686940c4"
      unitRef="U_USD">69577000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a613c3d9-8372-4ff1-9b67-609500a6441a"
      decimals="-3"
      id="F_ee797dd1-1ae7-4a4d-bad9-456805e710c2"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7ee2b185-99f7-4bd5-9ca0-f9d76e4edb87"
      decimals="-3"
      id="F_cd03764b-9187-4af8-9c90-ffe1c6f6c61e"
      unitRef="U_USD">11671000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0cee2f31-d69c-4bb4-80be-9b786c85fd34"
      decimals="-3"
      id="F_a66b7b2b-9b05-49df-9d1f-791595d6b93a"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_43bd04fb-3740-4cf7-b83c-a9a404955351"
      decimals="-3"
      id="F_edc65077-5aea-4207-b683-87137bcfb1b6"
      unitRef="U_USD">11671000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_22d38837-90bd-43aa-9c93-8f13f37f99e1"
      decimals="-3"
      id="F_faa42cfe-cfa9-498e-b195-52a214c9d899"
      unitRef="U_USD">115062000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_2a31bc5a-9b88-4b0c-a97e-5b7a3ab157b0"
      decimals="-3"
      id="F_c34d7c3f-e3bf-4343-a813-bed92c2a8784"
      unitRef="U_USD">7490000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_2113c554-0c81-4a7b-979d-5577fd8f2940"
      decimals="-3"
      id="F_55c2f5ad-39cb-4e8c-a3ee-eca7aa5362cc"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e8193643-0d56-40a9-b0e8-aa7a9093b9b1"
      decimals="-3"
      id="F_b7ec89af-390b-4eae-80df-3a3aabab5238"
      unitRef="U_USD">122552000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_63ea549e-a21c-49a4-aa4c-6bb788b17014"
      decimals="-3"
      id="F_9eb4fdf0-7b88-4f44-8126-d30596e18200"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_dff92dc7-7e5a-4082-a3f9-80aea9d28b77"
      decimals="-3"
      id="F_a2b724e5-65b2-4c9d-8fe2-5388ed40681a"
      unitRef="U_USD">36290000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1b53b7d9-62ee-44e4-a34f-0d741a2336fd"
      decimals="-3"
      id="F_4e58e139-7b9b-469e-a18d-28d63d352628"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d5bbb135-9ec5-40dc-99e5-5f2b31f645d2"
      decimals="-3"
      id="F_7d0a1c70-8e8a-4282-bf59-48967ad8f7c7"
      unitRef="U_USD">36290000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_51f3d1d1-4794-40b6-9e06-602baca00e1a"
      decimals="-3"
      id="F_ef47d2e7-3f28-4477-b449-bd2695250319"
      unitRef="U_USD">257879000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_77c53b90-3f1c-4948-9874-3efee2daaf4c"
      decimals="-3"
      id="F_cd8579ca-3582-4fe6-a84f-b903ccd9cbd9"
      unitRef="U_USD">125028000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_bcf2dda4-ea5e-486c-b486-680ccab2876c"
      decimals="-3"
      id="F_540c1f51-6f50-41cd-9418-6fb5b1d7b5c8"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5ea749b2-350e-4a76-be5d-6ec287b9f397"
      decimals="-3"
      id="F_90a2623a-8d05-4967-b7c8-b3b130890eee"
      unitRef="U_USD">382907000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_739e5e64-0cd3-46ad-bc1c-ca25045bf637"
      decimals="-3"
      id="F_b9f00b14-200f-407c-89df-15a4265a2a34"
      unitRef="U_USD">306801000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7192706f-bc17-41ba-8cf3-0a9e6b1ad84d"
      decimals="-3"
      id="F_f41ee61e-1724-4b87-a1a1-bef2d8b88f6e"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a19bca81-450f-43b2-9071-1243ab1b452a"
      decimals="-3"
      id="F_bbbb6aa3-f3a0-4c2c-aa52-db71381e0c3a"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_07471f87-b4eb-4e19-b637-f10364df9c08"
      decimals="-3"
      id="F_74cb1bfd-9285-411e-8858-cbe36fc3deee"
      unitRef="U_USD">306801000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9b39dc12-964c-4b06-983f-1dd2a2960d34"
      decimals="-3"
      id="F_85e1b017-25a1-4415-a416-16c6b082f432"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_39142c7c-f586-4ac5-b162-38a428111720"
      decimals="-3"
      id="F_4a1a9fc5-e2ed-4127-8ad2-cb8531c09d1e"
      unitRef="U_USD">90008000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1f06d786-a166-4605-9c3f-8826e794ff47"
      decimals="-3"
      id="F_09e304dc-6fc3-4d84-90ae-3585462e03dc"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a90b5a54-f1c7-43a2-a245-7aab2d94f07b"
      decimals="-3"
      id="F_c0b3a536-1148-4a7c-8897-048c14b4e91d"
      unitRef="U_USD">90008000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_18f69ced-ee72-4bc6-9740-8d6abfc2c287"
      decimals="-3"
      id="F_e3a6aeb3-cca2-4e05-9164-3746f0cbf4a8"
      unitRef="U_USD">19473000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5e8a8262-f68c-4d54-b803-90f9002df20b"
      decimals="-3"
      id="F_64e1eabf-5206-483b-9db0-57ce1dd6ed0b"
      unitRef="U_USD">30943000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_02b50e0e-46e6-4a57-acee-f328831ee84b"
      decimals="-3"
      id="F_3099e979-bb4e-4ca8-b3bc-0ccde3e619cd"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_79158f11-43a3-45ef-a4fa-baf694b1a1dd"
      decimals="-3"
      id="F_b3beaa0a-ddba-4e03-8f36-7a75011ea284"
      unitRef="U_USD">50416000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a69bb320-f60a-431d-9ea6-2f940a271bbb"
      decimals="-3"
      id="F_7b710e4f-7669-49b2-92c1-480006a7a7c4"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_61fc95eb-f3e2-41fe-a985-6942d28b52ef"
      decimals="-3"
      id="F_c6392449-069e-4eff-bac9-f2222840d55a"
      unitRef="U_USD">4818000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_08d37b25-304c-48fb-acac-c44b7eb4f93d"
      decimals="-3"
      id="F_4b33a4b0-341c-4a61-8314-b4e8dcf87235"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c0384758-481a-481e-9efc-b953da92377b"
      decimals="-3"
      id="F_d6cc365d-97a3-478b-a1e0-0b21f23c21ec"
      unitRef="U_USD">4818000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_03e46424-d2af-4dcd-b68b-3725a6f17401"
      decimals="-3"
      id="F_088155c3-08bf-4895-816d-264930bec9e5"
      unitRef="U_USD">326274000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d7ebe7a9-9b3e-43ca-b7d5-0155ac61a792"
      decimals="-3"
      id="F_73a9181a-3854-4d71-965c-51c735e969d0"
      unitRef="U_USD">125769000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_eccfdb09-aec6-4147-bb3a-627442594df7"
      decimals="-3"
      id="F_b9604817-f66f-427c-9e33-fb71abd7dadc"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0fd1591b-b097-48b9-96e0-c77fef141b7f"
      decimals="-3"
      id="F_582bb91f-e507-4c12-aaa4-0517f8d28d61"
      unitRef="U_USD">452043000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:NetAssetValuePerShare
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="2"
      id="F_a4b1dc26-1e45-4004-8aa1-c2b67e43a447"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1</us-gaap:NetAssetValuePerShare>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_9d55c613-7b54-42bb-a37a-6def7091311b">&lt;p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;5.	Balance Sheet Components&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prepaid expenses and other current assets consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:60.692%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:15.603%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.7%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:16.802999999999997%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid research and development costs ($&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;million and $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&lt;br/&gt;&#160;&#160;&#160;&#160;million from related party in 2024 and 2023, respectively)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,085&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other receivables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;906&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued Liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:63.473%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.86%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:13.943%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.7%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:15.023%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Compensation and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued research and development services ($&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;million and $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;br/&gt;&#160;&#160;&#160;&#160;&#160;million due to related party in 2024 and 2023, respectively)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,442&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;926&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued clinical trial and preclinical costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_24c4e62d-80c5-4550-bcb6-cc96473d5afc">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prepaid expenses and other current assets consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:60.692%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:15.603%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.7%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:16.802999999999997%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid research and development costs ($&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;million and $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&lt;br/&gt;&#160;&#160;&#160;&#160;million from related party in 2024 and 2023, respectively)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,085&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other receivables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;906&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <nmra:PrepaidResearchAndDevelopmentCosts
      contextRef="C_7da00584-584d-4a38-a226-8df0e7c5789c"
      decimals="-5"
      id="F_0da3cd0d-f91e-420b-9600-c31dbb454977"
      unitRef="U_USD">9400000</nmra:PrepaidResearchAndDevelopmentCosts>
    <nmra:PrepaidResearchAndDevelopmentCosts
      contextRef="C_b7c53efd-2f73-4e8f-aeaf-4c1bb51e739b"
      decimals="-5"
      id="F_d95b9b56-7066-41a4-8c90-b3ba542c7a09"
      unitRef="U_USD">6300000</nmra:PrepaidResearchAndDevelopmentCosts>
    <nmra:PrepaidResearchAndDevelopmentCosts
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_fe62a08d-2cb2-49d7-b6fe-06d54ac4bf27"
      unitRef="U_USD">14603000</nmra:PrepaidResearchAndDevelopmentCosts>
    <nmra:PrepaidResearchAndDevelopmentCosts
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_53bce9b3-2e8a-45e4-a23f-70a88d165e3c"
      unitRef="U_USD">19085000</nmra:PrepaidResearchAndDevelopmentCosts>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_abb50c77-9e73-43af-9585-55af4d8b004a"
      unitRef="U_USD">4561000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_e7ff0bed-c6ad-4365-b32c-d55265241f2f"
      unitRef="U_USD">4273000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_d2d6acc2-30c0-4e40-bbdc-9a55f9559828"
      unitRef="U_USD">906000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_4ab02bfc-32c5-4fbf-ba79-f81473b18757"
      unitRef="U_USD">939000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_4aad6850-9d44-4d92-8be2-24ff710eec50"
      unitRef="U_USD">20070000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_67dbae1a-3971-44eb-a827-3c848e8821f6"
      unitRef="U_USD">24297000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_8972c27c-5d66-44fa-ad0a-4513f9014bbb">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued Liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:63.473%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.86%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:13.943%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.7%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:15.023%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Compensation and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued research and development services ($&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;million and $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;br/&gt;&#160;&#160;&#160;&#160;&#160;million due to related party in 2024 and 2023, respectively)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,442&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;926&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued clinical trial and preclinical costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_dfe9241c-04ef-419f-ae7c-9f14751cea48"
      unitRef="U_USD">4660000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_ebbdc20c-b9c5-4b6c-bb83-05941acd0c36"
      unitRef="U_USD">10011000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <nmra:AccruedResearchAndDevelopmentServicesDueToRelatedParty
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-5"
      id="F_7f20196c-56a6-40ab-9fdb-487fc02976f2"
      unitRef="U_USD">6300000</nmra:AccruedResearchAndDevelopmentServicesDueToRelatedParty>
    <nmra:AccruedResearchAndDevelopmentServicesDueToRelatedParty
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-5"
      id="F_24545204-e59c-4996-a6bf-870575f062c7"
      unitRef="U_USD">3100000</nmra:AccruedResearchAndDevelopmentServicesDueToRelatedParty>
    <nmra:AccruedResearchAndDevelopmentServices
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_b3780bce-476b-4093-92f8-2e3d59a0d5ba"
      unitRef="U_USD">7442000</nmra:AccruedResearchAndDevelopmentServices>
    <nmra:AccruedResearchAndDevelopmentServices
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_493b20ce-a0df-479b-a792-9744b6c06f9c"
      unitRef="U_USD">5004000</nmra:AccruedResearchAndDevelopmentServices>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_2e53c8f7-3e41-4109-bc3d-44f3c102098a"
      unitRef="U_USD">926000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_ea5ae909-f3b5-419f-b1fb-50231a24ae4f"
      unitRef="U_USD">787000</us-gaap:AccruedProfessionalFeesCurrent>
    <nmra:AccruedClinicalTrialAndPreclinicalCosts
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_4d4a5e92-6b5b-4999-abc6-59b145b0ef0a"
      unitRef="U_USD">5923000</nmra:AccruedClinicalTrialAndPreclinicalCosts>
    <nmra:AccruedClinicalTrialAndPreclinicalCosts
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_2e6552ec-f90b-4a57-acf1-0b1486db2616"
      unitRef="U_USD">4705000</nmra:AccruedClinicalTrialAndPreclinicalCosts>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_96f9b162-5511-484c-9912-56e790cf5575"
      unitRef="U_USD">542000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_1eb44274-759f-4d7b-bd19-18b810e83a39"
      unitRef="U_USD">750000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_c2f0d2ab-b193-43ee-b8c7-b94bcd0fd3ab"
      unitRef="U_USD">19493000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_884acf9e-2115-4f33-b211-b79d6b7b8a24"
      decimals="-3"
      id="F_3d74997d-26ad-40ce-92af-799053dfc355"
      unitRef="U_USD">21257000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_f8f7658b-5477-49db-bb4a-cd3e79ad295d">&lt;p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;6.	Acquisitions of Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;BlackThorn Therapeutics, Inc.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2020, the Company entered into an agreement and plan of merger (BlackThorn Merger Agreement) to acquire all of the equity interests of BlackThorn Therapeutics, Inc. (BlackThorn), which became effective in September 2020. The Company acquired BlackThorn for its in-process research and development programs, including an antagonist of the kappa opioid veceptor (navacaprant (NMRA-140)) for the treatment of major depressive disorders and an antagonist of the vasopressin 1a veceptor (NMRA-511) for the treatment of agitation in Alzheimer's disease. The Company also gained access to a cloud-based computational psychiatry and data platform that was being developed to support drug target identification, patient stratification and objective clinical trial endpoints. Both navacaprant and NMRA-511 were exclusively licensed to BlackThorn by The Scripps Research Institute (TSRI). The acquisition was accounted for as an acquisition of assets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The BlackThorn Merger Agreement requires the Company to pay the former stockholders of BlackThorn contingent consideration (i) with respect to navacaprant, in the form of development and regulatory approval milestones of up to an aggregate amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;365.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which includes a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;milestone payment that became due in October 2023 upon dosing the first patient in the Phase 3 clinical trial for navacaprant,&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and sales-based milestones of up to an aggregate amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;450.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and (ii) with respect to NMRA-511, in the form of development and regulatory approval milestones of up to an aggregate amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and sales-based milestones of up to an aggregate amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million (BlackThorn Milestones). At the Company&#x2019;s sole discretion, the BlackThorn Milestone payments may be settled in cash or shares of the Company, or a combination of both, subject to the provisions of the BlackThorn Merger Agreement, other than one development milestone in the amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which must be settled in cash. None of the BlackThorn Milestones were subject to liability classification and/or derivative accounting and any such contingent consideration will be recognized when the contingency is resolved, and the consideration becomes payable. The Company settled the Phase 3 navacaprant dosing milestone in December 2023 by issuing &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,072,445&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its common stock based on the volume weighted average price per share prior to the date the milestone was met and paying cash of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to the former stockholders of BlackThorn and participants in the carveout plan (discussed &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;below). As a result, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in acquired in-process research and developed expenses in the fourth quarter of 2023 related to the BlackThorn Milestones. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ne of the other Blackthorn Milestones have been achieved and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; such amounts were deemed due or payable as of March 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;BlackThorn Carveout Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The BlackThorn Merger Agreement required that the Company establish a carveout plan (the BlackThorn Carveout Plan), pursuant to which each BlackThorn stock option holder as of immediately prior to the closing date was allocated a certain number of units (the BlackThorn Carveout Units) based on the number of shares underlying the outstanding options held by each participant at that time. Each BlackThorn Carveout Unit represents a right to receive a portion of the BlackThorn Milestone payment (the BlackThorn Carveout Payments) upon the later of (i) the achievement of a BlackThorn Milestone and (ii) the vesting of the BlackThorn Carveout Unit.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The BlackThorn Carveout Units vest based on time-based schedules that mirror the vesting schedules for the original option awards held by each participant. As of the closing date in September 2020, a portion of the BlackThorn Carveout Units corresponding to the pre-acquisition service periods were fully vested (Vested Carveout Units). The remainder of the BlackThorn Carveout Units vest subject to the continued service of the participants.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Vested Carveout Units represent contingent consideration for the acquisition as they are attributable to pre-acquisition services rendered by the participants and continuing service is not required for the participants to receive future payments upon a BlackThorn Milestone being achieved. The Company recognizes the contingent consideration obligation for the Vested Carveout Units when the contingency is resolved, and the consideration becomes payable. The BlackThorn Carveout Units that were unvested as of the closing date are dependent on the continued service of participants and were deemed to be a compensation arrangement. The Company recognizes compensation starting from the time payment becomes probable over each participant&#x2019;s service period.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company settled the Phase 3 navacaprant dosing milestone in December 2023. The Company recognized contingent consideration related to Vested Carveout Units, which was included in acquired in-process research and developed expenses in the fourth quarter of 2023 related to the BlackThorn Milestones as described above. In addition, the Company recognized and paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in compensation related to the BlackThorn Carveout Units that were a compensatory arrangement in 2023. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ne of the other BlackThorn Milestones had been achieved and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; such amounts were deemed due or payable as of March 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Syllable Life Sciences, Inc.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In September 2020, the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Company entered into an agreement and plan of merger (Syllable Merger Agreement) to acquire all of the outstanding equity of Syllable Life Sciences, Inc. (Syllable). The Company acquired Syllable to gain access the rights granted to Syllable under an exclusive license agreement (as amended, the Harvard License Agreement) with President and Fellows of Harvard College (Harvard) and an associated behavior analysis machine learning and computer vision software tool which Syllable was developing to identify and quantify behavior as an indicator of neurological conditions. The transaction was accounted for as an acquisition of assets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The former stockholders of Syllable are entitled to contingent consideration in the form of development milestones of up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million (Syllable Milestones). At the Company&#x2019;s sole discretion, the Syllable Milestone payments may be settled, in cash or shares equity of the Company, or a combination of both, subject to the provisions of the Syllable Merger Agreement and were not subject to liability classification and/or derivative accounting. Any such contingent consideration will be recognized when the contingency is resolved, and the consideration becomes payable. As of March 31, 2024, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ne of the Syllable Milestones had been achieved and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; such amounts were deemed due or payable.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Alairion, Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2020, the Company entered into an agreement and plan of merger (Alairion Merger Agreement) to acquire all of the outstanding equity of Alairion, Inc. (Alairion). The acquisition of Alairion allowed the Company to expand its program pipeline by gaining rights to two preclinical stage research and development programs focused on the treatment of sleep disorders, an H1 receptor antagonist program (the H1 Program) and a GABA receptor positive allosteric modulator program (the GABA Program). The acquisition also provided the Company with access to a license for software that records sleep and related drug discovery and optimization technology platform. The transaction was accounted for as an acquisition of assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The holders of Alairion common stock outstanding as of immediately prior to the closing date received non-transferable rights to future milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million upon the achievement of specified development events and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;135.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million upon the achievement of specified commercialization events related to the H1 Program and the GABA Program (the Alairion Milestones).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Alairion Milestone payments may be settled, at the Company&#x2019;s sole discretion, in cash or shares of the Company, or a combination of both, subject to the provisions of the Alairion Merger Agreement. None of the Alairion Milestones were subject to liability classification and/or derivative accounting and any such contingent consideration will be recognized when the contingency is resolved, and the consideration becomes payable. As of March 31, 2024, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ne of the Alairion Milestones have been recognized. In March 2022, the Company paused the active program acquired from Alairion while it assesses pre-IND feedback received from the FDA and continues to consider alternative options for that program.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Amgen Inc. Licenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In September 2021, the Company entered into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; license agreements with Amgen Inc. (Amgen) pursuant to which it obtained exclusive, worldwide licenses to develop, manufacture, use, commercialize and distribute products containing compounds that are directed to, in one case, CK1&#x3b4;, and in the other case, glucocerebrosidase (GCase), both for the treatment of neurodegenerative diseases (the Amgen License Agreements) and related know-how and clinical material (collectively, the Amgen IPR&amp;amp;D Assets). The Company accounted for these transactions as acquisitions of assets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Concurrently, the Company also executed a research collaboration agreement as well as a stock purchase agreement with Amgen. Both agreements were deemed to be separate transactions and not accounted for as part of the acquisition of assets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The total upfront consideration transferred to Amgen of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares of the Company's Series A-2 convertible preferred stock, with an acquisition date fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;157.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was allocated to the Amgen IPR&amp;amp;D Assets and expensed in 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under these &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; license agreements, Amgen is eligible to receive contingent consideration up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;360.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in commercial milestone payments per product payable in cash with a compound directed to CK1&#x3b4; and up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;360.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in commercial milestone payments per product payable in cash with a compound directed to GCase, in each case, upon the achievement of certain sales thresholds and single digit royalties on potential future net sales, related to CK1&#x3b4; or GCase (the Amgen Milestones). Such contingent consideration was not subject to liability classification and/or derivative accounting and will be recognized when the contingency is resolved, and the consideration becomes payable. As of March 31, 2024, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ne of the Amgen Milestones had been achieved and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; such amounts were deemed due or payable.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition, until a specified period of time following the achievement of the first successful Phase 2 clinical trial for any licensed product, if the Company chooses to sell, transfer, sublicense or divest rights to a licensed product in certain major markets, Amgen has a period of time to enter into an agreement with the Company for such rights. The Company determined that these rights of first negotiation were not freestanding instruments from the Amgen License Agreements and did not meet the definition of a derivative.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Vanderbilt License&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In February 2022, the Company and Vanderbilt University (Vanderbilt) entered into a license agreement (Vanderbilt License Agreement). Pursuant to the Vanderbilt License Agreement, as amended, the Company obtained an exclusive, worldwide royalty-bearing, sublicensable (subject to certain restrictions) license under certain patent rights and a non-exclusive, worldwide, royalty-bearing, sublicensable (subject to certain restrictions) license under certain know-how covering small molecule positive allosteric modulators (PAMs) predominantly of the muscarinic acetylcholine receptor subtype 4 (M4) to develop, manufacture, and commercialize products, processes and services covered by such patent rights or that incorporate or use such know-how, for any and uses (the Vanderbilt IPR&amp;amp;D Assets). Concurrently, the Company also executed a sponsored research agreement (see Note 8) with Vanderbilt. The sponsored research agreement was deemed to be a separate transaction and not accounted for as part of the acquisition of assets. The acquisition of Vanderbilt IPR&amp;amp;D Assets became effective in February 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The licensed patent rights are subject to Vanderbilt&#x2019;s right to use the patent rights for research, internal non-commercial use, and educational purposes. The Company intends to develop the PAMs for the treatment of schizophrenia and other neuropsychiatric disorders. The Company has agreed to use commercially reasonable efforts to develop and commercialize licensed products, and to achieve certain development milestones.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company paid Vanderbilt a non-refundable, non-creditable upfront cash payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the Vanderbilt IPR&amp;amp;D Assets, which was immediately recognized as acquired in-process research and development expense in the condensed consolidated statement of operations and comprehensive loss as it was determined to have no alternative future use as of the acquisition date. Under the Vanderbilt License Agreement, Vanderbilt is eligible to receive contingent consideration payable in cash up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million upon the achievement of specified development milestones and up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;380.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million upon the achievement of commercial milestone events as well as tiered royalties at mid-single digit percentages on potential future net sales, subject to specified reductions for the lack of patent coverage, generic entry and payment obligations for third-party licenses (the Vanderbilt Milestones). In addition, the Company is obligated to pay Vanderbilt low-double-digit percentage of sublicense income it receives for sublicenses entered into before the achievement of a specified event. Such contingent consideration was not subject to liability classification and/or derivative accounting and will be recognized when the contingency is resolved, and the consideration becomes payable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; In October 2023, a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million Vanderbilt Milestone was achieved and settled in cash in November 2023 and was recognized in acquired in-process research and developed expenses in the fourth quarter of 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ne of the other Vanderbilt Milestones had been achieved and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; such amounts were deemed due or payable as of March 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition, the Company also had an exclusive option, exercisable for a specified period of time, to negotiate an exclusive license to certain patent rights conceived or developed by Vanderbilt in the course of carrying out the sponsored research pursuant to a sponsored research agreement the between the Company and Vanderbilt, which was entered into at the same time as the Vanderbilt License Agreement. The Company determined that the right to negotiate was not a freestanding instrument from the Vanderbilt License Agreement and did not meet the definition of a derivativ&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;e. The Company exercised the above disclosed exclusive option and the parties executed an agreement in December 2023 pursuant to which the Company licensed certain patent rights in return for a payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million that was recognized in acquired in-process research and developed expenses in the fourth quarter of 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="C_9e7d5678-cc71-4b15-86ec-dc798d97ec7a"
      decimals="INF"
      id="F_29491aa1-9fa0-416f-9e8b-7b15ae77b63e"
      unitRef="U_USD">365000000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <nmra:MilestonePaymentDueDescription
      contextRef="C_f813a615-5ec3-4225-add3-4edef1f0b0da"
      id="F_9e10a45f-02f1-4a33-88b7-f54426cb0661">milestone payment that became due in October 2023 upon dosing the first patient in the Phase 3 clinical trial for navacaprant,</nmra:MilestonePaymentDueDescription>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="C_14e89b9f-b5c9-4179-91f4-e162088b136c"
      decimals="INF"
      id="F_9350c617-c7d6-40b3-a82b-ad8b76820581"
      unitRef="U_USD">450000000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="C_c7dcb4ff-f9ea-4129-bb6e-4ce2d5a96a56"
      decimals="INF"
      id="F_7949898a-e7c3-4d84-a109-e9f2c1a6ccbc"
      unitRef="U_USD">100000000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="C_c04ac888-4277-45d9-a4b1-48542ea0cbd2"
      decimals="INF"
      id="F_0c98c338-56bb-497d-90db-a11a48069579"
      unitRef="U_USD">100000000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <nmra:ContingentConsiderationMilestonePaymentSettledInCash
      contextRef="C_f4c941c3-9b74-4cf3-bf81-e52a1de6cb41"
      decimals="-5"
      id="F_42a585a4-0f8d-4fb2-b818-457f05891775"
      unitRef="U_USD">10000000</nmra:ContingentConsiderationMilestonePaymentSettledInCash>
    <nmra:SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet
      contextRef="C_43d25bda-98a9-43db-9b57-e1c5583f0e82"
      decimals="0"
      id="F_58e4835c-72b6-4e14-aee6-740900412661"
      unitRef="U_shares">6072445</nmra:SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="C_2ea68049-f744-4490-8038-a161b824989a"
      decimals="-5"
      id="F_c5da03ea-067f-4d36-a954-557d0e0cd635"
      unitRef="U_USD">2300000</us-gaap:PaymentsToAcquireBusinessesGross>
    <nmra:AcquiredInProcessResearchAndDevelopedExpense
      contextRef="C_ba11dd75-605e-4c4e-9798-9cc2968450e3"
      decimals="-5"
      id="F_1e355293-e563-4ffd-96b5-1fd221149ffd"
      unitRef="U_USD">60800000</nmra:AcquiredInProcessResearchAndDevelopedExpense>
    <nmra:NumberOfMilestoneAchieved
      contextRef="C_ec34d5ee-6cf7-4a70-a875-58e1015081f3"
      decimals="INF"
      id="F_588a6283-da7b-48bf-8dc6-5444505365d4"
      unitRef="U_Milestones">0</nmra:NumberOfMilestoneAchieved>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="C_b52dabe9-8de8-4682-9783-5765240d1d61"
      decimals="INF"
      id="F_9c0510b3-5b49-46c0-b49d-78cdeed9066e"
      unitRef="U_USD">0</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
      contextRef="C_b9e1e62e-8665-4095-88dc-e415a74bf039"
      decimals="-5"
      id="F_7252b5c9-5342-499d-b6cd-5282124c4470"
      unitRef="U_USD">1800000</us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable>
    <nmra:NumberOfMilestoneAchieved
      contextRef="C_52904f82-0764-43ac-8bcb-0b6094dd317b"
      decimals="INF"
      id="F_690a9b1a-d9dc-4082-b6f6-0a47d5291855"
      unitRef="U_Milestones">0</nmra:NumberOfMilestoneAchieved>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="C_a5ae6113-d278-4442-b891-5cdcd2698c04"
      decimals="INF"
      id="F_236fe411-4e05-4702-9fb9-c3a85941fb3a"
      unitRef="U_USD">0</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="C_e9c77ce3-3b44-4cf6-b432-fc188546ac82"
      decimals="INF"
      id="F_81cc288a-b972-45c5-8ff2-67b221c039d0"
      unitRef="U_USD">5000000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <nmra:NumberOfMilestoneAchieved
      contextRef="C_727eaf32-52e9-4c5c-a6c1-0994953c8d5b"
      decimals="INF"
      id="F_11638da2-34a6-4b10-8917-ac47201d6bf1"
      unitRef="U_Milestones">0</nmra:NumberOfMilestoneAchieved>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="C_27e98a1d-ba3b-4cf3-99f9-3fdadc737b90"
      decimals="INF"
      id="F_80104984-94f7-4657-a742-4599295ac2cf"
      unitRef="U_USD">0</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <nmra:ContingentConsiderationMilestonePayment
      contextRef="C_d5c12c1d-523a-4e2f-a7e6-1b8c3d85f7ed"
      decimals="INF"
      id="F_9d38274a-b806-4423-beab-90c3b68ce3bf"
      unitRef="U_USD">33500000</nmra:ContingentConsiderationMilestonePayment>
    <nmra:ContingentConsiderationMilestonePayment
      contextRef="C_a0e6e5ef-74d3-4484-9f60-7605a23196e7"
      decimals="-5"
      id="F_486cf307-9a74-4f74-b682-26403fa32a93"
      unitRef="U_USD">135000000</nmra:ContingentConsiderationMilestonePayment>
    <nmra:NumberOfMilestoneAchieved
      contextRef="C_7427bdec-5be3-45d2-91f7-391af97bab20"
      decimals="INF"
      id="F_46bc85ab-1a70-47be-9474-a62896d8d7eb"
      unitRef="U_Milestones">0</nmra:NumberOfMilestoneAchieved>
    <nmra:NumberOfLicenseAgreements
      contextRef="C_57949529-090f-4b07-8503-88af5ca1f576"
      decimals="INF"
      id="F_ed67d1f8-09be-4bb3-b4c9-4b8420f0bd9c"
      unitRef="U_Agreements">2</nmra:NumberOfLicenseAgreements>
    <nmra:UpfrontConsiderationTransferredShares
      contextRef="C_af1ae46a-387b-4cc6-b7c4-deac557cbf45"
      decimals="-5"
      id="F_812d903f-c40b-4439-85b2-129c550bae8e"
      unitRef="U_shares">20000000</nmra:UpfrontConsiderationTransferredShares>
    <nmra:AcquisitionDateFairValueOfSharesTransferred
      contextRef="C_af1ae46a-387b-4cc6-b7c4-deac557cbf45"
      decimals="-5"
      id="F_e14f2fdc-512e-452a-9944-7a9f4d3fa979"
      unitRef="U_USD">157000000</nmra:AcquisitionDateFairValueOfSharesTransferred>
    <nmra:NumberOfLicenseAgreements
      contextRef="C_57949529-090f-4b07-8503-88af5ca1f576"
      decimals="INF"
      id="F_79b53ca4-de41-4323-91eb-0137f76c28f0"
      unitRef="U_Agreements">2</nmra:NumberOfLicenseAgreements>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="C_9a1bec7e-9028-4893-9a01-f2631f4b8268"
      decimals="INF"
      id="F_b9f50c3b-6c8b-4811-addf-f434c2358a9e"
      unitRef="U_USD">360000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="C_b006d350-7cd4-4054-a767-ad0723607854"
      decimals="INF"
      id="F_838f0539-fb8a-4ae1-87e2-c227bf6ac5f7"
      unitRef="U_USD">360000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <nmra:NumberOfMilestoneAchieved
      contextRef="C_38d1ee4e-868f-457c-9d3a-08007be1e356"
      decimals="INF"
      id="F_96b1c9ed-c746-4a1e-a445-3807e93880b3"
      unitRef="U_Milestones">0</nmra:NumberOfMilestoneAchieved>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="C_96f5c202-287c-4650-8120-d3a9b7c6fa82"
      decimals="INF"
      id="F_ff0a49a9-4979-4526-8b50-ceaef819171e"
      unitRef="U_USD">0</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <nmra:UpfrontCashPayment
      contextRef="C_4a88c6ce-e846-4492-ae0b-e6b735a43fb1"
      decimals="-5"
      id="F_ef484f24-4b6a-4221-9f97-eddcb2857ea6"
      unitRef="U_USD">13000000</nmra:UpfrontCashPayment>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="C_6fcb7871-8d09-408d-8dc0-0412fca292a2"
      decimals="INF"
      id="F_8a1abb5b-bf17-4826-9835-9461c627ffc4"
      unitRef="U_USD">42400000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="C_d05c50a8-ba36-4fd1-84d9-0b85ac41d16f"
      decimals="INF"
      id="F_9e761cc8-067d-4f5b-b713-8d0bd01f2f7a"
      unitRef="U_USD">380000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <nmra:ContingentConsiderationMilestonePaymentSettledInCash
      contextRef="C_5eeee25b-8ab1-4a9f-98dc-9fd6387ddc80"
      decimals="-5"
      id="F_29ef8772-6fc1-4121-99cc-8df4904eeadd"
      unitRef="U_USD">2000000</nmra:ContingentConsiderationMilestonePaymentSettledInCash>
    <nmra:NumberOfMilestoneAchieved
      contextRef="C_4fd44d42-dc78-4882-9e7d-7c2d3d98f539"
      decimals="INF"
      id="F_a8d30bda-f092-4ab1-b83a-dd0fdc317601"
      unitRef="U_Milestones">0</nmra:NumberOfMilestoneAchieved>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="C_638d684a-75f7-48d0-a1b0-227583ccf014"
      decimals="INF"
      id="F_0f9b1916-b614-4e3e-a95e-d22aa338e39c"
      unitRef="U_USD">0</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <nmra:AcquiredInProcessResearchAndDevelopment
      contextRef="C_0311f6e7-f6e3-443f-9af6-6ed78e813333"
      decimals="-5"
      id="F_26235c2f-f0a6-434b-888e-cf9feb915f29"
      unitRef="U_USD">800000</nmra:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_f3ef9db2-7d45-4ff4-b425-606eb8ea1bd4">&lt;p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;7.	Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Indemnification&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors&#x2019; and officers&#x2019; insurance.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Other Commitments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has various manufacturing, clinical, research and other contracts with vendors in the conduct of the normal course of its business. Such contracts are generally terminable with advanced written notice and payment for any products or services received by the Company through the effective time of termination and any non-cancelable and non-refundable obligations incurred by the vendor at the effective time of the termination. In the case of terminating a clinical trial agreement at a particular site, the Company would also be obligated to provide continued support for appropriate medical procedures at that site until completion or termination.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_e4f718a8-f5f0-4fee-9989-8e127c7a965f">&lt;p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;8.	Strategic License and Research and Collaboration Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2015 TSRI License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the acquisition of BlackThorn (see Note 6), the Company gained certain exclusive rights to intellectual property related to Kappa Opioid Receptor and V1aR Receptor Antagonist programs as well as an oxytocin receptors positive allosteric modulator program (collectively, the TSRI Programs) under a license agreement between BlackThorn and TSRI originally entered into in November 2015 (as amended, the 2015 TSRI License Agreement). The technology licensed under the 2015 TSRI License Agreement is used in the Company&#x2019;s navacaprant and NMRA-511 research and development programs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:18pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Pursuant to the 2015 TSRI License Agreement, the Company is obligated, among other things, to pay TSRI (i) a nominal annual license fee due and payable on the first day of each calendar year and after the fourth anniversary creditable against any royalties due for such calendar year, (ii) development and regulatory milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in aggregate for the first product from each TSRI Program, which are contingent upon achieving specific development and regulatory milestone events, (iii) commercial milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in aggregate for each occurrence, which are contingent upon achieving specified commercialization milestone events, (iv) tiered low-single digit royalties on future net sales of each royalty-bearing product and (v) a percentage ranging from the mid-single digits to sub teen double digits of any sublicensing revenues the Company receives. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In October 2023, the Phase 3 navacaprant dosing milestone was met and the Company paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to TSRI, which was recognized in acquired in-process research and developed expenses in the fourth quarter of 2023. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ne of the other milestones have&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; been achieved and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; royalties were due under the 2015 TSRI License Agreement as of March 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Collaboration Agreement with Amgen&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In September 2021, and concurrently with the Amgen License Agreements (see Note 6), the Company entered into a research collaboration agreement with Amgen (Amgen Collaboration Agreement) to collectively discover drug targets, biomarkers, and other insights associated with central nervous system (CNS) diseases utilizing Amgen&#x2019;s deCODE genetics and human data research capabilities. The Company received exclusive rights under intellectual property generated in the collaboration to exploit therapeutic compounds and diagnostics for use with therapeutics in the CNS field and Amgen received exclusive rights to exploit therapeutic&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;compounds and diagnostics for use with therapeutics outside of the CNS field. The agreement is governed by the Joint Research Committee (JRC), which is made up of equal representatives from each of the Company and Amgen to manage the progress and direction of research and development activities. All decisions made by the JRC shall be by consensus with each party having one vote, and if the JRC cannot reach a consensus, the dispute shall be referred to each company&#x2019;s executive officers. If the executive officers fail to reach a consensus, the Company will have final decision-making authority provided that the matter does not relate to the approval of, or any material change to, a project, decisions to acquire rights from a third party, decisions or activities that are in conflict with Amgen&#x2019;s database usage or data access rights, or the approval of external costs and expenses relating to certain new data generation activities or certain new dataset acquisitions, as such matters require mutual agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In return for Amgen performing research and development activities under the agreement, the Company is committed to making non-refundable, non-creditable quarterly payments over the first two years totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and for the third year $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. Additionally, the Company will reimburse Amgen for certain direct, out-of-pocket external costs and expenses that are incurred in the performance of the activities under the Amgen Collaboration Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The term of the agreement is up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, although it will terminate after three years if the Company and Amgen do not mutually agree upon a compensation structure for years four and five. If the parties do not reach an agreement at least 30 days prior to the end of year three, the Amgen Collaboration Agreement will automatically terminate upon its third anniversary. Further, either party can terminate the Amgen Collaboration Agreement upon material uncured breach or bankruptcy by the other party, in which case all amounts that have become due through the date of termination are non-refundable.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:18pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Amgen also has an exclusive option to negotiate, and the right of first negotiation, to obtain exclusive, worldwide licenses to research, develop, commercialize, and otherwise exploit up to two therapeutic compounds or any pharmaceutical product containing such therapeutic compound arising from the collaboration. That right exists with respect to each compound for a certain period of time following positive Phase 2 results for that compound. The Company determined that these rights were not freestanding instruments from the Amgen Collaboration Agreement and did not meet the definition of a derivative. Upon execution of the Amgen Collaboration Agreement in September 2021, the Company was obligated to start paying Amgen non-refundable quarterly payments. As of March 31, 2024 and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; December 31, 2023, the related prepaid research and development costs included in the condensed consolidated balance sheets were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, within prepaid expenses and other current assets. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; research and development expense was incurred during the three months ended March 31, 2024. The Company&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of related research and development expenses during the three months ended March 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Sponsored Research Agreement with Vanderbilt&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In February 2022, concurrently with the Vanderbilt License Agreement (see Note 6), the Company entered into a sponsored research agreement with Vanderbilt (Vanderbilt Research Agreement), pursuant to which Vanderbilt agreed to provide the Company research services to develop a M4 PAM back-up program.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In return for Vanderbilt performing research and development activities under the agreement, the Company agreed to make quarterly payments for research up to a total of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million on an annual basis. The term of the agreement ended in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. In addition, the Company also had an exclusive option to negotiate an exclusive license to certain patent rights conceived or developed by Vanderbilt in the course of carrying out the sponsored research (see Note 6).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Parkinson's Research Ventures Funding Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In March 2024, the Company entered into a research funding agreement with Parkinson's Research Ventures Limited (PRV), pursuant to which PRV agreed to provide the Company funding up to a total of &#xa3;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in two tranches to carry out preclinical research and development activities related to the Company&#x2019;s NLPR3 program.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The first tranche of &#xa3;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was due upon execution of the agreement and was received in March 2024, for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Company is eligible to receive the second tranche of &#xa3;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million upon the completion of certain development milestones. The Company concluded the funding arrangement was an obligation to perform services and the funding received is recognized as a contra-R&amp;amp;D expense as project costs are incurred. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; costs were incurred during the three months ended March 31, 2024. Upon achievement of certain development, regulatory or commercial trigger events, the Company agreed to pay PRV in aggregate an amount equal to no more than four times the funding provided by PRV i.e., a maximum repayment amount of up to &#xa3;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The trigger event payments meet the derivative scope exception under Accounting Standards Codification (ASC) 815 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Derivatives and Hedging,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and therefore do not need to be bifurcated and separately accounted for.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <nmra:DevelopmentAndRegulatoryMilestonePayments
      contextRef="C_cb7d09d2-6022-4de5-837f-3706586031b6"
      decimals="INF"
      id="F_71f606f3-cbd7-495f-907b-18512106e4d6"
      unitRef="U_USD">1500000</nmra:DevelopmentAndRegulatoryMilestonePayments>
    <nmra:CommercialMilestonePayments
      contextRef="C_cb7d09d2-6022-4de5-837f-3706586031b6"
      decimals="INF"
      id="F_1b661d9b-912f-41a5-8e5f-ce7aade77de0"
      unitRef="U_USD">3500000</nmra:CommercialMilestonePayments>
    <nmra:MilestonePayments
      contextRef="C_26c72768-5590-4025-8159-fc37393751a8"
      decimals="-5"
      id="F_f896790d-5c5d-4f8a-8620-4d63c8d8773f"
      unitRef="U_USD">300000</nmra:MilestonePayments>
    <nmra:MilestonesAchieved
      contextRef="C_10a4bee1-f023-4318-b204-afcaf55d14c2"
      decimals="INF"
      id="F_23c48ac5-5d19-4cde-897c-b231930c9f9b"
      unitRef="U_USD">0</nmra:MilestonesAchieved>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="C_10a4bee1-f023-4318-b204-afcaf55d14c2"
      decimals="INF"
      id="F_2536f419-37b8-4732-947f-60bae20e71e9"
      unitRef="U_USD">0</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <nmra:ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears
      contextRef="C_61a3990c-bdca-4b24-aaa5-3144c2b02eed"
      decimals="-5"
      id="F_1fd2bfea-b11e-4969-b990-ab9f43763cec"
      unitRef="U_USD">50000000</nmra:ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears>
    <nmra:ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear
      contextRef="C_98e4cbee-233e-4294-91dc-1bfd8e5796c3"
      decimals="INF"
      id="F_d2da8675-8b60-40c7-a2a4-b1367b6eca8c"
      unitRef="U_USD">12500000</nmra:ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear>
    <nmra:CollaborationAgreementTerminationDescription
      contextRef="C_61a3990c-bdca-4b24-aaa5-3144c2b02eed"
      id="F_29e1841b-f9f6-46aa-aec9-f2b2a90cdc94">The term of the agreement is up to five years, although it will terminate after three years if the Company and Amgen do not mutually agree upon a compensation structure for years four and five. If the parties do not reach an agreement at least 30 days prior to the end of year three, the Amgen Collaboration Agreement will automatically terminate upon its third anniversary. Further, either party can terminate the Amgen Collaboration Agreement upon material uncured breach or bankruptcy by the other party, in which case all amounts that have become due through the date of termination are non-refundable.</nmra:CollaborationAgreementTerminationDescription>
    <nmra:CollaborationAgreementTerm
      contextRef="C_3c8b66e7-6cb2-408d-90ae-bc995d83fe8b"
      id="F_e938ee1b-7ca2-4123-82a5-b64f8b44cb31">P5Y</nmra:CollaborationAgreementTerm>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_24425110-363c-4304-86c3-338011263481"
      decimals="-5"
      id="F_a65c07e3-8f18-4834-8199-266f14ff3600"
      unitRef="U_USD">9400000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_4252d2b2-e04b-48d1-85b6-0e7e74735ae9"
      decimals="-5"
      id="F_14e43f4b-f737-4979-a9e5-a80427d1ea05"
      unitRef="U_USD">6300000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_61a3990c-bdca-4b24-aaa5-3144c2b02eed"
      decimals="-6"
      id="F_627494d7-59bc-4dfe-bb14-095311ed979a"
      unitRef="U_USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_29e92089-1d1d-45de-90cf-b5665e9d2c96"
      decimals="-5"
      id="F_943956c3-152f-4a26-808f-cdf2330323b2"
      unitRef="U_USD">8100000</us-gaap:ResearchAndDevelopmentExpense>
    <nmra:ResearchAndCollaborationAgreementQuarterlyPayments
      contextRef="C_6e7d7080-8e14-4f39-8b8c-749fc8d79976"
      decimals="-5"
      id="F_a9022a59-d11d-4134-af18-edd5382cc134"
      unitRef="U_USD">1700000</nmra:ResearchAndCollaborationAgreementQuarterlyPayments>
    <nmra:ResearchAgreementExpiryDate
      contextRef="C_3492c0b5-ea1d-4cce-912d-8ddfd975d853"
      id="F_700e3994-1bc6-45d8-8c4b-fa7d6d5124a4">2023-09</nmra:ResearchAgreementExpiryDate>
    <nmra:FundsProvidedForPreClinicalResearchAndDevelopmentActivities
      contextRef="C_6d6c1116-4ad2-4a9c-88a8-b3a45ef44006"
      decimals="-5"
      id="F_ae6fc0d2-0688-49e5-b8fe-ff8b94c76a31"
      unitRef="U_GBP">2100000</nmra:FundsProvidedForPreClinicalResearchAndDevelopmentActivities>
    <nmra:FundsReceivedUponExecutionOfAgreement
      contextRef="C_b09e08a3-63fc-490c-a2b1-f49e28aca678"
      decimals="-5"
      id="F_e7076630-9f5e-4fe7-896c-a5b004457915"
      unitRef="U_GBP">900000</nmra:FundsReceivedUponExecutionOfAgreement>
    <nmra:PaymentsForExecutionOfAgreement
      contextRef="C_b09e08a3-63fc-490c-a2b1-f49e28aca678"
      decimals="-5"
      id="F_aed71e16-2308-469e-8422-1eef13d0b362"
      unitRef="U_USD">1100000</nmra:PaymentsForExecutionOfAgreement>
    <nmra:FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone
      contextRef="C_b09e08a3-63fc-490c-a2b1-f49e28aca678"
      decimals="-5"
      id="F_eb9970c3-cf34-4fd2-919c-cca43747ae0c"
      unitRef="U_GBP">1200000</nmra:FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_b09e08a3-63fc-490c-a2b1-f49e28aca678"
      decimals="INF"
      id="F_a49d7932-f948-450c-be4a-77b4f12a5cb3"
      unitRef="U_USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <nmra:MaximumRepaymentAmountAgreedToPay
      contextRef="C_b09e08a3-63fc-490c-a2b1-f49e28aca678"
      decimals="-5"
      id="F_40a0bf84-2f95-4699-9b58-c51a3d4de179"
      unitRef="U_GBP">8400000</nmra:MaximumRepaymentAmountAgreedToPay>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_1ef1cebf-c3ff-4d3b-914e-fb4e42cf5750">&lt;p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;9.	Stockholders&#x2019; Equity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Subsequent to the IPO, the Company's board of directors has the authority to issue up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of preferred stock in one or more series with rights, preferences and privileges to be determined. There are &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of preferred stock issued and outstanding as of March 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Common stock outstanding in the condensed consolidated balance sheet and condensed consolidated statement of stockholders&#x2019; equity as of March 31, 2024 includes &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;447,931&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of restricted stock that vest based on service conditions and are subject to the Company&#x2019;s right of repurchase upon termination of services and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;637,240&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of restricted stock that vest based on performance conditions (see Note 10). &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Common stock reserved for future issuance consisted of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:78.02%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.7%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:18.28%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares reserved for options and restricted stock units issued under the plans&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,084&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares reserved for future issuance under the plans&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,049&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition, the Company may be required to issue additional shares of its capital stock if certain milestone conditions are met pursuant to the contingent consideration associated with the Company&#x2019;s acquisitions of assets (see Note 6). In December 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,072,445&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock were issued related to BlackThorn Merger Agreement upon achievement of the Phase 3 navacaprant dosing milestone that was met in October 2023. As of March 31, 2024, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares have been reserved for potential future issuances as no other BlackThorn Milestones have been achieved.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_eae3f164-5e78-4151-9e37-d2d160340f1e"
      decimals="INF"
      id="F_2f999c82-dee1-4094-a946-4bbb466b9bc5"
      unitRef="U_shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="INF"
      id="F_4ae0491d-8700-42be-a7d3-f3df5eb70f77"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="INF"
      id="F_31f95567-da32-482e-833c-f5099be9d810"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="C_241e97c5-2790-4988-bdd5-728453731091"
      decimals="0"
      id="F_bd456ed3-96e9-488a-97ee-6bd52f10b13c"
      unitRef="U_shares">447931</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="C_da6c85e3-9c01-4bd3-ae51-498329b996bc"
      decimals="0"
      id="F_5fa15bb1-9118-43f0-92b9-156910fc2b05"
      unitRef="U_shares">637240</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <nmra:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_b8b3ed85-1705-44c1-b1ea-7054558f6944">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Common stock reserved for future issuance consisted of the following:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:78.02%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.7%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:18.28%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares reserved for options and restricted stock units issued under the plans&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,084&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares reserved for future issuance under the plans&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,049&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</nmra:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_c76761b1-4f4c-4b1c-9b56-2a77a0b656cd"
      decimals="-3"
      id="F_df725ebb-1115-4200-a625-af79fcda532f"
      unitRef="U_shares">17084000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b533a66d-d823-48df-b3a5-6934efcf05e7"
      decimals="-3"
      id="F_f9cb1b06-bf25-4b3f-93cf-e07d79910d8d"
      unitRef="U_shares">19965000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_6a59c933-f461-45be-9258-2eeefba9dd39"
      decimals="-3"
      id="F_8cef0eee-d84d-4e67-8d7d-cbcba7af9674"
      unitRef="U_shares">37049000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <nmra:SharesIssuedUponAchievementOfMilestone
      contextRef="C_7642d8ba-9722-4366-8e63-768f192c1673"
      decimals="INF"
      id="F_d1626199-2cb9-4d2a-ace4-24179016a17b"
      unitRef="U_shares">6072445</nmra:SharesIssuedUponAchievementOfMilestone>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_e555a578-5b2d-4468-956c-3321ccffb3aa"
      decimals="INF"
      id="F_136f755b-00df-4787-be64-aad7f7724854"
      unitRef="U_shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_378ba44f-0ca4-48a1-91cf-b0bfa66a237b">&lt;p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10.	Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In September 2023, the Company adopted the 2023 Equity Incentive Plan (the 2023 Plan) that became effective in connection with the Company&#x2019;s IPO. The 2023 Plan provides for the grant of stock options, restricted stock awards, restricted stock unit awards, and other stock-based awards to employees, directors, and non-employee service providers of the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Awards granted under the 2023 Plan expire no later than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; from the date of grant. The price of stock options shall not be less than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the estimated fair value on the date of grant and typically vest over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; period although may be granted with different vesting terms. The 2023 Plan initially reserved &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,373,061&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock for the issuance of future awards and provides for an automatic annual increase in the number of shares of common stock reserved for future issuance under the 2023 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023 Employee Share Purchase Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In September 2023, the Company adopted the 2023 Employee Share Purchase Plan (the 2023 ESPP) that became effective in connection with the Company&#x2019;s IPO. The 2023 ESPP initially reserved &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,526,984&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock for the issuance of future awards and provides for an automatic annual increase in the number of shares of common stock reserved for future issuance under the 2023 ESPP.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2020 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In January 2020, the Company adopted the 2020 Equity Incentive Plan (the 2020 Plan) that provides for the grant of stock options, restricted stock awards, restricted stock unit awards, and other stock-based awards to employees, directors, and non-employee service providers of the Company. The 2020 Plan was suspended in connection with the Company&#x2019;s IPO and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; further grants will be made under the 2020 Plan. The 2020 Plan continues to govern the terms and conditions of outstanding awards granted under the 2020 Plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2015 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Upon the closing of the BlackThorn acquisition in September 2020, the Company assumed BlackThorn&#x2019;s 2015 Equity Incentive Plan (the 2015 Plan, and collectively with the 2020 Plan and 2023 Plan, the Plans), pursuant to which outstanding stock options previously granted under the 2015 Plan converted into stock options to purchase common stock of the Company, which remain subject to the terms and conditions of the 2015 Plan. The 2015 Plan was suspended in connection with the closing of the acquisition of BlackThorn in September 2020.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock Option Activity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:41.692%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:13.877%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.42%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:10.058%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:11.418%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.42%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:10.118%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Outstanding&lt;br/&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price Per&lt;br/&gt;Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic &lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands, except per share amounts and years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;146,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Canceled and forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90,736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested as of March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable as of March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The stock option activity table above excludes options granted to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;446,068&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock that were originally granted with market conditions to one of the Company&#x2019;s executives.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted Stock Activity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s Plans allow for the grant of restricted common stock and restricted stock units to certain employees, executives, non-employee scientific advisors, and third-party service providers. The restrictions lapse over time primarily according to service-based vesting conditions of each award. In the event of a voluntary or involuntary termination of the holder&#x2019;s continuous provision of services to the Company, any unvested portion of the restricted stock award is automatically forfeited.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s restricted stock activity:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:45.46%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.74%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.28%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:11.64%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.86%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:10.8%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Shares of&lt;br/&gt;Restricted&lt;br/&gt;Common&lt;br/&gt;Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;br/&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Shares of&lt;br/&gt;Restricted&lt;br/&gt;Stock&lt;br/&gt;Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average Grant&lt;br/&gt;Date Fair&lt;br/&gt;Value Per&lt;br/&gt;Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding and unvested as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;840&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited and canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding and unvested as of March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The restricted stock activity table above excludes &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;254,896&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of restricted common stock issued to certain of the Company&#x2019;s scientific advisors which vest based on the achievement of certain performance conditions to be separately defined and approved by the Company&#x2019;s board of directors. As the performance conditions had not been determined as of March 31, 2024, the criteria for establishing a grant date, and accordingly a measurement date, were not met as of that date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Award with Market and Performance Conditions&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2021, the Company granted stock options to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;446,068&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its common stock to one of its executive officers with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.52&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share that contained both market and service conditions (the Market Award). Subject to the holder&#x2019;s continued service, the Market Award provided for vesting in four equal tranches once the Company&#x2019;s stock price exceeded certain thresholds. The original grant-date fair value of the Market Award of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was determined using a Monte Carlo simulation model using an expected volatility of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and risk-free rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In January 2022, the Company amended the terms of the Market Award such that the award would vest in three modified tranches. One tranche of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;223,034&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; stock options was based on a performance condition and two tranches of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;111,517&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; stock options each were based on revised Company stock price thresholds and/or vesting schedules, subject to the holder&#x2019;s continued service. The modification resulting in a performance-based tranche was determined to be a probable-to-improbable modification and the modification resulting in two revised market-based tranches were determined to be probable-to-probable modifications. The modification resulted in $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in total incremental expense.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2023, the Company amended the terms such that vesting schedule for the two tranches of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;111,517&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; stock options each that were based on the Company stock price thresholds would instead vest monthly over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, subject to the holder&#x2019;s continued service. The modification of the two market-based tranches were deemed to be probable-to-probable modifications. The modification resulted in $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in total incremental expense.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The unrecognized original grant-date fair value, together with incremental expense, is recognized as compensation for each tranche over the requisite service period. For the three months ended March 31, 2024 stock-based compensation related to the tranches was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, including expense related to the performance-based tranche for which the condition was met upon completion o&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;f the Company's IPO. For the three months ended March 31, 2023, stock-based compensation related to the market-based tranches was not material and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; expense was recognized for the performance-based tranche as the performance condition was not probable of being met.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Awards with Performance Conditions&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In 2020, the Company approved grants of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;700,965&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; stock options and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;892,136&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of restricted common stock to certain of the Company&#x2019;s scientific advisors, which vest based on the achievement of performance conditions to be determined and continued service to the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of March 31, 2024, the Company&#x2019;s board of directors established performance conditions for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;401,462&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; stock options, such that the criteria for establishing a grant date, and accordingly a measurement date, were met for these performance stock options and the remaining &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;299,503&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; stock options with performance conditions to be established were cancelled in July 2023 because certain of the Company&#x2019;s scientific advisors were terminated. Further, as of March 31, 2024, the performance conditions for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;382,344&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;restricted &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;common stock were established,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;254,896&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of restricted common stock with performance conditions to be established were cancelled in July 2023 because the consulting agreements with certain of the Company&#x2019;s scientific advisors were terminated, and the performance conditions for the remaining &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;254,896&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of restricted common stock have yet to be established.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes total stock-based compensation included in the Company&#x2019;s condensed consolidated statements of operations and comprehensive loss:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.734%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.64%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:12.082%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:13.043000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of March 31, 2024, there was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of unrecognized stock-based compensation related to stock options and restricted stock outstanding, respectively, including stock options and restricted common stock for which achievement of milestones was not probable, which were expected to be recognized over a weighted-average remaining service period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years and&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_376fc925-1109-451f-b742-d347b9400872"
      id="F_a8412ec6-6747-4cad-a51a-e65a2edf80e5">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_42afd269-c212-4524-8ff6-bdd4937462c1"
      decimals="INF"
      id="F_195b1328-6384-486e-a709-5618f8a5d8e2"
      unitRef="U_pure">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_376fc925-1109-451f-b742-d347b9400872"
      id="F_3bf6dbef-69d8-43c1-ba82-5d872c03d7f5">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_cc78fb10-fe96-458e-9b51-d23d300acb4b"
      decimals="INF"
      id="F_091522ba-fb96-43b5-8a16-dc1b5108849c"
      unitRef="U_shares">16373061</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_df6fdf4a-265c-48a0-90df-8045faa562ed"
      decimals="INF"
      id="F_ed5fc810-10e0-4afd-bb0a-8808e1ddc9f8"
      unitRef="U_shares">1526984</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_8eca9c19-7868-4c41-b853-b66e96530c89"
      decimals="INF"
      id="F_d48870cd-cd9e-4a94-a4bd-9f3653d6ab7c"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_be3f0803-d18f-4544-8296-1deaebe168e0">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock Option Activity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:41.692%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:13.877%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.42%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:10.058%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:11.418%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.42%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:10.118%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Outstanding&lt;br/&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price Per&lt;br/&gt;Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic &lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands, except per share amounts and years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;146,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Canceled and forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90,736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested as of March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable as of March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_2b466a11-59bd-42da-b1ba-1391e584e43b"
      decimals="-3"
      id="F_66d52b8b-3f04-487a-b658-f0f7fc5678e2"
      unitRef="U_shares">13783000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_2b466a11-59bd-42da-b1ba-1391e584e43b"
      decimals="2"
      id="F_cd523eb7-f300-44cd-812e-9b1fe65e9f6e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_1ad31ded-f058-420f-adc9-5e78ca23eebb"
      id="F_074145c5-e271-4c61-b3f9-037a53d9b580">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_2b466a11-59bd-42da-b1ba-1391e584e43b"
      decimals="-3"
      id="F_973fc961-ea91-4525-b721-309688fed3bf"
      unitRef="U_USD">146966000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_9e81dd9f-5d49-4381-8c61-747848c7d435"
      decimals="-3"
      id="F_646feb95-8bc0-499a-8a44-8a2c441319cc"
      unitRef="U_shares">2841000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_9e81dd9f-5d49-4381-8c61-747848c7d435"
      decimals="2"
      id="F_aa6e17b6-50d9-4557-9e35-1b5432f12f49"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_9e81dd9f-5d49-4381-8c61-747848c7d435"
      decimals="-3"
      id="F_7450e597-fb8c-43a6-844f-d1703bd38d11"
      unitRef="U_shares">525000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_9e81dd9f-5d49-4381-8c61-747848c7d435"
      decimals="2"
      id="F_333219f4-7a13-45b0-ae93-935271e55e10"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_9e81dd9f-5d49-4381-8c61-747848c7d435"
      decimals="-3"
      id="F_d439e03f-158d-4b0a-baa8-b2656850c8df"
      unitRef="U_shares">884000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_9e81dd9f-5d49-4381-8c61-747848c7d435"
      decimals="2"
      id="F_b84f3685-b05d-4c46-8d9d-c2452cedf2cb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_9e81dd9f-5d49-4381-8c61-747848c7d435"
      decimals="-3"
      id="F_a64515a7-84ba-4323-b8a0-8b14915379f5"
      unitRef="U_shares">85000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_9e81dd9f-5d49-4381-8c61-747848c7d435"
      decimals="2"
      id="F_0d568806-f559-4e69-a8b9-0bb7c51c2633"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_1c88b9f4-137c-4a7d-a570-37859d14341b"
      decimals="-3"
      id="F_62fdda0e-946b-4529-8f37-05cec5063b73"
      unitRef="U_shares">15130000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_1c88b9f4-137c-4a7d-a570-37859d14341b"
      decimals="2"
      id="F_f2cbd004-e011-4c1b-bf2f-e0146547cb90"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_9e81dd9f-5d49-4381-8c61-747848c7d435"
      id="F_7b79cc8b-f06c-4088-8bc9-e00a1224110b">P8Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_1c88b9f4-137c-4a7d-a570-37859d14341b"
      decimals="-3"
      id="F_1ff4f571-b70a-4377-9a38-2c0b4b83cc3d"
      unitRef="U_USD">90736000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_1c88b9f4-137c-4a7d-a570-37859d14341b"
      decimals="-3"
      id="F_b009c4ac-c39e-4932-a032-7d7509b89501"
      unitRef="U_shares">3667000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_1c88b9f4-137c-4a7d-a570-37859d14341b"
      decimals="2"
      id="F_5a65e5d8-00fa-4f14-9aac-0522b20c5fb5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_9e81dd9f-5d49-4381-8c61-747848c7d435"
      id="F_5cf3f81e-4d69-4385-8e28-3af06510a230">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_1c88b9f4-137c-4a7d-a570-37859d14341b"
      decimals="-3"
      id="F_3ca9d750-a2b1-476e-bb70-24518555e156"
      unitRef="U_USD">34256000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_1c88b9f4-137c-4a7d-a570-37859d14341b"
      decimals="-3"
      id="F_f2da9ba4-28c0-469a-8b6b-c7293d25ba39"
      unitRef="U_shares">3659000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_1c88b9f4-137c-4a7d-a570-37859d14341b"
      decimals="2"
      id="F_dad4992d-e152-45c5-b1d0-0f9e1de8c5e3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_25ceaf91-1b38-4a20-a46a-fa85069e2727">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_1c88b9f4-137c-4a7d-a570-37859d14341b"
      decimals="-3"
      id="F_9e9a481e-5d07-493f-b2f6-2c25524a38a6"
      unitRef="U_USD">34145000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="C_d082d3da-55b1-47ee-a8c5-4a74e9aacbc1"
      decimals="INF"
      id="F_8703996a-45c4-4bce-b345-247c2680464f"
      unitRef="U_shares">446068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_ea720ed3-72f2-4aa3-a277-cee873c48072">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s restricted stock activity:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:45.46%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.74%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.28%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:11.64%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.86%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:10.8%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Shares of&lt;br/&gt;Restricted&lt;br/&gt;Common&lt;br/&gt;Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;br/&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Shares of&lt;br/&gt;Restricted&lt;br/&gt;Stock&lt;br/&gt;Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average Grant&lt;br/&gt;Date Fair&lt;br/&gt;Value Per&lt;br/&gt;Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding and unvested as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;840&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited and canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding and unvested as of March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_345bf6ed-eb39-4b95-8e9c-d73a88a49e29"
      decimals="-3"
      id="F_ab42e0ba-246c-40c2-8046-bfc1b5a9e188"
      unitRef="U_shares">840000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_345bf6ed-eb39-4b95-8e9c-d73a88a49e29"
      decimals="2"
      id="F_18726885-3971-4f51-ac45-1a1995a45a1e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0a096f27-ed84-4bfd-9a47-aba4b2779d76"
      decimals="-3"
      id="F_55f35dd9-fa13-4daa-b3ec-8e44223b0a8e"
      unitRef="U_shares">353000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0a096f27-ed84-4bfd-9a47-aba4b2779d76"
      decimals="2"
      id="F_4391cf48-d8d7-4f04-a699-8a2e3624d91b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_b8b16692-cbc0-4367-b249-644373e8d0f7"
      decimals="-3"
      id="F_b54049d5-1b6f-4683-8835-204f3bae8c72"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_b8b16692-cbc0-4367-b249-644373e8d0f7"
      decimals="0"
      id="F_4120c0cf-753b-4b2c-ae1c-845b97b8af74"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_4fa032ad-c930-4482-a337-4a8a1b1ede42"
      decimals="-3"
      id="F_af909d70-029c-4406-ade5-7db7953f7063"
      unitRef="U_shares">1165000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_4fa032ad-c930-4482-a337-4a8a1b1ede42"
      decimals="2"
      id="F_e328ac90-d91c-4053-bd1a-e9298e4d3c52"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_b8b16692-cbc0-4367-b249-644373e8d0f7"
      decimals="-3"
      id="F_43a98596-f210-4896-9b44-9ddc34ba63ff"
      unitRef="U_shares">190000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_b8b16692-cbc0-4367-b249-644373e8d0f7"
      decimals="2"
      id="F_b7bfc494-5bf5-4733-a5c2-83a18ec2ae0d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_4fa032ad-c930-4482-a337-4a8a1b1ede42"
      decimals="-3"
      id="F_ffd3f149-4bd9-47bf-a662-8d2a3229df99"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_4fa032ad-c930-4482-a337-4a8a1b1ede42"
      decimals="0"
      id="F_76add3bc-9de7-448c-9578-0a4e31322617"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_b8b16692-cbc0-4367-b249-644373e8d0f7"
      decimals="-3"
      id="F_52b19b59-f3b3-4162-a66e-64db0a1503be"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_b8b16692-cbc0-4367-b249-644373e8d0f7"
      decimals="0"
      id="F_03bc0b60-2974-4873-b093-2dbf4dd604c0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_4fa032ad-c930-4482-a337-4a8a1b1ede42"
      decimals="-3"
      id="F_091e1838-f174-4021-a739-fc26282319a9"
      unitRef="U_shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_4fa032ad-c930-4482-a337-4a8a1b1ede42"
      decimals="2"
      id="F_9ec30fa8-8c7b-444c-b595-5d9ca72c6371"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_e06ff9ea-6ac1-463f-a171-26aa417330c4"
      decimals="-3"
      id="F_6a4fe474-2677-4d9e-b874-2e8851d163cb"
      unitRef="U_shares">650000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_e06ff9ea-6ac1-463f-a171-26aa417330c4"
      decimals="2"
      id="F_d46e8cb1-7156-441b-ab0c-6dd62981c7cd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_e4e3a7e0-9ae1-4a99-a9a2-37ef23ba354a"
      decimals="-3"
      id="F_3ed2a24c-8915-41da-9cc5-615f17430902"
      unitRef="U_shares">1508000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_e4e3a7e0-9ae1-4a99-a9a2-37ef23ba354a"
      decimals="2"
      id="F_b319a3fa-c1c5-4d8c-a7ed-dc9ed3d91f64"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_28cf5026-31c2-4237-a961-7cf7d3167b00"
      decimals="INF"
      id="F_22f3f9b5-c5c8-4f37-9e5a-fa0890d281e4"
      unitRef="U_shares">254896</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_909c052f-7ffa-437f-92ce-194f4b68b6f0"
      decimals="INF"
      id="F_25451282-cd44-46c1-a167-2024b58b2e3f"
      unitRef="U_shares">446068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_395f7b48-e0c5-40be-babe-b38226abdb22"
      decimals="INF"
      id="F_a1a245fc-13d7-4d38-8032-12abfce7b30d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <nmra:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue
      contextRef="C_d5479116-b1c4-4d64-a307-24d1e08db08f"
      decimals="-5"
      id="F_2ba44f46-7ca4-452d-9ae0-ab067d0f2a4c"
      unitRef="U_USD">900000</nmra:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_d5479116-b1c4-4d64-a307-24d1e08db08f"
      decimals="INF"
      id="F_64ff4917-7d4f-4f85-8a26-82eb780dada6"
      unitRef="U_pure">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_d5479116-b1c4-4d64-a307-24d1e08db08f"
      decimals="INF"
      id="F_0997d74c-aead-425f-91d3-b29bf0de4499"
      unitRef="U_pure">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_33ed239b-f1e7-4dbe-9413-6d412b79e979"
      decimals="INF"
      id="F_b0206696-7614-4ede-acb3-75d413952300"
      unitRef="U_shares">223034</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_1eca2e79-7a8a-4acf-aa36-a5b1bfaffd3a"
      decimals="INF"
      id="F_e183219a-42f3-405e-84c7-547651a659b9"
      unitRef="U_shares">111517</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_f506a8da-d1e3-4763-89af-d777851aeab1"
      decimals="INF"
      id="F_884ea0df-61a5-4f34-ad23-72cb3318e252"
      unitRef="U_shares">111517</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <nmra:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification
      contextRef="C_7a1aaed2-b5ef-4825-a2cb-ef3ae69d40ab"
      decimals="-5"
      id="F_54e955cd-f02f-4785-bbb2-277105e25e09"
      unitRef="U_USD">300000</nmra:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_cf493e6f-190e-4be5-9281-315bbffa2f51"
      decimals="INF"
      id="F_f6ceffca-6368-4b46-981f-825a0e64c889"
      unitRef="U_shares">111517</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_7a80754f-9ec5-4887-bba9-4311a2728d25"
      decimals="INF"
      id="F_90d0f39a-ea10-4ea3-aed5-d720a8b4be68"
      unitRef="U_shares">111517</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_a8941767-b9c2-4978-8d8c-996384d2b743"
      id="F_f71d0437-8a7a-417c-894b-cb3e24506585">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <nmra:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification
      contextRef="C_a8941767-b9c2-4978-8d8c-996384d2b743"
      decimals="-5"
      id="F_b0a9fe4a-a8ec-4d89-b9e3-cabde7897202"
      unitRef="U_USD">100000</nmra:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_93cb25ef-3bf9-4722-9f0f-76e81b2a808d"
      decimals="-2"
      id="F_31d822dd-051d-47ce-82f8-4062008d593f"
      unitRef="U_USD">100</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5ba84d33-97e9-4add-951a-69e5ffd8a70a"
      decimals="INF"
      id="F_59a38d55-646a-4c7c-a736-1c9a89efe5a3"
      unitRef="U_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_2491722f-cf98-415e-ae66-46193d72f8d6"
      decimals="INF"
      id="F_3d894baa-5c2e-45fb-a2e4-6af86b7fbf4e"
      unitRef="U_shares">700965</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_05417fea-1510-4361-a4a9-baae7ef69f42"
      decimals="INF"
      id="F_427e6e06-31a2-4769-a71a-fa4e423fb832"
      unitRef="U_shares">892136</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_a162142f-a9f4-4c93-8b5d-13311233637b"
      decimals="INF"
      id="F_1db665eb-3653-48a4-b544-ec0c91f5085d"
      unitRef="U_shares">401462</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_d76dcd2b-4bbc-41b1-8598-911a369433df"
      decimals="INF"
      id="F_cb726891-1ecc-4674-a11e-1e503ae4ede6"
      unitRef="U_shares">299503</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_aff62d54-a840-4155-a58f-4ca78842f976"
      decimals="INF"
      id="F_eccac582-ab7e-4831-ace5-852ba00546b3"
      unitRef="U_shares">382344</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_8afd36af-329a-4960-a319-26b63e51bf46"
      decimals="INF"
      id="F_9094eaf3-a162-4e2e-9ec3-4fbda6efc7aa"
      unitRef="U_shares">254896</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_aff62d54-a840-4155-a58f-4ca78842f976"
      decimals="0"
      id="F_105102b5-4030-4101-803a-510ae9d398e8"
      unitRef="U_shares">254896</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_67f7b646-5a36-4525-9f1a-323a0c7b4c3f">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes total stock-based compensation included in the Company&#x2019;s condensed consolidated statements of operations and comprehensive loss:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.734%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.64%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:12.082%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:13.043000000000001%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9d7f8b41-ab55-4cad-89a8-122b00ff6bb3"
      decimals="-3"
      id="F_6cd9b3e0-0ace-4a87-9bdd-c310af6457b0"
      unitRef="U_USD">2812000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ba9c409c-cf95-4c6b-a1de-281f2042bc5f"
      decimals="-3"
      id="F_c8e8e148-a2f8-4831-aebe-24832dccaa3e"
      unitRef="U_USD">1403000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1bb45cba-2398-4df6-8cdb-80b9b69e2e24"
      decimals="-3"
      id="F_b2b029ca-c24a-4805-9985-b5ec47c48de9"
      unitRef="U_USD">4561000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_fa50bcc6-f909-4f28-9b54-3cce67927d90"
      decimals="-3"
      id="F_0f8d2934-a390-4414-81f9-e97fa82595f1"
      unitRef="U_USD">792000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_3458ae92-ff34-4cb8-bf87-8e3fd1294f67"
      unitRef="U_USD">7373000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_8331aa64-be29-4977-9e2c-1779fdc5287c"
      unitRef="U_USD">2195000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_5832b785-c82b-4724-84f7-7e1c54e65756"
      decimals="-5"
      id="F_4eb076ac-a23d-48d3-aa8f-ec615d4f448e"
      unitRef="U_USD">89700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_e06ff9ea-6ac1-463f-a171-26aa417330c4"
      decimals="-5"
      id="F_21c4a091-93d9-43c8-8efb-05acbf49d9be"
      unitRef="U_USD">28200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_785b6f2c-3814-4a67-a525-c56234244751"
      id="F_bb7b135c-5de2-446c-953d-8c2d94fbf788">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_b8b16692-cbc0-4367-b249-644373e8d0f7"
      id="F_de0d6d3d-1432-4de3-be91-f850de448125">P3Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_294c7710-f690-4151-a188-b4cdcb4e5f96">&lt;p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;11.	Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the computation of basic and diluted net loss per share:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:58.352%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:16.323%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:17.442999999999998%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;53,721&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;157,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following outstanding potentially dilutive common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Convertible preferred stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;104,417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock options and restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,084&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Performance stock options (with performance conditions to be established)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Early exercised stock options subject to future vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested restricted stock awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Performance restricted stock (with performance conditions to be established)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_295cf180-346f-4992-982f-a7a350dc5e76">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the computation of basic and diluted net loss per share:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:58.352%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:16.323%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:17.442999999999998%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;53,721&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;157,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_7d47d0c4-98c3-46a9-aada-ef709464e1af"
      unitRef="U_USD">-53721000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_de3d8d88-0ea2-4929-b640-ba70b527c6f7"
      unitRef="U_USD">-35625000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_d2b2bedb-6ebe-4837-8e28-dcb5b8874ccd"
      unitRef="U_shares">157943000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_a1d90e25-a335-4440-b60b-e1747c62a555"
      unitRef="U_shares">157943000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_463fabb4-6240-4268-bc3c-899c2448f76f"
      unitRef="U_shares">29277000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_50fe71e6-97fd-4fd0-a757-98edb8493b5d"
      unitRef="U_shares">29277000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="2"
      id="F_0f7d3c49-9c24-4174-9e60-7f43c66c0ea6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="2"
      id="F_66e6e894-267f-4a58-aa1f-0d009233fc3b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="2"
      id="F_34c0feb9-75cb-45ee-a776-b1098c1c6e39"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="2"
      id="F_50fb3df0-b2f9-472d-9050-263523ed0e83"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_f130a879-c953-499f-af37-404aba724fc9">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following outstanding potentially dilutive common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Convertible preferred stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;104,417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock options and restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,084&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Performance stock options (with performance conditions to be established)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Early exercised stock options subject to future vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested restricted stock awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Performance restricted stock (with performance conditions to be established)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_014dbf4d-9c71-491e-bae9-913a30763050"
      decimals="-3"
      id="F_cb552cd7-3c0e-4f2a-a1a3-b16387e6acd3"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0f5b5752-1f37-4791-b9a2-a1fd4665f647"
      decimals="-3"
      id="F_f46f02bb-bea9-45f3-a8f7-ca7a0735e323"
      unitRef="U_shares">104417000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_2a684aa7-255a-43da-9bf9-acf6d3b4352e"
      decimals="-3"
      id="F_89add92d-94c7-47ff-a81b-9103d52d9dd0"
      unitRef="U_shares">17084000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ce5b0975-4f9d-4afa-a419-e3ce04cc3ecb"
      decimals="-3"
      id="F_36174d1d-aa36-44d3-a883-423e1ec4b37d"
      unitRef="U_shares">9777000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_15533d05-1a02-4a98-bae1-62dca64d295c"
      decimals="-3"
      id="F_7bf6b1ac-da1c-4ab7-9101-d2f2e656f5d7"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_4a935b0c-89b2-44d4-8a74-37a27e755eae"
      decimals="-3"
      id="F_5582ac9b-f1d5-47c6-b7ac-a97356f6011c"
      unitRef="U_shares">300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_34c9a333-0792-46d3-8d3d-3200c56c14bf"
      decimals="-3"
      id="F_2263d476-ff07-48b6-ab9f-97f8f39c322e"
      unitRef="U_shares">55000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c07a2ba4-b437-458f-928b-576f968fde0c"
      decimals="-3"
      id="F_eba61142-3ee3-4256-8856-b2854ab44446"
      unitRef="U_shares">116000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_776fbd65-9035-41d6-b661-57b9c9289144"
      decimals="-3"
      id="F_c5f86da8-2220-40f8-873e-b9ec655e0276"
      unitRef="U_shares">650000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_187481d3-58da-4836-be9f-97cca6f7c199"
      decimals="-3"
      id="F_f0cb0e78-158f-4bff-a80c-dc86eef925a4"
      unitRef="U_shares">2314000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a7fa44ea-606a-4dcc-824f-a24a6ed67327"
      decimals="-3"
      id="F_4d1408a2-0f17-484b-a169-9eefe9695f0c"
      unitRef="U_shares">255000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3e1fdf9f-0c41-49d6-bdc7-817ef4cf3889"
      decimals="-3"
      id="F_a7ec12c9-ac56-41b9-bc34-105ca47bbb83"
      unitRef="U_shares">510000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      decimals="-3"
      id="F_b0aa36bd-c593-45b2-8dc9-aad3a6b0f86a"
      unitRef="U_shares">18044000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_00a508a8-d895-4261-b068-9f4d68a32812"
      decimals="-3"
      id="F_9c9ea7df-3f4f-4884-9980-c387417dc004"
      unitRef="U_shares">117434000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_387b8b88-6529-413e-9474-299a471851cb"
      id="F_82546d90-daf7-4b49-9645-c610dabbbcda">&lt;p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12.	Related Party Transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of March 31, 2024 and December 31, 2023, the Company was obligated to pay Amgen $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, under the Amgen Collaboration Agreement, which was recorded within current liabilities on the condensed consolidated balance sheets. As of March 31, 2024 and December 31, 2023, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, related to amounts prepayable to Amgen were recorded as prepaid expenses and other current assets on the condensed consolidated balance sheets. During the three months ended March 31, 2024 and 2023, the Company recorded &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;nil&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, of research and development expenses with Amgen.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <nmra:RelatedPartyTransactionObligationWithRelatedParty
      contextRef="C_24425110-363c-4304-86c3-338011263481"
      decimals="-5"
      id="F_e2368e10-9279-4437-afa9-ef5c2973faf2"
      unitRef="U_USD">6300000</nmra:RelatedPartyTransactionObligationWithRelatedParty>
    <nmra:RelatedPartyTransactionObligationWithRelatedParty
      contextRef="C_4252d2b2-e04b-48d1-85b6-0e7e74735ae9"
      decimals="-5"
      id="F_a4a42939-036c-4a2b-9ea5-aea8849c5d63"
      unitRef="U_USD">3100000</nmra:RelatedPartyTransactionObligationWithRelatedParty>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_24425110-363c-4304-86c3-338011263481"
      decimals="-5"
      id="F_d7f38d90-433e-41cd-9e43-2ad2520dd0e5"
      unitRef="U_USD">9400000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_4252d2b2-e04b-48d1-85b6-0e7e74735ae9"
      decimals="-5"
      id="F_5470acc7-b99b-4722-8d81-380cb9b4aa68"
      unitRef="U_USD">6300000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_61a3990c-bdca-4b24-aaa5-3144c2b02eed"
      decimals="-6"
      id="F_3c10d6da-9d42-42ab-9c48-97cf9eb7cd27"
      unitRef="U_USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_29e92089-1d1d-45de-90cf-b5665e9d2c96"
      decimals="-5"
      id="F_4eed374d-701a-42e3-89e9-59c3a86948e8"
      unitRef="U_USD">8100000</us-gaap:ResearchAndDevelopmentExpense>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
